Gastroenterology

Cumulative Index

1999–2003

AUTHOR INDEX TO VOLUMES 116–125

Aagesen TH. *See* Thornstensen L
Aaltonen LA
  See Hemminki A
  See Prior TW
Aalykke C, Hallas J, Lauritsen K. *H. pylori* and Risk of Ulcer Bleeding Among Users of NSAIDs. Reply, 118:451–c
Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. *Helicobacter pylori* and Risk of Ulcer Bleeding Among Users of Nonsteroidal Anti-Inflammatory Drugs: A Case-Control Study, 116: 1305
Aarons SJ. *See* O'Sullivan GC
Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. Therapeutic Effects of Vasoactive Intestinal Peptide in the Trinitrobenzene Sulfonic Acid Mice Model of Crohn's Disease, 124:961
Abadir A. *See* Boushey RP
Abbiati R. *See* Marchesini G
Abdalla. *See* Fitzgerald RC
Abdalla AM. *See* Peek RM Jr
Abdel-Rahman WM. *See* Raevaara TE
Abe A. *See* Takeuchi T
Abe T. *See* Kakyo M
Abe T, Suzuki T, Ito S, Unno M, Onogawa T, Tokui T. The Human Hepatocyte-specific Organic Anion Transporter Encoded by the SLC21A8 Gene. Reply, 122:1546–c
Abell GA. *See* Honda M
Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, LeBlanc I, Lindberg G, Konturek J, Nowak T, Quigley EMM, Tougas G, Starkebaum W. Gastric Electrical Stimulation for Medically Refractory Gastroparesis, 125:421
Abell T, Van Cutsen E, Abrahamsson H, Huizinga JD, Konturek JW, Galmiche JP, Voeller G, Filez L, Everts B, Waterfall WE, Domschke W, des Varannes SB, Familoni BO, Bourgeois IM, Jansens J, Tougas G
  Gastric Neurostimulation For Gastroparesis: Time To Pick Up the Pace, 125:979–ss
  Gastric Neurostimulation For Gastroparesis: Time To Pick Up the Pace. Reply, 125:981–ss
Abergel A. *See* Moreau R
Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and Immunomodulators: Postoperative Infectious Complication Risk in Inflammatory Bowel Disease Patients, 125:320
Abeygunasekera S. *See* Chitturi S
Abitbol J-L. *See* Delvaux M
Abouassi S, Sanyal A, Schubert ML. β-Blocker Plus Nitrate for Primary Prophylaxis of Variceal Bleeding. Comment, 119:1170–ss
Aboukameel A. *See* Marciniak DJ
Abou-Saif A, Lei J, McDonald TJ, Chakrabarti S, Waxman IF, Shojamanesh H, Schrump DS, Kleiner DE, Gibril F, Jensen RT. A New Cause of Zollinger-Ellison Syndrome: Non-Small Cell Lung Cancer, 120: 1271–cr
Abraczinskas DA. *Liver Disease: Diagnosis and Management*, 120:584–pmr
Abraham BP. *See* Micci M-A
Abraham JM. *See* Selaru FM
Abrahamsson H. *See* Abell T
Abramowicz D. *See* Louis H
Abreu MT
  See Dubinsky MC
Abreu MT. *Innovative Concepts in Inflammatory Bowel Disease*, 119:876–pmr
Abreu MT, Palladino AA, Arnold ET, Kwon RS, McRoberts JA. Modulation of Barrier Function During Fas-Mediated Apoptosis in Human Intestinal Epithelial Cells, 119:1524
Abreu MT, Taylor KD, Lin Y-C, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in *NOD2* Are Associated With Fibrostenosing Disease in Patients With Crohn's Disease, 123: 679
Abreu-Martin MT. *See* Vasiliauskas EA
Abu-Elmagd KM. *See* Türler A
Accardo S. *See* Zentilin P
Accatino L. *See* Arrese M
ACCENT I Study Group. *See* Hanauer SB
Achem SR. Chest Pain and Serotonin: A Possible Link? Comment, 121:495–ss
Achkar E. *Handbook of Gastroenterology*, 116: 500–pmr
Achkar J-P
  See Hugot J-P
  See Parsi MA
  See Shen B
Ackerman S. *See* Michetti P
Ackermann H. *See* Leuschner M
Ackrill AM. *See* Paterson M
Ackroyd R. *See* Gough M
Acquaviva AM. *See* Zarrilli R
Actis GC. Comments on Experimental Use of Intravenous Cyclosporine (CsA) Alone to Treat Severe Ulcerative Colitis, 121:1530–c
Adachi K. *See* Kazumori H
Adachi M. *See* Hashida H
Adachi Y. *See* Ishihara T
Adachi Y, Gabazza EC, Ishihara T. Etiology of Fasting Hyperbilirubinemia: Genetic Factors Versus Enhanced Enterohepatic Cycling of Bilirubin. Reply, 117:1254–c
Adachi Y, Lee C-T, Coffee K, Yamagata N, Ohm JE, Park K-H, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP. Effects of Gastric Blockade of the Insulin-like Growth Factor Receptor in Human Colon Cancer Cell Lines, 123:1191
Adams DH
  See Butterworth JR
  See Kurkijärvi R
Adams E. *See* Sandler RS
Adams MB. *See* Lu G
Adams PC. *See* Bacon BR
Adamson MD. *See* Jonsson JR
Adani GL, Baccarani U, Risaliti A, Aoki T, Avital I. The Role of Cytomegalovirus in Inflammatory Bowel Disease and Gastrointestinal Lymphoma, 123:390–c
Adani GL, Baccarani U, Risaliti A, Donini A, Aoki T, Avital I. Appendicectomy and Crohn's Disease: Clinical and Genetic Associations, 125:1563–c
Adegboyega PA. *See* di Mari JF
Adelstein S. *See* Wong RCW
Adkisson W. *See* Corley DA
Adler DR. *See* Su C
Adler G
  See Greten FR
  See Hofbauer B
  See Michl P
  See Paxian S

KEY TO ABBREVIATIONS

aga—American Gastroenterological Association
c—Correspondence
cc—Comment From the Editors
cr—Case Reports
gn—Gastroenterology News
e—Editorials
im—Image of the Month
pmr—Print and Media Reviews
rc—Rapid Communications
ss—Selected Summaries
srr—Special Reports and Reviews
tmig—This Month in Gastroenterology
vidd—Viewpoints in Digestive Diseases

See Reinshagen M
See Seufferlein T
See Steinkamp M
See Steinle AU
See Wagner M
See Weber CK
Adrian TE. *See* Schneider MB
Adsay VN. *See* Marciniak DJ
Aepinus C. *See* Sotlar K
Afdhal N. *See* Yang C
Afdhal NH
See Nunes DP
See Wang DQ-H
Afdhal NH. *Biomedical Research Reports: Hepatitis C*, 121:227–pmr
Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR. Lovastatin Augments Sulindac-Induced Apoptosis in Colon Cancer Cells and Potentiates Chemopreventive Effects of Sulindac, 117:838
Aggerbeck LP. *See* Berriot-Varoqueaux N
Agnantis NJ. *See* Roukos DH
Agrawal S. *See* Bhagat L
Ahida T. *See* Orii F
Ahlenstiehl G. *See* Woitas RP
Ahlenstiel G. *See* Woitas RP
Ahlman B. *See* Charlton M
Ahlquist DA
See Gluecker TM
See Harewood GC
See Johnson CD
Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal Cancer Screening by Detection of Altered Human DNA in Stool: Feasibility of a Multitarget Assay Panel, 119:1219
Ahmad M. Omeprazole Test and 24-Hour Esophageal pH Monitoring in Diagnosing GERD, 116:1012–c
Ahmad MM. *See* Hildeand P
Ahmad T. *See* Orchard TR
Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP. The Molecular Classification of the Clinical Manifestations of Crohn's Disease, 122:853–rc
Ahmad T, Orchard T, Armuzzi A, Jewell D, Marshall S. NOD2 Insertion Mutation in a Cretan Crohn's Disease Population. Reply, 124:273–c
Ahmad U. *See* Camilleri M
Ahmed S. *See* Varro A
Ahmed SNS. *See* Samuel D
Ahmet Deger B. *See* Hokelek M
Ahnen D. *See* Baron JA
Ahnen DJ
See Lieberman DA
See Maltzman T
Ahrens CH. *See* Thornstensen L
Ahuja V, Sharma MP. High Recurrence Rate of *Helicobacter pylori* Infection in Developing Countries, 123:653–c
Aihara T, Fujishita T, Kanatani K, Furutani K, Nakamura E, Taketo MM, Matsui M, Chen D, Okabe S. Impaired Gastric Secretion and Lack of Trophic Responses to Hypergastrinemia in M_3 Muscarinic Receptor Knockout Mice, 125:1774
Aimone-Gastin I. *See* Guéant J-L
Akagi T. *See* Yokota K
Akamatsu T
See Hamano H
See Noguchi H
Akanuma M
See Hirata Y
See Maeda S
Akb.rali HI
See Jin X
See Prasad M
Akedo H. *See* Kusama T
Åkerbrant H. *See* Björk J
Akhtar M. *See* Gobert AP
Akiba H. *See* Totsuka T
Akimoto S, 118:497
Akira S
See Kanai T
See Shimizu H
Akita K, Okuno M, Enya M, Imai S, Moriwaki H, Kawada N, Suzuki Y, Kojima S. Impaired Liver Regeneration in Mice by Lipopolysaccharide Via TNF-α/Kallikrein-Mediated Activation of Latent TGF-β, 123:352
Akkermans LMA. *See* Stam R
Akman D. *See* Drossman DA
Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline Improves Short-term Survival in Severe Acute Alcoholic Hepatitis: A Double-Blind, Placebo-Controlled Trial, 119:1637
Akyuz F. *See* Besisik F
Alanen K. *See* Salmi M
Albanese A. *See* Maria G
Albano E. *See* Carini R
Albano F. *See* Canani RB
Albertazzi A. *See* Ballestri M
Alberti A. *See* Gerotto M
Alberti F. *See* Girelli D
Alberts DS
See Maltzman T
See Martínez ME
Alberts DS, Martinez ME, Roe DJ, Marshall JR, Sampliner RE, Hamilton SR, Issa J-P, Batta AK, Salen G. Diet and Colon Cancer: Strike Out the Bran. Reply, 119:591–ss
Albillos A
See García-Pagán JC
See González-Abraldes J
See Pérez-Páramo M
Albillos A, Pérez-Páramo M, Muñoz J. Prokinetics Reduce Bacterial Translocation in Cirrhosis: Will Sweeping the Gut Keep the Fluid Clean? Reply, 120:315–ss
Albrecht J
See McHutchison JG
See Poynard T
Albrecht J. Glucose-Derived Osmolytes and Energy Impairment in Brain Edema Accompanying Liver Failure: The Role of Glutamine Reevaluated, 125:976–e
Albrecht JK
See McHutchison JG
See Samuel D
Albright C. *See* Veltkamp C
Al-Chaer ED, Kawasaki M, Pasricha PJ. A New Model of Chronic Visceral Hypersensitivity in Adult Rats Induced by Colon Irritation During Postnatal Development, 119:1276
Aldeguer X. *See* Sort P
Aldersley MA. *See* Hamlin PJ
Alderuccio F. *See* Marshall ACJ
Alexander G. *See* Tomasetto C
Alexander GJM. *See* Féray C
Alfalah M. *See* Ritz V
Alfert J. *See* Rivera-Nieves J
Al-Garawi A. *See* Bataller R
Al-Ghnaniem R. *See* Pufulete M
Algoufi T. *See* Huizinga JD
Al-Haider W. *See* Chen D
Ali GN. *See* Williams RBH
Ali I, Campbell WB, Sarna SK. Impaired Activation of Cytosolic Phospholipase A_2 in Inflamed Canine Colonic Circular Muscle, 119:62
Ali I, Sarna SK. Selective Modulation of PKC Isozymes by Inflammation in Canine Colonic Circular Muscle Cells, 122:483
Ali L. *See* Schneider A
Aliaga Martínez L. *See* Hidalgo-Tenorio C
Alila H. *See* Berg DJ
Alison MR. *See* Forbes SJ
Alkrakawi A. *See* Clouse RE
Allard J. *See* Oudit GY
Allcock RJ. *See* De la Concha EG
Allemeyer EH. *See* Heuschen UA
Allen BA. *See* Terdiman JP
Allen JI. *See* Baron JA
Allen M. *See* Vazquez-Sequeiros E

Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Confined Treatment, 125:1543–ss
Allen-Mersh YG. *See* Miao YM
Allez M. *See* van de Wal Y
Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T Cells With Regulatory Function After Interaction With Intestinal Epithelial Cells, 123:1516
Allison MC. *See* Gordon FH
Almer S
See Bergquist A
See Elmberg M
See Hugot J-P
Alofaituli G. *See* Jensen DM
Aloni S. *See* Hove TT
Alonso M. *See* Rudolph JA
Alonzi T. *See* Blindenbacher A
Alper SL. *See* Lencer WI
Alpers DH
Colonic Microbiota, Nutrition and Health, 119:1410–pmr
Why Should Psychotherapy Be a Useful Approach to Management of Patients With Nonulcer Dyspepsia?, 119:869–e
Alpini G
See Alvaro D
See LeSage G
Alpini G, Glaser S, Alvaro D, Ueno Y, Marzioni M, Francis H, Baiocchi L, Stati T, Barbaro B, Phinizy JL, Mauldin J, Lesage G. Bile Acid Depletion and Repletion Regulate Cholangiocyte Growth and Secretion by a Phosphatidylinositol 3-Kinase-Dependent Pathway in Rats, 123:1226
Alpini G, Glaser SS, Ueno Y, Rodgers R, Phinizy JL, Francis H, Baiocchi L, Holcomb LA, Caligiuri A, LeSage GD. Bile Acid Feeding Induces Cholangiocyte Proliferation and Secretion: Evidence for Bile Acid-Regulated Ductal Secretion, 116:179
Alric L. *See* Bureau C
Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette J-C, Péron J-M, Vinel J-P, Durand D, Izopet J, Poynard T, Duffaut M, Rostaing L. Long-term Impact of Renal Transplantation on Liver Fibrosis During Hepatitis C Virus, 123:1494
Alsahli M. *See* Farrell RJ
Alter H. *See* Ghany MG
Alter HJ
See Farci P
See Promrat K
See Umemura T
Altorki NK. *See* Zhang F
Altschuler EL
See Kane SV
See Kast RE
Altuna R. *See* Bosch-Marcé M
Alvarez F. *See* Lapierre P
Alvarez-Castells A. *See* Junquera F
Alvaro D
See Alpini G
See Gigliozzi A
See LeSage G
Alvaro D, Alpini G, Onori P, Franchitto A, Glaser S, Sage G le, Gigliozzi A, Vetuschi A, Morini S, Attili AF, Gaudio E. Effect of Ovariectomy on the Proliferative Capacity of Intrahepatic Rat Cholangiocytes, 123:336
Alvaro D, Alpini G, Onori P, Perego L, Svegliati Baroni G, Franchitto A, Baiocchi L, Glaser SS, Le Sage G, Folli F, Gaudio E. Estrogens Stimulate Proliferation of the Intrahepatic Biliary Epithelium in Rats, 119:1681
Alvaro D, Gigliozzi A, Marucci L, Alpini G, Barbaro BB, Monterubbianesi R, Minetola L, Grazia Mancino M, Medina JF, Attila AF, Benedetti A. Corticosteroids Modulate the Secretory Processes of the Rat Intrahepatic Biliary Epithelium, 122:1057
Alves CC. *See* Machado JC
Alzuguren P. *See* Bustos M
Amadesi S. *See* Trevisani M
Amagaya S. *See* Yamamoto M
Amano K. *See* Bruggraber SFA
Amaral J. *See* Chen Q
Amaral J, Xiao Z-L, Chen Q, Yu P, Biancani P, Behar J. Gallbladder Muscle Dysfunstion in Patients With Chronic Acalculous Disease, 120:506
Amaris M. *See* Mintchev MP
Amedei A. *See* D'Elios MM
Amenta PS. *See* Lin JL-C
Amer M. *See* Caplan MS
American Gastroenterological Association
Abstracts Submitted to DDW, 125:605–aga
Committee on Training and Education. List of Available Training Programs, 117:461, 117:972
Joint Statement on Missions and Submissions of Papers to AGA Journals, 123:877–aga
Medical Position Statement: Diagnosis and Care of Patients With Anal Fissure, 124:233–aga
Medical Position Statement: Epidemiology, Diagnosis, and Treatment of Pancreatic Ductal Adenocarcinoma, 117:1463–aga
Medical Position Statement: Evaluation and Management of Occult and Obscure Gastrointestinal Bleeding, 118:197–aga
Medical Position Statement: Evaluation of Liver Chemistry Tests, 123:1364–aga
Medical Position Statement: Guidelines for the Evaluation and Management of Chronic Diarrhea, 116:1461–aga
Medical Position Statement: Guidelines for the Evaluation of Food Allergies, 120:1023–aga
Medical Position Statement: Guidelines on Constipation, 119:1761–aga
Medical Position Statement: Guidelines on Osteoporosis in Gastrointestinal Disease, 124:791–aga
Medical Position Statement: Hereditary Colorectal Cancer and Genetic Testing, 121:195–aga
Medical Position Statement: Irritable Bowel Syndrome, 123:2105–aga
Medical Position Statement: Nausea and Vomiting, 120:261–aga
Medical Position Statement: Nonalcoholic Fatty Liver Disease, 123:1702–aga
Medical Position Statement: Osteoporosis in Hepatic Disorders, 125:937–aga
Medical Position Statement: Parenteral Nutrition, 121:966–aga
Medical Position Statement: Perianal Crohn's Disease, 125:1503–aga
Medical Position Statement: Short Bowel Syndrome and Intestinal Transplantation, 124:1105–aga
Medical Position Statement on Anorectal Testing Techniques, 116:732–aga
Medical Position Statement on Management of Oropharyngeal Dysphagia, 116:452–aga
Medical Position Statement on Obesity, 123:879–aga
Policy Statement on the Precertification of Pharmaceuticals, 121:965–aga
Presentation of the Julius M. Friedenwald Medal to Tadataka Yamada, M. D, 124:1965–aga
Presidential Address, 123:2100–aga
Review on Obesity, 123:882–aga
Standards for Office-Based Gastrointestinal Endoscopy Services, 121:440–aga
Technical Review of Osteoporosis in Gastrointestinal Diseases, 124:795–aga
Technical Review on Irritable Bowel Syndrome, 123:2108–aga
Technical Review on Nonalcoholic Fatty Liver Disease, 123:1705–aga
Technical Review on Parenteral Nutrition, 121:970–aga

Technical Review on the Diagnosis and Care of Patients With Anal Fissure, 124:235–aga
Technical Review on the Evaluation of Food Allergy in Gastrointestinal Disorders, 120:1026–aga
Technical Review on the Evaluation of Liver Chemistry Tests, 123: 1367–aga
Training the Gastroenterologist of the Future: The Gastroenterology Core Curriculum, 124:1055–aga
Ames PRJ. *See* Amitrano L
Amigo L. *See* Zanlungo A
Amin A. *See* Miao YM
Amitai H. *See* Hove TT
Amitrano L, Guardascione MA, Brancaccio V, Iannaccone L, Ames PRJ, Balzano A. Portal and Mesenteric Venous Thrombosis in Cirrhotic Patients, 123: 1409–co
Amlot PL. *See* Gordon FH
Ammann RW, Muellhaupt B
The Natural History of Pain in Alcoholic Chronic Pancreatitis, 116:1132
The "Natural" History of Pain in Chronic Pancreatitis. Reply, 118: 236–c
Pain in Alcoholic Chronic Pancreatitis. Reply, 117:1026–c
Amo A del. *See* León F
Amodio P. *See* Marchesini G
Amorim A. *See* Machado JC
Amorosi A
See Palli D
See Rubio CA
Amsellem S. *See* Mansouri A
Ananthanarayanan M. *See* Young Kim J
Anastopoulos H. *See* Sakoulas G
Andersen LP. *See* Thjodleifsson B
Anderson CMH. *See* Thwaites DT
Anderson DC. *See* Sans M
Anderson FH. *See* Lai C-L
Anderson GJ. *See* Frazer DM
Anderson JM. *See* Rahner C
Anderson JM. Maintaining a Defense as the Injured Leave the Field: Apoptosis and Barrier Function in the Intestine, 119: 1783–e
Anderson MA
See Buttar NS
See Krishnadath KK
Anderson OD. *See* Molberg Ø
Anderson PK. *See* Triadafilopoulos G
Andersson A. *See* Lundell L
Andersson N. *See* Mills JC
Andersson P. *See* Rubio CA
Andersson RE. Discussion on Appendectomy Is Followed by Increased Risk of Crohn's Disease. Reply, 125:997–c
Andersson RE, Olaison G, Tysk C, Ekbom A Appendectomy Is Followed by Increased Risk of Crohn's Disease, 124:40
Is the Appendix a Vestigial Organ? Its Role in Ulcerative Colitis, 121:730–ss
Ando M. *See* Uwatoku R
Ando Y. *See* Jonsson JR
Andoh A, Takaya H, Saotome T, Shimada M, Hata K, Araki Y, Nakmura F, Shintani Y, Fujiyama Y, Bamba T. Cytokine Regulation of Chemokine (IL-8, MCP-1, and RANTES) Gene Expression in Human Pancreatic Periacinar Myofibroblasts, 119:211
Andra's D. *See* Ohana M
André F. *See* Soubeyran P
André F, Rigot V, Remacle-Bonnet M, Luis J, Pommier G, Marvaldi J. Protein Kinases C-γ and -δ Are Involved in Insulin-like Growth Factor I-Induced Migration of Colonic Epithelial Cells, 116:64
Andres P. *Gastrointestinal Radiology Companion: Imaging Fundamentals.* Comment, 117:743–pmr
Andresen L, Eugen-Olsen J, Perner A. NF-kB in IBD: Does Binding to DNA Imply Transcriptional Activity?, 116:1504–c
Andreu M
See Guarner C
See Panés J
Andreu V. *See* Escorsell À
Andrew DP. *See* Papdakis KA
Andrews N. *See* Harris HE
Andriulli A
See Chen J-M
See Mangia A
See Rosina F
Andriulli A, Annese V, Facciorusso D, Giacobbe A. First, Do Not Harm: Power, Oppression, and Violence of Liver Biopsy, 125:272–c
Andus T
See Hausmann M
See Merger M
See Neef B
Angeletti S. *See* Marignani M
Angeli P
See Morales-Ruiz M
See Primignani M
Angulo P. *See* Feldstein AE
Angulo P, Dickson ER
Low-Dose Methotrexate in Primary Biliary Cirrhosis. Reply, 117:1511–c
Methotrexate in the Treatment of Primary Biliary Cirrhosis: The Hype and the Hope, 117:492–e
Angulo P, Lindor KD. Insulin Resistance and Mitochondrial Abnormalities in NASH: A Cool Look Into a Burning Issue, 120:1282–e
Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to Adefovir Dipivoxil Therapy Associated With the Selection of a Novel Mutation in the HBV Polymerase, 125:292–rc
Angus PW
See Froomes PRA
See Paizis G
Angus PW, Froomes PR, Morgan DJ, Smallwood RA. Hepatic Oxygen Supplementation as Therapy in Cirrhotic Liver Disease. Reply, 117: 1025–c
Anlauf M. *See* Feurle GE
Annese V
See Andriulli A
See Prantera C
Annibale B. *See* Peghini PL
Annovazzi A, Peeters M, Maenhout A, Signore A, Dierckx R, Van de Wiele C. 18-Fluorodeoxyglucose Positron Emission Tomography in Nonendocrine Neoplastic Disorders of the Gastrointestinal Tract, 125:1235–srr
Annunziato F. *See* Bonacchi A
Annunziato L. *See* Canani RB
Ansari AA
See Bruggraber SFA
See Kita H
Ansari S. *See* Lu J
Anschuetz G. *See* Fontana RJ
Anthony A. *See* Sigthorsson G
Antignac C. *See* Guillem P
Antignano LV. *See* Triadafilopoulos G
Anton PM
See Mykoniatis A
See Savidge TC
See Wlk M
Anton-Culver H. *See* Theuer CP
Antonelli E. *See* Fiorucci S
Antonioli D. *See* Teitelbaum JE
Antonioli DA. *See* Bitton A
Antoniu BA. *See* Keck T
Antonsson M. *See* Lehmann A
Aoki T. *See* Adani GL
Aoshi T. *See* Sugimoto K
Apicella A. *See* Zarrilli R
Apolone G. *See* Marchesini G
Appelmelk BJ
See D'Elios MM
See Martin SL
Appleby P. *See* Pufulete M
Appleyard M, Fireman T, Glukhovsky A, Jacob H, Shreiver R, Kadirkamanathan S, Lavy A, Lewkowicz S, Gan S, Scapa E, Shofti R, Swain P, Zaretsky A. A Randomized Trial Comparing

Wireless Capsule Endoscopy With Push Enteroscopy for the Detection of Small-Bowel Lesions, 119:1431–rc
Arai M. *See* Ikeda H
Arakawa Y
See Shiratori Y
See Yoshida H
Araki H. *See* Takeuchi K
Araki Y. *See* Andoh A
Arantes V, Raju GS. Combo Cap Takes a Big Bite, Yet a Smoothie to Swallow. Comment, 125:621–ss
Arasaradnam RP, Riley SA. Optimal Medical Therapy With Proton Pump Inhibitor Infusion to Prevent Recurrent Ulcer Hemorrhage in Patients With Adherent Clots, 125: 276–c
Arase Y. *See* Ikeda K
Arbol LR del. *See* González-Aaldes J
Arce Y. *See* Sans M
Archer D. *See* Varro A
Archimandritis A, Blatsos V, Skandalis N. Image of the Month, 120:336–im
Arcot AN. *See* Prior TW
Arden NK. *See* van Staa T-P
Ardill JE. *See* Gillen D
Ardite E. *See* Sans M
Ardizzone J-F. *See* Chamouard P
Arebi N, Healey ZV, Bliss PW, Ghatei M, van Noorden S, Playford RJ, Calam J. Nitric Oxide Regulates the Release of Somatostatin From Cultured Gastric Rabbit Primary D-Cells, 123:566
Arefin MS. *See* Hildeand P
Areias JA. *See* Jonas MM
Arends J-W. *See* Hermsen M
Arendt-Nielsen L. *See* Pedersen J
Areni A. *See* Calabrese C
Arentz-Hansen H. *See* Molberg Ø
Arentz-Hansen H, McAdam SN, Molberg Ø, Fleckenstein B, Lundin KEA, Jørgensen TJD, Jung G, Roepstorff P, Sollid LM. Celiac Lesion T Cells Recognize Epitopes That Cluster in Regions of Gliadins Rich in Proline Residues, 123:803
Argenzio RA. *See* Rhoads JM
Arguello M. *See* Oshima M
Ariel A. *See* Chowers Y
Arimura Y. *See* Kurata A
Armengol JR. *See* Junquera F
Armenian B. *See* Frossard JL
Armuzzi A. *See* Ahmad T
Arnold CN. *See* Goel A
Arnold ET. *See* Abreu MT
Arnold M. *See* French SJ
Arnold R. *See* Feurle GE
Arnott IDR. *See* Gillett HR
Aronow BJ. *See* Bates MD
Aronson JF. *See* Atchison CR
Arosio C. *See* Piperno A
Arranz A. *See* Abad C
Arrese M, Accatino L. Is Intrahepatic Cholestasis of Pregnancy an MDR3-Related Disease?, 125:1922–c
Arroyo V
See Bataller R
See Bosch-Marcé M
See Ginès P
See Ginés P
See Guevara M
See Morales-Ruiz M
See Ortega R
See Poo J-L
See Ros J
See Sort P
See Titos E
Arroyo V, Guevara M, Ginès P. Hepatorenal Syndrome in Cirrhosis: Pathogenesis and Treatment, 122:1658
Arruda SMB de, Passaro DJ, Yang S, Parsonnet J. Variability of Serologic Testing for *H. pylori* Using U.S. and Peruvian Antigens, 120:325–c
Arsenault JE. *The New Eating Right for a Bad Gut*. 119:876–pmr
Arseneau KO
See Bickston SJ
See Cominelli F
See Keates AC
Arteaga CL. *See* Adachi Y
Arteel GE
Oxidants and Antioxidants in Alcohol-Induced Liver Disease, 124:778–srr
Oxidative Stress and Digestive Diseases. 125: 1279–pmr
Arteel GE. *See* McKim SE
Arthur MJP. *See* Wright MC
Arthur MJP. Reversibility of Liver Fibrosis and Cirrhosis Following Treatment for Hepatitis C, 122:1525–e
Artinger M. *See* Grossmann J
Arts J. *See* Van Assche G
Artursson P. *See* Gulberg E
Arvand M. *See* Schmidt W
Arvelo F. *See* Bras-Gonçalves RA
Asa SL. *See* Yusta B
Asai N. *See* Iwashita T
Asaka M. *See* Ohkawara T
Asakawa A
See Inui A
See Ueno N
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Nijima A, Fujino MA, Kasuga M. Ghrelin Is an Appetite-Stimulatory Signal From Stomach With Structural Resemblance to Motilin, 120:337–rc
Asakawa A, Inui A, Ueno N, Makino S, Fujino MA, Kasuga M. Urocortin Reduces Food Intake and Gastric Emptying in Lean and *ob/ob* Obese Mice, 116:1287–rc
Asakawa A, Inui A, Yuzuriha H, Ueno N, Katsuura G, Fujimiya M, Fujino MA, Niijima A, Meguid MM, Kasuga M. Characterization of the Effects of Pancreatic Polypeptide in the Regulation of Energy Balance, 124: 1325
Asakura H. *See* Matsuda Y
Asano G. *See* Kornmann M
Asano T. *See* Hara T
Ascher NL. *See* Yao FY
Asfaha S. *See* Wallace JL
Ashby D. *See* Evans RC
Ashley C. *See* Howard L
Ashton C. *See* Bassett M
Ashwood P. *See* Evans SM
Askin MP. *See* Zuckerman GR
Askling J. *See* Elmberg M
Askling J, Linet M, Gridley G, Halstensen TS, Ekström K, Ekbom A. Cancer Incidence in a Population-Based Cohort of Individuals Hospitalized With Celiac Disease or Dermatitis Herpetiformis in Sweden, 123:1428
Asnafi V
See Mention J-J
See Verkarre V
Asnong K. *See* Van Assche G
Assman PS. *See* Sierro F
Atanasova E. *See* Camilleri M
Atchison CR, West AB, Balakumaran A, Hargus SJ, Pohl LR, Daiker DH, Aronson JF, Hoffmann WE, Shipp BK, Treinen-Moslen M. Drug-Enterocyte Adducts Play a Causal Role in Diclofenac Enteropathy in Rats, 119:1537
Aten J. *See* de Vree JML
Atherton CT. *See* Wight NJ
Atherton J. *See* van Doorn L-J
Atherton JC. *See* Byrne MF
Atherton JC, Wight NJ. *H. pylori* and Risk of Ulcer Bleeding Among Users of NSAIDs, 118:451–c
Atillasoy EO. *See* Holt Pr
Atreya R. *See* Neurath MF
Attar A, Flourié B, Rambaud J-C, Franchisseur C, Ruszniewski P, Bouhnik Y. Antibiotic Efficacy in Small Intestinal Bacterial Overgrowth-Related Chronic Diarrhea: A Crossover, Randomized Trial, 117:794
Attie AD. *See* Cohen P
Attila AF. *See* Alvaro D
Attili AF. *See* Alvaro D
Attoub S. *See* Goïot H
Attwood S. *See* Burdyga G
Attwood SEA. *See* Haigh CR

Au W-Y. *See* Lau GKK
Audrain S. *See* Cézard JP
Audrezet M-P. *See* Chen J-M
Augenlicht L. *See* Velcich A
Augenlicht LH. *See* Mariadason JM
Augustyn DH. American Gastroenterological Association: Our New President–Martin Brotman, M.D., 122:1512–aga
Aulitzky W. *See* Schwab M
Auricchio S. *See* Maiuri L
Ausina V. *See* Pérez-Páramo M
Austin CP, Figueroa DJ, Feighner SD, Howard AD. Identifying the Motilin Receptor: Science, Serendipity, or Simply Business? Reply, 117:1504–ss
Autenrieth IB. *See* Waidmann M
Autschbach F. *See* Heuschen UA
Auwerx J
See Desreumaux P
See Dubuquoy L
Avdic A. *See* Sandler RS
Avidan B, Sonnenberg A, Schnell TG, Sontag SJ
Coughing, Wheezing, and Acid, 123: 1398–ss
Gastric Surgery Is Not Risk for Barrett's Esophagus or Esophageal Adenocarcinoma, 121:1281
Avila MA
See García-Trevijano ER
See Martínez-Chantar ML
Avital I
See Adani GL
Axon ATR. *See* Moayyedi P
Ayela P. *See* Bastid C
Ayres A
See Angus P
See Bonacini M
Azar N. *See* Condat B
Aziz Q
See Sarkar S
See Turnbull GK
Aziz S. *See* Marth T
Azpiroz F
See Caldarella MP
See Distrutti E
See Fernández-Fraga X
See Serra J
Azpiroz F, Malagelada J-R, Distrutti E. Development of a Tensotat for Gastric Perception Studies. Reply, 118:642–c
Azuma M
See Nakazawa A
See Totsuka T
Azzaroli F
See Lee J
See Mehal WZ
Azzoni C
See Peghini PL
See Rindi G
Azzurri A. *See* D'Elios MM

Baak J. *See* Hermsen M
Baak JPA. *See* Hausen AZ
Baatar D. *See* Jones MK
Baatar D, Kawanaka H, Szabo IL, Pai R, Jones MK, Kitano S, Tarnawski AS. Esophageal Ulceration Activates Keratinocyte Growth Factor and Its Receptor in Rats: Implications for Ulcer Healing, 122:458
Baba E. *See* Kamihira T
Babcock GF. *See* Heinen CD
Babic DZ. *See* Poljak M
Baccarani U. *See* Adani GL
Bacchetti P. *See* Yao FY
Bach SP, Chinery R, O'Dwyer ST, Potten CS, Coffey RJ, Watson AJM. Pyrrolidinedithiocarbamate Increases the Therapeutic Index of 5-Fluorouracil in a Mouse Model, 118: 81
Bachman R. *See* Terdiman JP
Bachmann D. *See* Michetti P
Bachmann O. *See* Rossmann H
Bachwich DR. *See* Muir AJ
Backman V. *See* Wallace MB
Backmund M. *See* Gerlach JT
Backmund M, Schomerus P. Acute Pancreatitis and Pericardial Effusion in Behçet's Disease, 117:286–c
Bacon BR
See Britton RS
See Parkkila S
Bacon BR. Hemochromatosis: Diagnosis and Managment, 120:718
Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular Medicine and Hemochromatosis: At the Crossroads, 116:193
Bacq Y, Jacquemin E, Balabaud C, Jeannot E, Scotto B, Branchereau S, Laurent C, Bourlier P, Pariente D, De Muret A, Fabre M, Bioulac-Sage P, Zucman-Rossi J. Familial Liver Adenomatosis Associated with Hepatocyte Nuclear Factor 1α Inactivation, 125:1470–cr
Badia IB. *See* Jonas MM
Badizadegan K
See Teitelbaum JE
See Wallace MB
Bado A
See Goïot H
See Sobhani I
Badur S. *See* Besisik F
Bae H-I. *See* Kim GE
Baek SJ. *See* Kim K-S
Baerg RD. *See* Sandborn WJ
Baert F
See D'Haens G
See Vermeire S
Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, 125:1544–ss
Baert F, Schmit A, D'Haens G, Dedeurwaerdere F, Louis E, Cabooter M, de Vos M, Fontaine F, Naegels S, Schurmans P, Stals H, Geboes K, Rutgeerts P. Budesonide in Collagenous Colitis: A Double-Blind Placebo-Controlled Trial With Histologic Follow-Up, 122:20
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor Necrosis Factor α Antibody (Infliximab) Therapy Profoundly Down-regulates the Inflammation in Crohn's Ileocolitis, 116:22
Baeten CG. *See* Madoff RD
Baffy G, Strate LL, Krinsky ML. Image of the Month, 118:252
Baggio LL. *See* Boushey RP
Baglin A-C. *See* Izzedine H
Bagni A. *See* Ballestri M
Bagnol D
See Takahashi T
See Yazdani A
Bagnoli S. *See* Palli D
Bahr MJ, Rosenau J, Manns MP. Discussion on the Association Between Hepatitis C Infection and Survival After Orthotopic Liver Transplantation, 123:2160–co
Bahram S. *See* Dupic F
Bailey ST. *See* Su CG
Bailey-Wilson JE. *See* Brant SR
Baillie J. *See* Byrne MF
Baillie J, Paulson EK, Vitellas KM. Biliary Imaging: A Review, 124:1686
Bain C, Fatmi A, Zoulim F, Zarski J-P, Trépo C, Inchauspé G. Impaired Allostimulatory Function of Dendritic Cells in Chronic Hepatitis C Infection, 120:512
Bain V. *See* Poynard T
Bain VG. *See* Dahlan Y
Baiocchi L
See Alpini G
See Alvaro D
See LeSage G
Baird A. Human M Cells Delivered in a Box. Reply, 121:1521–ss
Baird AW. *See* Gulberg E
Baixeras E. *See* Bustos M
Bajaj-Elliott M. *See* Pollok RCG
Baker BS. *See* Porter WM
Bala S. *See* Raevaara TE

Balaban DH, Yamamoto Y, Liu J, Pehlivanov N, Wisniewski R, DeSilvey D, Mittal RK. Sustained Esophageal Contraction: A Marker of Esophageal Chest Pain Identified by Intraluminal Ultrasonography, 116:29
Balabaud C. *See* Bacq Y
Balakumaran A. *See* Atchison CR
Balanzó J
See García-Pagán JC
See Guarner C
See Villanueva C
Balart L. *See* Jeffers L
Balatsinou C. *See* Caldarella MP
Balazs L. *See* Deng W
Balcom JH IV. *See* Keck T
Baldari CT. *See* D'Elios MM
Baldessari AE. *See* Parisi MA
Baldo M. *See* Ördög T
Balestrieri A. *See* Farci P
Balian A
See Hammel PR
See Veyradier A
Balish E. *See* Veltkamp C
Balistreri WF. *See* Bezerra JA
Baljeet S. *See* Shirvani VN
Balk SP. *See* Saubermann LJ
Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk Virus-like Particles Given Orally to Volunteers: Phase I Study, 117:40
Ballardini G. *See* Spirli C
Baller J. *See* van Waarde WM
Ballestri M, Baraldi A, Gatti AM, Furci L, Bagni A, Loria P, Rapaná RM, Carulli N, Albertazzi A. Liver and Kidney Foreign Bodies Granulomatosis in a Patient With Malocclusion, Bruxism, and Worn Dental Prostheses, 121: 1234–cr
Ballinger A, Tarek E-H, Perrett D, Turvill J, Obeid O, Dryden S, Williams G, Farthing, MJG. The Role of Medial Hypothalamic Serotonin in the Suppression of Feeding in a Rat Model of Colitis, 118:544
Ballmann M. *See* Bronsveld I
Balzano A. *See* Amitrano L
Bamba T. *See* Andoh A
Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr., Yawn BP, Dickson ER, Melton LJ III. Incidence, Clinical Spectrum, and Outcomes of Primary Sclerosing Cholangitis in a United States Community, 125:1364
Bamford P. *See* el Asmar R
Bamias G. *See* Rivera-Nieves J
Bañares R
See Escorsell À
See González-Aaldes J
Bancroft JD. *See* Kurbegov AC
Bandara P. *See* Hui JM
Bandi JC
See Escorsell À
See Guevara M
Bandi J-C. *See* Moitinho E
Bandyopadhyay K. *See* De BK
Banerjee S. *See* Spencer DM
Banerjee S, LaMont JT. Treatment of Strongyloides Infections. Reply, 119: 1805–c
Bangdiwala SI. *See* Drossman DA
Bangdiwala SI. *Using and Understanding Medical Statistics*. 122:835–pmr
Bank S. *See* Sands BE
Bansi DS. *See* Mitchell SA
Bantel H, Domschke W, Schultze-Osthoff K. Molecular Mechanisms of Glucocorticoid Resistance, 119: 1178–c
Banwait K. *See* DiMarino M
Bao W. *See* Hanauer SB
Bao ZQ. *See* Collier-Hyams LS
Baragiotta A. *See* Goldblatt J
Baraldi A. *See* Ballestri M
Barange K. *See* Bureau C
Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G. Hyperleptinemia Prevents Increased Plasma Ghrelin Concentration During Short-Term Moderate Caloric Restriction in Rats, 124:1188–rc
Barbara G
See Berčík P
See De Giorgio R
See Van Assche G
Barbara G, De Giorgio R, Stanghellini V, Gionchetti P, Campieri M, Corinaldesi R. Relapsing Ulcerative Colitis After Spinal Cord Stimulation: A Case of Intestinal Neurogenic Inflammation?, 117:1255–c
Barbaro B
See Alpini G
See Alvaro D
Barbato M, Viola F, Lo Russo L, Lucarelli S, Frediani T, Cardi E. Microscopic and Collagenous Colitis in Treated Celiac Disease Due to Food Allergy?, 116:778–c
Barbazza R. *See* Isaacson PG
Barbe U
See Mention J-J
See Verkarre V
Barber J. *See* Lai C-L
Barbier O. *See* Claudel T
Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart J-C, Staels B. FXR Induces the UGT2B4 Enzyme in Hepatocytes: A Potential Mechanism of Negative Feedback Control of FXR Activity, 124:1926
Barcherini S. *See* Citarda F
Bardag-Gorce F, French BA, Li J, Riley NE, Yuan QX, Valinluck V, Fu P, Ingelman-Sundberg M, Yoon S, French SW. The Importance of Cycling of Blood Alcohol Levels in the Pathogenesis of Experimental Alcoholic Liver Disease in Rats, 123: 325
Bardella E. *See* Trevisani M
Bardet P. *See* Malka D
Bardhan KD
See Lind T
See Moayyedi P
Bardhan P. *See* Hildeand P
Bardoel AFJ. *See* Van Belzen MJ
Bardonnet K. *See* Godot V
Bardou M. *See* Rahme E
Barel C. *See* Marion-Audibert A-M
Barendse GAM. *See* Kemler MA
Barfoot R. *See* Tomlinson I
Barish MA. *See* Johnson CD
Baritaki S. *See* Roussomoustakaki M
Barkholt L. *See* Féray C
Barkin JS. *See* Madanick RD
Barkun A. *See* Mulcahy HE
Barkun AN. *See* Rahme E
Barletta G. *See* La Villa G
Barmada MM
See Pfützer R
See Pfützer RH
See Schneider A
Bar-Meir S
See Chowers MY
See Chowers Y
Barmeyer C. *See* Schmitz H
Barnard JA. *See* Sizemore N
Barnardo M. *See* Ahmad T
Barnes R. *See* Berge KE
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU, Sandler RS, Halabi S, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. Aspirin and the Prevention of Colorectal Neoplasia, 125:1539–ss
Baroni G. *See* Cianchi F
Baroni GS. *See* di Sario A
Barraud L. *See* Rollier C
Barrett KE
See Chow JYC

See Resta-Lenert S
Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, O'Keane JC, Crowe J. Whomsoever Ignores the Natural History of the Hepatitis C Virus is Doomed to Treat It, 122:578–ss
Barrett TA
See Guehler SR
See Lee H-O
Barriere E. *See* Tazi KA
Barrow RK. *See* Watkins CC
Barry M. *See* Green PHR
Barshack I
See Chowers MY
See Chowers Y
Bartelsman J. *See* Hommes D
Bartenschlager R. *See* Wedemeyer H
Barth P. *See* Waldegger S
Bartholomeusz A. *See* Angus P
Bartoli R
See Pérez-Páramo M
See Zoli G
Bartram CI. *See* Vaizey CJ
Bartram H-P. *See* Miehlke S
Barut A
See Obermayer-Straub P
See Vogel A
Basa NR. *See* Luckey A
Basak G. *See* Kamiński R
Bashey R. *See* Zhu J
Basilisco G. *See* Massironi S
Basque JR. *See* Tremblay E
Bass BL. *See* Li L
Bass D. *Gastroenteritis Viruses*, 123:651–pmr
Bass NM. *See* Yao FY
Bassendine MF
See Goldblatt J
See Smith BC
Bassett M, Ashton C, Gavaghan T, Hillman L, Kaye G, Clarke A. Propofol for Endoscopy Sedation, 124: 1162–c
Bassi A, Hyde J, Foster P. Image of the Month, 124:287–im
Bassi C. *See* Talamini G
Basten A. *See* Wong RCW
Bastid C, Ayela P, Sahel J. Percutaneous Ethanol Injection Therapy of Large Hepatic Tumors: A Stereotaxic Echo-Guided Approach, 116:504–c
Bästlein E. *See* Miehlke S
Bataller R
See Ortega R
See Titos E
Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, Colmenero J, Nicolás JM, Jiménez W, Weich N, Gutiérrez-Ramos J-C, Arroyo V, Rodés J. Activated Human Hepatic Stellate Cells Express the Renin-Angiotensin System and Synthesize Angiotensin II, 125:117
Bates MD. *See* Cohran VC
Bates MD, Erwin CR, Sanford LP, Wiginton D, Bezerra JA, Schatzman LC, Jegga AG, Ley-Ebert C, Williams SS, Steinbrecher KA, Warner BW, Cohen MB, Aronow BJ. Novel Genes and Functional Relationships in the Adult Mouse Gastrointestinal Tract Identified by Microarray Analysis, 122:1467
Bath R. *See* Laine L
Bathgate A, MacGilchrist A, Piris J, Garden J. Multiple Focal Nodular Hyperplasia in Klippel-Trénaunay Syndrome, 117:284–c
Bathgate T. *See* Thomas LA
Batignani G
See Bonacchi A
See Failli P
See Marra F
Batkai S. *See* Sun Z
Batra AK. *See* Bonkovsky HL
Batta AK
See Alberts DS
See Morton DH
Battaglia G. *See* Primignani M
Batteiger B. *See* Nowak TV
Batteux F. *See* Malassagne B
Battezzati PM. *See* Longo M
Battezzati PM, Longo M, Crosignani A, Podda M. Hypercholesterolemia in Primary Biliary Cirrhosis: Getting to the Heart of the Matter. Reply, 124: 856–ss
Battle E. *See* Rivera-Nieves J
Batts KP. *See* Kim WR
Bauer AJ
See Kalff JC
See Moore BA
See Schwarz NT
See Türler A
Bauer CA. *See* van den Brande JMH
Bauer M. *See* Straumann A
Bauer P. *See* Lochs H
Bauer WM, Fackler W, Kongara K, Matteoni C, Shen B, Vaezi M. It's Time to Bring the Best and Brightest Back to Gatroenterology, 116:1014–c
Bauerfeind P. *See* Hildeand P
Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS. Matrix Metalloproteinase Levels Are Elevated in Inflammatory Bowel Disease, 117: 814
Baulieux J. *See* Samuel D
Baumann E. *See* Stern HS
Baumann R. *See* Chamouard P
Baumelou A. *See* Izzedine H
Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, Greenberg HB, Ito S, Liang TJ. Hepatitis C Virus-like Particles Synthesized in Insect Cells as a Potential Vaccine Candidate, 117: 1397
Baumgart DC. *See* Telega GW
Bayerdörffer E
See Lind T
See Miehlke S
Bayguinov JR. *See* Ward SM
Bayguinov O. *See* Porcher C
Bayless TM
See Brant SR
See Hugot J-P
Bayley J-P, Verweij CL. Differential HFE Allele Expression in Hemochromatosis Heterozygotes, 123:652–c
Bazzocchi G. *See* Gionchetti P
Bazzoli F. *See* Palli D
Beach M. *See* Baron JA
Beard MR
See Lerat H
See Okuda M
Beau P. *See* Messing B
Beauchamp RD. *See* Fujimoto K
Beaufils H. *See* Izzedine H
Beaugerie L. *See* Cosnes J
Beaulieu J-F
See Deschênes C
See Vachon PH
Beavers K. *The Transplant Patient: Biological, Psychiatric, and Ethical Issues in Organ Transplantation*, 124:580–pmr
Beavers K, Theodore D. *Gastroenterology Teaching Project 006: Viral Hepatitis*, 125:991–pmr
Bechi P. *See* Cianchi F
Bechtold O. *See* Waidmann M
Beck GJ. *See* Baron JA
Beck IT. Possible Mechanisms for Ischemic Colitis During Alosetron Therapy, 121:231–c
Beck P. *See* Saubermann LJ
Beck PL, Xavier R, Lu N, Nanda NN, Dinauer M, Podolsky DK, Seed B. Mechanisms of NSAID-Induced Gastrointestinal Injury Defined Using Mutant Mice, 119:699
Becker EM. *See* Frazer DM
Becker JM. *See* Huang CS
Becker M
See Bhatia E
See Witt H
Beckers A. *See* Cadiot G
Bedda S. *See* Malassagne B
Bedossa P. *See* Paradis V
Beejay U. *See* Stone CD
Beejay U, Wolfe MM. Cyclooxygenase 2

Selective Inhibitors: Panacea or Flash in the Pan?, 117:1002–e
Befeler AS, Di Bisceglie AM. Hepatocellular Carcinoma: Diagnosis and Treatment, 122:1609
Befrits R. *See* Rubio CA
Beger HG. *See* Kornmann M
Beglinger C
See Degen LP
See Hildeand P
See Schneider A
See Straumann A
Bègue B. *See* Mention J-J
Behar J
See Amaral J
See Cao W
See Chen Q
See Xiao Z-L
Behrmann C. *See* Kleber G
Behrns KE. *Surgery of the Liver and Biliary Tract*. 121:1524–pmr
Beigelman C. *See* Hammel PR
Beil M. *See* Wagner M
Bekkering FC. *See* Eland IA
Bélaïche J
See Eland IA
See Hugot J-P
See Laharie D
See Vermeire S
Belchis D. *See* Morton DH
Belghiti J
See Colle IO
See Condat B
See Malka D
See Paradis V
Bell JI. *See* Satsangi J
Bell JK. *See* Levine DS
Bell MS. *See* Jonas MM
Bellaiche M. *See* Cézard JP
Belley A, Chadee K. Prostaglandin E_2 Stimulates Rat and Human Colonic Mucin Exocytosis Via the EP_4 Receptor, 117:1352
Bellobuono A. *See* Schalm SW
Bellocco R
See Ekström AM
See Serafini M
Beltrame A. *See* Sander G
Belyea B. *See* Kozaiwa K
Belzer I. *See* Hove TT
Ben Ahmed M. *See* Mention J-J
Benages A. *See* Minguez M
Benagiano M. *See* D'Elios MM
Benahmed M, Mention J-J, Matysiak-Budnik T, Cerf-Bensussan N. Celiac Disease: A Future Without Gluten-Free Diet??, 125:1264–e
Benali S. *See* Bourlière M
Benamouzig R. *See* Gaudichon C
Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S. Daily Soluble Aspirin and Prevention of Colorectal Adenoma Recurrence: One-Year Results of the APACC Trial, 125:328
Benathan M. *See* Frossard J-L
Benckhuijsen W. *See* Vader W
Bendayan M. *See* Bruneau N
Bendele A. *See* Jeffers M
Bendia E
See Benedetti A
See di Sario A
Benedetti A
See Alvaro D
See di Sario A
See LeSage G
Benedetti A, Di Sario A, Casini A, Ridolfi F, Bendia E, Pigini P, Tonnini C, D'Ambrosio L, Feliciangeli G, Macarri G, Svegliati-Baroni G. Inhibition of the Na^+/H^+ Exchanger Reduces Rat Hepatic Stellate Cell Activity and Liver Fibrosis: An In Vitro and In Vivo Study, 120:545
Beneduce A. *See* Gianotti L
Bengtsson C. *See* Tindberg Y
Benhamou JP. *See* Condat B
Benhamou Y. *See* Poynard T
Benhattar J. *See* Bian Y-S
Benjaminov F, Wong F, Blendis L, Halpern Z. Treatment of Hepatoportal Venous Thrombosis: The Role of Anticoagulation. Comment, 120:578–ss
Benkov K. *See* Beyer K
Benner K. *See* Sanyal AJ
Bennett BL. *See* Hatano E
Bennett CF. *See* Musso A
Bennett HPJ. *See* Mathews CJ
Bennett R. *See* Hamilton J
Benninga MA. *See* van Ginkel R
Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute Hepatitis Induced by Greater Celandine *(Chelidonium majus)*. 117:1234–cr
Bennink R. *See* Kuiken S
Bennink RJ. *See* de Jonge WJ
Benos DJ. *See* Fuller CM
Bensaid M. *See* Dupic F
Benson GD. *See* Bruggraber SFA
Benson JT. *See* Bambha K
Bentley RC
See Kohli V
See Sindram D
Bentzel CJ. *See* Schmitz H
Benz C, Utermöhlen O, Wulf A, Villmow B, Dries V, Goeser T, Koszinowski U, Busch DH. Activated Virus-Specific T Cells Are Indicators of Anti-CMV Immune Reactions in Liver Transplant Patients, 122:1201
Beran RL. National Resident Matching Program, 117:509–c
Beraza N. *See* Bustos M
Berčík P
See Der T
See Huizinga JD
Berčík P, Bouley L, Dutoit P, Blum AL, Kučera P. Quantitative Analysis of Intestinal Motor Patterns: Spatiotemporal Organization of Nonneural Pacemaker Sites in the Rat Ileum, 119:386
Berčík P, de Giorgio R, Blennerhassett P, Verdú EF, Barbara G, Collins SM. Immune-Mediated Neural Dysfunction in a Murine Model of Chronic *Helicobacter pylori* Infection, 123:1205
Berčík P, Kučera P. Organization of Intestinal Pacemakers. Reply, 120:320–c
Berenguer M. *See* Prieto M
Bérézíat G. *See* Rosmorduc O
Berezin I
See Der T
See Huizinga JD
Berg CL, Williams JM. Image of the Month, 117:6
Berg DE. *See* Dubois A
Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earler KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid Development of Colitis in NSAID-Treated IL-10-Deficient Mice, 123:1527
Berg PA. *See* Klein R
Berg T. *See* van Bömmel F
Bergamaschi G, Rolandi V, Cazzola M. Differential HFE Allele Expression in Hemochromatosis Heterozygotes, 120:1309–c
Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. Diet and Disease: The "Phyte" Over Intestinal Cholesterol, 121:1255–ss
Berger A. *See* Torrisani J
Berger DL. *Prognosis and Outcomes in Surgical Disease*. 119:273–pmr
Berger HG, Gansauge F, Mayer JM. Experimental Colitis and Reduction of Food Intake: What Are the Mechanisms, 118:625–e
Berger V. *See* Boushey RP
Berghe PV. *See* Tack J
Bergman A. *See* Björk J
Bergoffen J. *See* Terdiman JP
Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, Hultcranz R, Lindgren S, Prytz H, Sandberg-Gertzen H, Almer S,

Granath F, Broome U. Primary Sclerosing Cholangitis: A Premalignant Condition, 123:647–ss
Berin MC. *See* Yu LCH
Berisha F. *See* Evans SM
Berlin JA. *See* Forman LM
Berman JM, Cheung RJ, Weinberg DS. Surveying the Masses. Reply, 119: 1403–ss
Berman MP. *See* D'Elios MM
Berman S. *See* Naliboff BD
Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD, Mayer EA. Condition-Specific Deactivation of Brain Regions by 5-HT$_3$ Receptor Antagonist Alosetron, 123:969
Bernades P
See Hammel PR
See Malka D
Bernard B
See Lunel F
See Moreau R
Bernard O
See Crosnier C
See Viola S
Bernard P-H. *See* Féray C
Bernardo F. *See* Gustavo C
Bernatsky S. Discussion on Inflammatory Bowel Disease Is Not Associated With an Increased Risk of Lymphoma, 123: 653–c
Berndtsson I. *See* Ørding Olsen K
Berneau J. *See* Colle IO
Bernhard G. *See* Eckardt VF
Bernstein CN. *See* Leslie WD
ALMs Versus DALMs in Ulcerative Colitis: Polypectomy or Colectomy?, 117:1488–e
The Color of Dysplasia in Ulcerative Colitis, 124:1135–e
Bernstein CN, Blanchard JF. The Epidemiology of Crohn's Disease, 116: 1503–c
Berr F
See Huster D
See Ortner MEJ
Berrebi D. *See* Desreumaux P
Berriot-Varoqueaux N, Dannoura AH, Moreau A, Verthier N, Sassolas A, Cadiot G, Lachaux A, Munck A, Schmitz J, Aggerbeck LP, Samson-Bouma M-E. Apolipoprotein B48 Glycosylation in Abetalipoproteinemia and Anderson's Disease, 121:1101–
Berry K. *See* Ramsey SD
Berson A. *See* Mansouri A
Berstad AE, Høgåsen K, Bukholm G, Moran AP, Brandtzaeg P. Complement Activation Directly Induced by *Helicobacter pylori*, 120: 1108
Bertario L, Sala P, Radice P, Russo A. Ileorectal Anastomosis in Patients With Familial Adenomatous Polyposis, 121:502–c
Berti I. *See* el Asmar R
Bertilsson L. *See* Sagar M
Bertoletti A. *See* Maini MK
Bertolino P. *See* Bowen DG
Besisik F, Karaca C, Akyuz F, Horosanh O, Onel D, Badur S, Sever MS, Danahoglu A, Demir K, Kaymakoglu S, Cakaloglu Y, Okten A. Occult HBV Infection-Both Hidden and Mysterious, 125:1903–ss
Besone F. *See* Vorobioff JD
Bessa X, Elizalde JI, Boix L, Piñol V, Lacy AM, Saló J, Piqué JM, Castells A. Lack of Prognostic Influence of Circulating Tumor Cells in Peripheral Blood of Patients With Colorectal Cancer, 120:1084
Bessa X, Elizalde JI, Mitjans F, Piñol V, Miquel R, Panés J, Piulats J, Piqué JM, Castells A. Leukocyte Recruitment in Colon Cancer: Role of Cell Adhesion Molecules, Nitric Oxide, and Transforming Growth Factor β1, 122:1121
Besselsen DG. *See* Boivin GP
Besser GM. *See* Veysey MJ
Bethke B. *See* Miehlke S
Bethwaite P. *See* Chadwick VS
Bettaieb A. *See* Millet A
Betz UAK. *See* Streetz KL
Beutivoglio AR. *See* Maria G
Beutler B. *See* Brown GR
Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. In Search of Vulcan: Where Are All the Iron Men (and Women)? Reply, 123:950–ss
Bevins CL. *See* Shen B
Beyak MJ, Xue S, Collman PI, Valdez DT, Diamant NE. Central Nervous System Nitric Oxide Induces Oropharyngeal Swallowing and Esophageal Peristalsis in the Cat, 119:377
Beyer K, Castro R, Birnhaum A, Benkov K, Pittman N, Sampson HA. Insights Into Milk Protein Allergy: Microenvironment Matters, 124:259–ss
Beyer K, Sampson HA. Insights Into Milk Protein Allergy: Microenvironment Matters. Reply, 124:261–ss
Bezerra J. *See* Rudolph JA
Bezerra JA. *See* Bates MD
Bezerra JA, Balistreri WF. Intrahepatic Cholestasis: Order out of Chaos, 117: 1496–e
Bhagat L
See Frossard J-L
See Hofbauer B
See Lee HS
See Saluja AK
Bhagat L, Singh VP, Song AM, van Acker GJD, Agrawal S, Steer ML, Saluja AK. Thermal Stress-Induced HSP70 Mediates Protection Against Intrapancreatic Trypsinogen Activation and Acute Pancreatitis in Rats, 122: 156
Bhagat M. *See* Hofbauer B
Bhan AK
See de Jong YP
See Mizoguchi A
See Mizoguchi E
Bhargava KK. *See* Joseph B
Bharucha AE
Fecal Incontinence, 124:1672
Gastrointestinal Motility, 120:1056–pmr
Innervation of the Gastrointestinal Tract, 125:1907–pmr
Bhathal PS
See Dixon JB
See Hardwick JCH
Bhatia AM. *See* Kobayashi H
Bhatia E, Choudhuri G, Sikora SS, Landt O, Kage A, Becker M, Witt H. Tropical Calcific Pancreatitis: Strong Association With *SPINK1* Trypsin Inhibitor Mutations, 123:1020
Bhatia M
See Frossard J-L
See Hofbauer B
Bhattacharya R, Kowdley KV. Iron and *HFE* Mutations in Nonalcoholic Steatohepatitis: Innocent Bystanders or Accessories to the Crime? Comment, 125:616–ss
Bhattacharya SD. *See* Lin JL-C
Bhattacharyya AK
See Maltzman T
See Martínez ME
Bhendwal S. *See* Agarwal B
Bi Y. *See* Ji B
Biagi F, Parnell NDJ, Thomas PD, Ellis HJ, Ciclitira PJ. A New Model for the Pathogenesis of Celiac Disease, 116: 1277–c
Bian Y-S, Osterheld M-C, Fontolliet C, Bosman FT, Benhattar J. p16 Inactivation by Methylation of the CDKN2A Promoter Occurs Early During Neoplastic Progression in Barrett's Esophagus, 122:1112
Biancani P
See Amaral J
See Cao W
See Chen Q
See Xiao Z-L

Bianchi G. *See* Marchesini G
Bianchi L. *See* Kamal SM
Bianchi P. *See* Laghi L
Bianchi Porro G. *See* Prantera C
Bianco F. *See* Boillot O
Bianco MA. *See* Cipolletta L
Biancone L, del Vecchio Blanco G, Pallone F, Castiglione F, Bresci G, Sturniolo G. Immunomodulatory Drugs in Crohn's Disease Patients With Hepatitis B or C Virus Infection, 122:593–c
Biancone L, Tosti C, De Nigris F, Fantini M, Pallone F. Selective Cyclooxygenase-2 Inhibitors and Relapse of Inflammatory Bowel Disease, 125:637–c
Biankin AV, Kench JG, Henshall SM, Sutherland RL. The Premalignant Lesions for Pancreatic Cancer; Will Pan-IN's Pan Out? Reply, 123:647–ss
Biankin AV, Kench JG, Morey AL, Lee CS, Biankin SA, Head DR, Hugh TB, Henshall SM, Sutherland RL. The Premalignant Lesions for Pancreatic Cancer; Will Pan-IN's Pan Out?, 123: 645–ss
Biankin SA. *See* Biankin AV
Bickmore WA. *See* Newsome PN
Bickston SJ
See Lawrence C
See Rivera-Nieves J
Bickston SJ, Cominelli F. Recombinant Interleukin 10 for the Treatment of Active Crohn's Disease: Lessons in Biologic Therapy, 119:1781–e
Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The Relationship Between Infliximab Treatment and Lymphoma in Crohn's Disease, 117:1433–cr
Bièche I. *See* Paradis V
Biecker E. *See* Schepke M
Bieger D. *See* Dong H
Bielefeldt K. *See* Lamb K
Bielefeldt K, Ozaki N, Gebhart GF
Experimental Ulcers Alter Voltage-Sensitive Sodium Currents in Rat Gastric Sensory Neurons, 122:394
Mild Gastritis Alters Voltage-Sensitive Sodium Currents in Gastric Sensory Neurons in Rats, 122:752
Bienvenu T. *See* Dray X
Bifulco M. *See* Ligresti A
Bijleveld CMA. *See* Jansen PLM
Bilder CR. *See* Goin JC
Bilker WB. *See* Lewis JD
Biller JA. *Pediatric Gastrointestinal Disease.* 121:739–pmr
Billiar TR
See Jaiswal M
See Kalff JC
See Schwarz NT
Bilzer M, Gerbes AL. Sensitivity of Cold-Preserved Rat Liver to Single-Pass Reperfusion. Reply, 118:450–c
Bilzer M, Paumgartner G, Gerbes AL. Glutathione Protects the Rat Liver Against Reperfusion Injury After Hypothermic Preservation, 117:200
Binder HJ
See Geibel JP
See Ramakrishna BS
Binder S. *See* De Winter H
Binder SW
See Hassard PV
See Papdakis KA
Binder V
See Hugot J-P
See Jess T
See Winther KV
Binion DG. *See* Hatoum OA
Biolo G. *See* Barazzoni R
Biondi ML. *See* Selmi C
Bioulac-Sage P. *See* Bacq Y
Birchard K. *Gastrointestinal Radiology: A Pattern Approach.* 124:1557–pmr
Birchmeier C. *See* Smits R
Birchmeier W. *See* Smits R
Bird N. *See* Gough M
Birkett A. *See* Chen M
Birnhaum A. *See* Beyer K
Bischoff SC. *See* Ockenga J
Bisgaard ML
See Bülow C
See Bülow S
Bishop LA. *See* Higham AD
Bishop WP. *Pediatric Gastroenterology and Nutrition in Clinical Practice.* 123:2155–pmr
Bismuth H
See Féray C
See Samuel D
Bisogno T
See Izzo AA
See Ligresti A
See Pinto L
Bissonette EA. *See* El-Rifai W
Biswas J. *See* De BK
Biswas PK. *See* De BK
Bitton A. *See* Steinhart AH
Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, deB Edwardes MD, Stevens AC. Clinical, Biological, and Histologic Parameters as Predictors of Relapse in Ulcerative Colitis, 120:13
Bitton A, Wild G, DeB Edwardes MD, Peppercorn MA, Stevens AC. The Predictive Parameters for Relapse in Ulcerative Colitis. Reply, 121:1262–c
Bizollon T
See Féray C
See Samuel D
Bjarnason I
See Sigthorsson G
See Thjodleifsson B
See Tibble JA
Bjarnason I, Helgason KO, Geirsson ÁJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson Ó, Thjodleifsson B. Subclinical Intestinal Inflammation and Sacroiliac Changes in Relatives of Patients With Ankylosing Spondylitis, 125:1598
Bjerknes M, Cheng H. Clonal Analysis of Mouse Intestinal Epithelial Progenitors, 116:7–rc
Bjerring P. *See* Pedersen J
Björk J
See Bülow C
See Bülow S
Björk J, Åkerbrant H, Iselius L, Bergman A, Engwall Y, Wahlström J, Martinsson T, Nordling M, Hultcrantz R. Periampullary Adenomas and Adenocarcinomas in Familial Adenomatous Polyposis: Cumulative Risks and *APC* Gene Mutations, 121:1127–
Björkhem I. *See* Vlahcevic ZR
Bjorkman D. *See* Schoenfeld P
Bjorkman DJ. *Acute Gastrointestinal Bleeding, Diagnosis, and Treatment.* 125: 1279–pmr
Blackburn GL. *See* Mun EC
Blackman CJ. *See* Drossman DA
Blackmore CG. *See* Higham AD
Blackshaw LA. *See* Lehmann A
Blackshaw S. *See* Watkins CC
Blackstone M. Pancreatitis From Bile Reflux-Again?, 124:863–c
Blackstone ME. Enterokinase in Cerulein Pancreatitis, 118:452–c
Blackstone MO
$CD4^+$ T Cells in Cerulein-Induced Pancreatitis, 119:881–c
ICAM-1 in Cerulein-Induced Pancreatitis, 117:748–c
IL-10 in Post ERCP Pancreatitis, 121: 233–c
Inner Hygiene: Constipation and the Pursuit of Health in Modern Society., 120:317–pmr
Pain in Alcoholic Chronic Pancreatitis, 117:1026–c
Serine Protease Inhibitors and F-Actin Redistribution, 122:591–c
Bladen CL. *See* Thwaites DT

Blam ME, Metz DC. Image of the Month, 119:292–im
Blanc P. *See* Moreau R
Blanchard TG, Czinn SJ. *Helicobacter pylori* Acquisition and Transmission: Where Does It All Begin?, 121:483–e
Blanco J-L. *See* Michetti P
Blank MA. *See* Lanza FL
Blanke CD. *See* Demetri GD
Blanquart C. *See* Barbier O
Blaser K. *See* Straumann A
Blaser MJ
See Cover TL
See Dubois A
See Peek RM Jr
See van Doorn L-J
Blatsos V. *See* Archimandritis A
Blei AT
See Córdoba J
See Vagquero J
Blendis L. *See* Benjaminov F
Blendis L. *Ascites and Renal Disorders in Liver Disease*, 117:1023–pmr
Blendis L, Bomzon A, Wong F. Herbal Remedies for the Liver: Myths, Proofs, and Treatments. Comment, 117:1250–ss
Blendis L, Brill S, Oren R. Hepatogenous Diabetes: Reduced Insulin Sensitivity and Increased Awareness. Comment, 119:1800–ss
Blendis L, Halpern Z, Oren R. The Prevention of Hepatocellular Carcinoma by Interferon: The Story Continues. Comment, 120:1302–ss
Blendis L, Konikoff FM. Therapy For HCV Nonresponders: Is Two Enough? Comment, 121:1017–ss
Blendis L, Lurie Y, Oren R
"A La Carte" Treatment of Portal Hypertension or Just "Hors d'Oeuvres." Comment, 124:1993–ss
Occult HBV Infection-Both Hidden and Mysterious. Comment, 125:1903–ss
Pathogenesis of Sodium Retention in Preascites: Have We Reached the Heart of the Problem? Comment, 124: 858–ss
Blendis L, Lurie Y. Primary Sclerosing Cholangitis: A Premalignant Condition. Comment, 123:647–ss
Blendis L, Oren R, Halpern Z. Interferon Treatment of HCV: Do We Need A Virological Response? Comment, 122: 237–ss
Blendis L. Telipressin and Albumin for HRS: An Advance in Therapy? Comment, 124:1553–ss
Blendis L, Wong F
Hepatoportal Thromboses Are No Longer Idiopathic. Comment, 119: 874–ss
Lamivudine For Hepatitis B: The End of the Beginning? Comment, 121:223–ss
A Marker for Predictions of HCC Recurrence Post-Resection? Comment, 123:2152–ss
More Therapy for Hepatorenal Syndrome. Comment, 116:1264–ss
Portopulmonary Hypertension: An Increasingly Important Complication of Cirrhosis. Comment, 125:623–ss
Prevention of Varices Rebleeding: Are Drugs Better After All? Comment, 122:832–ss
Sympathetic Hyperactivity in Pre-Ascites. Comment, 122:1539–ss
Transplantation for Hepatitis C: Good News and Bad News. Comment, 117: 502–ss
Blendis L, Wong F, Sherman M. Interferon Therapy Prevents Hepatocellular Carcinoma in Some Patients With Chronic HCV: The Role of Fibrosis. Comment, 118:447–ss
Blennerhassett P. *See* Berčík P
Blennerhassett PA. *See* Galeazzi F
Blennow M. *See* Tindberg Y
Blikslager AT. *See* Rhoads JM
Blindenbacher A, Duong F, Hunziker L, Stutvoet STD, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M, Monica NL, Heim MH. Expression of Hepatitis C Virus Proteins Inhibits Interferon α Signaling in the Liver of Transgenic Mice, 124:1465
Blinn G. *See* Peters M
Bliss CM. *See* Schroy PC III
Bliss CM Jr. *See* Schroy PC III
Bliss PW. *See* Arebi N
Bloemena E. *See* Hausen AZ
Blok BM. *See* Schoon EJ
Bloks V
See Hooiveld GJEJ
See Meerman L
See van Waarde WM
Bloks VW. *See* Kok T
Bloom SR. *See* Murray CDR
Blot WJ. *See* El-Omar EM
Blough RI. *See* Lowy AM
Bluestone JA. *See* Guehler SR
Blüher S. *See* Mykoniatis A
Blum AL
See Berčík P
See Koelz HR
See Michetti P
Blum AL. *H. pylori* and Nonulcer Dyspepsia: Not Guilty As Charged. Reply, 117:1251–ss
Blum HE
See Blindenbacher A
See Geissler M
See Grimm CF
Blum S. *See* Castillo S
Blumberg RS
See Hershberg RM
See Katayama K
See Mizoguchi A
See Nakajima A
See Saubermann LJ
See van de Wal Y
Blumberg RS
David and Goliath: Discovery in the Industrial Age of Science, 119:5–ce
The Leadership of Innovation, 116:787–ce
Blumenthall A. *See* Stern HS
Bluteau O. *See* Laurent-Puig P
Boadas J. *See* Villanueva C
Bobbaers H. *See* Wilmer A
Bock CT. *See* Klein C
Bock C-T, Buerke B, Tillmann HL, Tacke F, Kliem V, Manns MP, Trautwein C. Relevance of Hepatitis B Core Gene Deletions in Patients After Kidney Transplantation, 124:1809
Bock C-T, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of Hepatitis B Virus Polymerase Mutants With Enhanced Replication by Lamivudine Treatment After Liver Transplantation, 122:264
Boddi V. *See* Cianchi F
Bode G. *See* Brenner H
Bode JG
See Fischer R
See Müschen M
Bode U. *See* Weissenborn K
Bödeker H. *See* Malka D
Bodenheimer HC Jr. *See* Liu LU
Bodian C
See Francella A
See Friedman S
Bodin L. *See* Halfvarson J
Boeckxstaens G. *See* Kuiken S
Boeckxstaens GE
See de Jonge WJ
See van Ginkel R
Boeckxstaens GE. Drink Test in Functional Dyspepsia. Reply, 122:2094–c
Boeckxstaens GE, Hirsch DP, van den Elzen BDJ, Heisterkamp SH, Tytgat GNJ. Impaired Drinking Capacity in Patients With Functional Dyspepsia: Relationship With Proximal Stomach Function, 121:1054
Boeing H. *See* Brenner H
Boelle P-Y. *See* Rosmorduc O
Boerma D, Rauws EA, Keulemans YC, Janssen IM, Bolwerk CJ, Timmer R,

Boerma EJ, Obertop H, Huibregtse K, Gouma DJ. Cholecystectomy After Treatment of Choledocholithiasis: On Firmer Ground, 125:617–ss
Boerma EJ. *See* Boerma D
Bohan A. *See* Denson LA
Böhmig M. *See* Ding W-Q
Bohn E. *See* Waidmann M
Boileau AC. *See* Richmond BL
Boillot O, Bianco F, Viale J-P, Mion F, Mechet I, Gille D, Delaye J, Paliard P, Plauchu H. Liver Transplantation Resolves the Hyperdynamic Circulation in Hereditary Hemorrhagic Telangiectasia With Hepatic Involvement, 116:187–cr
Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W. Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis, 116:557
Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey RJ. Pathology of Mouse Models of Intestinal Cancer: Consensus Report and Recommendations, 124:762–srr
Boivin M. *See* Bouin M
Boix L. *See* Bessa X
Bojarski C. *See* Bürgel N
Bokemeyer M. *See* Weissenborn K
Böker KHW
See Ockenga J
See Wedemeyer H
Boku K, Ohno T, Saeki T, Hayashi H, Hayashi I, Katori M, Murata T, Narumiya S, Saigenji K, Majima M. Adaptive Cytoprotection Mediated by Prostaglandin I_2 Is Attributable to Sensitization of CGRP-Containing Sensory Nerves, 120:134
Boland CR
See Carethers JM
See Goel A
See Ricciardiello L
Boland CR, Laghi L, Ricciardiello L, Chauhan DP, Marra G, Chang DK, Randolph A, Chang CL. JC Virus and Human Colon Carcinoma: An Intriguing and Inconclusive Association. Comment, 124:269–c
Bolder U, Schmidt A, Landmann L, Kidder V, Tange S, Jauch K-W. Heat Stress Prevents Impairment of Bile Acid Transport in Endotoxemic Rats by a Posttranscriptional Mechanism, 122: 962
Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu H-T, Cerrè C, Oude Elferink RPJ, Hofmann AF. Sulindac Is Excreted Into Bile by a Canalicular Bile Salt Pump and Undergoes a Cholehepatic Circulation in Rats, 117:962
Bollinger RR. *See* Muir AJ
Bolognese J. *See* Laine L
Bolognini L. *See* di Sario A
Bolwerk CJ. *See* Boerma D
Bombardier C. *See* Laine L
Bomford AB. *See* Vautier G
Bomzon A. *See* Blendis L
Bonacchi A. *See* Marra F
Bonacchi A, Petrai I, DeFranco RMS, Lazzeri E, Annunziato F, Efsen E, Cosmi L, Romagnani P, Milani S, Failli P, Batignani G, Liotta F, Laffi G, Pinzani M, Gentilini P, Marra F. The Chemokine CCL21 Modulates Lymphocyte Recruitment and Fibrosis in Chronic Hepatitis C, 125:1060
Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant Hepatitis B Due to a Lamivudine-Resistant Mutant of HBV in a Patient Coinfected With HIV, 122:244–c
Bond GJ. *See* Türler A
Bond J. *See* Winawer S
Bond JH
See Baron JA
See Lieberman DA
See Mandel JS
Bonen DK. *See* Hugot J-P
Bonen DK, Cho JH. The Genetics of Inflammatory Bowel Disease, 124: 521–srr
Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nuñez G. Crohn's Disease-Associated NOD2 Variants Share a Signaling Defect in Response to Lipopolysaccharide and Peptidoglycan, 124:140
Boni C. *See* Maini MK
Bonifer C. *See* Scott DJ
Bonis PAL. *See* Cheng SJ
Bonis PAL, Kaplan M
Low-Dose Methotrexate in Primary Biliary Cirrhosis, 117:1511–c
Methotrexate Improves Biochemical Tests in Patients With Primary Biliary Cirrhosis Who Respond Incompletely to Ursodiol, 117:395
Bonis PAL. *Natural Ways to Digestive Health-Interfaces Between Conventional and Alternative Medicine.* 121:498–pmr
Bonkovsky HL, Batra AK. *Atlas of the Liver.* 120:1305–pmr
Bonnaud G. *See* Cadiot G
Bono F. *See* Conway EM
Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, Rommens JM. The Genetics of Shwachman Diamond Syndrome, 125: 1541–ss
Booker S. *See* Rashid A
Booker SV
See Cruz-Correa M
See Giardiello FM
Boone D. *See* Ren H
Boone DL. *See* Kojima K
Boonen A, Dagnelie PC, Feleus A, Hesselink M, Muris JW, Stockbrügger RW, Russel MG. IBD Indirect Costs: The Sleeping Giant?, 125:982–ss
Boot H. *See* Liu H
Bootello A. *See* León F
Booth CE, Kirkup AJ, Hicks GA, Humphrey PPA, Grundy D. Somatostatin sst_2 Receptor-Mediated Inhibition of Mesenteric Afferent Nerves of the Jejunum in the Anesthetized Rat, 121:358
Booth IW. *See* Müller T
Booth M, Dehn TCB. Effect of Esophageal Dysmotility on Surgical Outcomes, 122:1183–c
Booth M. Discussion on Simultaneous Intraesophageal Impedance and pH Measurement of Acid and Nonacid Gastrointestinal Reflux: Effect of Omeprazole, 122:1545–c
Boparai N. *See* Matteoni CA
Borda E. *See* Goin JC
Bordas JM. *See* Junquera F
Bordas N. *See* Poo J-L
Bordato J. *See* Vorobioff JD
Bordet T. *See* Bustos M
Bordi C
See Jensen RT
See Peghini PL
See Rindi G
See Solcia E
Bordi C, Fave GD, Jensen RT. Discussion on the Effects of Chronic Hypergastrinemia on Human Enterochromaffin-like Cells: Insights From Patients With Sporadic Gastrinomas. Reply, 125:627–c
Borén T. *See* Lindén S
Bornstein JD, Rockey DC. Hepatitis C: Beyond the Liver. Comment, 124: 1158–ss
Bornstein SR. *See* Franchimont D
Borot N. *See* Dupic F
Borrelli F. *See* Izzo AA
Borsukova H. *See* Drobnik W
Bortolotti M. Esophageal Mucosa Resistance: The "Cinderella" of GERD

Pathophysiological Research, 125:1558–c
Bortolotti M, Mari C, Lopilato C, Porrazzo G, Miglioli M. Effects of Sildenafil on Esophageal Motility of Patients With Idiopathic Achalasia, 118:253
Bos C. *See* Gaudichon C
Bos NA. *See* Jiang H-Q
Boscá L. *See* Callejas NA
Bosch J
See Escorsell À
See García-Pagán JC
See Ginés P
See González-Abraldes J
See Graupera M
See Guevara M
See Moitinho E
Bosch-Marcé M
See Poo J-L
See Titos E
Bosch-Marcé M, Clària J, Titos E, Masferrer JL, Altuna R, Poo J-L, Jiménez W, Arroyo V, Rivera F, Rodés J. Selective Inhibition of Cyclooxygenase 2 Spares Renal Function and Prostaglandin Synthesis in Cirrhotic Rats With Ascites, 116: 1167
Bosma PJ
See Buskens CJ
See de Vree JML
Bosman FT. *See* Bian Y-S
Bosserhoff AK. *See* Mühlbauer M
Bossuyt X
See Joossens S
See Vermeire S
Bot AGM. *See* Vaandrager AB
Botla R. *See* Akriviadis E
Botta F. *See* Giannini E
Botta-Fridlund D. *See* Féray C
Bouchard V. *See* Vachon PH
Boudet MJ. *See* Condat B
Boudreau F. *See* Rings EHHM
Bouhnik Y. *See* Attar A
Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal Distention Testing in Patients With Irritable Bowel Syndrome: Sensitivity, Specificity and Predictive Values of Pain Sensory Thresholds, 122:1771
Bouisson M
See Clerc P
See Torrisani J
Bouley L. *See* Berêik P
Bouma BE. *See* Poneros JM
Bouma BN. *See* Lisman T
Bouma G. *See* Franchimont D
Bouma G, Kaushiva A, Strober W. Experimental Murine Colitis Is Regulated by Two Genetic Loci, Including One on Chromosome 11 That Regulates IL-12 Responses, 123: 554
Bounds BC. *Endosonography in Gastroenterology*, 118:234–pmr
Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride Accelerates Gastrointestinal and Colonic Transit in Patients With Constipation Without a Rectal Evacuation Disorder, 120:354
Bourgeois IM. *See* Abell T
Bourlier P. *See* Bacq Y
Bourlière M, Halfon P, Quentin Y, David P, Mengotti C, Portal I, Khiri H, Benali S, Perrier H, Boustière C, Jullien M, Lambot G. Covert Transmission of Hepatitis C Virus During Bloody Fisticuffs, 119:507–cr
Bourreille A. *See* Segain J-P
Bouscarel B, Kroll SD, Fromm H. Signal Transduction and Hepatocellular Bile Acid Transport: Cross Talk Between Bile Acids and Second Messengers, 117:433–srr
Boushey RP. *See* Xiao Q
Boushey RP, Abadir A, Flamez D, Baggio LL, Li Y, Berger V, Marshall BA, Finegood D, Wang TC, Schuit F, Drucker DJ. Hypoglycemia, Defective Islet Glucagon Secretion, but Normal Islet Mass in Mice With a Disruption of the Gastrin Gene, 125:1164
Boussac M. *See* Niel G van
Boustière C. *See* Bourlière M
Bousvaros A. *See* Bitton A
Bourron-Ruault MC. *See* Messing B
Bouwens L. *See* Rooman I
Bouwer HGA. *See* Rosen HR
Bouzourene H. *See* Michetti M
Bovara M. *See* De Giorgio R
Bove KE. *See* Setchell KDR
Bovee-Oudenhoven IMJ, Lettink-Wissink MLG, Van Doesburg W, Witteman BJM, Van Der Meer R. Diarrhea Caused by Enterotoxigenic *Escherichia coli* Infection of Humans Is Inhibited by Dietary Calcium, 125:469
Bowden S. *See* Shaw T
Bowen DG, Warren A, Davis T, Hoffmann MW, McCaughan GW, Fazekas de St. Groth B, Bertolino P. Cytokine-Dependent Bystander Hepatitis Due to Intrahepatic Murine CD8$^+$ T-Cell Activation by Bone Marrow-Derived Cells, 123:1252
Bowes KL. *See* Mintchev MP
Bowlus CL, Lie BA. Discussion on the Role of Hemochromatosis Susceptibility Gene Mutation in Protecting Against Iron Deficiency in Celiac Disease, 124: 1562–c
Boyer JL
See Cho WK
See Denson LA
See Gigliozzi A
See Lee J
See Lee JM
Boyer JL. A Biliary Milestone: Functional Expression of the Human Bile Salt Export Pump, 123:1733–e
Boyer N. *See* di Martino V
Boyer TD. *See* Chalasani N
Boyer TD. Transjugular Intrahepatic Portosystemic Shunt: Current Status, 124:1700
Boyle S. *See* Newsome PN
Boynton KA. *See* Ahlquist DA
Bozymski EM. *See* Shaheen NJ
Bozzetti F, Braga M, Gianotti L, Gavazzi C, Mariani L
One If By Gut and Two If IV, 122:1536–ss
One If By Gut and Two If IV. Reply, 122:1538–ss
Bozzini C, Roetto A, Alberti F, Daraio F, Colombari R, Oliviero O, Corrocher R, Camaschella C. Clinical and Pathological Findings in Hemochromatosis Type 3 Due to a Novel Mutation in Transferrin Receptor 2 Gene. *See* Girelli D
Braakman T
See D'Haens G
See Rutgeerts P
Braat H. *See* van den Brande JMH
Brabant G
See Mix H
See Ockenga J
Brackmann HH. *See* Woitas RP
Bradford BU
See Enomoto N
See Froh M
See Yin M
Bradshaw B. *See* Drossman DA
Brady HR. *See* Goh J
Braga M
See Bozzetti F
See Gianotti L
Bragado MJ, Tashiro M, Williams JA. Regulation of the Initiation of Pancreatic Digestive Enzyme Protein Synthesis by Cholecystokinin in Rat Pancreas In Vivo, 119:1731
Bramble MG. Endoscopy for Upper Gastrointestinal Symptoms: Sooner Rather Than Later. Reply, 119:873–ss
Brancaccio V. *See* Amitrano L
Brancati FL. *See* Clark JM
Branch MA. *See* Eloubeidi MA
Branchereau S. *See* Bacq Y

Branchi A. *See* Valenti L
Brand RE. *See* Lynch HT
Brand S. *See* Poneros JM
Brand S, Sakaguchi T, Gu X, Colgan SP, Reinecker H-C. Fractalkine-Mediated Signals Regulate Cell-Survival and Immune-Modulatory Responses in Intestinal Epithelial Cells, 122:166
Brand SJ, Morise Z, Tagerud S, Mazzola L, Granger DN, Grisham MB. Role of the Proteasome in Indomethacin-Induced Gastropathy, 116:865
Brändén L. *See* Lehmann A
Brandt EB. *See* Straumann A
Brandt L. *See* Elmberg M
Brandt LJ. Thrombophilia and Colon Ischemia: *Aura Popularis?*, 121:724–e
Brandtzaeg P. *See* Berstad AE
Brandwein SL. *Case Studies in Gatroenterology*, 116:501–pmr
Bransfield K. *See* Hamlin PJ
Brant SR
See Bonen DK
See Hugot J-P
Brant SR, Panhuysen CIM, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, Ravenhill G, Kirshner BS, Hanauer SB, Cho JH, Bayless TM. Linkage Heterogeneity for the *IBD1* Locus in Crohn's Disease Pedigrees by Disease Onset and Severity, 119:1483
Bras-Gonçalves RA, Pocard M, Formento J-L, Poirson-Bichat F, Pinieux G de, Pandrea I, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Lesuffleur T, Dutrillaux B, Poupon M-F. Synergistic Efficacy of 3*n*-Butyrate and 5-Fluorouracil in Human Colorectal Cancer Xenografts via Modulation of DNA Synthesis, 120:874
Brasitus TA. *See* Kim KE
Brasitus TA
Letter from the President, 120:1279–aga
This Month in GASTROENTEROLOGY, 116:1–tmig, 116:233–tmig, 116:509–tmig, 116:783–tmig, 116:1023–tmig, 116:1281–tmig, 117:1, 117:291, 117:521, 117:755, 117:1037, 117:1265, 118:1, 118:247, 118:457–tmig, 120:1071
Braun J
See Landers CJ
See Sutton CL
Braun J, Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR. Optimal Cases and Sites to Search for Primary Microbial Agents in Crohn's Disease. Reply, 120:1066–c
Braun J. Unsettling Facts of Life: Bacterial Commensalism, Epitheal Adherence, and Inflammatory Bowel Disease, 122:228–e
Braun S. *See* Obermayer-Straub P
Bräutigam K. *See* Rosenstiel P
Braverman IM. Skin Signs of Gastrointestinal Disease, 124:1595
Brayden D. *See* Gulberg E
Brazer W. *See* Keates AC
Breaverman T. *See* Papdakis KA
Brechot C. *See* Hermine O
Breen PA. *See* Cummings DE
Breier G. *See* Marschall ZV
Breitkopf K. *See* Dooley S
Bremer C. *See* Marten K
Bremner-Danielsen M. *See* Lehmann A
Brenard R. *See* Hautekeete ML
Brenna E. *See* Waldum H
Brennan M-L. *See* Gukovskaya AS
Brennen M. *Johns Hopkins Manual for Gastrointestinal Endoscopy Nursing*, 124:579–pmr
Brenner D. *See* Streetz K
Brenner DA
See Enomoto N
See Hatano E
See Iimuro Y
See Rhoads JM
Comment From the Editor, 121:3–ce
Introduction, 124:1573
Jon Isenberg, 125:1571–gn
Moderate Alcohol Drinking: Effects on the Heart and Liver, 119:1399–e
Brenner DA, Zimmer D. Comment From the Editors, 123:5–ce
Brenner H. *See* Rothenbacher D
Brenner H, Bode G, Boeing H
Helicobacter pylori Infection Among Offspring of Patients With Stomach Cancer, 118:31
When Enthusiasm Is Infectious. Reply, 119:275–c
Brenner MB. *See* Bukowski JF
Brennetot C, Duval A, Hamelin R, Pinto M, Oliveira C, Seruca R, Schwartz S Jr. Frequent Ki-*ras* Mutations in Gastric Tumors of the MSI Phenotype, 125:1282–c
Brensinger C. *See* Lewis JD
Brensinger JD. *See* Giardiello FM
Brentnail TA. *See* Emond MJ
Brentnall TA
See Rulyak SJ
See Tung BY
Brentnall TA. Ursodiol: Good Drug Makes Good, 124:1139–e
Bresalier R. *See* Baron JA
Bresalier RS
See Carethers JM
See Dudas SP
See Sternberg LR
Bresalier RS
Aspirin and the Prevention of Colorectal Neoplasia, 125:1540–ss
Calcium, Chemoprevention, and Cancer: A Small Step Forward (A Long Way to Go). Comment, 116:1262
Chemoprevention Comes to Clinical Practice: COX-2 Inhibition in Familial Adenomatous Polyposis. Comment, 119:1797–ss
Chemoprevention of Intestinal Polyposis by COX-2 Inhibition: From Mouse to Man. Comment, 122:235–ss
Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer: Are We There Yet? Comment, 117:1502–ss, 118:231–ss
Intestinal Mucin and Colorectal Cancer: It's Not Just Goo. Comment, 123:649–ss
Prevention of Colorectal Cancer: Tumor Progression, Chemoprevention, and COX-2 Inhibition. Comment, 119:267–ss
Primary Chemoprevention of Familial Adenomatous Polyposis With Sulindac: More Questions Than Answers. Comment, 123:380–ss
Transforming Growth Factor β and Tumor-Suppressing Pathways: It Doesn't Matter How You Get There, As Long As You Get There. Comment, 117:500–ss
Bresalier RS, Ho SB. Molecular Staging of Colorectal Cancer: A Step Forward. Comment, 116:769–ss
Bresci G. *See* Biancone L
Bressau F. *See* Wagner M
Brett C. *See* Laine L
Breukel C. *See* Smits R
Brewsaugh T. *See* Setchell KDR
Brewster WR. *See* Theuer CP
Bridger S. *See* Tibble JA
Brieger A. *See* Trojan J
Brigelius-Flohé. *See* Wingler K
Briggs D. *See* Butterworth JR
Briggs W. *See* Akriviadis E
Brigidi P. *See* Gionchetti P
Brill S. *See* Blendis L
Brimnes J. *See* Allez M
Brind A, Fryer A, Hurlstone A, Fisher N, Pirmohamed M. The Role of Polymorphism in Manganese Superoxide Dismutase in Susceptibility to Alcoholic Liver Disease, 124:2000–c
Brink JA. *See* Johnson CD
Brink MA. *See* van den Brink GR
Brink MA, Slors JFM, Keulmans YCA, Mok KS, De Waart Dr, Carey MC, Groen AK, Tytgat GNJ. Enterohepatic Cycling of Bilirubin: A

Putative Mechanism for Pigment Gallstone Formation in Ileal Crohn's Disease, 116:1420
Brinkmann G. *See* Lankisch PG
Brinkmann U. *See* Schwab M
Brisinda G. *See* Maria G
Briskin M. *See* Salmi M
Brissot P
See Dupic F
See Mendler M-H
See Moirand R
Britton H. *See* Hugot J-P
Britton RS. *See* Parkkila S
Britton RS, Bacon BR. Hereditary Hemochromatosis and Alcohol: A Fibrogenic Cocktail, 122:563–e
Brizi MG. *See* Costamagna G
Broekaert D. *See* Fischler B
Bromfield A. *See* Lala S
Bronk SF. *See* Canbay A
Bronner MP. *See* Tung BY
Bronowicki JP. *See* Hermine O
Bronowicki J-P. *See* Moreau R
Bronson RT. *See* Girnun GD
Bronsveld I, Mekus F, Buman J, Ballmann M, Greipel J, Hundrieser J, Halley DJJ, Laabs U, Busche R, de Jonge HR, Tümmler B, Veeze HJ, European CF Twin and Sibling Study Consortium. Residual Chloride Secretion in Intestinal Tissue of DF508 Homozygous Twins and Siblings With Cystic Fibrosis, 119:32
Brookes SJH. *See* Lynn PA
Broome U. *See* Bergquist A
Brosgart C
See Angus P
See Westland C
Brotman M. Presidential Address, 125: 1878–aga
Brousse N
See Mention J-J
See Verkarre V
Brouwer JT
See Eland IA
See Schalm SW
Brown A. *Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine.* 123:650–pmr
Brown DR. *See* Pinto L
Brown EM. *See* Cheng I
Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D. Tumor Necrosis Factor Inhibitor Ameliorates Murine Intestinal Graft-Versus-Host Disease, 116:593
Brown L. *See* Moayyedi P
Brown NA. *See* Fontana RJ
Brown RS Jr
See Chu C-J
See Russo MW
See Shiva Kumar K
Brown RS Jr. MELD and the Practicing Gastroenterologist, 125:1009–gn
Brown V. *See* Maiuri L
Browning J. *See* Debard N
Bru C. *See* Escorsell À
Brubaker PL. *See* Xiao Q
Bruch H-P. *See* Wedel T
Bruckner-Tuderman L. *See* Zimmer K-P
Brugge W. *See* Thompson C
Bruggraber SFA, Leung PSC, Amano K, Quan C, Kurth MJ, Nantz MH, Benson GD, Van de Water J, Luketic V, Roche TE, Ansari AA, Coppel RL, Gershwin ME. Autoreactivity to Lipoate and a Conjugated Form of Lipoate in Primary Biliary Cirrhosis, 125:1705
Bruguera M. *See* Sánchez-Tapias JM
Bruijnzeel AW. *See* Stam R
Brule AJC van den. *See* Hausen AZ
Brummer R-JM. *See* Schoon EJ
Brünagel G. *See* Türler A
Bruneau N, Bendayan M, Gingras D, Ghitescu L, Levy E, Lombardo D. Circulating Bile Salt-Dependent Lipase Originates From the Pancreas Via Intestinal Transcytosis, 124:470
Brunello F. *See* Bugianesi E
Bruni N. *See* Rajas F
Bruno R, Sacchi P, Malfitano A, Filice G. YMDD-Mutant HBV Strain as a Cause of Liver Failure in an HIV-Infected Patient, 121:1027–c
Brunskill APJ. *See* Pfützer RH
Brunt EM. *See* Lyra AC
Brusse LS. *See* van Staa T-P
Bruzzese E. *See* Canani RB
Brzezinski A
See Parsi MA
See Shen B
Bucala R. *See* Huang XR
Buccigrossi V. *See* Canani RB
Buchan AMJ, Squires PE, Ring M, Meloche RM. Mechanism of Action of the Calcium-Sensing Receptor in Human Antral Gastrin Cells, 120: 1128
Bucher KA. *See* Straumann A
Buchholz M. *See* Michl P
Büchler C. *See* Drobnik W
Büchler MW
See Kleeff J
See Liao Q
See Mayerle J
See Reubi JC
See Saurer L
Buchman AL. *See* Sands BE
Buchman AL, Scolapio J, Fryer J. American Gastroenterological Association Technical Review on Short Bowel Syndrome and Intestinal Transplantation, 124:1111–aga
Buckingham RB. *See* Kobayashi H
Budinger S. *See* Baron JA
Buenger L. *See* Holtmann G
Bueno L
See Coelho A-M
See Ferrier L
Buéno L. *See* Julia V
Buerke B. *See* Bock C-T
Buffler P. *See* Corley DA
Buffler PA. *See* Corley DA
Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, de Paolos P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the Natural History of Nonalcoholic Steatohepatitis: From Cryptogenic Cirrhosis to Hepatocellular Carcinoma, 123:134
Buijs RM. *See* de Jonge WJ
Bukholm G. *See* Berstad AE
Bukowski JF, Brenner MB. How Do Intestinal T Cells Sense the Dietary and Microbial Environment? Reply, 118:446–ss
Bukowski JF, Morita CT, Brenner MB. How Do Intestinal T Cells Sense the Dietary and Microbial Environment?, 118:444–ss
Bulfone-Paus S. *See* Stallmach A
Bull L
See Morton DH
See Salen G
Büller HA
See van Ginkel R
See Verburg M
Bulone L. *See* Slonim AE
Bülow C. *See* Bülow S
Bülow C, Vasen H, Järvinen H, Björk J, Bisgaard ML, Bülow S. Ileorectal Anastomosis Is Appropriate for a Subset of Patients With Familial Adenomatous Polyposis, 119:1454
Bülow S. *See* Bülow C
Bülow S, Vasen H, Bülow C, Bisgaard ML, Järvinen H, Björk J
Ileorectal Anastomosis in Patients With Familial Adenomatous Polyposis. Reply, 121:502–c
Ileorectal Anastomosis Is Appropriate for a Subset of Patients With Familial Adenomatous Polyposis. Reply, 121: 504–c
Bültmann B. *See* Sotlar K
Buman J. *See* Bronsveld I
Bunce M. *See* Ahmad T
Büning J. *See* Zimmer K-P
Bunnett NW. *See* Trevisani M
Bunnik EM. *See* Vader LW

Burak KW, Le T, Swain MG. Increased Sensitivity to the Locomotor-Activating Effects of Corticotropin-Releasing Hormone in Cholestatic Rats, 122:681
Burckhardt B. *See* Frossard JL
Burde R. *See* Marschall ZV
Burdyga G, Lal S, Spiller D, Jiang W, Thompson D, Attwood S, Saeed S, Grundy D, Varro A, Dimaline R, Dockray GJ. Localization of Orexin-1 Receptors to Vagal Afferent Neurons in the Rat and Humans, 124:129
Bureau C, Peron J-M, Alric L, Morales J, Sanchez J, Barange K, Payen J-L, Vinel J-P. "A La Carte" Treatment of Portal Hypertension or Just "Hors d'Oeuvres," 124:1993–ss
Buret AG. *See* Scott KG-E
Buret AG, Meddings J, Scott KGE. Infection With *Giardia* and Intestinal Permeability in Humans. Reply, 125: 279–c
Burgart L
See He C-L
See Vazquez-Sequeiros E
Burgart LJ
See Buttar NS
See Dayharsh GA
See Feldstein AE
See Huntsman DG
See Lyford GL
See Miyoshi H
See Taniai M
Bürgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke J-D. Mechanisms of Diarrhea in Collagenous Colitis, 123:433
Burgos-Vargas R. *See* Laine L
Burgstahler AD. *See* Nathanson MH
Burgstahler AG. *See* Leite MF
Buri C. *See* Saurer L
Burke C. Risk Stratification for Periampullary Carcinoma in Patients With Familial Adenomatous Polyposis: Does Theodore Know What to Do Now?, 121:1246–e
Burke CA. *See* Baron JA
Burke MJ. *See* Masyuk AI
Burkly LC. *See* Wang LC
Burn P. *See* Miao YM
Burns C. *See* Ley K
Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody Blockade of ICAM-1 and VCAM-1 Ameliorates Inflammation in the SAMP-1/Yit Adoptive Transfer Model of Crohn's Disease, 121:1428
Burnstock G. *See* Wynn G
Burra P. *See* Féray C
Burrell LM. *See* Paizis G
Burrin DG
See Guan X
See van der Schoor SRD
Burroughs AK. *See* Patch D
Burt AD. *See* Smith BC
Burt R. *See* Winawer S
Burt RW
Colon Cancer Screening, 119:837–srr
Gastric Fundic Gland Polyps, 125:1462
Burton DD
See Bouras EP
See Coulie B
Buscail L. *See* Torrisani J
Busch DH. *See* Benz C
Busch M. *See* Fischbach W
Busche R. *See* Bronsveld I
Büschenfelde K-HMZ. *See* Peters M
Bush KT, Nigam SK. Less Degradation, More Shock, Please, 116:994–e
Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV. Glial Cells, Mucosal Integrity, and Inflammatory Bowel Disease, 116:493–ss
Buskens CJ, van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJA, van Lanschot JJB, Ristimäki A. Prognostic Significance of Elevated Cyclooxygenase 2 Expression in Patients With Adenocarcinoma of the Esophagus, 122:1800
Bustos M, Beraza N, Lasarte J-J, Baixeras E, Alzuguren P, Bordet T, Prieto J. Protection Against Liver Damage by Cardiotrophin-1: A Hepatocyte Survival Factor Up-Regulated in the Regenerating Liver in Rats, 125:192
Busuttil RW. *See* Saab S
Butcher EC. *See* Salmi M
Butel J. *See* Moreau R
Butler J. *See* Schoenfeld P
Buttar NS. *See* Krishnadath KK
Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of Esophageal Adenocarcinoma By COX-2 Inhibitors in an Animal Model of Barrett's Esophagus, 122:1100
Butters RR. *See* Cheng I
Butterworth JR, Cooper BT, Rosenberg WMC, Purkiss M, Jobson S, Hathaway M, Briggs D, Howell WM, Wood GM, Adams DH, Iqbal TH
Discussion on the Role of Hemochromatosis Susceptibility Gene Mutation in Protecting Against Iron Deficiency in Celiac Disease. Reply, 124:1564–c
The Role of Hemochromatosis Susceptibility Gene Mutations in Protecting Against Iron Deficiency in Celiac Disease, 123:444
Butterworth RF
See Chatauret N
See Rose C
Büttner C. *See* Steiner M
Buyse M. *See* Sobhani I
Buzoni-Gatel D
See Li W
See Luangsay S
Buzoni-Gatel D, Debbabi H, Mennechet FJD, Martin V, Lepage AC, Schwartzman JD, Kasper LH. Murine Ileitis After Intracellular Parasite Infection Is Controlled by TGF-β-Producing Intraepithelial Lymphocytes, 120:914
Byers T
See Baron JA
See Maltzman T
Byrd JC
See Dudas SP
See Sternberg LR
Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The Human Bile Salt Export Pump: Characterization of Substrate Specificity and Identification of Inhibitors, 123:1649
Byrne MF, Baillie J
Propofol for Conscious Sedation?, 123: 373–e
Propofol for Endoscopy Sedation. Reply, 124:1162–c
Byrne MF, Jowell PS. Gastrointestinal Imaging: Endoscopic Ultrasound, 122: 1631
Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ, Cox DM. *Helicobacter pylori* Binds von Willebrand Factor and Interacts With GPIb to Induce Platelet Aggregation, 124:1846
Byth K. *See* Hui JM
Bytzer P
See Lassen A
See Lassen AT

Caballería J
See Cabré E
See Martínez-Chantar ML
Cabooter M. *See* Baert F
Cabral AM. *See* Allen SA
Cabré E
See Panés J
See Pérez-Páramo M
Cabré E, Rodríguez-Iglesias P, Caballería J, Quer JC, Sánchez-Lombraña JL, Parés A, Papo M, Planas R, Gassull MA.

Nutritional Therapy for Alcoholic Hepatitis: New Life for an Old Idea, 120:1053–ss
Caca K
See Huster D
See Ortner MEJ
Caccamo L. *See* Féray C
Cacoub P
See Alric L
See Hermine O
Cadelina G
See Shah V
See Tsai M-H
Cadiot G. *See* Berriot-Varoqueaux N
Cadiot G, Vuagnat A, Doukhan I, Murat A, Bonnaud G, Delemer B, Thiéfin G, Beckers A, Veyrac M, Proye C, Ruszniewski P, Mignon M. Prognostic Factors in Patients With Zollinger-Ellison Syndrome and Multiple Endocrine Neoplasia Type 1, 116:286
Cadranel J-F
See Di Martino V
See Lunel F
Caenepeel P. *See* Tack J
Cahalon L. *See* Chowers Y
Cahill A. *See* Hoek JB
Cahill PA. *See* Theodorakis NG
Cai B. *See* Sands BE
Cai H. *See* Radaeva S
Cai J. *See* Nagata H
Cai X. *See* Loren DE
Caillat-Zucman S. *See* Renou C
Cailleau-Thomas A. *See* Marionneau S
Cain C. *See* Holtmann G
Cajal SR Y. *See* Losa JH
Cakaloglu Y. *See* Besisik F
Calabrese C, Areni A, Miglioli M, DiFebo G. Omeprazole and Ultrastructural Modifications Occurring in Reflux Esophagitis, 122:837–c
Calahorra B
See Ginés P
See Ortega R
Calam J. *See* Arebi N
Caldarella MP, Azpiroz F, Malagelada JR. Antro-Fundic Dysfunctions in Functional Dyspepsia, 124:1220
Caldarella MP, Balatsinou C, Milano A, Laterza F, Neri M. There Is a Relationship Between Celiac Disease and Patients With Symptoms of Irritable Bowel Syndrome, 123:1408–co
Caldarella MP, Serra J, Azpiroz F, Malagelada J-R. Prokinetic Effects in Patients With Intestinal Gas Retention, 122:1748
Caldas C
See Machado JC
See Pharoah P
See Pharoah PDP
Caldas C, Huntsman D. Hereditary Diffuse Gastric Cancer: More Answers or More Questions? Reply, 122:831–ss
Calder NA. *See* Wight NJ
Caletti G. *See* Liu H
Caletti G, Togliani T, Fusaroli P, Sabattini E, Khodadadian E, Gamberi B, Gobbi M, Pileri S. Consecutive Regression of Concurrent Laryngeal and Gastric MALT Lymphoma After Anti-*Helicobacter pylori* Therapy, 124:537–cr
Caligiuri A
See Alpini G
See Failli P
See LeSage G
See Marra F
Caligiuri A, de Franco RMS, Romanelli RG, Gentilini A, Meucci M, Failli P, Mazzetti L, Rombouts K, Geerts A, Vanasia M, Gentilini P, Marra F, Pinzani M. Antifibrogenic Effects of Canrenone, an Antialdosteronic Drug, on Human Hepatic Stellate Cells, 124:504
Calleja JL. *See* García-Pagán JC
Callejas NA, Boscá L, Williams CS, DuBois RN, Martín-Sanz P. Regulation of Cyclooxygenase 2 Expression in Hepatocytes by CCAAT/Enhancer-Binding Proteins, 119:493
Calmus Y. *See* Malassagne B
Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ
Hypnotherapy for Functional Dyspepsia: Do the Results Add Up? Reply, 125:637–c
Calvert EL, Houghton LH, Cooper P, Morris J, Whorwell PJ
Long-term Improvement in Functional Dyspepsia Using Hypnotherapy, 123:1778
Calvo BF. *See* Kim K-S
Camarero C. *See* León F
Camaschella C. *See* Girelli D
Camellini L, Merighi A, Primerano AM, Rigo G. Is Small-Caliber Esophagogastroduodenoscopy More Tolerable Than Conventional One in Unsedated Patients?, 119:878–c
Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR III, Pedersen NL. Gastroesophageal Reflux Disease in Monozygotic and Dizygotic Twins, 122:55
Cameron JL. *See* Sato N
Camilleri M
See Bouras EP
See Coulie B
See Lee JS
See Mueller LA
See Murray JA
See Prather CM
See Thumshirn M
Camilleri M
Management of the Irritable Bowel Syndrome, 120:652
Management of the Irritable Bowel Syndrome. Reply, 121:1528–c
New Insights Into the Pathogenesis of Rumination: What's Coming Up Next. Reply, 116:1008–ss
On the Threshold of Translating Basic Enteric Neuroscience Advances, 116:5–ce
Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R. Serotonin-Transporter Polymorphism Pharmacogenetics in Diarrhea-Predominant Irritable Bowel Syndrome, 123:425
Camilleri M, Delgado-Aros S. Much To Do About Gas, 123:933–e
Camilleri M, Podolsky DK
Comment From the Editor, 119:1429
Comment From the Editors, 120:5–ce
Cammà C. *See* Cottone M
Cammarota G, Cianci R, Gasbarrini G. Long-Term Omeprazole Treatment and Risk of Gastric Cancer, 119:1176–c
Campbell EA. *See* Bush TG
Campbell J. *See* Öhd JF
Campbell S. *See* Gillett HR
Campbell WB. *See* Ali I
Campbell-Sargent C. *See* Sanyal AJ
Campieri M
See Barbara G
See Gionchetti P
Campieri M, Gionchetti P. Probiotics in Inflammatory Bowel Disease: New Insight to Pathogenesis or a Possible Therapeutic Alernative?, 116:1246–e
Campos ML. *See* Machado JC
Canani RB, Cirillo P, Mallardo G, Buccigrossi V, Secondo A, Annunziato L, Bruzzese E, Albano F, Selvaggi F, Guarino A. Effects of HIV-1 Tat Protein on Ion Secretion and on Cell Proliferation in Human Intestinal Epithelial Cells, 124:368
Canbay A. *See* Feldstein AE
Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas Enhances Fibrogenesis in the Bile Duct Ligated Mouse: A Link Between Apoptosis and Fibrosis, 123:1323
Candalh C
See Matysiak-Budnik T
See Niel G van
Canedo P. *See* Machado JC

Canfield DR. *See* Mattapallil JJ
Canga C, Vakil N. What Is the Right Age Cutoff for Immediate Endoscopic Investigation of Dyspepsia?, 123:2149–ss
Canossa M. *See* De Giorgio R
Canto MI. *See* Cruz-Correa MR
Canva V. *See* Dharancy S
Cao C. *See* Chadker S
Cao H. *See* Chen X-M
Cao W, Harnett KM, Behar J, Biancani P. Group I Secreted PLA2 in the Maintenance of Human Lower Esophageal Sphincter Tone, 119:1243
Cao W, Picolo VE, Zhang L, Behar J, Biancani P, Kirber MT. Gq-Linked NK2 Receptors Mediate Neurally Induced Contraction of Human Sigmoid Circular Smooth Muscle, 119:51
Capasso F
See Izzo AA
See Pinto L
Capasso R. *See* Izzo AA
Capdeville R. *See* Demetri GD
Capella C
See Rindi G
See Solcia E
Capellá G. *See* Torrisani J
Caplan MS, Miller-Catchpole R, Kaup S, Russell T, Lickerman M, Amer M, Xiao Y, Thomson R Jr. Bifidobacterial Supplementation Reduces the Incidence of Necrotizing Enterocolitis in a Neonatal Rat Model, 117:577
Capocaccia R. *See* Citarda F
Caporale R. *See* Marra F
Cappelli M. *See* Stern HS
Cappello S. *See* De Giorgio R
Capron M. *See* Desreumaux P
Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: A Novel Serum and Histochemical Marker for Hepatocellular Carcinoma, 125:89
Capussotti L. *See* Bugianesi E
Carbon C. *See* Sobhani I
Carbone DP. *See* Adachi Y
Carbone I. *See* Laghi A
Carbonez A. *See* Baert F
Carbonnel F. *See* Cosnes J
Card T, Hubbard R, Logan RFA. Mortality in Inflammatory Bowel Disease: A Population-Based Cohort Study, 125:1583
Card TR. *See* West J
Cardanel J-F. *See* Moreau R
Cardenas A. *See* Ortega R
Cardi E. *See* Barbato M
Carding SR. *See* Telega GW
Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch Repair Proficiency and In Vitro Response to 5-Fluorouracil, 117:123
Carey HV. *See* Kim M
Carey MC
See Brink MA
See Eckhardt ERM
See Kauffman JM
See Lammert F
See Madara JL
See Wittenburg H
Carey W. *See* Chu C-J
Cargill G. *See* Faure C
Cariers A. *See* Fischer R
Cariglia N. *See* Thjodleifsson B
Carini R, Albano E. Recent Insights on the Mechanisms of Liver Preconditioning, 125:1480–srr
Cario E. *See* Mizoguchi E
Cario-Toumaniantz C. *See* Segain J-P
Carithers RL Jr. *Handbook of Liver Disease*, 116:500–pmr
Carl V. *See* Kozaiwa K
Carloni E. *See* Kim JJ
Carlos TM. *See* Kalff JC
Carlson PJ. *See* Camilleri M
Carlsson A. *See* Lehmann A
Carlsson J. *See* Myrvold HE
Carlsson P. *See* Spodsberg N
Carlstedt I. *See* Lindén S
Carlstrom K. *See* Chow JYC
Carmiel-Haggai M, Cederbaum AI, Nieto N. Binge Ethanol Exposure Increases Liver Injury in Obese Rats, 125:1818
Carneiro F
See Huntsman DG
See Machado JC
See van Doorn L-J
Caro AD. *See* Carrière F
Caro JD. *See* Carrière F
Carpenter RL. *See* Taguchi A
Carpinelli L. *See* Primignani M
Carrat F. *See* Corpechot C
Carratù R. *See* de Magistris L
Carraway RE. *See* Gui X
Carrière F, Renou C, Lopez V, Caro JD, Ferrato F, Lengsfeld H, Caro AD, Laugier R, Verger R. The Specific Activities of Human Digestive Lipases Measured From the In Vivo and In Vitro Lipolysis of Test Meals, 119:949
Carroccio A, Soresi M, Di Prima L, Montalto G. Screening for Celiac Disease in Patients With Chronic Liver Disease, 125:1289–c
Carswell A. *See* Mowat C
Carta A. *See* Primignani M
Cartenì M. *See* de Magistris L
Carter BA, Karpen SJ. Diet and Disease: The "Phyte" Over Intestinal Cholesterol. Comment, 121:1255–ss
Carter MJ. *See* Sanders DS
Carter MJ, Di Giovine FS, Cox A, Goodfellow P, Jones S, Shorthouse AJ, Duff GW, Lobo AJ. The Interleukin 1 Receptor Antagonist Gene Allele 2 as a Predictor of Pouchitis Following Colectomy and IPAA in Ulcerative Colitis, 121:805
Carter R. *See* Murray B
Cartot A. *See* Quinton JF
Cartwright EJ. *See* Scott DJ
Carucci P
See Bugianesi E
See Cramp ME
Carulli N. *See* Ballestri M
Carvalho B. *See* Thorstensen L
Carvalho R. *See* Machado JC
Carver RS, Stevenson MC, Scheving LA, Russell WE. Diverse Expression of ErbB Receptor Proteins During Rat Liver Development and Regeneration, 123:2017
Casado FJ. *See* Valdés R
Casagrande F. *See* Spirli C
Casanovas T. *See* Féray C
Casciani E. *See* Pappalardo G
Cascio MG
See Ligresti A
See Pinto L
Cascorbi I. *See* Schwab M
Caselitz M. *See* Weissenborn K
Caselmann WH
See Diepolder HM
See Schepke M
Casini A
See Benedetti A
See Galli A
Casini-Raggi V. *See* Tountas NA
Caspari R. *See* Friedl W
Caspary WF. *See* Holtmeier W
Cassai N. *See* Charney AN
Cassetta E. *See* Maria G
Cassiman D. *See* Clotman F
Casson D. *See* Somsouk M
Castagliuolo I
See Keates AC
See Morteau O
See Riegler M
Castell DO
See Triadafilopoulos G
See Vela MF
Castell DO
Esophageal Manometry Prior to Antireflux Surgery: Required, Preferred, or Even Needed?, 121:214–e
Gastroenterology: A Career for a Lifetime, 117:1459–aga
Castell DO, Katz PO. High-Dose Omeprazole in Patients With Noncardiac Chest Pain. Reply, 116:227–c

Castell DO, Katzka DA. Importance of Adequate Acid Suppression in the Management of Barrett's Esophagus, 117:1510–c
Castells A
See Bessa X
See Lacy AM
Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, Rustgi AK. Mapping of a Target Region of Allelic Loss to a 0.5-cM Interval on Chromosome 22q13 in Human Colorectal Cancer, 117:831
Castells L. *See* Sort P
Castiglia M. *See* Lok ASF
Castiglione F. *See* Biancone L
Castillo S, Ramaiah B, Blum S, Remy P. The Value of Serologic Markers in Indeterminate Colitis: A Prospective Follow-up Study, 125:999–c
Castro R. *See* Beyer K
Catalano C. *See* Laghi A
Catalano MF. *See* Fazel A
Catalano PJ. *See* Green RJ
Catassi C
See el Asmar R
See Fasano A
Cattan D. Discussion on the Effects of Chronic Hypergastrinemia on Human Enterochromaffin-like Cells: Insights From Patients With Sporadic Gastrinomas, 125:627–c
Cattaneo M, Vecchi M. Inflammatory Bowel Disease and the Risk of Thrombosis, 117:280–c
Cattin L. *See* Barazzoni R
Cattori V
See Ismair MG
See Reichel C
Cauch-Dudek K. *See* Springer JE
Cavallaro R. *See* Ciacci C
Cavina E. *See* Madoff RD
Cazzola M. *See* Bergamaschi G
Cebra JJ
See He W
See Jiang H-Q
Cecchetti L. *See* Di Stefano M
Cecchini F. *See* Selmi C
Cecio A. *See* Izzo AA
Cedarbaum JM. *See* Coulie B
Cederbaum AI. *See* Carmiel-Haggai M
Cederbaum AI. Effects of Alcohol on Hepatic Mitochondrial Function and DNA, 117:265–e
Cederberg C. *See* Lind T
Cejudo-Martín P
See Morales-Ruiz M
See Ros J
Çelik AF, Pamuk GE, Pamuk ÖN. The Predictive Parameters for Relapse in Ulcerative Colitis, 121:1261–c
Cellier C
See Matysiak-Budnik T
See Mention J-J
See Verkarre V
Cello JP
See Corley DA
See Garcia RT
Cenac N. *See* Ferrier L
Ceni E. *See* Galli A
Cepinskas G. *See* Lush CW
Ceponis P. *See* Söderholm JD
Cerbone AM. *See* Madonna P
Cereghini S. *See* Clotman F
Cerf-Bensussan N. *See* Niel G van
See Benahmed M
See Matysiak-Budnik T
See Mention J-J
See Verkarre V
Ceroti M. *See* Palli D
Cerrè C. *See* Bolder U
Cerutti R. *See* Prantera C
Cervoni J-P. *See* Moreau R
Cestari R. *See* Primignani M
Cezard J-P. *See* Hugot J-P
Cézard JP, Duhamel JF, Meyer M, Pharaon I, Bellaiche M, Maurage C, Ginies JL, Vaillant JM, Girardet JP, Lamireau T, Poujol A, Morali A, Sarles J, Olives JP, Whately-Smith C, Audrain S, Lecomte JM. Efficacy and Tolerability of Racecadotril in Acute Diarrhea in Children, 120:799
Chadee K. *See* Belley A
Chadwick RB. *See* Prior TW
Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the Mucosal Immune System in Irritable Bowel Syndrome, 122:1778
Chadwick VS, Chen W, Shu D, Paulus B, Wilson I, Bethwaite P, Tie A. Immune Activation in Irritable Bowel Syndrome: Wrong Title or Wrong Disease? Part 2. Reply, 124:1163–c
Chagneau C. *See* Pateron D
Chait BT. *See* Doyle DA
Chak A. In Pursuit of the Hidden, the Occult, and the Obscure. Reply, 117: 273–ss
Chakder S, Cao C, Lynn RB, Rattan S. Heme Oxygenase Activity in the Internal Anal Sphincter: Effects of Nonadrnergic, Noncholinergic Nerve Stimulation, 118: 477
Chakrabarti S. *See* Abou-Saif A
Chakravarti S. *See* Lawrance IC
Chalasani N
See Eversman D
See Jeffers L
Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, Boyer TD. Determinants of Mortality in Patients With Advanced Cirrhosis After Transjugular Intrahepatic Portosystemic Shunting, 118:138
Chalmers D
See D'Haens G
See Ford AC
Chamaillard M. *See* Hugot J-P
Chamouard P. G20210A Prothrombin Gene Mutation and Other Trombophilic Polymorphisms in Patients With Portal or Hepatic Venous Thrombosis. Reply, 120:1060–c
Chamouard P, Pencreach E, Maloisel F, Grunebaum L, Ardizzone J-F, Meyer A, Gaub M-P, Goetz J, Baumann R, Uring-Lambert B, Levy S, Dufour P, Hauptmann G, Oudet P. Frequent Factor II G20210A Mutation in Idiopathic Portal Vein Thrombosis, 116:144
Chan AOO
See Kim SG
See Lai KC
Chan FKL. *See* Sung JJY
Chan FKL, Chung S, Suen BY, Lee YT, Leung WK, Leung VKS, Wu JCY, Lau JYW, Hui Y, Lai MS, Chan HLY, Sung JJY. Elimination of *Helicobacter pylori* or Acid in High-Risk Users of Aspirin or Nonsteroidal Medications: Final Answer?, 122:238–ss
Chan FKL. Elimination of *Helicobacter pylori* or Acid in High-Risk Users of Aspirin or Nonsteroidal Medications: Final Answer? Reply, 122:240–ss
Chan HLY. *See* Chan FKL
Chan KLY. *See* Leung WK
Chan PKS. *See* Leung WK
Chang C-F. *See* Liu C-J
Chang CL
See Boland CR
See Ricciardiello L
Chang C-S, Chen L-T, Yang J-C, Lin J-T, Chang K-C, Wang J-T. Isolation of a *Helicobacter pylori* Protein, FldA, Associated With Mucosa-Associated Lymphoid Tissue Lymphoma of the Stomach, 117:82
Chang DK
See Boland CR
See Ricciardiello L
Chang EB
See Kojima K
See Musch MW
See Ren H
See Ropeleski MJ
See Sugi K
Chang EB. This Month in GASTROENTEROLOGY, 121:239–

tmig, 121:511–tmig, 121:751–tmig, 121:1033–tmig, 121:1269–tmig, 122:1–tmig, 122:253–tmig, 122:599–tmig, 122:847–tmig, 122:1195–tmig, 122:1715–tmig, 123:1–tmig, 123:963–tmig, 123:1421–tmig, 123:1757–tmig, 124:1–tmig, 124:281–tmig, 124:593–tmig, 124:873–tmig, 124:1173–tmig, 124:1721–tmig, 125:1–tmig, 125:285–tmig, 125:647–tmig, 125:1005–tmig, 125:1295–tmig

Chang K-C. *See* Chang C-S

Chang L
See Berman SM
See Helmer KS
See Naliboff BD

Chang L, Heitkemper MM. Gender Differences in Irritable Bowel Syndrome, 123:1686–srr

Chang P-F. *See* Huang C-S

Chang T-T
See Lai C-L
See Liaw Y-F

Chang W-C. *See* Cooper HS

Chang-De J. *See* Yamamoto H

Chanson M
See Frossard JL
See Frossard J-L

Chao W. *See* Sung JJY

Chapkin RS. *See* Fields AP

Chapman K. *See* Wallace JL

Chapman M. *See* Francella A

Chapman MAS, Cole A. In Vivo Colonic Butyrate Metabolism and Colonic Permeability in Extensive Ulcerative Colitis, 117:745–c

Chapman RW. *See* Mitchell SA

Chapman RWG. *See* Satsangi J

Chapple K. *See* Hull M

Chapusot C. *See* Laurent-Puig P

Chaput J-C. *See* Veyradier A

Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet Amyloid Polypeptide Is Not a Satisfactory Marker for Detecting Pancreatic Cancer, 121:640

Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, Clain JE, Norton IA, Pearson RK, Petersen BT, Wiersema MJ, Farnell MB, Sarr MG. Study of Recurrence After Surgical Resection of Intraductal Papillary Mucinous Neoplasm of the Pancreas, 123:1500

Charitanski D. *See* Izzedine H

Charlotte F
See Alric L
See Sobesky R

Charlton M
Branched-Chain Amino Acid-Enriched Supplements as Therapy for Liver Disease: Rasputin Lives, 124:1980–e
Patient and Graft Survival Following Liver Transplantation for Hepatitis C: Much Ado About Something, 122:1161–e

Charlton M, Ahlman B, Nair KS. The Effect of Insulin on Human Small Intestinal Mucosal Protein Synthesis, 118:299

Charney AN, Egnor RW, Cassai N, Sidhu GS. Carbon Dioxide Affects Rat Colonic Na^+ Absorption by Modulating Vesicular Traffic, 122:318

Charrier G. *See* Quinton JF

Chassande O. *See* Plateroti M

Chatauret N, Zwingmann C, Rose C, Leibfritz D, Butterworth RF. Effects of Hypothermia on Brain Glucose Metabolism in Acute Liver Failure: A $^1H/^{13}C$-Nuclear Magnetic Resonance Study, 125:815

Chatterjee N. *See* Reynaert H

Chattopadhyay N. *See* Cheng I

Chauchan SS, Zucker SD. Hypercholesterolemia in Primary Biliary Cirrhosis: Getting to the Heart of the Matter. Comment, 124:855–ss

Chaudier B. *See* Granel B

Chauhan DP
See Boland CR
See Carethers JM

Chaussade S. *See* Benamouzig R

Chauveau D. *See* Hammel PR

Chayama K. *See* Ikeda K

Chayvialle J-A. *See* Marion-Audibert A-M

Chazan SG. *See* Levin TR

Checklin H. *See* Lidums I

Chejfec G
See Lieberman DA
See Sontag SJ

Chelvanayagam S. *See* Norton C

Chemello L. *See* Schalm SW

Chen A, Seiden M. *Nutrition and Women's Cancer*. 117:278–pmr

Chen D
See Aihara T
See Wang TC

Chen D, Zhao C-M, Al-Haider W, Håkanson R, Rehfeld JF, Kopin AS. Differentiation of Gastric ECL Cells Is Altered in CCK_2 Receptor-Deficient Mice, 123:577

Chen D, Zhao C-M, Dockray GJ, Varro A, van Hoek A, Sinclair NF, Wang TC, Koh TJ. Glycine-Extended Gastrin Synergizes With Gastrin 17 to Stimulate Acid Secretion in Gastrin-Deficient Mice, 119:756

Chen D-S
See Kao J-H
See Liu C-J
See Schalm SW
See Yeh S-H

Chen E-S. *See* Huang C-S

Chen F, Ma L, Sartor RB, Li F, Xiong H, Sun A-Q, Shneider B. Inflammatory-Mediated Repression of the Rat Ileal Sodium-Dependent Bile Acid Transporter by c-Fos Nuclear Translocation, 123:2005

Chen FF
See Bonen DK
See Hugot J-P

Chen GJ. *See* Pineau BC

Chen H
See Collier-Hyams LS
See Hirota S

Chen J. *See* Walsh SV

Chen JDZ, Qian L, Ouyang H, Yin J. Enteric Neuromuscular Disorders and Pain Group. Gastric Electrical Stimulation With Short Pulses Reduces Vomiting but not Dysrhythmias in Dogs, 124:401

Chen J-M, Ferec C. Wanted: A Consensus Nomenclature for Cationic Trypsinogen Mutations, 119:277–c

Chen J-M, Marcier B, Audrezet M-P, Raguenes O, Quere I, Ferec C. Mutations of the Pancreatic Secretory Trypsin Inhibitor (PSTI) Gene in Idiopathic Chronic Pancreatitis, 120:1061–c

Chen J-M, Raguenes O, Ferec C, Deprez PH, Verellen-Dumoulin C, Andriulli A. The A16V Signal Peptide Cleavage Site Mutation in the Cationic Trypsinogen Gene and Chronic Pancreatitis, 117:1509–c

Chen J-T
See Chen Y-J
See Yeh S-H

Chen L-T. *See* Chang C-S

Chen M. *See* He D

Chen M, Sällberg M, Sönnerborg A, Weiland O, Mattsson L, Jin L, Brikett A, Peterson D, Milich DR. Limited Humoral Immunity in Hepatitis C Virus Infection, 116:135

Chen M-H. *See* Lo G-H

Chen P-J
See Chen Y-J
See Kao J-H
See Liu C-J
See Yeh S-H

Chen Q
See Amaral J
See Xiao Z-L

Chen Q, Amaral J, Biancani P, Behar J. Excess Membrane Cholesterol Alters Human Gallbladder Muscle

Contractility and Membrane Fluidity, 116:678
Chen R-N. *See* Lai C-L
Chen S-S. *See* Westland C
Chen TC. *See* Koutkia P
Chen W
See Chadwick VS
See Rhoads JM
Chen W-C
See Huang C-S
See Lo G-H
Chen X, Ji B, Han B, Ernst SA, Simeone D, Logsdon CD. NF-κB Activation in Pancreas Induces Pancreatic and Systemic Inflammatory Response, 122: 448
Chen X-M, Huang BQ, Splinter PL, Cao H, Zhu G, McNiven MA, LaRusso NF. *Cryptosporidium parvum* Invasion of Biliary Epithelia Requires Host Cell Tyrosine Phosphorylation of Cortactin Via c-Src, 125:216
Chen X-M, LaRusso NF. Mechanisms of Attachment and Internalization of *Cryptosporidium parvum* to Biliary and Intestinal Epithelial Cells, 118:368
Chen Y-C, Liaw Y-F. Outcomes of Patients With Seroclearance of HBsAg: Different Facets of a Truth. Reply, 125:275–c
Chen Y-C, Sheen I-S, Chu C-M, Liaw Y-F. Prognosis Following Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients With or Without Concurrent Infection, 123:1084
Chen Y-J, Yeh S-H, Chen J-T, Wu C-C, Hsu M-T, Tsai S-F, Chen P-J, Lin C-H. Chromosomal Changes and Clonality Relationship Between Primary and Recurrent Hepatocellular Carcinoma, 119:431
Chen Y-W. *See* Yeh S-H
Chen Y-X. *See* Huang XR
Chenard M-P. *See* Tomasetto C
Cheng H
See Bjerknes M
See Orchard TR
Cheng H-C. *See* Lau GKK
Cheng I, Qureshi I, Chattopadhyay N, Qureshi A, Butters RR, Hall AE, Cima RR, Rogers KV, Hebert SC, Geibel JP, Brown EM, Soybel DI. Expression of an Extracellular Calcium-Sensing Receptor in Rat Stomach, 116:118
Cheng L. *See* Papdakis KA
Cheng SJ, Bonis PAL, Lau J, Pham NQ, Wong JB. Therapy For HCV Nonresponders: Is Two Enough?, 121: 1017–ss
Cheng SJ, Bonis PAL, Lau J, Wong JB. Therapy For HCV Nonresponders: Is Two Enough? Reply, 121:1018–ss
Cheng T-I, Huang AT. Colorectal Cancer Incidence Differs Within Ethnic Chinese, 125:1913–c
Cheng Y. *See* Gobert AP
Cheong K. *See* Hawkins N
Cherikuri A. *See* Farrell RJ
Cheroutre H. *See* De Winter H
Cherqui D. *See* Mathieu D
Chery C. *See* Guéant J-L
Chetwynd A. *See* Prince M
Cheung M. *See* Lau GKK
Cheung RJ. *See* Berman JM
Chevallier M. *See* Samuel D
Chey WD
See Halser WL
See Ladabaum U
Chi AL. *See* Khan ZE
Chiavetta J-A. *See* Delage G
Chiba M, Nakamura T, Hoshina S, Kitagawa Y. Optimal Cases and Sites to Search for Primary Microbial Agents in Crohn's Disease, 120:1066–c
Chiba T
See Inoue F
See Kanai M
See Kazumori H
See Ohana M
See Okazaki K
See Yoshida M
Chiba T
Is *Reg* Gene Mutation Involved in the Development of Enterochromaffin-like Cell Carcinoid Tumors?, 116:1489–e
Chien DY. *See* Farci P
Chien R-N. *See* Liaw Y-F
Chillakuru RA. *See* Jeffers M
Chinery R. *See* Bach SP
Ching CK. *See* Zhu GH
Ching J. *See* Sung JJY
Ching JYL. *See* Sung JJY
Ching SS. *See* Muralikrishnan VP
Chiron A. *See* Michel P
Chitkara D, Talley NJ. Hypnotherapy for Functional Dyspepsia: Do the Results Add Up?, 125:636–c
Chitkara DK, Cremonini F, Talley NJ. Psychotherapy and Paroxetine: Cost Effective for Severe IBS, or a Waste of Resources, 125:1554–c
Chitturi S, Farrell G, Georg J. Iron and *HFE* Mutations in Nonalcoholic Steatohepatitis: Innocent Bystanders or Accessories to the Crime? Reply, 125: 617–ss
Chitturi S, Weltman M, Farrell GC, McDonald D, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J. Iron and *HFE* Mutations in Nonalcoholic Steatohepatitis: Innocent Bystanders or Accessories to the Crime?, 125:615–ss
Cho CH
See Guo X
See Huang XR
Cho DH. *See* Framson PE
Cho JH
See Bonen DK
See Brant SR
See Hugot J-P
Cho KR. *See* Hinoi T
Cho WK, Boyer JL. Vasoactive Intestinal Polypeptide Is a Potent Regulator of Bile Secretion From Rat Cholangiocytes, 117:420
Choi AMK. *See* Moore BA
Choi HK, Chu KW, Law WL
Can Gastrografin Heal the Obstructed Bowel?, 124:852–ss
Can Gastrografin Heal the Obstructed Bowel? Reply, 124:853–ss
Choi M-G. *See* Thumshirn M
Choi SK. *See* Iimuro Y
Choi S-W. *See* Kim Y-I
Chokshi S. *See* Cramp ME
Chong AK,. Comments Regarding Article Comparing Small Bowel Radiographs and Video Capsule Endoscopy, 125: 276–c
Choo K. *See* Shah V
Chopra S. *See* Resnick RH
Chou S. *See* Rosen HR
Choudhuri G. *See* Bhatia E
Chow EJ. *See* Pimentel M
Chow JYC, Carlstrom K, Barrett KE. Growth Hormone Reduces Chloride Secretion in Human Colonic Epithelial Cells Via EGF Receptor and Extracellular Regulated Kinase, 125: 1114
Chow W-H
See El-Omar EM
See Ye W
Chowdhury JR. *See* Sauter BV
Chowers MY, Keller N, Tal R, Barshack I, Lang R, Bar-Meir S, Chowers Y. Human Gastrin: A *Helicobacter pylori*-Specific Growth Factor, 117:1113
Chowers Y. *See* Chowers MY
Chowers Y, Lider O, Schor H, Barshack I, Tal R, Ariel A, Bar-Meir S, Cohen IR, Cahalon L. Disaccharides Derived From Heparin or Heparan Sulfate Regulate IL-8 and IL-1β Secretion by Intestinal Epithelial Cells, 120:449
Choy P. *See* Zhang M
Christiana S. *See* Jacob P
Christiansen J. *See* Madoff RD
Christie GR, Ford D, Howard A, Clark MA, Hirst BH. Glycine Supply to

Human Enterocytes Mediated by High-Affinity Basolateral GLYT1, 120:439
Christofi F. *See* Kim M
Chrousos GP. *See* Franchimont D
Chu C-J, Hussain M, Lok ASF. Hepatitis B Virus Genotype B Is Associated With Earlier HBeAg Seroconversion Compared With Hepatitis B Virus Genotype C, 122:1756
Chu C-J, Keeffe EB, Han S-H, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr., Luketic VA, Terrault N, Lok ASF, U.S. HBV Epidemiology Study Group. Hepatitis B Virus Genotypes in the United States: Results of a Nationwide Study, 125:444
Chu C-M. *See* Chen Y-C
Chu KM. *See* Lai KC
Chu KW. *See* Choi HK
Chua CN. *See* Orchard TR
Chui MS. *See* Wege H
Chun A. *See* Desautels SG
Chun B. *See* Huang XR
Chun YS. *See* Huntsman DG
Chung C. *See* Vagquero J
Chung DC. The Genetic Basis of Colorectal Cancer: Insights Into Critical Pathways of Tumorigenesis, 119:854–srr
Chung DH
See Ethridge RT
See Kim S
Chung DH, Ethrifge RT, Kim S, Owens-Stowall S, Hernandez A, Kelly DR, Evers BM. Necrotizing Enterocolitis: A Closer Look, 121:1016–ss
Chung RT
See Contreras AM
See Moriguchi H
See Somsouk M
Chung S. *See* Chan FKL
Chung SCS. *See* Sung JJY
Church NI, Dallal HJ, Masson J, Mowat NAG, Johnston DA, Radini E, Turner M, Fullarton G, Prescott RJ, Palmer KR. A Randomized Trial Comparing Heater Probe Plus Thrombin With Heater Probe Plus Placebo for Bleeding Peptic Ulcer, 125:396
Church T. *See* Ederer F
Church TR
See Baron JA
See Mandel JS
Churchill GA. *See* Wittenburg H
Chutaputti A. *See* Sugauchi F
Chvatchko Y. *See* Hove TT
Ciacci C. *See* Maiuri L
Ciacci C, Cavallaro R, Valle N della, d'Argenio G. The Use of Serum tTG-ab Assay in Patients on Gluten-free Diet as a Measure of Dietetic Compliance, 122:588–c
Cianchi F. *See* D'Elios MM
Cianchi F, Cortesini C, Bechi P, Fantappiè O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini EM. Up-regulation of Cyclooxygenase-2 Gene Expression Correlates With Tumor Angiogenesis in Human Colorectal Cancer, 121:1339
Cianci R. *See* Cammarota G
Cicala M. *See* Deviere J
Ciclitira PJ
See Biagi F
See Fraser JS
Cilley RE. *See* Teitelbaum DH
Cima RR. *See* Cheng I
Cipolletta L, Bianco MA, Marmo R, Rotondano G, Piscopo R, Vingiani AM, Meucci C. Hemoclips-Clips to Clasp the Bleeder, 123:1399–ss
Cipolletta L, Bianco MA, Rotondano G, Marmo R, Meucci C, Piscopo R. Endoscopic Blockade to Prevent Resurfacing of Esophageal Varices, 124:1545–ss
Cirillo P. *See* Canani RB
Citarda F. *See* Crespi M
Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Effectiveness of Colonoscopy in Preventing Colorectal Cancer, 121:1521–ss
Cividini A, Rebucci C, Silini E, Mondelli MU. Is the Natural History of Hepatitis C Virus Carriers With Normal Aminotransferase Really Benign?, 121:1526–c
Clain JE
See Chari ST
See Harewood GC
See Schwartz DA
See Vazquez-Sequeiros E
Clapper ML. *See* Cooper HS
Clare M. *See* Czaja AJ
Claria J. *See* Graupera M
Clària J
See Bosch-Marcé M
See Ros J
See Titos E
Clark JM, Brancati FL, Diehl AM. Nonalcoholic Fatty Liver Disease, 122: 1649
Clark JM, Diehl AM. Defining Nonalcoholic Fatty Liver Disease: Implications for Epidemiologic Studies, 124:248–e
Clark MA. *See* Christie GR
Clark WS. *See* Chalasani N
Clarke A
See Bassett M
See O'Sullivan GC
Clarke CM. *See* Parisi MA
Clarke LL
See Gawenis LR
See Walker NM
Claudel T. *See* Barbier O
Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart J-C, Gonzalez FJ, Staels B. Farnesoid X Receptor Agonists Suppress Hepatic Apolipoprotein CIII Expression, 125:544
Clavien PA. *See* Kadry Z
Clavien P-A
See Kohli V
See Rüdiger HA
See Selzner M
See Selzner N
See Sindram D
Cleary KR. *See* Sinicrope FA
Clement M. *See* Marionneau S
Clerc P, Leung-Theung-Long S, Wang TC, Dockray GJ, Bouisson M, Delisle M-B, Vaysse N, Pradayrol L, Fourmy D, Dufresne M. Expression of CCK2 Receptors in the Murine Pancreas: Proliferation, Transdifferentiation of Acinar Cells, and Neoplasia, 122:428
Cleton-Jansen A-M. *See* Liefers G-J
Clive-Hayes P. *See* Helmy A
Clore JN. *See* Sanyal AJ
Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jasquemin P, Roskams T, Rousseau GQ, Lemaigre FP. Transcription Factors and Cholangiocyte Development, 124:263–ss
Clouse RE. Managing Functional Bowel Disorders From the Top Down: Lessons From a Well-Designed Treatment Trial, 125:249–e
Clouse RE, Staiano A, Alrakawi, A.Topographic Analysis of Esophageal Double-Peaked Waves, 118:469
Clouston AD. *See* Jonsson JR
Clyne M, O Cróinín T, Drumm B. Mimicry of Blood Group Antigen A by *Helicobacter mustelae and H. pylori*. Reply, 116:505–c
Cobb S, Wood T, Tessarollo L, Velasco M, Given R, Varro A, Tarasova N, Singh P. Deletion of Functional Gastrin Gene Markedly Increases Colon Carcinogenesis in Response to Azoxymethane in Mice, 123:516
Cockram A. *See* Barrett S
Cocks TM, Sozzi V, Moffatt JD, Selemidis S. Protease-Activated Receptors Mediate Apamin-Sensitive Relaxation of Mouse and Guinea Pig Gastrointestinal Smooth Muscle, 116: 586

Coelho A-M, Vergnolle N, Guiard B, Fioramonti J, Bueno L. Proteinases and Proteinase-Activated Receptor 2: A Possible Role to Promote Visceral Hyperalgesia in Rats, 122:1034
Coffee K. *See* Adachi Y
Coffey RJ
See Bach SP
See Boivin GP
See Sizemore N
See Wang TC
Coffey RJ Jr
See Means AL
See Song SY
Cohard M
See Deviére J
See Fedorak RN
See Samuel D
See Schreiber S
Cohavy O. *See* Landers CJ
Cohen A
See Bitton A
See Steinhart AH
Cohen H. *See* Havlik RJ
Cohen IR. *See* Chowers Y
Cohen LB. *See* Ehrenpreis ED
Cohen MB
See Bates MD
See Steinecher KA
Our New President-Ralph A. Giannella, M.D, 116:1238–aga
Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, Sharma R, Hudgins LC, Ntambi JM, Friedman JM, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Attie AD. Leptin Signaling and Obesity: Weight and See, 124:1546–ss
Cohen RB. *See* Bickston SJ
Cohen RD. *See* Ehrenpreis ED
Cohen RD
Cost-Utility of Initial Medical Management for Crohn's Disease Perianal Fistula, 122:1186–c
Forecast for Using Metabolite Measurements in the Dosing of Azathioprine or 6-Mercaptopurine for IBD Patients: "Partly Cloudy" Comment, 122:2083–ss
IBD Indirect Costs: The Sleeping Giant? Comment, 125:983–ss
Infliximab at 5 Years-Tweaking the Recipe for Success? Comment, 125: 1903–ss
Infliximab In Ulcerative Colitis: Is There a Placebo (Effect) in the House? Comment, 124:1990–ss
The Mesalamine Wards Heat Up-Enter Balsalazide. Comment, 124:574–ss
Methotrexate in IBD - Move Over 6-MP? Not So Fast. . .Comment, 123: 1738–ss
Cohen S. *See* DiMarino M
Cohen SL. *See* Doyle DA
Cohen Z. *See* Thompson-Fawcett MW
Cohen-Solal A. *See* Colle IO
Cohen-Solal L. *See* Guillem P
Cohn JA. *See* Noone PG
Comment From the Editors, 124:878–ce
Comment from the Editors, 122:257–ce
Cohn SM. *See* Rivera-Nieves J
Cohran VC, Bates MD. Leptin Signaling and Obesity: Weight and See. Comment, 124:1547–ss
Coiana A. *See* Farci P
Colditz GA
See Giovannucci E
See Leitzmann MF
Cole A. *See* Chapman MAS
Cole BF. *See* Baron JA
Cole D. *See* Rubin L
Cole DEC. *See* Springer JE
Cole SP. *See* Hase K
Colell A. *See* Lluis JM
Coletta L. *See* Hull M
Coletta PL. *See* Scott DJ
Colgan SP
See Brand S
See van de Wal Y
Colin J-F. *See* di Martino V
Colin R. *See* Michel P
Coll S. *See* Guarner C
Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Berneau J, Marty J, Lebrec D, Valla D, Durand F. Portopulmonary Hypertension: An Increasingly Important Complication of Cirrhosis, 125:622–ss
Colledge D. *See* Angus P
Collen D. *See* Conway EM
Collet A. *See* Degen LP
Collier-Hyams LS, Neish AS. Suppression of Pathogenesis: Bacteria Lead the Way. Reply, 124:1552–ss
Collier-Hyams LS, Zeng BH, Sun J, Tomlinson AD, Bao ZQ, Chen H, Madara JL, Orth K, Neish AS. Suppression of Pathogenesis: Bacteria Lead the Way, 124:1550–ss
Collin P. *See* Kaukinen K
Collin P, Kaukinen K, Mäki M, Vehmanen P, Partanen J, Färkkilä M, Halme L, Höckerstedt K. Discussion on Celiac Disease in Patients With Severe Liver Disease: Gluten-Free Diet May Reverse Hepatic Failure. Reply, 123: 2159–co
Collins CG, O'Sullivan GC, Shanahan F. Effective Therapy for Advanced Gastrointestinal Stromal Tumors. Comment, 124:1152–ss
Collins JK. *See* O'Sullivan GC
Collins SM
See Berčík P
See Der T
See Galeazzi F
See Huizinga JD
See Mayer EA
See Van Assche G
Collins SM. A Case for an Immunological Basis for Irritable Bowel Syndrome, 122:2078–e
Collman PI. *See* Beyak MJ
Colmenero J. *See* Bataller R
Colombari R. *See* Girelli D
Colombel JF
See Hanauer SB
See Sandborn WJ
Colombel J-F
See Desreumaux P
See Dubuquoy L
See Ferrier L
See Hugot J-P
See Joossens S
See Laharie D
See Mention J-J
See Quinton JF
See Tamboli CP
See Vermeire S
Colombel J-F
Is Antibody Testing for Inflammatory Bowel Disease Clinically Useful? Reply, 116:1002–ss
Colombo MP. *See* Paglia P
Colombo MP, Guzmán CA, Pietrangelo A, Paglia P. Mutant *Salmonella* as Vectors for Gene Therapy. Reply, 121:225–ss
Cominelli F
See Bickston SJ
See Burns RC
See Kozaiwa K
See Rivera-Nieves J
See Tountas NA
Cominelli F, Arseneau KO, Connors AF Jr. Cost-Utility of Initial Medical Management for Crohn's Disease Perianal Fistula. Reply, 122:1187–c
Comiskey M. *See* de Jong YP
Compton CC. *See* Poneros JM
Condat B, Pessione F, Denninger MH, Hillaire S, Valla D, Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, Boudet MJ, Hay JM, Erlinger S, Benhamou JP, Belghiti J, Valla D. Treatment of Hepatoportal Venous Thrombosis: The Role of Anticoagulation, 120:578–ss
Condat B, Pessione F, Hillaire S, Denninger M-H, Guillin M-C, Poliquin M, Hadengue A, Erlinger S,

Valla D. Current Outcome of Portal Vein Thrombosis in Adults: Risk and Benefit of Anticoagulant Therapy, 120:490
Condat B, Zeitoun G, Valla D. Treatment of Hepatoportal Venous Thrombosis: The Role of Anticoagulation. Reply, 120:579–ss
Condon TP. *See* Musso A
Condreay LD. *See* Lau DT-Y
Conejero L. *See* De la Concha EG
Conell C. *See* Levin TR
Conklin DS. *See* McCaffrey AP
Conlon CA. *See* French SJ
Connelly A. *See* Martin C
Connor HD
See McKim SE
See Wheeler MD
Connor P. *See* Turvill JL
Connors AF Jr. *See* Cominelli F
Connors LG. *See* Laine L
Conoscitore P. *See* Rosina F
Conrad DH. *See* Yu LCH
Conrad PG. *See* Terdiman JP
Constantini PK. *See* Czaja AJ
Conte D. *See* Fracanzani AL
Contos MJ
See Sanyal AJ
See Shiffman ML
Contreras AM. *See* Moriguchi H
Contreras AM, Chung RT. Hepatitis C Virus in Solid Organ Transplantation: Not Always a Bad Thing, 123:1729–e
Conway EM, Pollefeyt S, Steiner-Mosonyi M, Luo W, Devriese A, Lupu F, Bono F, Leducq N, Dol F, Schaeffer P, Collen D, Herbert J-M. Deficiency of Survivin in Transgenic Mice Exacerbates Fas-Induced Apoptosis Via Mitochondrial Pathways, 123:619
Conway EM. Survivin in Liver. Reply, 124:1566–c
Conway JD, Morgan D. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Treatment.* 125:1549–pmr
Conwell DL. *See* Vargo JJ
Cook D. *See* Schoenfeld P
Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A. Stress Management, 116:773–ss
Cook IJ. *See* Williams RBH
Cook IJ, Kahrilas PJ. AGA Technical Review on Management of Oropharyngeal Dysphagia, 116:455–aga
Cook JT. *See* Ahmad T
Cooke HJ. *See* Kim M
Cookson S. *See* Czaja AJ
Cooper BT. *See* Butterworth JR
Cooper C. *See* van Staa T-P
Cooper CJ. *See* Lee H-O
Cooper HS, Everley L, Chang W-C, Pfeiffer G, Lee B, Murthy S, Clapper ML. The Role of Mutant Apc in the Development of Dysplasia and Cancer in the Mouse Model of Dextran Sulfate Sodium-Induced Colitis, 121:1407
Cooper JN. *See* Saadeh S
Cooper ME. *See* Paizis G
Cooper P. *See* Calvert EL
Cooperative Study Group. *See* Prantera C
Cope K, Risby T, Diehl AM. Increased Gastrointestinal Ethanol Production in Obese Mice: Implications for Fatty Liver Disease Pathogenesis, 119:1340
Coppa GV. *See* el Asmar R
Coppel RL
See Bruggraber SFA
See Kita H
Coppin H. *See* Dupic F
Coppola A. *See* Madonna P
Coppola AG, Raufman J-P. Image of the Month, 121:245–im
Coquelle A. *See* Bras-Gonçalves RA
Corazza GR
See Di Stefano M
See Martucci S
See Zoli G
Corazza N. *See* van de Wal Y
Corbaz A. *See* Hove TT
Corbin I. *See* Zhang M
Corcoran PA. *See* Byrne MF
Córdoba J, Crespin J, Gottstein J, Blei AT. Mild Hypothermia Modifies Ammonia-Induced Brain Edema in Rats After Portacaval Anastomosis, 116:686
Corey LA. *See* Levy RL
Corey M
See Durno C
See Otley A
Corinaldesi R
See Barbara G
See De Giorgio R
See Tonini M
Corless C. *See* Demetri GD
Corless CL. *See* Rosen HR
Corleto VD. *See* Peghini PL
Corley D. NSAIDs and Esophageal Cancer. Reply, 125:1915–c
Corley DA. *See* Triadafilopoulos G
Corley DA, Cello JP, Adkisson W, Ko W-F, Kerlikowske K. Octreotide for Acute Esophageal Variceal Bleeding: A Meta-analysis, 120:946
Corley DA, Katz P, Wo JM, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe MM. Improvement of Gastroesophageal Reflux Symptoms After Radiofrequency Energy: A Randomized, Sham-Controlled Trial, 125:668
Corley DA, Kerlikowske K, Verma R, Buffler P. Protective Association of Aspirin/NSAIDs and Esophageal Cancer: A Systematic Review and Meta-Analysis, 124:47
Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and Survival in Barrett's Adenocarcinomas: A Population-Based Study, 122:633
Cornaggia M. *See* Testino G
Cornberg M. *See* Jaeckel E
Cornberg MC. *See* Manns M
Cornelisse CJ. *See* Liefers G-J
Cornelius JR. *See* Heinen CD
Cornet DA. *See* Filipi CJ
Cornish A. *See* Madsen K
Cornwall S. *See* van de Wal Y
Corona R. *See* Méndez-Sánchez N
Corpataux JM. *See* Halkic N
Corpechot C, Carrat F, Poupon R, Poupon R-E. Primary Biliary Cirrhosis: Incidence and Predictive Factors of Cirrhosis Development in Ursodiol-Treated Patients, 122:652
Correa P. *See* van Doorn L-J
Correas J-M. *See* Hammel PR
Corrocher R. *See* Girelli D
Cortesini C. *See* Cianchi F
Cortez-Pinto H, Lin HZ, Yang SQ, Da Costa SO, Diehl AM. Lipids Up-regulate Uncoupling Protein 2 Expression in Rat Hepatocytes, 116:1184
Corthésy-Theulaz I. *See* Michetti P
Cortot A
See Desreumaux P
See Hellers G
See Hugot J-P
See Laharie D
See Thomsen Ø
Cosentino M. *See* Giaroni C
Cosenza V. *See* Ligresti A
Cosmi L. *See* Bonacchi A
Cosnes J, Beaugerie L, Carbonnel F, Gendre J-P. Smoking Cessation and the Course of Crohn's Disease: An Intervention Study, 120:1093
Costa F. *See* D'Elios MM
Costa J. *See* Sánchez-Tapias JM
Costa M. *See* Lynn PA
Costagliola A. *See* Izzo AA
Costamagna G. *See* Deviere J
Costamagna G, Pandolfi M, Mutignani M, Spada C, Perri V. Barraging the Biliary Tree, 122:1533–ss

Costamagna G, Riccioni ME. New System of Double-Balloon Enteroscopy for Diagnosis and Treatment of Small Intestinal Disorders. Reply, 125:1556–c
Costamagna G, Shah SK, Riccioni ME, Foschia F, Mutignani M, Perri V, Vecchioli A, Brizi MG, Picciocchi A, Marano P. A Prospective Trial Comparing Small Bowel Radiographs and Video Capsule Endoscopy for Suspected Small Bowel Disease, 123:999
Coste T. *See* Benamouzig R
Côté A. *See* Vachon PH
Cote J. *See* Wight NJ
Cotler SJ
See Kaplan M
See Tung BY
Cotton PB
See Mulcahy HE
See Varadarajulu S
Cottone M. *See* Prantera C
Cottone M, Cammà C
Mesalamine and Relapse Prevention in Crohn's Disease, 119:597–c
Mesalamine Maintenance Therapy for Crohn's Disease. Reply, 120:585–c
Cottone M, Di Mitri R. Postsurgical Recurrence in Crohn's Disease, 116: 1013–c
Coudray-Lucas C. *See* Crenn P
Coughlan B. *See* Barrett S
Coulaud J-P. *See* di Martino V
Coulie B, Szarka LA, Camilleri M, Burton DD, McKinzie S, Stambler N, Cedarbaum JM. Recombinant Human Neurotrophic Factors Accelerate Colonic Transit and Relieve Constipation in Humans, 119:41
Coulie BJ, Miller LJ. Identification of Motilin-Related Peptide, 120:588–c
Coumaros D. *See* Moreau R
Couse T. *See* Shibahara T
Coutele C. *See* Forbes SJ
Coutinho SV, Gebhart GF. A Role for Spinal Nitric Oxide in Mediating Visceral Hyperalgesia in the Rat, 116: 1399
Couturier D. *See* Benamouzig R
Cova L. *See* Rollier C
Cover TL. *See* Graham JE
Cover TL, Blaser MJ. *Helicobacter pylori* Factors Associated With Disease, 117: 257–e
Cox A. *See* Carter MJ
Cox AD. *See* Sizemore N
Cox DM. *See* Byrne MF
Cox HJ. *See* Bush TG
Cozzolongo R. *See* Rosina F
Crabb DW. *See* Galli A
Crabtree JE. *See* Webb PM
Cramer T
See Höcker M
See Marschall ZV
Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C Virus-Specific T-Cell Reactivity During Interferon and Ribavirin Treatment in Chronic Hepatitis C, 118:346
Crawford DHG. *See* Fletcher LM
Crawford HC, Krishna US, Israel DA, Matrisian LM, Washington MK, Peek RM Jr. *Helicobacter pylori* Strain-Selective Induction of Matrix Metalloproteinase-7 In Vitro and Within Gastric Mucosa, 125:1125
Crawford JM. *See* Wallace MB
Crawley SC
See Kim GE
See Terdiman JP
Crawshaw J. *See* Ahmad T
Creed F. *See* Hamilton J
Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson B, The North of England IBS Research Group. The Cost-effectiveness of Psychotherapy and Paroxetine for Severe Irritable Bowel Syndrome, 124:303
Creed F. Psychotherapy and Paroxetine: Cost Effective for Severe IBS, or a Waste of Resources. Reply, 125:1555–c
Crema F. *See* Tonini M
Crémieux A-C. *See* Sobhani I
Cremonini F
See Chitkara DK
See Delgado-Aros S
Crenn P. *See* Messing B
Crenn P, Coudray-Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive Plasma Citrulline Concentration Is a Marker of Absorptive Enterocyte Mass and Intestinal Failure in Humans, 119:1496
Crenn P, Vahedi K, Lavergne-Slove A, Cynober L, Matuchansky C, Messing B. Plasma Citrulline: A Marker of Enterocyte Mass in Villous Atrophy-Associated Small Bowel Disease, 124: 1210
Crespi M. *See* Citarda F
Crespi M, Citarda F. Effectiveness of Colonoscopy in Preventing Colorectal Cancer. Reply, 121:1522–ss
Crespin J. *See* Córdoba J
Crispe IN. *See* Mehal WZ
Croft C. *See* Pedowitz SD
Croitoru K. *See* Steinhart AH
Crone SA, Negro A, Trumpp A, Giovannini M, Lee K-F. Hirschsprung Lost His Nerve, 125:1900–ss
Cronin K. *See* Sandler RS
Croog V. *See* Ullman T
Crook J. *See* Schoenfeld P
Crosby HA, Kelly DA, Strain AJ. Human Hepatic Stem-like Cells Isolated Using *c-kit* or CD34 Can Differentiate Into Biliary Epithelium, 120:534
Crosby MA. *See* Shaheen NJ
Crosignani A
See Battezzati PM
See Longo M
Crosnier C, Driancourt C, Raynaud N, Dhorne-Pollet S, Pollet N, Bernard O, Hadchouel M, Meunier-Rotival M. Mutations in *JAGGED1* Gene Are Predominantly Sporadic in Alagille Syndrome, 116:1141
Cross D. *See* Ladabaum U
Cross SS. *See* Baugh MD
Crotty B. *See* Katelaris PH
Croucher PJP
See Cuthbert AP
See Hampe J
Croucher PJP, Mascheretti S, Foelsch UR, Hampe J, Schreiber S, Mathew CG. Lack of Association Between the C3435T *MDR1* Gene Polymorphism and Inflammatory Bowel Disease in Two Independent Northern European Populations, 125:1919–c
Crowe J. *See* Barrett S
Crowell T. *See* Wang LC
Crowson CS. *See* Loftus EV Jr
Cruess D. *See* Schoenfeld P
Cruickshank WW. *See* Keates AC
Cruz-Correa M. *See* Giardiello FM
Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term Treatment With Sulindac in Familial Adenomatous Polyposis: A Prospective Cohort Study, 122:641
Cruz-Correa MR, Canto MI, Kalloo AN. Prevalence and Distinctive Biologic Features of Flat Colorectal Adenomas in a North American Population, 122:842–c
Cryer B, Feldman M
Effects of Very Low Dose Daily, Long-term Aspirin Therapy on Gastric, Duodenal, and Rectal Prostaglandin Levels and on Mucosal Injury in Healthy Humans, 117:17
Gastrointestinal Effects of Low-Dose Aspirin. Reply, 117:1506–c
Cuber JC. *See* Piche T
Cuffari C, Lichtenstein GR. Maintenance Infliximab Therapy in Patients With Crohn's Disease: How Long, How Much, How Frequent? Comment, 124:1989–ss
Cugnenc P-H
See Laurent-Puig P
See Mention J-J

Cui G. *See* Khan ZE
Cui Y
See Helmer KS
See Keppler D
Cui Z-Y. *See* Lok ASF
Cullen DJ. *See* Gochee PA
Cullen S. *See* Ahmad T
Culver PJ. *See* Kuganeswaran E
Cumings M. *See* Napierkowski JJ
Cumings MD. *See* Rex DK
Cummings DE, Foster KE. Ghrelin-Leptin Tango in Body-Weight Regulation, 124:1532–e
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. The Stomach and Weight Reduction: The Role of Ghrelin, 124: 575–ss
Cummings OW
See Nowak TV
See Rex DK
Cummins A, Thompson F. Sensitivity of Anti-endomysial Antibody in Detecting Celiac Disease, 122:246–c
Cuppone R. *See* Rosina F
Curiel DT. *See* Yamamoto M
Curtin K. *See* Samowitz WS
Cusso X. *See* Villanueva C
Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJP, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The Contribution of *NOD2* Gene Mutations to the Risk and Site of Disease in Inflammatory Bowel Disease, 122:866–rc
Cynober L. *See* Crenn P
Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine Polymorphisms Associated With Clinical Features and Treatment Outcome in Type 1 Autoimmune Hepatitis, 117:645
Czaja AJ, Homburger HA. Autoantibodies in Liver Disease, 120:239–srr
Czaja AJ, Lindor KD. Failure of Budesonide in a Pilot Study of Treatment-Dependent Autoimmune Hepatitis, 119:1213
Czernichow P. *See* Michel P
Czimmer J. *See* Luckey A
Czinn SJ. *See* Blanchard TG
Czinn SJ, Nedrud JG. Working Toward a *Helicobacter pylori* Vaccine, 116:990–e

Da Costa SO. *See* Cortez-Pinto H
da Glória F Pegado M. *See* van Doorn L-J
Dachman AH. *See* Johnson CD
DaCosta CM. *See* Williams KL
Dagher I. *See* Veyradier A
Dagnelie PC. *See* Boonen A
Dagorn J-C
See Malka D
See Soubeyran P
D'Agostino G. *See* Tonini M
D'Agruma L. *See* Mangia A
Dahan K. *See* Laurent-Puig P
Dahele A. *See* Gillett HR
Dahill S. *See* Taha AS
Dahl M-L. *See* Sagar M
Dahl SV. *See* Kurz AK
Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-Onset Primary Biliary Cirrhosis, 125:1476–cr
Dahm HH. *See* Leuschner M
Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, Enders GH. $p16^{INK4A}$ Expression Begins Early in Human Colon Neoplasia and Correlates Inversely With Markers of Cell Proliferation, 119:929
Daiker DH. *See* Atchison CR
Dal Pero F. *See* Gerotto M
Dalakas E. *See* Newsome PN
d'Albasio G. *See* Palli D
Dalekos G. *See* Obermayer-Straub P
Dallal HJ. *See* Church NI
Dallinga JW. *See* Vermeer ITM
Dallob A. *See* Wight NJ
Dalton CB. *See* Drossman DA
Dalton HR. *See* McGovern DPB
Daluja AK. *See* Hofbauer B
Dalwadi H
See Braun J
See Sutton CL
Daly AK. *See* Smith BC
Daly L. *See* Rowland M
Dam JV. *See* Wallace MB
D'Amato M
See McLaughlin J
See Pappalardo G
D'Amato RJ. *See* Fishman SJ
D'Ambrosio L. *See* Benedetti A
Damdinsuren B. *See* Yamamoto H
D'Amico G, Pietros G, Tarantino I, Pagliaro L. Emergency Sclerotherapy Versus Vasoactive Drugs for Variceal Bleeding in Cirrhosis: A Cochrane Meta-Analysis, 124:1277
Damore MB. *See* Slonim AE
Danahoglu A. *See* Besisik F
Dandekar S. *See* Mattapallil JJ
Danese S. *See* Papa A
Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C. Platelets Trigger a CD40-Dependent Inflammatory Response in the Microvasculature of Inflammatory Bowel Disease Patients, 124:1249
Dangler CA
See Fox JG
See Wang TC
Daniel EE. *See* Sanders KM
Daniels G. *See* Vinall LE
Daniels S. *See* Shaker R
Danielsen EM. *See* Hansen GH
Danielsen EM, Sjöström H, Norén O, Danielsen GM. Sucrase-Isomaltase: An Epithelial Chloride Channel?, 121: 741–c
Danielsen GM. *See* Danielsen EM
Danielsson A. *See* Bergquist A
Dankert J. *See* Schultsz C
Danko R. *See* Ördög T
Dannenberg AJ. *See* Zhang F
Dannoura AH. *See* Berriot-Varoqueaux N
Daraio F. *See* Girelli D
Daré S. *See* Gaudichon C
D'Argenio G
See Ciacci C
See Ligresti A
Dargère D. *See* Paradis V
Darke C. *See* Ravine D
Darling AL. *The First Year—Crohn's Disease and Ulcerative Colitis: An Essential Guide for the Newly Diagnosed*, 123: 953–pmr
Das D. *See* De BK
Das KM. *See* Lin JL-C
Das U. *See* De BK
Dasari RR. *See* Wallace MB
Date T. *See* Kato T
Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K, Nakazato M. The Role of the Gastric Afferent Vagal Nerve in Ghrelin-Induced Feeding and Growth Hormone Secretion in Rats, 123:1120
Datz C. *See* Kazemi-Shirazi L
Daum F. *See* Markowitz J
Davenport C. *See* Varia I
Davern TJ. Increasing the *RISC* for HCV. Comment, 125:1547–ss
David P. *See* Bourlière M
David V
See Mendler M-H
See Moirand R
Davidson NO
See Newberry EP
See Wang LC
Davidson NO. Phospolipid Flippase, Low HDL Levels, and Intestinal Fat Absorption: A New Look at the ABCs of Enterohepatic Lipid Flux, 118:225–e
Davidson RD. *See* Salto-Tellez M
Davies DR. *See* Baugh MD
Davies S. *See* Lala S
Davis A. *See* Wedemeyer H
Davis B. *See* Laine L
Davis GL. *See* Nelson DR
Davis R. *See* Fontana RJ
Davis T. *See* Bowen DG

Davison J. *See* van Sickle M
Davydova J. *See* Yamamoto M
Day CL. *See* Somsouk M
Day CP
See McRae CA
See Smith BC
Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr Virus–Positive Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine or 6-Mercaptopurine, 122:72
De BK, Sen S, Biswas PK, Mandal SK, Das D, Das U, Guru S, Bandyopadhyay K. Occurence of Hepatopulmonary Syndrome in Budd-Chiari Syndrome and the Role of Venous Decompression, 122:896
De BK, Sen S, Biswas PK, Sanyal R, Majumdar D, Biswas J. Hepato-pulmonary Syndrome in Inferior Vena Cava Obstruction Responding to Cavoplasty, 118:192–cr
de Boer W. *See* van Doorn L-J
de Boni M. *See* Isaacson PG
de Carle DJ. *See* Williams RBH
de Franchis R. *See* Primignani M
de Franco RMS. *See* Caligiuri A
De Giacomo C. Management of the Irritable Bowel Syndrome, 121:1527–c
De Giorgio R
See Barbara G
See Berčík P
See Sternini C
See Trevisani M
De Giorgio R, Bovara M, Barbara G, Canossa M, Sarnelli G, De Ponti F, Stanghellini V, Tonini M, Cappello S, Pagnotta E, Nobile-Orazio E, Corinaldesi R. Anti-HuD-Induced Neuronal Apoptosis Underlying Paraneoplastic Gut Dysmotility, 125:70
de Goeij A. *See* Hermsen M
de Groot PG. *See* Lisman T
de Gucht V. *See* Fischler B
De Haan W. *See* Vader LW
de Jong D. *See* Liu H
de Jong EC. *See* van Montfrans C
de Jong J. *See* Hellemans K
de Jong YP
See Mizoguchi E
See Saubermann LJ
de Jong YP, Comiskey M, Kalled SL, Mizoguchi E, Flavell RA, Bhan AK, Terhorst C. Chronic Murine Colitis Is Dependent on the CD154/CD40 Pathway and Can Be Attenuated by Anti-CD154 Administration, 119:715
de Jonge HR
See Bronsveld I
See Vaandrager AB
de Jonge WJ, van den Wijngaard RM, The FO, ter Beek M-L, Bennink RJ, Tytgat GNJ, Buijs RM, Reitsma PH, van Deventer J, Boeckxstaens GE. Postoperative Ileus Is Maintained by Intestinal Immune Infiltrates That Activate Inhibitory Neural Pathways in Mice, 125:1137
De Kerguenec C. *See* Mansouri A
de la Chapelle A. *See* Prior TW
De la Concha EG, Fernandez-Arquero M, Lopez-Nava G, Martin E, Allcock RJ, Conejero L, Paredes JG, Diaz-Rubio M. Susceptibility to Severe Ulcerative Colitis Is Associated With Polymorphism in the Central MHC Gene IKBL, 119:1491
de la Motte C
See Danese S
See Musso A
De La Revilla J, De Tejada AH, Garrido A. Image of the Month, 125:653–im
De Las Heras D. *See* Ortega R
De Maddalena C. *See* Zehender G
de Maertelaer V. *See* Deviere J
de Magalhaes Queiroz DM. *See* van Doorn L-J
de Magalhães Queiroz DM, Santos A. Isolation of a *Helicobacter* Strain From the Human Liver, 121:1023–c
de Magistris L, Secondulfo M, Sapone A, Carratù R, Iafusco D, Prisco F, Generoso M, Cartenì M, Mezzogiorno A, Esposito V. Infection With *Giardia* and Intestinal Permeability in Humans, 125:277–c
de Marino FA. *See* Persico M
De Muret A. *See* Bacq Y
De Nigris F. *See* Biancone L
De Petrocellis L. *See* Ligresti A
De Ponti F
See De Giorgio R
See Giaroni C
De Ridder RJJ, Stronkhorst A. Effect of Long-Term Lamivudine Therapy on Histological Outcome in Chronic Hepatitis B, 125:1286–c
de Ru A. *See* Vader W
de Silva A. *See* Ahmad T
de Simone C. *See* Madsen K
de Souza RR. *See* Sander G
De Tejada AH. *See* De La Revilla J
de Vos M
See Baert F
See Vermeire S
de Vree JML, Ottenhoff R, Bosma PJ, Smith AJ, Aten J, Oude Elferink RPJ. Correction of Liver Disease by Hepatocyte Transplantation in a Mouse Model of Progressive Familial Intrahepatic Cholestasis, 119:1720
De Waart DR. *See* Brink MA
De Winter H, Elewaut D, Turovskaya O, Huflejt M, Shimeld C, Hagenbaugh A, Binder S, Takahashi I, Kronenberg M, Cheroutre H. Recombinant Interleukin 10 Produced by Intestinal Epithelial Cells in Mice, 122:1829
De Wit MJ. *See* van Rees BP
DeB Edwardes MD. *See* Bitton A
Debard N. *See* Sierro F
Debard N, Sierro F, Browning J, Kraehenbuhl J-P. Effect of Mature Lymphocytes and Lymphotoxins on the Development of the Follicle-Associated Epithelium and M Cells in Mouse Peyer's Patches, 120:1173
Debbabi H
See Buzoni-Gatel D
See Li W
Debeugny S. *See* Laharie D
Deboer G. *See* Capurro M
DeBruin MF. *See* Sands BE
Decaux G. *See* Gerbes AL
Dechelotte P. *See* Viola S
Decker JM. *See* Meng G
Dedeurwaerdere F. *See* Baert F
Dedio J. *See* König P
Deeb S. *See* Dubuquoy L
Deegler LL. *See* Jeffers M
Deem R. *See* Papdakis KA
DeFranco RMS
See Bonacchi A
See Failli P
Degen LP, Peng F, Collet A, Rossi L, Ketterer S, Serrano Y, Larsen F, Beglinger C, Hildebrand P. Blockade of GRP Receptors Inhibits Gastric Emptying and Gallbladder Contraction but Accelerates Small Intestinal Transit, 120:361
Deger E. *See* Hokelek M
Degos F. *See* di Martino V
Degott C
See Demeilliers C
See di Martino V
See Paradis V
Dehertogh D. *See* Lai C-L
Dehn TCB. *See* Booth M
Dehondt G. *See* Tack J
Deibert D. *See* Rössle M
Dejaco C, Ferenci P, Gangl A. Image of the Month, 116:1028–im
Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Moser G. Azathioprine Treatment and Male Fertility in Inflammatory Bowel Disease, 121:1048–
Dekker J. *See* Verburg M

Dekker LRC. *See* Jones EA
Del Bene R. *See* La Villa G
Del Prete G. *See* D'Elios MM
del Sero G. *See* Fiorucci S
del Soldato P
See Fiorucci S
See Wallace JL
Del Valle J. *See* Dubois A
del Vecchio Blanco G. *See* Biancone L
Delage G, Infante-Rivard C, Chiavetta J-A, Willems B, Pi D, Fast M. Risk Factors for Acquisition of Hepatitis C Virus Infection in Blood Donors: Results of a Case-Control Study, 116: 893
Delaney W. *See* Angus P
Delaney W IV. *See* Westland C
Delarive J. *See* Miehlke S
Delavelle J. *See* Spahr L
Delaye J. *See* Boillot O
Delcambre F. *See* Guillem P
DeLegge MH. *Intestinal Failure*, 123:2154–pmr
Delemer B. *See* Cadiot G
DeLeve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) in the Rat Is Prevented by Matrix Metalloproteinase Inhibition, 125:882
Delgado M. *See* Abad C
Delgado S. *See* Lacy AM
Delgado-Aros S. *See* Camilleri M
Delgado-Aros S, Cremonini F. Role of Fecal Calprotectin Test in the Work-up of IBS Patients, 124:1164–c
Delgado-Mije D. *See* Romero-Gómez M
D'Elios MM, Amedei A, Manghetti M, Costa F, Baldari CT, Quazi AS, Telford JL, Romagnani S, Del Prete G. Impaired T-Cell Regulation of B-Cell Growth in *Helicobacter pylori*-Related Gastric Low-Grade MALT Lymphoma, 117:1105
D'Elios MM, Berman MP, Azzurri A, Amedei A, Benagiano M, Pont JJ de, Cianchi F, Vandenbroucke-Grauls CM, Romagnani S, Appelmelk BJ, Prete G del. H^+,K^+-ATPase (Proton Pump) Is the Target Autoantigen of Th1-Type Cytotoxic T Cells in Autoimmune Gastritis, 120:377
Delisle M-B. *See* Clerc P
Delle Fave G. *See* Peghini PL
Dellinger EP
See Cummings DE
See Flum DR
Dell'Oro R. *See* Pozzi M
Delmas B. *See* Hermine O
Delpech M. *See* Granel B
Delude RL. *See* Sappington PL
Delvaux M. Do We Need to Perform Rectal Distention Tests to Diagnose IBS in Clinical Practice?, 122:2075–e
Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol J-L, Frexinos J. The k Agonist Fedotozine Relieves Hypersensitivity to Colonic Distention in Patients With Irritable Bowel Syndrome, 116:38
Delwaide J. *See* Eland IA
Demanet C. *See* Hautekeete ML
Demchyshyn L. *See* Yusta B
Demedts I. *See* Tack J
Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Lettéron P, Degott C, Feldmann G, Pessayre D, Fromenty B. Impaired Adaptive Resynthesis and Prolonged Depletion of Hepatic Mitochondrial DNA After Repeated Alcohol Binges in Mice, 123:1278
Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Effective Therapy for Advanced Gastrointestinal Stromal Tumors, 124:1151–ss
DeMichele SJ. *See* Pacht ER
Demir K. *See* Besisik F
Demmler K. *See* Whitehead RH
Demols A, Devière J. $CD4^+$ T Cells in Cerulein-Induced Pancreatitis. Reply, 119:882–c
Demols A, Le Moine O, Desalle F, Quertinmont E, Van Laethem J-L, Devière J, 118:582
Deng W, Balazs L, Wang D-A, Middlesworth L van, Tigyi G, Johnson LR. Lysophosphatidic Acid Protects and Rescues Intestinal Epithelial Cells From Radiation- and Chemotherapy-Induced Apoptosis, 123:206
Deng Y. *See* Van Assche G
Denk H
See Fickert P
See Wagner M
Denninger MH. *See* Condat B
Denninger M-H. *See* Condat B
Denson LA. *See* Spirlì C
Denson LA, Bohan A, Held MA, Boyer JL. Organ-Specific Alterations in RARα: RXRα Abundance Regulate Rat Mrp2 (Abcc2) Expression in Obstructive Cholestasis, 123:599
Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ. The Orphan Nuclear Receptor, shp, Mediates Bile Acid-Induced Inhibition of the Rat Bile Acid Transporter, ntcp, 121:140
Dent J
See Liaw Y-F
See Lidums I
See Zhang Q
Dent JC. *See* Lai C-L
Deprez PH. *See* Chen J-M
Der CJ. *See* Sizemore N
Der T. *See* Huizinga JD
Der T, Berčík P, Donnelly G, Jackson T, Berezin I, Collins SM, Huizinga JD. Interstitial Cells of Cajal and Inflammation-Induced Motor Dysfunction in the Mouse Small Intestine, 119:1590
Deray G. *See* Izzedine H
Derbyshire S. *See* Mayer EA
Derbyshire SW. *See* Berman SM
Derbyshire SWG. *See* Naliboff BD
Deren JJ
See Lewis JD
See Su C
des Varannes SB
See Abell T
See Piche T
Desalle F. *See* Demols A
Desautels SG, Slivka A, Hutson WR, Chun A, Mitrani C, DiLorenzo C, Wald A. Postcholecystectomy Pain Syndrome: Pathophysiology of Abdominal Pain in Sphincter of Oddi Type III, 116:900
Deschênes C, Vézina A, Beaulieu J-F, Rivard N. Role of $p27^{Kip1}$ in Human Intestinal Cell Differentiation, 120: 423
DeSilvey D. *See* Balaban DH
Desmet VJ, Roskams T. Reversal of Cirrhosis: Evidence-Based Medicine?, 125:629–c
Desoignie R. *See* Kozar RA
Desremaux P. *See* Dharancy S
Desreumaux P
See Dubuquoy L
See Ferrier L
Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, Hafraoui S, Emilie D, Ectors N, Peuchmaur M, Cortot A, Capron M, Auwerx J, Colombel J-F. Inflammatory Alterations in Mesenteric Adipose Tissue in Crohn's Disease, 117:73
Detjen KM. *See* Scholz A
Deugnier Y
See Mendler M-H
See Moirand R
Deulofeu R. *See* Poo J-L

DeVault KR. *Gastroesophageal Reflux Disease*, 120:583–pmr
Devesa M. *See* Madoff RD
Devière J
See Demols A
See Louis H
See Van Gossum A
Deviére J. *See* Maertelaer V de
Deviére J, Le Moine O, Van Laethem J-L, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleuken 10 Reduces the Incidence of Pancreatitis After Therapeutic Endoscopic Retrograde Cholangiopancreatography, 120:498
Deviere J, Pastorelli A, Louis H, de Maertelaer V, Lehman G, Cicala M, Le Moine O, Silverman D, Costamagna G. And Now. . .Fattening the Lower Esophageal Sphincter, 123:944–ss
Devine RM. *See* Schwartz DA
Devriese A. *See* Conway EM
Dewar D. *See* Stern HS
DeWoody KL. *See* Rutgeerts P
Deyra J. *See* Benamouzig R
Dhaene K. *See* Pedrazzoli S
D'Haens G
See Baert F
See Rutgeerts P
See Van Assche G
D'Haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and Histological Healing With Infliximab Anti-Tumor Necrosis Factor Antibodies in Crohn's Disease: A European Multicenter Trial, 116: 1029
Dharancy S, Canva V, Gambiez L, Paris J-C, Desremaux P. Hepatic Deficiency of Interleukin 10 in Chronic Hepatitis C, 119:1411–c
D'Hoore A. *See* Van Assche G
Dhorne-Pollet S. *See* Crosnier C
Dhumeaux D. *See* Mathieu D
Di Bisceglie AM
See Befeler AS
See Lau DT-Y
See Lyra AC
Di Bisceglie AM
Hepatitis C Virus, 116:224–pmr
Di Carlo V. *See* Gianotti L
Di Cristofano A. *See* Kim S
Di Felice G. *See* Boirivant M
Di Giacomo Russo G. *See* Persico M
Di Giovine FS
See Carter MJ
See Tountas NA
Di Giulio E. *See* Laghi A
Di Lelio A. *See* Pozzi M
Di Leo V. *See* Yu LCH
di Mari JF, Mifflin RC, Adegboyega PA, Saada JI, Powell DW. IL-1α-Induced COX-2 Expression in Human Intestinal Myofibroblasts Is Dependent on a PKCζ-ROS Pathway, 124:1855
Di Martino V
See Alric L
See Poynard T
Di Martino V, Rosenheim M, Dorent R, Opolon P, Cadranel J-F, Gandjbachkh I, Lunel F. Hepatitis B Infection in Heart Transplant Recipients. Reply, 120:1313–c
Di Martino V, Thevenot T, Colin J-F, Boyer N, Martinot M, Degos F, Coulaud J-P, Vilde J-L, Vachon F, Degott C, Valla D, Marcellin P. Influence of HIV Infection on the Response to Interferon Therapy and the Long-term Outcome of Chronic Hepatitis B, 123:1812
Di Marzo V
See Izzo AA
See Ligresti A
See Pinto L
Di Mitri R. *See* Cottone M
Di Popolo A. *See* Zarrilli R
Di Prima L. *See* Carroccio A
Di Sario A. *See* Benedetti A
Di Sario A, Bendia E, Baroni GS, Ridolfi F, Bolognini L, Feliciangeli G, Jezequel AM, Orlandi F, Benedetti A. Intracellular Pathways Mediating Na^+/H^+ Exchange Activation by Platelet-Derived Growth Factor in Rat Hepatic Stellate Cells, 116:1155
Di Stefano M, Veneto G, Malservisi S, Cecchetti L, Minguzzi L, Strocchi A, Corazza GR. Lactose Malabsorption and Intolerance and Peak Bone Mass, 122:1793
Di Virgilio F. *See* Spirlì C
Diamant NE
See Beyak MJ
See Drossman DA
See Ji J
See Martino R
Diamant NE, Kamm MA, Wald A, Whitehead WE. AGA Technical Review on Anorectal Testing Techniques, 116:735–aga
Diaz G. *See* Farci P
Díaz VM, Planagumà J, Thomson TM, Reventós J, Paciucci R. Tissue Plasminogen Activator Is Required for the Growth, Invasion, and Angiogenesis of Pancreatic Tumor Cells, 122:806–vidd
Diaz-Cano S. *See* Smits R
Diaz-Rubio M. *See* De la Concha EG
DiBaise JK. *See* Triadafilopoulos G
DiCarlo V. *See* Pedrazzoli S
Dicay M. *See* Fiorucci S
Dick A. *See* Spannagl M
Dickson ER
See Angulo P
See Bambha K
See Kim WR
Dickstein G. *See* Kaplan MM
Diehl AM
See Clark JM
See Cope K
See Cortez-Pinto H
See Li Z
See Sun Z
Diehl AM. The Benefits of Becoming Sensitive: Insulin and Pancreatic Cancer, 120:1292–e
Diehl NN
See Sandborn WJ
See Schwartz DA
Dieleman LA. *See* Williams KL
Dieleman LA. *Gut Ecology*, 124:1998–pmr
Dienes HP. *See* Klein C
Dienstag J. *See* McHutchison JG
Dienstag JL. *See* Lok ASF
Dienstag JL. Comment From the Editors, 117:525
Dienstag JL, Gardner SD, Woessner M. Effect of Long-Term Lamivudine Therapy on Histological Outcome in Chronic Hepatitis B. Reply, 125:1287–c
Dienstag JL, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological Outcome During Long-term Lamivudine Therapy, 124:105
Diep CB. *See* Thornstensen L
Diepolder HM. *See* Gerlach JT
Diepolder HM, Ries G, Jung M-C, Schlicht H-J, Gerlach J-T, Grüner N, Caselmann WH, Pape GR. Differential Antigen-Processing Pathways of the Hepatitis B Virus e and Core Proteins, 116:650
Dierckx R. *See* Annovazzi A
Dierkhising R. *See* Vazquez-Sequeiros E
Dietel M. *See* Swidsinski A
Dietrich M. *See* Jaeckel E
Dietschy JM. *See* Repa JJ
DiFebo G. *See* Calabrese C
Dignass AU
See Schulte C
See Sturm A
Dikeman K. *See* Shaker R
Dikic I. *See* Soubeyran P
Dikov MM. *See* Adachi Y
Dill B. *See* Dill JE
Dill JE, Dill B
Biopsychosocial Treatment of Irritable Bowel Syndrome, 125:1554–c

Gallbladder Disease; Acalculus or Not?, 121:1529–c
Dill JE. Endoscopic Ultrasonography for Gallbladder Disease, 116:1018–c
Dill-Macky MJ. *See* Oudit GY
DiLorenzo C. *See* Desautels SG
Pseudo-obstruction: Current Approaches, 116:980–vidd
DiMagno EP
See Chari ST
See Suzuki A
DiMagno EP
Gene Mutations and Idiopathic Chronic Pancreatitis: Clinical Implications and Testing, 121:1509–e
Pancreatic Cancer, 125:1552–pmr
Toward Understanding (and Management) of Painful Chronic Pancreatitis, 116:1252–e
DiMagno EP, Reber HA, Tempero MA. AGA Technical Review on the Epidemiology, Diagnosis, and Treatment of Pancreatic Ductal Adenocarcinoma, 117:1464–aga
Dimaline R
See Burdyga G
See Haigh CR
See Higham AD
See Khan ZE
See Varro A
DiMarino AJ. *See* DiMarino M
DiMarino M, Banwait K, Rattan S, Cohen S, DiMarino AJ. β3 Adrenergic Stimulation Inhibits the Opossum Lower Esophageal Sphincter, 123:1508
Dimartino V. *See* Lunel F
Dimitrijevic S. *See* Demetri GD
Dimoulios P. *See* Roussomoustakaki M
Dinauer M. *See* Beck PL
Ding W-Q, Kuntz S, Böhmig M, Wiedenmann B, Miller LJ. Dominant Negative Action of an Abnormal Secretin Receptor Arising From mRNA Missplicing in a Gastrinoma, 122:500–cr
Ding W-X. *See* Zhao Y
Ding X-Z. *See* Schneider MB
Dinkel H-P. *See* Dufour J-F
Dionigi R. *See* Pedrazzoli S
Disdier P. *See* Granel B
Diss TC. *See* Isaacson PG
Distrutti E
See Azpiroz F
See Fiorucci S
Distrutti E, Azpiroz F, Soldevilla A, Malagelada J-R. Gastric Wall Tension Determines Perception of Gastric Distention, 116:1035
Dits H. *See* Wilmer A
Dittie A. *See* Hellemans K
Diwakaran HH, Stolar CG, Prather CM. Image of the Month, 121:516–im
Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese, 121:91
Dixon JB, O'Brien PE, Bhathal PS. A Wilder View on Diagnostic Criteria of Nonalcoholic Steatohepatitis. Reply, 122:841–c
Dixon JL. *See* Fletcher LM
Dixon MF. *See* Moayyedi P
Djian J. *See* Gerbes AL
Dlude RL. *See* Tomita M
Dobbins AC. *See* Higham AD
Dobrindt U. *See* Waidmann M
Dockray GJ
See Burdyga G
See Chen D
See Clerc P
See Higham AD
See McLaughlin J
See Ottewell PD
See Varro A
See Wang TC
Dockray GJ. Transepithelial Signaling: Making Sense of Stomach Contents, 120:1280–e
Dodson F. *See* Vargas HE
Doetschman T. *See* Boivin GP
Dogan A. *See* Liu H
Doggett B. *See* Parisi MA
Doglioni C. *See* Isaacson PG
Dohi T, Fujihashi K, Kiyono H, Elson CO, McGhee JR. Mice Deficient in Th1- and Th2-Type Cytokines Develop Distinct Forms of Hapten-Induced Colitis, 119:724
Dohi T, Fujihashi K, Koga T, Shirai Y, Kawamura YI, Ejima C, Kato R, Saitoh K, McGhee JR. T Helper Type-2 Cells Induce Ileal Villus Atrophy, Goblet Cell Metaplasia, and Wasting Disease in T Cell-Deficient Mice, 124:672
Dol F. *See* Conway EM
Dolan-O'Keefe M, Nicks HS. Inhibition of Cytoplasmic Phospholipase A_2 Expression by Glucocorticoids in Rat Intestinal Epithelial Cells, 116:855
Doll MA. *See* McKim SE
Dombrowski F. *See* Häussinger D
Domchek SM. *Selected Topics in Clinical Oncology*, 120:583–pmr
Dominguez J. *See* Schoenfeld P
Dominguez JA. *See* Dvorak B
Dominitz JA. *See* Ioannou GN
Domon-Dell C. *See* Kim S
Domschke W
See Abell T
See Bantel H
See Lerch MM
See Lügering A
See Mayerle J
Donahue P. *See* Umemura T
Donaldson P. *See* Satsangi J
Donaldson PT. *See* Czaja AJ
Dong H, Loomis CW, Bieger D. Distal and Deglutitive Inhibition in the Rat Esophagus: Role of Inhibitory Neurotransmission in the Nucleus Tractus Solitarii, 118:328
Dongiovanni P. *See* Valenti L
Donini A. *See* Adani GL
Donnelly G
See Der T
See Huizinga JD
Donnelly S. *See* Farrell RJ
Donnenberg MS. *See* McNamara BP
Dono K. *See* Yamamoto H
Donoghue S
See Ghosh G
See Gordon FH
Donohue JH. *See* Huntsman DG
Donovan JM. *See* Eckhardt ERM
Donowitz M. *See* Sandler RS
Doo E
See Ghany MG
See Lau DT-Y
Doo E, Liang TJ. Molecular Anatomy and Pathophysiologic Implicatons of Drug Resistance in Hepatitis B Virus Infection, 120:1000–srr
Dooley JS. *See* Wallace DF
Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten Dijke P, Gressner AM. Smad7 Prevents Activation of Hepatic Stellate Cells and Liver Fibrosis in Rats, 125:178
Dore MP. *See* Graham DY
Dorent R
See Di Martino V
See Lunel F
Dorrell N, Martino MC, Stabler RA, Ward SJ, Zhang ZW, McColm AA, Farthing MJG, Wren BW. Characterization of *Helicobacter pylori* PldA, a Phospholipase With a Role in Colonization of the Gastric Mucosa, 117:1098
d'Orta C. *See* Pappalardo G
Dorta G. *See* Miehlke S
Dotan I. *See* Allez M
Doukhan I. *See* Cadiot G
Dove WF. *See* Boivin GP
Dovidio M. *See* Syngal S
Dowling RH
See Thomas LA
See Veysey MJ
Dowling RH, Thomas LA. Intestinal Motility and Bacterial Overgrowth in

Patients With Gallstones. Reply, 120: 1312–c
Doyle DA, Morais J, Pfuetzner RH, Kuto A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. The Potassium Channel and How It Works, 116: 216–ss
Doyle J. *See* Madsen K
Drachenberg CB. *See* Fu S
Dragosics B. *See* Fischbach W
Dranoff JA. *See* Hirata K
Dray X, Marteau P, Bienvenu T, Dusser D, Hubert D. Discussion on Genotype and Phenotype Correlations in Patients With Cystic Fibrosis and Pancreatitis, 125:1286–c
Drewes AM. *See* Pedersen J
Driancourt C. *See* Crosnier C
Dries V. *See* Benz C
Drijfhout JW. *See* Vader LW
Drillenburg P. *See* Hove TT
Driman DK, Tougas G, Riddell R. Long-Term Effects of Omeprazole on the Gastric Mucosa, 119:1176–c
Drobek S. *See* Zender L
Drobnik W, Lindenthal B, Lieser B, Ritter M, Weber TC, Liebisch G, Giesa U, Igel M, Borsukova H, Büchler C, Fung-Leung WP, Von Bergmann K, Schmitz G. ATP-Binding Cassette Transporter A1 (ABCA1) Affects Total Body Sterol Metabolism, 120:1203
Drolet J-F. *See* Vachon PH
Drori S. *See* Girnun GD
Drossman DA
Comment From the Editors, 124:6–ce
Irritable Bowel Syndrome: How Far Do You Go in the Workup?, 121:1512–e
Drossman DA. Challenges in the Physician-Patient Relationship: Feeling "Drained," 121:1037–ce
Drossman DA, Ringel Y, Vogt BA, Leserman J, Lin W, Smith JK, Whitehead W. Alterations of Brain Activity Associated With Resolution of Emotional Distress and Pain in a Case of Severe Irritable Bowel Syndrome, 124:754–cr
Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V, Akman D, Frusciante K, Le T, Meyer K, Bradshaw B, Mikula K, Morris CB, Blackman CJ, Hu Y, Jia H, Li JZ, Koch GG, Bangdiwala SI. Cognitive-Behavioral Therapy Versus Education and Desipramine Versus Placebo for Moderate to Severe Functional Bowel Disorders, 125:19
Drouin E. *See* Steinhart AH
Droz D. *See* Granel B
Drucker DJ
See Boushey RP
See Xiao Q
See Yusta B
Drucker DJ. Biological Actions and Therapeutic Potential of the Glucagon-like Peptides, 122:531–srr
Druker BJ. *See* Demetri GD
Drumm B
See Clyne M
See Rowland M
Drumm B, Rowland M, Imrie C. Sensitivity of Urease-Based Test on Diagnosis of *Helicobacter pylori* in Children and the Elderly, 116:1505–c
Drumm ML. *See* Steagall WK
Dryden S. *See* Ballinger A
Du Bois R. *See* Slikowski MX
Du M-Q. *See* Liu H
Du Sart D. *See* Gochee PA
Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine Can Cause Serious Liver Injury in Inflammatory Bowel Disease Patients, 125:298
Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP Metabolite Profiles Provide a Biochemical Explanation for 6-MP Resistance in Patients With Inflammatory Bowel Disease, 122:903
Dubois A. *See* Mysore JV
Dubois A, Berg DE, Incecik ET, Fiala N, Heman-Ackah LM, De Valle J, Yang M, Wirth H-P, Perez-Perez GI, Blaser MJ. Host Specificity of *Helicobacter pylori* Strains and Host Responses in Experimentally Challenged Nonhuman Primates, 116:90
Dubois A, Zopf D. *H. pylori* Adhesion and Lewis X, 119:1414–c
Dubois R. *See* Kawai N
DuBois RN
See Callejas NA
See Shattuck-Brandt RL
DuBois RN
Comment From the Editors, 122:1719–ce
The Physician-Scientist in Gastroenterology, 125:652–ce
Will an Aspirin a Day Keep the Endoscopy Away?, 125:612–e
DuBois RN, Washington MK. COX-2 in Murine Intestinal Tumors. Reply, 119:600–c
Dubuquoy L, Jansson EÅ, Deeb S, Rakotobe S, Karoui M, Colombel J-F, Auwerx J, Pettersson S, Desreumaux P. Impaired Expression of Peroxisome Proliferator-Activated Receptor γ in Ulcerative Colitis, 124:1265
Ducerf C. *See* Samuel D
Duchmann R
See Knolle PA
See May E
Ducloux S. *See* Moreau R
Ducot B. *See* Féray C
Ducrotte P. *See* Michel P
Dudas S. *See* Sternberg LR
Dudas SP, Yunker CK, Sternberg LR, Byrd JC, Bresalier RS. Expression of Human Intestinal Mucin Is Modulated by the β-Galactoside Binding Protein Galectin-3 in Colon Cancer, 123:817
Dudiak KM. *See* Schwartz DA
Duerr RH
See Bonen DK
See Hugot J-P
Duerschmied D. *See* Wagner M
Duff GW. *See* Carter MJ
Duffaut M. *See* Alric L
Dufour G. *See* Vachon PH
Dufour J-F, Dinkel H-P, Zimmerman A. Image of the Month, 125:1010–im
Dufour P. *See* Chamouard P
Dufresne M. *See* Clerc P
Dugave C. *See* Matysiak-Budnik T
Duggan C, Lencer WI. A Novel Development in Oral Rehydration Therapy. Comment, 119:591–ss
Duhamel C. *See* Moreau R
Duhamel JF. *See* Cézard JP
Dühmke E. *See* Fischbach W
Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM
Discussion on Preoperative Prevalence of Barrett's Esophagus in Esophageal Adenocarcinoma: A Systemic Review. Reply, 123:955–co
Preoperative Prevalence of Barrett's Esophagus in Esophageal Adenocarcinoma: A Systematic Review, 122:26
Dulai GS. Surveying the Case for Surveillance, 122:820–e
Duley J. *See* McGovern DPB
Duman JG. *See* Karvar S
Dumont B. *See* Lunel F
Dumortier J. *See* Marion-Audibert A-M
Dumot JA. *See* Vargo JJ
Duncan S. *See* Drossman DA
Duner E. *See* Spirli C
Dünker N, Schmitt K, Schuster N, Krieglstein K. The Role of Transforming Growth Factor Beta-2, Beta-3 in Mediating Apoptosis in the Murine Intestinal Mucosa, 122:1364
Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative Importance of

Enterochromaffin Cell Hyperplasia, Anxiety, and Depression in Postinfectious IBS, 125:1651
Dunlop SP, Sherwood AJ, Wilkinson SP. Inflammation of the Gastric Cardia, 116:228–c
Dunne D. *See* Rex DK
Dunne DP. *See* Filipi CJ
Dunstan FDJ. *See* Evans RC
Duong F. *See* Blindenbacher A
Dupas J-L. *See* Laharie D
DuPasquier R. *See* Spahr L
Dupic F, Fruchon S, Bensaid M, Borot N, Radosavljevic M, Loreal O, Brissot P, Gilfillan S, Bahram S, Coppin H, Roth M-P. Inactivation of the Hemochromatosis Gene Differentially Regulates Duodenal Expression of Iron-Related mRNAs Between Mouse Strains, 122:745
Durand D. *See* Alric L
Durand F
See Colle IO
See Moreau R
Duran-Sandoval D
See Barbier O
See Claudel T
Durell BG. *See* Li W
Durie P. *See* Durno C
Durie PR. *See* Boocock GR
Durno C, Corey M, Zielenski J, Tullis E, Tsui L-C, Durie P. Genotype and Phenotype Correlations in Patients With Cystic Fibrosis and Pancreatitis, 123:1857
Dusetti NJ. *See* Malka D
Dusser D. *See* Dray X
Duthilleul P. *See* Quinton JF
Dutoit P. *See* Berčík P
Dutrillaux B. *See* Bras-Gonçalves RA
Duval A
See Brennetot C
See Suraweera N
Duval A, Iacopetta B, Thorstensen L, Meling GI, Lothe RA, Thuille B, Suraweera N, Thomas G, Hamelin R. Gender Difference for Mismatch Repair Deficiency in Human Colorectal Cancer, 121:1027–c
Dvorak AM. Neuroendocrine Cell Secretory Granules Are Not Bacteria in Inflammatory Bowel Disease, 125: 1288–c
Dvorak B, Halpern MD, Holubec H, Williams CS, McWilliam DL, Dominguez JA, Stepankova R, Payne CM, McCusky RS. NEC, EGF, Milk and Spit, 123:383–ss
Dvorak B. NEC, EGF, Milk and Spit. Reply, 123:384–ss
Dwinell MB, Eckmann L, Leopard JD, Varki NM, Kagnoff MF. Chemokine Receptor Expression by Human Intestinal Epithelial Cells, 117:359
Dwinell MB, Lügering N, Eckmann L, Kagnoff MF. Regulated Production of Interferon-Inducible T-Cell Chemoattractants by Human Intestinal Epithelial Cells, 120:49
Dyan A. *See* Francella A
Dydensborg AB. *See* Vachon PH

Eaker IY. *See* Hiba MR
Earler KA. *See* Berg DJ
Easley K. *See* Goldblum JR
Easterling C. *See* Shaker R
Eastwood C. *See* Jiang W
Ebert M. *See* Wagner M
Echenagusia A. *See* Escorsell À
Echevarria W. *See* Denson LA
Eckardt VF
Chest Pain in Achalasia Is an Age-Dependent Phenomenon. Reply, 117: 1258–c
Does Surveillance Endoscopy Improve Life Expectancy in Those With Barrett's Esophagus? Reply, 121:1517–ss
Eckardt VF, Grebe P. Image of the Month, 123:7–im
Eckardt VF, Kanzler G, Bernhard G. Does Surveillance Endoscopy Improve Life Expectancy in Those With Barrett's Esophagus?, 121:1516–ss
Eckardt VF, Stauf B, Bernhard G. Chest Pain in Achalasia: Patient Characteristics and Clinical Course, 116:1300
Eckert ED. *See* Faris PL
Eckert K. *See* Streetz K
Eckhard M. *See* Zender L
Eckhardt ERM, Wang DQ-H, Donovan JM, Carey MC. Dietary Sphingomyelin Suppresses Intestinal Cholesterol Absorption By Decreasing Thermodynamic Activity of Cholesterol Monomers, 122:947
Eckmann L
See Dwinell MB
See Hase K
See Maaser C
Eclache-Saudreau V. *See* Hermine O
Ectors N. *See* Desreumaux P
Edderkaoui M. *See* Vaquero EC
Edelmann W. *See* Girnun GD
Ederer F. *See* Mandel JS
Ederer F, Church T, Mandel J. What Will You Be When You Grow Up? Reply, 121:733–ss
Edge AS. *See* Nagata H
Edmundowicz S. *See* Corley DA
Edmundowicz SA
See Filipi CJ
See Triadafilopoulos G
Edmundson S. *See* Liaw Y-F
Edwards E. *See* Wiesner R
Edwards JE. *See* Radford-Smith GL
Edwards LJ. *See* Muir AJ
Edwards MJ. *See* Lentsch AB
Edwards R. *See* Angus P
Efsen A. *See* Marra F
Efsen E. *See* Bonacchi A
Egan LJ, Sandborn WJ. PPAR-γ Ligand Antidiabetic Drugs: Good News for Colitis? Comment, 118:229–ss
Egekvist H. *See* Pedersen J
Egger B. *See* Steinkamp M
Eggersten G. *See* Vlahcevic ZR
Eggo MC. *See* Zhu GH
Egnor RW. *See* Charney AN
Ehlers RA. *See* Ethridge RT
Ehmer U. *See* Vogel A
Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide Therapy for Patients With Refractory Crohn's Disease: An Open-Label Trial, 117:1271
Eichelbaum M. *See* Schwab M
Einarsdottir AS. *See* Bjarnason I
Einerhand AWC. *See* Verburg M
Einspahr J. *See* Maltzman T
Eiras P. *See* León F
Eisel W. *See* LeSage G
Eisele S. *See* Grimm CF
Eisen G. *See* Spiegel BMR
Eisen G. *Evidence-Based Gastroenterology*, 124:861–pmr
Eisen GM. *See* Lieberman DA
Eisenberg B. *See* Demetri GD
Eisendrath P. *See* Deviére J
Ejima C. *See* Dohi T
Ekbom A
See Andersson RE
See Askling J
See Bergquist A
See Elmberg M
See Lagergren J
Ekbom A
Early Virus Infections and Inflammatory Bowel Disease: Back to the Drawing Board?, 116:988–e
Ekkelenkamp K. *See* Stam R
Ekström AM. *See* Serafini M
Ekström AM, Wolk A, Bellocco R, Serafini M. Fruits and Vegetables: Do They Protect From Gastric Cancer? Reply, 124:2007–c
Ekström K. *See* Askling J
El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, Catassi C, Fasano A. Host-Dependent Zonulin Secretion Causes the Impairment of the Small Intestine Barrier Function After Bacterial Exposure, 123:1607

El Marjou F. *See* Janssen K-P
El Sayed Khalifa K. *See* Kamal SM
El Younsi M. *See* Condat B
Eland IA, Rasch MC, Sturkenboom MJCM, Bekkering FC, Brouwer JT, Delwaide J, Belaiche J, Houbiers G, Stricker BHCh. Acute Pancreatitis Attributed to the Use of Interferon Alfa-2b, 119:230
El-Assal O
See Radaeva S
See Sun Z
Eldridge KP. *See* Harris HE
Elena M. *See* Sans M
Elena S. *See* Liu H
Elewaut D. *See* De Winter H
Eling TE. *See* Kim K-S
Elizalde JI
See Bessa X
See Sans M
Elkström AM, Held M, Hansson L-E, Engstrand L, Nyrén O. *Helicobacter pylori* in Gastric Cancer Established by CagA Immunoblot as a Marker of Past Infection, 121:784
Ellemunter H. *See* Müller T
Ellis HJ
See Biagi F
See Fraser JS
Ellis L. *See* Boocock GR
Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg-Gertzén H, Askling J. Cancer Risk in Patients With Hereditary Hemochromatosis and in Their First-Degree Relatives, 125:1733
El-Nujumi A. *See* El-Omar EM
El-Omar E. *See* McColl KEL
El-Omar E, McColl KEL. When Enthusiasm Is Infectious. Reply, 119:276–c
El-Omar EM
See Furuta T
See McColl KEL
El-Omar EM, Chow W-H, Rabkin CS. Gastric Cancer and *H. pylori:* Host Genetics Open the Way, 121:1002–e
El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D, Williams C, Fullarton G, McColl KEL. Increased Prevalence of Precancerous Changes in Relatives of Gastric Cancer Patients: Critical Role of *H. pylori*, 118:22
El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow W-H. Increased Risk of Noncardia Gastric Cancer Associated With Proinflammatory Cytokine Gene Polymorphisms, 124:1193
Eloubeidi MA. *See* Mulcahy HE
Eloubeidi MA, Branch M, Treem WR. Image of the Month, 118:462–im
El-Rifai W, Frierson HF Jr, Moskaluk CA, Harper JC, Petroni GR, Bissonette EA, Jones DR, Knuutila S, Powell SM. Genetic Differences Between Adenocarcinomas Arising in Barrett's Esophagus and Gastric Mucosa, 121:592
Elsaleh H, Shannon B, Iacopetta B
Microsatellite Instability as a Molecular Marker for Very Good Survival in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy, 120:1310–c
The Microsatellite Instability Phenotype in Human Colorectal Carcinoma: Relationship to Sex, Age, and Tumor Site, 121:230–c
El-Serag HB, Everhart JE. Diabetes Increases the Risk of Acute Hepatic Failure, 122:1822
El-Serag HB, Gilger M, Kuebeler M, Rabeneck L. Extra-esophageal Associations of Gastroesophageal Reflux Disease in Children Without Neurologic Defects, 121:1294
El-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric Disorders Among Veterans With Hepatitis C Infection, 123:476
Elson CO
See Dohi T
See Fedorak RN
Elson CO
Commensal Bacteria as Targets in Crohn's Disease, 119:254–e
Ely SA. "High-Grade MALT" *vs.* Diffuse Large B Cell Lymphoma, 123:956–co
El-Zimaity HMT. *See* Yamaoka Y
Emerick KM, Whitington PF. Itchin' for a Diversion, 124:1155–ss
Emery PW. *See* Pufulete M
Emilie D
See Desreumaux P
See Ferrier L
Emilio D. *See* Testino G
Emmanuel AV. *See* Murray CDR
Emmermann A. *See* Fibbe C
Emmott S. *See* Drossman DA
Emond JC. *See* Shiva Kumar K
Emond MJ. *See* Tung BY
Emond MJ, Tung BY, Brentnail TA. Ursodiol Prevents UC-Associated CRC. Reply, 121:492–ss
Emre S. *See* Liu LU
Emslie-Smith AM. *See* Mueller LA
Encke J. *See* Grimm CF
Enders GH. *See* Dai CY
Enerbäck S. *See* Spodsberg N
Eng C
See Girnun GD
See Syngal S
Eng F. *See* Yang C
Eng SC, Kowdley KV. Expansion of Criteria for Liver Transplantation in HCC: A Slippery Slope? Comment, 122:580–ss
Engel B. *See* Schwarz NT
Engels LGJB. *See* Vermeer ITM
Engelsgjerd M, Farraye FA, Odze RD. Polypectomy May Be Adequate Treatment for Adenoma-Like Dysplastic Lesions in Chronic Ulcerative Colitis, 117:1288
Engstrand L. *See* Elkström AM
Engwall Y. *See* Björk J
Enomoto A. *See* Enomoto N
Enomoto N. *See* Tsune I
Enomoto N, Ikejima K, Yamashina S, Enomoto A, Nishiura T, Nishimura T, Brenner DA, Schemmer P, Bradford BU, Rivera CA, Zhong Z, Thurman RG. Alcoholic Steatosis: The Kupffer Cell A Villain?, 120:581–ss
Enomoto N, Takei Y, Hirose M, Ikejima K, Miwa H, Kitamura T, Sato N. Thalidomide Prevents Alcoholic Liver Injury in Rats Through Suppression of Kupffer Cell Sensitization and TNF-α Production, 123:291
Enteric Neuromuscular Disorders and Pain Group. *See* Chen JDZ
Enya M. *See* Akita K
Epperson A. *See* Ward SM
Erhard J. *See* Heller J
Erhardtsen E. *See* Jeffers L
Erlinger S. *See* Condat B
Ernst O. *See* Desreumaux P
Ernst RD. *See* Johnson CD
Ernst SA
See Chen X
See Wojcikiewicz RJH
Ertan A. *See* Younes M
Erwin CR. *See* Bates MD
Erwin CR, Jarboe M, Warner BW. Zeroing in on the "Holy Grail." Comment, 125:267–ss
Erwin CR, Warner BW. Hirschsprung Lost His Nerve. Comment, 125:1901–ss
Escolano S. *See* Condat B
Escorsell À
See González-Aaldes J
See Moitinho E
Escorsell À, Bañares R, Garcìa-Pagán JC, Bosch J. Some Tips for the Prevention of Recurrent Variceal Hemorrhage? Reply, 123:386–ss
Escorsell À, Bañares R, Garcìa-Pagán JC, Gilabert R, Moitinho E, Piqueras B,

Bru C, Echenagusia A, Granados A, Bosch J. Some Tips for the Prevention of Recurrent Variceal Hemorrhage?, 123:384–ss
Escorsell À, Bandi JC, Andreu V, Moitinho E, García-Pagán JC, Bosch J, Rodés J. Desensitization to the Effects of Intravenous Octreotide in Cirrhotic Patients With Portal Hypertension, 120:161
Eskandari MK. *See* Schwarz NT
Esmaili A. *See* Li L
Espeland MA. *See* Pineau BC
Espi A. *See* Minguez M
Esposito V. *See* de Magistris L
Esteban R. *See* Féray C
Esters N. *See* Vermeire S
Estes MK. *See* Ball JM
Esteve M. *See* Panés J
Etemad B, Whitcomb DC. Chronic Pancreatitis: Diagnosis, Classification, and New Genetic Developments, 120: 682
Ethridge RT, Chung DH, Slogoff M, Ehlers RA, Hellmich MR, Rajaraman S, Saito H, Uchida T, Evers BM. Cyclooxygenase-2 Gene Disruption Attenuates the Severity of Acute Pancreatitis and Pancreatitis-Associated Lung Injury, 123:1311
Ethrifge RT. *See* Chung DH
Ettori F. *See* Colle IO
Etzioni R. *See* Ramsey SD
Eugen-Olsen J. *See* Andresen L
The Eurogast Study Group. *See* Webb PM
Eurohep Study Group for Viral Hepatitis. *See* Schalm SW
European CF Twin and Sibling Study Consortium. *See* Bronsveld I
European Concerted Action on Viral Hepatitis (Eurohep) Group. European Collaborative Study on Factors Influencing Outcome After Liver Transplantation for Hepatitis C Virus, 117:619
Evans GS. *See* Baugh MD
Evans JF. *See* Oshima M
Evans MJ, Rice CM. Hepatitis C Virus Replicons Finally Get to Second Base, 125:1892–e
Evans RC, Fear S, Ashby D, Hackett A, Williams E, van der Vliet M, Dunstan FDJ, Rhodes JM. Diet and Colorectal Cancer: An Investigation of the Lectin/Galactose Hypothesis, 122:1784
Evans S. *See* Murray B
Evans SM, Ashwood P, Warley A, Berisha F, Thompson RPH, Powell JJ. The Role of Dietary Microparticles and Calcium in Apoptosis and Interleukin-1β Release of Intestinal Macrophages, 123:1543
Everhart JE
See El-Serag HB
See Ruhl CE
See Sandler RS
Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and Ethnic Differences in Gallbladder Disease in the United States, 117:632
Everley L. *See* Cooper HS
Evers BM
See Chung DH
See Ethridge RT
See Kim S
Eversman D, Chalasani N. A Case of Infective Endotipsitis, 117:514–c
Everson GT. MELD: The Answer or Just More Questions?, 124:251–e
Everts B. *See* Abell T
Everwand J. *See* Gaudichon C
Evrovski J. *See* Springer JE
Exley M. *See* Saubermann LJ
Eysselein VE. *See* Reinshagen M
Ezaki T. *See* Uwatoku R
Ezerzer F. *See* Martino R
Ezzat W. *See* Kamal SM

Fabre M
See Bacq Y
See Viola S
Fabris L. *See* Spirlì C
Facchini F, Hua N, Stoohs R
Effect of Iron Depletion in Carbohydrate-Intolerant Patients With Clinical Evidence of Nonalcoholic Fatty Liver Disease, 122:930
Effect of Iron Depletion in Patients With Nonalcoholic Fatty Liver Disease Without Carbohydrate Intolerance. Reply, 124:866–c
Faccino RM. *See* Fiorucci S
Facciorusso D. *See* Andriulli A
Fackler W. *See* Bauer WM
Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term Effect of H_2RA Therapy on Nocturnal Gastric Acid Breakthrough, 122:625
Fagerhol MK. *See* Tibble JA
Faigel DO, Fennerty MB
"Cutting the Cord" for Capsule Endoscopy, 123:1385–e
Discussion on "Cutting the Cord" for Capsule Endoscopy. Reply, 125:998–c
Failli P
See Bonacchi A
See Caligiuri A
Failli P, DeFranco RMS, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laffi G, Gentilini P, Pinzani M. Nitrovasodilators Inhibit Platelet-Derived Growth Factor-Induced Proliferation and Migration of Activated Human Hepatic Stellate Cells, 119:479
Falchuk KR. *See* Farrell RJ
Falk GW
See Goldblum JR
See Ormsby AH
Falk GW
Barrett's Esophagus, 122:1569
Barrett's Esophagus and Heater Probe. Reply, 124:2009–c
Falk W
See Hausmann M
See Leeb SN
See Steidler L
Faller LD. *See* Gukovskaya AS
Fällman M. *See* Su B
Fallon MB. *See* Zhang J
Fallon MB. Hepatopulmonary Syndrome: A Good Relationship Gone Bad, 125: 1261–e
Falus A. *See* Tanaka S
Familoni BO. *See* Abell T
Fan K. *See* Holt PR
Fan S. *See* Radaeva S
Fan X. *See* Lyra AC
Fan Y. *See* Yang H
Fanelli FR. *See* Marchesini G
Fang R, Santiago NA, Olds LC, Sibley E. The Homeodomain Protein Cdx2 Regulates Lactase Gene Promoter Activity During Enterocyte Differentiation, 118:115
Fantappiè O. *See* Cianchi F
Fantaske R. *See* Yusta B
Fantini M
See Biancone L
See Rosenstiel P
Fantry GT. *See* Fu S
Fantuzzi G. *See* Siegmund B
Färber L. *See* Merger M
Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. Predicting the Outcome of Hepatitis C Virus Infection, 120:312–ss
Fargion S
See Fracanzani AL
See Valenti L
Faris PL, Goodale RL, Kim S-W, Meller WH, Eckert ED, Hartman BK. 5-HT, Antagonist Therapy of Bulimia Nervosa: A Peripherally Active Agent for a Central Nervous System Eating Disorder? Comment, 119:272–ss
Färkkila M. *See* Kaukinen K
Färkkilä M
See Collin P

See Kaukinen K
See Turunen U
Farnell MB. *See* Chari ST
Farraye FA
See Engelsgjerd M
See Fletcher RH
See Huang CS
Farrell G. *See* Chitturi S
Farrell GC
See Chitturi S
See Hui JM
See Leclercq IA
Farrell JJ. *Methods in Disease: Investigating the Gastrointestinal Tract.* 116:1009–pmr
Farrell JJ, Wang TC. *Acid Related Disease: Biology and Treatment.* 117:743–pmr
Farrell RJ, Alsahli M, Jeen Y-T, Falchuk KR, Peppercorn MA, Michetti P. Intravenous Hydrocortisone Premedication Reduces Antibodies to Infliximab in Crohn's Disease: A Randomized Controlled Trial, 124:917
Farrell RJ. *Fast Facts-Coeliac Disease.* 119: 595–pmr
Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PWN, Weir DG, Kelleher D. High Multidrug Resistance (P-Glycoprotein 170) Expression in Inflammatory Bowel Disease Patients Who Fail Medical Therapy, 118:279
Farrugia G
See He C-L
See Holm AN
See Lyford GL
Farrugia G, Holm AN, Rich A, Sarr MG, Szurszewski JH, Rae JL. A Mechanosensitive Calcium Channel in Human Intestinal Smooth Muscle Cells, 117:900
Farrugia G. Is Constipation Caused by a Loss of Colonic Interstitial Cells of Cajal? Reply, 125:265–ss
Farthing JG
See Ballinger A
See Turvill JL
Farthing MJG
See Dorrell N
See Kelly P
See Pollok RCG
See Zoli G
Fasano A. *See* el Asmar R
Fasano A, Catassi C. Current Approaches to Diagnostic and Treatment of Celiac Disease: An Evolving Spectrum, 120: 636
Fass R, Ofman JJ, Fennerty MB. High-Dose Omeprazole in Patients With Noncardiac Chest Pain. Reply, 116: 226–c
Fass R, Ofman JJ. Omeprazole Test and 24-Hour Esophageal pH Monitoring in Diagnosing GERD. Reply, 116:1012–c
Fast M. *See* Delage G
Fatmi A. *See* Bain C
Fattinger K
See Kullak-Ublick GA
See Stieger B
Faubion WA. *See* Sandborn WJ
Faubion WA, Sandborn WJ. Probiotic Therapy with *E. Coli* for Ulcerative Colitis: Take the Good With the Bad. Comment, 118:630–ss
Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The Natural History of Corticosteroid Therapy for Inflammatory Bowel Disease: A Population-Based Study, 121:255
Faucheron J-L. *See* Madoff RD
Faure C, Viarme F, Cargill G, Navarro J, Gaultier C, Trang H. Abnormal Esophageal Motility in Children With Congenital Central Hypoventilation Syndrome, 122:1258
Fave GD
See Bordi C
See Jensen RT
Fazekas de St. Groth B. *See* Bowen DG
Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Prophylactic Pancreatic Duct Stenting: A Panacea?, 125:1274–ss
Fazio VW
See Sandborn WJ
See Shen B
Feagan B. *See* Fedorak RN
Feagan BG
See Hanauer SB
See Sandborn WJ
See Silverstein MD
See Steinhart AH
Feagan BG, McDonald JWD. Mesalamine Maintenance Therapy for Crohn's Disease, 120:585–c
Fear S. *See* Evans RC
Fearon ER. *See* Hinoi T
Fedele CG. *See* Losa JH
Fedele S. *See* Mignogna MD
Feder J. *See* Rosmorduc O
Feder O
Fundamentals of Gastrointestinal Radiology. 122:1541–pmr
Gastrointestinal Imaging: Case Review Series. 122:1541–pmr
Federici B
See Fiorucci S
See Santucci L
Fedorak MN. *See* Schreiber S
Fedorak RN
See Madsen KL
See Sandborn WJ
Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant Human Interleukin 10 in the Treatment of Patients With Mild to Moderately Active Crohn's Disease, 119:1473
Fehr J. *See* Kamal SM
Feighery C, O'Keefe J. TNF-α Production by Intra-Epithelial T Cells in Celiac Disease, 125:1560–c
Feighner SD. *See* Austin CP
Feinle C, Rades T, Otto B, Fried M. Fat Digestion Modulates Gastrointestinal Sensations Induced by Gastric Distention and Duodenal Lipid in Humans, 120:1100
Feins NR. *See* Fishman SJ
Feinstone S. *See* Wedemeyer H
Feld MS. *See* Wallace MB
Feld SI. *See* Levy RL
Feldman HI. *See* Forman LM
Feldman M. *See* Cryer B
Feldman RE. Discussion on "Cutting the Cord" for Capsule Endoscopy, 125: 998–c
Feldmann G
See Demeilliers C
See Mansouri A
Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte Apoptosis and Fas Expression Are Prominent Features of Human Nonalcoholic Steatohepatitis, 125:437
Feleus A. *See* Boonen A
Feliciangeli G
See Benedetti A
See di Sario A
Felipe A. *See* Valdés R
Felitti VJ. *See* Beutler E
Felton JS. *See* Fontana FJ
Fendrick M. *See* Inadomi JM
Fenger C. *See* Jorgensen OD
Fennerty MB
See Faigel DO
See Fass R
See Laine L
See Sonnenberg A
Fennerty MB
Barrett's-Related Esophageal Cancer: Has the Final Hurdle Been Cleared, Now Paving the Way for Human Chemoprevention Trials?, 122:1171–e
Gastric Intestinal Metaplasia on Routine Endoscopic Biopsy, 125:586
Fensterer H. *See* Weber CK
Fenwick SW, Toogood GJ, Lodge JPA, Hull MA. The Effect of the Selective

Cyclooxygenase-2 Inhibitor Rofecoxib on Human Colorectal Cancer Liver Metastases, 125:716
Feranchak AP. *See* Schlenker T
Feray C. *See* Samuel D
Féray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, Loinaz C, Gigou M, Burra P, Barkholt L, Esteban R, Bizollon T, Lerut J, Minello-Franza A, Bernard P-H, Nachbaur K, Botta-Fridlund D, Bismuth H, Schalm SW, Samuel D. European Collaborative Study on Factors Influencing Outcome After Liver Transplantation for Hepatitis C Virus, 117:619
Féray C, Shouval D, Samuel D. Will Transplantation of a Hepatitis C-Infected Graft Improve the Outcome of Liver Transplantation in HCV Patients?, 117:263–e
Ferec C. *See* Chen J-M
Ferenci P
See Dejaco C
See Kazemi-Shirazi L
See Peck-Radosavljevic M
Ferguson A. *See* Zavros Y
Fernandes L. *See* Creed F
Fernandez-Arquero M. *See* De la Concha EG
Fernandez-Bañares F. *See* Panés J
Fernández-Bermejo M. *See* García-Monzón C
Fernández-Checa JC
See Lluis JM
See Sans M
Fernández-del Castillo C
See Hartwig W
See Keck T
Fernández-Estívariz C. *See* Ziegler TR
Fernandez-Estivariz C, Ziegler TR. *Artificial Nutrition Support in Clinical Practice. 2nd Edition*, 123:1744–pmr
Fernández-Fraga X, Azpiroz F, Malagelada J-R. Significance of Pelvic Floor Muscles in Anal Incontinence, 123:1441
Fernandez-Soria V. *See* Losa JH
Fernández-Torres C. *See* Hidalgo-Tenorio C
Fernández-Varo G
See Morales-Ruiz M
See Ros J
Ferrari C. *See* Maini MK
Ferrato F. *See* Carrière F
Ferreira-Gonzalez A. *See* Shiffman ML
Ferrell L. *See* Yao FY
Ferrentino N. *See* Speer CA
Ferret P-J. *See* Malassagne B
Ferrier L, Mazelin L, Cenac N, Desreumaux P, Janin A, Emilie D, Colombel J-F, Garcia-Villar R, Fioramonti J, Bueno L. Stress-Induced Disruption of Colonic Epithelial Barrier: Role of Interferon-γ and Myosin Light Chain Kinase in Mice, 125:795
Ferris CD
See He C-L
See Watkins CC
Ferris CD. Are Things Looking Up for the Treatment of Gastroparesis? Sildenafil in Animal Models of Diabetic Gastroparhy. Reply, 120:577–ss
Ferrucci J. *See* Winawer S
Feu F
See Junquera F
See Panés J
Feurle GE, Anlauf M, Hamscher G, Arnold R, Klöppel G, Weihe E. Xenin-Immunoreactive Cells and Extractable Xenin in Neuroendocrine Tumors of Duodenal Origin, 123:1616
Fevery J. Pigment Gallstones in Crohn's Disease, 116:1491–e
Fiala N. *See* Dubois A
Fiasse R
See Laharie D
See Vermeire S
Fibbe C. *See* Layer P
Fibbe C, Layer P, Keller J, Strate U, Emmermann A, Zornig C. Esophageal Motility in Reflux Disease Before and After Fundoplication: A Prospective, Randomized, Clinical, and Manometric Study, 121:5
Fickert P
See Trauner M
See Wagner M
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M. Effects of Ursodeoxycholic and Cholic Acid Feeding on Hepatocellular Transporter Expression in Mouse Liver, 121:170
Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall H-U, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M. Ursodeoxycholic Acid Aggravates Bile Infarcts in Bile Duct-Ligated and *Mdr2* Knockout Mice via Disruption of Cholangioles, 123:1238
Fields AP, Chapkin RS. Signaling to Colon Cancer. Reply, 117:1499–ss
Fields J. *See* Leclercq IA
Fiers W. *See* Steidler L
Figueiredo C
See Machado JC
See van Doorn L-J
Figueroa CD. *See* Trevisani M
Figueroa DJ. *See* Austin CP
Figura N. *See* Yamaoka Y
Fihn B-M, Sjöqvist A, Jodal M. Permeability of the Rat Small Intestinal Epithelium Along the Villus-Crypt Axis: Effects of Glucose Transport, 119:1029
Filez L. *See* Abell T
Filice G. *See* Bruno R
Filipi C. Management of GERD in the Millennium: Is There Room for Endoscopy? Reply, 121:1251–ss
Filipi CJ, Lehman GA, Rothstein RI, Raijman I, Stiegmann GV, Waring JP, Hunter JG, Gostout CJ, Edmundowicz SA, Dunne DP, Watson PA, Cornet DA. Management of GERD in the Millennium: Is There Room for Endoscopy?, 121:1249–ss
Filiz F. *See* Shan L
Filmus J. *See* Capurro M
Finch R. *See* Pfützer RH
Fine KD. Microscopic and Collagenous Clitis in Treated Celiac Disease Due to Food Allergy? Reply, 116:778–c
Fine KD, Schiller LR. AGA Technical Review on the Evaluation and Management of Chronic Diarrhea, 116:1464–aga
Finegood D. *See* Boushey RP
Fink D. *See* Carethers JM
Fink MP
See Sappington PL
See Tomita M
Finkel Y. *See* Hugot J-P
Finlayson NDC. *See* Lui HF
Finn AL, Kuzhikandathil EV, Oxford GS, Itoh-Lindstrom Y. Sucrase-Isomaltase Is an Adenosine 3',5'-Cyclic Monophosphate-Dependent Epithelial Chloride Channel, 120:117
Finn AL, Oxford GS. Sucrase-Isomaltase: An Epithelial Chloride Channel? Reply, 121:742–c
Fiocchi C
See Danese S
See Grossmann J
See Lawrance IC
See Musso A
See Sturm A
Fiocchi C. From Immune Activation to Gut Tissue Injury: The Pieces of the Puzzle Are Coming Together, 117: 1238–e
Fioramonti J
See Coelho A-M
See Ferrier L
Fiorelli G. *See* Valenti L
Fiorotto R. *See* Spirlì C
Fiorucci S
See Santucci L
See Wallace JL

Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B, Mannucci R, del Soldato P, Morelli A. Gastrointestinal Safety of Nitric Oxide-Derived Aspirin Is Related to Inhibition of ICE-like Cysteine Proteases in Rats, 116:1089
Fiorucci S, Menezes de Lima O Jr, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A, Wallace JL. Cyclooxygenase-2-Derived Lipoxin A_4 Increases Gastric Resistance to Aspirin-Induced Damage, 123:1598
Fiorucci S, Santucci L, Antonelli E, Distrutti E, del Sero G, Morelli O, Romani L, Federici B, del Soldato P, Morelli A. NO-Aspirin Protects From T Cell-Mediated Liver Injury by Inhibiting Caspase-Dependent Processing of Th1-like Cytokines, 118: 404
Fiorucci S, Santucci L, Gresele P, Faccino RM, del Soldato P, Morelli A. Gastrointestinal Safety of NO-Aspirin (NCX-4016) in Healthy Human Volunteers: A Proof of Concept Endoscopic Study, 124:600
Fireman T. *See* Appleyard M
Firth M, Prather CM. Gastrointestinal Motility Problems in the Elderly Patient, 122:1688
Firth TA. *See* Guarraci FA
Fischbach W, Dragosics B, Kolve-Goebeler M-E, Ohmann C, Greiner A, Yang Q, Verreet P, Horstmann O, Busch M, Dühmke E, Müller-Hermelink H-K, Wilms K. Primary Gastric B-Cell Lymphoma: Results of a Prospective Multicenter Study, 119:1191
Fischbach W. *Helicobacter pylori* Eradication Therapy in Primary High-grade Gastric MALT Lymphoma, 123:393–c
Fischer B. *See* Straumann A
Fischer H. *See* Müller T
Fischer L. *See* Kalinina T
Fischer R. *See* Graf D
Fischer R, Cariers A, Reinehr R, Häussinger D. Caspase 9-Dependent Killing of Hepatic Stellate Cells by Activated Kupffer Cells, 123:845
Fischer R, Schmitt M, Bode JG, Häussinger D. Expression of the Peripheral-type Benzodiazepine Receptor and Apoptosis Induction in Hepatic Stellate Cells, 120:1212
Fischler B. *See* Tack J
Fischler B, Tack J, de Gucht V, Shkedy Z, Persoons P, Broekaert D, Molenberghs G, Janssens J. Heterogeneity of Symptom Pattern, Psychosocial Factors, and Pathophysiological Mechanisms in Severe Functional Dyspepsia, 124:903
Fishbach A. *See* Terdiman JP
Fishbein TM. *See* Liu LU
Fishbein TM, Gondolesi GE, Kaufman SS. Intestinal Transplantation for Gut Failure, 124:1615
Fisher H. *See* Rubio CA
Fisher JK. *See* Kuganeswaran E
Fisher N. *See* Brind A
Fisher R. *See* Strom S
Fisher RS. *See* Friedel D
Fisher SA. *See* Cuthbert AP
Fishman SJ, Feins NR, D'Amato RJ, Folkman J. Thalidomide Therapy for Crohn's Disease, 119:596–c
Fishman V, Friedel D. Inverse Association Between Intake of Cereal Fiber and Risk of Gastric Cardia Cancer, 121:1024–c
Fitch MD. *See* Jørgensen JR
Fitz JG
See Roman RM
See Schlenker T
Fitzgerald DJ. *See* Byrne MF
Fitzgerald L. *See* Berman SM
Fitzgerald P. *See* Huizinga JD
Fitzgerald RC. *See* Ouatu-Lascar R
Fitzgerald RC, Abdalla. Gastrin-Induced Hyperproliferation in Barrett's Esophagus, 125:1921–c
Fitzgerald RC, Lovat L. Significance of Genetic Abnormalities After Photodynamic Therapy, 120:1064–c
Fitzmaurice M. *See* Wallace MB
Flagella M. *See* Walker NM
Flake GP. *See* Kim K-S
Flamand V. *See* Louis H
Flamez D
See Boushey RP
See Rooman I
Flämig G. *See* Reinshagen M
Flamm SL. *See* Green RM
Flanigan A. *See* Su CG
Flärdh M. *See* Lehmann A
Flæte NS. *See* Molberg Ø
Flavell RA. *See* de Jong YP
Fleckenstein B. *See* Arentz-Hansen H
Fleig WE
See Kleber G
See Lochs H
Fleig WE, Kleber G. Hepatic Artery Flow Change and Hepatocyte Oxygenation in Human Cirrhosis. Reply, 117:1256–c
Fleischer AS, Meltzer, S, James SP. Colon Polyps in Beckwith-Wiedemann Syndrome:Role of Imprinted Genes, 118:637–c
Fleischer DE. *See* Lieberman DA
Fleming KA. *See* Mitchell SA
Fleming RE. *See* Parkkila S
Fleming SE. *See* Jørgensen JR
Fletcher CD. *See* Demetri GD
Fletcher J, McColl KEL. Evidence for Pooling of Gastric Secretions in the Proximal Stomach in Humans Using Single Photon Computed Tomography. Reply, 123:2158–co
Fletcher J, Wirz A, Young J, Vallance R, McColl KEL. Unbuffered Highly Acidic Gastric Juice Exists at the Gastroesophageal Junction After a Meal, 121:775
Fletcher JA. *See* Demetri GD
Fletcher JG
See Johnson CD
See Schwartz DA
Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess Alcohol Greatly Increases the Prevalence of Cirrhosis in Hereditary Hemochromatosis, 122:281
Fletcher R. *See* Winawer S
Fletcher RH, Farraye FA. Screening Flexible Sigmoidoscopy: Effectiveness Is Not Enough, 117:486–e
Fleurot C. *See* Moreau R
Florian S. *See* Wingler K
Florin THJ. *See* Radford-Smith GL
Flourié B. *See* Attar A
Flum DR. Burst Appendix or Technology Bust. Reply, 123:382–ss
Flum DR, Morris A, Koepsell T, Dellinger EP. Burst Appendix or Technology Bust, 123:381–ss
Fodde R. *See* Smits R
Foelsch UR
See Croucher PJP
See Hampe J
Fogel EL, Sherman S. Acute Biliary Pancreatitis: When Should the Endoscopist Intervene?, 125:229
Foglia G. *See* Pozzi M
Folkman J. *See* Fishman SJ
Folli F. *See* Alvaro D
Folwaczny C
See Radlmayr M
See Spannagl M
Folwaczny C. Heparin Therapy for Ulcerative Colitis, 120:1308–c
Folwaczny C, Jäger G, Schnettler D, Wiebecke B, Loeschke K. Search for Mumps Virus Genome in Intestinal Biopsy Specimens of Patients With IBD, 117:1252–c
Fong DYT. *See* Lau GKK
Fontaine F. *See* Baert F
Fontana FJ, Lown KS, Paine MF, Fortlage L, Santella RM, Felton JS, Knize MG, Greenberg A, Watkins PB. Effects of a Chargrilled Meat Diet on Expression

of CYP3A, CYP1A, and P-Glycoprotein Levels in Healthy Volunteers, 117:89
Fontana RJ, Hann H-WL, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of Early Mortality in Patients With Decompensated Chronic Hepatitis B Treated With Antiviral Therapy, 123:719
Fontolliet C. *See* Bian Y-S
Foody W, Heuman DD, Mihas AA, Schubert ML. Nutritional Therapy for Alcoholic Hepatitis: New Life for an Old Idea. Comment, 120:1053–ss
Forbes A. *See* Cuthbert AP
Forbes GM. *See* Katelaris PH
Forbes SJ, Themis M, Alison MR, Sarosi I, Coutelle C, Hodgson HJF. Synergistic Growth Factors Enhance Rat Liver Proliferation and Enable Retroviral Gene Transfer Via a Peripheral Vein, 118:591
Forbes SJ, Vig P, Poulsom R, Alison MR, Wright NA. Bone Marrow-Derived Liver Stem Cells: Their Therapeutic Potential, 123:654–c
Forcione DG. *Gastrointestinal Disease in Primary Care*, 119:1803–pmr
Ford AC, Ridpath J, Chalmers D. Image of the Month, 122:1720–im
Ford D. *See* Christie GR
Forde KA. *Neoplasms of the Colon, Rectum, and Anus*, 119:1803–pmr
Fordtran JS. *See* Gruy-Kapral C
Forgacs I. *See* Tibble JA
Forman D. *See* Webb PM
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The Association Between Hepatitis C Infection and Survival After Orthotopic Liver Transplantation, 122:888
Forman LM, Lucey MR. Discussion on the Association Between Hepatitis C Infection and Survival After Orthotopic Liver Transplantation. Reply, 123:2160–co
Formento J-L. *See* Bras-Gonçalves RA
Forrest EH. *See* Lui HF
Forrester L. *See* Newsome PN
Forsberg G. *See* Hammarström M-L
Forsberg G, Hernell O, Melgar S, Israelsson A, Hammarström S, Hammarström M-L. Paradoxical Coexpression of Proinflammatory and Down-regulatory Cytokines in Intestinal T Cells in Childhood Celiac Disease, 123:667
Forte JG. *See* Karvar S
Fortes P. *See* Martínez-Chantar ML
Fortlage L. *See* Fontana FJ
Foschia F. *See* Costamagna G
Foss H-D. *See* Schmitz H
Fossard JL. *See* Hofbauer B
Fossati L. *See* Piperno A
Fossi S. *See* Palli D
Foster GR. *See* Paterson M
Foster KE. *See* Cummings DE
Foster P. *See* Bassi A
Foster R
See Sigthorsson G
See Tibble JA
Foster SJ. *See* Bonen DK
Fouquet C. *See* Janssen K-P
Fourmy D. *See* Clerc P
Fouweather MG. *See* Gordon FH
Fox EA. *See* Syngal S
Fox IJ. *See* Nagata H
Fox JG. *See* Wang TC
Fox JG. Isolation of a *Helicobacter* Strain From the Human Liver. Reply, 121:1024–c
Fox JG, Wang TC, Rogers AB, Poutahidis T, Ge Z, Taylor N, Dangler CA, Israel DA, Krishna U, Gaus K, Peek RM Jr. Host and Microbial Constituents Influence *Helicobacter pylori*-Induced Cancer in a Murine Model of Hypergastrinemia, 124:1879
Fox VL. *See* Teitelbaum JE
Fracanzani AL. *See* Valenti L
Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S
Hereditary Hemochromatosis and Cancer Risk: More Fuel to the Fire?, 121:1251–ss
Hereditary Hemochromatosis and Cancer Risk: More Fuel to the Fire? Reply, 121:1252–ss
Fracchia M, Galatola G. Patients With Biliary Microlithiasis: Are They A Separate Breed? Reply, 121:1015–ss
Fracehia M, Pellegrino S, Secreto P, Gallo L, Masoero G, Pera A, Galatola G. Patients With Biliary Microlithiasis: Are They A Separate Breed?, 121:1014–ss
Fragale A. *See* Velcich A
Fraichard A. *See* Plateroti M
Fraioli F. *See* Gigliozzi A
Framson PE, Cho DH, Lee LY, Hershberg RM. Polarized Expression and Function of the Costimulatory Molecule CD58 on Human Intestinal Epithelial Cells, 116:1054
France R. *See* Kinney T
Francella A. *See* Present DH
Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The Safety of 6-Mercaptopurine for Childbearing Patients With Inflammatory Bowel Disease: A Retrospective Cohort Study, 124:9
Franchimont D, Bouma G, Galon J, Wolkersdörfer GW, Haidan A, Chrousos GP, Bornstein SR. Adrenal Cortical Activation in Murine Colitis, 119:1560
Franchisseur C. *See* Attar A
Franchitto A. *See* Alvaro D
Francis H
See Alpini G
See LeSage G
Francis J. *See* French SJ
François E. *See* Van Gossum A
Frankhuijzen AC. *See* Stam R
Franklin CL
See Gawenis LR
See Lowry PW
Frans E. *See* Wilmer A
Franzè A. *See* Prantera C
Franzén LE. *See* Söderholm JD
Fraquelli M. *See* Fracanzani AL
Fraser AG, Morton D, McGovern D. Methotrexate in IBD - Move Over 6-MP? Not So Fast.., 123:1737–ss
Fraser JS, Ellis HJ, Moodie S, Ciclitira PJ. Serologic Tests for Celiac Disease. Reply, 124:586–c
Frattaroli FM. *See* Pappalardo G
Fraumeni JF Jr. *See* El-Omar EM
Frayling I. *See* Tomlinson I
Frayo RS. *See* Cummings DE
Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D, Anderson GJ. Hepcidin Expression Inversely Correlates With the Expression of Duodenal Iron Transporters and Iron Absorption in Rats, 123:835
Frazier ML. *See* Sinicrope FA
Frederiksen SL. *See* Kjaergard LL
Frediani T. *See* Barbato M
Freedman J, Ye W, Näslund E, Lagergren J. Association Between Cholecystectomy and Adenocarcinoma of the Esophagus, 121:548
Freedman SD, Kern HF, Scheele GA. Pancreatic Acinar Cell Dysfunction in CFTR$^{-/-}$ Mice Is Associated With Impairments in Luminal pH and Endocytosis, 121:950
Freeman KB. *Nutrition in the Infant: Problems and Practical Procedures*, 122:241–pmr
Freeman ML. Prevention of Post-ERCP Pancreatitis: Pharmacologic Solution or Patient Selection and Pancreatic Stents?, 124:1977–e
Freeman MW. *See* Rigotti A
Freeman R. *See* Wiesner R
Freeman TC. *See* Bush TG
Freile I. *See* Pérez-Páramo M

French BA. *See* Bardag-Gorce F
French G. *See* Thomas LA
French S. Mallory Bodies, Like the Mutant of ATP7B Seen in Wilson's Disease, Are Aggresomes, 121:1264–c
French SJ, Conlon CA, Mutuma ST, Arnold M, Read NW, Meijer G, Francis J. The Effects of Intestinal Infusion of Long-Chain Fatty Acids on Food Intake in Humans, 119:943
French SW
See Bardag-Gorce F
See McPhaul LW
Frericks B. *See* Zender L
Fretz C. *See* Lunel F
Freund J-N
See Kim S
See Plateroti M
Frexinos J. *See* Delvaux M
Frick J-S. *See* Waidmann M
Fried M
See Feinle C
See Ismair MG
See Jung D
Fried MW
See Russo MW
See Ziegler TR
Clinical Research: At the Crossroads, 121:515–ce
Comment from the Editors, 123:1761–ce
Friedel D. *See* Fishman V
Friedel D, Fisher RS. Possible Mechanisms for Ischemic Colitis During Alosetron Therapy. Reply, 121:232–c
Friedel D, Ozick LA. High-Dose Omeprazole in Patients With Noncardiac Chest Pain, 116:226–c
Friedel D, Thomas R, Fisher RS. Ischemic Colitis During Treatment With Alosetron, 120:557–cr
Friedel DM, Gbadehan E. Rebound Hypersecretion After Omeprazole, 117:513–c
Friedl W, Mangold E, Caspari R, Lamberti C, Propping P. Ileorectal Anastomosis Is Appropriate for a Subset of Patients With Familial Adenomatous Polyposis, 121:503–c
Friedman JM. *See* Cohen P
Friedman LS. Our New President—Daniel K. Podolsky, 124:1524–aga
Friedman S. *See* Rubin PH
Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and Surveillance Colonoscopy in Chronic Crohn's Colitis, 120:820
Friedman SL. The Virtuosity of Hepatic Stellate Cells, 117:1244–e
Frierson HF Jr. *See* El-Rifai W
Friess H
See Kleeff J
See Liao Q
See Mayerle J
See Reubi JC
See Saurer L
Frigo G. *See* Giaroni C
Fritsch J. *See* Kiesslich R
Frizell E. *See* Zhu J
Froh M. *See* Wheeler MD
Froh M, Wheeler MD, Smutney O, Zhong Z, Bradford BU, Thurman RG. New Method of Delivering Gene-Altered Kupffer Cells to Rat Liver: Studies in an Ischemia-Reperfusion Model, 124:172
Fromenty B
See Demeilliers C
See Mansouri A
Fromm H. *See* Bouscarel B
Fromm M
See Bürgel N
See Gitter AH
See Schmitz H
Fromm MF. *See* Schwab M
Froomes PR. *See* Angus PW
Froomes PRA, Morgan DJ, Smallwood RA, Angus PW. Comparative Effects of Oxygen Supplementation on Theophylline and Acetaminophen Clearance in Human Cirrhosis, 116:915
Frossard J-L. *See* Lee HS
Frossard JL, Kwak B, Chanson M, Morel P, Hadengue A, Mach F. CD40 Ligand-Deficient Mice Are Protected Against Cerulein-Induced Acute Pancreatitis and Pancreatitis-Associated Lung Injury, 121:184
Frossard J-L, Rubbia-Brandt L, Wallig MA, Benathan M, Ott T, Morel P, Hadengue A, Suter S, Willecke K, Chanson M. Severe Acute Pancreatitis and Reduced Acinar Cell Apoptosis in the Exocrine Pancreas of Mice Deficient for the Cx32 Gene, 124:481
Frossard J-L, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, Steer ML. The Role of Intercellular Adhesion Molecule 1 and Neutrophils in Acute Pancreatitis and Pancreatitis-Associated Lung Injury, 116:694
Frossard JL, Spahr L, Queneau PE, Giostra E, Burckhardt B, Ory G, Saussure P de, Armenian B, Peyer R de, Hadengue A. Erythromycin Intravenous Bolus Infusion in Acute Upper Gastrointestinal Bleeding: A Randomized, Controlled, Double-Blind Trial, 123:17
Fruchart J. *See* Claudel T
Fruchart J-C
See Barbier O
See Claudel T
Fruchon S. *See* Dupic F
Frühwirth M. *See* Müller T
Frusciante K. *See* Drossman DA
Fry J. *See* Westland C
Fry L. *See* Porter WM
Fryer A. *See* Brind A
Fryer J. *See* Buchman AL
Fu P. *See* Bardag-Gorce F
Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT. Increased Expression and Cellular Localization of Inducible Nitric Oxide Synthase and Cyclooxygenase 2 in *Helicobacter pylori* Gastritis, 116:1319
Fu Y. *See* Guan RJ
Fuchs C. *See* Giovannucci E
Fuchs FD. *See* Sander G
Fuchs GJ. *See* Rabbani GH
Fuchs K-H. *See* Timm S
Fuchsbichler A
See Fickert P
See Wagner M
Fuhrmann V. *See* Schenk P
Fujihashi K. *See* Dohi T
Fujimiya M
See Asakawa A
See Ueno N
Fujimori H, Miura S, Koseki S, Hokari R, Komoto S, Hara Y, Hachimura S, Kaminogawa S, Ishii H. Intravital Observation of Adhesion of Lamina Propia Lymphocytes to Microvessels of Small Intestine in Mice, 122:734
Fujimori T. *See* Noguchi H
Fujimoto K
See Iwakiri R
See Tsunada S
Fujimoto K, Beauchamp RD, Whitehead RH. Identification and Isolation of Candidate Human Colonic Clonogenic Cells Based on Cell Surface Integrin Expression, 123:1941
Fujino MA. *See* Asakawa A
Fujioka Y. *See* Kurata A
Fujisawa N. *See* Osawa E
Fujishita T. *See* Aihara T
Fujita M. *See* Satoh A
Fujita T
See Ohnishi H
See Ueda N
Fujiwara K. *See* Ikeda H
Fujiyama S
See Shiratori Y
See Yoshida H
Fujiyama Y. *See* Andoh A
Fukahi K. *See* Kornmann M
Fukuda K. *See* Yamamoto M

Fukuda R. *See* Kazumori H
Fukuda T. *See* Ikejima K
Fukuda Y
See Inoue N
See Shimizu H
Fukui H
See Kazumori H
See Noguchi H
Fukui K. *See* Kamada Y
Fukuizumi K. *See* Nagao Y
Fukushima M. *See* Hamano H
Fukushima N. *See* Sato N
Fullarton G
See Church NI
See El-Omar EM
Fuller CM, Benos DJ. Identification of a New Chloride Channel: A Sweet Story?, 120:299–e
Fuller CR. *See* Williams KL
Fuller H. *See* Cook D
Fullerton S. *See* Mertz H
Funahashi T. *See* Kamada Y
Fung JJ. *See* Vargas HE
Fung PCW. *See* Huang XR
Fung-Leung WP. *See* Drobnik W
Furci L. *See* Ballestri M
Furey WF. *See* Pfützer RH
Furlan D. *See* Suraweera N
Furness JB. *See* Southwell BR
Furth EE. *See* Dai CY
Furth EE. *Pathology of the Gallbladder, Biliary Tracts, and Pancreas*, 121:1022–pmr
Furukawa O. *See* Takeuchi K
Furusaka A. *See* Kato T
Furuta GT
See Nieuwenhuis EES
See Rosen R
See Teitelbaum JE
See Yuan Q
Furuta GT. More Than Food Traffics Into the Esophagus. Comment, 123:946–ss
Furuta K. *See* Harada M
Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimurra H. Interleukin 1β Polymorphisms Increase Risk of Hypochlorhydria and Atrophic Gastritis and Reduce Risk of Duodenal Ulcer Recurrence in Japan, 123:92
Furutani K. *See* Aihara T
Furuya N. *See* Hamano H
Fusaro RM. *See* Lynch HT
Fusaroli P. *See* Caletti G
Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti-Interleukin 12 Treatment Regulates Apoptosis of Th1 T Cells in Experimental Colitis in Mice, 117:1078

Gabazza EC
See Adachi Y
See Ishihara T
Gäbele E. *See* McKim SE
Gagneten S. *See* Wedemeyer H
Gaiennie J. *See* Abreu MT
Gaisano HY. *See* Ji J
Galandiuk S. *See* Sands BE
Galanko J
See Martin C
See Sandborn WJ
Galanski M. *See* Zender L
Galatola G
See Fracchia M
See Fracchia M
Galeazzi F, Blennerhassett PA, Qiu B, O'Byrne PM, Collins SM. Cigarette Smoke Aggravates Experimental Colitis in Rats, 117:877
Galle PR. *See* Kiesslich R
See Neurath MF
See Peters M
Gallego A. *See* Villanueva C
Gallego S. *See* Lomax RB
Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A. Antidiabetic Thiazolidinediones Inhibit Collagen Synthesis and Hepatic Stellate Cell Activation In Vivo and In Vitro, 122:1924
Galli M. *See* Zehender G
Galligan JJ. *See* Takahashi T
Gallo L. *See* Fracchia M
Gallo RL. *See* Hase K
Gallucci RM. *See* Yin M
Galmiche JP
See Abell T
See Piche T
Galmiche J-P. *See* Segain J-P
Galon J. *See* Franchimont D
Gamberi B. *See* Caletti G
Gambiez L
See Desreumaux P
See Dharancy S
Gamen M. *See* Vorobioff JD
Gammon MD. *See* El-Omar EM
Gan S. *See* Appleyard M
Gandjbachkh I
See Di Martino V
See Lunel F
Gandjini H. *See* Gerbes AL
Gangl A
See Dejaco C
See Fedorak RN
See Peck-Radosavljevic M
See Schreiber S
Ganiats T. *See* Winawer S
Gannon M. *See* Song SY
Gansauge F
See Berger HG
See Weber CK
Gao B
See Radaeva S
See Reichel C
See Sun Z
Gao C. *See* Pedersen J
Gao C, Liu S, Hu HZ, Gao N, Kim GY, Xia Y, Wood JD. Serine Proteases Excite Myenteric Neurons Through Protease-Activated Receptors in Guinea Pig Small Intestine, 125:1554
Gao N. *See* Gao C
Gaou I. *See* Mansouri A
Garaud J-J. *See* McHutchison JG
Garber JE. *See* Syngal S
García AG. *See* Lomax RB
García N. *See* Prieto J
Garcia Rodriguez RA, Hernandez-Diaz S. Will the Safest Analgesic Please Stand Up, 122:1535–ss
Garcia RT, Cello JP, Nguyen MH, Rogers SJ, Rodas A, Trinh HN, Stollman NH, Schlueck G, McQuaid KR. Unsedated Ultrathin EGD Is Well Accepted When Compared With Conventional Sedated EGD: A Multicenter Randomized Trial, 125:1606
Garcia-Foncillas J. *See* Lucena J-F
Garcia-Granero E. *See* Minguez M
García-Monzón C, Fernández-Bermejo M. A Wilder View on Diagnostic Criteria of Nonalcoholic Steatohepatitis, 122:840–c
Garcia-Pagan JC
See Guevara M
Garcia-Pagán JC
See Escorsell À
García-Pagán JC
See Escorsell À
See González-Aaldes J
García-Pagán J-C
See Graupera M
See Moitinho E
García-Pagán JC, Villanueva C, Vila MC, Albillos A, Genescà J, Ruiz-del-Arbol L, Planas R, Rodriguez M, Calleja JL, González A, Solà R, Balanzó J, Bosch J. Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive β-blockers, 121:908
García-Ruiz C. *See* Lluis JM
García-Trevijano ER. *See* Martínez-Chantar ML
García-Trevijano ER, Martínez-Chantar ML, Latasa MU, Mato JM, Avila MA. NO Sensitizes Rat Hepatocytes to Growth Factor-Induced Proliferation by the Modulation of S-Adenosylmethionine Levels, 122:1355
Garcia-Tsao G
See Ginés P
See Groszmann RJ
Garcia-Tsao G
Current Management of the .

Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis, 120:726
Identifying New Risk Factors for Spontaneous Bacterial Peritonitis: How Important Is it?, 117:495–e
García-Tsao G
Angiotensin II Receptor Antagonists in the Pharmacological Therapy of Portal Hypertension: A Caution. Comment, 117:740–ss
Prokinetics Reduce Bacterial Translocation in Cirrhosis: Will Sweeping the Gut Keep the Fluid Clean? Comment, 120:314–ss
Garcia-Valdecasas JC. *See* Lacy AM
Garcia-Villar R. *See* Ferrier L
Garcí-Buey L. *See* Gisbert JP
Garden J. *See* Bathgate A
Gardner S. *See* Dienstag JL
Gardner SD
See Dienstag JL
See Fontana RJ
See Jonas MM
See Lok ASF
Gardner TB. *See* Robertson DJ
Garewal H. *See* Lieberman DA
Garlick NM. *See* Wight NJ
Garnero A. *See* Zentilin P
Garret C. *See* Shiffman ML
Garrett E. *See* Giardello FM
Garrido A. *See* De La Revilla J
Gartung C. *See* Gerloff T
Gasbarrini A. *See* Papa A
Gasbarrini G
See Cammarota G
See Papa A
See Zoli G
Gasche C. *See* Dejaco C
Gassull M
See Hugot J-P
See Pérez-Páramo M
Gassull MA
See Cabré E
See Panés J
Gaston JSH. *See* Orchard TR
Gastwirt PC, Matthews JB. *Upper Digestive Surgery: Oesphagus, Stomach and Small Intestine*, 119:1173–pmr
Gates LK Jr, Holladay DV. A Syndrome of Hereditary Pancreatic Adrenocarcinoma and Cysts of the Liver and Kidneys, 122:796–cr
Gatta A
See Gerotto M
See Merkel C
See Primignani M
Gatti AM. *See* Ballestri M
Gatzy J. *See* Rhoads JM
Gaub M-P. *See* Chamouard P
Gaudichon C, Bos C, Morens C, Petzke KJ, Mariotti F, Everwand J, Benamouzig R, Daré S, Tomé D, Metges CC. Ilial Losses of Nitrogen and Amino Acids in Humans and Their Importance to the Assessment of Amino Acid Requirements, 123:50
Gaudio E. *See* Alvaro D
Gauldie J. *See* Van Assche G
Gaultier C. *See* Faure C
Gaus K. *See* Fox JG
Gauthier A. *See* Maillot C
Gauthier J. *See* Lau DT-Y
Gauthier K. *See* Plateroti M
Gauthier R. *See* Vachon PH
Gavaghan T. *See* Bassett M
Gavazzi C. *See* Bozzetti F
Gawenis LR. *See* Walker NM
Gawenis LR, Franklin CL, Simpson JE, Palmer BA, Walker NM, Wiggins TM, Clarke LL. cAMP Inhibition of Murine Intestinal Na^+/H^+ Exchange Requires CFTR-Mediated Cell Shrinkage of Villus Epithelium, 125:1148
Gawrieh S. *See* Kaplan M
Gaylinn BD. *See* Rincon JP del
Gbadehan E. *See* Friedel DM
Ge Z. *See* Fox JG
Gebhardt T. *See* Zender L
Gebhart GF
See Bielefeldt K
See Coutinho SV
See Julia V
See Lamb K
See Zhuo M
Geboes K
See Baert F
See Baert FJ
See Desreumaux P
See D'Haens G
See Joossens S
Geenen JE. *See* Fazel A
Geerling BJ. *See* Schoon EJ
Geerling I
See Reinshagen M
See Steinkamp M
Geerts A
See Caligiuri A
See Hellemans K
See Reynaert H
Geffner M. *See* Samuel D
Gehnen N. *See* Heller J
Geibel JP. *See* Cheng I
Geibel JP, Rajendran VM, Binder HJ. Na^+-Dependent Fluid Absorption in Intact Perfused Rat Colonic Crypts, 120:144
Geibel JP, Singh S, Rajendran VM, Binder HJ. HCO_3^- Secretion in the Rat Colonic Crypt Is Closely Linked to Cl^- Secretion, 118:101
Geier A. *See* Gerloff T
Geiman DE. *See* Giardello FM
Geirsson ÁJ. *See* Bjarnason I
Geisser MS. *See* Mandel JS
Geissler M. *See* Grimm CF
Geissler M, Mohr L, Weth R, Köhler G, Grimm CF, Krohne TU, Weizsäcker F von, Blum HE. Immunotherapy Directed Against α-Fetoprotein Results in Autoimmune Liver Disease During Liver Regeneration in Mice, 121:931
Gelbart T. *See* Beutler E
Gelbmann CM. *See* Leeb SN
Geleziunas R. *See* Mori N
Geller SA. *See* Dubinsky MC
Gemmen E. *See* Sandler RS
Gendre J-P. *See* Cosnes J
Generoso M. *See* de Magistris L
Genescà J. *See* García-Pagán JC
Geng X. *See* Lin JL-C
Genning C. *See* Sanyal AJ
Genschel J. *See* Steiner M
Genser D. *See* Lochs H
Genta RM. A Year in the Life of the Gastric Mucosa, 119:252–e
Gentilini A
See Caligiuri A
See Failli P
Gentilini P
See Bonacchi A
See Caligiuri A
See Failli P
See La Villa G
See Marra F
Georg J. *See* Chitturi S
George J
See Chitturi S
See Hui JM
Geppetti P. *See* Trevisani M
Gerard C. *See* Morteau O
Gerard NP. *See* Morteau O
Gerbes A, Rössle M. Management of Refractory Ascites: Are Tips or Taps Tops? Reply, 120:312–ss
Gerbes AL
See Bilzer M
See Rössle M
Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, Djian J, The VPA Study Group. Therapy of Hyponatremia in Cirrhosis With a Vasopressin Receptor Antagonist: A Randomized Double-Blind Multicenter Trial, 124:933
Gerken G
See Holtmann G
See Knolle PA
Gerl H. *See* Steiner M
Gerlach J-T. *See* Diepolder HM
Gerlach JT, Diepolder HM, Jung M-C, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA,

Santantonio T, Pape GR. Recurrence of Hepatitis C Virus After Loss of Virus-Specific CD4+ T-Cell Response in Acute Hepatitis C, 117:933
Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute Hepatitis C: High Rate of Both Spontaneous and Treatment-Induced Viral Clearance, 125:80
Gerloff T, Geier A, Stieger B, Hagenbuch B, Meier PJ, Matern S, Gartung C. Differential Expression of Basolateral and Canalicular Organic Anion Transporters During Regeneration of Rat Liver, 117:1408
Germann T. *See* Knolle PA
Gerotto M, Dal Pero F, Pontisso P, Noventa F, Gatta A, Alberti A. Two PKR Inhibitor HCV Proteins Correlate With Early but Not Sustained Response to Interferon, 119:1649
Gershwin ME
See Bruggraber SFA
See Kamihira T
See Kita H
See Shimoda S
Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's Esophagus in Asymptomatic Individuals, 123:461
Gertz BJ. *See* Wight NJ
Gerunda G. *See* Patch D
Geubel AP. *See* Hautekeete ML
Gevers A. *See* Wilmer A
Ghany M. *See* Promrat K
Ghany MG. *See* Lau DT-Y
Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of Fibrosis in Chronic Hepatitis C, 124:97
Ghatei M. *See* Arebi N
Ghilain A. *See* Deviére J
Ghitescu L. *See* Bruneau N
Ghosh G, Goldblum R, Rask-Madsen J, Rutgeerts P, Vyhnalek P. Treatment of Crohn's Disease: Is Blocking Adhesion the Answer? Reply, 125:1277–ss
Ghosh G, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Treatment of Crohn's Disease: Is Blocking Adhesion the Answer?, 125:1276–ss
Ghosh S. *See* Gillett HR
Ghosh S. Human M Cells Delivered in a Box. Comment, 121:1520–ss
Ghoussoub J-J. *See* Lunel F
Giacobbe A. *See* Andriulli A
Giaffer MH
See Gleeson D
See Hendrickse MT
Giannella RA. *See* Steinecher KA
Giannini E, Botta F, Testa R. Utility of the MELD Score for Assessing 3-Month Survival in Patients With Liver Cirrhosis: One More Positive Answer, 125:993–c
Gianotti L. *See* Bozzetti F
Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A Randomized Controlled Trial of Preoperative Oral Supplementation With a Specialized Diet in Patients With Gastrointestinal Cancer, 122:1763
Giardello FM, Yang VW, Hyland LM, Krush AJ, Peterson G, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJA, Hamilton S. Primary Chemoprevention of Familial Adenomatous Polyposis With Sulindac: More Questions Than Answers, 123:379–ss
Giardiello FM
See Cruz-Correa M
See Rashid A
Giardiello FM, Brensinger JD, Petersen GM. AGA Technical Review of Hereditary Colorectal Cancer and Genetic Testing, 121:198–aga
Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA. Very High Risk of Cancer in Familial Peutz-Jeghers Syndrome, 119:1447
Giaretti W. *See* Hermsen M
Giaroni C, De Ponti F, Cosentino M, Lecchini S, Frigo G. Plasticity in the Enteric Nervous System, 117:1438–srr
Gibadulinová A. *See* Gut MO
Gibbons SJ. *See* Holm AN
Gibbs C
See Angus P
See Bonacini M
See Westland C
Gibril F
See Abou-Saif A
See Peghini PL
Gibson PR. *See* Mariadason JM
Giesa U. *See* Drobnik W
Giese T. *See* Stallmach A
Gigliozzi A
See Alvaro D
See Lee J
Gigliozzi A, Fraioli F, Sundaram P, Lee J, Mennone A, Alvaro D, Boyer JL. Molecular Identification and Functional Characterization pf Mdr1a in Rat Cholangiocytes, 119:1113
Gigou M. *See* Féray C
Gil A. *See* Valdés R
Gilabert R
See Escorsell À
See Guevara M
Gilfillan S. *See* Dupic F
Gilger M. *See* El-Serag HB
Gilger MA. *See* Ball JM
Gill N, Malik A, Potti A, Talukdar R, Saberi A, Mehdi SA. HER-2/neu Overexpression in Colonic Malignancies, 122:248–c
Gille D. *See* Boillot O
Gillen D
See El-Omar EM
See McColl KEL
See Mowat C
Gillen D, Wirz AA, Ardill JE, McColl KEL. Rebound Hypersecretion After Omeprazole and Its Relation to On-Treatment Acid Suppression and *Helicobacter pylori* Status, 116:239
Gilles T. *See* Hugot J-P
Gillett HR, Arnott IDR, McIntyre M, Campbell S, Dahele A, Priest M, Jackson R, Ghosh S. Successful Infliximab Treatment for Steroid-Refractory Celiac Disease: A Case Report, 122:800–cr
Gilman J. *See* Holt PR
Gilmour D. *See* Mowat C
Gines P. *See* Ortega R
Ginès P
See Arroyo V
See Bataller R
See Gerbes AL
See Guevara M
See Sort P
See Titos E
Ginès P, Calahorra B, Arroyo V. Albumin for Refractory Ascites. Reply, 125:1284–c
Ginès P, Ortega R, Guevara M, Arroyo V. Telipressin and Albumin for HRS: An Advance in Therapy? Reply, 124:1554–ss
Ginés P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, Planas R, Bosch J, Arroyo V, Rodés J. Transjugular Intrahepatic Portosystemic Shunting Versus Paracentesis Plus Albumin for Refractory Ascites in Cirrhosis, 123:1839
Gingras D. *See* Bruneau N
Ginies JL. *See* Cézard JP

Ginsberg GG. *Advances in Gastrointestinal Endoscopy*, 122:242–pmr
Gionchetti P
See Barbara G
See Campieri M
Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of Pouchitis Onset With Probiotic Therapy: A Double-Blind, Placebo-Controlled Trial, 124:1202
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral Bacteriotherapy as Maintenance Treatment in Patients With Chronic Pouchitis: A Double-Blind, Placebo-Controlled Trial, 119:305
Giorgio R de. *See* Tonini M
Giostra E
See Frossard JL
See Moreau R
See Spahr L
Giovannini M. *See* Crone SA
Giovannucci E. Chemoprevention of Colon Cancer: Have You Had Your Multivitamin Today? Reply, 116:1004–ss
Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC. Chemoprevention of Colon Cancer: Have You Had Your Multivitamin Today?, 116:1003–ss
Giovannucci EL. *See* Leitzmann MF
Girard B. *See* Benamouzig R
Girardet JP. *See* Cézard JP
Giraud V. *See* Veyradier A
Girelli D, Bozzini C, Roetto A, Alberti F, Daraio F, Colombari, Oliviero O, Corrocher R, Camaschella C. Clinical and Pathological Findings in Hemochromatosis Type 3 Due to a Novel Mutation in Transferrin Receptor 2 Gene, 122:1295
Giri R. *See* Wege H
Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, Spiegelman BM. The Role of PPARγ in Colon Cancer: Is it as Simple as APC?, 125:619–ss
Girnun GD, Spiegelman BM. PPARγ Ligands: Taking Ppart in Chemoprevention, 124:564–e
Gironella M. *See* Sans M
Gisbert JP, Garcí-Buey L, Pajares JM, Moreno-Otero R. Prevalence of Hepatitis C Virus Infection in B-Cell Non-Hodgkin's Lymphoma: Systemic Review and Meta-Analysis, 125:1723
Gish R. *See* Westland C
Gish RG. *See* Sugauchi F
Gismondi V. *See* Lowy AM
Gitlin JD. Wilson Disease, 125:1868–srr
Gitlin N. *The Liver Biology and Pathobiology, 4th edition*, 125:1909–pmr
Gitter AH, Wullstein F, Fromm M, Schulzke JD. Epithelial Barrier Defects in Ulcerative Colitis: Characterization and Quantification by Electrophysiological Imaging, 121: 1320
Gittes GK. *See* Kobayashi H
Giuliani A. *See* Rosina F
Giussani CS. *See* Longo M
Given R
See Cobb S
See Singh P
Givens RC, Watkins PB. Pharmacogenetics and Clinical Gastroenterology, 125: 240–srr
Glaser S
See Alpini G
See Alvaro D
See LeSage G
Glaser SS
See Alpini G
See Alvaro D
Glass J. *See* Yeh K-Y
Glatz-Krieger K. *See* Hildeand P
Glatzle J, Sternini C, Robin C, Zittel TT, Wong H, Reeve JR Jr, Raybould HE. Expression of 5-HT_3 Receptors in the Rat Gastrointestinal Tract, 123:217
Glazier KD. *See* Lin JL-C
Gleeson D. *See* Hendrickse MT
Gleeson D, Underwood JCE, Hendrickse MT, Giaffer MH. Low-Dose Methotrexate in Primary Biliary Cirrhosis. Reply, 117:1511–c
Gleeson PA. *See* Scarff KL
Gleich G. *See* Teitelbaum JE
Glick JM. *See* Zanlungo A
Glinghammar B, Rafter J. Colonic Luminal Contents Induce Cyclooxygenase 2 Transcription in Human Colon Carcinoma Cells, 120:401
Gluecker TM, Johnson CD, Wilson LA, MacCarty RL, Welch TJ, Vanness DJ, Ahlquist DA. Extracolonic Findings at CT Colongraphy: Evaluation of Prevalence and Cost in a Screening Population, 124:911
Glukhovsky A. *See* Appleyard M
Gluud C. *See* Kjaergard LL
Goardman LA. *See* Schwartz DA
Gobbi M. *See* Caletti G
Gobert AP, McGee DJ, Akhtar M, Mendz GL, Newton JC, Cheng Y, Mobley HLT, Wilson KT. Persistence and Pathogenesis: A Great Defense Facilitates a Good Offense, 122:2084–ss
Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A Population-Based Study of the Biochemical and Clinical Expression of the H63D Hemochromatosis Mutation, 122:646
Goddard M. *See* Nowak TV
Goddon R. *See* Viola S
Godfrey VL. *See* Boivin GP
Godinho E. *See* Colle IO
Godot V, Harraga S, Podorigora G, Liance M, Bardonnet K, Vuitton DA. IFNα-2a Protects Mice Against a Helminth Infection of the Liver and Modulates Immune Responses, 124:1441
Godson C. *See* Goh J
Goebell H
See Schulte C
See Sturm A
Goedert J. *See* El-Omar EM
Goedert JJ. *See* Zhang M
Goel A, Arnold CN, Boland CR. Multistep Progression of Colorectal Cancer in the Setting of Microsatellite Instability: New Details and Novel Insights, 121: 1497–e
Goeser T. *See* Benz C
Goetz J. *See* Chamouard P
Goff JS. *See* Triadafilopoulos G
Goggins M
See Lynch HT
See Sato N
Goh J. *See* Barrett S
Goh J, Godson C, Brady HR, MacMathuna P. Lipoxins: Pro-resolution Lipid Mediators in Intestinal Inflammation, 124:1043–srr
Goin JC, Sterin-Borda L, Bilder CR, Monastra Varrica L, Iantorno G, Ríos MC, Borda E. Functional Implications of Circulating Muscarinic Cholinergic Receptor Autoantibodies in Chagasic Patients With Achalasia, 117:798
Goïot H. *See* Sobhani I
Goïot H, Attoub S, Kermorgant S, Laigneau J-P, Lardeux B, Lehy T, Lewin MJM, Bado A. Antral Mucosa Expresses Functional Leptin Receptors Coupled to STAT-3 Signaling, Which Is Involved in the Control of Gastric Secretions in the Rat, 121:1417
Göke M. *See* Leeb SN
Golab J. *See* Kamiński R
Golberg T. *See* Slonim AE
Gold DM. *See* Vaizey CJ
Goldblatt F, Gordon TP, Waterman SA. Antibody-Mediated Gastrointestinal Dysmotility in Scleroderma, 123:1144

Goldblatt J, Jones DEJ. Discussion on the True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study. Reply, 124:582–c
Goldblatt J, Taylor PJS, Lipman T, Prince MI, Baragiotta A, Bassendine MF, James OFW, Jones DEJ. The True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study, 122: 1235
Goldblum JR. *See* Ormsby AH
Goldblum JR, Peek RM, Vicari JJ, Easley K, Falk GW, Richter JE, Rice TW. Inflammation of the Gastric Cardia. Reply, 116:229–c
Goldblum R. *See* Ghosh G
Goldenring JR
See Song SY
See Wang TC
Goldin E. *See* Ghosh G
Goldin RD. *See* Dienstag JL
Goldkind L. Rofecoxib Versus Placebo Ulcer Rates, 118:638–c
Goldman M. *See* Louis H
Goldstein E
See Friedman S
See Rubin PH
Gomariz RP. *See* Abad C
Gómez C. *See* Guarner C
Gondolesi GE. *See* Fishbein TM
Gong A-Y. *See* Masyuk AI
Gong Y. *See* Zhang M
Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H-H, von Wasielewski R. Prognostic Significance of Calcium-Binding Protein S100A4 in Colorectal Cancer, 123:1478
Gonzales S. *See* Thomson M
González A. *See* García-Pagán JC
Gonzalez CM. *See* Promrat K
Gonzalez DE. *See* Zolotarevsky Y
Gonzalez FJ
See Claudel T
See Girnun GD
See Wagner M
González M. *See* González-Aaldes J
González-Abraldes J, Albillos A, Bañares R, Arbol LR del, Moitinho E, Rodríguez C, González M, Escorsell A, García-Pagán JC, Bosch J. Randomized Comparison of Long-term Losartan Versus Propranolol in Lowering Portal Pressure in Cirrhosis, 121:382
Goodale RL. *See* Faris PL
Goodfellow P. *See* Carter MJ
Goodman C. *See* Sandler RS
Goodman SN. *See* Giardiello FM
Goodman Z. *See* Poynard T
Goos C. *See* Hillebrandt S
Gordon D
Another Possible Target for Antiobesity Drugs, 116:511–gn
Colon Tumor Precursors Identified by Magnifying Endoscopy, 116:235–gn
Epidemiologic Evidence Underscores Role for Folate as Foiler of Colon Cancer, 116:3–gn
Fiber and Colorectal Cancer: Poor Relations?, 116:785–gn
Gastroenterology News, 117:3, 117:293, 117:523, 117:757, 117:1039, 118:3, 118:249, 118:460–gn, 119:3, 119: 1427, 120:3–gn, 120:333–gn, 120: 785, 121:1–gn, 121:241–gn, 121: 1035–gn
Gastrointestinal Effects of New Cox-2-Inhibiting Drugs Are Debated, 116: 511–gn
Genomes of Two *H. pylori* Strains Reveal Few Clues, 116:786–gn
GI Groups Join With Other Subspecialties in Challenging HCFA in Court, 116:3–gn
GLP-2 Cloning May Lead to Therapy for Intestinal Deficiency Diseases, 116: 786–gn
Gorden Steps Down From NIDDK Post, 116:236–gn
H. Pylori in Nonulcer Dyspepsia: To Treat or Not to Treat?, 116:511–gn
Hepatitis Drugs Win Approval, 116: 236–gn
Irradiation of Meat Is Approved, but Will It Be Used?, 116:785–gn
Manpower Issue Remains Murky, 116: 1283–gn
Mutation in Human Bile Salt Exporter Pump Causes Progressive Familial Intrahepatic Cholestasis, 116:4–gn
New FDA Rules a Boon to Pediatric Research-and Some Drug Companies, 116:1025–gn
NIH Looks to Parlay Budget Boon toward More Patient-Oriented Research, 116:3–gn
Olestra Study Hard to Digest, Critic Charges, 116:1026–gn
Report of Hepatitis A Outbreak Raises Concerns, 116:1283–gn
Researchers Fret as NIH Budget Is Squeezed, 116:1025–gn
SRC Mutation Enhances Colon Cancer Growth, 116:1025–gn
Taste-Receptor Breakthrough Is Bittersweet, 116:1284–gn
Two More Studies Weigh in on Interferon-Ribavirin Combination for Hepatitis C, 116:4–gn
Yet Another Drug Company Merger Proposed, 116:236–gn
Gordon D, Podolsky DK. Gastroenterology News, 119:611
Gordon FH. *See* Ghosh G
Gordon FH, Lai CWY, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A Randomized Placebo-Controlled Trial of a Humanized Monoclonal Antibody to α4 Integrin in Active Crohn's Disease, 121:268
Gordon JI
See Mills JC
See Wong MH
Gordon S. *See* Sandborn WJ
Gordon SC. *See* McHutchison JG
Gordon SC. New Insights into Acute Hepatitis C, 125:253–e
Gordon SR. *See* Robertson DJ
Gordon TP. *See* Goldblatt F
Gorelick FS. *See* Gukovskaya AS
Comment From the Editors, 117:295
Patient Competence, 119:613–ce
Gores GJ
See Canbay A
See Feldstein AE
See Jaiswal M
See Miyoshi H
See Taniai M
See Yoon J-H
Gores GJ. A Spotlight on Cholangiocarcinoma, 125:1536–e
Gornbein J
See Dulai GS
See Jensen DM
Gosert R. *See* Lerat H
Goshima H. *See* Icatlo FC Jr
Gösling T. *See* Zender L
Goss KH. *See* Heinen CD
Gostout CJ
See Filipi CJ
See Sorbi D
Gottesdiener K. *See* Wight NJ
Gottstein J. *See* Córdoba J
Gotwald T. *See* Rettenbacher T
Gotwals PJ. *See* Zheng H
Götze O. *See* Silberg DG
Gotzsche PC. *See* Hrobjartsson A
Goudoever JB van. *See* van der Schoor SRD
Gough M, Kelty C, Bird N, Majeed A, Ackroyd R. Discussion on Preoperative Prevalence of Barrett's Esophagus in Esophageal Adenocarcinoma: A Systemic Review, 123:955–co
Goulis J. *See* Patch D
Gouma DJ. *See* Boerma D
Gouma DJ. Cholecystectomy after Treatment of Choledocholithiasis: On Firmer Ground. Reply, 125:618–ss
Gout S. *See* Pufulete M

Gouw A. *See* Jansen PLM
Gouysse G. *See* Marion-Audibert A-M
Gower-Rousseau C
See Hugot J-P
See Laharie D
Goyal RK
See Mashimo H
See Sang Q
See Sivarao DV
Graber P. *See* Hove TT
Grady WM
Genetic Testing for High-Risk Colon Cancer Patients, 124:1574
GISTs: The Revolution Continues, 125: 967–e
Grady WM, Markowitz S. Transforming Growth Factor β and Tumor-Suppressing Pathways: It Doesn't Matter How You Get There, As Long As You Get There. Reply, 117:500–ss
Grady WM, Peek RM Jr. Hereditary Diffuse Gastric Cancer: More Answers or More Questions? Comment, 122:830–ss
Graf D
See Häussinger D
See Kurz AK
See Reinehr R
Graf D, Kurz AK, Fischer R, Reinehr R, Häussinger D. Taurolithocholic Acid-3 Sulfate Induces CD95 Trafficking and Apoptosis in a c-Jun N-terminal Kinase Dependent Manner, 122:1411
Graf GA. *See* Berge KE
Graf R
See Selzner M
See Selzner N
Graff J. *See* Jeppesen PB
Graff M. *See* Zhu Y
Graham DY
See Ball JM
See Hwang I-R
See Kim JJ
See Rungta M
See Yamaoka Y
Graham DY
Helicobacter pylori: Molecular and Cellular Biology, 121:740–pmr
Therapeutic Roles of Selective COX-2 Inhibitors, 122:241–pmr
Graham DY, Dore MP. The QUADRATE Study: A Proposal for a Change in the Reporting of Pharmaceutical Supported Trials, 125:639–c
Graham DY, Moon N. Low-Dose Aspirin May or May Not Damage the Gastric Mucosa, 117:1506–c
Graham JE, Peek RM Jr, Krishna U, Cover TL. Global Analysis of *Helicobacter pylori* Gene Expression in Human Gastric Mucosa, 123:1637
Graham MF
See Li L
See Meng G
Gralnek IM
See Jensen DM
See Spiegel BMR
Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The Impact of Irritable Bowel Syndrome on Health-Related Quality of Life, 119:654
Gramlich T
See Matteoni CA
See Saadeh S
Gramlich TL. *See* Ormsby AH
Granados A. *See* Escorsell À
Granath F
See Bergquist A
See Tindberg Y
Grancher K. *See* Markowitz J
Grand RJ. *See* Montgomery RK
Grandbastien B
See Laharie D
See Quinton JF
Grande B. *See* Shaker R
Grandis DD. *See* Restivo DA
Grandis JR. *See* Schwarz NT
Granel B, Serratrice J, Valleix S, Grateau G, Droz D, Lafon J, Sault M-C, Chaudier B, Disdier P, Laugier R, Delpech M, Weiller P-J. A Family With Gastrointestinal Amyloidosis Associated With Variant Lysozyme, 123:1346–cr
Granger DN
See Brand SJ
See Yeh K-Y
Granholm NA. *See* Richmond BL
Granström M
See Su B
See Tindberg Y
Grassi G. *See* Pozzi M
Grasso AW. *See* Grossmann J
Grateau G. *See* Granel B
Gratz KF. *See* Widjaja A
Graupera M, García-Pagán J-C, Titos E, Claria J, Massaguer A, Bosch J, Rodés J. 5-Lipoxygenase Inhibition Reduces Intrahepatic Vascular Resistance of Cirrhotic Rat Livers: A Possible Role of Cysteinyl-Leukotrienes, 122:387
Graves LM. *See* Rhoads JM
Gray DF
See Dienstag JL
See Lai C-L
Gray GM. *See* Shan L
Grazia Mancino M. *See* Alvaro D
Grebe J. *See* Hampe J
Grebe P. *See* Eckardt VF
Greco L. *See* Ventura A
Green A. *See* Radford-Smith GL
Green AK, Zolle O, Simpson AWM. Atrial Natriuretic Peptide Attenuates Ca^{2+} Oscillations and Modulates Plasma Membrane Ca^{2+} Fluxes in Rat Hepatocytes, 123:1291
Green CA. *See* Vinall LE
Green HR. *See* Murray JA
Green JRB. Balsalazide and Azathioprine or 6-Mercaptopurine. Reply, 117:1514–c
Green JT. *See* Richardson CE
Green PHR. *See* Papdakis KA
Green PHR, Barry M, Matsutani M. Serologic Tests for Celiac Disease, 124:585–c
Green RJ, Metlay JP, Propert K, Catalano PJ, MacDonald JS, Mayer RJ, Haller DG. Seek and Ye Shall Find, 123: 1401–ss
Green RM, Flamm SL
Elevated Serum Transaminases and Celiac Disease: Possible Modifications of a Diagnostic Algorithm. Reply, 125: 280–C
First, Do Not Harm: Power, Oppression, and Violence of Liver Biopsy. Reply, 125:273–c
Greenberg A. *See* Fontana FJ
Greenberg E. *See* Sandborn WJ
Greenberg ER. *See* Baron JA
Greenberg GR. *See* Steinhart AH
Greenberg HB. *See* Baumert TF
Greenberger NJ. *Small Bowel Disorders*, 121: 1257–pmr
Greenhalgh CJ, Miller ME, Hilton DJ, Lund PK. Suppressors of Cytokine Signaling: Relevance to Gastrointestinal Function and Disease, 123:2064–srr
Greenlees C. *See* Gordon FH
Greenslade L. *See* Patch D
Greensmith MJ. *See* Jonas MM
Greenstein A. *Principles and Practice of Surgery for the Colon, Rectum and Anus*, 116:1502–pmr
Gregersen H. *See* Pedersen J
Gregersen H. Development of a Tensotat for Gastric Perception Studies, 118: 641–c
Gregor M
See Jacob P
See Rossmann H
See Schwab M
Greiner A
See Fischbach W
See Timm S
Greiner A, Timm S. "High-Grade MALT" *vs.* Diffuse Large B Cell Lymphoma, 123:1411–co
Greipel J. *See* Bronsveld I
Grenard P. *See* Li L
Grenier A. *See* Vachon PH

Grenman S. *See* Salmi M
Grenther WB. *See* Veltkamp C
Gresele P. *See* Fiorucci S
Gress TM
See Michl P
See Wagner M
See Weber CK
Gressner AM. *See* Dooley S
Gressner AM. The Up-and-Down of Hepatic Stellate Cells in Tissue Injury: Apoptosis Restores Cellular Homeostasis, 120:1286–e
Gretch DR. *See* Rosen HR
Greten FR. *See* Wagner M
Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM. Stat3 and NF-κB Activation Prevents Apoptosis in Pancreatic Carcinogenesis, 123:2052
Greten TF. *See* Greten FR
Gridley G. *See* Askling J
Grieken NCT van. *See* Hausen AZ
Griffith L. *See* Cook D
Griffiths AM. *See* Otley A
Griffiths DA. *See* Lok ASF
Grimm CF. *See* Geissler M
Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, Eisele S, Encke J, Blum HE, Geissler M. Mouse α-Fetoprotein-Specific DNA-Based Immunotherapy of Hepatocellular Carcinoma Leads to Tumor Regression in Mice, 119:1104
Grimm I. *See* Thiny M
Grimm I
Gastroenterological Endoscopy, 125:270–pmr
Gastroenterology Teaching Project 007: Pancreatitis, 125:991–pmr
Grimm IS
See Robertson D
See Russo M
Grisham JW. *Atlas of Tumor Pathology: Tumors of the Liver and Intrahepatic Bile Ducts*, 122:586–pmr
Grisham MB. *See* Brand SJ
NF-kB Activation in Acute Pancreatitis: Protective, Detrimental, or Inconsequential?, 116:489–e
Grishin NV. *See* Berge KE
Gritzmann N. *See* Rettenbacher T
Grize L. *See* Straumann A
Grizzle WE. *See* Zhang J
Groden J
See Boivin GP
See Heinen CD
See Lowy AM
Groden J. Touch and Go: Mediating Cell-to-Cell Interactions and Wnt Signaling in Gastrointestinal Tumor Formation, 119:1161–e
Grodet A. *See* Demeilliers C
Groen AK
See Brink MA
See Voshol PJ
Groenen P. *See* Vermeire S
Groneberg DA. *See* Jacob P
Gross JB. *Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management*, 122:1542–pmr
Gross P. *See* Gerbes AL
Gross V. *See* Lochs H
Grossmann J. *See* Steinkamp M
Grossmann J, Artinger M, Grasso AW, Kung H-J, Schölmerich J, Fiocchi C, Levine AD. Hierarchical Cleavage of Focal Adhesion Kinase by Caspases Alters Signal Transduction During Apoptosis of Intestinal Epithelial Cells, 120:79
Groszmann RJ
See Shah V
See Tsai M-H
See Wiest R
Groszmann RJ, Garcia-Tsao G. Endoscopic Variceal Banding *vs.* Pharmacological Therapy for the Prevention of Recurrent Variceal Hemorrhage: What Makes the Difference?, 123:1388–e
The Groupe Francophone d'Etude de la Malaide de von Hippel-Lindau. *See* Hammel PR
Grove J. *See* Smith BC
Growcott J. *See* Sarkar S
Gruber SB, Petersen GM, Kinzler KW, Vogelstein B. Cancer, Crash Sites, and the New Genetics of Neoplasia, 116:210–e
Gruener NH. *See* Gerlach JT
Gruenthal K. *See* Samowitz WS
Grundmann A. *See* Knittel T
Grundmann D. *See* Streetz K
Grundy D
See Booth CE
See Burdyga G
See Haupt W
See Jiang W
Grunebaum L. *See* Chamouard P
Gruner M. *See* Viola S
Grüner N. *See* Diepolder HM
Gruppuso PA. *See* Khamzina L
Gruy-Kapral C, Little KH, Fordtran JS, Meziere TL, Hagey LR, Hofmann AF. Conjugated Bile Acid Replacement Therapy for Short-Bowel Syndrome, 116:15
Gschossmann J. *See* Holtmann G
Gu Cho Y. *See* Sug Kim H
Gu LH. *See* Ziegler TR
Gu X. *See* Brand S
Gualdi GF. *See* Pappalardo G
Guan R
See Lai C-L
See Liaw Y-F
Guan RJ, Fu Y, Holt PR, Pardee AB. Association of K-*ras* Mutations With *p16* Methylation in Human Colon Cancer, 116:1063
Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG. GLP-2-Mediated Up-Regulation of Intestinal Blood Flow and Glucose Uptake Is Nitric Oxide-Dependent in TPN-Fed Piglets, 125:136
Guardascione MA. *See* Amitrano L
Guardiola J, Xiol X, Nolla JM. Influence of Vitamin D Receptor Gene Polymorphism on Bone Mineral Density in Primary Biliary Cirrhosis, 119:599–c
Guarino A. *See* Canani RB
Guarner C. *See* Villanueva C
Guarner C, Solà R, Soriano G, Andreu M, Novella MT, Vila MC, Sàbat M, Coll S, Ortiz J, Gómez C, Balanzó J. Risk of a First Community-Acquired Spontaneous Bacterial Peritonitis in Cirrhotics With Low Ascitic Fluid Protein Levels, 117:414
Guarnieri G. *See* Barazzoni R
Guarraci FA, Pozo MJ, Palomares SM, Firth TA, Mawe GM. Opioid Agonists Inhibit Excitatory Neurotransmission in Ganglia and at the Neuromuscular Junction in Guinea Pig Gallbladder, 122:340
Gudbjartsson D. *See* Bjarnason I
Gudbjartsson DF. *See* Thjodleifsson B
Gudjonsson H. *See* Thjodleifsson B
Gudnason V. *See* Thjodleifsson B
Guéant J-L, Chery C, Namour F, Aimone-Gastin I, Wustinger M. Decreased Affinity of Urinary Intrinsic Factor-Cobalamin Receptor in a Case of Gräsbeck-Imerslund Syndrome, 116:1274–c
Guehler SR, Bluestone JA, Barrett TA. Activation and Peripheral Expansion of Murine T-Cell Receptor γδ Intraepithelial Lymphocytes, 116:327
Guelinckx PJ. *See* Madoff RD
Guerra CT. *See* Failli P
Guerrero RA. *See* Ball JM
Guevara M
See Arroyo V
See Ginès P
See Ortega R
See Sort P
Guevara M, Ginès P, Arroyo V. More Therapy for Hepatorenal Syndrome. Reply, 116:1265–ss

Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, Garcia-Pagan JC, Bosch J, Arroyo V, Rodés J. More Therapy for Hepatorenal Syndrome, 116:1262–ss
Gugenheim J. *See* Féray C
Gugger M. *See* Reubi JC
Guha S. *See* Dulai GS
Gui D. *See* Maria G
Gui X, Carraway RE. Enhancement of Jejunal Absorption of Conjugated Bile Acid by Neurotensin in Rats, 120:151
Guiard B. *See* Coelho A-M
Guilford P. *See* Pharoah P
Guilford PJ. *See* Huntsman DG
Guillem P, Delcambre F, Cohen-Solal L, Triboulet J-P, Antignac C, Heidet L, Quandalle P. Diffuse Esophageal Leiomyomatosis With Perirectal Involvement Mimicking Hirschsprung Disease, 120:216–cr
Guillin M-C. *See* Condat B
Gukovskaya AS
See Lugea A
See Pandol SJ
See Vaquero EC
Gukovskaya AS, Mouria M, Gukovsky I, Reyes CN, Kasho VN, Faller LD, Pandol SJ. Ethanol Metabolism and Transcription Factor Activation in Pancreatic Acinar Cells in Rats, 122: 106
Gukovskaya AS, Vaquero E, Zaninovic V, Gorelick FS, Lusis AJ, Brennan M-L, Holland S, Pandol SJ. Neutrophils and NADPH Oxidase Mediate Intrapancreatic Trypsin Activation in Murine Experimental Acute Pancreatitis, 122:973
Gukovsky I
See Gukovskaya AS
See Lugea A
See Pandol SJ
See Vaquero EC
Gulberg E, Leonard M, Karlsson J, Hopkins AM, Brayden D, Baird AW, Artursson P. Human M Cells Delivered in a Box, 121:1520–ss
Gülberg V
See Gerbes AL
See Rössle M
Gulbis JM. *See* Doyle DA
Gum JR Jr. *See* Terdiman JP
Gunckel M. *See* Leeb SN
Gunson BK. *See* Kurkijärvi R
Guo BP, Mekalanos JJ. The Politics of *H. pylori*-Challenged Mice: Liberal Permissiveness Versus Conservative Restriction, 124:577–ss
Guo GL. *See* Wagner M
Guo J. *See* Liao Q
Guo X, Wang WP, Ko JKS, Cho CH. Involvement of Neutrophils and Free Radicals in the Potentiating Effects of Passive Cigarette Smoking on Inflammatory Bowel Disease in Rats, 117:884
Gupta S
See Joseph B
See Malhi H
See Wege H
Guralnik J. *See* Havlik RJ
Gurnot D. *See* Moreau R
Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition of Indoleamine 2,3-Dioxygenase Augments Trinitrobenzene Sulfonic Acid Colitis in Mice, 125:1762
Guru S. *See* De BK
Gusella JF. *See* Castells A
Guss J. *See* Holt PR
Gustavo C, Pedro V, Bernardo F, Silvia S. Discussion on Randomized Comparison of Long-Term Losartan Versus Propranolol in Lowering Portal Pressure in Cirrhosis, 122:1544–c
Gut MO, Parkkila S, Vernerová Z, Rohde E, Závada J, Höcker M, Pastorek J, Karttunen T, Gibadulinová A, Závadová Z, Knobeloch K-P, Wiedenmann B, Svoboda J, Horak I, Pastoreková S. Gastric Hyperplasia in Mice With Targeted Disruption of the Carbonic Anhydrase Gene *Car9*. 123: 1889
Gutherie E. *See* Hamilton J
Guthrie E. *See* Creed F
Gutierrez O. *See* Yamaoka Y
Gutiérrez-Ramos J-C. *See* Bataller R
Gutierrez-Tous R. *See* Romero-Gómez M
Gutterman DD. *See* Hatoum OA
Guyader D. *See* Mendler M-H
Guyatt F. *See* Schoenfeld P
Guyatt G. *See* Cook D
Guzail MA. *See* Smith BC
Guzmán CA
See Colombo MP
See Paglia P
Gyr N
See Hildeand P
See Schneider A

Haas JE. *See* Kurbegov AC
Habano W, Nakamura S-I
Mitochondrial DNA Alteration in Gastric Cancer. Reply, 119:1808–c
Somatic Mutations in Mitochondrial DNA Do Not Associate With Nuclear Microsatellite Instability in Gastrointestinal Cancer. Reply, 119: 1906–c
Habel LA. *See* Corley DA
Haber GB. *Diseases of the Gallbladder and Bile Duct: Diagnosis & Treatment*, 122: 2089–pmr
Haber MM. *See* Kozar RA
Habib A. *See* Li L
Hachimura S. *See* Fujimori H
Hackett A. *See* Evans RC
Hackl F. *See* Kazemi-Shirazi L
Hadchouel M
See Crosnier C
See Jansen PLM
Haddad F. *See* Shah V
Hadengue A
See Condat B
See Frossard JL
See Frossard J-L
See Moreau R
See Spahr L
Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate Increases Lumbar Spine Bone Mineral Density in Patients With Crohn's Disease, 119:639
Hadziyannis S. *See* Westland C
Hadziyannis SJ. *See* Manesis EK
Hafraoui S. *See* Desreumaux P
Hagen J. *See* He D
Hagen S. *See* He D
Hagen SJ. *See* Saubermann LJ
Hagenbaugh A. *See* De Winter H
Hagenbuch B
See Gerloff T
See Ismair MG
See Kullak-Ublick GA
See Reichel C
Hagey LR
See Bolder U
See Gruy-Kapral C
Hagge-Greenberg A. *See* Cohen P
Haggitt RC. *See* Tung BY
Haglund C. *See* Buskens CJ
Hahn AB. *See* Verne GN
Hahn EG
See Benninger J
See Schuppan D
Haidan A. *See* Franchimont D
Haigh C. *See* Varro A
Haigh CR, Attwood SEA, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, Varro A, Dimaline R. Gastrin Induces Proliferation in Barrett's Metaplasia Through Activation of the CCK_2 Receptor, 124:615
Haigh CR, Kirton C, Pritchard DM, Varro A, Dimaline R, Attwood SEA, Thompson DG, Jankowski JA
Can Proton Pump Inhibitors Be Blamed for the Rising Incidence of Esophageal Cancer? Reply, 125:1912–c
Gastrin-Induced Hyperproliferation in

Barrett's Esophagus. Reply, 125:1921–c
Haigh WG, Lee SP. Identification of Oxysterols in Human Bile and Pigment Gallstones, 121:118
Haile RW. *See* Baron JA
Hajoui O. *See* Lapierre P
Håkanson R. *See* Chen D
Halabi S. *See* Baron JA
Halberg RB. *See* Boivin GP
Haldar N. *See* Satsangi J
Haldeman KM. *See* Williams KL
Halfon P
See Bourlière M
See Renou C
Half-Onn E, Pomeranz I, Leichtmann G. Image of the Month, 121:756–im
Halfvarson J, Bodin L, Tysk C, Lindberg E, Järnerot G. Inflammatory Bowel Disease in a Swedish Twin Cohort: A Long-Term Follow-up of Concordance and Clinical Characteristics, 124:1767
Halimi C. *See* Moreau R
Halkic N, Scholl B, Corpataux JA. Image of the Month, 116:1286–im
Hall AE. *See* Cheng I
Hall R. *See* Cook D
Hallas J. *See* Aalykke C
Haller DG. *See* Green RJ
Halley DJJ. *See* Bronsveld I
Halligan S. *See* Vaizey CJ
Halme L
See Collin P
See Kaukinen K
Halpern MD, Holubec H, Williams CS, McWilliam DL, Dominguez JA, Stepankova R, Payne CM, McCusky RS. NEC, EGF, Milk and Spit. *See* Dvorak B
Halpern Z
See Benjaminov F
See Blendis L
Halser WL, Chey WD. Nausea and Vomiting, 125:1860
Halser WL. Lactulose Breath Testing, Bacterial Overgrowth, and IBS: Just a Lot of Hot Air? Comment, 125:1898–ss
Halstensen TS. *See* Askling J
Halttunen T, Mäki M. Serum Immunoglodbulin A From Patients With Celiac Disease Inhibits Human T84 Intestinal Crypt Epithelial Cell Differentiation, 116:566
Halvorsen RA Jr. *See* Johnson CD
Hamada K
See Shindo M
See Tanaka S
Hamamoto N. *See* Matsumoto A
Hamano H. *See* Kawa S
Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nakaido T, Nakayama K, Usuda N, Kiyosawa K. The Importance of Autoimmune Pancreatitis, 121:1518–ss
Hamasuna R. *See* Uchino H
Hamdy S. *See* Turnbull GK
Hameister H. *See* Paxian S
Hamelin R
See Brennetot C
See Duval A
See Suraweera N
Hamilton F. *See* Schoenfeld P
Hamilton J, Gutherie E, Creed F, Thompson D, Tomenson B, Bennett R, Moriarty K, Stephens W, Liston R. A Randomized Controlled Trial of Psychotherapy in Patients With Chronic Functional Dyspepsia, 119:661
Hamilton JR. *See* Mathews CJ
Hamilton MI. *See* Gordon FH
Hamilton S. *See* Giardello FM
Hamilton SR
See Alberts DS
See Kim SG
See Rashid A
See Shen L
Hamlet A, Thoreson A-C, Nilsson O, Svennerholm A-M, Olbe L. Duodenal *Helicobacter pylori* Infection Differs in *cagA* Genotype Between Asymptomatic Subjects and Patients With Duodenal Ulcers, 116:259
Hamlin PJ, Komolmit P, Bransfield K, Jones PF, Smith NR, Aldersley MA, Howdle PD, Markham AF, Robinson PA. Identification of Multiple Candidate Genes for IBD Susceptibility Using High-Density Transcript Mapping in the IBD2 Locus on Chromosome 12q, 117:1029–c
Hamm L. *See* Berman SM
Hammann A. *See* Millet A
Hammarström M-L. *See* Forsberg G
Hammarström M-L, Forsberg G, Hernell O, Hammarström S. TNF-α Production by Intra-Epithelial T Cells in Celiac Disease. Reply, 125:1561–c
Hammarström S
See Forsberg G
See Hammarström M-L
Hammel JP. *See* Parsi MA
Hammel P. *See* Malka D
Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas J-M, Chauveau D, Balian A, Beigelman C, O'Toole D, Bernades P, Ruszniewski P, Richard S, The Groupe Francophone d'Etude de la Malaide de von Hippel-Lindau. Pancreatic Involvement in von Hippel-Lindau Disease, 119:1087
Hammoud R. *See* Malassagne B
Hamoudi R. *See* Tomlinson I
Hamoudi RA. *See* Liu H
Hampe J
See Croucher PJP
See Cuthbert AP
Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJP, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M, Mirza MM, Foelsch UR, Vatn M, Schreiber S. The Genesis of IBD Genetics, 123:2148–ss
Hamscher G. *See* Feurle GE
Hamzavi J. *See* Dooley S
Han B. *See* Chen X
Han J. *See* Vachon PH
Han JP. *See* Pineau BC
Han S. *See* Akriviadis E
Han S-H. *See* Chu C-J
Han SHB. *See* Saab S
Hanada S. *See* Harada M
Hanai H. *See* Sugimoto K
Hanash S. *See* Hinoi T
Hanauer SB
See Brant SR
See Ehrenpreis ED
See Fedorak RN
See Hugot J-P
See Rutgeerts P
See Sandborn WJ
See Sands BE
See Schreiber S
Hanauer SB. Considerations in the Management of Steroid-dependent Crohn's Disease, 125:906
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group. Maintenance Infliximab Therapy in Patients With Crohn's Disease: How Long, How Much, How Frequent?, 124:1988–ss
Hanberg A. *See* Rubio CA
Hanck C, Hatz C. Treatment of Strongyloides Infections, 119:1805–c
Handa M. *See* Kamihira T
Handin RI. A Hitchhiker's Guide to the Galaxy-An *H. pylori* Travel Guide, 124:1983–e
Hang T. *See* Abreu MT
Hann HWL. *See* Dienstag JL
Hann H-WL. *See* Fontana RJ
Hanna MG Jr. *See* van den Eertwegh AJM
Hannon GJ. *See* McCaffrey AP
Hanrahan JW. *See* Mathews CJ
Hans W. *See* Steidler L

Hansen BE. *See* Schalm SW
Hansen BS. *See* Jeppesen PB
Hansen GH, Niels-Christiansen L-L, Immerdal L, Hunziker W, Kenny AJ, Danielsen EM. Transcytosis of Immunoglobulin A in the Mouse Enterocyte Occurs Through Glycolipid Raft- and Rab17-Containing Compartments, 116:610
Hansen JM. *See* Wildner-Christensen M
Hanson RB. *See* Thumshirn M
Hansson L-E. *See* Elkström AM
Hansson-Brändén L. *See* Lehmann A
Haorah J. *See* Schneider MB
Haouzi D. *See* Mansouri A
Happ J. *See* Leuschner M
Hara AK. *See* Johnson CD
Hara T, Yamaguchi T, Ishihara T, Tsuyuguchi T, Kondo F, Kato K, Asano T, Saisho H. Diagnosis and Patient Management of Intraductal Papillary-Mucinous Tumor of the Pancreas by Using Peroral Pancreatoscopy and Intraductal Ultrasonography, 122:34
Harada K. *See* Kamihira T
Harada M
See Kamihira T
See Shimoda S
Harada M, Kawaguchi T, Kumemura H, Sata M. Where Is the Site That ATP7B Transports Copper Within Hepatocytes?, 125:1911–c
Harada M, Kumemura H, Sata M. Mallory Bodies, Like the Mutant of ATP7B Seen in Wilson's Disease, Are Aggresomes. Reply, 121:1265–c
Harada M, Sakisaka S, Terada K, Kimura R, Kawaguchi T, Koga H, Kim M, Taniguchi E, Hanada S, Suganuma T, Furuta K, Sugiyama T, Sata M. A Mutation of the Wilson Disease Protein, ATP7B, Is Degraded in the Proteasomes and Forms Protein Aggregates, 120:967
Hardman CM. *See* Porter WM
Hardwick JCH. *See* van den Brink GR
Hardwick JCH, van den Brink GR, Offerhaus GJ, Deventer SJH van, Peppelenbosch MP. Leptin Is a Growth Factor for Colonic Epithelial Cells, 121:79
Harewood GC, Wiersema MJ, Nelson H, MacCarty RL, Olson JE, Clain JE, Ahlquist DA, Jondal ML. A Prospective, Blinded Assessment of the Impact of Preoperative Staging on the Management of Rectal Cancer, 123:24
Harewood L. *See* Springer JE
Harfarth H. *See* Merger M
Hargus SJ. *See* Atchison CR
Harishinghani M. *Double Contrast Gastrointestinal Radiology*, 121:1022–pmr
Harms A. *See* Obermayer-Straub P
Harmsen W. *See* Vazquez-Sequeiros E
Harmsen WS
See Faubion WA Jr
See Johnson CD
See Schwartz DA
See Silverstein MD
Harnett KM. *See* Cao W
Harnois C. *See* Vachon PH
Harpaz N
See Friedman S
See Rubin PH
See Selaru FM
See Ullman T
Harper A. *See* Wiesner R
Harper JC. *See* El-Rifai W
Harper S. *See* Laine L
Harpole D. *Esophageal Surgery*, 125:625–pmr
Harraga S. *See* Godot V
Harrington JJ. *See* Ahlquist DA
Harris D. *See* Vader W
Harris HE, Ramsay ME, Andrews N, Eldridge KP
Understanding the Course, 124:261–ss
Understanding the Course. Reply, 124:263–ss
Harris PC. *See* Masyuk TV
Harris RC Jr. *See* Means AL
Harrison DJ. *See* Newsome PN
Harrison R. *See* Ramsey SD
Harrison S. *See* Trevisani M
Hart N. *See* Maltzman T
Hart PS. *See* Pfützer RH
Hartman BK. *See* Faris PL
Hartmann A. *See* Mühlbauer M
Hartmann B
See Guan X
See Jeppesen PB
Hartwig W, Jimenez RE, Werner J, Lewandrowski KB, Warshaw AL, Fernández-del Castillo C. Interstitial Trypsinogen Release and Its Relevance to the Transformation of Mild Into Necrotizing Pancreatitis in Rats, 117:717
Haruna H. *See* Shimizu T
Harvey PJ, LeCouteur D, McLean AJ. Hepatic Oxygen Supplementation as Therapy in Cirrhotic Liver Disease, 117:1025–c
Hasan M. *See* Hildeand P
Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, Obonyo M, Gallo RL, Eckmann L, Kagnoff MF. Expression of LL-37 by Human Gastric Epithelial Cells as a Potential Host Defense Mechanism Against *Helicobacter pylori*, 125:1613
Hasebe O. *See* Kawa S
Hasel C. *See* Sträter J
Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, Yamaoka Y, Miyake M. Aminopeptidase N Is Involved in Cell Motility and Angiogenesis: Its Clinical Significance in Human Colon Cancer, 122:376
Hashimoto M. *See* Iwashita T
Hasler WL
See Ladabaum U
See Quigley EMM
Hasler WL
Air Apparent: Studies of Gas and Bloating in IBS. Comment, 122:576–ss
Are Things Looking Up for the Treatment of Gastroparesis? Sildenafil in Animal Models of Diabetic Gastropathy. Comment, 120:576–ss
Baclofen Effects on Esophageal Function: A Possible Therapy for GERD? Comment, 123:1736–ss
The Benefits of Dietary Fiber on Glycemic Control in Type 2 Diabetes: Relevance to Gastroenterologists. Comment, 119:1168–ss
The Brute Force Approach to Electrical Stimulation of Gastric Emptying: A Future Treatment for Refractory Gastroparesis?, 118:433–e
Celiac Sprue as a Possible Cause of Symptoms in Presumed Irritable Bowel Syndrome. Comment, 122:2086–ss
Expanding Spectrum of Clinical Uses for Botulinum Toxin: Healing of Chronic Anal Fissures. Comment, 116:222–ss
Garlic Breath Explained: Why Brushing Your Teeth Won't Help. Comment, 117:1248–ss
Gastric Neurostimulation for Gastroparesis: Time to Pick up the Pace. Comment, 125:980–ss
5-HT$_3$ Antagonist Therapy of Bulimia Nervosa: A Peripherally Active Agent for a Central Nervous System Eating Disorder? Comment, 119:271–ss
Is Constipation Caused by a Loss of Colonic Interstitial Cells of Cajal? Comment, 125:264–ss
Neostigmine for Acute Colonic Pseudo-Obstruction: New Use for and Old Drug? Comment, 118:443–ss
New Insights Into the Pathogenesis of Rumination: What's Coming up Next. Comment, 116:1007–ss
Persistent Colonic Inflammation in Postinfectious IBS: Symptom Cause or Curiosity? Comment, 121:493–ss

The Problem of Delayed Emesis After Cancer Chemotherapy: A Possible New Treatment. Comment, 117:737–ss
The Stomach and Weight Reduction: The Role of Ghrelin. Comment, 124: 576–ss
Hass D. *See* Aberra FN
Hassard PV
See Dubinsky MC
See Vasiliauskas EA
Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-Tumor Necrosis Factor Monoclonal Antibody Therapy for Gastrointestinal Behçet's Disease: A Case Report, 120:995–cr
Hassoun HT. *See* Kozar RA
Hata K. *See* Andoh A
Hata S. *See* Maeyama H
Hatano E, Bennett BL, Manning AM, Qian T, Lemasters JJ, Brenner DA. NF-κB Stimulates Inducible Nitric Oxide Synthase to Protect Mouse Hepatocytes From TNF-α- and Fas-Mediated Apoptosis, 120:1251
Hathaway M. *See* Butterworth JR
Hatlebakk J. *See* Myrvold HE
Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired Microvascular Dysfunction in Inflammatory Bowel Disease: Loss of Nitric Oxide-Mediated Vasodilation, 125:58
Hattlebakk J. *See* Lundell L
Hatz C. *See* Hanck C
Haubrich WS
Apoptosis, 119:1805–c
Babcock of the Babcock Clamp, 121:244
Beaumont of the Beaumont Gastric Fistula, 116:14
Blumer of Blumer's shelf, 118:30
Crohn of Crohn's Disease, 116:1034
Cullen of Cullen's Sign, 122:280
Doppler of the Doppler Ultrasound Effect, 125:1590
Einhorn of the Einhorn String Test, 117:10
Hartmann of the Hartmann Pouch, 124: 888
Hering of the Canals of Hering, AAA
Infelfinger of the Ingelfinger Rule, 116: 854
Jeghers of the Peutz-Jeghers Syndrome, 117:1262
Klatskin of the Klatskin Tumor, 116: 1309
Kussmaul Who Pioneered Gastroscopy, 121:1038
Lieberkühn of the Crypts of Lieberkühn, 124:7
Mall of the Space of Mall, 121:791
Mallory and Weiss of the Mallory-Weiss Syndrome, 121:541
Mallory of Mallory Bodies, 117:769
Meigs of Meigs' Syndrome, 123:699
Meissner of Meissner's Plexus, 116:247
Ménétrier of Ménétrier's Disease, 123: 1414
Moynihan of Moynihan's "Hunger Pain," 123:32
Murphy of Murphy's Sign, 124:292
Nissen of the Nissen Fundoplication, 125:6–gn
Oddi of the Sphincter of Oddi, 116:542
Plummer and Vinson of the Plummer-Vinson Syndrome, 117:1526
Riolan of the Arc of Riolan, 124:607
Röntgen of Roentgenology, 125:1566
Salmon of Salmonellosis, 119:1453
Schindler Who Pioneered Gastroscopy, 117:326
Stolen Glory: The McKinley Assassination, 124:266–pmr
Whipple of Whipple's Disease, 117:576
Hauer-Jensen M. *See* Zheng H
Hauff P. *See* Scholz A
Haupt W, Jiang W, Kreis ME, Grundy D. Prostaglandin EP Receptor Subtypes Have Distinctive Effects on Jejunal Afferent Sensitivity in the Rat, 119: 1580
Hauptmann G. *See* Chamouard P
Hausch F. *See* Shan L
Hausen AZ, Grieken NCT van, Meijer GA, Hermsen MAJA, Bloemena E, Meuwissen SGM, Baak JPA, Meijer CJLM, Kuipers EJ, Brule AJC van den. Distinct Chromosomal Aberrations in Epstein-Barr Virus-Carrying Gastric Carcinomas Tested by Comparative Genomic Hybridization, 121:612
Hausmann M, Kiessling S, Mestermann S, Webb G, Spöttl T, Andus T, Schölmerich J, Herfarth H, Ray K, Falk W, Rogler G. Toll-like Receptors 2 and 4 Are Up-regulated During Intestinal Inflammation, 122:1987
Häussinger D
See Fischer R
See Graf D
See Kubitz R
See Kurz AK
See Müschen M
See Reinehr R
Häussinger D, Jurz AK, Wettstein M, Graf D, vom Dahl S, Schliess F. Involvement of Integrins and Src in Tauroursodeoxycholate-Induced and Swelling-Induced Choleresis, 124:1476
Häussinger D. Liver Fibrosis and Na^+/H^+ Exchange, 120:572–e
Häussinger D, Schliess F, Dombrowski F, vom Dahl S. Involvement of $p38^{MAPK}$ in the Regulation of Proteolysis by Liver Cell Hydration, 116:921
Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PSH, Rahier J, Geubel AP. HLA Association of Amoxicillin-Clavulanate-Induced Hepatitis, 117:1181
Havinga R
See Kok T
See Meerman L
See van Waarde WM
See Voshol PJ
Havlik RJ, Guralnik J, Sayer B, Pahor M, Cohen H. Antihypertensive Drugs and Gastrointestinal Hemorrhage: Causation or Confounding?, 119:1416–c
Havu N. *See* Lundell L
Hawkey CJ
See Laine L
See Taha AS
See Wight NJ
Hawkey CJ. Nonsteroidal Anti-inflammatory Drug Gastropathy, 119: 521–srr
Hawkins N, Norrie M, Cheong K, Mokany E, Ku S-L, Meagher A, O'Connor T, Ward R. CpG Island Methylation in Sporadic Colorectal Cancers and Its Relationship to Microsatellite Instability, 122:1376
Hay JM. *See* Condat B
Hayakawa T
See Jin C
See Katayama K
See Shimizu H
Hayashi A. *See* Huntsman DG
Hayashi H. *See* Boku K
Hayashi I. *See* Boku K
Hayashi N
See Kawai N
See Kuzushita N
See Takehara T
Hayashi S. *See* Yokota K
Hayashi T
See Miyanishi K
See Rachmilewitz D
See Takayama T
Hayashibara T. *See* Mori N
Hayes PC
See Lui HF
See Newsome PN
See Tripathi D
Hays RD. *See* Gralnek IM
He CL. *See* Lyford GL
He C-L, Burgart L, Wang L, Pemberton J, Young-Fadok T, Szurszewski J, Farrugia G. Decreased Interstitial Cell

of Cajal Volume in Patients With Slow-Transit Constipation, 118:14
He C-L, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of Interstitial Cells of Cajal and Inhibitory Innervation in Insulin-Dependent Diabetes, 121:427–cr
He D, Hagen J, Pothoulakis C, Chen M, Medina ND, Warny M, LaMont JT. *Clostridium difficile* Toxin A Causes Early Damage to Mitochondria in Cultured Cells, 119:139
He D, Sougioultzis S, Hagen S, Liu J, Keates S, Keates AC, Pothoulakis C, Lamont JT. *Clostridium difficile* Toxin A Triggers Human Colonocyte IL-8 Release via Mitochondrial Oxygen Radical Generation, 122:1047
He W, Wang M-L, Jiang H-Q, Steppan CM, Shin ME, Thurnheer MC, Cebra JJ, Lazar MA, Wu GD. Bacterial Colonization Leads to the Colonic Secretion of RELMβ/FIZZ2, A Novel Goblet Cell-Specific Protein, 125:1388
He XD. *See* Prasad M
He X-S. *See* Kita H
Head DR. *See* Biankin AV
Healey ZV. *See* Arebi N
Healy J. *See* Miao YM
Heathcote EJ
See Dahlan Y
See Dienstag JL
See Lok ASF
See Springer JE
Heathcote J
See Poynard T
See Rubin L
Hebden JM. *See* Spiller RC
Hebert PC. Better Pale Than Yellow. Reply, 117:1017–ss
Hebert SC. *See* Cheng I
Hecht G
See McNamara BP
See Zolotarevsky Y
Hecketsweiler P. *See* Michel P
Hedenbro J. *See* Lindén S
Heeckt P. *See* Türler A
Heeren T. *See* Schroy PC III
Hegenbarth S. *See* Knolle PA
Heidenreich R. *See* Marschall ZV
Heidet L. *See* Guillem P
Heim MH. *See* Blindenbacher A
Hein DW. *See* McKim SE
Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T, Groden J. The APC Tumor Suppressor Controls Entry Into S-Phase Through Its Ability to Regulate the Cyclin D/RB Pathway, 123:751
Heinrich MC. *See* Demetri GD
Heinze S. *See* Scholz A
Heinz-Erian P. *See* Müller T
Heinzow BG. *See* McLean AJ
Heirman C. *See* Hellemans K
Heisterkamp SH. *See* Boeckxstaens GE
Heitkemper MM. *See* Chang L
Heizer WD. *Clinical Nutrition of the Essential Trace Elements and Minerals. The Guide for Health Professionals,* 122:834–pmr
Held M. *See* Elkström AM
Held MA. *See* Denson LA
Helenowski I. *See* Vagquero J
Helfand M. *See* Lieberman DA
Helgason KO. *See* Bjarnason I
Hellblom M. *See* Lind T
Hellemans K. *See* Reynaert H
Hellemans K, Michalik L, Dittie A, Knorr A, Rombouts K, de Jong J, Heirman C, Quartier E, Schuit F, Wahli W, Geerts A. Peroxisome Proliferator-Activated Receptor-β Signaling Contributes to Enhanced Proliferation of Hepatic Stellate Cells, 124:184
Heller J
See Pateron D
See Schepke M
See Tazi KA
Heller J, Schepke M, Gehnen N, Molderings GJ, Müller A, Erhard J, Spengler U, Sauerbruch T. Altered Adrenergic Responsiveness of Endothelium-Denuded Hepatic Arteries and Portal Veins in Patients With Cirrhosis, 116:387
Heller T. *See* Promrat K
Hellerbrand C. *See* Mühlbauer M
Hellers G, Cortot A, Jewell D, Leijonmarck CE, Löfberg R, Malchow H, Nilsson L-G, Pallone F, Pena S, Persson T, Prantera C, Rutgeerts P, and the IOIBD Budensonide Study Group. Oral Budesonide for Prevention of Postsurgical Recureence in Crohn's Disease, 116:294
Hellmich MR. *See* Ethridge RT
Helmer KS, West SD, Shipley GL, Chang L, Cui Y, Mailman D, Mercer DW. Gastric Nitric Oxide Synthase Expression During Endotoxemia: Implications in Mucosal Defense in Rats, 123:173
Helmy A, Jalan, R, Newby ED, Clive-Hayes P, Webb DJ. Role of Angiotensin II in Regulation of Basal and Sympathetically Stimulated Vascular Tone in Early and Advanced Cirrhosis, 118:565
Helper DJ. *See* Rex DK
Helwig U. *See* Gionchetti P
Heman-Ackah LM
See Dubois A
See Mysore JV
Hembree MJ. *See* Kobayashi H
Hemers E. *See* Varro A
Hemmerle C. *See* Trojan J
Hemminki A, Joensuu H. Microsatellite Instability as a Molecular Marker for Very Good Survival in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy. Reply, 120:1310–c
Hemminki A, Mecklin J-P, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite Instability Is a Favorable Prognostic Indicator in Patients With Colorectal Cancer Receiving Chemotherapy, 119:921
Hendrickse MT. *See* Gleeson D
Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JCE, Gleeson D. Low-Dose Methotrexate Is Ineffective in Primary Biliary Cirrhosis: Long-term Results of a Placebo-Controlled Trial, 117:400
Hendrickson BA. *See* Kojima K
Heneghan M, Rockey DC. Is TIPS Shunt Effective for Secondary Prophylaxis of Gastric Variceal Hemorrhage? Comment, 125:263–ss
Heneghan MA. *See* Moran AP
Henin D. *See* Sobhani I
Hennemann A. *See* Holtmeier W
Hennies HC. *See* Witt H
Henning SJ. *See* Hwang ST
Henricks WH. *See* Ormsby AH
Henriksson C. *See* Cameron AJ
Henrion J. *See* Hautekeete ML
Henry E. *See* Iijima K
Henry J. *See* Sorbi D
Henry JF. *See* van der Schoor SRD
Henshall SM. *See* Biankin AV
Hepburn M. *See* Terdiman JP
Herbert J-M. *See* Conway EM
Herfarth C. *See* Heuschen UA
Herfarth H
See Hausmann M
See Mühlbauer M
See Schwab M
Herion D
See Baumert TF
See Ghany MG
See Lau DT-Y
Herman BA. *See* Johnson CD
Herman JG. *p*16INK4: Involvement Early and Often in Gastrointestinal Malignancies, 116:483–e
Hermans J. *See* Liefers G-J
Hermelin B. *See* Rosmorduc O
Hermine O. *See* Verkarre V
Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B,

Troussard X. Hepatitis C: Beyond the Liver, 124:1157–ss
Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, Roemen G, Arends J-W, Williams R, Giaretti W, de Goeij A, Meijer G. Colorectal Adenoma to Carcinoma Progression Follows Multiple Pathways of Chromosomal Instability, 123:1109
Hermsen MAJA. *See* Hausen AZ
Hernandez A. *See* Chung DH
Hernandez-Diaz S. *See* Garcia Rodriguez RA
Hernell O
See Forsberg G
See Hammarström M-L
Herraiz M. *See* Lucena J-F
Herranz M. *See* Michetti P
Herrero JI
See Lucena JF
See Lucena J-F
Herreros B. *See* Minguez M
Herrine SK. *Schiff's Disease of the Liver*, 116: 1501–pmr
Herrmann G. *See* Leuschner M
Hershberg R
See Niel G van
See van de Wal Y
Hershberg RM
See Framson PE
See Lu J
Hershberg RM, Blumberg RS. What's So (Co)stimulating About the Intestinal Epithelium?, 117:726–e
Hertzog P. *See* Ng AY-N
Hervatin F. *See* Sobhani I
Hervieu V. *See* Marion-Audibert A-M
Hesdorffer C. *See* Shiva Kumar K
Hesselink M. *See* Boonen A
Heubi JE. *See* Setchell KDR
Heuman DD. *See* Foody W
Heuman DM, Mihas AA. Utility of the MELD Score for Assessing 3-Month Survival in Patients With Liver Cirrhosis: One More Positive Answer, 125:992–c
Heun Lee J. *See* Sug Kim H
Heuschen G. *See* Heuschen UA
Heuschen UA, Hinz U, Allemeyer EH. Discussion of "Backwash Ileitis Is Strongly Associated With Colorectal Carcinoma in Ulcerative Colitis" Reply, 122:246–c
Heuschen UA, Hinz U, Allemeyer EH, Lucas M, Heuschen G, Herfarth C. Protecting the Pouch: Diversion Is Not the Answer, 123:1403–ss
Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, Herfarth C, Heuschen G. Backwash Ileitis Is Strongly Associated With Colorectal Carcinoma in Ulcerative Colitis, 120:841
Hewlett B. *See* Huizinga JD
Heyer J. *See* Velcich A
Heyman M
See Matysiak-Budnik T
See Niel G van
Heyman RA. *See* Repa JJ
Heymer P. *See* Miehlke S
Heys SD. Nutrition in the ICU: Are All Systematics Go? Reply, 117:1500–ss
Hiba MR, Eaker IY. Image of the Month, 119:894–im
Hibi T
See Inoue N
See Kanai T
See Nakazawa A
See Totsuka T
Hicks GA. *See* Booth CE
Hidaka E. *See* Maeyama H
Hidalgo-Tenorio C, Mediavilla JD, Fernández-Torres C, León Ruiz L, Aliaga Martínez L, Jiménez-Alonso J. Renovascular Hypertension Consequent to Giant Cyst of the Liver, 121:745–c
Hiele M. *See* Van Assche G
Hiele MI. *See* Baert FJ
Hietaranta A. *See* Lee HS
Higaki K. *See* Mizoguchi A
Higashimoto Y. *See* Miyazaki Y
Higashiyama S
See Kiso S
See Miyazaki Y
Hige S. *See* Ohkawara T
Higgins CF. *See* Byrne JA
Higham AD, Bishop LA, Dimaline R, Blackmore CG, Dobbins AC, Varro A, Thompson DG, Dockray GJ. Mutations of *Reg*Iα Are Associated With Enterochromaffin-like Cell Tumor Development in Patients With Hypergastrinemia, 116:1310
Higuchi H
See Canbay A
See Taniai M
See Yoon J-H
Hilaret G. *See* Segain J-P
Hildebrand P. *See* Degen LP
Hildebrand P, Bardhan P, Rossi L, Parvin S, Rahman A, Arefin MS, Hasan M, Ahmad MM, Glatz-Krieger K, Terracciano L, Bauerfeind P, Beglinger C, Gyr N, Khan AKA. Recrudescence and Reinfection With *Helicobacter pylori* After Eradication Therapy in Bangladeshi Adults, 121:792
Hilkens J. *See* Vinall LE
Hill M. *See* Everhart JE
Hillaire S. *See* Condat B
Hillard C. *See* van Sickle M
Hillebrand G. *See* Santer R
Hillebrandt S, Goos C, Matern S, Lammert F. Genome-Wide Analysis of Hepatic Fibrosis in Inbred Mice Identifies the Susceptibility Locus *Hfib1* on Chromosome 15, 123:2041
Hillman L. *See* Bassett M
Hilton DJ. *See* Greenhalgh CJ
Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, Fearon ER. CDX2 Regulates Liver Intestine-Cadherin Expression in Normal and Malignant Colon Epithelium and Intestinal Metaplasia, 123:1565
Hinojosa J. *See* Panés J
Hinoue T. *See* Läuffer JM
Hinrichs DJ. *See* Rosen HR
Hinz U. *See* Heuschen UA
Hirai Y. *See* Yokota K
Hirano I, Tatum RP, Shi G, Sang Q, Joehl RJ, Kahrilas PJ. Manometric Heterogeneity in Patients With Idiopathic Achalasia, 120:789
Hiraoka S. *See* Miyazaki Y
Hirata K. *See* Shibao K
Hirata K, Nathanson MH. Bile Duct Epithelia Regulate Biliary Bicarbonate Excretion in Normal Rat Liver, 121:396
Hirata K, Pusl T, O'Neill AF, Dranoff JA, Nathanson MH. The Type II Inositol 1,4,5-Trisphosphate Receptor Can Trigger Ca^{2+} Waves in Rat Hepatocytes, 122:1087
Hirata Y. *See* Maeda S
Hirata Y, Maeda S, Mitsuno Y, Tateishi K, Yanai A, Akanuma M, Yoshida H, Kawabe T, Shiratori Y, Omata M. *H. pylori* CagA Protein Activates Serum Response Element-Driven Transcription Independently of Tyrosine Phosphorylation, 123:1962
Hirayama T. *See* Mori N
Hirohashi S, 118:497
Hirose M
See Enomoto N
See Ikejima K
See Tsune I
Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A, Takabayashi A, Obayashi T, Okuno T, Kinoshita K, Chen H, Shinomura Y, Kitamura Y. Familial Gastrointestinal Stromal Tumors Associated With Dysphagia and Novel Type Germline Mutation of KIT Gene, 122:1493–cr
Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-Function Mutations of Platelet-Derived Growth Factor Receptor α Gene in Gastrointestinal Stromal Tumors, 125:660–rc

Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH. Specialized Intestinal Metaplasia, Dysplasia, and Cancer of the Esophagus and Esophagogastric Junction: Prevalence and Clinical Data, 116:277
Hirsch DP. *See* Boeckxstaens GE
Hirst BH. *See* Christie GR
Hisamatsu T, Suzuki M, Reinecker H-C, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 Functions as an Antibacterial Factor in Human Intestinal Epithelial Cells, 124:993
Hisatomi H. *See* Shiraki K
Hislop WS. *See* Lui HF
Hittelet A. *See* Van Gossum A
Hiwatashi N. *See* Negoro K
Ho JJL. *See* Kim GE
Ho Kim S. *See* Sug Kim H
Ho NJ. *See* Beutler E
Ho SB. *See* Bresalier RS
Ho W. *See* van Sickle MD
Hobbs HH. *See* Berge KE
Hobson AR. *See* Sarkar S
Höcker M
See Gut MO
See Marschall ZV
Höcker M, Cramer T, O'Connor DT, Rosewicz S, Wiedenmann B, Wang TC. Neuroendocrine-Specific and Gastrin-Dependent Expression of a Chromogranin A-Luciferase Fusion Gene in Transgenic Mice, 121:43
Höckerstedt K
See Collin P
See Kaukinen K
Hocking M. *See* Abell T
Hodge MR. *See* Papdakis KA
Hodgson HJF. *See* Forbes SJ
Hodgson S. *See* Tomlinson I
Hoedemaeker I. *See* van den Brande JMH
Hoek JB, Cahill A, Pastorino JG. Alcohol and Mitochondria: A Dysfunctional Relationship, 122:2049–srr
Hoerger T. *See* Pignone M
Hofbauer B. *See* Frossard J-L
Hofbauer B, Daluja AK, Learch MM, Bhagat L, Bhagat M, Bhatia M, Lee HS, Fossard JL, Adler G, Steer ML. Early Trypsinogen Activation in Acute Pancreatitis, 116:770–ss
Hofer H. *See* Peck-Radosavljevic M
Hofer S. *See* Müller T
Hofer U. *See* Schepke M
Hoffman BJ. *See* Verne GN
Hoffman MR. *See* Sindram D
Hoffman R. *See* Lochs H
Hoffman RM. *See* Inadomi JM
Hoffmann J. *See* Stallmach A
Hoffmann MW. *See* Bowen DG
Hoffmann R. *See* Gerlach JT
Hoffmann U. *See* Swidsinski A
Hoffmann WE. *See* Atchison CR
Hoffmeister A. *See* Teich N
Hofmann AF
See Bolder U
See Gruy-Kapral C
Hofmann AF
Bile Acids, Cholesterol, Gallstone Calcification, and the Enterohepatic Circulation of Bilirubin, 116:1276–c
Bile Acids: From Genomics to Disease and Therapy, 125:1280–pmr
Hofmann CM. *See* Shiffman ML
Hofmann F. *See* Vaandrager AB
Hofmann WJ. *See* Schaefer M
Hogan SP. *See* Straumann A
Høgåsen K. *See* Berstad AE
Hohloch K. *See* Kewenig S
Hokama A, Kinjo F, Kinjo N. Image of the Month, 125:1302–im
Hokari R
See Fujimori H
See Matsuzaki K
Hokelek M, Ahmet Deger B, Deger E, Tutar E, Sunbul M. Ivermectin Used in Percutaneous Drug Injection Method for the Treatment of Liver Hydatid Disease in Sheep, 122:956
Hol EM. *See* McPhaul LW
Holcomb LA. *See* Alpini G
Holick MF. *See* Koutkia P
Holl V. *See* Rössle M
Holladay DV. *See* Gates LK Jr
Holland S. *See* Gukovskaya AS
Holland SM. *See* Uzel G
Hollander A. *See* Schalm SW
Hollander AP. *See* Baugh MD
Hollerweger A. *See* Rettenbacher T
Holloway RH
See Lidums I
See Zhang Q
Holm AN. *See* Farrugia G
Holm AN, Rich A, Miller SM, Strege P, Ou Y, Gibbons SJ, Sarr MG, Szurszewski JH, Rae JL, Farrugia G. Sodium Current in Human Jejunal Circular Smooth Muscle Cells, 122:178
Holm L. *See* Johansson M
Holm R. *See* Thorstensen L
Holmes L. *See* Schoenfeld P
Holst JJ
See Guan X
See Jeppesen PB
See Piche T
Holt PR
See Agarwal B
See Guan RJ
Holt PR, Atillasoy EO, Gilman J, Guss J, Moss SF, Newmark H, Fan K, Yang K, Lipkin M. Calcium, Chemoprevention, and Cancer: A Small Step Forward (A Long Way to Go), 116:1261–ss
Holthaus K. *See* Yang C
Holtmann G, Cain C, Malfertheiner P. Gastric *Helicobacter pylori* Infection Accelerates Healing of Reflux Esophagitis During Treatment With the Proton Pump Inhibitor Pantoprazole, 117:11
Holtmann G, Gschossmann J, Buenger L, Gerken G, Talley NJ. Do Changes in Visceral Sensory Function Determine the Development of Dyspepsia During Treatment With Aspirin?, 123:1451
Holtmann G. (Post) Inflammatory Visceral Hyperalgesia: Don't We Believe What We Don't See?, 122:823–e
Holtmann M. *See* Kiesslich R
Holtmeier W, Hennemann A, Caspary WF. IgA and IgM V_H Repertoires in Human Colon: Evidence for Clonally Expanded B Cells That Are Widely Disseminated, 119:1253
Holubec H. *See* Dvorak B
Holzer B. *See* Rosen HR
Holzer P. *See* Shahbazian A
Homberg J-C. *See* Lapierre P
Homburger HA
See Czaja AJ
See Kim WR
Hommes D. Discussion on Predictors of Response to Infliximab in Patients With Crohn's Disease, 124:2002–c
Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, MacPherson B, Tytgat G, Peppelenbosch M, van Deventer S. Inhibition of Stress-Activated MAP Kinase Induces Clinical Improvement in Moderate to Severe Crohn's Disease, 122:7–rc
Hommes DW. *See* van den Brande JMH
Homoncik-Kraml M. *See* Peck-Radosavljevic M
Honda H. *See* Ikejima K
Honda M. *See* Lerat H
Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential Gene Expression Between Chronic Hepatitis B and C Hepatic Lesion, 120:955
Honda M, Kaneko S, Matsushita E, Kobayashi K, Abell GA, Lemon SM. Cell Cycle Regulation of Hepatitis C Virus Internal Ribosomal Entry Site-Directed Translation, 118:152
Hong CV. *See* Mills JC
Hong F
See Radaeva S
See Sun Z

Hong F, Swain P, Mills T. Fantastic Voyage Through the Gut, 122:828–ss
Hong Z. *See* Yao N
Hoofnagle JH
See Bacon BR
See Ghany MG
See Howell C
See Lau DT-Y
See Promrat K
Hoogerwerf WA, Pasricha PJ. Taking Control of Fecal Incontinence: Early Results of an Artificial Sphincter Device. Comment, 116:1005–ss
Hooijberg E. *See* van Montfrans C
Hooiveld GJEJ. *See* Jansen PLM
Hooiveld GJEJ, Vos TA, Scheffer GL, van Goor H, Koning H, Bloks V, Loot AE, Meijer DKF, Jansen PLM, Kuipers F, Müller M. 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors (Statins) Induce Hepatic Expression of the Phospholipid Translocase mdr2 in Rats, 117:678
Hoon Ahn S, Kramvis A, Kawai S, Spangenberg H, Li J, Kimbi G, Kew M, Wands J, Tong S. Sequence Variation Upstream of Precore Translation Initiation Codon Reduces Hepatitis B Virus e Antigen Production, 125:1370
Hoon VK. *See* Sternberg LR
Hopf U. *See* van Bömmel F
Hopkins AM
See Gulberg E
See Walsh SV
Hopper KD. *See* Johnson CD
Hoppert M. *See* Huster D
Hor SY. *See* Lala S
Horak I. *See* Gut MO
Hori M
See Kawai N
See Kuzushita N
See Takehara T
Horibe Y. *See* Hase K
Horie T. *See* Masubuchi Y
Horiuchi A
See Hamano H
See Kawa S
Horiuchi Y
Does Ursodeoxycholic Acid Cause Lichenoid Eruption? Reply, 122:1547–c
Lichenoid Eruptions Due to Ursodeoxycholic Acid Administration, 121:501–c
Horn MJ. *See* Jonsson JR
Horosanh O. *See* Besisik F
Horowitz B
See Porcher C
See Ward SM
Horsmans Y. *See* Hautekeete ML
Horstmann O. *See* Fischbach W
Hoshina S. *See* Chiba M
Hoshino E. *See* Kazumori H
Hoshino S. *See* Sun Z
Hosokawa M. *See* Tanaka T
Hospodar-Scott K. *See* Pinto L
Hossack M. *See* Mowat C
Hotz-Behoftsitz C. *See* Sigthorsson G
Houbiers G. *See* Eland IA
Houghton LA. *See* Calvert EL
Houghton LH. *See* Calvert EL
Houghton M. *See* Rosen HR
Houlihan PS. *See* Rashid A
Houlston R. *See* Tomlinson I
Houlston RS, Tomlinson IPM. Polymorphisms and Colorectal Tumor Risk, 121:282
Houwen RHJ
See Müller T
See Van Belzen MJ
Hove TT, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, Drillenburg P, Deventer SJH van, Chvatchko Y, Velde AAT. Blockade of Endogenous IL-18 Ameliorates TNBS-Induced Colitis by Decreasing Local TNF-α Production, 121:1372
Howard A. *See* Christie GR
Howard AD. *See* Austin CP
Howard L, Ashley C. Management of Complications in Patients Receiving Home Parenteral Nutrition, 124:1651
Howard T. *See* Wiesner R
Howdle PD. *See* Hamlin PJ
Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: Summary of a Workshop, 119:1385–srr
Howell SB. *See* Carethers JM
Howell WM. *See* Butterworth JR
Hrachovec J, Patel P. Weight-based Ribavirin With Pegylated Interferon alfa 2b: Benefits, Risks, and the Origin of the Evidence, 124:2003–c
Hrobjartsson A, Gotzsche PC. Is There a Place for Pacebos?, 121:1253–ss
Hruban RH. *See* Sato N
Hsu M-T. *See* Chen Y-J
Hsu P-I. *See* Lo G-H
Hu HZ. *See* Gao C
Hu MS. *See* Li W
Hu WHC. *See* Lai KC
Hu Y. *See* Drossman DA
Hua NW. *See* Facchini FS
Huang AT. *See* Cheng T-I
Huang BQ
See Chen X-M
See Masyuk TV
Huang CS, Becker JM, Farraye FA. Successful Closure of Ileal Pouch-Vaginal Fistulas With Infliximab, 125:631–c
Huang C-S, Chang P-F, Huang M-J, Chen E-S, Chen W-C. Glucose-6-Phosphate Dehydrogenase Deficiency, the UDP-Glucuronosyl Transferase 1A1 Gene, and Neonatal Hyperbilirubinemia, 123:127
Huang FS, Warner BW. Necrotizing Enterocolitis: A Closer Look. Comment, 121:1016–ss
Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-Analysis of the Relationship Between *CagA* Seropositivity and Gastric Cancer, 125:1636
Huang L. *See* Yusta B
Huang M-J. *See* Huang C-S
Huang P. *See* Marionneau S
Huang XR, Hui CWC, Chen Y-X, Chun B, Wong Y, Fung PCW, Metz C, Cho CH, Hui WM, Bucala R, Lam S-K, Lan HY. Macrophage Migration Inhibitory Factor Is an Important Mediator in the Pathogenesis of Gastric Inflammation in Rats, 121:619
Hubbard R
See Card T
See West J
Hubbard W. *See* Giardello FM
Huber R. *See* Kullak-Ublick GA
Hubert D. *See* Dray X
Hübner G. *See* Kleber G
Hudgins LC. *See* Cohen P
Hudson M. *See* McRae CA
Hudson N. *See* Taha AS
Huerre M. *See* Touati E
Huet P-M. *See* Rose C
Huflejt M. *See* De Winter H
Huggins KW. *See* Richmond BL
Hugh TB. *See* Biankin AV
Hughes A. *See* Sarkar S
Hughes J. *See* Yadav D
Hugot J-P. *See* Vermeire S
Hugot J-P, Chamaillard M, Zouali H, Lesage H, Lesage S, Cezard J-P, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel J-F, Sahbatou M, Gilles T, Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar J-P, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. The NOD2 Gene and Crohn's Disease: Another Triumph for Genetics, 122: 826–ss
Hui CWC. *See* Huang XR
Hui DY. *See* Richmond BL
Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW,

George J. Insulin Resistance Is Associated With Chronic Hepatitis C and Virus Infection Fibrosis Progression, 125:1695
Hui WM
See Huang XR
See Lai KC
Hui Y. *See* Chan FKL
Huibregtse K. *See* Boerma D
Huizinga JD
See Abell T
See Der T
Huizinga JD, Berezin I, Sircar K, Hewlett B, Donnelly G, Berčík P, Ross C, Algoufi T, Fitzgerald P, Der T, Riddell RH, Collins SM, Jacobson K. Development of Interstitial Cells of Cajal in a Full-Term Infant Without an Enteric Nervous System, 120:561–cr
Huizinga JD, Zhu Y, Ye J, Molleman A. High-Conductance Chloride Channels Generate Pacemaker Currents in Interstitial Cells of Cajal, 123:1627
Hull M, Chapple K, Coletta L, Poulsom R. COX-2 in Murine Intestinal Tumors, 119:600–c
Hull MA
See Fenwick SW
See Scott DJ
Hull TL. *See* Lyford GL
Hull TL. *Surgery of the Anus, Rectum and Colon*, 119:1173–pmr
Hultcrantz R
See Björk J
See Elmberg M
Hultcranz R. *See* Bergquist A
Humphrey PPA
See Booth CE
See Jiang W
Hundrieser J. *See* Bronsveld I
Hunt N. *See* Mitchell SA
Hunt RH
See Huang JQ
See Lanza FL
Hunt RH. *A Brief History of Endoscopy*, 121: 738–pmr
Hunt SC. Posttraumatic Stress Disorder, 116:227–c
Hunter AGW. *See* Stern HS
Hunter DJ. *See* Giovannucci E
Hunter JG. *See* Filipi CJ
Huntsman D
See Caldas C
See Pharoah P
Huntsman DG, Carneiro F, Lewis FR, MacLeod PM, Hayashi A, Monaghan KG, Maung R, Seruca R, Jackson CE, Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, Donohue JH. Hereditary Diffuse Gastric Cancer: More Answers or More Questions?, 122:830–ss
Hunyady B. *See* Tanaka S
Hunziker L. *See* Blindenbacher A
Hunziker W. *See* Hansen GH
Huo T-I, Wu J-C, Lee S-D. Outcomes of Patients With Seroclearance of HBsAg: Different Facets of a Truth, 125:274–c
Huraux JM. *See* Lunel F
Hurley M. *See* Saadeh S
Hurlstone A. *See* Brind A
Hurlstone DP. *See* Sanders DS
Hurst SD. *See* Lee H-O
Hurtig M. *See* Lindén S
Hussain M. *See* Chu C-J
Huster D. *See* Ortner MEJ
Huster D, Caca K, Lutsenko S. Where Is the Site That ATP7B Transports Copper Within Hepatocytes? Reply, 125:1911–c
Huster D, Hoppert M, Lutsenko S, Zinke J, Lehmann C, Mössner J, Berr F, Caca K. Defective Cellular Localization of Mutant ATP7B in Wilson's Disease Patients and Hepatoma Cell Lines, 124:335
Hutson WR. *See* Desautels SG
Hwa Soung Y. *See* Sug Kim H
Hwan Kim K. *See* Young Kim J
Hwang I-R, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of Interleukin 1 Polymorphisms on Gastric Mucosal Interleukin 1β Production in *Helicobacter pylori* Infection, 123:1793
Hwang ST, Urizar NL, Moore DD, Henning SJ. Bile Acids Regulate the Ontogenic Expression of Ileal Bile Acid Binding Protein in the Rat via the Farnesoid X Receptor, 122:1483
Hybiske K. *See* Karvar S
Hyde J. *See* Bassi A
Hyland LM. *See* Giardello FM
Hylemon PB. *See* Vlahcevic ZR
Hylind LM. *See* Cruz-Correa M
Hynes SO. *See* Moran AP
Hytiroglou P. *See* Selaru FM
Hyung Lee S. *See* Sug Kim H
Hyunglee S. *See* Park WS

Iacobuzio-Donahue CA. *See* Sato N
Iacopetta B
See Duval A
See Elsaleh H
See Suraweera N
Iafusco D. *See* de Magistris L
Iannaccone L. *See* Amitrano L
Iantorno G. *See* Goin JC
Ibdah JA. *See* Yang Z
Ibdah JA. Is It HELLPFUL to Consider the Hanging LCHAD in Pregnancy-Associated Liver Disease? Reply, 124: 1550–ss
Icatlo FC Jr, Goshima H, Kimura N, Kodama Y. Acid-Dependent Adherence of *Helicobacter pylori* Urease to Diverse Polysaccharides, 119:358
Ichaï P. *See* Moreau R
Ichida T
See Matsuda Y
See Sugauchi F
Ichihara M. *See* Iwashita T
Ichikawa A
See Miyakura Y
See Takeuchi K
See Tanaka S
Ideo G. *See* Poynard T
Ido K. *See* Yamamoto H
Igarashi S. *See* Miyakura Y
Igel M. *See* Drobnik W
Iida MHK. *See* Parisi MA
Iijima H. *See* van de Wal Y
Iijima K, Henry E, Moriya A, Wirz A, Kelman AW, McColl KEL. Dietary Nitrate Generates Potentially Mutagenic Concentrations of Nitric Oxide at the Gastroesophageal Junction, 122:1248
Iijima Y. *See* Maeyama H
Iimura M. *See* Hase K
Iimuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi SK, Brenner DA, Yamaoka Y. Delivery of Matrix Metalloproteinase-1 Attenuates Established Liver Fibrosis in the Rat, 124:445
Iiyama R
See Kanai T
See Totsuka T
Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. A Marker for Predictions of HCC Recurrence Post-Resection?, 123:2152–ss
Ikeda H, Satoh H, Yanase M, Inoue Y, Tomiya T, Arai M, Tejima K, Nagashima K, Maekawa H, Yahagi N, Yatomi Y, Sakurada S, Takuwa Y, Ogata I, Kimura S, Fujiwara K. Antiproliferative Property of Sphingosine 1-Phosphate in Rat Hepatocytes Involves Activation of Rho Via Edg-5, 124:459
Ikeda JS. *See* Rath HC
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. The Prevention of Hepatocellular

Carcinoma by Interferon: The Story Continues, 120:1302–ss
Ikeda K, Kumada H
Interferon Therapy Prevents Hepatocellular Carcinoma in Some Patients With Chronic HCV: The Role of Fibrosis. Reply, 118:447–ss
The Prevention of Hepatocellular Carcinoma by Interferon: The Story Continues. Reply, 120:1303–ss
Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Kobayashi M, Nakamura I, Murashima N, Kumada H, Kawanishi M. Interferon Therapy Prevents Hepatocellular Carcinoma in Some Patients With Chronic HCV: The Role of Fibrosis, 118:446–ss
Ikeda M. *See* Kanai T
Ikejima K
See Enomoto N
See Tsune I
Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang Y-J, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin Receptor-Mediated Signaling Regulates Hepatic Profibrogenic and Remodeling of Extracellular Matrix in the Rat, 122: 1399
Ilan Y. *See* Sauter BV
Ilstrup DM. *See* Johnson CD
Imai K. *See* Yamamoto H
Imai S. *See* Akita K
Imamura K. *See* Kobayashi I
Imamura M
See Kobayashi H
See Okazaki K
Imamura S. *See* Yamaoka Y
Imanishi J. *See* Yamaoka Y
Imazeki F. *See* Shiratori Y
Immerdal L. *See* Hansen GH
Imperiale TF. *See* Lieberman DA
Imperiale TF, Ransohoff DF. What's Right and What's Left? Reply, 120:1050–ss
Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. What's Right and What's Left?, 120: 1049–ss
Imrie C
See Drumm B
See Murray B
Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, Swanson KM, Sonnenberg A. Step-Down Management of Gastroesophageal Reflux Disease, 121: 1095–
Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick M, Vakil N. Dollars and Sense in Preventing Esophageal Cancer, 125:1268–ss
Inadomi JM, Vakil N. Dollars and Sense in Preventing Esophageal Cancer. Reply, 125:1270–ss
Incecik ET. *See* Dubois A
Inchauspé G. *See* Bain C
Infante-Rivard C. *See* Delage G
Ingelman-Sundberg M. *See* Bardag-Gorce F
Innaccone R. *See* Laghi A
Ino Y. *See* Castells A
Inohara N
See Bonen DK
See Hugot J-P
See Inoue N
Inoue F, Chiba T. Regression of MALT Lymphoma of the Rectum After Anti-*H. pylori* Therapy in a Patient Negative for *H. Pylori*, 117:514–c
Inoue K. *See* Takeuchi T
Inoue M. *See* Kusama T
Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Núñez G, Kishi Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T. Lack of Common NOD2 Variants in Japanese Patients With Crohn's Disease, 123:86
Inoue N, Watanabe M, Sato T, Okazawa A, Yamazaki M, Kanai T, Ogata H, Iwao Y, Ishii H, Hibi T. Restricted V_H Gene Usage in Lamina Propria B Cells Producing Anticolon Antibody From Patients With Ulcerative Colitis, 121: 15
Inoue Y
See Claudel T
See Ikeda H
Inui A
See Asakawa A
See Ueno N
Inui A, Asakawa A. Leptin and Gastric Neuroendocrine System, 123:1751–co
Inui A. Emesis, Appetite, and Endocannabinoids, 123:655–c
Inui Y. *See* Kiso S
Invernizzi P. *See* Longo M
Ioannou GN, Kowdley KV. In Search of Vulcan: Where Are All the Iron Men (and Women)? Comment, 123:949–ss
Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is Obesity a Risk Factor for Cirrhosis-Related Death or Hospitalization? A Population-Based Cohort Study, 125:1053
The IOIBD Budesonide Study Group. *See* Hellers G
Iovanna JL
See Malka D
See Soubeyran P
Iqbal TH. *See* Butterworth JR
Irani AN. *See* Malhi H
Iravani M. *See* Kaur BS
Iredale JP. *See* Wright MC
Irimura T. *See* Uwatoku R
Irvine EJ. *See* Huang JQ
Irvine EJ, Marshall JK. Increased Intestinal Permeability Precedes the Onset of Crohn's Disease in a Subject With Familial Risk, 119:1740–cr
Isa AM. *See* Prior TW
Isaacs K. *See* Schreiber S
Isaacs K. *Inflammatory Bowel Disease: A Clinician's Guide*, 124:860–pmr
Isaacs KL. *See* Sandborn WJ
Isaacs KL. *Clinical Imaging of the Small Intestine, Second Edition*, 123:388–pmr
Isaacson PG. *See* Liu H
Isaacson PG, Diss TC, Wotherspoon AC, Barbazza R, de Boni M, Doglioni C. Long-term Follow-up of Gastric MALT Lymphoma Treated by Eradication of *H. pylori* With Antibiotics, 117:750–c
Isayama F. *See* McKim SE
Isbister W. *See* Madoff RD
Iselius L. *See* Björk J
Isenberg JI. *See* Tuo B-G
Ishibashi H
See Kamihira T
See Shimoda S
Ishida T. *See* Sugauchi F
Ishige H. *See* Yamamoto M
Ishiguchi T. *See* Takahashi T
Ishiguro H. *See* Jin C
Ishihara S. *See* Kazumori H
Ishihara T
See Adachi Y
See Hara T
Ishihara T, Gabazza EC, Adachi Y, Sato H, Maruo Y. Genetic Basis of Fasting Hyperbilirubinemia, 116:1272–c
Ishii H
See Fujimori H
See Inoue N
See Kanai T
See Nakazawa A
Ishii Y, Ochiai A, Yamada T, Akimoto S, Yanagihara K, Kitajima M, Hirohashi, S. Integrin$\alpha 6\beta$ as a Suppressor and a Predictive Marker for Peritoneal Dissemination in Human Gastric Cancer, 118:497
Ishikawa S. *See* Kobayashi I
Ishimaru A. *See* Yamaoka Y
Ishimine S. *See* Osawa E
Ishimura Y. *See* Kyokane T
Ishiwata T
See Kleeff J
See Kornmann M
Ismail HF. *See* Berg DJ
Ismair MG. *See* Kullak-Ublick GA

Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA. Hepatic Uptake of Cholecystokinin Octapeptide by Organic Anion-Transporting Polypeptides OATP4 and OATP8 of Rat and Human Liver, 121:1185–
Isozaki K. *See* Hirota S
Israel DA
See Crawford HC
See Fox JG
Israel ES. *Liver Disease in Children*, 121: 1523–pmr
Israelsson A. *See* Forsberg G
Issa J-P. *See* Alberts DS
Issa J-PJ
See Kim SG
See Shen L
Issa R. *See* Wright MC
Issacs K. *Gastroenterology Teaching Project 004: Inflammatory Bowel Disease-Pathology*, 125:990–pmr
Ito A. *See* Kuzushita N
Ito H. *See* Satoh A
Ito M. *See* Nagata H
Ito N. *See* Kiso S
Ito O. *See* Jin C
Ito S
See Abe T
See Baumert TF
See Wang TC
Ito T
See Kawai N
See Yamamoto M
Itoh F. *See* Yamamoto H
Itoh H. *See* Uchino H
Itoh K. *See* Matsuzaki K
Itoh M. *See* Kuno A
Itoh-Lindstrom Y. *See* Finn AL
Itzkan I. *See* Wallace MB
Itzkowitz S. *See* Ullman T
Itzkowitz SH. *See* Boivin GP
Iwakiri R. *See* Tsunada S
Iwakiri R, Sakemi T, Fujimoto K. Dimethylsulfoxide for Renal Dysfunction Caused by Systemic Amyloidosis Complicating Crohn's Disease, 117:1031–c
Iwakiri Y. *See* Tsai M-H
Iwakura Y. *See* Yoshida M
Iwamoto M. *See* Ueno N
Iwan A. *See* Woitas RP
Iwanaga T. *See* Ohkawara T
Iwao Y. *See* Inoue N
Iwasaki T. *See* Kusama T
Iwasashi H. *See* Kakyo M
Iwashita T, Kurokawa K, Qiao S, Murakami H, Asai N, Kawai K, Hashimoto M, Watanabe T, Ichihara M, Takahashi M. Functional Analysis of RET With Hirschsprung Mutations Affecting Its Kinase Domain, 121:24
Iwawaki T. *See* Kiso S
Izopet J. *See* Alric L
Izumi N. *See* Moriguchi H
Izumi Y. *See* Kanai M
Izzedine H, Simon J, Piette A-M, Lucsko M, Baumelou A, Charitanski D, Kernaonet E, Baglin A-C, Deray G, Beaufils H. Primary Chronic Interstitial Nephritis in Crohn's Disease, 123:1436
Izzo AA. *See* Pinto L
Izzo AA, Capasso F, Costagliola A, Bisogno T, Marsicano G, Ligresti A, Matias I, Capasso R, Pinto L, Borrelli F, Cecio A, Lutz B, Mascolo N, Di Marzo V. An Endogenous Cannabinoid Tone Attenuates Cholera Toxin-Induced Fluid Accumulation in Mice, 125:765

Jack DL. *See* Kelly P
Jackson CE. *See* Huntsman DG
Jackson E. *See* Tripathi D
Jackson R. *See* Gillett HR
Jackson T. *See* Der T
Jacob H. *See* Appleyard M
Jacob P, Christiana S, Rossman H, Lamprecht G, Vieillard-Baron D, Müller R, Gregor M, Seidler U. Role of $Na^+HCO_3^-$ Cotransporter NBC1, Na^+/H^+ Exchanger NHE1, and Carbonic Anhydrase in Rabbit Duodenal Bicarbonate Secretion, 119: 406
Jacob P, Rossmann H, Lamprecht G, Kretz A, Neff C, Lin-Wu E, Gregor M, Groneberg DA, Kere J, Seidler U. Down-regulated in Adenoma Mediates Apical Cl^-/HCO_3^- Exchange in Rabbit, Rat, and Human Duodenum, 122:709
Jacob R. *See* Ritz V
Jacobson BC
Atlas of Gastrointestinal Endoscopy & Endoscopic Biopsies, 120:1305–pmr
Sleisenger & Fordtran's Gastrointestinal and Liver Disease Review and Assessment to Accompany Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 116: 1269–pmr
Jacobson BC, Van Dam J. Giving Cancer Therapy a Shot in the Arm. Comment, 117:1015–ss
Jacobson I. *See* Purow D
Jacobson K. *See* Huizinga JD
Jacquemin E
See Bacq Y
See Jansen PLM
Jacyna M. *See* Schreiber S
Jae Kim C. *See* Sug Kim H
Jaeckel E. *See* Manns MP
Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns M. Acute HCV: The Early Bird Catches the Virus, 122:1175–ss
Jaeckel EM. *See* Manns M
Jaeschke H, Lemasters JJ. Apoptosis Versus Oncotic Necrosis in Hepatic Ischemia/ Reperfusion Injury, 125:1246–srr
Jaffrat P. *See* Malassagne B
Jaffrey S. *See* Watkins CC
Jäger G. *See* Folwaczny C
Jagmohan-Changur S. *See* Smits R
Jahnsen J. *See* Hampe J
Jain A. *See* Fuss IJ
Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ. Nitric Oxide-Mediated Inhibition of DNA Repair Potentiates Oxidative DNA Damage in Cholangiocytes, 120:190
Jakobisiak M. *See* Kamiński
Jalan R
See Helmy A
See Kapoor D
See Lui HF
See Sen SM
See Shawcross DL
Jalkanen S
See Kurkijärvi R
See Salmi M
Jamal HZ, Weglarz TC, Sandgren EP. Cryopreserved Mouse Hepatocytes Retain Regenerative Capacity In Vivo, 118:390
Jamal R. *See* Inadomi JM
Jamard C. *See* Rollier C
James OFW
See Goldblatt J
See McRae CA
See Prince M
James SP
See Fleischer AD
See Fu S
James SP
This Month at the NIH: NIDDK Forms Hepatotoxicity Clinical Research Network, 125:1008–gn
This Month at the NIH: NIDDK Special Emphasis Program Announcements, 125:5–gn
This Month at the NIH: NIH Roadmap: Accelerating Medical Discovery to Improve Health, 125:1573–gn
This Month at the NIH: Redesign of Digestive Sciences Integrated Review Group, 125:651–gn
Jamieson PM. *See* Luckey A
Janatuinen E. *See* Lundell L
Janecke A. *See* Müller T
Janicek M. *See* Demetri GD
Janin A. *See* Ferrier L

Jankowski JA. *See* Haigh CR
Jankowski JA, Provenzale D, Moayyedi P. Esophageal Adenocarcinoma Arising From Barrett's Metaplasia Has Regional Variations in the West, 122: 588–c
Janoff EN, Smith PD. Emerging Concepts in Gastrointestinal Aspects of HIV-1 Pathogenesis and Management, 120: 607
Jansen PLM
See Hooiveld GJEJ
See Kok T
See Meerman L
Jansen PLM, Müller M. Early Events in Sepsis-Associated Cholestasis, 116: 486–e
Jansen PLM, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJEJ, Koning JH, Kuipers F, Bijleveld CMA, Gouw A, van Goor H, Thompson RJ, Müller M. Hepatocanalicular Bile Salt Export Pump Deficiency in Patients With Progressive Familial Intrahepatic Cholestasis, 117:1370
Jansens J. *See* Abell T
Janssen HLA. *See* Lisman T
Janssen IM. *See* Boerma D
Janssen K-P, El Marjou F, Pinto D, Sastre X, Rouillard D, Fouquet C, Soussi T, Louvard D, Robine S. Targeted Expression of Oncogenic K-*ras* in Intestinal Epithelium Causes Spontaneous Tumorigenesis in Mice, 123:492
Janssens J
See Fischler B
See Tack J
Jansson EÅ. *See* Dubuquoy L
Jaramillo E. *See* Rubio CA
Jaramillo EJ. *See* Rubio CA
Jarboe M. *See* Erwin CR
Järnerot G. *See* Halfvarson J
Jaruga B
See Radaeva S
See Sun Z
Järvinen H
See Bülow C
See Bülow S
See Hemminki A
Jasani B. *See* Richardson CE
Jasquemin P. *See* Clotman F
Jass JR. *Gastrointestinal Polyps*, 124:266–pmr
Jass JR, Whitehall VLJ, Young J, Leggett BA. Emerging Concepts in Colorectal Neoplasia, 123:862
Jauch K-W. *See* Bolder U
Javaid MK. *See* van Staa T-P
Javed NH. *See* Kim M
Jeannin J-F. *See* Millet A
Jeannot E
See Bacq Y
See Laurent-Puig P
Jeejeebhoy KN. *Encyclopedia of Human Nutrition*, 117:278–pmr
Jeen Y-T. *See* Farrell RJ
Jeffers L. *See* Howell C
Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and Efficacy of Recombinant Factor VIIa in Patients With Liver Disease Undergoing Laparoscopic Liver Biopsy, 123:118
Jeffers LJ. *See* Molina E
Jeffers M, McDonald WF, Chillakuru RA, Yang M, Nakase H, Deegler LL, Sylander ED, Rittman B, Bendele A, Sartor RB, Lichenstein HS. A Novel Human Fibroblast Growth Factor Treats Experimental Intestinal Inflammation, 123:1151
Jegga AG. *See* Bates MD
Jenkins D
See Dunlop SP
See Spiller RC
Jenkins PJ. *See* Veysey MJ
Jenkins TD. *Atlas of Tumor Pathology, Tumors of the Esophagus and Stomach*, 117:508–pmr
Jensen DM. *See* Kaplan M
Jensen DM
Endoscopic Screening for Varices in Cirrhosis: Findings, Implications, and Outcomes, 122:1620
What to Choose for Diagnosis of Bleeding Colonic Angiomas: Colonoscopy, Angiography, or Helical Computed Tomography Angiography?, 119:581–e
Jensen DM, Kovacs TOG, Jutabha R, Machicado GA, Gralnek IM, Savides TJ, Smith J, Jensen ME, Alofaituli G, Gornbein J. Randomized Trial of Medical or Endoscopic Therapy to Prevent Recurrent Ulcer Hemorrhage in Patients With Adherent Clots, 123: 407
Jensen J. *See* Lehmann A
Jensen ME. *See* Jensen DM
Jensen RT
See Abou-Saif A
See Bordi C
See Peghini PL
Jensen RT, Fave GD, Bordi C. Discussion on the Effect of Chronic Hypergastrinemia on Human Enterochromaffin-Like Cells: Insights From Patients With Sporadic Gastrinomas. Reply, 124:1565–c
Jensen T. *See* Molberg Ø
Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Mortensen PB. Glucagon-like Peptide 2 Improves Nutrient Absorption and Nutritional Status in Short-Bowel Patients With No Colon, 120:806
Jess T. *See* Winther KV
Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and Causes of Death in Crohn's Disease: Follow-up of a Population-Based Cohort in Copenhagen County, Denmark, 122:1808
Jessner W. *See* Peck-Radosavljevic M
Jewell D
See Ahmad T
See Hellers G
See Thomsen Ø
Jewell DP
See Ahmad T
See Orchard TR
See Satsangi J
See Vermeire S
Jewell DP. *Advanced Therapy of Inflammatory Bowel Disease*, 122:585–pmr
Jewell L. *See* Madsen K
Jewell LD
See Dahlan Y
See Madsen KL
Jezequel AM. *See* di Sario A
Ji B. *See* Chen X
Ji B, Bi Y, Simeone D, Mortensen RM, Logsdon CD. Human Pancreatic Acinar Cells Lack Functional Responses to Cholecystokinin and Gastrin, 121:1380
Ji C, Kaplowitz N. Betaine Reduces Hyperhomocysteinemia, Endoplasmic Reticulum Stress, and Liver Injury in Alcohol-Fed Mice, 124: 1488
Ji J, Salapatek AMF, Lau H, Wang G, Gaisano HY, Diamant NE. SNAP-25, a SNARE Protein, Inhibits Two Types of K^+ Channels in Esophageal Smooth Muscle, 122:993
Jia H. *See* Drossman DA
Jiang H-Q. *See* He W
Jiang H-Q, Kushnir N, Thurnheer MC, Bos NA, Cebra JJ. Monoassociation of SCID Mice With *Helicobacter muridarum*, But Not Four Other Enterics Provokes IBD Upon Receipt of T Cells, 122:1346
Jiang W
See Burdyga G
See Haupt W
See Su CG
Jiang W, Kreis ME, Eastwood C, Kirkup

AJ, Humphrey PPA, Grundy D. 5-HT_3 and Histamine H_1 Receptors Mediate Afferent Nerve Sensitivity to Intestinal Anaphylaxis in Rats, 119: 1267
Jiang X. *See* Marionneau S
Jijon H. *See* Madsen K
Jimenez RE. *See* Hartwig W
Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Kay J, Turner JR. Dialysis-Related Amyloidosis: An Important Cause of Gastrointestinal Symptoms in Patients With End-Stage Renal Disease, 116:217–ss
Jimènez W. *See* Titos E
Jiménez W
See Bataller R
See Bosch-Marcé M
See Guevara M
See Morales-Ruiz M
See Poo J-L
See Ros J
Jiménez-Alonso J. *See* Hidalgo-Tenorio C
Jiminez W. *See* Ortega R
Jin C, Naruse S, Kitagawa M, Ishiguro H, Muxin W, Nakajima M, Yokohata K, Ito O, Hayakawa T. Motilin Regulates Interdigestive Gastric Blood Flow in Dogs, 123:1578
Jin L. *See* Chen M
Jin S. *See* Knolle PA
Jin X, Morsy N, Shoeb F, Zavzavadjian J, Akbarali HI. Coupling of M_2 Muscarinic Receptor to L-Type Ca^{2+} Channel Via c-src Kinase in Rabbit Colonic Circular Smooth Muscle, 123: 827
Jin X-L. *See* Shibata C
Jin Yoo N. *See* Sug Kim H
Jiricny J. *See* Trojan J
Jobin C. *See* Weaver SA
Jobin C. Intestinal Epithelial Cells and Innate Immunity in the Intestine: Is CARD15/Nod2 Another Player?, 124: 1145–e
Jobson S. *See* Butterworth JR
Jodal M. *See* Fihn B-M
Joehl RJ. *See* Hirano I
Joensuu H
See Demetri GD
See Hemminki A
Joh T. *See* Kuno A
Johannessen I. *See* Newsome PN
Johanson J. *See* Laine L
Johansson M, Synnerstad I, Holm L. Acid Transport Through Channels in the Mucous Layer of Rat Stomach, 119: 1297
Johansson S. *See* Su B
Johnson CD. *See* Gluecker TM
Johnson CD, Harmsen WS, Wilson LA, MacCarty RL, Welch TJ, Ilstrup DM, Ahlquist DA. Prospective Blinded Evaluation of Computed Tomographic Colonography for Screen Detection of Colorectal Polyps, 125:311
Johnson CD, Toledano AY, Herman BA, Dachman AH, McFarland EG, Barish MA, Brink JA, Ernst RD, Fletcher JG, Halvorsen RA Jr., Hara AK, Hopper KD, Koehler RE, Lu DSK, Macari M, MacCarty RL, Miller FH, Morrin M, Paulson EK, Yee J, Zalis M. Computerized Tomographic Colonography: Performance Evaluation in a Retrospective Multicenter Setting, 125:688
Johnson CP. *See* Lu G
Johnson D. *See* Winawer S
Johnson LK. *See* Levine DS
Johnson LR
See Deng W
See Ray RM
Johnson MH. *See* Bush TG
Johnson T. *See* Sandborn WJ
Johnston DA. *See* Church NI
Jon Spechler S. *See* Souza RF
Jonas MM, Kelley DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM
All *Kid*ding Aside With the Use of Lamivudine in Children With Chronic Hepatitis, 123:1741–ss
All *Kid*ding Aside With the Use of Lamivudine in Children With Chronic Hepatitis. Reply, 123:1743–ss
Jondal M. *See* Vazquez-Sequeiros E
Jondal ML. *See* Harewood GC
Jondeau K. *See* Hermine O
Jones DEJ
See Goldblatt J
See McRae CA
Jones DR. *See* El-Rifai W
Jones EA, Dekker LRC. Florid Opioid Withdrawal-like Reaction Precipitated by Naltrexone in a Patient With Chronic Cholestasis, 118:431–cr
Jones KR
See Levy RL
See Whitehead WE
Jones MK. *See* Baatar D
Jones MK, Kawanaka H, Baatar D, Szabó IL, Tsugawa K, Pai R, Koh GY, Kim I, Sarfeh IJ, Tarnawski AS. Gene Therapy for Gastric Ulcers With Single Local Injection of Naked DNA Encoding VEGF and Angiopoietin-1, 121:1040–rc
Jones MN. *See* McLaughlin J
Jones PF. *See* Hamlin PJ
Jones S. *See* Carter MJ
Jong YP de. *See* Veltkamp C
Jonnalagadda S
Cholecystectomy After Treatment of Choledocholithiasis: On Firmer Ground. Comment, 125:617–ss
And Now. . .Fattening the Lower Esophageal Sphincter. Comment, 123: 945–ss
Prophylactic Pancreatic Duct Stenting: A Panacea? Comment, 125:1275–ss
Small Bowel Photography: The Jury Needs Evidence. Comment, 124:1150–ss
Virtual Colonography—A Step Forward? Comment, 124:258–ss
Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis, 121:148
Joossens S. *See* Vermeire S
Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel J-F. The Value of Serologic Markers in Indeterminate Colitis: A Prospective Follow-up Study, 122: 1242
Joossens S, Van Steen K, Vermeire S, Reinisch W, Colombel J-F, Rutgeerts P. The Value of Serologic Markers in Indeterminate Colitis: A Prospective Follow-up Study. Reply, 125:999–c
Jørgensen JR, Fitch MD, Mortensen PB, Fleming SE. In Vivo Absorption of Medium-Chain Fatty Acids by the Rat Colon Exceeds That of Short-Chain Fatty Acids, 120:1152
Jorgensen OD, Kronborg O, Fenger C. The Winner After 7 Rounds–Fecal Occult Blood Testing!, 122:2081–ss
Jørgensen TJD. *See* Arentz-Hansen H
Joseph B, Malhi H, Bhargava KK, Palestro CJ, McCuskey RS, Gupta S. Kupffer Cells Participate in Early Clearance of Syngeneic Hepatocytes Transplanted in the Rat Liver, 123:1677
Joshi SN. *See* Poulos JE
Jostock T. *See* Peters M
Jothy S. *See* Mayer B
Jouanolle A-M
See Mendler M-H
See Moirand R
Jowell PS
See Byrne MF
See Mulcahy HE
See Noone PG
Juarranz MG. *See* Abad C
Judd LM. *See* Scarff KL

Judge T, Lichtenstein GR
Is the Appendix a Vestigial Organ? Its Role in Ulcerative Colitis. Comment, 121:731–ss
The NOD2 Gene and Crohn's Disease: Another Triumph for Genetics. Comment, 122:827–ss
Judge TA, Lichtenstein GR
Novel Medical Therapies for Crohn's Disease: Is There Room for Growth? Comment, 120:309–ss
Protecting the Pouch: Diversion Is Not the Answer. Comment, 123:1403–ss
Julia V, Su X, Buéno L, Gebhart GF. Role of Neurokinin 3 Receptors on Responses to Colorectal Distention in the Rat: Electrophysiological and Behavioral Studies, 116:1124
Julien B. *See* Li L
Julkunen R. *See* Myrvold HE
Jullian E. *See* Benamouzig R
Jullien M. *See* Bourlière M
Jung D, Podvinec M, Meyer UA, Mangelsdorf DJ, Fried M, Meier PJ, Kullak-Ublick GA. Human Organic Anion Transporting Polypeptide 8 Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor, 122:1954
Jung G. *See* Arentz-Hansen H
Jung J. *See* Lin X
Jung M. *See* Kiesslich R
Jung M-C
See Diepolder HM
See Gerlach JT
Jung Y. *See* Pandol SJ
Jungermann K. *See* Silberg DG
Junquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM, Saperas E, Piqué JM, Malagelada J-R. A Multicenter, Randomized, Clinical Trial of Hormonal Therapy in the Prevention of Rebleeding From Gastrointestinal Angiodysplasia, 121: 1073–
Junquera F, Quiroga S, Saperas E, Pérez-Lafuente M, Videla S, Alvarez-Castells A, Miró JRA, Malagelada J-R. Accuracy of Helical Computed Tomographic Angiography for the Diagnosis of Colonic Angiodysplasia, 119:293
Junquera F, Saperas E, Piqué JM. Hormonal Therapy in Angiodysplasia: Should We Completely Abandon Its Use? Reply, 123:2156–co
Jurz AK. *See* Häussinger D
Jutabha R. *See* Jensen DM
Juul S. *See* Ørding Olsen K

Kadakol A. *See* Sauter BV
Kadirkamanathan S. *See* Appleyard M
Kadowaki T
See Katayama K
See Nakajima A
See Osawa E
Kadry Z, Clavien PA. *Atlas of Liver Transplantation*, 124:1556–pmr
Kaestner KH. *See* Silberg DG
Kaga T
See Asakawa A
See Ueno N
Kage A. *See* Bhatia E
Kagnoff MF
See Dwinell MB
See Hase K
See Maaser C
Kagnoff MF. Celiac Disease Pathogenesis: The Plot Thickens, 123:939–e
Kahn KL. *See* Dulai GS
Kahrilas PJ
See Cook IJ
See Hirano I
See Pandolfino JE
Radiofrequency Energy Treatment of GERD, 125:970–e
Kahrilis PJ. Refractory Heartburn, 124: 1941–cm
Kaiser AM. Discussion of "Backwash Ileitis Is Strongly Associated With Colorectal Carcinoma in Ulcerative Colitis," 122: 245–c
Kaiser GC, Yan F, Polk DB. Mesalamine Blocks Tumor Necrosis Factor Growth Inhibition and Nuclear Factor κB Activation in Mouse Colonocytes, 116:602
Kaiserlian D
See van de Wal Y
See Zimmer K-P
Kajiyama M. *See* Maeyama H
Kakiuchi Y. *See* Kawai N
Kakumu S. *See* Sugauchi F
Kakyo M, Unno M, Tokui T, Nakagomi R, Nishio T, Iwasashi H, Nakai D, Seki M, Suzuki M, Naitoh T, Matsuno S, Yawo H, Abe T. Molecular Characterization and Functional Regulation of a Novel Rat Liver-Specific Organic Anion Transporter rlst-1, 117:770–rc
Kalff JC
See Schwarz NT
See Türler A
Kalff JC, Carlos TM, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Surgically Induced Leukocytic Infiltrates Within the Rat Intestinal Muscularis Mediate Postoperative Ileus, 117:378
Kalff JC, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Role of Inducible Nitric Oxide Synthase in Postoperative Intestinal Smooth Muscle Dysfunction in Rodents, 118: 316
Kalinina T, Riu A, Fischer L, Santantonio T, Will H, Sterneck M. Selection of a Secretion-Incompetent Mutant in the Serum of a Patient With Severe Hepatitis B, 125:1077
Kalk JF. *See* Schneider AW
Kalled SL. *See* de Jong YP
Kallen K-J. *See* Streetz KL
Kalloo AN. *See* Cruz-Correa MR
Kalluri R. *See* Yang C
Kalousek MB. Discussion on Probiotic Bacteria Enhance Murine and Human Intestinal Epithelial Function, 123: 391–c
Kam L. *See* Tountas NA
Kam LY
See Abreu MT
See Dubinsky MC
See Vasiliauskas EA
Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J-I, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced Carbon Tetrachloride-Induced Liver Fibrosis in Mice Lacking Adiponectin, 125:1796
Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon Alone or With Ribavirin Enhances HCV-Specific CD4$^+$ T-Helper 1 Responses in Patients With Chronic Hepatitis C, 123:1070
Kamal SM, Raseneck JW, Bianchi L, Tawil A al, El Sayed Khalifa K, Peter T, Mansour H, Ezzat W, Koziel M. Acute Hepatitis C Without and With Schistosomiasis: Correlation With Hepatitis C-Specific CD4$^+$ T-Cell and Cytokine Response, 121:646
Kamath P
See Wiesner R
See Wiesner RH
Kamath PS. *See* Ginés P
Kamean J. *See* Chalasani N
Kameyama T. *See* Nagao Y
Kamihira T. *See* Shimoda S
Kamihira T, Shimoda S, Harada K, Kawano A, Handa M, Baba E, Tsuneyama K, Nakamura M, Ishibashi H, Nakanuma Y, Gershwin ME, Harada M. Characterization of Distinct Costimulation Dependent and Independent Autoreactive T-Cell Clones in Primary Biliary Cirrhosis, 125:1379
Kaminogawa S. *See* Fujimori H
Kamiński R, Kozar K, Kopeć M, Basak G,

Skierski JS, Koronkiewicz M, Jakobisiak M, Golab J. Discussion on 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Reduce Human Pancreatic Cancer Cell Invasion and Metastasis, 123:1747–co
Kamisaki Y. *See* Katayama K
Kamisako T. *See* Reichel C
Kamm MA
See Diamant NE
See Murray CDR
See Norton C
See Vaizey CJ
Kammer PP. *See* Thumshirn M
Kanai M. *See* Hashida H
Kanai M, Konda Y, Nakajima T, Izumi Y, Takeuchi T, Chiba T. TGF-α Inhibits Apoptosis of Murine Gastric Pit Cells Through an NF-κB-Dependent Pathway, 121:56
Kanai T
See Inoue N
See Nakazawa A
See Totsuka T
Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T. Interleukin 18 Is a Potent Proliferative Factor for Intestinal Mucosal Lymph ytes in Crohn's Disease, 119:1[illegible]
Kanai T, Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, Ishii H, Totsuka T, Iiyama R, Okamoto R, Ikeda M, Kurimoto M, Takeda K, Akira S, Hibi T. Macrophage-Derived IL-18-Mediated Intestinal Inflammation in the Murine Model of Crohn's Disease, 121:875
Kanamaru C. *See* Ueda N
Kanatani K. *See* Aihara T
Kanauchi O. *See* Saubermann LJ
Kanayama S. *See* Miyazaki Y
Kandolf R
See Sotlar K
See Waldegger S
Kane SV. *See* Ehrenpreis ED
Kane SV, Altschuler EL, Kast RE. Crohn's Disease Remission on Bupropion, 125: 1290–c
Kaneko K. *See* Shimizu T
Kaneko M. *See* Mayer B
Kaneko S. *See* Honda M
Kanel G. *See* DeLeve LD
Kang D. *See* Lin X
Kang E. *See* Silberg DG
Kang Y-M. *See* Lamb K
Kangawa K. *See* Date Y
Kanto T
See Kuzushita N
See Takehara T
Kanzler G. *See* Eckardt VF
Kanzler S. *See* Kiesslich R
Kao J-H. *See* Liu C-J
Kao J-H, Chen D-S. Clinical Relevance of Hepatitis B Virus Genotypes Ba and Bj in Taiwan, 125:1916–c
Kao J-H, Chen P-J, Lai M-Y, Chen D-S
Basal Core Promoter Mutations of Hepatitis B Virus Increase the Risk of Hepatocellular Carcinoma in Hepatitis B Carriers, 124:327
Hepatitis B Genotypes Correlate With Clinical Outcomes in Patients With Chronic Hepatitis B, 118:554
Kapadia C. Alcoholic Steatosis: The Kupffer Cell A Villain? Comment, 120:582–ss
Kapadia CR
Coughing, Wheezing, and Acid. Comment, 123:1399–ss
The Curse of the Functional Dyspeptic: Too Sensitive a Visceral Afferent Nervous System? Comment, 116:496–ss
Endoscopy for Upper Gastrointestinal Symptoms: Sooner Rather Than Later. Comment, 119:872–ss
Patients With Biliary Microlithiasis: Are They A Separate Breed? Comment, 121:1014–ss
Why Patients on Long-Term Intravenous Hyperalimentation Are Prone to Infections. Comment, 116:1495–ss
Kapel N. *See* Seguy D
Kaplan K. *See* Napierkowski JJ
Kaplan M
See Bonis PAL
See Kita H
Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Neutralizing Antibodies in Hepatitis C Virus Infection: A Review of Immunological and Clinical Characteristics, 125:597–srr
Kaplan MM. *See* Bonis PAL
Kaplan MM. Primary Biliary Cirrhosis: Past, Present, and Future, 123:1392–e
Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A Prospective Trial of Colchicine and Methotrexate in the Treatment of Primary Biliary Cirrhosis, 117:1173
Kaplowitz N
See Ji C
See Lluis JM
Kaplowitz N
Comment From the Editors, 117:759
Comment Fromthe Editors, 120:335–ce
Kapoor D, Williams R, Jalan R. MARS: A New Treatment for Hepatorenal Failure. Comment, 119:1799–ss
Kappas AM. *See* Roukos DH
Kappeler A. *See* Saurer L
Kappes JC. *See* Meng G
Kapur RP. *See* Parisi MA
Kapur S. *See* Shiva Kumar K
Karaca C. *See* Besisik F
Karalis K
See Mykoniatis A
See Wlk M
Karaliuskas R. *See* Hugot J-P
Karam SM. *See* Tomasetto C
Kargman S. *See* Oshima M
Karikoski R. *See* Ruuska TH
Kariola R. *See* Raevaara TE
Kärkkäinen P. *See* Rautemaa R
Karlsson J. *See* Gulberg E
Karmeli F. *See* Rachmilewitz D
Karminsky N. *See* Rozen P
Karnes WE Jr. *See* Weller SG
Karoui M. *See* Dubuquoy L
Karp DD. *See* Baron JA
Karpen SJ
See Carter BA
See Denson LA
See Kurbegov AC
Kärrberg L. *See* Lehmann A
Karrer F. *See* Kurbegov AC
Kartheuser A. *See* Laurent-Puig P
Karttunen T. *See* Gut MO
Karvar S, Yao X, Duman JG, Hybiske K, Liu Y, Forte JG. Intracellular Distribution and Functional Importance of Vesicle-Associated Membrane Protein 2 in Gastric Parietal Cells, 123:281
Kasahara A
See Kuzushita N
See Takehara T
Kaserer K. *See* Kazemi-Shirazi L
Kashani N
See Liebman H
See Liebman HA
Kashima K. *See* Yamaoka Y
Kasho VN. *See* Gukovskaya AS
Kaskas B. *See* Schwab M
Kasper LH
See Buzoni-Gatel D
See Li W
See Luangsay S
Kassab GS. *See* Mittal RK
Kast RE. *See* Kane SV
Kast RE, Altschuler EL. Remission of Crohn's Disease on Bupropion, 121: 1260–c
Kasuga M
See Asakawa A
See Noguchi H
See Ueno N
Katai H. *See* Suzuki K
Kataoka H. *See* Uchino H
Katayama K. *See* Kuzushita N
Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa

S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T. A Novel PPARγ Gene Therapy to Control Inflammation Associated With Inflammatory Bowel Disease in a Murine Model, 124:1315
Katelaris PH, Forbes GM, Talley NJ, Crotty B
The QUADRATE Study: A Proposal for a Change in the Reporting of Pharmaceutical Supported Trials. Reply, 125:640–c
A Randomized Comparison of Quadruple and Triple Therapies for *Helicobacter pylori* Eradication: The QUADRATE Study, 123:1763
Kato H. *See* Sugauchi F
Kato J
See Miyanishi K
See Niitsu Y
See Takayama T
Kato K. *See* Hara T
Kato M. *See* Ohkawara T
Kato R. *See* Dohi T
Kato S
See Matsuzaki K
See Takeuchi K
Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. Efficient Replication of the Genotype 2a Hepatitis C Virus Subgenomic Replicon, 125:1808
Katori M. *See* Boku K
Katsume A. *See* Takeuchi T
Katsuura G. *See* Asakawa A
Katsuyama T. *See* Maeyama H
Katsuyama Y. *See* Kawa S
Katz J. *See* Parsi MA
Katz JA. *See* Danese S
Katz JA. Prevention Is the Best Defense: Probiotic Prophylaxis of Pouchitis, 124:1535–e
Katz P. *See* Corley DA
Katz PO. *See* Vela MF
Katz S
See Sandborn WJ
See Sands BE
Katzka DA
See Castell DO
See Su C
Kauffman JM, Carey MC. *Cholelithiasis: Causes and Treatment*, 116:1010–pmr
Kaufman SS. *See* Fishbein TM
Kaufmann SH. *See* Yoon J-H
Kaukinen K. *See* Collin P
Kaukinen K, Collin P, Mäki M, Partanen J, Halme L, Färkkilä M, Höckerstedt K. Screening for Celiac Disease in Patients With Chronic Liver Disease. Reply, 125:1290–c
Kaukinen K, Halme L, Collin P, Färkkila M, Mäki M, Vehmanen P, Partanen J, Höckerstedt K. Celiac Disease in Patients With Severe Liver Disease: Gluten-Free Diet May Reverse Hepatic Failure, 122:880
Kaup FJ. *See* Kewenig S
Kaup S. *See* Caplan MS
Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib Inhibits Cyclooxygenase 2 Expression and Activity and Reduces Cell Proliferation in Barrett's Esophagus, 123:60
Kaur M. *See* Shirvani VN
Kaushiva A. *See* Bouma G
Kawa S. *See* Hamano H
Kawa S, Hamano H, Kiyosawa K. The Importance of Autoimmune Pancreatitis. Reply, 121:1519–ss
Kawa S, Ota M, Yoshizawa K, Horiuchi A, Hamano H, Ochi Y, Nakayama K, Tokutake Y, Katsuyama Y, Saito S, Hasebe O, Kiyosawa KD. HLA DRB1*0405-DQB1*0401 Haplotype Is Associated With Autoimmune Pancreatitis in the Japanese Population, 122:1264
Kawabe T. *See* Hirata Y
Kawada N
See Akita K
See Uwatoku R
Kawaguchi A. *See* Matsuzaki K
Kawaguchi R. *See* Takeuchi T
Kawaguchi T. *See* Harada M
Kawahara Y. *See* Yokota K
Kawai H. *See* Honda M
Kawai K. *See* Iwashita T
Kawai N, Tsuji S, Tsuji M, Ito T, Yasumaru M, Kakiuchi Y, Kimura A, Komori M, Sasaki Y, Hayashi N, Kawano S, Dubois R, Hori M. Tumor Necrosis Factor α Stimulates Invasion of Src-Activated Intestinal Cells, 122:331
Kawai S. *See* Hoon Ahn S
Kawamori T. *See* Osawa E
Kawamura N. *See* Maeyama H
Kawamura YI. *See* Dohi T
Kawanaka H. *See* Baatar D
Kawanami C. *See* Okazaki K
Kawanishi M. *See* Ikeda K
Kawano A
See Kamihira T
See Shimoda S
Kawano S. *See* Kawai N
Kawasaki M. *See* Al-Chaer ED
Kawashima K. *See* Kazumori H
Kawata S. *See* Kiso S
Kay J. *See* Jimenez RE
Kay MA. *See* McCaffrey AP
Kayazawa M. *See* Matsumoto A
Kaye G. *See* Bassett M
Kayed H. *See* Reubi JC
Kaymakoglu S. *See* Besisik F
Kayser A. *See* Obermayer-Straub P
Kazandjian M. *See* Shaker R
Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, Kaserer K, Hackl F, Polli C, Steindl PE, Penner E, Ferenci P. The Relation of Iron Status and Hemochromatosis Gene Mutations in Patients With Chronic Hepatitis C, 116:127
Kazumori H, Ishihara S, Hoshino E, Kawashima K, Moriyama N, Suetsugu H, Sato H, Adachi K, Fukuda R, Watanabe M, Takasawa S, Okamoto H, Fukui H, Chiba T, Kinoshita Y. Neutrophil Chemoattractant 2β Regulates Expression of the *Reg* Gene in Injured Gastric Mucosa in Rats, 119:1610
Keach J. *See* Pardi DS
Keates AC. *See* He D
Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau KO, Brazer W, Kelly CP. Interleukin 16 Is Up-regulated in Crohn's Disease and Participates in TNBS Colitis in Mice, 119:972
Keates S. *See* He D
Keck T, Balcom JH IV, Fernández-del Castillo C, Antoniu BA, Warshaw AL. Matrix Metalloproteinase-9 Promotes Neutrophil Migration and Alveolar Capillary Leakage in Pancreatitis-Associated Lung Injury in the Rat, 122:188
Kedinger M. *See* Plateroti M
Keeffe EB. *See* Chu C-J
Keeffe EB. Liver Transplantation: Current Status and Novel Approaches to Liver Replacement, 120:749
Keeling PWN. *See* Farrell RJ
Keifer JA. *See* Pedowitz SD
Keilbaugh SA. *See* Su CG
Keim V
See Ockenga J
See Teich N
Keku TO. *See* Martin C
Kelemen LI. *See* Jonsson JR
Kelleher D
See Farrell RJ
See Ryan BM
Keller J. *See* Fibbe C
Keller N. *See* Chowers MY
Kelley DA. *See* Jonas MM
Kellow JE. Sphincter of Oddi Dysfunction Type III: Another Manifestation of Visceral Hyperalgesia?, 116:996–e
Kelly CP
See Keates AC
See Michetti M

Kelly DA. *See* Crosby HA
Kelly DR. *See* Chung DH
Kelly J. *See* O'Sullivan GC
Kelly P, Jack DL, Naeem A, Mandanda B, Pollok RCG, Klein NJ, Turner MW, Farthing MJG. Mannose-Binding Lectin Is a Component of Innate Mucosal Defense Against *Cryptosporidium parvum* in AIDS, 119:1236
Kelman AW. *See* Iijima K
Kelty C. *See* Gough M
Kemler MA, Barendse GAM, van Kleef M
Relapsing Ulcerative Colitis After Spinal Cord Stimulation: A Case of Intestinal Neurogenic Inflammation? Reply, 117:1255–c
Relapsing Ulcerative Colitis Associated With Spinal Cord Stimulation, 117: 215–cr
Kench JG
See Biankin AV
See Hui JM
Kendziorski CM. *See* Cohen P
Kennedy DJ. *See* Thwaites DT
Kenny AJ. *See* Hansen GH
Keppler D
See Rost D
See Tsujii H
Keppler D, König J, Cui Y. The Human Hepatocyte-specific Organic Anion Transporter Encoded by the SLC21A8 Gene, 122:1545–c
Kerbel RS. *See* Mayer B
Kere J. *See* Jacob P
Keresztes R. *See* Baron JA
Kerlikowske K. *See* Corley DA
Kermorgant S. *See* Goïot H
Kern HF. *See* Freedman SD
Kern M. *See* Shaker R
Kern M, Shaker R
Cerebral Cortical Registration of Subliminal Visceral Stimulation, 122: 290
Further Characterization of Human Brain Processing of Viscero-Sensation: The Role of Gender and a Word of Caution, 124:1975–e
Kern SE. *See* Lynch HT
Kernaonet E. *See* Izzedine H
Kerner W. *See* Steiner M
Kerrigan SW. *See* Byrne MF
Keshav S. *See* Lala S
Kessler R. *See* Mertz H
Ketterer S. *See* Degen LP
Keulemans YC. *See* Boerma D
Keulemans YCA. *See* Brink MA
Kew M. *See* Hoon Ahn S
Kew M. *Hepatitis B and the Prevention of Primary Cancer of the Liver*, 124:1997–pmr
Kewenig S, Schneider T, Hohloch K, Lampe-Dreyer K, Ullrich R, Stolte N, Stahl-Hennig C, Kaup FJ, Stallmach A, Zeitz M. Rapid Mucosal CD4$^+$ T-Cell Depletion and Enteropathy in Simian Immunodeficiency Virus-Infected Rhesus Macaques, 116:1115
Khalid A, Whitcomb DC
The Importance of Autoimmune Pancreatitis. Comment, 121:1518–ss
The Premalignant Lesions for Pancreatic Cancer; Will Pan-IN's Pan Out? Comment, 123:646–ss
Khamnehei N. *See* Kaur BS
Khamzina L, Gruppuso PA, Wands JR. Insulin Signaling Through Insulin Receptor Substrate 1 and 2 in Normal Liver Development, 125:572
Khan AKA
See Hildeand P
See Schneider A
Khan MA. *See* Chalasani N
Khan ZE, Wang TC, Cui G, Chi AL, Dimaline R. Transcriptional Regulation of the Human Trefoil Factor, TFF1, by Gastrin, 125:510
Khare M. *See* Everhart JE
Khatun M. *See* Rabbani GH
Khazaie K. *See* Marten K
Khiri H. *See* Bourlière M
Khodadadian E. *See* Caletti G
Khokar F. *See* Ghany MG
Khokhar F. *See* Lau DT-Y
Khosla C. *See* Shan L
Kidd M. *See* Läuffer JM
Kidder V. *See* Bolder U
Kiely MD. *See* O'Sullivan GC
Kiese B. *See* Demetri GD
Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, Nafe B, Jung M, Galle PR, Neurath MF. Methylene Blue-Aided Chromoendoscopy for the Detection of Intraepithelial Neoplasia and Colon Cancer in Ulcerative Colitis, 124:880–rc
Kiessling S
See Hausmann M
See Leeb SN
Kihara S. *See* Kamada Y
Kikkawa A. *See* Tsunada S
Kikuchi S
See Hwang I-R
See Yamaoka Y
Kilbourne A. *See* Gralnek IM
Kilian A. *See* Fedorak RN
Kim GE, Bae H-I, Park H-U, Kuan S-F, Crawley SC, Ho JJL, Kim YS. Aberrant Expression of MUC5AC and MUC6 Gastric Mucins and Sialyl Tn Antigen in Intraepithelial Neoplasms of the Pancreas, 123:1052
Kim GY. *See* Gao C
Kim H. *See* Park WS
Kim HJ. *See* Camilleri M
Kim HS
See Maaser C
See Park WS
See Saubermann LJ
Kim I. *See* Jones MK
Kim J
See Braun J
See Sutton CL
Kim JG. *See* Yamaoka Y
Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. *Helicobacter pylori* Impairs DNA Mismatch Repair in Gastric Epithelial Cells, 123:542
Kim J-S, Qian T, Lemasters JJ. Mitochondrial Permeability Transition in the Switch From Necrotic to Apoptotic Cell Death in Ischemic Rat Hepatocytes, 124:494
Kim JY, Kim KH, Lee MG, Shin DM, Muallem S, Suchy FJ. Pancreatitis From Bile Reflux-Again? Reply, 124: 864–c
Kim KE, Brasitus TA. This Month in GASTROENTEROLOGY, 119:1, 119:287, 119:609, 119:889, 119:1185
Kim KE. This Month in GASTROENTEROLOGY, 119:1425, 120:1, 120:331, 120:783
Kim KH. *See* Kim JY
Kim K-S, Baek SJ, Flake GP, Loftin CD, Calvo BF, Eling TE. Expression and Regulation of Nonsteroidal Anti-inflammatory Drug-Activated Gene 1 in Human and Mouse Tissue, 122: 1388
Kim M
See Harada M
See Saab S
Kim M, Cooke HJ, Javed NH, Carey HV, Christofi F, Raybould HE. D-Glucose Release 5-Hydroxytryptamine From Human BON Cells as a Model of Enterochromaffin Cells, 121:1400
Kim M-H, Lee S-K, Myung S-J. Pancreatic Stenting After Biliary Sphincterotomy in Patients With Sphincter of Oddi Dysfunction, 117:283–c
Kim MS. *See* Triadafilopoulos G
Kim R. *See* Wiesner R
Kim S. *See* Chung DH
Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund J-N, Evers BM. *PTEN* and TNF-α Regulation of the Intestinal-Specific *Cdx-2* Homeobox Gene

Through a PI3K, PKB/Akt, and NF-κB-Dependent Pathway, 123:1163
Kim SG, Chan AO-O, Wu T-T, Issa J-PJ, Hamilton SR, Rashid A. Epigenetic and Genetic Alterations in Duodenal Carcinomas Are Distinct From Biliary and Ampullary Carcinomas, 124:1300
Kim S-W. *See* Faris PL
Kim SY. *See* Park WS
Kim W-H. *See* Radaeva S
Kim WR
See Bambha K
See Wiesner RH
Kim WR, Lindor KD, Locke GR III, Therneau TM, Homburger HA, Batts KP, Yawn BP, Petz JL, Melton LJ III, Dickson ER. Epidemiology and Natural History of Primary Biliary Cirrhosis in a U. S. Community, 119: 1631
Kim Y-I, Shirkwadkar S, Choi S-W, Puchyr M, Wang Y, Mason JB. Effects of Dietary Folate on DNA Strand Breaks Within Mutation-Prone Exons of the p53 Gene in Rat Colon, 119:151
Kim YS
See Kim GE
See Park WS
See Terdiman JP
Kimbi G. *See* Hoon Ahn S
Kimm SYS. *Child and Adolescent Obesity: Causes and Consequences, Prevention and Management*, 125:1908–pmr
Kimmey MB
See Ponec RJ
See Tung BY
Kimmey MB. *Abdominal Ultrasound*, 123: 388–pmr
Kim-Schluger L. *See* Liu LU
Kimura A. *See* Kawai N
Kimura N. *See* Icatlo FC Jr
Kimura R. *See* Harada M
Kimura S. *See* Ikeda H
King A. *See* Thomas LA
King AS. *See* Maini MK
King K. *See* Cuthbert AP
King M. *See* Vinall LE
Kingham JGC. Discussion on the True Impact of Fatigue in Primary Biliary Cirrhosis: A Population Study, 124: 582–c
Kinjo F. *See* Hokama A
Kinjo N. *See* Hokama A
Kinkhabwala M. *See* Shiva Kumar K
Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Infliximab at 5 Years-Tweaking the Recipe for Success?, 125:1902–ss
Kinoshita K. *See* Hirota S
Kinoshita Y. *See* Kazumori H
Kinouchi Y
See Inoue N
See Negoro K
Kinzler KW. *See* Gruber SB
Kip S. *See* Masyuk AI
Kirber MT. *See* Cao W
Kirby A. *See* Cook D
Kirchner T. *See* Benninger J
Kirk DR. *See* Scott KG-E
Kirk L. *See* Winawer S
Kirkup AJ
See Booth CE
See Jiang W
Kirsch H. *See* Neef B
Kirschner BS. *See* Hugot J-P
Kirshner BS. *See* Brant SR
Kirsner JB. *A History of Gastroenterology at the Millennium*, 121:738–pmr
Kirton C. *See* Haigh CR
Kirton CM. *See* Haigh CR
Kishi Y. *See* Inoue N
Kishibe K, Yamada Y, Ogawa K. Production of Nerve Growth Factor by Mouse Hepatocellular Carcinoma Cells and Expression of TrkA in Tumor-Associated Arteries in Mice, 122:1978
Kiso S. *See* Kamada Y
Kiso S, Kawata S, Tamura S, Inui Y, Yoshida Y, Sawai Y, Umeki S, Ito N, Yamada A, Miyagawa J-I, Higashiyama S, Iwawaki T, Saito M, Taniguchi N, Matsuzawa Y, Kohno K. Liver Regeneration in Heparin-Binding EGF-like Growth Factor Transgenic Mice After Partial Hepatectomy, 124:701
Kita H. *See* Yamamoto H
Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He X-S, Koning F, Mikayama T, Van de Water J, Coppel RL, Kaplan M, Gershwin ME. Quantitation and Phenotypic Analysis of Natural Killer T Cells in Primary Biliary Cirrhosis Using a Human CD1d Tetramer, 123:1031
Kita M. *See* Yamaoka Y
Kita T. *See* Yoshida M
Kitagawa M. *See* Jin C
Kitagawa Y
See Chiba M
See Matsuzaki K
Kitajima M, 118:497
Kitamura S, 120:108
Kitamura T
See Enomoto N
See Ikejima K
Kitamura Y. *See* Hirota S
Kitano S. *See* Baatar D
Kiyono H. *See* Dohi T
Kiyosawa K
See Hamano H
See Kawa S
Kiyosawa KD. *See* Kawa S
Kjaergard LL, Frederiksen SL, Gluud C. Validity of Randomized Clinical Trials in GASTROENTEROLOGY During 1994-2000, 122:1156–srr
Kjartansson Ó. *See* Bjarnason I
Kjeld M. *See* Thjodleifsson B
Kjellin A. *See* Mashimo H
Klar E. *See* Rost D
Kleber G. *See* Fleig WE
Kleber G, Steudel N, Behrmann C, Zipprich A, Hübner G, Lotterer E, Fleig WE. Hepatic Arterial Flow Volume and Reserve in Patients With Cirrhosis: Use of Intra-arterial Doppler and Adenosine Infusion, 116:906
Klee GG. *See* Chari ST
Kleeff J
See Liao Q
See Reubi JC
Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Büchler MW, Korc M. Bone Morphogenetic Protein 2 Exerts Diverse Effects on Cell Growth In Vitro and Is Epressed in Human Pancreatic Cancer In Vitro, 116:1202
Kleen N. *See* Marth T
Klein AS. *See* Sun Z
Klein C. *See* Streetz KL
Klein C, Bock CT, Wedemeyer H, Wüstefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C. Inhibition of Hepatitis B Virus Replication In Vivo by Nucleoside Analogues and siRNA, 125:9–rc
Klein CP. *See* Schneider AW
Klein IK. *See* Weller SG
Klein NJ. *See* Kelly P
Klein R, Berg PA. Glutathione *S*-transferase as a Major Autoantigen in Anti-SLA-Positive Autoimmune Hepatitis, 116:1015–c
Klein RS. Discussion on Frequency of the HIV-Protective CC Chemokine Receptor 5-Δ32/Δ32 Genotype Is Increased in Hepatitis C, 124:1558–c
Klein S
Comment From the Editors, 123:967–ce
A Primer of Nutritional Support for Gastroenterologists, 122:1677
Kleiner DE
See Abou-Saif A
See Ghany MG
See Lau DT-Y
See Promrat K
See Uzel G
Kleinjans JCS. *See* Vermeer ITM
Kleinman RE. *Clinical Pediatric Gastroenterology*, 116:1269–pmr

Klement G. *See* Mayer B
Klempnauer J
See Bock C-T
See Gongoll S
Kleoudis CS. *See* Sandborn WJ
Klersy C. *See* Rindi G
Kliem V. *See* Bock C-T
Kline M. *See* Corley DA
Klingel K. *See* Waldegger S
Klinkenberg-Knol EC. *See* Kuipers EJ
Klinkenberg-Knol EC, The Long-Term Study Group. Long-Term Effects of Omeprazole on the Gastric Mucosa. Reply, 119:1176–c
Kloppel G. *See* Pedrazzoli S
Klöppel G. *See* Feurle GE
Klump B. *See* Hampe J
Kneip S. *See* Vogel A
Knisely AS
See Morton DH
See Salen G
Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, Ramadori G. Rat Liver Myofibroblasts and Hepatic Stellate Cells: Different Cell Populations of the Fibroblast Lineage With Fibrogenic Potential, 117:1205
Knize MG. *See* Fontana FJ
Knobeloch K-P. *See* Gut MO
Knoblock KM. *Inflammatory Bowel Disease: A Guide for Patients and Their Families*, 116:776–pmr
Knoll K. *See* Maltzman T
Knolle PA, Schmitt E, Jin S, Germann T, Duchmann R, Hegenbarth S, Gerken G, Lohse AW. Induction of Cytokine Production in Naive $CD4^+$ T Cells by Antigen-Presenting Murine Liver Sinusoidal Endothelial Cells but Failure to Induce Differentiation Toward T_{h1} Cells, 116:1428
Knorr A. *See* Hellemans K
Knowles MR. *See* Noone PG
Knudsen ES. *See* Heinen CD
Knudsen GM. *See* Strauss GI
Knuutila S. *See* El-Rifai W
Ko JKS. *See* Guo X
Ko W-F. *See* Corley DA
Kobayashi H, Spilde TL, Bhatia AM, Buckingham RB, Hembree MJ, Prasadan K, Preuett BL, Imamura M, Gittes GK. Retinoid Signaling Controls Mouse Pancreatic Exocrine Lineage Selection Through Epithelial-Mesenchymal Interactions, 123:1331
Kobayashi I, Imamura K, Kubota M, Ishikawa S, Yamada M, Tonoki H, Okano M, Storch WB, Moriuchi T, Sakiyama Y, Kobayashi K. Identification of an Autoimmune Enteropathy-Related 75-Kilodalton Antigen, 117:823
Kobayashi K
See Honda M
See Kobayashi I
See Yokota K
Kobayashi M
See Ikeda K
See Moriguchi H
Kobayashi S. *See* Yamamoto H
Kobeiter H. *See* Mathieu D
Kobold D. *See* Knittel T
Koch GG. *See* Drossman DA
Koch K. *See* Abell T
Koch RO. *See* Zoller H
Kochman ML. *Practice of Therapeutic Endoscopy*, 121:227–pmr
Köck R. *See* Zender L
Kodama T
See Hwang I-R
See Yamaoka Y
Kodama Y. *See* Icatlo FC Jr
Koduru S. *See* Zaki M
Koehler HH. *See* Kiesslich R
Koehler RE. *See* Johnson CD
Koelz HR, Blum AL, Modlin IM. Costs of GERD: Facts and Fictions. Comment, 125:982–ss
Koepsell T. *See* Flum DR
Koezuka Y
See Saubermann LJ
See van de Wal Y
Koff RS
Hepatitis B and C. Management and Treatment, 122:1181–pmr
Viral Hepatitis, 117:506–pmr
Koga H. *See* Harada M
Koga T. *See* Dohi T
Kogawa K. *See* Miyanishi K
Koh GY. *See* Jones MK
Koh J. *See* Dai CY
Koh T. *See* Wang TC
Koh TJ. *See* Chen D
Kohara M. *See* Takeuchi T
Kohgo Y. *See* Orii F
Köhler G. *See* Geissler M
Köhler L. *See* Madoff RD
Kohli V, Madden JF, Bentley RC, Clavien P-A. Calpain Mediates Ischemic Injury of the Liver Through Modulation of Apoptosis Necrosis, 116:168
Kohn N. *See* Markowitz J
Kohno H. *See* Tanaka T
Kohno K. *See* Kiso S
Kohno N. *See* Hashida H
Kohno S. *See* Nakamuta K
Kohno Y. *See* Satoh A
Koide Y. *See* Sugimoto K
Koike Y. *See* Inoue N
Koizumi M. *See* Masamune A
Kojima K. *See* Ren H
Kojima K, Musch MW, Ren H, Boone DL, Hendrickson BA, Ma A, Chang EB. Enteric Flora and Lymphocyte-Derived Cytokines Determine Expression of Heat Shock Proteins in Mouse Colonic Epithelial Cells, 124:1395
Kojima S. *See* Akita K
Kok T, Wolters H, Bloks VW, Havinga R, Jansen PLM, Staels B, Kuipers F. Induction of Hepatic ABC Transporter Expression Is Part of the PPARα-Mediated Fasting Response in the Mouse, 124:160
Kokazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, Matsuhima Y, Katamura K, Ohmori K, Chiba T. Autoimmune-Related Pancreatitis Is Associated With Autoantibodies and a Th1/Th2-type Cellular Immune Response, 118:573
Kokkola A. *See* Rautemaa R
Kola I. *See* Ng AY-N
Koleva M, Schlaf G, Landmann R, Götze O, Jungermann K, Schieferdecker HL. Induction of Anaphylatoxin C5a Receptors in Rat Hepatocytes by Lipopolysaccharide In Vivo: Mediation by Interleukin-6 From Kupffer Cells, 122:697
Kolios G. *See* Weaver SA
Kolodner RD. *See* Syngal S
Kolve-Goebeler M-E. *See* Fischbach W
Komatsu Y. *See* Yamamoto M
Komolmit P. *See* Hamlin PJ
Komori M. *See* Kawai N
Komoto S. *See* Fujimori H
Konda Y. *See* Kanai M
Kondo F. *See* Hara T
Kondo K. *See* Hashida H
Kondo M
See Tanaka N
See Yamamoto H
Kondo Y. *See* Shen L
Kondrup J. *See* Strauss GI
Kongara K. *See* Bauer WM
König J
See Keppler D
See Rost D
See Tsujii H
König P, Dedio J, Müller-Esterl W, Kummer W. Distribution of the Novel eNOS-Interacting Protein NOSIP in the Liver, Pancreas, and Gastrointestinal Tract of the Rat, 123:314
Konikoff F. *See* Strul H
Konikoff FM. *See* Blendis L
Koning F
See Kita H
See Vader LW
See Vader W

Koning H. *See* Hooiveld GJEJ
Koning JH. *See* Jansen PLM
Koningsberger JC. *See* Schreiber S
Konishi F. *See* Miyakura Y
Kono H
  See Wheeler MD
  See Yin M
Konturek J. *See* Abell T
Konturek JW. *See* Abell T
Koono M. *See* Uchino H
Koopen NR. *See* Meerman L
Kooy Y. *See* Vader W
Kooy YMC. *See* Vader LW
Kopeć M. *See* Kamiński
Kopin AS. *See* Chen D
Korber B. *See* Lyra AC
Korc M
  See Kleeff J
  See Kornmann M
  See Liao Q
Kordich JJ. *See* Lowy AM
Koretz RI
  Is There a Place for Pacebos?, 121:1254–ss
  Making End Points Meet. Comment, 116:1267–ss
  One If By Gut and Two If IV. Comment, 122:1537–ss
  Stress Management. Comment, 116:773–ss
Koretz RL
  Better Pale Than Yellow. Comment, 117:1017–ss
  Confined Treatment, 125:1543–ss
  Getting Fat in the ICU. Comment, 119:592–ss
  Growing Pains, 118:633–ss
  Look Ma, No Blades. Comment, 124:1992–ss
  Nutrition in the ICU: Are All Systematics Go? Comment, 117:1500–ss
  Protein Shakes. Comment, 122:583–ss
  Seek and Ye Shall Find. Comment, 123:1402–ss
  Surveying the Masses. Comment, 119:1403–ss
  Truth Is Not Determined by a Majority Vote. Comment, 124:1154–ss
  Understanding the Course. Comment, 124:262–ss
  What Will You Be When You Grow Up? Comment, 121:732–ss
  What's Right and What's Left? Comment, 120:1049–ss
Kornbluth A. *See* Su C
Kornfeldt D. *See* Bergquist A
Kornmann M. *See* Sträter J
Kornmann M, Ishiwata T, Matsuda K, Lopez ME, Fukahi K, Asano G, Beger HG, Korc M. IIIc Isoform of Fibroblast Growth Factor Receptor 1 Is Overexpressed in Human Pancreatic Cancer and Enhances Tumorigenicity of Hamster Ductal Cells, 123:301
Koronkiewicz M. *See* Kamiński
Koruda MJ. *See* Muir AJ
Koruda MJ. *Shackelford's Surgery of the Alimentary Tract. 5th Edition.* 123:951–pmr
Koseki S. *See* Fujimori H
Kosykh V
  See Barbier O
  See Claudel T
Koszinowski U. *See* Benz C
Kotake K. *See* Miyakura Y
Koteliansky VE. *See* Zheng H
Kothe C. *See* D'Haens G
Kotloff KL. *See* Michetti P
Kouroumalis EA
  See Koutroubakis IE
  See Papdakis KA
  See Roussomoustakaki M
Koutkia P, Lu Z, Chen TC, Holick MF. Treatment of Vitamin D Deficiency Due to Crohn's Disease With Tanning Bed Ultraviolet B Radiation, 121:1485–cr
Koutroubakis I. *See* Roussomoustakaki M
Koutroubakis IE, Sfiridaki A, Theodoropoulou A, Kouroumalis EA. Role of Acquired and Hereditary Thrombotic Risk Factors in Colon Ischemia of Ambulatory Patients, 121:561
Koutsoudakis G. *See* Roussomoustakaki M
Koutsouris A
  See McNamara BP
  See Zolotarevsky Y
Kovacs TOG. *See* Jensen DM
Koval G. *See* Levine DS
Köveker G. *See* Sotlar K
Kowalik T. *See* Heinen CD
Kowdley KV
  See Bhattacharya R
  See Eng SC
  See Ioannou GN
  See Mallory MA
  See Sanyal AJ
  See Tung BY
Kowdley KV
  Another Link in the Iron Chain?, 118:632–ss
  Does Interferon Therapy Prevent Hepatocellular Carcinoma in Patients With Chronic Hepatitis C? Comment, 117:738–ss
  Is Hepatic Fibrosis Reversible With Therapy in Hepatitis C? Comment, 120:580–ss
  Lamivudine for Chronic Hepatitis B: The Magic Bullet or Just Another Bright Prospect? Comment, 116:1498–ss
Koyama Y. *See* Miyakura Y
Kozaiwa K, Sugawara K, Smith MF Jr., Carl V, Yamschikov V, Belyea B, McEwen SB, Moskaluk CA, Pizarro TT, Cominelli F, McDuffie M. Identification of a Quantitative Trait Locus for Ileitis in a Spontaneous Mouse Model of Crohn's Disease: SAMP1/YitFc, 125:477
Kozar K. *See* Kamiński R
Kozar RA, Schultz SG, Hassoun HT, Desoignie R, Weisbrodt NW, Haber MM, Moore FA. The Type of Sodium-Coupled Solute Modulates Small Bowel Mucosal Injury, Transport Function, and ATP After Ischemia/Reperfusion Injury in Rats, 123:810
Kozarek R. *See* Kinney T
Kozarsky K. *See* Zanlungo A
Koziel M. *See* Kamal SM
Koziel MJ. *See* Rosen HR
Koziol DE. *See* Promrat K
Koziol JA. *See* Beutler E
Kraehenbuhl J-P
  See Debard N
  See Michetti M
  See Sierro F
Krambovitis E. *See* Roussomoustakaki M
Kramer CB. *See* Maltzman T
Kramer W
  See Lee J
  See Meerman L
Krammer H-J. *See* Wedel T
Kramvis A. *See* Hoon Ahn S
Krasnykh V. *See* Yamamoto M
Kravetz D. *See* Vorobioff JD
Krawczak M. *See* Hampe J
Kreil A. *See* Peck-Radosavljevic M
Kreipe H-H. *See* Gongoll S
Kreis ME
  See Haupt W
  See Jiang W
Kreiss C. *See* Michetti P
Kremer W. *See* Wiesner RH
Kremers W. *See* Wiesner R
Kremers WK. *See* Pardi DS
Kresina TF. *See* Bacon BR
Kretz A. *See* Jacob P
Krieglstein K. *See* Dünker N
Krinksy ML. *See* Baffy G
Krishna U
  See Fox JG
  See Graham JE
Krishna US. *See* Crawford HC
Krishnadath KK. *See* Buttar NS
Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA, Lutzke LS, Liu W. Persistent Genetic

Abnormalities in Barrett's Esophagus After Photodynamic Therapy, 119: 624–rc
Krishnan KR. *See* Varia I
Krishnan KR. Chest Pain and Serotonin: A Possible Link? Reply, 121:496–ss
Kristjansson K
See Bjarnason I
See Thjodleifsson B
Krogfelt K. *See* Aalykke C
Krohne TU
See Geissler M
See Grimm CF
Kroll SD. *See* Bouscarel B
Krom R. *See* Wiesner R
Kronborg O. *See* Jorgensen OD
Kronborg O. The Winner After 7 Rounds–Fecal Occult Blood Testing! Reply, 122:2082–ss
Kronenberg HM. *See* Leder BZ
Kronenberg M
See De Winter H
See Kita H
Krush AJ. *See* Giardello FM
Krysiak PS, Preiksaitis HG. Tachykinins Contribute to Nerve-Mediated Contractions in the Human Esophagus, 120:39
Ku S-L. *See* Hawkins N
Kuan S-F. *See* Kim GE
Kubicka S
See Klein C
See Zender L
Kubitz R. *See* Müschen M
Kubitz R, Wettstein M, Warskulat U, Häussinger D. Regulation of the Multidrug Resistance Protein 2 in the Rat Liver by Lipopolysaccharide and Dexamethasone, 116:401
Kubota M. *See* Kobayashi I
Kubota N. *See* Nakajima A
Kučera P. *See* Berčík P
Kučera P. Slow Waves, Spike Patches, and "Propagating Contractions." Reply, 121:742–c
Kucharzik T. *See* Lügering A
Kucherlapati R
See Girnun GD
See Velcich A
Kuebeler M. *See* El-Serag HB
Kuganeswaran E, Culver PJ, Fisher JK. Image of the Month, 119:6–im
Kühbacher T. *See* Rosenstiel P
Kühnel F. *See* Zender L
Kuhns DB. *See* Uzel G
Kuhns MC. *See* Lau DT-Y
Kuick R. *See* Hinoi T
Kuiken S, van den Elzen B, Tytgat G, Boeckxstaens G, Bennink R. Evidence for Pooling of Gastric Secretions in the Proximal Stomach in Humans Using Single Photon Computed Tomography, 123:2157–co
Kuipers EJ. *See* Hausen AZ
Kuipers EJ, Klinkenberg-Knol EC. *Helicobacter pylori*, Acid, and Omeprazole Revisited: Bacterial Eradication and Rebound Hypersecretion, 116:479–e
Kuipers EJ, Klinkenberg-Knol EC, Meuwissen SGM. Omeprazole and Accelerated Onset of Atrophic Gastritis, 118:239–c
Kuipers F
See Barbier O
See Hooiveld GJEJ
See Jansen PLM
See Kok T
See Meerman L
See Roelofsen H
See Schaefer M
See van Waarde WM
See Voshol PJ
Kukan M. Sensitivity of Cold-Preserved Rat Liver to Single-Pass Reperfusion, 118:450–c
Kullak-Ublick GA
See Ismair MG
See Jung D
See Stieger B
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic Anion-Transporting Polypeptide B (OATP-B) and Its Functional Comparison With Three Other OATPs of Human Liver, 120: 525
Kumada H. *See* Ikeda K
Kumar D. *See* Rowland M
Kumar R. *See* Mandal M
Kumar U. *See* Reynaert H
Kumaran V. *See* Wege H
Kumashiro R. *See* Nagao Y
Kumemura H. *See* Harada M
Kummer W. *See* König P
Kung H-J. *See* Grossmann J
Kung NNS. *See* Sung JJY
Kunik M. *See* El-Serag HB
Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S, Nakazawa T, Ohara H, Nomura T, Joh T, Shirai T, Itoh M. Angiotensin-Converting Enzyme Inhibitor Attenuates Pancreatic Inflammation and Fibrosis in Male Wistar Bonn/Kobori Rats, 124:1010
Kunos G. *See* Sun Z
Kunsch S
See Michl P
See Wagner M
Kuntz S. *See* Ding W-Q
Kuntz SM. *See* Sternini C
Kunzendorf U. *See* Stallmach A
Kuo A. *See* Doyle DA
Kuo B. *The Esophagogastric Junction*, 116: 224–pmr
Kuo F. *See* Wang LC
Kuo PC. *See* Vlahcevic ZR
Kupfer B. *See* Woitas RP
Kuraishi A. *See* Maeyama H
Kurata A, Nonaka T, Arimura Y, Nunokawa M, Terado Y, Sudo K, Fujioka Y. Multiple Ulcers With Perforation of the Small Intestine in Buerger's Disease: A Case Report, 125:911–cr
Kurbegov AC, Karpen SJ. Itchin' for a Diversion. Comment, 124:1156–ss
Kurbegov AC, Setchell KDR, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ. Biliary Diversion for Progressive Familial Intrahepatic Cholestasis: Improved Liver Morphology and Bile Acid Profile, 125:1227–cr
Kurimoto M. *See* Kanai T
Kurkijärvi R, Yegutkin GG, Gunson BK, Jalkanen S, Salmi M, Adams DH. Circulating Soluble Vascular Adhesion Protein 1 Accounts for the Increased Serum Monoamine Oxidase Activity in Chronic Liver Disease, 119:1096
Kurokawa K. *See* Iwashita T
Kuroki T. *See* Shiratori Y
Kurth MJ. *See* Bruggraber SFA
Kurtz RC, Zhang Z-F. Gastric Cardia Cancer and Dietary Fiber, 120:568–e
Kurz A
See Bonacini M
See Taguchi A
Kurz AK. *See* Graf D
Kurz AK, Graf D, Schmitt M, Dahl SV, Häussinger D. Tauroursodesoxycholate-Induced Choleresis Involves $p38^{MAPK}$ Activation and Translocation of the Bile Salt Export Pump in Rats, 121: 407
Kusama T, Mukai M, Inoue M, Nakamura H. Discussion on 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Reduce Human Pancreatic Cancer Cell Invasion and Metastasis. Reply, 123:1747–co
Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H. 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Reduce Human Pancreatic Cancer Cell Invasion and Metastasis, 122:308
Kushnir N. *See* Jiang H-Q

Kuzhikandathil EV. *See* Finn AL
Kuzushita N, Hayashi N, Kanto T, Takehara T, Tatsumi T, Katayama K, Ohkawa K, Ito A, Kasahara A, Moribe T, Sasaki Y, Hori M. Involvement of Transporter Associated With Antigen Processing 2 (*TAP2*) Gene Polymorphisms in Hepatitis C Virus Infection, 116:1149
Kvietys PR. *See* Lush CW
Kwak B. *See* Frossard JL
Kwiterovich P. *See* Berge KE
Kwok SPY. *See* Sung JJY
Kwon RS. *See* Abreu MT
Kwong E. *See* Oshima M
Kyokane T, Norimizu S, Taniai H, Yamaguchi T, Takeoka S, Tsuchida E, Naito M, Nimura Y, Ishimura Y, Suematsu M. Carbon Monoxide From Heme Catabolism in Endotoxic-Induced Rat Liver Protects Against Hepatobiliary Dysfunction, 120:1227

La Rosa. *See* Rindi G
La Villa G, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, Pantaleo P, Mazzocchi V, Gentilini P. Pathogenesis of Sodium Retention in Preascites: Have We Reached the Heart of the Problem?, 124:858–ss
Laabs U. *See* Bronsveld I
Labigne A. *See* Touati E
Lachaux A. *See* Berriot-Varoqueaux N
Lacy AM. *See* Bessa X
Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM, Visa J. Look Ma, No Blades, 124:1991–ss
Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Gastric Distention Correlates With Activation of Multiple Cortical and Subcortical Regions, 120:369
Ladhoff A. *See* Swidsinski A
Laethem J-L. *See* Demols A
Laffi G
See Bonacchi A
See Failli P
See La Villa G
See Marra F
Lafon J. *See* Granel B
LaFontaine LJ. *See* Madoff RD
Laganière M. *See* Bouin M
Lagergren J
See Cameron AJ
See Freedman J
See Inadomi JM
See Terry P
See Ye W
Lagergren J, Ye W, Ekbom A. Intestinal Cancer After Cholecystectomy: Is Bile Involved in Carcinogenesis?, 121:542
Laghi A, Innaccone R, Carbone I, Catalano C, Di Giulio E, Schillaci A, Passariello R. Virtual Colonography—A Step Forward?, 124:258–ss
Laghi L
See Boland CR
See Ricciardiello L
Laghi L, Bianchi P, Malesci A. Gender Difference for Promoter Methylation Pattern of hMLH1 and p16 in Sporadic MSI Colorectal Cancer, 124:1165–c
Lagier E. *See* Delvaux M
Laharie D, Debeugny S, Peeters M, Van Gossum A, Gower-Rousseau C, Bélaïche J, Fiasse R, Dupas J-L, Lerebours E, Piotte S, Cortot A, Vermeire S, Grandbastien B, Colombel J-F. Inflammatory Bowel Disease in Spouses and Their Offspring, 120:816
Lai CL
See Lai KC
See Zhu GH
Lai C-L
See Liaw Y-F
See Lok ASF
See Sugauchi F
Lai C-L, Chen R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF. Lamivudine for Chronic Hepatitis B: The Magic Bullet or Just Another Bright Prospect?, 116:1498–ss
Lai C-L, Rosmawati M, Lao J, van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir Is Superior to Lamivudine in Reducing Hepatitis B Virus DNA in Patients With Chronic Hepatitis B Infection, 123:1831
Lai CWY. *See* Gordon FH
Lai KC, Hui WM, Lam SK. An Aspirin a Day Keeps the Cardiologist Away (But What About the Gastroenterologist?) Reply, 124:573–ss
Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM, Hu WHC, Lau GKK, Wong WM, Yuen MF, Chan AOO, Lai CL, Wong J. An Aspirin a Day Keeps the Cardiologist Away (But What About the Gastroenterologist?), 124:572–ss
Lai K-H. *See* Lo G-H
Lai LSF. *See* Lau GKK
Lai MMC. Hepatitis C Virus Proteins: Direct Link to Hepatic Oxidative Stress, Steatosis, Carcinogenesis and More, 122:568–e
Lai MS. *See* Chan FKL
Lai MY. *See* Schalm SW
Lai M-Y
See Kao J-H
See Liu C-J
Laigneau J-P
See Goiot H
See Sobhani I
Laine L. *See* Schoenfeld P
Laine L
Approaches to Nonsteroidal Anti-Inflammatory Drug Use in the High-Risk Patient, 120:594
Comment From the Editors, 124:1726–ce
Management of Ulcers With Adherent Clots, 123:632–e
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the Risk of NSAID-Related Upper Gastrointestinal Clinical Events: Results of a Double-Blind Outcomes Study in Patients With Rheumatoid Arthritis, 123:1006
Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C. Serious Lower Gastrointestinal Clinical Events With Nonselective NSAID or Coxib Use, 124:288
Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J. A Randomized Trial Comparing the Effect of Rofecoxib, a Cyclooxygenase 2-Specific Inhibitor, With That of Ibuprofen on the Gastroduodenal Mucosa of Patients With Osteoarthritis, 117:776
Laine L, Schoenfeld P, Fennerty MB. *Helicobacter pylori* and Nonulcer Dyspepsia: Looking Beyond the Bug, 121:735–ss
Laine L, Wogen J, Yu H. Gastrointestinal Health Care Resource Utilization With Chronic Use of COX-2-Specific Inhibitors Versus Traditional NSAIDs, 125:389
Laissue JA. *See* Reubi JC
Lake J
See Wiesner R
See Wiesner RH
Lal S. *See* Burdyga G
Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, Ogunbiyi O, Nuñez G, Keshav S. Crohn's Disease and the NOD2 Gene: A Role for Paneth Cells, 125:47
Lam SK
See Lai KC
See Zhu GH
Lam S-K. *See* Huang XR
Lam WK. *See* Scott DJ
Lamb K, Kang Y-M, Gebhart GF, Bielefeldt K. Gastric Inflammation

Triggers Hypersensitivity to Acid in Awake Rats, 125:1410
Lambert JC. *See* McKim SE
Lamberti C. *See* Friedl W
Lambot G. *See* Bourlière M
Lamireau T. *See* Cézard JP
Lamm M. *See* Myrvold HE
Lammers KM. *See* Gionchetti P
Lammers W, Slack JR. Slow Waves, Spike Patches, and "Propagating Contractions," 121:742–c
Lammert F
See Fickert P
See Hillebrandt S
Lammert F, Carey MC, Paigen B. Chromosomal Organization of Candidate Genes Involved in Cholesterol Gallstone Formation: A Murine Gallstone Map, 120:221–srr
LaMont JT. *See* Podolsky DK
Gastritis, 119:1409–pmr
Merde: Excursions in Scientific, Cultural and Socio-Historical Coprology, 119:1174–pmr
The Renaissance of Probiotics and Prebiotics, 119:291–ce
Unlocking the Secrets of the Porcelain Vase, 119:1397–e
See Banerjee S
See He D
Lamont JT. *See* He D
LaMont JT. Comment from the Editors, 117:5
Lampe-Dreyer K. *See* Kewenig S
Lamprecht G. *See* Jacob P
Lan H. *See* Cohen P
Lan HY. *See* Huang XR
Lanas A, Royo Y, Ortego J, Molina M, Sáinz R. Experimental Esophagitis Induced by Acid and Pepsin in Rabbits Mimicking Human Reflux Esophagitis, 116:97
Landberg G. *See* Öhd JF
Landers C
See Braun J
See Sutton CL
Landers CJ. *See* Abreu MT
Landers CJ, Cohavy O, Misra R, Yang H, Lin Y-C, Braun J, Targan SR. Selected Loss of Tolerance Evidenced by Crohn's Disease-Associated Immune Responses to Auto- and Microbial Antigens, 123:689
Landmann L
See Bolder U
See Kullak-Ublick GA
See Rahner C
Landmann R. *See* Silberg DG
Landry J. *See* Vachon PH
Landt O. *See* Bhatia E
Lang DM. *See* Lyra AC
Lang F. *See* Waldegger S
Lang L
Bio-containable, Recombinant Organism for IBD Therapy, 125:1007–gn
Bone Marrow Cell Spontaneously Fuse With Liver, Brain, and Heart Cells, 125:1572–gn
Frequent Dieting By Adolescents May Actually Promote Weight Gain, 125:1572–gn
Gastroenterology News, 121:753–gn, 121:1271–gn, 122:3–gn, 122:255–gn, 122:601–gn, 122:849–gn, 124:4–gn, 124:284–gn, 124:596–gn, 124:876–gn, 124:1176–gn
Gene Family Analysis Uncovers New Therapeutic Targets for Colorectal Cancers, 125:4–gn
GI Coding and Billing AnswerLine in Second Year, 125:4–gn
House and Senate Pass Versions of Medicare Prescription Drug Legislation, 125:650–gn
A Key Role for FDA GI Drug Advisory Committee in Expedited Reviews, 125:289–gn
Senate Amendment Aims to Hike NIH Funding, 125:1007–gn
Strategic Planning Taskforce Tackles AGA Priorities, 125:1008–gn
Studies Explore Effects of Carbohydrate Restriction in Obesity, 125:650–gn
Survey Highlights Myths Surrounding HCV, 125:289–gn
Lang R. *See* Chowers MY
Lang T. *See* Ikejima K
Langholz E
See Jess T
See Winther KV
Langman MJS. *See* Ransford RAJ
Langman MJS, Ransford RAJ. How Safe are the Safest IBD Drugs? Reply, 124:1988–ss
Lankisch PG. *See* Lowenfels AB
Lankisch PG, Petersen F, Brinkmann G. An Enormous Ventral (Epigastric) Hernia as a Cause of Acute Pancreatitis: Pfeffer's Closed Duodenal Loop Model in the Animal, First Seen in a Human, 124:865–c
Lannoy VJ. *See* Clotman F
Lanza FL. Gastrointestinal Effects of Low-Dose Aspirin, 117:1506–c
Lanza FL, Hunt RH, Thomson ABR, Provenza JM, Blank MA. Endoscopic Comparison of Esophageal and Gastroduodenal Effects of Risedronate and Alendronate in Postmenopausal Women, 119:631
Lanza S. *See* Restivo DA
Lanzendörfer M. *See* Waldegger S
Lao J. *See* Lai C-L
Lapierre P, Hajoui O, Homberg J-C, Alvarez F. Formiminotransferase Cyclodeaminase Is an Organ-Specific Autoantigen Recognized by Sera of Patients With Autoimmune Hepatitis, 116:643
Laposata M. The Prothrombin G20210A Mutation: A New High-Prevalence Congenital Risk Factor for Thrombosis, 116:213–e
Lardeux B. *See* Goïot H
Lardon J. *See* Rooman I
Lareau F. *See* Vachon PH
Large O. *See* Ahmad T
Larkin GN
See Imperiale TF
See Lieberman DA
Larrubia JR. *See* Maini MK
Larsen F. *See* Degen LP
Larsen FS. *See* Strauss GI
Larson RA. *See* Ropeleski MJ
Larusso EM. *See* Török NJ
LaRusso NF
See Chen X-M
See Jaiswal M
See Masyuk AI
See Masyuk TV
Larusso NF. *See* Spirlì C
Lasarte J-J. *See* Bustos M
Lashner BA
See Parsi MA
See Schreiber S
See Shen B
Laskus T. *See* Vargas HE
Lassen A, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB
Helicobacter Eradication Versus Prompt Endoscopy for Dyspepsia, 120:1299–ss
Helicobacter Eradication Versus Prompt Endoscopy for Dyspepsia. Reply, 120:1300–ss
Latasa MU
See García-Trevijano ER
See Martínez-Chantar ML
Laterza F. *See* Caldarella MP
Lau DT-Y, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Lamivudine For Hepatitis B: The End of the Beginning?, 121:222–ss
Lau DT-Y, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of Chronic Delta Hepatitis After 12 Years of Interferon Alfa Therapy, 117:1229–cr
Lau GKK. *See* Lai KC
Lau GKK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, Nanji A, Yuen S-T, Williams R, Naoumov NV. Resolution of Chronic Hepatitis

B and Anti-HBs Seroconversion in Humans by Adoptive Transfer of Immunity to Hepatitis B Core Antigen, 122:614
Lau GKK, Yiu HHY, Fong DYT, Cheng H-C, Au W-Y, Lai LSF, Cheung M, Zhang H-Y, Lie A, Ngan R, Liang R. Early Is Superior to Deferred Preemptive Lamivudine Therapy for Hepatitis B Patients Undergoing Chemotherapy, 125:1742
Lau H. *See* Ji J
Lau J. *See* Cheng SJ
Lau JYN. *See* Yao N
Lau JYW
See Chan FKL
See Sung JJY
Lauer GM. *See* Somsouk M
Läuffer JM, Modlin IM, Hinoue T, Kidd M, Zhang T, Schmid SW, Tang LH. Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Gastric Enterochromaffin-like Cell Proliferation in Rats, 116:623
Laugier R
See Carrière F
See Granel B
Laurberg S. *See* Ørding Olsen K
Laurence J. Potential Roles for Chemokine Receptor CCR5 in the Pathobiology of Hepatitis C Infection, 122:2069–e
Laurendeau I. *See* Paradis V
Laurent C. *See* Bacq Y
Laurent-Puig P
See Hugot J-P
See Torrisani J
Laurent-Puig P, Plomteux O, Bluteau O, Zinzindohoué F, Jeannot E, Dahan K, Kartheuser A, Chapusot C, Cugnenc P-H, Zucman-Rossi J. Frequent Mutations of Hepatocyte Nuclear Factor 1 in Colorectal Cancer With Microsatellite Instability, 124:1311
Lauritsen JM. *See* Aalykke C
Lauritsen K. *See* Aalykke C
Lautenbach E, Lichtenstein GR. Postsurgical Recurrence in Crohn's Disease. Reply, 116:1013–c
Lavergne A. *See* Liu H
Lavergne-Slove A. *See* Crenn P
Lavezo LA. *See* Inadomi JM
Lavu K, Minocha A. Mesenteric Inflammatory Veno-occlusive Disorder: A Rare Entity Mimicking Inflammatory Bowel Disorder, 125:236–cr
Lavy A. *See* Appleyard M
Law WL. *See* Choi HK
Lawrance IC, Wu F, Leite AZA, Willis J, West GA, Fiocchi C, Chakravarti S. A Murine Model of Chronic Inflammation-Induced Intestinal Fibrosis Down-Regulated by Antisense NF-κB, 125:1750
Lawrence C, Shaffer HA, Bickston SJ. Image of the Month, 125:291–im
Laxton CD. *See* Paterson M
Layden TJ. *See* Owens CA
Layer P. *See* Fibbe C
Layer P, Fibbe C, Zornig C. Effect of Esophageal Dysmotility on Surgical Outcomes. Reply, 122:1183–c
Lazar MA
See He W
See Su CG
See Wu GD
Lazas DJ. *See* Hirota WK
Lazeyras F. *See* Spahr L
Lazridis KN, Kamath PS. Image of the Month, 116:238–im
Lazrus JM. *See* Jimenez RE
Lazzeri E. *See* Bonacchi A
Le Couteur DG. *See* McLean AJ
Le Gall J-Y
See Mendler M-H
See Moirand R
Le HT. *See* Wege H
Le Moine A. *See* Louis H
Le Moine O
See Demols A
See Deviere J
See Deviére J
Le Moine P. *See* Louis H
Le Moullac-Vaidye B. *See* Marionneau S
Le Pendu J. *See* Marionneau S
Le Sage G. *See* Alvaro D
Le T
See Burak KW
See Drossman DA
Leach SD
See Means AL
See Song SY
See Wagner M
Leader LM. *See* Ziegler TR
Learch MM. *See* Hofbauer B
Learish RD. *See* Micci M-A
Leasa D. *See* Cook D
Leather AJM. *See* Pufulete M
LeBeaut A
See Fedorak RN
See Schreiber S
LeBlanc I. *See* Abell T
Leboff MS. *See* Leslie WD
Lebrec D
See Colle IO
See Moreau R
See Pateron D
See Tazi KA
Lecchini S. *See* Giaroni C
Leceta J. *See* Abad C
Lechago J. *See* Younes M
Lechin F, van der Dijs B. Gallbladder Muscle Dysfunction and Neuroautonomic Disorders, 123:1407–co
Lechmann M. *See* Baumert TF
Leclercq IA, Fields J, Farrell GC. Leptin-Specific Mechanisms for Impaired Liver Regeneration in *ob/ob* Mice After Toxic Injury, 124:1451
Lecomte JM. *See* Cézard JP
LeCouteur D. *See* Harvey PJ
Leddin DJ. *See* Steinhart AH
Leder BZ, Kronenberg HM. Gastroenterologists and Choosing the Right Bisphosphonate, 119:866–e
Leder G
See Michl P
See Weber CK
Leducq N. *See* Conway EM
Lee B. *See* Cooper HS
Lee CK. *See* Maini MK
Lee CS. *See* Biankin AV
Lee C-T. *See* Adachi Y
Lee DC. *See* Troyer KL
Lee FD. *See* Taha AS
Lee HK. *See* Park WS
Lee H-O, Miller SD, Hurst SD, Tan L-J, Cooper CJ, Barrett TA. Interferon Gamma Induction During Oral Tolerance Reduces T-Cell Migration to Sites of Inflammation, 119:129
Lee HS
See Frossard J-L
See Hofbauer B
Lee HS, Bhagat L, Frossard J-L, Hietaranta A, Singh VP, Steer ML, Saluja AK. Water Immersion Stress Induces Heat Shock Protein 60 Expression and Protects Against Pancreatitis in Rats, 119:220
Lee J
See Gigliozzi A
See Rachmilewitz D
Lee J, Azzaroli F, Wang L, Soroka CJ, Gigliozzi A, Setchell KDR, Kramer W, Boyer JL. Adaptive Regulation of Bile Salt Transporters in Kidney and Liver in Obstructive Cholestasis in the Rat, 121:1473
Lee JA. *See* Young Kim J
Lee JH. *See* Park WS
Lee JM, Trauner M, Soroka CJ, Stieger B, Meier PJ, Boyer JL. Expression of the Bile Salt Export Pump Is Maintained After Chronic Cholestasis in the Rat, 118:163
Lee JS, Camilleri M. Image of the Month, 119:614–im
Lee JY. *See* Park WS
Lee K-F. *See* Crone SA
Lee LY. *See* Framson PE
Lee MG
See Kim JY

See Young Kim J
Lee N. *See* Leung WK
Lee P-H. *See* Yeh S-H
Lee R. *See* Vargas HE
Lee S. *See* Brant SR
Lee S-D. *See* Huo T-I
Lee SH. *See* Park WS
Lee SK. *See* Park WS
Lee S-K. *See* Kim M-H
Lee SN. *See* Park WS
Lee SP. *See* Haigh WG
Lee SS
See Poynard T
See Ward CA
Lee WM
See McHutchison JG
See Vagquero J
Lee YT
See Chan FKL
See Sung JJY
Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Göke M, Schölmerich J, Gelbmann CM, Rogler G. Reduced Migration of Fibroblasts in Inflammatory Bowel Disease: Role of Inflammatory Mediators and Focal Adhesion Kinase, 125:1341
Leebeek FWG. *See* Lisman T
Lees-Miller SP. *See* Scott KG-E
Lefèbvre O. *See* Tomasetto C
Lefkowitch J. *See* Shiva Kumar K
Lefrère F. *See* Hermine O
Legarde AE. *See* Stern HS
Leggett BA. *See* Jass JR
Legum C. *See* Rozen P
Lehman A. *See* Lidums I
Lehman G. *See* Deviere J
Lehman GA. *See* Filipi CJ
Lehman GA. *Clinical Practice of ERCP*. 117: 507–pmr
Lehmann A. *See* Zhang Q
Lehmann A, Antonsson M, Bremner-Danielsen M, Flärdh M, Hansson-Brändén L, Kärrberg L. Activation of the $GABA_B$ Receptor Inhibits Transient Lower Esophageal Sphincter Relaxations in Dogs, 117:1147
Lehmann A, Blackshaw LA, Brändén L, Carlsson A, Jensen J, Nygren E, Smid SD. Cannabinoid Receptor Agonism Inhibits Transient Lower Esophageal Sphincter Relaxations and Reflux in Dogs, 123:1129
Lehmann C. *See* Huster D
Lehn N. *See* Miehlke S
Lehr HA. *See* Siegmund B
Lehr H-A. *See* Waidmann M
Lehy T
See Goïot H
See Sobhani I
Lei J. *See* Abou-Saif A
Leibfritz D. *See* Chatauret N
Leider-Trejo L. *See* Rachmilewitz D
Leifeld L. *See* Streetz K
Leijonmarck CE. *See* Hellers G
Leite AZA. *See* Lawrance IC
Leite MF, Burgstahler AG, Nathanson MH. Ca^{2+} Waves Require Sequential Activation of Inositol Triphosphate Receptors and Ryanodine Receptors in Pancreatic Acini, 122:415
Leiter AB. *See* Ratineau C
Leitzmann MF, Stampfer MJ, Willett WC, Spiegelman D, Colditz GA, Giovannucci EL. Coffee Intake Is Associated With Lower Risk of Symptomatic Gallstone Disease in Women, 123:1823
Lemaigre FP. *See* Clotman F
Lemasters JJ
See Hatano E
See Jaeschke H
See Kim J-S
See Zhao Y
Comment From the Editors, 124:286–ce
Seeing Is Believing: A Revolution in Imaging, 121:1273–ce
Lemoine M. *See* Sinicrope FA
Lemon SM
See Honda M
See Lerat H
See Okuda M
Lemonnier C. *See* Samuel D
Lencer WI. *See* Duggan C
Lencer WI
Floating the Molecular Machinery for T-Cell Activation. Comment, 117: 503–ss
Mucosal Vaccination: "All Politics Are Local." Comment, 116:498–ss
Signaling to Colon Cancer. Comment, 117:1499–ss
Lencer WI, Alper SL. The Potassium Channel and How It Works. Comment, 116:217–ss
Lengsfeld H. *See* Carrière F
Lentsch AB, Yoshidome H, Warner RL, Ward PA, Edwards MJ. Secretory Leukocyte Protease Inhibitor in Mice Regulates Local and Remote Organ Inflammatory Injury Induced by Hepatic Ischemia/Reperfusion, 117:953
León F, Roldán E, Sanchez L, Camarero C, Bootello A, Roy G. Human Small-Intestinal Epithelium Contains Functional Natural Killer Lymphocytes, 125:345
León F, R-Pena R, Camarero C, Sánchez L, Eiras P, Amo A del, Bootello A, Roy G. Limitations of Anti-Guinea Pig Liver Transglutaminase IgA in Screening of Celiac Disease, 120:586–c
León Ruiz L. *See* Hidalgo-Tenorio C
Leonard M. *See* Gulberg E
Leone N. *See* Bugianesi E
Leoni LM. *See* Rachmilewitz D
Leontovich O. *See* Buttar NS
Leopard JD. *See* Dwinell MB
Lepage AC. *See* Buzoni-Gatel D
Lepard K. *See* Takahashi T
Leppert MF. *See* Samowitz WS
Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao S-Y, Weinman SA, Lemon SM. Steatosis and Liver Cancer in Transgenic Mice Expressing the Structural and Nonstructural Proteins of Hepatitis C Virus, 122:352
Lerch MM. *See* Mayerle J
Lerch MM, Domschke W. Abraham Vater of the Ampulla (Papilla) of Vater, 118:379
Lerebours E. *See* Laharie D
Leroy K. *See* Suraweera N
Lerut J. *See* Féray C
Lesage G. *See* Alpini G
LeSage G, Alvaro D, Benedetti A, Glaser S, Marucci L, Baiocchi L, Eisel W, Caligiuri A, Phinizy JL, Rodgers R, Francis H, Alpini G. Cholinergic System Modulates Growth, Apoptosis, and Secretion of Cholangiocytes From Bile Duct-Ligated Rats, 117:191
LeSage GD. *See* Alpini G
Lesage H. *See* Hugot J-P
Lesage S. *See* Hugot J-P
Leserman J. *See* Drossman DA
Leslie WD, Bernstein CN, Leboff MS. AGA Technical Review on Osteoporosis in Hepatic Disorders, 125:941–aga
Lesser M. *See* Markowitz J
Lessie M. *See* Promrat K
Lesuffleur T. *See* Bras-Gonçalves RA
Lettéron P
See Demeilliers C
See Mansouri A
Lettink-Wissink MLG. *See* Bovee-Oudenhoven IMJ
Leufkens H. *See* van Staa T-P
Leung J. *See* Mulcahy HE
Leung N. *See* Lok ASF
Leung NWY
See Lai C-L
See Liaw Y-F
Leung PSC. *See* Bruggraber SFA
Leung VKS. *See* Chan FKL
Leung WK
See Chan FKL
See Kim JJ
See Sung JJY

Leung WK, To K-F, Chan PKS, Chan KLY, Wu AKL, Lee N, Yuen KY, Sung JJY. Enteric Involvement of Severe Acute Respiratory Syndrome Associated Coronavirus Infection, 125: 1011–rc
Leung-Theung-Long S. *See* Clerc P
Leuschner M, Maier K-P, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H, Happ J, Leuschner U. Oral Budesonide and Ursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: Results of a Prospective Double-Blind Trial, 117:918
Leuschner U
See Leuschner M
See Tsujii H
Levander K
See Lundell L
See Myrvold HE
Levin T. *See* Winawer S
Levin TR. *See* Terdiman JP
See Corley DA
See Terdiman JP
Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications of Screening Flexible Sigmoidoscopy, 123:1786
Levine AD
See Grossmann J
See Musso A
See Spencer DM
Levine DS, Riff DS, Pruitt R, Weuble L, Koval G, Sales D, Bell JK, Johnson LK. The Mesalamine Wards Heat Up-Enter Balsalazide, 124:574–ss
Levine JS. *Origins and Directions of Inflammatory Bowel Disease. Early Studies of the "Nonspecific" Inflammatory Bowel Diseases*. 124:861–pmr
Levy E. *See* Bruneau N
Levy MJ. *See* Vazquez-Sequeiros E
Lévy P. *See* Malka D
Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable Bowel Syndrome in Twins: Heredity and Social Learning Both Contribute to Etiology, 121:799
Levy S
See Chamouard P
See Moreau R
Lewandrowski KB. *See* Hartwig W
Lewin MJM. *See* Goïot H
Lewis BS. *See* Zuckerman GR
Lewis BS, Swain P. Small Bowel Photography: The Jury Needs Evidence, 124:1150–ss
Lewis CM. *See* Cuthbert AP
Lewis FR. *See* Huntsman DG
Lewis JD
See Aberra FN
See Forman LM
See Su C
See Su CG
Lewis JD
Are Two Tests Better Than One? Comment, 122:236–ss
Barrett's Esophagus: The Long and the Short of It. Comment, 119:1165–ss
Burst Appendix or Technology Bust. Comment, 123:381–ss
Cost-Effectiveness of Screening for Colorectal Cancer: The Dollar Is In the Details. Comment, 124:857–ss
The Genesis of IBD Genetics. Comment, 123:2148–ss
How Safe are the Safest IBD Drugs? Comment, 124:1986–ss
The Many Faces of Low-Grade Dysplasia, 125:1531–e
Population Screening and Treatment of *Helicobacter Pylori*. Comment, 119: 1795–ss
Ursodiol Prevents UC-Associated CRC. Comment, 121:491–ss
What Lies Beyond the View of the Sigmoidoscope? Comment, 120:1052–ss
Will the Safest Analgesic Please Stand Up. Comment, 122:1536–ss
Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL
Inflammatory Bowel Disease Is Not Associated With an Increased Risk of Lymphoma, 121:1080
The Role of Cytomegalovirus in Inflammatory Bowel Disease and Gastrointestinal Lymphoma. Reply, 123:390–c
Lewkowicz S. *See* Appleyard M
Ley C, Parsonnet J. *Helicobacter pylori* Infection and Gastric Cancer, 120: 324–c
Ley K. *See* Burns RC
Ley K, Burns C. Adhesion Molecules in Lymphocyte Trafficking and Colitis, 121:1008–e
Ley-Ebert C. *See* Bates MD
Leytin A. *See* Selaru FM
Li C. *See* Syngal S
Li F. *See* Chen F
Li H
See Micci M-A
See Zein NN
Li J
See Bardag-Gorce F
See Hoon Ahn S
Li JZ. *See* Drossman DA
Li K. *See* Okuda M
Li L. *See* Repa JJ
Li L, Grenard P, Van Nhieu JT, Julien B, Mallat A, Habib A, Lotersztajn S. Heme Oxygenase-1 Is an Antifibrogenic Protein in Human Hepatic Myofibroblasts, 125:460
Li L, Liu L, Rao JN, Esmaili A, Strauch ED, Bass BL, Wang J-Y. JunD Stabilization Results in Inhibition of Normal Intestinal Epithelial Cell Growth Through P21 After Polyamine Depletion, 764
Li L, Meng G, Graham MF, Shaw GM, Smith PD. Intestinal Macrophages Disply Reduced Permissiveness to Human Immunodeficiency Virus 1 and Decreased Surface CCR5, 116: 1043
Li MKW. *See* Sung JJY
Li R. *See* Wittenburg H
Li W, Buzoni-Gatel D, Debbabi H, Hu MS, Mennechet FKD, Durell BG, Noelle RJ, Kasper LH. CD40/CD154 Ligation Is Required for the Development of Acute Ileitis Following Oral Infection With an Intracellular Pathogen in Mice, 122: 762
Li Y. *See* Boushey RP
Li Z, Lin H, Yang S, Diehl AM. Murine Leptin Deficiency Alters Kupffer Cell Production of Cytokines That Regulate the Innate Immune System, 123:1304
Liance M. *See* Godot V
Liang JT. *See* Thomson M
Liang R. *See* Lau GKK
Liang TJ
See Baumert TF
See Doo E
See Ghany MG
See Lau DT-Y
See Promrat K
Liang TJ. Comment From the Editors, 117: 1041
Liao Q, Guo J, Kleeff J, Zimmermann A, Büchler MW, Korc M, Friess H. Down-Regulation of the Dual-Specificity Phosphatase MKP-1 Suppresses Tumorigenicity of Pancreatic Cancer Cells, 124:1830
Liaw Y-F. *See* Chen Y-C
Liaw Y-F, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Chien R-N, Dent J, Roman L, Edmundson S, Lai C-L. Effects of Extended Lamivudine Therapy in Asian Patients With Chronic Hepatitis B, 119:172
Libby E. *See* Mulcahy HE
Licato LL. *See* Rhoads JM
Lichenstein HS. *See* Jeffers M
Lichtenstein GR
See Aberra FN
See Bickston SJ

See Cuffari C
See Hanauer SB
See Judge T
See Judge TA
See Lautenbach E
See Su C
See Su CG
Lichtenstein GR. Treatment of Fistulizing Crohn's Disease, 119:1132–srr
Lickerman M. *See* Caplan MS
Liddle C. *See* Chitturi S
Liddle RA
Bringing New Therapies to Patients-What Is the Proper Physician-Industry Relationship?, 125:7–ce
Comment from the Editors, 122:851–ce
Malcolm P. Tyor, M.D., (1923-2003) AGA President 1981-1982, 125:288–gn
Lider O. *See* Chowers Y
Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of Transient Lower Esophageal Sphincter Relaxations and Reflux by the $GABA_B$ Agonist Baclofen in Normal Subjects, 118:7
Lie A. *See* Lau GKK
Lie BA. *See* Bowlus CL
Lieb K. *See* Reinshagen M
Lieberman D. *See* Inadomi JM
Lieberman D
Cancer Screening: A Practical Guide for Physicians, 125:271–pmr
Colorectal Cancer: Not an Equal Opportunity Cancer, 120:1043–e
Lieberman DA, De Garmo PL, Fleischer DE, Eisen GM, Helfand M. Patterns of Endoscopy Use in the United States, 618:619–srr
Lieberman DA, Weiss DG. Are Two Tests Better Than One?, 122:236–ss
Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G, Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. What Lies Beyond the View of the Sigmoidoscope?, 120:1051–ss
Liebetruth J. *See* Ortner MEJ
Liebisch G. *See* Drobnik W
Liebman H, Sutherland D, Kashani N. Thrombosis, Factor V Leiden, and Inflammatory Bowel Disease. Reply, 116:779–c
Liebman HA, Kashani N, Sutherland D. Inflammatory Bowel Disease and the Risk of Thrombosis. Reply, 117:280–c
Liedman B
See Lundell L
See Myrvold HE
Liedtke W. *See* Cohen P
Liefers G-J, Cleton-Jansen A-M, van De Velde CJH, Hermans J, van Krieken JHJM, Cornelisse CJ, Tollenaar RAEM. Molecular Staging of Colorectal Cancer: A Step Forward, 116:769–ss
Liefers GJ, Tollenaar RAEM, Cleton-Jansen AM. Molecular Staging of Colorectal Cancer: A Step Forward. Reply, 116:770–ss
Lieser B. *See* Drobnik W
Lightdale CJ. *Cancer of the Upper Gastrointestinal Tract*, 125:987–pmr
Ligresti A. *See* Izzo AA
Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'Argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V. Possible Endocannabinoid Control of Colorectal Cancer Growth, 125:677
Limburg P. *See* Sargent D
Lin C-H. *See* Chen Y-J
Lin C-K. *See* Lo G-H
Lin CY
See Imperiale TF
See Lieberman DA
Lin H. *See* Li Z
Lin HC. *See* Pimentel M
Lin HH. *See* Samowitz WS
Lin HZ. *See* Cortez-Pinto H
Lin JJ-C. *See* Lin JL-C
Lin JL-C, Geng X, Bhattacharya SD, Yu J-R, Reiter RS, Sastri B, Glazier KD, Mirza ZK, Wang KK, Amenta PS, Das KM, Lin JJ-C. Isolation and Sequencing of a Novel Tropomyosin Isoform Preferentially Associated With Colon Cancer, 123:152
Lin J-T. *See* Chang C-S
Lin O. *See* Kaur BS
Lin R. *See* Chitturi S
Lin S-R. *See* Sung JJY
Lin W. *See* Drossman DA
Lin X, Jung J, Kang D, Xu B, Zaret KS, Zoghbi H. Prenylcystein Carboxylmethyltransferase Is Essential for the Earliest Stages of Liver Development in Mice, 123:345
Lin Y-C
See Abreu MT
See Landers CJ
Linares J-L. *See* Tomasetto C
Lind T, Mégraud F, Unge P, Bayerdörffer E, O'Morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C. The MACH2 Study: Role of Omeprazole in Eradication of *Helicobacter pylori* With 1-Week Triple Therapies, 116:248
Lindberg E. *See* Halfvarson J
Lindberg G
See Abell T
See Brown GR
See Törnblom H
Lindblom A. *See* Rubio CA
Linde H-J. *See* Rath HC
Lindén S, Nordman H, Hedenbro J, Hurtig M, Borén T, Carlstedt I. Strain- and Blood Group-Dependent Binding of *Helicobacter pylori* to Human Gastric MUC5AC Glycoforms, 123:1923
Lindenthal B. *See* Drobnik W
Lindgren S
See Bergquist A
See Elmberg M
Lindholm PF. *See* Shi X-Z
Lindor KD
See Angulo P
See Czaja AJ
See Feldstein AE
See Kim WR
See Pardi DS
See Sorbi D
Lindor NM. *See* Huntsman DG
Lindsay K
See McHutchison JG
See Poynard T
Lindstrom J. *See* Richardson CE
Linet M. *See* Askling J
Ling L. *See* Wang LC
Ling M-H. *See* Poynard T
Ling M-S. *See* Poynard T
Ling Y. *See* Zhang J
Linton KJ. *See* Byrne JA
Lin-Wu E. *See* Jacob P
Liotta F. *See* Bonacchi A
Lipkin M
See Holt PR
See Velcich A
Lipman T. *See* Goldblatt J
Lipscomb S. *See* Schoenfeld P
Lipsky JJ
See Lowry PW
See Sandborn WJ
Liptay S
See Paxian S
See Seufferlein T
See Weber CK
Lisman T, Leebeek FWG, Mosnier LO, Bouma BN, Meijers JCM, Janssen HLA, Nieuwenhuis HK, de Groot PG. Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis, 121:131
Lissitzky J-C. *See* Soubeyran P
Liston R. *See* Hamilton J
Litin S. *See* Winawer S
Little J. *See* Benamouzig R
Little KH. *See* Gruy-Kapral C
Little NR

See Jonas MM
See Lok ASF
Liu C, Russell RM, Seitz HK, Wang X-D. Ethanol Enhances Retinoic Acid Metabolism Into Polar Metabolites in Rat Liver via Induction of Cytochrome P4502E1, 120:179
Liu C-J, Chen P-J, Lai M-Y, Kao J-H, Chang C-F, Wu H-L, Shau W-Y, Chen D-S. A Prospective Study Characterizing Full-Length Hepatitis B Virus Genomes During Acute Exacerbation, 124:80
Liu H. *See* Ward CA
Liu H, Ye H, Ruskone-Fourmestraux A, de Jong D, Pileri S, Thiede C, Lavergne A, Boot H, Caletti G, Wündisch T, Molina T, Taal BG, Elena S, Thomas T, Zinzani PL, Neubauer A, Stolte M, Hamoudi RA, Dogan A, Isaacson PG, Du M-Q. T(11;18) Is a Marker for All Stage Gastric MALT Lymphomas That Will Not Respond to *H. pylori* Eradication, 122:1286
Liu J
See Balaban DH
See He D
See Wlk M
Liu L
See Li L
See Wege H
Liu LU, Schiano TD, Min AD, Kim-Schluger L, Schwartz ME, Emre S, Fishbein TM, Bodenheimer HC Jr, Miller CM. Syngeneic Living-Donor Liver Transplantation Without the Use of Immunosuppression, 123:1341–cr
Liu S. *See* Gao C
Liu S-L. *See* Zhu J
Liu TC. *See* Selaru FM
Liu W. *See* Krishnadath KK
Liu X, Rusch NJ, Striessnig J, Sarna SK. Down-regulation of L-Type Calcium Channels in Inflamed Circular Smooth Muscle Cells of the Canine Colon, 120:480
Liu Y
See Karvar S
See Radaeva S
Liu YC. *See* Matteoni CA
Liu Z-Y. *See* Wang LC
Lledo S. *See* Minguez M
Lluis JM, Colell A, García-Ruiz C, Kaplowitz N, Fernández-Checa JC. Acetaldehyde Impairs Mitochondrial Glutathione Transport in HepG2 Cells Through Endoplasmic Reticulum Stress, 124:708
Lo G-H, Chen W-C, Chen M-H, Hsu P-I, Lin C-K, Tsai W-L, Lai K-H. Banding Ligation Versus Nadolol and Isosorbide Mononitrate for the Prevention of Esophageal Variceal Rebleeding, 123:728
Lo Russo L. *See* Barbato M
Lobaccaro JA. *See* Repa JJ
Lobb R. *See* Sans M
Lobo AJ
See Baugh MD
See Carter MJ
Locarnini S
See Angus P
See Bock C-T
See Bonacini M
See Klein C
See Shaw T
Lochs H
See Ockenga J
See Ortner MEJ
See Sandborn WJ
See Steiner M
See Swidsinski A
Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffman R, Gross V, Plauth M, Staun M, Nesje LB. Prophylaxis of Postoperative Relapse in Crohn's Disease With Mesalamine: European Cooperative Crohn's Disease Study VI, 118:264
Lock G. *See* Mühlbauer M
Lock RJ. *See* Porter WM
Locke GR, Pemberton JH, Phillips SF
AGA Medical Position Statement: Guidelines on Constipation, 119:1761–aga
AGA Technical Review on Constipation, 119:1766–aga
Locke GR III
See Cameron AJ
See Kim WR
Lockhart RR. *My Mom Has Hepatitis C*. 120:1056–pmr
Lodge JPA. *See* Fenwick SW
Loening-Baucke V. *See* Swidsinski A
Loesch K. *See* Lerat H
Loeschke K
See Folwaczny C
See Spannagl M
Loewy J. *See* Sands BE
Löfberg H. *See* Öhd JF
Löfberg R
See Hellers G
See Sandborn WJ
Löffler J. *See* Waidmann M
Loftin CD. *See* Kim K-S
Loftus CG, Loftus EV Jr. Cancer Risk in Celiac Disease, 123:1726–e
Loftus EV. *See* Ricart E
Loftus EV Jr
See Bambha K
See Dayharsh GA
See Faubion WA Jr
See Loftus CG
See Pardi DS
See Sandborn WJ
See Schwartz DA
See Silverstein MD
Loftus EV Jr
The Epidemiology of Crohn's Disease. Reply, 116:1504–c
Mortality in Inflammatory Bowel Disease: Peril and Promise, 125:1881–e
Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ III. Long-term Fracture Risk in Patients With Crohn's Disease: A Population-Based Study in Olmsted County, Minnesota, 123:468
Loftus EV Jr, Sandborn WJ. Lymphoma Risk in Inflammatory Bowel Disease: Influences of Referral Bias and Therapy, 121:1239–e
Logan RFA
See Card T
See West J
Loges S. *See* Obermayer-Straub P
Logsdon CD
See Chen X
See Ji B
Logue E. *See* Varia I
Loguercio C. *See* Marchesini G
Lohmann J. *See* Jeppesen PB
Löhr M. *See* Michl P
Lohse AW. *See* Knolle PA
Loinaz C. *See* Féray C
Loirand G. *See* Segain J-P
Lok AS, Heathcote EJ, Hoofnagle JH. Serum HBV-DNA Levels in Inactive Hepatitis B Virus Carriers. Reply, 122:2093–c
Lok ASF. *See* Chu C-J
Lok ASF, Lai C-L, Leung N, Yao G-B, Cui Z-Y, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-Term Safety of Lamivudine Treatment in Patients With Chronic Hepatitis B, 125:1714
Lok ASF. Lamivudine Therapy for Chronic Hepatitis B: Is Longer Duration of Treatment Better?, 119:263–e
Lomax RB, Gallego S, Novalbos J, García AG, Warhurst G. L-Type Calcium Channels in Enterochromaffin Cells From Guinea Pig and Human Duodenal Crypts: An In Situ Study, 117:1363
Lombard-Bohas C. *See* Marion-Audibert A-M
Lombardo D. *See* Bruneau N

Londe M. *See* Maiuri L
Long A. *See* Farrell RJ
Longo M. *See* Battezzati PM
Longo M, Crosignani A, Battezzati PM, Giussani CS, Invernizzi P, Zuin M, Podda M. Hypercholesterolemia in Primary Biliary Cirrhosis: Getting to the Heart of the Matter, 124:854–ss
The Long-Term Study Group. *See* Klinkenberg-Knol EC
Lönnqvist KE. *See* Raevaara TE
Lonroth H. *See* Mattsson A
Loof L. *See* Bergquist A
Lööf L. *See* Elmberg M
Loomis CW. *See* Dong H
Loonen H. *See* Otley A
Loot AE. *See* Hooiveld GJEJ
Lopez ME. *See* Kornmann M
Lopez V. *See* Carrière F
Lopez-Nava G. *See* De la Concha EG
Lopilato C. *See* Bortolotti M
Loprinzi CL. *See* Baron JA
Lora JM. *See* Bataller R
Lord RVN. Image of the Month, 117:1270
Loreal O. *See* Dupic F
Loren DE, Cai X, Metz DC. Image of the Month, 122:852–im
Lorenzen J. *See* Dooley S
Lorenzo-Zúñiga V. *See* Pérez-Páramo M
Loria P. *See* Ballestri M
Losa JH, Fernandez-Soria V, Parada C, Sanchez-Prieto R, Cajal SR Y, Fedele CG, Tenorio A. JC Virus and Human Colon Carcinoma: An Intriguing and Inconclusive Association, 124:268–c
Losco A. *See* Fracanzani AL
Losonsky G. *See* Michetti P
Lotersztajn S. *See* Li L
Lothe RA
See Duval A
See Thornstensen L
See Thorstensen L
Lotterer E. *See* Kleber G
Loughney TM. *See* Hirota WK
Louis DN. *See* Castells A
Louis E
See Baert F
See Vermeire S
Louis H. *See* Deviere J
Louis H, Le Moine A, Flamand V, Nagy N, Quertinmont E, Paulart F, Abramowicz D, Le Moine P, Goldman M, Devière J. Critical Role of Interleukin 5 and Eosinophils in Concanavalin A-Induced Hepatitis in Mice, 122:2001
Loukola A. *See* Prior TW
Louvard D. *See* Janssen K-P
Louvel D. *See* Delvaux M
Lovat L. *See* Fitzgerald RC
Lovato P. *See* Van Assche G
Lowenfels AB. *See* Rulyak SJ
Lowenfels AB, Lankisch PG, Maisonneuve P. What Is the Risk of Biliary Pancreatitis in Patients With Gallstones?, 119:879–c
Lown KS. *See* Fontana FJ
Lowry PW, Franklin CL, Weaver AL, Pike MG, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Forecast for Using Metabolite Measurements in the Dosing of Azathioprine or 6-Mercaptopurine for IBD Patients: "Partly Cloudy," 122:2082–ss
Lowry PW, Sandborn WJ. A Comparison of Budesonide and Mesalamine for Active Crohn's Disease. Comment, 116:1263–ss
Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and Azathioprine or 6-Mercaptopurine: Evidence for a Potentially Serious Drug Interaction, 116:1505–c
Lowy AM, Kordich JJ, Gismondi V, Varesco L, Blough RI, Groden J. Numerous Colonic Adenomas in an Individual With Bloom's Syndrome, 121:435–cr
Lu B. *See* Morteau O
Lu DSK. *See* Johnson CD
Lu G, Mazet B, Sun C, Qian X, Johnson CP, Adams MB, Roman RJ, Sarna SK. Inflammatory Modulation of Calcium-Activated Potassium Channels in Canine Colonic Circular Smooth Muscle Cells, 116:884
Lu J, Wang A, Ansari S, Hershberg RM, McKay DM. Colonic Bacterial Superantigens Evoke an Inflammatory Response and Exaggerate Disease in Mice Recovering From Colitis, 125:1785
Lu N. *See* Beck PL
Lu X. *See* Guan X
Lu Z. *See* Koutkia P
Luangsay S, Kasper LH, Rachinel N, Minns LA, Mennechet FJD, Vandewalle A, Buzoni-Gatel D. CCR5 Mediates Specific Migration of *Toxoplasma gondii*-Primed $CD8^+$ Lymphocytes to Inflammatory Intestinal Epithelial Cells, 125:491
Lucà MG. *See* McLaughlin J
Lucarelli S. *See* Barbato M
Lucas M. *See* Heuschen UA
Lucas PC. *See* Hinoi T
Lucena J-F, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J. A Multidrug Resistance 3 Gene Mutation Causing Cholelithiasis, Cholestasis of Pregnancy, and Adulthood Biliary Cirrhosis, 124:1037–cr
Lucena JF, Herrero JI, Quiroga J, Sangro B, Prieto J. Is Intrahepatic Cholestasis of Pregnancy an MDR3-Related Disease? Reply, 125:1923–c
Lucey MR. *See* Forman LM
Luck W. *See* Witt H
Luckey A, Wang L, Jamieson PM, Basa NR, Million M, Czimmer J, Vale W, Taché Y. Corticotropin-Releasing Factor Receptor 1-Deficient Mice Do Not Develop Postoperative Gastric Ileus, 125:654–rc
Lucsko M. *See* Izzedine H
Ludovica Francanzani A. *See* Valenti L
Ludwig L. *See* Steinkamp M
Lue YH. *See* McPhaul LW
Luetteke NC. *See* Troyer KL
Lugea A, Gukovsky I, Gukovskaya AS, Pandol SJ. Nonoxidative Ethanol Metabolites Alter Extracellular Matrix Protein Content in Rat Pancreas, 125:1845
Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab Induces Apoptosis in Monocytes From Patients With Chronic Active Crohn's Disease by Using a Caspase-Dependent Pathway, 121:1145–
Lügering N
See Dwinell MB
See Lügering A
Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR, Finlayson NDC, MacGilchrist AJ, Hayes PC. Primary Prophylaxis of Variceal Hemorrhage: A Randomized Controlled Trial Comparing Band Ligation, Propranolol, and Isosorbide Mononitrate, 123:735
Luis J. *See* André F
Luk P. *See* Oshima M
Luk YW. *See* Sung JJY
Luketic V. *See* Bruggraber SFA
Luketic VA
See Chu C-J
See Sanyal AJ
See Shiffman ML
Lund PK
See Greenhalgh CJ
See Martin C
See Williams KL
Lund PK
Comment From the Editors, 123:405–ce
The Flexible Ph.D, 125:1301–ce
Gender Equity in Biomedical Science: Comments From a Lone Female Associate Editor, 121:243–ce
Lundell L. *See* Myrvold HE

Lundell L
Lack of Effect of Acid Suppression Therapy on Gastric Atrophy, 118:453–c
Omeprazole and Accelerated Onset of Atrophic Gastritis. Reply, 118:240–c
Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, Hattlebakk J, Havu N, Janatuinen E, Levander K, Liedman B, Nyström P, Nordic Gerd Study Group. Lack of Effect of Acid Suppression Therapy on Gastric Atrophy, 117:319
Lundin KEA
See Arentz-Hansen H
See Molberg Ø
Lunel F. *See* Di Martino V
Lunel F, Cadranel J-F, Rosenheim M, Dorent R, Dimartino V, Payan C, Fretz C, Ghoussoub J-J, Bernard B, Dumont B, Perrin M, Gandjbachkh I, Huraux JM, Stuyver L, Opolon P. Hepatitis Virus Infections in Heart Transplant Recipients: Epidemiology, Natural History, Characteristics, and Impact on Survival, 119:1064
Luo B. *See* Zhang J
Luo W. *See* Conway EM
Lupien F. *See* Bouin M
Lupu F. *See* Conway EM
Luque T. *See* Pérez-Páramo M
Lurie Y. *See* Blendis L
Lush CW, Cepinskas G, Kvietys PR. Regulation of Intestinal Nuclear Factor-κB Activity and E-Selectin Expression During Sepsis: A Role for Peroxynitrite, 124:118
Lusis AJ. *See* Gukovskaya AS
Luster AD. Chemokines Regulate Lymphocyte Homing to the Intestinal Mucosa, 120:291–e
Luster MI. *See* Yin M
Lustig K. *See* Repa JJ
Lutsenko S. *See* Huster D
Lutz B. *See* Izzo AA
Lutzke LS
See Buttar NS
See Krishnadath KK
Luz A. *See* Smits R
Luzi L. *See* Perseghin G
Lyford GL, He CL, Soffer E, Hull TL, Strong SA, Senagore AJ, Burgart LJ, Young-Fadok T, Szurszewski JH, Farrugia G. Is Constipation Caused by a Loss of Colonic Interstitial Cells of Cajal?, 125:264–ss
Lymphadenectomy Group. *See* Pedrazzoli S
Lynch HT
See Raevaara TE
See Vasen HFA
Lynch HT, Brand RE, Lynch JF, Fusaro RM, Smyrk TC, Goggins M, Kern SE. Genetic Counseling and Testing for Germline *p16* Mutations in Two Pancreatic Cancer-Prone Families, 119: 1756–cr
Lynch JF. *See* Lynch HT
Lynch JP, Silberg DG. To Differentiate or Proliferate? The Interaction Between PI3K/PTEN and Cdx2, 123: 1395–e
Lynch PM. *See* Sinicrope FA
Lynch RG. *See* Berg DJ
Lynn PA, Olsson C, Zagorodnyuk V, Costa M, Brookes SJH. Rectal Intraganglionic Laminar Endings Are Transduction Sites of Extrinsic Mechanoreceptors in the Guinea Pig Rectum, 125:786
Lynn RB. *See* Chadker S
Lyons MA. *See* Wittenburg H
Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, Korber B, Perelson AS, di Bisceglie AM. Evolution of Hepatitis C Viral Quasispecies After Liver Transplantation, 123:1485

Ma A
See Kojima K
See Ren H
Ma L
See Chen F
See Fiorucci S
Ma MK. *See* Cummings DE
Maanen JMS van. *See* Vermeer ITM
Maaser C, Eckmann L, Paesold G, Kim HS, Kagnoff MF. Ubiquitous Production of Macrophage Migration Inhibitory Factor by Human Gastric and Intestinal Epithelium, 122:667
Macari M. *See* Johnson CD
Macarri G. *See* Benedetti A
MacCarty RL
See Gluecker TM
See Harewood GC
See Johnson CD
Macdonald GA, Powell LW. More Clues to the Relationship Between Hepatic Iron and Steatosis: An Association With Insulin Resistance?, 117:1241–e
MacDonald JS. *See* Green RJ
MacDonald TT. *See* Monteleone G
MacDonald TT. A Mouse Model of Intestinal Fibrosis?, 125:1889–e
MacGilchrist A. *See* Bathgate A
MacGilchrist AJ. *See* Lui HF
Mach F. *See* Frossard JL
Machado JC. *See* Máximo V
Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Alves CC, Campos ML, Van Doorn L-J, Caldas C, Seruca R, Carneiro F, Sobrinho-Simões M. A Proinflammatory Genetic Profile Increases the Risk for Chronic Atrophic Gastritis and Gastric Carcinoma, 125:364
Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simões M. Interleukin 1B and Interleukin 1RN Polymorphisms Are Associated With Increased Risk of Gastric Carcinoma, 121:823
Machicado GA. *See* Jensen DM
Macintyre E. *See* Verkarre V
Mackie K. *See* van Sickle M
MacKinnen R. *See* Doyle DA
MacLeod PM. *See* Huntsman DG
MacLeod RJ. *See* Mathews CJ
MacMathuna P. *See* Goh J
Macon WR. *See* Dayharsh GA
MacPherson B. *See* Hommes D
Macry J. *See* Hugot J-P
Madalinski MH
Higher or Lower Doses of Botulinum Toxin for the Treatment of Chronic Anal Fissure?, 124:1165–c
Nonsurgical Treatment Modalities for Chronic Anal Fissure Using Botulinum Toxin, 117:516–c
Madani N. *See* Rollier C
Madanick RD, Barkin JS. Hormonal Therapy in Angiodysplasia: Should We Completely Abandon Its Use?, 123:2156–co
Madara JL
See Collier-Hyams LS
See Shibahara T
Madara JL, Carey MC. Presentation of the Julius M. Friedenwald Medal to Jerry S. Trier, M. D, 116:1457–aga
Madden JF. *See* Kohli V
Madl C. *See* Schenk P
Madoff RD, Rosen HR, Baeten CG, LaFontaine LJ, Cavina E, Devesa M, Rouanet P, Christiansen J, Faucheron J-L, Isbister W, Köhler L, Guelinckx PJ, Pöhlman L. Safety and Efficacy of Dynamic Muscle Plasty for Anal Incontinence: Lessons From a Prospective, Multicenter Trial, 116: 549
Madon J. *See* Stieger B
Madonna P, Stefano V de, Coppola A, Cerbone AM, Minno G di. G20210A Prothrombin Gene Mutation and Other Trombophilic Polymorphisms in Patients With Portal or Hepatic Venous Thrombosis, 120:1059–c
Madsen JL. *See* Jeppesen PB
Madsen K
Combining T cells and IL-10:A New

Therapy for Crohn's Disease?, 123: 2140–e
Discussion on Probiotic Bacteria Enhance Murine and Human Intestinal Epithelial Function. Reply, 123:392–c
Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, de Simone C. Probiotic Bacteria Enhance Murine and Human Intestinal Epithelial Barrier Function, 121:580
Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. *Lactobacillus* Species Prevents Colitis in Interleukin 10 Gene-Deficient Mice, 116:1107
Maeda N. *See* Kamada Y
Maeda S. *See* Hirata Y
Maeda S, Yoshida H, Ogura K, Mitsuno Y, Hirata Y, Yamaji Y, Akanuma M, Shiratori Y, Omata M. *H. pylori* Activates NF-κB Through a Signaling Pathway Involving IκB Kinases, NF-κB–Inducing Kinase, TRAF2, and TRAF6 in Gastric Cancer Cells, 119: 97
Maehara S-I. *See* Tanaka S
Maehara Y. *See* Tanaka S
Maekawa H. *See* Ikeda H
Maekawa M. *See* Miyakura Y
Maenhout A. *See* Annovazzi A
Maertelaer V de, Moine O Le, Deviére J. IL-10 in Post ERCP Pancreatitis. Reply, 121:233–c
Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A, Mori H, Matsuda Y, Wada S, Sodeyama H, Nakata S, Kawamura N, Hata S, Watanabe M, Iijima Y, Katsuyama T. Familial Gastrointestinal Stromal Tumor With Hyperpigmentation: Association With a Germline Mutation of the *c-kit* Gene, 120:210–cr
Magazzù G. *See* Ventura A
Maggiore B. *See* Trevisani M
Magnusson K-E. *See* Söderholm JD
Mahadevan U, Sandborn WJ. Diagnosis and Management of Pouchitis, 124: 1636
Mahajan L. *See* Ogunmola NA
Mahmud N. *See* Farrell RJ
Mahoney DW. *See* Ahlquist DA
Mahr S, Neumayer N, Gerhard M, Classen M, Prinz C. IL-1β—Induced Apoptosis in Rat Gastric Enterochromaffin-like Cells is Mediatied by iNOS, NF-κB, and Bax Protein, 118:515
Mai M. *See* Ougolkov AV
Maier K-P. *See* Leuschner M
Maier-Dobersberger T. *See* Kazemi-Shirazi L
Maillot C, Million M, Wei JY, Gauthier A, Taché Y. Peripheral Corticotropin-Releasing Factor and Stress-Stimulated Colonic Motor Activity Involve Type 1 Receptor in Rats, 119:1569
Mailman D. *See* Helmer KS
Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, Larrubia JR, Webster GJM, McMichael AJ, Ferrari C, Williams R, Vergani D, Bertoletti A. Direct Ex Vivo Analysis of Hepatitis B Virus-Specific $CD8^+$ T Cells Associated With the Control of Infection, 117:1386
Maison P. *See* Mathieu D
Maisonneuve C. *See* Demeilliers C
Maisonneuve P
See Lowenfels AB
See Rulyak SJ
Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londe M. Interleukin 15 Mediates Epithelial Changes in Celiac Disease, 119:996
Maiwald M. *See* Rudi J
Majeed A. *See* Gough M
Majid N. *See* Rabbani GH
Majima M. *See* Boku K
Majumdar APN. *See* Marciniak DJ
Majumdar D. *See* De BK
Mak C. *See* McHutchison JG
Mäki M
See Collin P
See Halttunen T
See Kaukinen K
Makino S. *See* Asakawa A
Makishima M. *See* Denson LA
Makuuchi M. *See* Ijichi M
Mal H. *See* Colle IO
Malagelada JR. *See* Caldarella MP
Malagelada J-R
See Azpiroz F
See Caldarella MP
See Distrutti E
See Fernández-Fraga X
See Junquera F
See Serra J
Malassagne B, Ferret P-J, Hammoud R, Tulliez M, Bedda S, Trébéden H, Jaffrat P, Calmus Y, Weill B, Batteux F. The Superoxide Dismutase Mimetic MnTBAP Prevents Fas-Induced Acute Liver Failure in the Mouse, 121:1451
Malchow H. *See* Hellers G
Malchow HA. *See* Ghosh G
Malesci A. *See* Laghi L
Malfertheiner P. *See* Holtmann G
Malfitano A. *See* Bruno R
Malhi H
See Joseph B
See Wege H
Malhi H, Irani AN, Volenberg I, Schilsky ML, Gupta S. Early Cell Transplantation in LEC Rats Modeling Wilson's Disease Eliminates Hepatic Copper With Reversal of Liver Disease, 122:438
Malik A. *See* Gill N
Malka D, Hammel P, Sauvanet A, Rufat P, O'Toole D, Bardet P, Belghiti J, Bernades P, Ruszniewski P, Lévy P. Risk Factors for Diabetes Mellitus in Chronic Pancreatitis, 119:1324
Malka D, Vasseur S, Bödeker H, Ortiz EM, Dusetti NJ, Verrando P, Dagorn J-C, Iovanna JL. Tumor Necrosis Factor α Triggers Antiapoptotic Mechanisms in Rat Pancreatic Cells Through Pancreatitis-Associated Protein I Activation, 119:816
Malkhosyan SR, Yamamoto H, Piao Z, Perucho M. Late Onset and High Incidence of Colon Cancer of the Mutator Phenotype With Hypermethylated *hMLH1* Gene in Women, 119:598–c
Mallardo G. *See* Canani RB
Mallat A. *See* Li L
Mallet A. *See* Condat B
Mallet AI. *See* Veysey MJ
Mallo GV. *See* Soubeyran P
Mallory MA, Kowdley KV. Hereditary Hemochromatosis and Cancer Risk: More Fuel to the Fire? Comment, 121:1252–ss
Maloisel F. *See* Chamouard P
Malservisi S. *See* Di Stefano M
Maltzman T, Knoll K, Martinez ME, Byers T, Stevens BR, Marshall JR, Reid ME, Einspahr J, Hart N, Bhattacharyya AK, Kramer CB, Sampliner R, Alberts DS, Ahnen DJ. Ki-*ras* Proto-oncogene Mutations in Sporadic Colorectal Adenomas: Relationship to Histologic and Clinical Characteristics, 121:302
Man S. *See* Mayer B
Mancia G
See Piperno A
See Pozzi M
Mandal M, Olson DJ, Sharma T, Vadlamudi RK, Kumar R. Butyric Acid Induces Apoptosis by Up-regulating Bax Expression via Stimulation of the c-Jun N-Terminal Kinase/Activation Protein-1 Pathway in Human Colon Cancer Cells, 120:71
Mandal SK. *See* De BK
Mandanda B. *See* Kelly P
Mandel J. *See* Ederer F
Mandel JS. *See* Baron JA
Mandel JS, Church TR, Bond JH, Ederer

F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. What Will You Be When You Grow Up?, 121:732–ss
Mandelblatt J. *See* Pignone M
Mandelkern M
See Berman SM
See Naliboff BD
Mandelson MT. *See* Ramsey SD
Manesis EK, Hadziyannis SJ. Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B, 121:101
Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV-DNA Levels in Inactive Hepatitis B Virus Carriers, 122:2092–c
Mangelsdorf DJ
See Denson LA
See Jung D
See Repa JJ
Manghetti M. *See* D'Elios MM
Manghisi OG. *See* Rosina F
Mangia A, Santorio R, D'Agruma L, Andriulli A. HCV Chronic Infection and CCR5-Δ32/Δ32, 124:868–c
Mangion J. *See* Tomlinson I
Mangold E. *See* Friedl W
Mankertz J. *See* Bürgel N
Mann DA. *See* Wright MC
Mann EA. *See* Steinecher KA
Mann J. *See* Brant SR
Mann NS
No-Aspirin (NCX 4016), 125:1918–c
Optimal Use of Propranolol, 124:2005–c
Manning AM. *See* Hatano E
Manns M. *See* Poynard T
See Jaeckel E
See McHutchison JG
See Poynard T
See Streetz K
See Teich N
See Zender L
Manns M, Cornberg MC, Jaeckel EM. Acute HCV: The Early Bird Catches the Virus. Reply, 122:1176–ss
Manns MP
See Bahr MJ
See Bock C-T
See Klein C
See Mix H
See Obermayer-Straub P
See Ockenga J
See Strassburg CP
See Streetz KL
See Vogel A
See Wedemeyer H
See Weissenborn K
See Widjaja A
Manns MP, Jaeckel E. Searching for the Needle in the Haystack: Another Candidate Needle in Autoimmune Hepatitis?, 117:728–e
Mannucci R. *See* Fiorucci S
Mansfield J. *See* Cuthbert AP
Mansmann U. *See* Ortner MEJ
Mansour H. *See* Kamal SM
Mansouri A. *See* Demeilliers C
Mansouri A, Gaou I, De Kerguenec C, Amsellem S, Haouzi D, Berson A, Moreau A, Feldmann G, Lettéron P, Pessayre D, Fromenty B. An Alcoholic Binge Causes Massive Degradation of Hepatic Mitochondrial DNA in Mice, 117:181
Mantzaris GJ. Of Ciprofloxacin and Ulcerative Colitis, 117:281–c
Mantzoros C. *See* Mykoniatis A
Maouyo D. *See* Wu S
Marano P. *See* Costamagna G
Marcelin P. *See* Poynard T
Marcellin P
See di Martino V
See Westland C
Marchese-Ragona R. *See* Restivo DA
Marchesini G. *See* Bugianesi E
Marchesini G, Bianchi G, Amodio P, Salerno F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, Abbiati R. Factors Associated With Poor Health-Related Quality of Life of Patients With Cirrhosis, 120:170
Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Fanelli FR, Abbiati R. Nutritional Supplementation With Branched-Chain Amino Acids in Advanced Cirrhosis: A Double-Blind, Randomized Trial, 124:1792
Marcier B. *See* Chen J-M
Marciniak DJ, Moragoda L, Mohammad RM, Yu Y, Nagothu KK, Aboukameel A, Sarkar FH, Adsay VN, Rishi AK, Majumdar APN. Epidermal Growth Factor Receptor-Related Protein: A Potential Therapeutic Agent for Colorectal Cancer, 124:1337
Marcon N. *See* Baron JA
Marcucci MT. *Positive Options for Crohn's Disease, Self-Help and Treatment.*, 120: 317–pmr
Marcus EA. *See* Scott DR
Marcus V. *See* Thompson-Fawcett MW
Mari C. *See* Bortolotti M
Mari T. *See* Marignani M
Maria G, Brisinda G. Chronic Anal Fissure: Advances and Insights in Pathophysiology and Treatment, 125: 995–c
Maria G, Cassetta E, Gui D, Brisinda G, Beutivoglio AR, Albanese A. The Expanding Spectrum of Clinical Uses for Botulinum Toxin: Healing of Chronic Anal Fissures, 116:221–ss
Mariadason JM, Velcich A, Wilson AJ, Augenlicht LH, Gibson PR. Resistance to Butyrate-Induced Cell Differentiation and Apoptosis During Spontaneous Caco-2 Cell Differentiation, 120:889
Mariani L. *See* Bozzetti F
Marien G. *See* Vermeire S
Mariette X. *See* Hermine O
Marignani M, Mari T, Morini S, Angeletti S, Stroffolini T. Elevated Serum Transaminases and Celiac Disease: Possible Modifications of a Diagnostic Algorithm, 125:279–c
Marin IJ. *See* Poljak M
Marinelli RA. *See* Masyuk AI
Marini M
See Boirivant M
See Rivera-Nieves J
Marino CR. *See* Song SY
Marion-Audibert A-M, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle J-A, Partensky C, Scoazec J-Y. Low Microvessel Density Is an Unfavorable Histoprognostic Factor in Pancreatic Endocrine Tumors, 125:1094
Marionneau S, Ruvoën N, Le Moullac-Vaidye B, Clement M, Cailleau-Thomas A, Huang P, Jiang X, Le Pendu J. Norwalk Virus Binds to Histo-Blood Group Antigens Present on Gastroduodenal Epithelial Cells of Secretor Individuals, 122:1967
Mariotti F. *See* Gaudichon C
Märker-Hermann E. *See* May E
Markham AF
See Hamlin PJ
See Scott DJ
Markowitz J, Grancher K, Kohn N, Lesser M, Daum F, Pediatric 6mp Collaborative Group. A Multicenter Trial of 6-Mercaptopurine and Prednisone in Children With Newly Diagnosed Crohn's Disease, 119:895
Markowitz S. *See* Grady WM
Marlowe KJ. *See* McNiven MA
Marmo R. *See* Cipolletta L
Marmuse J-P. *See* Sobhani I
Marra F
See Bonacchi A
See Caligiuri A
See Failli P
Marra F, Efsen A, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of

Peroxisome Proliferator-Activated Receptor γ Modulate Profibrogenic and Proinflammatory Actions in Hepatic Stellate Cells, 119:466
Marra F. Leptin and Liver Fibrosis: A Matter of Fat, 122:1529–e
Marra G
See Boland CR
See Trojan J
Marschall H-M. *See* Wagner M
Marschall H-U. *See* Fickert P
Marschall ZV, Cramer T, Höcker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken E-O, Wiedenmann B, Rosewicz S. De Novo Expression of Vascular Endothelial Growth Factor in Human Pancreatic Cancer: Evidence for an Autocrine Mitogenic Loop, 119:1358
Marshall ACJ, Alderuccio F, Toh B-H. Fas/CD95 Is Required for Gastric Mucosal Damage in Autoimmune Gastritis, 123:780
Marshall BA. *See* Boushey RP
Marshall J. *See* Cook D
Marshall JB. Treatment of Patients With Dysphagia Caused by Benign Disorders of the Distal Esophagus, 118:235–c
Marshall JK. *See* Irvine EJ
Marshall JR
See Alberts DS
See Maltzman T
See Martínez ME
Marshall S. *See* Ahmad T
Marshall SE
See Ahmad T
See Satsangi J
Marsicano G. *See* Izzo AA
Marteau P. *See* Dray X
Marten K, Bremer C, Khazaie K, Sameni M, Sloane B, Tung C-H, Weissleder R. Detection of Dysplastic Intestinal Adenomas Using Enzyme-Sensing Molecular Beacons in Mice, 122:406
Marth T. *See* Fuss IJ
Marth T, Kleen N, Stallmach A, Ring S, Aziz S, Schmidt C, Strober W, Zeitz M, Schneider T. Dysregulated Peripheral and Mucosal Th1/Th2 Response in Whipple's Disease, 123:1468
Martí-Climent JM. *See* Prieto J
Martin A. *See* Benamouzig R
Martin C. *See* Sandborn WJ
Martin C, Connelly A, Keku TO, Mountcastle SB, Galanko J, Woosley JT, Schliebe B, Lund PK, Sandler RS. Nonsteroidal Anti-inflammatory Drugs, Apoptosis, and Colorectal Adenomas, 123:1770
Martin E. *See* De la Concha EG
Martin K. *See* Radlmayr M
Martin LG. *See* Chalasani N
Martin NG. *See* Radford-Smith GL
Martin P
See Dubinsky MC
See Saab S
Martin P. *The Oxford Textbook of Clinical Hepatology*, 118:449–pmr
Martin S, Navarro V, Vincent JP, Mazella J. Neurotensin Receptor-1 and -3 Complex Modulates the Cellular Signaling of Neurotensin in the HT29 Cell Line, 123:1135
Martin SL, McColm AA, Appelmelk BJ. *H. pylori* Adhesion and Lewis X, 119:1414–c
Martin SP. *See* Somogyi L
Martin V. *See* Buzoni-Gatel D
Martín-Duce A. *See* Martínez-Chantar ML
Martinez C. *See* Abad C
Martinez ME
See Alberts DS
See Maltzman T
Martínez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma Characteristics as Risk Factors for Recurrence of Advanced Adenomas, 120:1077
Martínez-Chantar ML. *See* García-Trevijano ER
Martínez-Chantar ML, García-Trevijano ER, Latasa MU, Martín-Duce A, Fortes P, Caballería J, Avila MA, Mato JM. Methionine Adenosyltransferase II β Subunit Gene Expression Provides a Proliferative Advantage in Human Hepatoma, 124:940
Martino MC. *See* Dorrell N
Martino R, Terrault N, Ezerzer F, Mikulis D, Diamant NE. Dysphagia in a Patient With Lateral Medullary Syndrome: Insight Into the Central Control of Swallowing, 121:420–cr
Martinot M. *See* di Martino V
Martín-Ruiz R. *See* Ros J
Martín-Sanz P. *See* Callejas NA
Martinsson T. *See* Björk J
Martucci S, Corazza GR. Spreading and Focusing of Gluten Epitopes in Celiac Disease, 122:2072–e
Marty J. *See* Colle IO
Marucci L
See Alvaro D
See LeSage G
Maruo Y. *See* Ishihara T
Maruyama H. *See* Kleeff J
Marvaldi J
See André F
See Soubeyran P
Marvizon JC. *See* Mayer EA
Marx C. *See* Schwab M
Marzioni M. *See* Alpini G
Mas A. *See* Sánchez-Tapias JM
Masala G. *See* Palli D
Masamune A
See Sakai Y
See Satoh A
Masamune A, Shimosegawa T, Masamune O, Makaida N, Koizumi M, Toyota T. *Helicobacter pylori*-Dependent Ceramide Production May Mediate Increased Interleukin 8 Expression in Human Gastric Cancer Cell Lines, 116:1330
Masamune O. *See* Masamune A
Mascheretti S
See Croucher PJP
See Cuthbert AP
See Hampe J
Mascolo N
See Izzo AA
See Pinto L
Masferrer JL. *See* Bosch-Marcé M
Mashima H. *See* Ueda N
Mashimo H, Kjellin A, Goyal RK. Gastric Stasis in Neuronal Nitric Oxide Synthase-Deficient Knockout Mice, 119:766
Mashimo HL. *See* Sivarao DV
Masini EM. *See* Cianchi F
Masoero G. *See* Fracchia M
Mason JB. *See* Kim Y-I
Mason R. *See* Corley DA
Mason RP
See McKim SE
See Wheeler MD
Massaguer A. *See* Graupera M
Massey B. *See* Shaker R
Massironi S, Basilisco G. Should Patients With IBS Be Submitted to Painful Rectal Distention in Clinical Practice?, 124:863–c
Masson J. *See* Church NI
Masson R. *See* Tomasetto C
Masubuchi Y, Masuda E, Horie T. Multiple Mechanisms in Indomethacin-Induced Impairment of Hepatic Cytochrome P450 Enzymes in Rats, 122:774
Masuda E. *See* Masubuchi Y
Masuda K. *See* Kuno A
Masyuk AI. *See* Masyuk TV
Masyuk AI, Gong A-Y, Kip S, Burke MJ, LaRusso NF. Perfused Rat Intrahepatic Bile Ducts Secrete and Absorb Water, Solute, and Ions, 119:1672
Masyuk AI, Marinelli RA, LaRusso NF. Water Transport by Epithelia of the Digestive Tract, 122:545–srr

Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, Punyashthiti R, Ritman EL, Torres VE, Harris PC, LaRusso NF. Defects in Cholangiocyte Fibrocystin Expression and Ciliary Structure in the PCK Rat, 125:1303–rc
Matczak E. Human Papillomavirus Infection: An Emerging Problem in Anal and Other Squamous Cell Cancers, 120:1046–e
Matern S
See Gerloff T
See Hillebrandt S
Mathew CG
See Croucher PJP
See Cuthbert AP
Mathews CJ, MacLeod RL, Zheng S-X, Hanrahan JW, Bennett HPJ, Hamilton JR. Charcterization of the Inhibitory Effect of Boiled Rice on Intestinal Chloride Secretion in Guinea Pig Crypt Cells, 116:1342
Mathieu D, Kobeiter H, Maison P, Rahmouni A, Cherqui D, Zafrani ES, Dhumeaux D, 118: 560
Mathurin P. *See* Sobesky R
Matias I
See Izzo AA
See Ligresti A
Maticic M. *See* Poljak M
Mato JM
See García-Trevijano ER
See Martínez-Chantar ML
Matrisian LM. *See* Crawford HC
Matsuda K. *See* Kornmann M
Matsuda Y. *See* Maeyama H
Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. *p*16INK4 Is Inactivated by Extensive CpG Methylation in Human Hepatocellular Carcinoma, 116:394
Matsuguchi T. *See* Shimizu H
Matsuhashi N
See Nakajima A
See Osawa E
Matsui H. *See* Noguchi H
Matsui M. *See* Aihara T
Matsui SM. A New Model System to Study Norwalk Virus Immunity, 117:255–e
Matsukura A. *See* Otani T
Matsukura S. *See* Date Y
Matsumoto A, Hamamoto N, Kayazawa M. Balloon Endoscopic Sclerotherapy, a Novel Treatment for High-Risk Gastric Fundal Varices: A Pilot Study, 117:515–c
Matsumoto H. *See* Kamada Y
Matsumoto S. *See* Burns RC
Matsumoto Y. *See* Kusama T
Matsumura M. *See* Ijichi M
Matsuno K. *See* Uwatoku R
Matsuno S
See Kakyo M
See Shibata C
Matsuo H. *See* Date Y
Matsushima Y. *See* Ohana M
Matsushita E. *See* Honda M
Matsushita M. *See* Okazaki K
Matsushita S. *See* Shimoda S
Matsutani M. *See* Green PHR
Matsuura N. *See* Yamamoto H
Matsuzaki H. *See* Schneider MB
Matsuzaki K, Nagao S, Kawaguchi A, Miyazaki J, Yoshida Y, Kitagawa Y, Nakajima H, Kato S, Hokari R, Tsuzuki Y, Itoh K, Niwa H, Miura S. Combo Cap Takes a Big Bite, Yet a Smoothie to Swallow, 125:621–ss
Matsuzawa J. *See* Matsuda Y
Matsuzawa Y
See Kamada Y
See Kiso S
See Miyazaki Y
Matsuzawa Y , 120:108
Mattapallil JJ, Dandekar S, Canfield DR, Solnick JV. A Predominant Th1 Type of Immune Response Is Induced Early During Acute *Helicobacter pylori* Infection in Rhesus Macaques, 118: 307
Matteoni C. *See* Bauer WM
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathological Severity, 116:1413
Matteuzzi D. *See* Gionchetti P
Matthews JB
See Gastwirt PC
See Mun EC
See Prasad M
See Riegler M
Matthews JB
Comment from the Editors, 118:461–ce
Minimally Invasive Surgery: How Goes the Revolution?, 116:513–ce
Matthews JB. Comment From the Editors, 120:1075–ce
Mattioli M. *See* Fracanzani AL
Mattson C. *See* Myrvold HE
Mattsson A, Lonroth H, Quiding-Jarbrink M, Svennerholm A-M. Mucosal Vaccination: "All Politics Are Local," 116:497–ss
Mattsson L. *See* Chen M
Matuchansky C
See Crenn P
See Messing B
Matulewicz T. *See* Pedowitz SD
Matysiak-Budnik T. *See* Benahmed M
Matysiak-Budnik T, Candalh C, Dugave C, Namane A, Cellier C, Cerf-Bensussan N, Heyman M. Alterations of the Intestinal Transport and Processing of Gliadin Peptides in Celiac Disease, 125:696
Matz B. *See* Woitas RP
Mauldin J. *See* Alpini G
Maung R. *See* Huntsman DG
Maurage C. *See* Cézard JP
Maurer KR. *See* Everhart JE
Maurer WG. *See* Vargo JJ
Mawe GM. *See* Guarraci FA
Máximo V, Soares P, Machado JC, Seruca R, Sobrinho-Simoes M. Mitochondrial DNA Alteration in Gastric Cancer, 119:1808–c
May E, Märker-Hermann E, Wittig BM, Zeitz M, Büschenfelde K-HMZ, Duchmann R. Identical T-Cell Expansions in the Colon Mucosa and the Synovium of a Patient With Enterogenic Spondyloarthropathy, 119: 1745–cr
Maydonovitch CL. *See* Hirota WK
Mayer B, Klement G, Kaneko M, Man S, Jothy S, Rak J, Kerbel RS. Multicellular Gastric Cancer Spheroids Recapitulate Growth Pattern and Differentiation Phenotype of Human Gastric Carcinomas, 121:839
Mayer EA
See Berman SM
See Gralnek IM
See Mertz H
See Naliboff BD
Mayer EA, Collins SM. Evolving Pathophysiologic Models of Functional Gastrointestinal Disorders, 122:2032–srr
Mayer EA, Derbyshire S, Naliboff BD. Cerebral Activation in Inflammatory Bowel Syndrome, 119:1418–c
Mayer EA, Marvizon JC. Neurokinin 3 Receptors in the Gut: A New Target for the Treatment of Visceral Pain?, 116:1250–e
Mayer J. *See* Jaeckel E
Mayer JM. *See* Berger HG
Mayer L
See Allez M
See Rutgeerts P
See Sandborn WJ
Mayer L
Comment From the Editor, 123:665–ce
Redefining Autoimmunity, 125:1574–ce
Mayer LF
See Hanauer SB
See van de Wal Y
Mayer M. *See* Lochs H
Mayer RJ. *See* Green RJ
Mayerle J, Friess H, Büchler MW, Schnekenburger J, Weiss FU, Zimmer

K-P, Domschke W, Lerch MM. Up-Regulation, Nuclear Import, and Tumor Growth Stimulation of the Adhesion Protein p120^{ctn} in Pancreatic Cancer, 124:949
Mayne ST. *See* El-Omar EM
Mays DC
See Lowry PW
See Sandborn WJ
Mayumi T. *See* Katayama K
Mazaki T, Tomioka K, Takayama T. Image of the Month, 123:1762–im
Mazelin L. *See* Ferrier L
Mazella J. *See* Martin S
Mazet B. *See* Lu G
Mazzaferro V. *See* Perseghin G
Mazzanti R. *See* Cianchi F
Mazzetti L. *See* Caligiuri A
Mazzocchi V. *See* La Villa G
Mazzola L. *See* Brand SJ
McAdam SN. *See* Arentz-Hansen H
McAulay KA. *See* Newsome PN
McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. Increasing the *RISC* for HCV, 125: 1546–ss
McCallum R. *See* Abell T
McCashland T. *See* Sanyal AJ
McCaughan GW
See Bowen DG
See Hui JM
McClain CJ. *See* Morgan TR
McClane B. *See* Michl P
McColl KEL
See El-Omar E
See El-Omar EM
See Fletcher J
See Gillen D
See Iijima K
See Mowat C
McColl KEL, El-Omar E. E-Cadherin Germline Mutations and Risk of Gastric Cancer, 123:1406–co
McColl KEL, Gillen D. Rebound Hypersecretion After Omeprazole. Reply, 117:513–c
McColl KEL, Murray LS, El-Omar EM. *H. pylori* and Nonulcer Dyspepsia: Not Guilty As Charged. Reply, 117:270–ss
McColl KEL, Murray LS, Gillen D. Omeprazole and Accelerated Onset of Atrophic Gastritis, 118:239–c
McColm AA
See Dorrell N
See Martin SL
McCormack SA. *See* Ray RM
McCormick BA. *See* Hisamatsu T
McCuen R. *See* Zaki M
McCullough AJ. *See* Matteoni CA
McCuskey RS. *See* Joseph B
McCusky RS. *See* Dvorak B
McDermott DH. *See* Promrat K
McDonald D. *See* Chitturi S
McDonald JWD
See Feagan BG
See Sandborn WJ
McDonald KG. *See* Gurtner GJ
McDonald TJ. *See* Abou-Saif A
McDonald V. *See* Pollok RCG
McDonald WF. *See* Jeffers M
McDuffie M. *See* Kozaiwa K
McDuffie MJ. *See* Rivera-Nieves J
McEwen SB. *See* Kozaiwa K
McFarland EG. *See* Johnson CD
McGee DJ. *See* Gobert AP
McGhee JR. *See* Dohi T
McGovern D. *See* Fraser AG
McGovern DPB, Travis SPL, Duley J, Shobowale-Bakre EM, Dalton HR. Azathioprine Intolerance in Patients With IBD May Be Imidazole-Related and Is Independent of TPMT Activity, 122:838–c
McHutchison J. *See* Poynard T
McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud J-J, Albrecht JK. Adherence to Combination Therapy Enhances Sustained Response in Genotype-1-Infected Patients With Chronic Hepatitis C, 123:1061
McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J. The Impact of Interferon Plus Ribavirin on Response to Therapy in Black Patients With Chronic Hepatitis C, 119:1317
McIntyre E. *See* Mention J-J
McIntyre M. *See* Gillett HR
McKaigney C. *See* Madsen K
McKay DM
See Lu J
See Yu LCH
McKeown-Eyssen G. *See* Baron JA
McKie AT
See Frazer DM
See Zoller H
McKim SE, Gäbele E, Isayama F, Lambert JC, Tucker LM, Wheeler MD, Connor HD, Mason RP, Doll MA, Hein DW, Arteel GE. Inducible Nitric Oxide Synthase Is Required in Alcohol-Induced Liver Injury: Studies With Knockout Mice, 125:1834
McKinley MJ. *See* Slonim AE
McKinsey DS, Trotter JF. Vegetative Infection of TIPS Leading to "Endotipsitis"?, 116:779–c
McKinzie S
See Bouras EP
See Camilleri M
See Coulie B
See Prather CM
McKnight W
See Fiorucci S
See Wallace JL
McKusick A. *See* Kaplan MM
McLaren CE. *See* Theuer CP
McLaughlin J, Lucà MG, Jones MN, D'Amato M, Dockray GJ, Thompson DG. Fatty Acid Chain Length Determines Cholecystokinin Secretion and Effect on Human Gastric Motility, 116:46
McLean AJ. *See* Harvey PJ
McLean AJ, Le Couteur DG, Heinzow BG. Hepatic Artery Flow Change and Hepatocyte Oxygenation in Human Cirrhosis, 117:1256–c
McLellan A. *See* Cook D
McLeod RS. *See* Thompson-Fawcett MW
McMahon BJ. *See* Snowball M
McMichael AJ. *See* Maini MK
McNamara BP, Koutsouris A, O'Connell CB, Nougayréde J-P, Donnenberg MS, Hecht G. Molecular Dissection of the Mechanisms Through Which Enteropathogenic *Escherichia coli* Induce Diarrhea, 121:496–ss
McNiven MA
See Chen X-M
See Török NJ
McNiven MA, Marlowe KJ. Contributions of Molecular Motor Enzymes to Vesicle-Based Protein Transport in Gastrointestinal Epithelial Cells, 116: 438–srr
McPhaul LW, Wang J, Hol EM, Sonnemans MAF, Riley N, Nguyen V, Xiao Yuan Q, Lue YH, van Leeuwen FW, French SW. Molecular Misreading of the Ubiquitin B Gene and Hepatic Mallory Body Formation, 122:1878
McQuaid KR. *See* Garcia RT
McRae CA, Prince MI, Hudson M, Day CP, James OFW, Jones DEJ. Pain as a Complication of Use of Opiate Antagonists for Symptom Control in Cholestasis, 125:591–cr
McRoberts JA. *See* Abreu MT
McWilliam DL. *See* Dvorak B
Meagher A. *See* Hawkins N
Means AL, Ray KC, Singh AB, Washington MK, Whitehead RH, Harris RC Jr, Wright CVE, Coffey RJ Jr, Leach SD. Overexpression of Heparin-Binding EGF-Like Growth Factor in Mouse Pancreas Results in Fibrosis and Epithelial Metaplasia, 124:1020

Mearin L. *See* Vader W
Mechet I. *See* Boillot O
Meckel S. *See* Grimm CF
Mecklenbeck S. *See* Zimmer K-P
Mecklin J-P
See Hemminki A
See Vasen HFA
Meda F. *See* Selmi C
Meddings J
See Brown GR
See Buret AG
Meddings JB
See Scott KG-E
See Thjodleifsson B
Meddings JB, Swain MG. Environmental Stress Induces a Generalized Increase in Gastrointestinal Permeability Mediated by Endogenous Glucocorticoids in the Rat, 119:1019
Mediavilla JD. *See* Hidalgo-Tenorio C
Medina J. *See* Repa JJ
Medina JF
See Alvaro D
See Lucena J-F
See Prieto J
Medina ND. *See* He D
Meerman L, Koopen NR, Bloks V, van Goor H, Havinga R, Wolthers BG, Kramer W, Stengelin S, Müller M, Kuipers F, Jansen PLM. Biliary Fibrosis Associated With Altered Bile Composition in a Mouse Model of Erythropoietic Protoporphyria, 117:696
Meglic J. *See* Poljak M
Mégraud F
See Lind T
See van Doorn L-J
Meguid MM. *See* Asakawa A
Mehal WZ, Azzaroli F, Crispe IN. Immunology of the Healthy Liver: Old Questions and New Insights, 120:250–srr
Mehdi SA. *See* Gill N
Meier E. *See* Miehlke S
Meier MA. *See* Romagnuolo J
Meier P. *See* Steiner M
Meier PJ
See Fickert P
See Gerloff T
See Ismair MG
See Jung D
See Kullak-Ublick GA
See Lee JM
See Noé J
See Reichel C
See Stieger B
Meijer CJLM. *See* Hausen AZ
Meijer DKF. *See* Hooiveld GJEJ
Meijer G
See French SJ
See Hermsen M
Meijer GA. *See* Hausen AZ
Meijer JWR. *See* Van Belzen MJ
Meijers JCM. *See* Lisman T
Meining A. *See* Stolte M
Mekalanos JJ. *See* Guo BP
Mekus F. *See* Bronsveld I
Melani L. *See* Tountas NA
Melgar S. *See* Forsberg G
Meling GI
See Duval A
See Thornstensen L
Meller WH. *See* Faris PL
Mello T. *See* Galli A
Mellon A. *See* Zhang M
Meloche RM. *See* Buchan AMJ
Melpolder JC. *See* Farci P
Melton LJ III
See Bambha K
See Kim WR
See Loftus EV Jr
Meltzer S. *See* Fleischer AD
Meltzer SJ
See Fu S
See Selaru FM
Meltzer SJ. Tumor Genomics *vs.* Tumor Genetics: A Paradigm Shift?, 121: 726–e
Memoli A. *See* Zarrilli R
Ménard D. *See* Tremblay E
Mencarelli A
See Fiorucci S
See Santucci L
Menconi MJ7. *See* Tomita M
Méndez-Sánchez N. Bile Acids, Cholesterol, Gallstone Calcification, and the Enterohepatic Circulation of Bilirubin. Reply, 116: 1277–c
Méndez-Sánchez N, Reyes MT, Corona R, Uribe M. Image of the Month, 123: 666–im
Méndez-Sánchez N, Uribe M. Intestinal Motility and Bacterial Overgrowth in Patients With Gallstones, 120: 1311–c
Mendler M-H, Turlin B, Moirand R, Jouanolle A-M, Sapey T, Guyader D, Le Gall J-Y, Brissot P, David V, Deugnier Y. Insulin Resistance-Associated Hepatic Iron Overload, 117:1155
Mendoza H. *See* Zanlungo A
Mendoza ME. *See* Thwaites DT
Mendz GL. *See* Gobert AP
Menezes de Lima O Jr. *See* Fiorucci S
Meng G. *See* Li L
Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham MF, Kappes JC, Mestecky J, Shaw GM, Smith PD. Viral Discrimination and Subversion of Host Defense at the Epithelial Gateway, 123:947–ss
Mengel M. *See* Gongoll S
Mengotti C. *See* Bourlière M
Mennechet FJD
See Buzoni-Gatel D
See Luangsay S
Mennechet FKD. *See* Li W
Mennone A
See Gigliozzi A
See Nathanson MH
Mentha G. *See* Spahr L
Mention J-J
See Benahmed M
See Verkarre V
Mention J-J, Ben Ahmed M, Bègue B, Barbe U, Verkarre V, Asnafi V, Colombel J-F, Cugnenc P-H, Ruemmele FM, McIntyre E, Brousse N, Cellier C, Cerf-Bensussan N. Interleukin 15: A Key to Disrupted Intraepithelial Lymphocyte Homeostasis and Lymphomagenesis in Celiac Disease, 125:730
Menzel J. Duplex Ultrasonography of TIPS: How Useful Is It?, 116:1272–c
Mercer DW. *See* Helmer KS
Merchant JL. *See* Zavros Y
See Rathinavelu S
See Zavros Y
Merger M, Harfarth H, Scholmerich J, Andus T, Färber L. Discussion on the Biologic Therapy of Inflammatory Bowel Disease, 124:2005–c
Meri S. *See* Rautemaa R
Merighi A. *See* Camellini L
Merion RM. *See* Wiesner R
Merkel C. *See* Patch D
Merkel C, Gatta A. β-Blocker Plus Nitrate for Primary Prophylaxis of Variceal Bleeding. Reply, 119:1170–ss
Merkle H. *See* Paxian S
Merle V. *See* Michel P
Merli M. *See* Marchesini G
Merlin F. *See* Vermeire S
Merrell M. *See* Promrat K
Mertens T. *See* Sträter J
Mertz H, Fullerton S, Naliboff B, Mayer EA. The Curse of the Functional Dyspeptic: Too Sensitive a Visceral Afferent Nervous System?, 116:495–ss
Mertz H, Kessler R. Cerebral Activation in Inflammatory Bowel Syndrome. Reply, 119:1418–c
Mertz H, *Rome II: The Functional Gastrointestinal Disorders*, 121:1523–pmr
Messerini L. *See* Cianchi F
Messing B. *See* Crenn P
See Crenn P
See Seguy D

Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud J-C, Matuchansky C. Long-term Survival and Parenteral Nutrition Dependence in Adult Patients With the Short Bowel Syndrome, 117:1043
Mestecky J. *See* Meng G
Mestermann S. *See* Hausmann M
Meszoely IM. *See* Song SY
Metcalf JV. *See* Prince M
Metges CC. *See* Gaudichon C
Metivier E. *See* Vautier G
Metlay JP. *See* Green RJ
Metwally MA, Zein CO, Zein NN. Regression of Hepatic Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C Treated With Interferon-Based Therapy, 124:1561–c
Metz C. *See* Huang XR
Metz DC
See Blam ME
See Loren DE
Metz MA. *See* Theodorakis NG
Metzler J. *See* Schwab M
Meucci C. *See* Cipolletta L
Meucci M. *See* Caligiuri A
Meuer SC. *See* Stallmach A
Meunier-Rotival M. *See* Crosnier C
Meuse L. *See* McCaffrey AP
Meuwissen SGM
See Hausen AZ
See Kuipers EJ
Meyer A. *See* Chamouard P
Meyer D. *See* Veyradier A
Meyer K. *See* Drossman DA
Meyer M
See Cézard JP
See Viola S
Meyer UA. *See* Jung D
Meyerhans A. *See* Schmidt W
Meyers WC. *Textbook of Bilio-Pancreatic Diseases*, 116:776–pmr
Meyerson SM. *See* Fazel A
Meziere TL. *See* Gruy-Kapral C
Mezzogiorno A. *See* de Magistris L
Miao YM, Amin A, Healy J, Burn P, Murugan N, Westaby D, Allen-Mersh YG. Virtual Virtual Colonoscopy?, 121:221–ss
Micci M-A. *See* Toma H
Micci M-A, Learish RD, Li H, Abraham BP, Pasricha PJ. Neural Stem Cells Express RET, Produce Nitric Oxide, and Survive Transplantation in the Gastrointestinal Tract, 121:757
Michael J. *See* Tomita M
Michalak A. *See* Rose C
Michalak S. *See* Grimm CF
Michalik L. *See* Hellemans K
Michalopoulos GK. *See* Monga SPS
Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, Czernichow P, Colin R. Postoperative Management of Stage II/III Colon Cancer: A Decision Analysis, 117:784
Michel V. *See* Touati E
Michelassi F. *See* Pedrazzoli S
Michetti M, Kelly CP, Kraehenbuhl J-P, Bouzourene H, Michetti P. Gastric Mucosal $\alpha_4\beta$--Integrin-Positive CD4 T Lymphocytes and Immune Protection Against *Helicobacter* Infection in Mice, 119:109
Michetti P
See Farrell RJ
See Michetti M
Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco J-L, Bachmann D, Herranz M, Saldinger PF, Corthésy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL. Oral Immunization With Urease and *Escherichia coli* Heat-Labile Enterotoxin Is Safe and Immunogenic in *Helicobacter pylori*-Infected Adults, 116:804
Michielsen PP
See Hautekeete ML
See Schalm SW
Michl P. *See* Weber CK
Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM. Claudin-4: A New Target for Pancreatic Cancer Treatment Using *Clostridium perfringens* Enterotoxin, 121:678
Michopoulos S. Barrett's Esophagus and Heater Probe, 124:2008–c
Mick R. *See* Dai CY
Middlesworth L van. *See* Deng W
Midolo P. *See* van Doorn L-J
Miehlke S, Heymer P, Bethke B, Bästlein E, Meier E, Bartram H-P, Wilhelms G, Lehn N, Dorta G, Delarive J, Tromm A, Bayerdörffer E, Stolte M. Budesonide Treatment for Collagenous Colitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, 123:978
Mieli-Vergani G. *See* Byrne JA
Mierau GW. *See* Kurbegov AC
Miettinen P
See Lundell L
See Myrvold HE
Mifflin RC. *See* di Mari JF
Miglietti M. *See* Fiorucci S
Miglioli M
See Bortolotti M
See Calabrese C
See Gionchetti P
Mignogna MD, Fedele S, Russo LL, Ruoppo E, Muzio LL. Unexpected Low Incidence of Oral Lichen Planus in an HCV Hyperendemic Area of Southern Italy, 121:1528–c
Mignon M
See Cadiot G
See Sobhani I
Mignotte B. *See* Millet A
Mihas AA
See Foody W
See Heuman DM
Mikayama T. *See* Kita H
Miki H. *See* Nakajima A
Mikolainis S. *See* Steinhart AH
Mikula K. *See* Drossman DA
Mikulaninec C. *See* Pineau BC
Mikulis D. *See* Martino R
Milani S. *See* Bonacchi A
Milano A. *See* Caldarella MP
Milano G. *See* Bras-Gonçalves RA
Milano J. *See* Sauter BV
Milazzo L. *See* Zehender G
Milella M. *See* Schalm SW
Milich DR. *See* Chen M
Do T Cells "See" the Hepatitis B Core and e Antigens Differently?, 116:765–e
Milione M. *See* Peghini PL
Milla PJ
See Pitera JE
See Ruuska TH
Milla PJ. Irritable Bowel Syndrome in Childhood, 120:287–e
Miller CM. *See* Liu LU
Miller FH. *See* Johnson CD
Miller GA. *See* Terdiman JP
Miller LJ
See Chari ST
See Coulie BJ
See Ding W-Q
See Sternini C
Miller M. *See* Westland C
Miller ME. *See* Greenhalgh CJ
Miller MJS. *See* Wallace JL
Miller RT. *See* Weiner ID
Miller SD. *See* Lee H-O
Miller SM. *See* Holm AN
Miller-Catchpole R. *See* Caplan MS
Millet A, Bettaieb A, Renaud F, Prevotat L, Hammann A, Solary E, Mignotte B, Jeannin J-F. Influence of the Nitric Oxide Donor Glyceryl Trinitrate on Apoptotic Pathways in Human Colon Cancer Cells, 123:235
Million M
See Luckey A
See Maillot C
Mills AS. *See* Shiffman ML
Mills JC, Andersson N, Hong CV, Stappenbeck TS, Gordon JI. Zeroing in on the "Holy Grail," 125:266–ss

Mills JC, Stappenbeck TS, Gordon JI. Zeroing in on the "Holy Grail." Reply, 125:267–ss
Mills PR. *See* Lui HF
Mills T. *See* Hong F
Min AD
See Chu C-J
See Liu LU
Min Shin D. *See* Young Kim J
Minami S. *See* Maeyama H
Minamoto T. *See* Ougolkov AV
Minana J. *See* Villanueva C
Miñana J. *See* Villanueva C
Mine T. *See* Ohnishi H
Minello-Franza A. *See* Féray C
Miner PB Jr. *See* Sands BE
Minetola L. *See* Alvaro D
Minguez M, Herreros B, Espi A, Garcia-Granero E, Sanchiz V, Mora F, Lledo S, Benages A. Long-term Follow-up (42 Months) of Chronic Anal Fissure After Healing With Botulinum Toxin, 123:112
Minguzzi L. *See* Di Stefano M
Minich DM. *See* Voshol PJ
Minno G di. *See* Madonna P
Minns LA. *See* Luangsay S
Minocha A. *See* Lavu K
Minoshima S. *See* Ladabaum U
Mintchev MP, Sanmiguel CP, Amaris M, Bowes KL. Microprocessor-Controlled Movement of Solid Gastric Content Using Sequential Neural Electrical Stimulation, 118:258
Minuk GS. *See* Poynard T
Minuk GY. *See* Zhang M
Mion F. *See* Boillot O
Miquel JF. *See* Zanlungo A
Miquel R. *See* Bessa X
Mirin B. *See* Sobhani I
Miró JRA. *See* Junquera F
Mirshahi F. *See* Sanyal AJ
Mirza MM
See Cuthbert AP
See Hampe J
Mirza ZK. *See* Lin JL-C
Mishra A. *See* Straumann A
Mishra A, Rothenberg ME. Intratracheal IL-13 Induces Eosinophilic Esophagitis by an IL-5, Eotaxin-1, STAT6-Dependent Mechanism, 125:1419
Misra R. *See* Landers CJ
Mita E. *See* Takehara T
Mitchell S. *See* Satsangi J
Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW. A Preliminary Trial of High-Dose Ursodeoxycholic Acid in Primary Sclerosing Cholangitis, 121:900
Mithieux G. *See* Rajas F
Mitic LL. *See* Rahner C
Mitjans F. *See* Bessa X
Mitrani C. *See* Desautels SG
Mitsuno Y
See Hirata Y
See Maeda S
Mittal RK. *See* Balaban DH
Mittal RK, Kassab GS. Esophagogastric Junction Opening: Does it Explain the Difference Between Normal Subjects and Patients With Reflux Disease?, 125:1258–e
Mittermaier C. *See* Dejaco C
Miura N
See Roelofsen H
See Yamamoto M
Miura S
See Fujimori H
See Matsuzaki K
Miwa H. *See* Enomoto N
Mix H, Manns MP, Wagner S, Widjaja A, Brabant G. Expression of Leptin and Its Receptor in the Human Stomach, 117:509–c
Miyagawa J-I
See Kamada Y
See Kiso S
Miyakawa Y. *See* Sugauchi F
Miyake M. *See* Hashida H
Miyakura Y, Sugano K, Konishi F, Ichikawa A, Maekawa M, Shitoh K, Igarashi S, Kotake K, Koyama Y, Nagai H. Extensive Methylation of h*MLH*1 Promoter Region Predominates in Proximal Colon Cancer With Microsatellite Instability, 121:1300
Miyamoto K-I. *See* Shiraga T
Miyamoto M. *See* Kato T
Miyanishi K. *See* Takayama T
Miyanishi K, Takayama T, Ohi M, Hayashi T, Nobuoka A, Nakajima T, Takimoto R, Kogawa K, Kato J, Sakamaki S, Niitsu Y. Glutathione S-Transferase-π Overexpression Is Closely Associated With K-*ras* Mutation During Human Colon Carcinogenesis, 121:865
Miyazaki J. *See* Matsuzaki K
Miyazaki J-I. *See* Ueno N
Miyazaki M. *See* Cohen P
Miyazaki Y, Hiraoka S, Tsutsui S, Kitamura S, Shinomura Y, Matsuzawa Y. Epidermal Growth Factor Receptor Mediates Stress-Induced Expression of Its Ligands in Rat Gastric Epithelial Cells, 120:108
Miyazaki Y, Shinomura Y, Tsutsui S, Zushi S, Higashimoto Y, Kanayama S, Higashiyama S, Taniguchi N, Matsuzawa Y. Gastrin Induces Heparin-Binding Epidermal Growth Factor-like Growth Factor in Rat Gastric Epithelial Cells Transfected With Gastrin Receptor, 116:78
Miyoshi E. *See* Capurro M
Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte Apoptosis After Bile Duct Ligation in the Mouse Involves Fas, 117:669
Mizerski J. *See* Jonas MM
Mizoguchi A. *See* Mizoguchi E
Mizoguchi A, Mizoguchi E, Bhan AK. The Critical Role of Interleukin 4 but Not Interferon Gamma in the Pathogenensis of Colitis in T-Cell Receptor α Mutant Mice, 116:320
Mizoguchi A, Mizoguchi E, Saubermann LJ, Higaki K, Blumberg RS, Bhan AK. Limited CD4 T-Cell Diversity Associated With Colitis in T-Cell Receptor α Mutant Mice Requires a T Helper 2 Environment, 119:983
Mizoguchi E. *See* Mizoguchi A
See de Jong YP
See Mizoguchi A
Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, Ooi CJ, Xavier RJ, Terhorst C, Podolsky DK, Bhan AK. Role of Tumor Necrosis Factor Receptor 2 (TNFR2) in Colonic Epithelial Hyperplasia and Chronic Intesinal Inflammation in Mice, 122: 134
Mizoguchi E, Xavier RJ, Reinecker H-C, Uchino H, Bhan AK, Podolsky DK, Mizoguchi A. Colonic Epithelial Functional Phenotype Varies With Type and Phase of Experimental Colitis, 125:148
Mizokami M. *See* Sugauchi F
See Kato T
See Sugauchi F
Mizue Y. *See* Ohkawara T
Mizuguchi H. *See* Katayama K
Mizumoto A. *See* Suzuki A
Mizuno M. *See* Yokota K
Mizuta Y. *See* Takahashi T
Moayyedi P. *See* Jankowski JA
Moayyedi P, Axon A. Population Screening and Treatment of *Helicobacter Pylori*. Reply, 119:1795–ss
Moayyedi P, Bardhan KD, Young L, Dixon MF, Brown L, Axon ATR. *Helicobacter pylori* Eradication Does not Exacerbate Reflux Symptoms in Gastroesophageal Reflux Disease, 121:1120–
Mobley HLT. *See* Gobert AP
Mocetti E. *See* Raevaara TE
Modigliani R
See Hugot J-P
See Sandborn WJ

Modlin IM
See Koelz HR
See Läuffer JM
See Peek RM Jr
Moffatt JD. *See* Cocks TM
Moffett J
See Rings EHHM
See Silberg DG
Mogyorosi A, Schubert ML. Dialysis-Related Amyloidosis: An Important Cause of Gastrointestinal Symptoms in Patients With End-Stage Renal Disease. Comment, 116:218–ss
Mogyorósi A, Schubert ML. Intravenous Albumin Reduces Mortality in Patients With Spontaneous Bacterial Peritonitis. Comment, 118:232–ss
Mogyorósi A, Schubert ML. Peritoneal Dialysis: An Under-Appreciated Cause of Acute Pancreatitis. Comment, 119: 1407–ss
Mohammad B. *See* Weissenborn K
Mohammad RM. *See* Marciniak DJ
Mohanty SP, Morgan D. *Healing Heartburn*, 124:860–pmr
Mohr L
See Geissler M
See Grimm CF
Mohr S. *See* Sturm A
Moine O Le. *See* Maertelaer V de
Moirand R. *See* Mendler M-H
Moirand R, Jouanolle A-M, Brissot P, Le Gall J-Y, David V, Deugnier Y. Phenotypic Expression of *HFE* Mutations: A French Study of 1110 Unrelated Iron-Overloaded Patients and Relatives, 116:372
Moitinho E
See Escorsell À
See González-Aaldes J
Moitinho E, Escorsell À, Bandi J-C, Salmerón J-M, García-Pagán J-C, Rodés J, Bosch J. Prognostic Value of Early Measurements of Portal Pressure in Acute Variceal Bleeding, 117:626
Mok KS. *See* Brink MA
Mokany E. *See* Hawkins N
Molberg O. *See* Shan L
Molberg Ø. *See* Arentz-Hansen H
Molberg Ø, Flæte NS, Jensen T, Lundin KEA, Arentz-Hansen H, Anderson OD, Uhlen AK, Sollid LM. Intestinal T-Cell Responses to High-Molecular-Weight Glutenins in Celiac Disease, 125:337
Molderings GJ. *See* Heller J
Moldoveanu Z. *See* Meng G
Molenberghs G. *See* Fischler B
Molina E, Jeffers LJ. *Undergraduate Teaching Project in Gastroenterology*, 116:1270–pmr
Molina M. *See* Lanas A
Molina T. *See* Liu H
Molleman A. *See* Huizinga JD
Møller J. *See* Troelsen JT
Møller K. *See* Strauss GI
Möller P. *See* Sträter J
Monaghan KG. *See* Huntsman DG
Monastra Varrica L. *See* Goin JC
Monath TP. *See* Michetti P
Mondelli MU. *See* Cividini A
Monden M. *See* Yamamoto H
Monga HK. *See* Monga SPS
Monga SPS, Monga HK, Tan X, Mulé K, Pediaditakis P, Michalopoulos GK. β-Catenin Antisense Studies in Embryonic Liver Cultures: Role in Proliferation, Apoptosis, and Lineage Specification, 124:202
Mongin SJ. *See* Mandel JS
Monica NL. *See* Blindenbacher A
Monsuur F. *See* Vermeire S
Montalto G. *See* Carroccio A
Montalto MC. *See* Wada K
Montano S. *See* Rajas F
Monteleone G, MacDonald TT, Wathen NC, Pallone F, Pender SLF. Enhancing Lamina Propria Th1 Cell Responses With Interleukin 12 Produces Severe Tissue Injury, 117: 1069
Montembault S. *See* Veyradier A
Monterubbianesi R. *See* Alvaro D
Montesani C. *See* Boirivant M
Montgomery RK, Mulberg AE, Grand RJ. Development of the Human Gastrointestinal Tract: Twenty Years of Progress, 116:702–srr
Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Paramyxovirus Infections in Childhood and Subsequent Inflammatory Bowel Disease, 116:796
Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Search for Mumps Virus Genome in Intestinal Biopsy Specimens of Patients With IBD. Reply, 117:1252–c
Moodie S. *See* Fraser JS
Mookerjee RP. *See* Sen SM
Moon N. *See* Graham DY
Moore BA. *See* Türler A
Moore BA, Otterbein LE, Türler A, Choi AMK, Bauer AJ. Inhaled Carbon Monoxide Suppresses the Development of Postoperative Ileus in the Murine Small Intestine, 124:377
Moore DD. *See* Hwang ST
Moore FA. *See* Kozar RA
Moore S. *See* Berg DJ
Mora F. *See* Minguez M
Moradpour D. *See* Blindenbacher A
Moragoda L. *See* Marciniak DJ
Morain CAO. *See* Qasim A
Morais J. *See* Doyle DA
Morales J. *See* Bureau C
Morales-Ruiz M. *See* Poo J-L
Morales-Ruiz M, Cejudo-Martín P, Fernández-Varo G, Tugues S, Ros J, Angeli P, Rivera F, Arroyo V, Rodés J, Sessa WC, Jiménez W. Transduction of the Liver With Activated Akt Normalizes Portal Pressure in Cirrhotic Rats, 125:522
Morali A. *See* Cézard JP
Moran AP. *See* Berstad AE
Moran AP, Hynes SO, Heneghan MA. Mimicry of Blood Group Antigen A by *Helicobacter mustelae and H. pylori*, 116:504–c
Moran T. *See* Hugot J-P
Moran TH. Pancreatic Polypeptide: More Than Just Another Gut Hormone?, 124:1542–e
Morante A. *See* Persico M
Moratto D. *See* Umemura T
Moreau A
See Berriot-Varoqueaux N
See Mansouri A
Moreau R
See Colle IO
See Pateron D
See Tazi KA
Moreau R, Durand F, Poynard T, Duhamel C, Cervoni J-P, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki J-P, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau J-M, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cardanel J-F. Terlipressin in Patients With Cirrhosis and Type 1 Hepatorenal Syndrome: A Retrospective Multicenter Study, 122: 922
Morel P
See Frossard JL
See Frossard J-L
Morelli A
See Fiorucci S
See Santucci L
See Wallace JL
Morelli MS, Zucker SD. A Role for the Appendix in Inflammatory Bowel Disease? Cut it Out. Comment, 125: 1271–ss
Morelli O. *See* Fiorucci S
Moreno ST. *See* Papdakis KA
Moreno-Otero R. *See* Gisbert JP
Morens C. *See* Gaudichon C
Morey AL. *See* Biankin AV

Morgan D
See Conway JD
See Mohanty SP
See Schoenfeld P
Morgan DJ
See Angus PW
See Froomes PRA
Morgan DR. *Diseases of the Gastrointestinal-Mucosa. The Acid Related Disorders*, 122:1181–pmr
Morgan JM. *See* Richardson CE
Morgan T. *See* McHutchison JG
Morgan TR, McClain CJ. Pentoxifylline and Alcoholic Hepatitis, 119:1787–e
Morham SG. *See* Sigthorsson G
Mori H. *See* Maeyama H
Mori N, Sato H, Hayashibara T, Senba M, Geleziunas R, Wada A, Hirayama T, Yamamoto N. *Helicobacter pylori* Induces Matrix Metalloproteinase-9 Through Activation of Nuclear Factor κB, 124:983
Mori Y. *See* Selaru FM
Moriarty K. *See* Hamilton J
Moribe T. *See* Kuzushita N
Moriguchi H, Chung RT, Contreras AM, Izumi N, Uemura T, Kobayashi M, Sato C. The Interferon Sensitivity Determining Region in the Era of Combination Therapies and the Rational Use of Such Therapies for Patients With HCV Genotype 1b Infection, 125:1284–c
Moriguchi H, Kobayashi M, Chung RT, Sato C. Optimal IFN Therapy for 40-year-old Patients With Severe HCV-1b Infection, 124:1166–c
Morimoto T. *See* Iimuro Y
Morin PJ. *See* Wu S
Morini S
See Alvaro D
See Marignani M
Morise Z. *See* Brand SJ
Morita CT. *See* Bukowski JF
Morita K. *See* Shiraga T
Moriuchi T. *See* Kobayashi I
Moriwaki H. *See* Akita K
Moriya A. *See* Iijima K
Moriyama M. *See* Shiratori Y
Moriyama N. *See* Kazumori H
Morran C. *See* Taha AS
Morrin M. *See* Johnson CD
Morris A. *See* Flum DR
Morris CB. *See* Drossman DA
Morris DL. *See* Montgomery SM
Morris J. *See* Calvert EL
Morrison JA. *See* Boocock GR
Morrow JB. *See* Vargo JJ
Morse MA. The Role of Glutathione *S*-Transferase P1-1 in Colorectal Cancer: Friend or Foe, 121:1010–e
Morsy N. *See* Jin X
Morteau O, Castagliuolo I, Mykoniatis A, Zacks J, Wlk M, Lu B, Pothoulakis C, Gerard NP, Gerard C. Genetic Deficiency in the Chemokine Receptor CCR1 Protects Against Acute *Clostridium difficile* Toxin A Enteritis in Mice, 122:725
Mortensen PB
See Jeppesen PB
See Jørgensen JR
See Lochs H
Mortensen RM. *See* Ji B
Morton D. *See* Fraser AG
Morton DH. *See* Salen G
Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, Puffenberger E, Bull L, Knisely AS. Abnormal Hepatic Sinusoidal Bile Acid Transport in an Amish Kindred Is Not Linked to *FIC1* and Is Improved by Ursodiol, 119:188
Mosca F. *See* Pedrazzoli S
Moseley RH. Bile-ology 101, 121:218–e
Moser A. *See* Setchell KDR
Moser G. *See* Dejaco C
Moskaluk CA
See Burns RC
See El-Rifai W
See Kozaiwa K
See Rivera-Nieves J
Mosnier LO. *See* Lisman T
Moss SF
See Holt PR
See Peek RM Jr
Mössner J
See Huster D
See Ortner MEJ
See Teich N
Mosterman B. *See* Yang C
Mostov KE. *See* van Ijzendoorn SCD
Motoki K. *See* Saubermann LJ
Mott LA. *See* Baron JA
Moucadel V. *See* Soubeyran P
Moum B. *See* Hampe J
Mountcastle SB. *See* Martin C
Mouria M. *See* Gukovskaya AS
Moussalli J. *See* Sobesky R
Mowat C, Carswell A, Wirz A, McColl KEL. Omeprazole and Dietary Nitrate Independently Affect Levels of Vitamin C and Nitrite in Gastric Juice, 116:813
Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, Wirz A, Preston T, McColl KEL. Omeprazole, *Helicobacter pylori* Status, and Alterations in the Intragastric Milieu Facilitating Bacterial *N*-Nitrosation, 119:339
Mowat NAG. *See* Church NI
Mrsny RJ. *See* Zolotarevsky Y
Muallem S
See Kim JY
See Young Kim J
Mucke L. *See* Bush TG
Mudter J. *See* Neurath MF
Mueller C. *See* Saurer L
Mueller E. *See* Girnun GD
Mueller F. *See* Wagner M
Mueller LA, Camilleri M, Emslie-Smith AM. Mitochondrial Neurogastrointestinal Encephalomyopathy: Manometric and Diagnostic Features, 116:959–cr
Muellhaupt B
See Amman RW
See Ammann RW
Mühlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, Lock G, Schölmerich J, Hellerbrand C. A Novel MCP-1 Gene Polymorphism Is Associated With Hepatic MCP-1 Expression and Severity of HCV-Related Liver Disease, 125:1085
Muir A. *Living With Hepatitis C: A Survivor's Guide*, 123:650–pmr
Muir AJ, Edwards LJ, Sanders LL, Bollinger RR, Koruda MJ, Bachwich DR, Provenzale D. Health-Related Quality of Life After Ileal Pouch Anal Anastomosis for Ulcerative Colitis: Right Answer – Wrong Question, 122:1179–ss
Muir AJ, Rockey DC. Acute HCV: The Early Bird Catches the Virus. Comment, 122:1175–ss
Mukai M. *See* Kusama T
Mukaida N. *See* Masamune A
Mulberg AE. *See* Montgomery RK
Mulcahy HE, Patel RS, Postic G, Eloubeidi MA, Vaughan JA, Wallace M, Barkun A, Jowell PS, Leung J, Libby E, Nickel N, Schutz S, Cotton PB. Yield of Colonoscopy for Non-Acute Rectal Bleeding, 123:2151–ss
Mulcahy-Hawes K. *See* Ahmad T
Mulchandani R. *See* Nilsson H-O
Mulder CJJ. *See* Van Belzen MJ
Mulé K. *See* Monga SPS
Mulholland MW. Progress in Understanding Acalculous Gallbladder Disease, 120:570–e
Mullen KD. *See* Saadeh S
Müller A. *See* Heller J
Müller C
See Schenk P
See Wingler K
Müller M
See Hooiveld GJEJ
See Jansen PLM
See Meerman L

See Schaefer M
See van Waarde WM
Müller R. *See* Jacob P
Müller T, Wijmenga C, Phillips AD, Janecke A, Houwen RHJ, Fischer H, Ellemunter H, Frühwirth M, Offner F, Hofer S, Müller W, Booth IW, Heinz-Erian P. Congenital Sodium Diarrhea Is an Autosomal Recessive Disorder of Sodium/Proton Exchange but Unrelated to Known Candidate Genes, 119:1506
Müller W
See Müller T
See Streetz KL
Müller-Alouf H. *See* Desreumaux P
Müller-Esterl W. *See* König P
Müller-Hermelink H-K. *See* Fischbach W
Mullerova I. *See* Lau GKK
Mun EC, Blackburn GL, Matthews JB. Current Status of Medical and Surgical Therapy for Obesity, 120:669
Munck A. *See* Berriot-Varoqueaux N
Munkholm P
See Jess T
See Winther KV
Muñoz J
See Albillos A
See Pérez-Páramo M
Muñoz RM. *See* Poo J-L
Munoz SJ. *See* Farci P
Munroe D. *See* Yusta B
Munteanu M. *See* Poynard T
Murai N. *See* Oshima M
Murakami A. *See* Tanaka T
Murakami H. *See* Iwashita T
Murakami M. *See* Hase K
Murakami N. *See* Date Y
Muralikrishnan VP, Ching SS, Whiteley GS. Image of the Month, 122:605–im
Murashima N. *See* Ikeda K
Murat A. *See* Cadiot G
Murata GH. *See* Inadomi JM
Murata I. *See* Nakamuta K
Murata T. *See* Boku K
Murdock RH Jr. *See* Sandborn WJ
Muris JW. *See* Boonen A
Murphy A. *See* Farrell RJ
Murphy GM
See Thomas LA
See Veysey MJ
Murphy PM. *See* Promrat K
Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac Reduces the Incidence of Acute Pancreatitis After Endoscopic Retrograde Cholangiopancreatography, 124:1786
Murray CDR, Kamm MA, Bloom SR, Emmanuel AV. Ghrelin for the Gastroenterologist: History and Potential, 125:1492–srr
Murray FE. *See* Byrne MF
Murray GI. *See* Wright MC
Murray JA, Camilleri M. The Fall and Rise of the Hiatal Hernia, 119:1779–e
Murray JA, Green HR. Biopsy Is the Gold Standard of Diagnosis of Celiac Sprue, 116:1273–c
Murray LS
See El-Omar EM
See McColl KEL
Murthy KK. *See* Thomson M
Murthy S
See Cooper HS
See Su CG
See Wu GD
Murugan N. *See* Miao YM
Muscará MN. *See* Wallace JL
Musch MW
See Kojima K
See Ren H
See Ropeleski MJ
See Sugi K
Musch MW, Sugi K, Straus D, Chang EB. Heat-Shock Protein 72 Protects Against Oxidant-Induced Injury of Barrier Function of Human Colonic Epithelial Caco2/bbe Cells, 117:115
Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Hässinger D. Involvement of CD95 (Apo-1/Fas) Ligand Expressed by Rat Kupffer Cells in Hepatic Immunoregulation, 116:666
Musso A. *See* Bugianesi E
Musso A, Condon TP, West GA, de la Motte C, Strong SA, Levine AD, Bennett CF, Fiocchi C. Regulation of ICAM-1-Mediated Fibroblast-T Cell Reciprocal Interaction: Implications for Modulation of Gut Inflammation, 117:546
Mutignani M. *See* Costamagna G
Mutuma ST. *See* French SJ
Muxin W. *See* Jin C
Muzio LL. *See* Mignogna MD
Mykoniatis A
See Morteau O
See Wlk M
Mykoniatis A, Anton PM, Wlk M, Wang CC, Ungsunan L, Blüher S, Venihaki M, Simeonidis S, Zacks J, Zhao D, Sougioultzis S, Karalis K, Mantzoros C, Pothoulakis C. Leptin Mediates *Clostridium difficile* Toxin A-Induced Enteritis in Mice, 124:683
Myrvold HE. *See* Lundell L
Myrvold HE, Lundell L, Miettinen P, Pedersen SA, Liedman B, Hatlebakk J, Julkunen R, Levander K, Lamm M, Mattson C, Carlsson J, Stålhammar NO. Cost Analysis of Antireflux Surgery Versus Medical Management, 122:1178–ss
Mysore JV, Wigginton T, Simon PM, Zopf D, Heman-Ackah LM, Dubois A. Treatment of *Helicobacter pylori* Infection in Rhesus Monkeys Using a Novel Antiadhesion Compound, 117:1316
Myung S-J. *See* Kim M-H

Nabais S. *See* Machado JC
Nachbaur K. *See* Féray C
Nadaf SR. *See* Adachi Y
Nadeau WJ. *See* Hisamatsu T
Nadel MR. *See* Levin TR
Naeem A. *See* Kelly P
Naegels S. *See* Baert F
Nafe B. *See* Kiesslich R
Nagai H. *See* Miyakura Y
Nagai R
See Katayama K
See Nakajima A
Nagano H. *See* Yamamoto H
Naganuma M. *See* Kanai T
Nagao S. *See* Matsuzaki K
Nagao Y, Fukuizumi K, Kumashiro R, Tanaka K, Sata M. The Prognosis for Life in an HCV Hyperendemic Area, 125:628–c
Nagao Y, Sata M, Fukuizumi K, Ryu F, Ueno T. High Incidence of Oral Lichen Planus in an HCV Hyperendemic Area, 119:883–c
Nagao Y, Sata M, Suzuki H, Kameyama T, Ueno T. Histological Improvement of Oral Lichen Planus in Patients With Chronic Hepatitis C Treated With Interferon, 117:283–c
Nagaretani H. *See* Kamada Y
Nagashima K. *See* Ikeda H
Nagashima Y. *See* Tanaka N
Nagata H, Ito M, Cai J, Edge AS, Platt JL, Fox IJ. Treatment of Cirrhosis and Liver Failure in Rats by Hepatocyte Xenotransplantation, 124:422
Nagata T
See Asakawa A
See Sugimoto K
Nagothu KK. *See* Marciniak DJ
Nagy A. *See* Tanaka S
Nagy N. *See* Louis H
Naidenko OV. *See* Kita H
Naim HY. *See* Ritz V
Naiman T. *See* Rozen P
Nair KS. *See* Charlton M
Nair S. *Management of Chronic Viral Hepatitis*, 123:2154–pmr
Nair S, Pitchumoni CS. Image of the Month, 117:296
Naito H. *See* Shibata C

Naito M
See Kyokane T
See Uwatoku R
Naitoh T. *See* Kakyo M
Nakagama H. *See* Osawa E
Nakagawa S. *See* Katayama K
Nakagomi R. *See* Kakyo M
Nakai D. *See* Kakyo M
Nakaido T. *See* Hamano H
Nakajima A
See Katayama K
See Osawa E
Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N. Endogenous PPARγ Mediates Anti-inflammatory Activity in Murine Ischemia-Reperfusion Injury, 120:460
Nakajima H. *See* Matsuzaki K
Nakajima M. *See* Jin C
Nakajima N. *See* Nakajima A
Nakajima T
See Kanai M
See Miyanishi K
See Takayama T
Nakajima Y. *See* Ueno N
Nakamaru K. *See* Kanai T
Nakamori S. *See* Yamamoto H
Nakamura E. *See* Aihara T
Nakamura H
See Kusama T
See Ohkawara T
Nakamura I. *See* Ikeda K
Nakamura M
See Kamihira T
See Shimoda S
Nakamura S. *See* Kuno A
Nakamura S-I. *See* Habano W
Nakamura T. *See* Chiba M
Nakamuta K, Murata I, Kohno S. Image of the Month, 124:599–im
Nakano I. *See* Shimizu H
Nakano T. *See* Shiraki K
Nakanuma Y. *See* Kamihira T
Nakase H
See Jeffers M
See Ohana M
See Okazaki K
Nakata S. *See* Maeyama H
Nakaya Y. *See* Ueno N
Nakayama K
See Hamano H
See Kawa S
Nakazato M. *See* Date Y
Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, Ishii H, Azuma M, Hibi T. Functional Expression of Costimulatory Molecule CD86 on Epithelial Cells in the Inflamed Colonic Mucosa, 117:536
Nakazawa T. *See* Kuno A
Nakmura F. *See* Andoh A
Naliboff B
See Gralnek IM
See Mertz H
Naliboff BD
See Berman SM
See Mayer EA
Naliboff BD, Berman S, Chang L, Derbyshire SWG, Suyenobu B, Vogt BA, Mandelkern M, Mayer EA. Sex-Related Differences in IBS Patients: Central Processing of Visceral Stimuli, 124:1738
Nally K. *See* Shanahan F
Nam KJ. *See* Vaquero EC
Namane A. *See* Matysiak-Budnik T
Nambiar P. *See* Girnun GD
Namburu SS. *See* Kaur BS
Namkung W. *See* Young Kim J
Namour F. *See* Guéant J-L
Nanda NN. *See* Beck PL
Nanji A. *See* Lau GKK
Nantz MH. *See* Bruggraber SFA
Naoumov NV
See Cramp ME
See Lau GKK
Naoumov NV. Hepatitis C Virus-Specific CD4+ T Cells: Do They Help or Damage?, 117:1012–e
Napierkowski JJ, Sachar DS, Cumings M, Kaplan K, Wong RKH. Image of the Month, 125:8–im
Narita R, Okubo Y, Otsuki M. Image of the Month, 121:4–im
Narkewicz M. *See* Kurbegov AC
Narumiya S
See Boku K
See Takeuchi K
See Walsh SV
Naruse S. *See* Jin C
Nascimbeni M. *See* Thomson M
Näslund E. *See* Freedman J
Nassir F. *See* Wang LC
The Nastra Group. *See* Sanyal AJ
Nathanson MH
See Hirata K
See Leite MF
See Shibao K
See Spirli C
Nathanson MH, Rios-Velez L, Burgstahler AD, Mennone A. Communications via Gap Junction Modulates Bile Secretion in the Isolated Perfused Rat Liver, 116:1176
National Institute of Health Consensus Development Conference statement: Management of Hepatitis C 2002 (June 10-12, 2002), 123:2082–mr
Navarra G. *See* Trevisani M
Navarro J. *See* Faure C
Navarro V. *See* Martin S
Navasa M. *See* Sort P
Naveau S. *See* Veyradier A
Navickis RJ. *See* Wilkes MM
Neal KR
See Dunlop SP
See Spiller RC
Neale K. *See* Tomlinson I
Nebel S. *See* Carethers JM
Nectoux J. *See* Paradis V
Nedrud JG. *See* Czinn SJ
Neef B, Kirsch H, Andus T. Image of the Month, 124:1179–im
Neef M. *See* Schepke M
Neff C. *See* Jacob P
Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T. Crohn's Disease Is Associated With Novel Polymorphisms in the 5'-Flanking Region of the Tumor Necrosis Factor Gene, 117:1062
Negro A. *See* Crone SA
Neirynck S. *See* Steidler L
Neish AS. *See* Collier-Hyams LS
Nelson DB
See Perdue DG
See Sawhney MS
Colonoscopy Versus Double-Contrast Barium Enema. Comment, 119:1402–ss
Cost Analysis of Antireflux Surgery Versus Medical Management. Comment, 122:1179–ss
Effectiveness of Colonoscopy in Preventing Colorectal Cancer. Comment, 121:1522–ss
Helicobacter Eradication Versus Prompt Endoscopy for Dyspepsia. Comment, 120:1300–ss
Nelson DJ. *See* Sugi K
Nelson DR, Davis GL
Hepatic Deficiency of Interleukin 10 in Chronic Hepatitis C. Reply, 119:1411–c
Interleukin 10: The Magic Bullet for Liver Fibrosis? Reply, 119:1412–c
Nelson H. *See* Harewood GC
Nelson JL. *See* Pacht ER
Nelson RC. *See* Thornton FJ
Nelson V. *See* Hassard PV
Neoptolemos J. *See* Pfützer RH
Neri M
See Caldarella MP
See Savarino V
Nervi F. *See* Zanlungo A
Nesbit RR Jr. Diagnosing Appendicitis, 125:272–c
Nesi G. *See* Rubio CA

Nesje LB. *See* Lochs H
Nespoli L. *See* Gianotti L
Ness TJ. Kappa Opioid Receptor Agonists Differentially Inhibit Two Classes of Rat Spinal Neurons Excited by Colorectal Distention, 117:388
Neubauer A. *See* Liu H
Neubauer K. *See* Knittel T
Neurath MF
See Fuss IJ
See Kiesslich R
Neurath MF, Atreya R, Mudter J, Rose-John S, Galle PR. Turning on T-Cell Death and Turning Off Crohn's Disease. Reply, 119:1166–ss
New Italian Endoscopic Club for the Study and Treatment of Esophageal Varices (NIEC). *See* Primignani M
Newberry EP, Davidson NO. Biliary Lipid Secretion, Membrane Pumps, and the Metabolic Response to Fasting: Distinct PPAR-ts of a Common Regulatory Pathway, 124:254–e
Newberry RD. *See* Gurtner GJ
Newby ED. *See* Helmy A
Newby K. *See* Varia I
Newman B. *See* Radford-Smith GL
Newman P. *See* Savidge TC
Newman SC. *See* Porter GA
Newman W. *See* Prince M
Newmark H. *See* Holt PR
Newsome PN, Johannessen I, Boyle S, Dalakas E, McAulay KA, Samuel K, Rae F, Forrester L, Turner ML, Hayes PC, Harrison DJ, Bickmore WA, Plevris JN. Human Cord Blood-Derived Cells Can Differentiate Into Hepatocytes in the Mouse Liver With No Evidence of Cellular Fusion, 124: 1891
Newton JC. *See* Gobert AP
Ng AY-N, Waring P, Ristevski S, Wang C, Wilson T, Pritchard M, Hertzog P, Kola I. Inactivation of the Transcription Factor Elf3 in Mice Results in Dysmorphogenesis and Altered Differentiation of Intestinal Epithelium, 122:1455
Ng EKW
See Sung JJY
See van Doorn L-J
Ng K-Y
See Lai C-L
See Liaw Y-F
Ngan R. *See* Lau GKK
Nguyen D, Buonomo C, Jonas M. Image of the Month, 119:1430–im
Nguyen MH. *See* Garcia RT
Nguyen N. *See* Strassburg CP
Nguyen R. *See* Demeilliers C
Nguyen V. *See* McPhaul LW
Nicholas C. *See* Velcich A
Nicholls RJ. *See* Vaizey CJ
Nichols M. *See* Samowitz WS
Nichols R. *See* Michetti P
Nick HS. *See* Dolan-O'Keefe M
Nickel N. *See* Mulcahy HE
Nicolae DL
See Bonen DK
See Hugot J-P
Nicolás JM. *See* Bataller R
Nicora A. *See* Vorobioff JD
Niederau C. *See* Poynard T
Niel G van, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N, Heyman M. Intestinal Epithelial Cells Secrete Exosome-like Vesicles, 121:337
Niels-Christiansen L-L. *See* Hansen GH
Nielsen CK. *See* Öhd JF
Nielsen OH. *See* Schreiber S
Niemelä O. *See* Parkkila S
Niero M. *See* Marchesini G
Nietert PJ. *See* Silverstein MD
Nieto N. *See* Carmiel-Haggai M
Nieuwenhuis EES, Furuta GT. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C. Comment, 125:263–ss
Nieuwenhuis HK. *See* Lisman T
Nigam SK. *See* Bush KT
Niijima A
See Asakawa A
See Date Y
Niitsu Y
See Dai CY
See Miyanishi K
See Takayama T
Niitsu Y, Takayama T, Kato J. The "Innocent Colon" and K-*ras* Mutation-Guilty By (ACF) Association? Reply, 124:274–c
Nijima A. *See* Asakawa A
Nikolaus S
See Hampe J
See Waetzig GH
Niles JL. *See* Bitton A
Nilolaus S. *See* Schreiber S
Nilsson H-O, Mulchandani R, Tranberg K-G, Stenram U, Wadström T. *Helicobacter* Species Identified in Liver From Patients With Cholangiocarcinoma and Hepatocellular Carcinoma, 120:323–c
Nilsson L-G. *See* Hellers G
Nilsson O. *See* Hamlet A
Nimura Y. *See* Kyokane T
Nion I. *See* Rosmorduc O
Niro G. *See* Rosina F
Nishi K. *See* Torihashi S
Nishi T
See Ohana M
See Torihashi S
Nishida T
See Hirota S
Nishiguchi S
See Shiratori Y
See Yoshida H
Nishihira J
See Ohkawara T
See Sakai Y
Nishikawa K. *See* Hirota S
Nishimura T. *See* Enomoto N
Nishio T
See Iimuro Y
See Kakyo M
Nishioka NS. *See* Poneros JM
Nishiura T. *See* Enomoto N
Nishizawa H. *See* Kamada Y
Nitschke T. *See* Shaker R
Nitta T. *See* Iimuro Y
Niwa H. *See* Matsuzaki K
Nobile-Orazio E. *See* De Giorgio R
Nobuoka A
See Miyanishi K
See Takayama T
Noé J, Stieger B, Meier PJ. Functional Expression of the Canalicular Bile Salt Export Pump of Human Liver, 123: 1659
Noelle RJ. *See* Li W
Noguchi H, Sakamoto C, Wada K, Akamatsu T, Uchida T, Tatsuguchi A, Matsui H, Fukui H, Fujimori T, Kasuga M. Expression of Heregulin α, erbB2, and erbB3 and Their Influences on Proliferation of Gastric Epithelial Cells, 117:1119
Nolla JM. *See* Guardiola J
Nolte W, Ramadori G. Albumin for Refractory Ascites, 125:1283–c
Noman M
See Baert F
See Van Assche G
See Vermeire S
Nomura T. *See* Kuno A
Nonaka T. *See* Kurata A
Noone PG, Zhou Z, Silverman LM, Jowell PS, Knowles MR, Cohn JA. Cystic Fibrosis Gene Mutations and Pancreatitis Risk: Relation to Epithelial Ion Transport and Trypsin Inhibitor Gene Mutations, 121:1310
Nordic Gerd Study Group. *See* Lundell L
Nordling M. *See* Björk J
Nordman H. *See* Lindén S
Norén O. *See* Danielsen EM
Norimizu S. *See* Kyokane T
Normandin L. *See* Rose C
Normark S. *See* Su B
Norrie M. *See* Hawkins N
Norris S. *See* Satsangi J
North American Azathioprine Study Group. Lack of Effect of Intravenous

Administration on Time to Respond to Azathioprine for Steroid-Treated Crohn's Disease, 117:527
The North of England IBS Research Group. *See* Creed F
Northover J. *See* Tomlinson I
Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized Controlled Trial of Biofeedback for Fecal Incontinence, 125:1320
Norton IA. *See* Chari ST
Norton ID
See Schwartz DA
See Vazquez-Sequeiros E
Norton P. *See* Zhu J
Nostrant TT. *See* Triadafilopoulos G
Not T. *See* el Asmar R
Nouel O. *See* Moreau R
Nougayréde J-P. *See* McNamara BP
Nourami M. *See* Ratziu V
Novak S. *See* Wight NJ
Novalbos J. *See* Lomax RB
Novella MT. *See* Guarner C
Novelli M. *See* Vinall LE
Noventa F. *See* Gerotto M
Novi G. *See* Rosen HR
Nowak T. *See* Abell T
Nowak TV, Goddard M, Batteiger B, Cummings OW. Evolution of Acute Cytomegalovirus Gastritis to Chronic Gastrointestinal Dysmotility in a Nonimmunocompromised Adult, 116: 953–cr
Ntambi JM. *See* Cohen P
Nunes DP, Afdhal NH, Offner GD. A Recombinant Bovine Gallbladder Mucin Polypeptide Binds Biliary Lipids and Accelerates Cholesterol Crystal Appearance Time, 116:936
Nunez G. *See* Hugot J-P
Nuñez G
See Bonen DK
See Lala S
Núñez G. *See* Inoue N
Nunokawa M. *See* Kurata A
Nurko S
See Rosen R
See Teitelbaum JE
Nusbaum S. *See* Verkarre V
Nusrat A. *See* Walsh SV
Nyberg B. *See* Törnblom H
Nygren E. *See* Lehmann A
Nylander DL. Chest Pain in Achalasia Is an Age-Dependent Phenomenon, 117: 1258–c
Nyren O. *See* Cameron AJ
Nyrén O
See Elkström AM
See Terry P
See Tindberg Y
See Ye W
Nyström P. *See* Lundell L
Nyström-Lahti M. *See* Raevaara TE

O Crónín T. *See* Clyne M
Obayashi T. *See* Hirota S
Obeid O. *See* Ballinger A
Oberhuber G. *See* Joossens S
Obermayer-Straub P, Perheentupa J, Braun S, Kayser A, Barut A, Loges S, Harms A, Dalekos G, Strassburg CP, Manns MP. Hepatic Autoantigens in Patients With Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, 121:668
Obermeier F. *See* Steidler L
Obert B. *See* Veyradier A
Obertop H. *See* Boerma D
Obonyo M. *See* Hase K
O'Brien M. *See* Savidge TC
O'Brien MJ. *See* Zauber AG
O'Brien PE
See Dixon JB
See Hardwick JCH
O'Brien TR. *See* Zhang M
O'Byrne PM. *See* Galeazzi F
Ochi Y. *See* Kawa S
Ochiai M. *See* Osawa E
Ochs A. *See* Rössle M
Ockenga J
See Teich N
See Widjaja A
Ockenga J, Bischoff SC, Tillmann HL, Rifai K, Widjaja A, Böker KHW, Manns MP, Brabant G. Elevated Leptin Correlates With Energy Expenditure in Cirrhotics, 119:1656
Ockenga J, Schuetz T, Lochs H. TIPS in Refractory Ascites in Cirrhosis: Not Only Survival Is the Clue, 125:997–c
Ockenga J, Vogel A, Teich N, Keim V, Manns MP, Strassburg CP. UDP Glucuronosyltransferase (UGT1A7) Gene Polymorphisms Increase the Risk of Chronic Pancreatitis and Pancreatic Cancer, 124:1802
O'Connell CB. *See* McNamara BP
O'Connell NC. *See* Setchell KDR
O'Connor C. *See* Varia I
O'Connor DT. *See* Höcker M
O'Connor JB. *See* Thornton FJ
O'Connor P. *See* Rowland M
O'Connor T. *See* Hawkins N
Ocran K. *See* Steiner M
Ocran KW. *See* Rickes S
Oda K. *See* Tsunada S
Oda Y. *See* Shindo M
Oddsson E. *See* Thjodleifsson B
Odermatt B. *See* Selzner N
O'Dwyer ST. *See* Bach SP
Odze RD. *See* Engelsgjerd M
O'Fallon WM. *See* Loftus EV Jr
Offergeld R. *See* Woitas RP
Offerhaus GJ. *See* Hardwick JCH
Offerhaus GJA
See Buskens CJ
See Giardello FM
See van Rees BP
Offerhaus JA. *See* Giardiello FM
Offner F. *See* Müller T
Offner GD. *See* Nunes DP
Ofman JJ
See Fass R
See Spiegel BMR
Ogata H
See Inoue N
See Nakazawa A
Ogata I. *See* Ikeda H
Ogata S. *See* Tsunada S
Ogawa K
See Kishibe K
See Kuno A
Ogg GS. *See* Maini MK
Oguma K. *See* Yokota K
Ogunbiyi O. *See* Lala S
Ogunmola NA, Wyllie R, Mahajan L. Image of the Month, 125:1575–im
Ogura K. *See* Maeda S
Ogura Y
See Bonen DK
See Hugot J-P
See Inoue N
See Lala S
Oh RR. *See* Park WS
Ohana M, Okazaki K, Oshima C, Andra's D, Nishi T, Uchida K, Uose S, Nakase H, Matsushima Y, Chiba T. A Critical Role for IL-7R Signaling in the Development of *Helicobacter felis*-Induced Gastritis in Mice, 121:329
Ohara H. *See* Kuno A
Ohashi A. *See* Hirota S
Öhd JF, Nielsen CK, Campbell J, Landberg G, Löfberg H, Sjölander A. Expression of the Leukotriene D_4 Receptor $CysLT_1$, COX-2, and Other Cell Survival Factors in Colorectal Adenocarcinomas, 124:57
Öhd JF, Wikström K, Sjölander A. Leukotrienes Induce Cell-Survival Signaling in Intestinal Epithelial Cells, 119:1007
Ohi M
See Miyanishi K
See Takayama T
Ohkawa K. *See* Kuzushita N
Ohkawara T, Nishihira J, Takeda H, Hige S, Kato M, Sugiyama T, Iwanaga T, Nakamura H, Mizue Y, Asaka M. Amelioration of Dextran Sulfate Sodium-Induced Colitis by Anti-

macrophage Migration Inhibitory Factor Antibody in Mice, 123:256
Ohm JE. *See* Adachi Y
Ohmann C. *See* Fischbach W
Ohmoto Y. *See* Ueno N
Ohnaka M. *See* Ueno N
Ohnami S. *See* Suzuki K
Ohnishi H. *See* Ueda N
Ohnishi H, Mine T, Shibata H, Ueda N, Tsuchida T, Fujita T. Involvement of Rab4 in Regulated Exocytosis of Rat Pancreatic Acini, 116:943
Ohnishi S. *See* Nakajima A
Ohno T
See Boku K
See Yamaoka Y
Ohtake N. *See* Yamamoto M
Ohtake T. *See* Hase K
Ohtsu H. *See* Tanaka S
Ohyama T. *See* Tsunada S
Oien K. *See* El-Omar EM
Okabe S
See Aihara T
See Tanaka S
Okada H. *See* Yokota K
Okamoto H. *See* Kazumori H
Okamoto M. *See* Kanai T
Okamoto R
See Kanai T
See Totsuka T
Okamoto S. *See* Kanai T
Okamoto Y. *See* Kamada Y
Okano M. *See* Kobayashi I
Okazaki K. *See* Ohana M
Okazaki K. Autoimmune Pancreatitis Is Increasing in Japan, 125:1557–c
Okazaki K, Onodera H, Watanabe N, Nakase H, Uose S, Matsushita M, Kawanami C, Imamura M, Chiba T. A Patient With Improvement of Ulcerative Colitis After Appendectomy, 119:502–cr
Okazawa A. *See* Kanai T
See Inoue N
See Kanai T
O'Keane JC. *See* Barrett S
O'Keefe J. *See* Feighery C
Okita M. *See* Ueno N
Okolicsanyi L. *See* Spirlì C
Okten A. *See* Besisik F
Okubo Y. *See* Narita R
Okuda M. *See* Lerat H
Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial Injury, Oxidative Stress, and Antioxidant Gene Expression Are Induced by Hepatitis C Virus Core Protein, 122:366
Okumura A. *See* Tanaka T
Okumura K. *See* Totsuka T
Okuno M. *See* Akita K
Okuno T
See Hirota S
See Shindo M
Olaison G
See Andersson RE
See Söderholm JD
Oland LD. *See* van Sickle MD
Olaru A. *See* Selaru FM
Olbe L. *See* Hamlet A
Oldach D. "Real-Time" Polymerase Chain Reaction, 116:763–e
Olden KW
Diagnosis of Irritable Bowel Syndrome, 122:1701
I. B. S. Relief: A Doctor, a Dietitian and a Psychologist Provide a Team Approach to Managing Irritable Bowel Syndrome, 116: 1501–pmr
Oldham SM. *See* Sizemore N
Olds LC. *See* Fang R
Oliveira C
See Brennetot C
See Machado JC
Olives JP. *See* Cézard JP
Olivi M. *See* Sobesky R
Oliviero O. *See* Girelli D
Olschewski M. *See* Rössle M
Olsen J. *See* Troelsen JT
Olson A. *See* Hanauer SB
Olson D. *See* Wang LC
Olson DJ. *See* Mandal M
Olson JE. *See* Harewood GC
Olsson C. *See* Lynn PA
Olsson R
See Bergquist A
See Elmberg M
Olsson S. *See* Elmberg M
Olynyk JK. *See* Gochee PA
Omary B. *See* Shirvani VN
Omata M
See Hirata Y
See Ijichi M
See Maeda S
See Shiratori Y
See Yoshida H
O'Morain C. *See* Lind T
O'Morain CA. *See* Hugot J-P
O'Neil BH. *Gastrointestinal Oncology: Principles and Practice*, 124:265–pmr
O'Neill AF. *See* Hirata K
Onel D. *See* Besisik F
Ong JP. *See* Saadeh S
Ong JP, Younossi ZM. Is Hepatocellular Carcinoma Part of the Natural History of Nonalcoholic Steatohepatitis?, 123: 375–e
Onodera H. *See* Okazaki K
Onogawa T. *See* Abe T
Onori P. *See* Alvaro D
Ooi CJ. *See* Mizoguchi E
Ootani A. *See* Tsunada S
Ootani H. *See* Tsunada S
Opekun AR. *See* Ball JM
Opolon P
See Di Martino V
See Lunel F
See Poynard T
See Sobesky R
Orchard T. *See* Ahmad T
Orchard TR. *See* Ahmad T
Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and Erythema Nodosum in Inflammatory Bowel Disease: Clinical Features and the Role of HLA Genes, 123:714
Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Gaston JSH, Jewell DP. Clinical Phenotype Is Related to HLA Genotype in the Peripheral Arthropathies of Inflammatory Bowel Disease, 118:274
Ørding Olsen K, Juul S, Berndtsson I, Öresland T, Laurberg S. Ulcerative Colitis: Female Fecundity Before Diagnosis, During Disease, and After Surgery Compared With a Population Sample, 122:15
Ördög T. *See* Ward SM
Ördög T, Baldo M, Danko R, Sanders KM. Plasticity of Electrical Pacemaking by Interstitial Cells of Cajal and Gastric Dysrhythmias in *W/W^{V}* Mutant Mice, 123:2028
Oren R. *See* Blendis L
Orenstein JM. *See* Meng G
Öresland T. *See* Ørding Olsen K
Orii F, Ahida T, Kohgo Y. Molecular Mechanisms of Glucocorticoid Resistance. Reply, 119:1178–c
Orito E. *See* Sugauchi F
Orlandi F. *See* di Sario A
Ormsby AH. *See* Shen B
Ormsby AH, Petras RE, Henricks WH, Rice RW, Rybicki LA, Goldblum JR. Separating Bad From Worse in Barrett's Esophagus, 125:260–ss
Ormsby AH. Separating Bad From Worse in Barrett's Esophagus. Reply, 125: 261–ss
Ormsby AH, Vaezi MF, Richter JE, Goldblum JR, Rice TW, Falk GW, Gramlich TL. Cytokeratin Immunoreactivity Patterns in the Diagnosis of Short-Segment Barrett's Esophagus, 119:683
O'Rourke K. *See* Stern HS
Orr-Urtreger A. *See* Rozen P
Ortega MA. *See* Valdés R
Ortega R. *See* Ginès P
Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiminez W, Arroyo V,

Rodes J. Telipressin and Albumin for HRS: An Advance in Therapy?, 124: 1552–ss
Ortego J. *See* Lanas A
Orth K. *See* Collier-Hyams LS
Ortiz EM. *See* Malka D
Ortiz J
See Guarner C
See Villanueva C
Ortiz-Berrocal J. *See* Pérez-Páramo M
Ortmann D. *See* Grimm CF
Ortner M. *See* Swidsinski A
Ortner MEJ, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful Photodynamic Therapy for Nonresectable Cholangiocarcinoma: A Randomized Prospective Study, 125:1355
Ory G. *See* Frossard JL
Osato MS. *See* Yamaoka Y
Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H. Peroxisome Proliferator-Activated Receptor γ Ligands Suppress Colon Carcinogenesis Induced by Azoxymethane in Mice, 124:361
Osborne B. *See* Aberra FN
Osborne C. *See* Lala S
Osei AM. *See* Allen SA
Oshima C. *See* Ohana M
Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo M, Evans JF. Chemoprevention of Intestinal Polyposis by COX-2 Inhibition: From Mouse to Man, 122:234–ss
Osterheld M-C. *See* Bian Y-S
O'Suilleabhain C. *See* Murray B
O'Sullivan GC
See Collins CG
See Shanahan F
O'Sullivan GC, Aarons SJ, Shanahan F. Mutant *Salmonella* as Vectors for Gene Therapy. Comment, 121:224–ss
O'Sullivan GC, Shanahan F
Excape from the *Smad* World by Colon Cancer. Comment, 116:1497–ss
Setback for Systemic Therapy of Esophageal Cancer: Right Concept, Disappointing Result. Comment, 117: 1020–ss
O'Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, Shanahan F. Micrometastases in Esophagogastric Cancer: High Detection Rate in Resected Rib Segments, 116:543
Ota H. *See* Maeyama H
Ota M. *See* Kawa S
Otani T, Matsukura A, Seyama Y. Serine Protease Inhibitors Cause F-Actin Redistribution in Pancreatic Acini?, 124:583–c
Otani T, Ozawa F. Water Immersion Stress Induces Heat Shock Protein Expression and Protects Against Pancreatitis, 121:744–c
Otley A, Loonen H, Parekh N, Corey M, Sherman PM, Griffiths AM. Assessing Activity of Pediatric Crohn's Disease: Which Index to Use?, 116:527
O'Toole D
See Farrell RJ
See Hammel PR
See Malka D
Otsuki M. *See* Narita R
Ott T. *See* Frossard J-L
Otte J-M, Rosenberg IM, Podolsky DK. Intestinal Myofibroblasts in Innate Immune Responses of the Intestine, 124:1866
Ottenhoff R. *See* de Vree JML
Otterbein LE. *See* Moore BA
Otterson MF. *See* Hatoum OA
Ottewell PD, Watson AJM, Wang TC, Varro A, Dockray GJ, Pritchard DM. Progastrin Stimulates Murine Colonic Epithelial Mitosis After DNA Damage, 124:1348
Otto B. *See* Feinle C
Ou Y. *See* Holm AN
Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G
Differentiation and Proliferation in Barrett's Esophagus and the Effects of Acid Suppression, 117:327
Importance of Adequate Acid Suppression in the Management of Barrett's Esophagus. Reply, 117:1510–c
Oude Elferink RPJ
See Bolder U
See de Vree JML
See Voshol PJ
Oudet P. *See* Chamouard P
Oudit GY, Dill-Macky MJ, Allard J. Image of the Month, 119:1190–im
Ougolkov AV, Yamashita K, Mai M, Minamoto T. Oncogenic β-Catenin and MMP-7 (Matrilysin) Cosegregate in Late-Stage Clinical Colon Cancer, 122:60
Ours TM. *See* Fackler WK
Ouyang A. American Gastroenterological Association: Presentation of the Julius M. Friedenwald Medal to Sidney Cohen, M.D, 122:2064–aga
Ouyang H. *See* Chen JDZ
Owen RJ. *See* Slater E
Owen RL. *Infections of the Gastrointestinal Tract*, 125:1550–pmr
Owen WF. *See* Jimenez RE
Owens CA, Layden TJ, Wiley T. Duplex Ultrasonography and TIPS. Reply, 117:511–c
Owens-Stowall S. *See* Chung DH
Owyang C
See Ladabaum U
See Takahashi T
See Yazdani A
Oxford GS. *See* Finn AL
Ozaki N. *See* Bielefeldt K
Ozawa F. *See* Otani T
Ozick LA. *See* Friedel D

Pacaud P. *See* Segain J-P
Pachen DMFA. *See* Vermeer ITM
Pacht ER, DeMichele SJ, Nelson JL, Wenneberg AK. Getting Fat in the ICU. Reply, 119:593–ss
Pacifico RJ. *See* Buttar NS
Pacini F. *See* Palli D
Paciucci R. *See* Díaz VM
Paesold G. *See* Maaser C
Paglia P. *See* Colombo MP
Paglia P, Terrazzini N, Schulze K, Guzmán CA, Colombo MP. Mutant *Salmonella* as Vectors for Gene Therapy, 121: 224–ss
Pagliaro L. *See* D'Amico G
Pagliocca A. *See* Varro A
Pagnotta E. *See* De Giorgio R
Påhlman L. *See* Madoff RD
Pahor M. *See* Havlik RJ
Pai R
See Baatar D
See Jones MK
Paigen B
See Lammert F
See Wittenburg H
Paillot B. *See* Michel P
Paine MF. *See* Fontana FJ
Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-Regulation of Components of the Renin-Angiotensin System in the Bile Duct-Ligated Rat Liver, 123:1667
Pajares JM. *See* Gisbert JP
Palacín A. *See* Sans M
Palazzetti B
See Fiorucci S
See Santucci L
Palazzi J. *See* Vorobioff JD
Palestro CJ. *See* Joseph B
Paliard P. *See* Boillot O
Palizban A. *See* Sigthorsson G
Palkovits M. *See* Tanaka S
Palladino AA. *See* Abreu MT
Palli D, Fossi S, Bazzoli F. Colonoscopic Screening of First-Degree Relatives of

Patients With Colorectal Cancer, 117: 747–c
Palli D, Masala G, Russo A, Saieva C, Bazzoli F. When Enthusiasm Is Infectious, 119:274–c
Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, Ceroti M, d'Albasio G, Pacini F, Amorosi A, Masala G. Hodgkin's Disease Risk Is Increased in Patients With Ulcerative Colitis, 119: 647
Pallone F
See Biancone L
See Hellers G
See Monteleone G
See Prantera C
Palmentieri B. *See* Persico M
Palmer BA. *See* Gawenis LR
Palmer KR. *See* Church NI
Palmer RH
COX-2 Selectivity and Lack of Gastrointestinal Toxicity: True, True and Unrelated?, 118:639–c
COX-2 Selectivity and Lack of Gastrointestinal Toxicity: True, True and Unrelated? Reply, 118:640–c
Palmer S. *See* Creed F
Palmer T. *See* Ghosh G
Palmeri A. *See* Restivo DA
Palomares SM. *See* Guarraci FA
Palsson O. *See* Whitehead WE
Palsson OS, Whitehead WE. The Growing Case for Hypnosis as Adjunctive Therapy for Functional Gastrointestinal Disorders, 123:2132–e
Pamuk GE. *See* Çelik AF
Pamuk ÖN. *See* Çelik AF
Pamukcu R. *See* Berg DJ
Pan A. *See* Wlk M
Pan H-N. *See* Sun Z
Pan W-H. *See* Savidge TC
Panaccione R
See Ricart E
See Schwartz DA
Panaccione R, Sandborn WJ
The Appendix in Ulcerative Colitis: A Not So Innocent Bystander. Comment, 117:272–ss
Is Antibody Testing for Inflammatory Bowel Disease Clinically Useful? Comment, 116:1001–ss
Pandak WM. *See* Vlahcevic ZR
Pandeya N. *See* Radford-Smith GL
Pandol SJ
See Gukovskaya AS
See Lugea A
See Vaquero EC
Pandol SJ, Periskic S, Gukovsky I, Zaninovic V, Jung Y, Zong Y, Solomon TE, Gukovskaya AS, Tsukamoto H. Ethanol Diet Increases the Sensitivity of Rats to Pancreatitis Induced by Cholecystokinin Octapeptide, 117:706
Pandolfi M. *See* Costamagna G
Pandolfi PP. *See* Kim S
Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric Junction Opening During Relaxation Distinguishes Nonhernia Reflux Patients, Hernia Patients and Normal Subjects, 125:1018
Pandrea I. *See* Bras-Gonçalves RA
Panella C. *See* Marchesini G
Panés J
See Bessa X
See Sans M
Panés J, Esteve M, Cabré E, Hinojosa J, Andreu M, Sans M, Fernandez-Bañares F, Feu F, Gassull MA, Piqué JM. Comparison of Health and Steroids in the Treatment of Moderate and Severe Ulcerative Colitis, 119:903
Panés J, Piqué JM. Heparin Therapy for Ulcerative Colitis. Reply, 120:1308–c
Panhuysen CIM. *See* Brant SR
Panigrahi P. *See* el Asmar R
Pantaleo P. *See* La Villa G
Pao Y. *See* Strul H
Paolos P de. *See* Bugianesi E
Paolotti D. *See* Rindi G
Papa A, Danese S, Gasbarrini G, Gasbarrini A. When Can Unfractionated Heparin Really Be Useful in the Treatment of Ulcerative Colitis?, 120:1307–c
Papadakis KA
See Abreu MT
See Dubinsky MC
See Vasiliauskas EA
Papadakis KA, Rosenbloom B, Targan SR. Anti-CD20 Chimeric Monoclonal Antibody (Rituximab) Treatment of Immune-Mediated Thrombocytopenia Associated With Crohn's Disease, 124: 583–c
Papadakis KA, Targan SR. Tumor Necrosis Factor: Biology and Therapeutic Inhibitors, 119:1148–srr
Papapetropoulos A. *See* Shah V
Papatheodoridis GV. *See* Manesis EK
Papdakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, Deem R, Breaverman T, Ponath PD, Andrew DP, Green PHR, Hodge MR, Binder SW, Targan SR. CCR9-Positive Lymphocytes and Thymus-Expressed Chemokine Distinguish Small Bowel From Colonic Crohn's Disease, 121:246
Pape GR
See Diepolder HM
See Gerlach JT
Papo M
See Cabré E
See Junquera F
Papp AC. *See* Prior TW
Pappalardo G, Polettini E, Frattaroli FM, Casciani E, d'Orta C, D'Amato M, Gualdi GF. Magnetic Resonance Colonography Versus Conventional Colonoscopy for the Detection of Colonic Endoluminal Lesions, 119:300
Parada C. *See* Losa JH
Parada LF. *See* Zhu Y
Paradis V, Bièche I, Dargère D, Laurendeau I, Nectoux J, Degott C, Belghiti J, Vidaud M, Bedossa P. A Quantitative Gene Expression Study Suggests a Role for Angiopoietins in Focal Nodular Hyperplasia, 124:651
Parashar B. *See* Sauter BV
Paraskevaidis E. *See* Roukos DH
Parc R. *See* Rosmorduc O
Pardee AB. *See* Guan RJ
Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic Acid as a Chemopreventive Agent in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis, 124:889
Pardo A. *See* Pérez-Páramo M
Paredes JG. *See* De la Concha EG
Parekh N. *See* Otley A
Parés A. *See* Cabré E
Pariente A. *See* Moreau R
Pariente D. *See* Bacq Y
Paris J-C. *See* Dharancy S
Parisi MA, Baldessari AE, Iida MHK, Clarke CM, Doggett B, Shirasawa S, Kapur RP. Genetic Background Modifies Intestinal Pseudo-obstruction and the Expression of a Reporter Gene in *Hox11L1-/-* Mice, 125:1428
Park CH. *See* Park WS
Park H-U. *See* Kim GE
Park J, Schulz S, Waldman SA. Intestine-Specific Activity of the Human Guanylyl Cyclase Promoter Is Regulated by Cdx2, 119:89
Park JY. *See* Park WS
Park K-H. *See* Adachi Y
Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, Park CH, Lee SK, Hyunglee S, Lee SN, Kim H, Yoo NM, Lee JY. Inactivating Mutations of *KILLER/DR5* Genes in Gastric Cancers, 121:1219–
Park WS, Oh RR, Park JY, Lee JH, Shin MS, Kim HS, Lee HK, Kim YS, Kim SY, Lee SH, Yoo NJ, Lee JY. Somatic Mutations of the Trefoil Factor Family 1 Gene in Gastric Cancer, 119:691
Park Y
See Ghany MG

See Lau DT-Y
See Promrat K
Parkes M. *See* Vermeire S
Parkkila S. *See* Gut MO
Parkkila S, Niemelä O, Britton RS, Fleming RE, Waheed A, Bacon BR, Sly WS. Molecular Aspects of Iron Absorption and HFE Expression, 121: 1489–srr
Parkman HP. *See* Quigley EMM
Parkos CA. *See* Walsh SV
Parnell NDJ. *See* Biagi F
Parrilla P. Gastric Surgery and Barrett's Esophagus, 123:954–co
Parrot I. *See* Shan L
Parsi MA, Achkar J-P, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of Response to Infliximab in Patients With Crohn's Disease, 123:707
Parsonnet J
See Arruda SMB de
See Ley C
When Enthusiasm Is Infectious. Reply, 119:275–c
When Heredity Is Infectious, 118:222–e
Partanen J
See Collin P
See Kaukinen K
Partensky C. *See* Marion-Audibert A-M
Parvin S
See Hildeand P
See Schneider A
Pascual S, Such J, Quilez C. Image of the Month, 122:258–im
Pashankar DS. Efficacy and Safety of Long-Term Omeprazole Treatment, 119: 1177–c
Paskett E. *See* Baron JA
Paskett ED. *See* Pineau BC
Pasquali C. *See* Pedrazzoli S
Pasricha P. Identifying the Motilin Receptor: Science, Serendipity, or Simply Business? Comment, 117:1504–ss
Pasricha PJ
See Al-Chaer ED
See Hoogerwerf WA
See Micci M-A
See Saitoh Y
See Toma H
Pasricha PJ, Motamedi M. Optical Biopsies, "Bioendoscopy," and Why the Sky Is Blue: The Coming Revolution in Gastrointestinal Imaging, 122:571–e
Passamonti M. *See* Vorobioff JD
Passariello R. *See* Laghi A
Passaro DJ. *See* Arruda SMB de
Pastacaldi S. *See* Marra F
Pastor-Anglada M. *See* Valdés R
Pastore G
See Jaeckel E
See Schalm SW
Pastorek J. *See* Gut MO
Pastoreková S. *See* Gut MO
Pastorelli A. *See* Deviere J
Pastorino JG. *See* Hoek JB
Patarroyo M. *See* Su B
Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, Burroughs AK. A Randomized, Controlled Trial of Medical Therapy Versus Endoscopic Ligation for the Prevention of Variceal Rebleeding in Patients With Cirrhosis, 123:1013
Patel A. *See* Ray RM
Patel K. *See* McHutchison JG
Patel NH. *See* Chalasani N
Patel P. *See* Hrachovec J
Patel RS. *See* Mulcahy HE
Patel YC. *See* Reynaert H
Pateron D. *See* Tazi KA
Pateron D, Tazi KA, Sogni P, Heller J, Chagneau C, Poirel O, Philippe M, Moreau R, Lebrec D. Role of Aortic Nitric Oxide Synthase 3 (eNOS) in the Systemic Vasodilation of Portal Hypertension, 119:196
Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. Hepatitis C Virus NS5A Protein Inhibits Interferon Antiviral Activity, but the Effects Do Not Correlate With Clinical Response, 117:1187
Patterson D. *See* Kinney T
Patti M. *See* Corley DA
Patti MG. *See* Triadafilopoulos G
Pauels HG. *See* Lügering A
Paulart F. *See* Louis H
Paulson EK
See Baillie J
See Johnson CD
Paulus B. *See* Chadwick VS
Paumgartner G. *See* Bilzer M
Pauwels M. *See* Moreau R
Pawlotsky J-M
Hepatitis C Virus: From Laboratory to Clinic, 124:1996–pmr
Molecular Diagnosis of Viral Hepatitis, 122:1554
Paxian S, Merkle H, Riemann M, Wilda M, Adler G, Hameister H, Liptay S, Pfeffer K, Schmid RM. Abnormal Organogenesis of Peyer's Patches in Mice Deficient for NF-κB1, NF-κB2, and Bcl-3, 122:1853
Payan C. *See* Lunel F
Payen J-L. *See* Bureau C
Payne CM. *See* Dvorak B
Peak RM Jr. Persistence and Pathogenesis: A Great Defense Facilitates a Good Offense. Comment, 122:2085–ss
Pearl DK. *See* Prior TW
Pearlstein GR. *See* Fuss IJ
Pearson L. *See* Baron JA
Pearson PL. *See* Van Belzen MJ
Pearson RK. *See* Chari ST
Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, Ferenci P. Rapid Suppression of Hematopoiesis by Standard or Pegylated Interferon-α, 123:141
Peddis G. *See* Farci P
Pedersen FM
See Lassen A
See Lassen AT
Pedersen J, Gao C, Egekvist H, Bjerring P, Arendt-Nielsen L, Gregersen H, Drewes AM. Pain and Biomechanical Responses to Distention of the Duodenum in Patients With Systemic Sclerosis, 124:1230
Pedersen NL. *See* Cameron AJ
Pedersen SA
See Lundell L
See Myrvold HE
Pederzoli P. *See* Pedrazzoli S
Pediaditakis P. *See* Monga SPS
Pediatric 6mp Collaborative Group. *See* Markowitz J
Pedowitz SD, Matulewicz T, Croft C, Rudolphu H, Strada D, Keifer JA, Topilow AA. The Lack of HER-2/neu Oncogene Amplification in Colorectal Malignancies, 125:1915–c
Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F, Lymphadenetomy Group. Extended Lymphadenectomy for Carcinoma of the Head of the Pancreas, 116:1499–ss
Pedro V. *See* Gustavo C
Peek RM. *See* Goldblum JR
Peek RM. Elimination of *Helicobacter pylori* or Acid in High-Risk Users of Aspirin or Nonsteroidal Medications: Final Answer? Comment, 122:239–ss
Peek RM Jr
See Crawford HC
See Fox JG
See Grady WM
See Graham JE
Peek RM Jr
Molecular Dissection of the Mechanisms Through Which Enteropathogenic *Escherichia coli* Induce Diarrhea. Comment, 121:497–ss
New Insights Into Microbially Initiated Gastric Malignancies: Beyond the

Usual Suspects. Comment, 123:1740–ss
The Politics of *H. pylori*-Challenged Mice: Liberal Permissiveness Versus Conservative Restriction. Comment, 124:578–ss
The Role of PPARγ in Colon Cancer: Is it as Simple as APC? Comment, 125: 620–ss
Suppression of Pathogenesis: Bacteria Lead the Way. Comment, 124:1551–ss
Peek RM Jr, Wirth H-P, Moss SF, Yang M, Abdalla AM, Tham KT, Zhang T, Tang LH, Modlin IM, Blaser MJ. *Helicobacter pylori* Alters Gastric Epithelial Cell Cycle Events and Gastrin Secretion in Mongolian Gerbils, 118:48
Peeters M
See Annovazzi A
See Baert FJ
See Joossens S
See Laharie D
See Vermeire S
Peghini PL, Annibale B, Azzoni C, Milione M, Corleto VD, Gibril F, Venzon DJ, Delle Fave G, Bordi C, Jensen RT. Effect of Chronic Hypergastrinemia on Human Enterochromaffin-like Cells: Insights From Patients With Sporadic Gastrinomas, 123:68
Pehlivanov N. *See* Balaban DH
Pelckmans P. *See* Vermeire S
Pellegrino S. *See* Fracehia M
Peltekova VD. *See* Springer JE
Peltomäki P. *See* Raevaara TE
Pemberton J. *See* He C-L
Pemberton JH
See Locke GR
See Schwartz DA
Pena S
See Hellers G
See van Doorn L-J
Peña S. *See* Vader W
Pencreach E. *See* Chamouard P
Pender SLF. *See* Monteleone G
Penfornis A. *See* Hammel PR
Peng B. *See* Demetri GD
Peng F. *See* Degen LP
Penington RC. *See* Weller SG
Penner E. *See* Kazemi-Shirazi L
Penninckx F. *See* Van Assche G
Peñuelas I. *See* Prieto J
Peppelenbosch M. *See* Hommes D
Peppelenbosch MP
See Hardwick JCH
See van den Brande JMH
See van den Brink GR
Peppelenbosch MP, Van Den Blink B, Van Deventer SJH, Hommes DW. Differential p38 Mitogen-Activated Protein Kinase Target Phosphorylation in Responders and Nonresponders to Infliximab. Reply, 125:635–c
Peppercorn MA
See Bitton A
See Farrell RJ
Pera A. *See* Fracehia M
Perarnau J-M. *See* Moreau R
Percesepe A. *See* Prior TW
Perdue DG, Nelson DB. Virtual Virtual Colonoscopy? Comment, 121:221–ss
Perdue MH
See Söderholm JD
See Yu LCH
Perego L. *See* Alvaro D
Perelman LT. *See* Wallace MB
Perelson AS. *See* Lyra AC
Pérez M. *See* Poo J-L
Pérez-Lafuente M. *See* Junquera F
Pérez-Páramo M. *See* Albillos A
Pérez-Páramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J, Pardo A, Bartoli R, Lorenzo-Zúûiga V, Planas R, Viûado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull M. Prokinetics Reduce Bacterial Translocation in Cirrhosis: Will Sweeping the Gut Keep the Fluid Clean?, 120:314–ss
Perez-Perez GI. *See* Dubois A
Perez-Piteira J. *See* Yamamoto H
Perheentupa J. *See* Obermayer-Straub P
Periskic S. *See* Pandol SJ
Perner A. *See* Andresen L
Pernthaler A. *See* Swidsinski A
Peron J-M. *See* Bureau C
Péron J-M. *See* Alric L
Perras H. *See* Stern HS
Perrett D. *See* Ballinger A
Perri V. *See* Costamagna G
Perrier H. *See* Bourlière M
Perrillo RP
See Chu C-J
See Fontana RJ
Perrillo RP
Acute Flares in Chronic Hepatitis B: The Natural and Unnatural History of an Immunologically Mediated Liver Disease, 120:1009–srr
Fulminant Hepatitis B Due to a Lamivudine-Resistant Mutant of HBV in a Patient Coinfected With HIV. Reply, 122:245–c
Perrin M. *See* Lunel F
Perry MJ. *See* Baugh MD
Perseghin G, Mazzaferro V, Luzi L. Hepatogenous Diabetes: Reduced Insulin Sensitivity and Increased Awareness. Reply, 119:1800–ss
Persico M, Palmentieri B, Morante A, Di Giacomo Russo G, de Marino FA, Torella R. Is the Natural History of Hepatitis C Virus Carriers With Normal Aminotransferase Really Benign? Reply, 121:1527–c
Persico M, Torella R. Controversies About the Histological Features of Chronic HCV Patients With Persistently Normal Alanine Transaminase Levels: What Can Be Done About the Present Definition? Reply, 123:1749–co
Persing DH. *See* Zein NN
Persoons P. *See* Fischler B
Persson T
See Hellers G
See Thomsen Ø
Perucho M
See Malkhosyan SR
See Schwartz S
See Suzuki K
See Yamamoto H
Pescatore P. *See* Vermeire S
Pessayre D
See Demeilliers C
See Mansouri A
Pessione F. *See* Condat B
Peter T. *See* Kamal SM
Peters G. *See* Gongoll S
Peters M. *See* Scholz A
Peters M, Blinn G, Jostock T, Schirmacher P, Büschenfelde K-HMZ, Galle PR, Rose-John S. Combined Interleukin 6 and Soluble Interleukin 6 Receptor Accelerates Murine Liver Regeneration, 119:1663
Peters S. *See* Cook D
Peters T. *See* Kamal SM
Petersen BT
See Chari ST
See Huntsman DG
Petersen F. *See* Lankisch PG
Petersen GM
See Giardiello FM
See Gruber SB
See Rashid A
Peterson D. *See* Chen M
Peterson G. *See* Giardello FM
Peterson KH. *See* Söderholm JD
Peterson LE. *See* Hwang I-R
Peters-Regehr T. *See* Müschen M
Pethig K. *See* Wedemeyer H
Petrai I. *See* Bonacchi A
Petras RE
See Ormsby AH
See Shen B
Petrelli N. *See* Baron JA
Petritsch W. *See* Lochs H
Petroni GR. *See* El-Rifai W
Pettersson E. *See* Thomsen Ø
Pettersson S. *See* Dubuquoy L
Petz JL. *See* Kim WR
Petzke KJ. *See* Gaudichon C

Peuchmaur M. *See* Desreumaux P
Peura DA
Helicobacter pylori *Handbook*, 117:1024–pmr
Mandate to Modify a Medicinal Mantra: Maybe Not Yet?, 124:842–e
Peyer R de. *See* Frossard JL
Pfau PR, Sivak MV Jr. Endoscopic Diagnostics, 120:763
Pfeffer K. *See* Paxian S
Pfeifer A. *See* Vaandrager AB
Pfeiffer G. *See* Cooper HS
Pfister K. *See* Stallmach A
Pfuetzner RH. *See* Doyle DA
Pfützer R, Barmada MM, Whitcomb DC. Mutations of the Pancreatic Secretory Trypsin Inhibitor (PSTI) Gene in Idiopathic Chronic Pancreatitis. Reply, 120:1063–c
Pfützer RH, Barmada MM, Brunskill APJ, Finch R, Hart PS, Neoptolemos J, Furey WF, Whitcomb DC. SPINK1/PSTI Polymorphisms Act as Disease Modifiers in Familial and Idiopathic Chronic Pancreatitis, 119:615–rc
Pfützer RH, Whitcomb DC
Trypsinogen Mutations in Chronic Pancreatitis, 117:1508–c
Wanted: A Consensus Nomenclature for Cationic Trypsinogen Mutations. Reply, 119:278–c
Pham NQ. *See* Cheng SJ
Pham T. *See* Sternini C
Pham TT. *See* McCaffrey AP
Phan TG. *See* Wong RCW
Pharaon I. *See* Cézard JP
Pharoah P. *See* Machado JC
Pharoah P, Caldas C, Huntsman D, Guilford P. E-Cadherin Germline Mutations and Risk of Gastric Cancer. Reply, 123:1406–co
Pharoah PDP, Guilford P, Caldas C. Incidence of Gastric Cancer and Breast Cancer in CDH1 (E-Cadherin) Mutation Carriers From Hereditary Diffuse Gastric Cancer Families, 121:1348
Philippe M. *See* Pateron D
Phillips AD. *See* Müller T
Phillips K. *See* Pineau BC
Phillips SF. *See* Locke GR
Phinizy JL
See Alpini G
See LeSage G
Pi D. *See* Delage G
Pianka JD, Sitaraman SV. Aortic Thrombosis With Spenic and Renal Embolization, 118:637–c
Pianko S. *See* McHutchison JG
Piantadosi S. *See* Giardello FM
Piao Z. *See* Malkhosyan SR
Piazza M. *See* Zehender G
Picabea E. *See* Vorobioff JD
Picciocchi A. *See* Costamagna G
Piche T, des Varannes SB, Sacher-Huvelin S, Holst JJ, Cuber JC, Galmiche JP. Colonic Fermentation Influences Lower Esophageal Sphincter Function in Gastroesophageal Reflux Disease, 124:894
Picolo VE. *See* Cao W
Picon PD. *See* Sander G
Piednoir B. *See* Benamouzig R
Pierce A. *See* Sanders DS
Pierceall WE. *See* Ahlquist DA
Piessevaux H. *See* Tack J
Pietrangelo A. *See* Colombo MP
Pietrangelo A. Hemochromatosis Gene Modifies Course of Hepatitis C Viral Infection, 124:1509–srr
Pietrangelo A. *Proteins of Iron Metabolism*, 125:1906–pmr
Pietros G. *See* D'Amico G
Piette A-M. *See* Izzedine H
Piette J-C. *See* Alric L
Pigini P. *See* Benedetti A
Pignata S. *See* Zarrilli R
Pignone M. *Colorectal Cancer in Clinical Practice: Prevention, Early Detection, and Management*, 125:1549–pmr
Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-Effectiveness of Screening for Colorectal Cancer: The Dollar Is In the Details, 124:856–ss
Pike MG
See Lowry PW
See Sandborn WJ
Pilarsky LM. *See* Yacyshyn BR
Pileri S
See Caletti G
See Liu H
Pilleul F. *See* Marion-Audibert A-M
Pimentel M, Chow EJ, Lin HC. Lactulose Breath Testing, Bacterial Overgrowth, and IBS: Just a Lot of Hot Air?, 125:1898–ss
Pimentel M. Lactulose Breath Testing, Bacterial Overgrowth, and IBS: Just a Lot of Hot Air? Reply, 125:1900–ss
Pincus J. *See* Schroy PC III
Pineau BC. *See* Verne GN
Pineau BC, Paskett ED, Chen GJ, Espeland MA, Phillips K, Han JP, Mikulaninec C, Vining DJ. Virtual Colonoscopy Using Oral Contrast Compared With Colonoscopy for the Detection of Patients With Colorectal Polyps, 125:304
Pinedo HM. *See* van den Eertwegh AJM
Pinieux G de. *See* Bras-Gonçalves RA
Pinkus GS. *See* Jimenez RE
Piñol V. *See* Bessa X
Pinson CW. *Malignant Liver Tumors: Current and Emerging Therapies*, 119:876–pmr
Pinto D. *See* Janssen K-P
Pinto L. *See* Izzo AA
Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, Capasso F. Endocannabinoids as Physiological Regulators of Colonic Propulsion in Mice, 123:227
Pinto M. *See* Brennetot C
Pinzani M
See Bonacchi A
See Caligiuri A
See Failli P
See Marra F
Piotte S. *See* Laharie D
Pipas JM. *See* Baron JA
Piperno A, Arosio C, Fossati L, Viganò M, Trombini P, Vergani A, Mancia G. Two Novel Nonsense Mutations of *HFE* Gene in Five Unrelated Italian Patients With Hemochromatosis, 119:441
Piqué JM
See Bessa X
See Junquera F
See Lacy AM
See Panés J
See Sans M
Piqueras B. *See* Escorsell À
Piris J. *See* Bathgate A
Pirlich M, Schachschal G, Wermke W. Image of the Month, 124:879–im
Pirmohamed M. *See* Brind A
Piscaglia F. *See* Knittel T
Piscopo R. *See* Cipolletta L
Piso P. *See* Gongoll S
Pitchumoni CS
See Nair S
See Yadav D
Pitera JE, Smith VV, Thorogood P, Milla PJ. Coordinated Expression of 3′ *Hox* Genes During Murine Embryonal Gut Development: An Enteric *Hox* Code, 117:1339
Pitman RS. *See* Saubermann LJ
Pitot HC. *See* Boivin GP
Pittman N. *See* Beyer K
Piulats J. *See* Bessa X
Pizarro TT
See Kozaiwa K
See Rivera-Nieves J
See Tountas NA
Pizcueta P. *See* Sans M
Pizzagalli F. *See* Kullak-Ublick GA
Planagumà A. *See* Ros J
Planagumà J. *See* Díaz VM
Planas R
See Cabré E
See García-Pagán JC

See Ginés P
See Pérez-Páramo M
See Sort P
Plasse T. *See* Hommes D
Platek A. *See* Moreau R
Plateroti M, Chassande O, Fraichard A, Gauthier K, Freund J-N, Samarut J, Kedinger M. Involvement of T3Rα– and β-receptor Subtypes in Mediation of T3 Functions During Postnatal Murine Intestinal Development, 116:1367
Plath T. *See* Marschall ZV
Platt JL. *See* Nagata H
Plauchu H. *See* Boillot O
Plauth M. *See* Lochs H
Playford RJ. *See* Arebi N
Plevris JN. *See* Newsome PN
Plomteux O. *See* Laurent-Puig P
Plotz G. *See* Trojan J
Plourde V. *See* Bouin M
Poblete MT. *See* Trevisani M
Pocard M. *See* Bras-Gonçalves RA
Podda M
See Battezzati PM
See Longo M
See Selmi C
Podolsky DK
See Beck PL
See Camilleri M
See Gordon D
See Hisamatsu T
See Mizoguchi E
See Otte J-M
See Sands BE
See Saubermann LJ
See Taupin D
Podolsky DK
Gastroenterology 2000: The Perfect Storm, 118:5–ce
Gastroenterology News, 119:289
Having an Impact: GASTROENTEROLOGY-The Journal, 116:1027–ce
Introduction, 120:593
Winning the War and Losing the Peace?, 119:893–ce
Podolsky DK, LaMont JT. So Where Are All the Celias?, 116:237–ce
Podorigora G. *See* Godot V
Podvinec M. *See* Jung D
Poggioli G. *See* Gionchetti P
Pogue-Geile KL. *See* Whitcomb DC
Pohl LR. *See* Atchison CR
Poirel O
See Pateron D
See Tazi KA
Poirson-Bichat F. *See* Bras-Gonçalves RA
Poitras P. *See* Bouin M
Celiac Disease-like Abnormalities in IBS: Wrong Title or Wrong Disease, 123:954–co
Immune Activation in Irritable Bowel Syndrome: Wrong Title or Wrong Disease? Part 2, 124:1163–c
Pojer C. *See* Fickert P
Pol S. *See* Renou C
Polettini E. *See* Pappalardo G
Poliquin M. *See* Condat B
Poljak M, Seme K, Marin IJ, Babic DZ, Maticic; M, Meglic J. Frequency of the 32-Base Pair Deletion in the Chemokine Receptor CCR5 Gene Is Not Increased in Hepatitis C Patients, 124:1558–c
Polk DB. *See* Kaiser GC
Pollefeyt S. *See* Conway EM
Pollet N. *See* Crosnier C
Polli C. *See* Kazemi-Shirazi L
Pollok RCG. *See* Kelly P
Pollok RCG, Farthing MJG, Bajaj-Elliott M, Sanderson IR, McDonald V. Interferon GAmma Induces Enterocyte Resistance Against Infection by the Intracellular Pathogen *Cryptosporidium parvum*, 120:99
Polson J. *See* Vagquero J
Pombo J. *See* Sigthorsson G
Pomier-Layrargues G. *See* Rose C
Pommier G. *See* André F
Ponath PD. *See* Papdakis KA
Poncet G. *See* Marion-Audibert A-M
Ponec RJ, Saunders MD, Kimmey MB
Neostigmine for Acute Colonic Pseudo-Obstruction: New Use for and Old Drug?, 118:443–ss
Neostigmine for Acute Colonic Pseudo-Obstruction: New Use for and Old Drug? Reply, 118:444–ss
Poneros JM, 118:636–pmr
Gastrointestinal Imaging: Case Review, 121:228–pmr
Poneros JM, Brand S, Bouma BE, Tearney GJ, Compton CC, Nishioka NS. Diagnosis of Specialized Intestinal Metaplasia by Optical Coherence Tomography, 120:7
Pont JJ de. *See* D'Elios MM
Ponti F de. *See* Tonini M
Pontisso P. *See* Gerotto M
Poo J-L. *See* Bosch-Marcé M
Poo J-L, Jiménez W, Muñoz RM, Bosch-Marcé M, Bordas N, Morales-Ruiz M, Pérez M, Deulofeu R, Solé M, Arroyo V, Rodés J. Chronic Blockade of Endothelin Receptors in Cirrhotic Rats: Hepatic and Hemocdynamic Effects, 116:161
Poordad FF. *See* Dubinsky MC
Popovic M. *See* Boocock GR
Porcher C, Horowitz B, Bayguinov O, Ward SM, Sanders KM. Constitutive Expression and Function of Cyclooxygenase-2 in Murine Gastric Muscles, 122:1442
Porrazzo G. *See* Bortolotti M
Porta N. *See* Michetti P
Portal I. *See* Bourlière M
Porte RJ. *See* Sindram D
Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeon-Related Factors and Outcome in Rectal Cancer, 116:220–ss
Porter WM, Unsworth DJ, Lock RJ, Hardman CM, Baker BS, Fry L. Tissue Transglutaminase Antibodies in Dermatitis Herpetiformis, 117:749–c
Portero F. *See* Pérez-Páramo M
Portmann BC. *See* Vautier G
Postic G. *See* Mulcahy HE
Postma C. *See* Hermsen M
Pothoulakis C
See He D
See Morteau O
See Mykoniatis A
See Riegler M
See Savidge TC
See Wlk M
Potten CS. *See* Bach SP
Potti A. *See* Gill N
Potti A. The Lack of HER-2/neu Oncogene Amplification in Colorectal Malignancies, Reply, 125:1916–c
Poujol A. *See* Cézard JP
Poulain D
See Joossens S
See Quinton JF
Poulos JE, Joshi SN, Presti ME. Image of the Month, 116:6–im
Poulsen SS. *See* Jeppesen PB
Poulsom R
See Forbes SJ
See Hull M
See Scott DJ
Pounder RE
See Gordon FH
See Montgomery SM
See Slater E
Pounder RE, Williams MP. Omeprazole and Accelerated Onset of Atrophic Gastritis, 118:238–c
Poupon M-F. *See* Bras-Gonçalves RA
Poupon R
See Corpechot C
See Rosmorduc O
Poupon R-E. *See* Corpechot C
Pour PM. *See* Schneider MB
Pourreyron C. *See* Marion-Audibert A-M
Poutahidis T. *See* Fox JG
Powell DW. *See* di Mari JF
Powell DW
The Future(s) of Gastroenterology and Hepatology: Four Scenarios for

Digestive Health in 2010 (Abstract), 116:1244
Gastroenterologists of the New Millennium. Reply, 117:1028–c
Powell EE. *See* Jonsson JR
Powell JJ. *See* Evans SM
Powell LW
See Bacon BR
See Fletcher LM
See Gochee PA
See Macdonald GA
Powell SM. *See* El-Rifai W
Poynard T
See Alric L
See McHutchison JG
See Moreau R
See Ratziu V
See Sobesky R
Poynard T
Truth Is Not Determined by a Majority Vote. Reply, 124:1155–ss
Poynard T, Marcelin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zuezem S, Trepo C, Albrecht J. Making End Points Meet, 116:1266–ss
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Albrecht J
Reversal of Cirrhosis: Evidence-Based Medicine? Reply, 125:6300–s
Weight-based Ribavirin With Pegylated Interferon alfa 2b: Benefits, Risks, and the Origin of the Evidence. Reply, 124:2004–c
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling M-H, Albrecht J. Impact of Pegylated Interferon Alfa-2b and Ribavirin on Liver Fibrosis in Patients With Chronic Hepatitis C, 122:1303
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling M-S, Albrecht J. PEG-Interferon Versus Conventional Interferon and Liver Fibrosis: Do We Have Evidence of Superiority? Reply, 124:584–c
Pozo MJ. *See* Guarraci FA
Pozzi M, Grassi G, Mancia G. Sympathetic Hyperactivity in Pre-Ascites. Reply, 122:1540–ss
Pozzi M, Grassi G, Redaelli E, Dell'Oro R, Ratti L, Redaelli A, Foglia G, Di Lelio A, Mancia G. Sympathetic Hyperactivity in Pre-Ascites, 122:1538–ss
Prada A. *See* Primignani M
Pradayrol L. *See* Clerc P
Prakash C. *See* Zuckerman GR
Prantera C. *See* Hellers G
Prantera C, Cottone M, Pallone F, Annese V, Franzè A, Cerutti R, Bianchi Porro G, Cooperative Study Group. Mesalamine in the Treatment of Mild to Moderate Active Crohn's Ileitis: Results of a Randomized, Multicenter Trial, 116:521
Prasad M, Matthews JB. Deflating Postoperative Ileus, 117:489–e
Prasad M, Matthews JB, He XD, Akbarali HI. Monochloramine Directly Modulates Ca^{2+}-Activated K^+ Channels in Rabbit Colonic Muscularis Mucosae, 117:906
Prasadan K. *See* Kobayashi H
Prather CM
See Diwakaran HH
See Firth M
Prather CM, Camilleri M, Zinsmeister AR, McKinzie A, Thomforde G. Tegserod Accelerated Orocecal Transit in Patients with Constipation-Predominant Irritable Bowel Syndrome, 118:463
Prats N. *See* Sans M
Preatoni P. *See* Primignani M
Prehn J. *See* Papdakis KA
Preiksaitis HG. *See* Krysiak PS
Prescott RJ. *See* Church NI
Present DH
See Francella A
See Friedman S
See Rubin PH
See Rutgeerts P
See Sandborn WJ
Present DH
Crohn's Fistula: Current Concepts in Management, 124:1629
Infliximab for the Treatment of Fistulas in Patients With Crohn's Disease. Reply, 117:1247–ss
Interaction of 6-Mercaptopurine and Azathioprine With 5-Aminosalicylic Acid Agents, 119:276–c
Present DH, Francella A. Discussion on the Safety of 6-Mercaptopurine for Childbearing Patients With Inflammatory Bowel Disease: A Retrospective Cohort Study. Reply, 125:1562–C
Presti ME. *See* Poulos JE
Preston T. *See* Mowat C
Prete G del. *See* D'Elios MM
Pretlow TP. *See* Boivin GP
Preuett BL. *See* Kobayashi H
Prevotat L. *See* Millet A
Price AB. *See* Salto-Tellez M
Price DA. *See* Jimenez RE
Priest M. *See* Gillett HR
Prieto J
See Bustos M
See Lucena JF
See Lucena J-F
See Qian C
Prieto J, García N, Martí-Climent JM, Peñuelas I, Richter JA, Medina JF. Assessment of Biliary Bicarbonate Secretion in Humans by Positron Emission Tomography, 117:167
Prieto M, Berenguer M. Transplantation for Hepatitis C: Good News and Bad News. Reply, 117:502–ss
Primerano AM. *See* Camellini L
Primi D. *See* Umemura T
Primignani M, Carpinelli L, Preatoni P, Battaglia G, Carta A, Prada A, Cestari R, Angeli P, Gatta A, Rossi A, Spinzi G, de Franchis R, New Italian Endoscopic Club for the Study and Treatment of Esophageal Varices (NIEC). Natural History of Portal Hypertensive Gastropathy in Patients With Liver Cirrhosis, 119:181
Primrose JN. *See* Wright MC
Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and Symptom Progression in a Geographically Based Cohort of Patients With Primary Biliary Cirrhosis: Follow-up for Up to 28 Years, 123:1044
Prince MI
See Goldblatt J
See McRae CA
Pringault E. *See* Sierro F
Prior TW, Chadwick RB, Papp AC, Arcot AN, Isa AM, Pearl DK, Stemmermann G, Percesepe A, Loukola A, Aaltonen LA, de la Chapelle A. The I1307K Polymorphism of the *APC* Gene in Colorectal Cancer, 116:58
Prisco F. *See* de Magistris L
Pritchard DM
See Haigh CR
See Ottewell PD
Pritchard M. *See* Ng AY-N
Pritts TA. *See* Robb BW
Proffitt V. *See* Drossman DA
Promrat K. *See* Ghany MG
Promrat K, McDermott DH, Gonzalez CM, Kleiner DE, Koziol DE, Lessie M, Merrell M, Soza A, Heller T, Ghany M, Park Y, Alter HJ, Hoofnagle JH, Murphy PM, Liang TJ. Associations of Chemokine System Polymorphisms With Clinical Outcomes and Treatment Responses of Chronic Hepatitis C, 124:352
Pronio AM. *See* Boirivant M
Pronk I. *See* van Montfrans C
Propert K. *See* Green RJ
Propping P. *See* Friedl W
Prout M. *See* Schroy PC III

Provenza JM. *See* Lanza FL
Provenzale D
See Jankowski JA
See Kaplan MM
See Muir AJ
Provenzale D. The Cost-effectiveness of Aspirin for Chemoprevention of Colorectal Cancer, 122:230–e
Proye C. *See* Cadiot G
Pruitt R. *See* Levine DS
Prytz H. *See* Bergquist A
Puchyr M. *See* Kim Y-I
Puente E. *See* Torrisani J
Puffenberger E. *See* Morton DH
Pufulete M, Al-Ghnaniem R, Leather AJM, Appleby P, Gout S, Terry C, Emery PW, Sanders TAB. Folate Status, Genomic DNA Hypomethylation, and Risk of Colorectal Adenoma and Cancer: A Case Control Study, 124: 1240
Pukrop T. *See* Sträter J
Punyashthiti R. *See* Masyuk TV
Puolakkainen P. *See* Rautemaa R
Purcell RH. *See* Farci P
Purdie DM
See Fletcher LM
See Jonsson JR
See Radford-Smith GL
Purkiss M. *See* Butterworth JR
Purnell JQ. *See* Cummings DE
Purow D, Jacobson I. *Chronic Viral Hepatitis Diagnosis and Therapeutics*. 125:1278–pmr
Pusl T. *See* Hirata K
Pyrsopoulos N. *See* Jeffers L

Qasim A, Seery J, Morain CAO. Osteoporosis in Newly Diagnosed Inflammatory Bowel Disease, 121: 504–c
Qian C, Sangro B, Prieto J. New Strategies to Enhance Gene Therapy Efficiency, 123:639–e
Qian L. *See* Chen JDZ
Qian T
See Hatano E
See Kim J-S
See Zhao Y
Qian X. *See* Lu G
Qiao S. *See* Iwashita T
Qin H. *See* Reynaert H
Qiu B
See Galeazzi F
See Keates AC
Qiu TH. *See* Troyer KL
Quadri A. *See* Fazel A
Quan C
See Bruggraber SFA
See Zolotarevsky Y
Quan H. *See* Laine L
Quandalle P. *See* Guillem P
Quaratino S. *See* Maiuri L
Quartier E
See Hellemans K
See Reynaert H
Quazi AS. *See* D'Elios MM
Queneau PE. *See* Frossard JL
Quentin Y. *See* Bourlière M
Quer JC. *See* Cabré E
Quere I. *See* Chen J-M
Quertinmont E
See Demols A
See Louis H
Quiding-Jarbrink M. *See* Mattsson A
Quigley EMM. *See* Abell T
Quigley EMM, Hasler WL, Parkman HP. AGA Technical Review on Nausea and Vomiting, 120:263–aga
Quilez C. *See* Pascual S
Quiñones V. *See* Zanlungo A
Quint WGV. *See* van Doorn L-J
Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cartot A, Grandbastien B, Charrier G, Targan SR, Colombel J-F, Poulain D. Is Antibody Testing for Inflammatory Bowel Disease Clinically Useful?, 116:1001–ss
Quiroga J
See Lucena JF
See Lucena J-F
Quiroga S. *See* Junquera F
Qureshi A. *See* Cheng I
Qureshi I. *See* Cheng I

Raaka SD. *See* Tung BY
Rabbani GH, Teka T, Zaman B, Majid N, Khatun M, Fuchs GJ. Clinical Studies in Persistent Diarrhea: Dietary Management With Green Banana or Pectin in Bangladeshi Children, 121: 554
Rabeneck L. *See* El-Serag HB
Rabine JC. *See* Triadafilopoulos G
Rabinovich GA. *See* Santucci L
Rabkin CS. *See* El-Omar EM
Rabkin J. *See* Rosen HR
Rachinel N. *See* Luangsay S
Rachmilewitz D. *See* Hanauer SB
Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E. Immunostimulatory DNA Ameliorates Experimental and Spontaneous Murine Colitis, 122:1428
Rachmilewitz D. On Smoking, Rats, and Inflammatory Bowel Disease, 117: 1008–e
Radaelli G. *See* Gianotti L
Radaeva S. *See* Sun Z
Radaeva S, Jaruga B, Hong F, Kim W-H, Fan S, Cai H, Strom S, Liu Y, El-Assal O, Gao B. Interferon-α Activates Multiple STAT Signals and Down-Regulates c-Met in Primary Human Hepatocytes, 122:1019
Rades T. *See* Feinle C
Radford-Smith GL, Edwards JE, Purdie DM, Pandeya N, Watson M, Martin NG, Green A, Newman B, Florin THJ. A Role for the Appendix in Inflammatory Bowel Disease? Cut it Out, 125:1270–ss
Radford-Smith GL, Florin THJ. A Role for the Appendix in Inflammatory Bowel Disease? Cut it Out. Reply, 125:1272–ss
Radford-Weiss I. *See* Verkarre V
Radhika A. *See* Shattuck-Brandt RL
Radice P. *See* Bertario L
Radini E. *See* Church NI
Radkowski M. *See* Vargas HE
Radlmayr M, Török HP, Martin K, Folwaczny C. The c-insertion Mutation of the *NOD2* Gene is Associated With Fistulizing and Fibrostenotic Phenotypes in Crohn's Disease, 122:2091–c
Radosavljevic M. *See* Dupic F
Rae F. *See* Newsome PN
Rae JL
See Farrugia G
See Holm AN
Raedle J. *See* Trojan J
Raevaara TE, Vaccaro C, Abdel-Rahman WM, Mocetti E, Bala S, Lönnqvist KE, Kariola R, Lynch HT, Peltomäki P, Nyström-Lahti M. Pathogenicity of the Hereditary Colorectal Cancer Mutation *hMLH1* del616 Linked to Shortage of the Functional Protein, 125:501
Rafter J. *See* Glinghammar B
Ragona RM. *See* Restivo DA
Raguenes O. *See* Chen J-M
Rahier J. *See* Hautekeete ML
Rahman A. *See* Hildeand P
Rahman N. *See* Tomlinson I
Rahmani EY. *See* Rex DK
Rahme E, Barkun AN, Toubouti Y, Bardou M. The Cyclooxygenase-2-Selective Inhibitors Rofecoxib and Celecoxib Prevent Colorectal Neoplasia Occurrence and Recurrence, 125:404
Rahmouni A. *See* Mathieu D
Rahner C. *See* Reichel C
Rahner C, Mitic LL, Anderson JM. Heterogeneity in Expression and Subcellular Localization of Claudins 2, 3, 4, and 5 in the Rat Liver, Pancreas, and Gut, 120:411
Rahner C, Stieger B, Landmann L. Apical Endocytosis in Rat Hepatocytes in Situ Involves Clathrin, Traverses a

Subapical Compartment, and Leads to Lysosomes, 119:1692
Raijman I. *See* Filipi CJ
Raimondo M. *See* Chari ST
Raingeard de la Blétière D. *See* Segain J-P
Raithel M. *See* Lochs H
Rajaraman S. *See* Ethridge RT
Rajas F, Bruni N, Montano S, Zitoun C, Mithieux G. The Glucose-6 Phosphatase Gene Is Expressed in Human and Rat Small Intestine: Regulation of Expression in Fasted and Diabetic Rats, 117:132
Rajendran VM. *See* Geibel JP
Raju GS. *See* Arantes V
Raju GS
Barraging the Biliary Tree. Comment, 122:1534–ss
Endoscopic Blockade to Prevent Resurfacing of Esophageal Varices. Comment, 124:1545–ss
Hello, Mr. Clips–Could You Chip in Please? Comment, 125:1896–ss
Hemoclips-Clips to Clasp the Bleeder. Comment, 123:1400–ss
Management of GERD in the Millennium: Is There Room for Endoscopy? Comment, 121:1250–ss
Raju GS, Yusuff T. Fantastic Voyage Through the Gut. Comment, 122: 829–ss
Rak J. *See* Mayer B
Rakela J
See Fontana RJ
See Vargas HE
Rakotobe S. *See* Dubuquoy L
Raldua D. *See* Thwaites DT
Ramadori G
See Knittel T
See Nolte W
Ramaiah B. *See* Castillo S
Ramakers J. *See* Streetz K
Ramakrishna BS, Binder HJ. A Novel Development in Oral Rehydration Therapy. Reply, 119:592–ss
Ramamirtham P. *See* Ricciardiello L
Ramanujam KS. *See* Fu S
Rambaud J-C
See Attar A
See Messing B
Ramesh V. *See* Castells A
Ramey WR. *See* Agarwal B
Ramos R. *See* Hugot J-P
Ramrakhiani S. *See* Lyra AC
Ramsay ME. *See* Harris HE
Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R. Cancer-Attributable Costs of Diagnosis and Care for Persons With Screen-Detected Versus Symptom-Detected Colorectal Cancer, 125:1645
Randolph A
See Boland CR
See Trojan J
Randolph AE. *See* Ricciardiello L
Rangwala SM. *See* Su CG
Ransford RAJ. *See* Langman MJS
Ransford RAJ, Langman MJS. How Safe are the Safest IBD Drugs?, 124:1986–ss
Ransil B. *See* Bitton A
Ransohoff DF
See Imperiale TF
See Lieberman DA
Ransohoff DF. Discovery-Based Research and Fishing, 125:290–ce
Ransohoff DS. Comment From the Editors, 122:1199–ce
Rao CV. *See* Agarwal B
Rao JN. *See* Li L
Rapallo A. *See* Hermsen M
Rapaná RM. *See* Ballestri M
Raposo G. *See* Niel G van
Rasch MC. *See* Eland IA
Rasenack JW. *See* Kamal SM
Raseneck JW. *See* Kamal SM
Rashid A
See Kim SG
See Shen L
Rashid A, Houlihan PS, Booker S, Petersen GM, Giardiello FM, Hamilton SR. Phenotypic and Molecular Characteristics of Hyperplastic Polyposis, 119:323
Rask-Madsen J. *See* Ghosh G
Ratcliffe J. *See* Creed F
Rath HC, Ikeda JS, Linde H-J, Schölmerich J, Wilson KH, Sartor RB. Varying Cecal Bacterial Loads Influences Colitis and Gastritis in HLA-B27 Transgenic Rats, 116:310
Rathey K. *See* Varia I
Rathinavelu S, Zavros Y, Merchant JL. New Insights Into Microbially Initiated Gastric Malignancies: Beyond the Usual Suspects. Reply, 123:1740–ss
Ratineau C, Ronco A, Leiter AB. Role of the Amino-Terminal Domain of Simian Virus 40 Early Region in Inducing Tumors in Secretin-Expressing Cells in Transgenic Mice, 119:1305
Rattan S
See Chadker S
See DiMarino M
Ratti L. *See* Pozzi M
Rattner DW. *Microlaparoscopy*. 121:228–pmr
Ratziu V
See Poynard T
See Sobesky R
Ratziu V, Nourami M, Poynard T. Discussion on Celiac Disease in Patients With Severe Liver Disease: Gluten-Free Diet May Reverse Hepatic Failure, 123:2158–co
Raufman J-P. *See* Coppola AG
Rautelin H. *See* Rautemaa R
Rautemaa R, Rautelin H, Puolakkainen P, Kokkola A, Kärkkäinen P, Meri S. Survival of *Helicobacter pylori* From Complement Lysis by Binding of GPI-Anchored Protectin (CD59), 120:470
Rauws EA. *See* Boerma D
Ravenhill G. *See* Brant SR
Ravine D, Darke C. Discussion on the Role of Hemochromatosis Susceptibility Gene Mutation in Protecting Against Iron Deficiency in Celiac Disease, 124: 1563–c
Rawlins M. *See* Kinney T
Ray K. *See* Hausmann M
Ray KC. *See* Means AL
Ray RM, Patel A, Viar MJ, McCormack SA, Zheng Y, Tigyi G, Johnson LR. RhoA Inactivation Inhibits Cell Migration But Does Not Mediate the Effects of Polyamine Depletion, 123: 196
Raybould HE
See Glatzle J
See Kim M
See Sternini C
Raychowdhury R. *See* Wang TC
Raynaud N. *See* Crosnier C
Raz E. *See* Rachmilewitz D
Read N. *See* Creed F
Read NW
Cerebral Activation in Inflammatory Bowel Syndrome. Reply, 119:1418–c
See French SJ
Functional Dyspepsia: A Case of Indecision, 116:761–e
Irritable Bowel Syndrome. 125:625–pmr
Real FX. A "Catastrophic Hypothesis" for Pancreas Cancer Progression, 124:1958–srr
Reber HA. *See* DiMagno EP
Reber M. *See* Clotman F
Reber P. *See* Saurer L
Rebucci C. *See* Cividini A
Rechreche H. *See* Soubeyran P
Redaelli A. *See* Pozzi M
Redaelli E. *See* Pozzi M
Reddy BS. *See* Agarwal B
Reddy KR
See Sanyal AJ
See Torres M
Redfern S. *See* Norton C
Redford K. *See* Vlahcevic ZR
Redhead DN. *See* Tripathi D
Redmond EM. *See* Theodorakis NG

Redston M. *See* Thompson-Fawcett MW
Reeds PJ. *See* van der Schoor SRD
Reeve JR Jr
See Glatzle J
See Sternini C
Reeves C. *See* Terdiman JP
Rehermann B
See Thomson M
See Wedemeyer H
Rehfeld JF. *See* Chen D
Reichel C, Gao B, van Montfoort J, Cattori V, Rahner C, Hagenbuch B, Stieger B, Kamisako T, Meier PJ. Localization and Function of the Organic Anion-Transporting Polypeptide Oatp2 in Rat Liver, 117:688
Reicin A. *See* Laine L
Reid AE. *See* McHutchison JG
Reid AE. Nonalcoholic Steatohepatitis, 121:710–srr
Reid ME
See Maltzman T
See Martínez ME
Reignat S. *See* Maini MK
Reinecker H-C
See Brand S
See Hisamatsu T
See Mizoguchi E
Reinehr R
See Fischer R
See Graf D
Reinehr R, Graf D, Häussinger D. Bile Salt-Induced Hepatocyte Apoptosis Involves Epidermal Growth Factor Receptor-Dependent CD95 Tyrosine Phosphorylation, 125:839
Reinholdt S. *See* Aalykke C
Reinisch W
See Dejaco C
See Joossens S
Reinisch W, Vogelsang H. Steroid Dependency in Crohn's Disease, 123: 393–c
Reinshagen M. *See* Steinkamp M
Reinshagen M, Rohm H, Steinkamp M, Lieb K, Geerling I, von Herbay A, Flämig G, Eysselein VE, Adler G. Protective Role of Neurotrophins in Experimental Inflammation of the Rat Gut, 119:368
Reisch J. *See* Vagquero J
Reiser M. *See* Rössle M
Reiter RS. *See* Lin JL-C
Reitsma JB
See Buskens CJ
See van Ginkel R
Reitsma PH. *See* de Jonge WJ
Remacle-Bonnet M. *See* André F
Remaut E. *See* Steidler L
Remer EM. *See* Saadeh S
Remy P. *See* Castillo S
Remzi FH. *See* Shen B
Ren H. *See* Kojima K
Ren H, Musch MW, Kojima K, Boone D, Ma A, Chang EB. Short-Chain Fatty Acids Induce Intestinal Epithelial Heat Shock Protein 25 Expression in Rats and IEC 18 Cells, 121:631
Renard P. *See* Moreau R
Renaud F. *See* Millet A
Renes IB. *See* Verburg M
Renou C. *See* Carrière F
Renou C, Pol S, Halfon P, Caillat-Zucman S. Controversies About the Histological Features of Chronic HCV Patients With Persistently Normal Alanine Transaminase Levels: What Can Be Done About the Present Definition?, 123:1748–co
Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ. Manipulating Intestinal Cholesterol Absorption and Hepatic Cholesterol and Bile Acid Metabolism by Activation of Deorphanized Nuclear Receptors, 120:1054–ss
Reperant M. *See* Suraweera N
Rerknimitr R. *See* Suzuki A
Resnick RH, Chopra S. Vitamin D Receptor Gene Analysis in Primary Biliary Cirrhosis, 119:1805–c
Resta-Lenert S, Barrett KE. Enteroinvasive Bacteria Alter Barrier and Transport Properties of Human Intestinal Epithelium: Role of iNOS and COX-2, 122:1069
Restivo DA, Lanza S, Marchese-Ragona R, Palmeri A. Improvement of Masseter Spasticity by Botulinum Toxin Facilitates PEG Placement in Amyotrophic Lateral Sclerosis, 123: 1749–co
Restivo DA, Ragona RM, Staffieri A, Grandis DD. Successful Botulinum Toxin Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy, 119:1416–c
Rettenbacher T, Hollerweger A, Gritzmann N, Gotwald T, Schwamberger K, Ulmer H, zur Nedden D. Appendicitis: Should Diagnostic Imaging Be Performed if the Clinical Presentation Is Highly Suggestive of the Disease?, 123:992
Reubi JC, Waser B, Gugger M, Friess H, Kleeff J, Kayed H, Büchler MW, Laissue JA. Distribution of CCK1 and CCK2 Receptors in Normal and Diseased Human Pancreatic Tissue, 125:98
Reumaux D. *See* Quinton JF
Reuter BK. *See* Wallace JL
Reventós J. *See* Díaz VM
Rex D
See Schoenfeld P
See Winawer S
Rex DK. *See* Suleiman S
Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RKH, Vasudeva RS, Dunne D, Rahmani EY, Helper DJ. Screening for Barrett's Esophagus in Colonoscopy Patients With and Without Heartburn, 125:1670
Rex DK. Is Virtual Colonoscopy Ready for Widespread Application?, 125:608–e
Reyes CN. *See* Gukovskaya AS
Reyes MT. *See* Méndez-Sánchez N
Reynaert H, Vaeyens F, Qin H, Hellemans K, Chatterjee N, Winand D, Quartier E, Schuit F, Urbain D, Kumar U, Patel YC, Geerts A. Somatostatin Suppresses Endothelin-1-Induced Rat Hepatic Stellate Cell Contraction via Somatostatin Receptor Subtype 1, 121:915
Reynaud D. *See* Alric L
Reynes M. *See* Samuel D
Reynisdottir I
See Bjarnason I
See Thjodleifsson B
Reynolds ER. *See* Sizemore N
Reynolds T. *See* Akriviadis E
Rhoads JM, Argenzio RA, Chen W, Graves LM, Licato LL, Blikslager AT, Smith J, Gatzy J, Brenner DA. Glutamine Metabolism Stimulates Intestinal Cell MAPKs by a cAMP-Inhibitable, Raf-Independent Mechanism, 118:90
Rhoads M. *Gastrointestinal Mucosal Repair and Experimental Therapeutics*, 124:1159–pmr
Rhodes J. *See* Richardson CE
Rhodes JM. *See* Evans RC
Rholl V. *See* Hirota WK
Riba J. *See* Pérez-Páramo M
Riberdy M. *See* Bouin M
Ribieras S. *See* Tomasetto C
Ricart E. *See* Sandborn WJ
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful Management of Crohn's Disease of the Ileoanal Pouch With Infliximab, 117:429–cr
Ricart E, Sandborn WJ. Infliximab for the Treatment of Fistulas in Patients With Crohn's Disease. Comment, 117: 1247–ss
Ricchi P. *See* Zarrilli R
Ricciardiello L. *See* Boland CR
Ricciardiello L, Laghi L, Ramamirtham P, Chang CL, Chang DK, Randolph AE, Boland CR. JC Virus DNA Sequences

Are Frequently Present in the Human Upper and Lower Gastrointestinal Tract, 119:1228
Riccioni ME. *See* Costamagna G
Rice RW. *See* Ormsby AH
Rice TW
See Goldblum JR
See Ormsby AH
Rich A
See Farrugia G
See Holm AN
Rich JD. *See* Allen SA
Rich M. *See* Shaheen NJ
Richard F. *See* Tamboli CP
Richard S. *See* Hammel PR
Richards N. *See* Boocock GR
Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Thomas GAO, Smith V. Megacystis-Microcolon-Intestinal Hypoperistalsis Syndrome and the Absence of the α3 Nicotinic Acetylcholine Receptor Subunit, 121:350
Richardson JA. *See* Zhu Y
Richardson P. *See* El-Serag HB
Richardson S. *See* Parsi MA
Richmond BL, Boileau AC, Zheng S, Huggins KW, Granholm NA, Tso P, Hui DY. Compensatory Phospholipid Digestion Is Required for Normal Cholesterol Absorption in Pancreatic Phospholipase A_2 Gene-Targeted Mice, 120:1193
Richter JA. *See* Prieto J
Richter JE
See Fackler WK
See Goldblum JR
See Ormsby AH
Richter JE. Antireflux Surgery and Adenocarcinoma of the Esophagus: Let the Truth Be Told, 121:1506–e
Rickes S, Ocran KW, Wermke W. Image of the Month, 124:1727–im
Riddell R
See Driman DK
See Söderholm JD
Riddell RH. *See* Huizinga JD
Ridolfi F
See Benedetti A
See di Sario A
See Galli A
Ridpath J. *See* Ford AC
Riecken EO. *See* Wahnschaffe U
Riecken E-O
See Marschall ZV
See Schmidt W
See Schmitz H
Rieder G. *See* Zavros Y
Riegler M, Castagliuolo I, Wang C, Wlk M, Sogukoglu T, Wenzl E, Matthews JB, Pothoulakis C. Neurotensis Stimulates Cl^- Secretion in Human Colonic Mucosa In Vitro: Role of Adenosine, 119:348
Riemann M. *See* Paxian S
Ries G. *See* Diepolder HM
Rifai K. *See* Ockenga J
Riff DS. *See* Levine DS
Rigby C. *See* Creed F
Rigda R. *See* Zhang Q
Rigney E. *See* Hendrickse MT
Rigo G. *See* Camellini L
Rigopoulou EI. *See* Lau GKK
Rigot V. *See* André F
Rigotti A. *See* Zanlungo A
Rigotti A, Freeman MW. Manipulating Intestinal Cholesterol Absorption and Hepatic Cholesterol and Bile Acid Metabolism by Activation of Deorphanized Nuclear Receptors, 120: 1055–ss
Riley N. *See* McPhaul LW
Riley NE. *See* Bardag-Gorce F
Riley SA. *See* Arasaradnam RP
Rincon JP del, Thorner MO, Gaylinn BD. Motilin-Related Peptide and Ghrelin: Lessons From Molecular Techniques, Peptide Chemistry, and Receptor Biology, 120:587–c
Rindi G. *See* Solcia E
Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E. ECL Cell Tumor and Poorly Differentiated Endocrine Carcinoma of the Stomach: Prognostic Evaluation by Pathological Analysis, 116:532
Ring M. *See* Buchan AMJ
Ring S. *See* Marth T
Ringel Y. *See* Drossman DA
Ringel Y
Gastroenterology Teaching Project 005: Irritable Bowel Syndrome, 125:990–pmr
Schuster Atlas of Gastrointestinal Motility in Health and Disease, Second Edition, 125: 1906–pmr
Rings EHHM, Boudreau F, Taylor JK, Moffett J, Suh ER, Traber PG. Phosphorylation of the Serine 60 Residue Within the Cdx2 Activation Domain Mediates Its Transactivation Capacity, 121:1437
Rio M-C. *See* Tomasetto C
Ríos MC. *See* Goin JC
Rios-Velez L. *See* Nathanson MH
Risaliti A. *See* Adani GL
Risby T. *See* Cope K
Risch HA. *See* El-Omar EM
Rishi AK. *See* Marciniak DJ
Ristevski S. *See* Ng AY-N
Ristimäki A. *See* Buskens CJ
Ritman EL. *See* Masyuk TV
Ritter M. *See* Drobnik W
Rittman B. *See* Jeffers M
Ritz V, Alfalah M, Zimmer K-P, Schmitz J, Jacob R, Naim HY. Congenital Sucrase-Isomaltase Deficiency Because of an Accumulation of the Mutant Enzyme in the Endoplasmic Reticulum, 125:1678
Riu A. *See* Kalinina T
Rivard N
See Deschênes C
See Tremblay E
Rivera CA. *See* Enomoto N
Rivera F
See Bosch-Marcé M
See Morales-Ruiz M
See Ros J
See Titos E
Rivera-Nieves J. *See* Burns RC
Rivera-Nieves J, Bamias G, Alfert J, Bickston SJ, Moskaluk CA, Cominelli F. Intestinal Ischemia and Peripheral Gangrene in a Patient With Chronic Renal Failure, 122:495–cr
Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, Moskaluk CA, Cohn SM, Cominelli F. Emergence of Perianal Fistulizing Disease in the SAMP1/YitFc Mouse, a Spontaneous Model of Chronic Ileitis, 124:972
Rivera-Nieves J, Battle E, Alfert J. Image of the Month, 118:6
Rivoal M. *See* Moreau R
Rizzello F. *See* Gionchetti P
Rizzetto M
See Bugianesi E
See Rosina F
Rizzo WB. *See* Sanyal AJ
Robb BW, Pritts TA, Warner BW. Health-Related Quality of Life After Ileal Pouch Anal Anastomosis for Ulcerative Colitis: Right Answer – Wrong Question. Comment, 112:1180–ss
Robert ME. *See* Shibao K
Roberts JP. *See* Yao FY
Roberts PJ
See Demetri GD
See Miyoshi H
Robertson D, Grimm IS. Chemoprevention of Colon Cancer: Have You Had Your Multivitamin Today? Comment, 116: 1004–ss
Robertson DAF. *See* Weaver SA
Robertson DJ. *See* Siegel CA
Robertson DJ, Gordon SR, Gardner TB. Image of the Month, 123:406–im
Robertson MA. *See* Samowitz WS
Robin C. *See* Glatzle J

Robine S. *See* Janssen K-P
Robinson M. *See* Sands BE
Robinson PA. *See* Hamlin PJ
Roblick UJ. *See* Wedel T
Rocca G. *See* Rosina F
Roccabianca M. *See* Soubeyran P
Roche B. *See* Samuel D
Roche J. *See* Moreau R
Roche TE. *See* Bruggraber SFA
Rockey DC
See Bornstein JD
See Heneghan M
See Muir AJ
Rockey DC
Gastroenterologists of the New Millennium, 117:1028–c
Predicting the Outcome of Hepatitis C Virus Infection. Comment, 120:313–ss
Rockman SP. *See* Whitehead RH
Rockstroh JK. *See* Woitas RP
Rodas A. *See* Garcia RT
Rodes J
See Ortega R
See Sort P
Rodés J
See Bataller R
See Bosch-Marcé M
See Escorsell À
See Ginés P
See Graupera M
See Guevara M
See Moitinho E
See Morales-Ruiz M
See Poo J-L
See Ros J
See Sánchez-Tapias JM
See Titos E
Rodgers R
See Alpini G
See LeSage G
Rodgers VD. *See* Sands BE
Rodica O-L. *See* Shirvani VN
Rodrigues CMP, Steer CJ. Bile Acids and Hepatocyte Apoptosis: Living/Leaving Life in the Fas Lane, 117:732–e
Rodríguez A. *See* Zanlungo A
Rodríguez C. *See* González-Aaldes J
Rodriguez M. *See* García-Pagán JC
Rodriguez Pena MS. *See* van Montfrans C
Rodríguez-Iglesias P. *See* Cabré E
Roe DJ. *See* Alberts DS
Roelofsen H. *See* Schaefer M
Roelofsen H, Wolters H, van Luyn MJA, Miura N, Kuipers F, Vonk RJ. Copper-Induced Apical Trafficking of ATP7B in Polarized Hepatoma Cells Provides a Mechanism for Biliary Copper Excretion, 119:782
Roemen G. *See* Hermsen M
Roepstorff P. *See* Arentz-Hansen H
Roesler B. *See* Kamal SM
Roetto A. *See* Girelli D
Rofecoxib Osteoarthritis Endoscopy Study Group. A Randomized Trial Comparing the Effect of Rofecoxib, a Cyclooxygenase 2-Specific Inhibitor, With That of Ibuprofen on the Gastroduodenal Mucosa of Patients With Osteoarthritis, 117:776
Rogers AB. *See* Fox JG
Rogers KV. *See* Cheng I
Rogers P. *See* Kita H
Rogers SJ. *See* Garcia RT
Rogge H. *See* Sands BE
Rogge JD
See Imperiale TF
See Lieberman DA
Rogler G
See Hausmann M
See Leeb SN
Rogler G, Schölmerich J. NF-kB in IBD: Does Binding to DNA Imply Transcriptional Activity? Reply, 116: 1505–c
Rognum TO. *See* Thornstensen L
Rohal PM. *See* Brant SR
Rohde E. *See* Gut MO
Röher H-D. *See* Schulte C
Rohm H. *See* Reinshagen M
Rojany M. *See* Abreu MT
Rolandi V. *See* Bergamaschi G
Roldán E. *See* León F
Rolke M. *See* Michl P
Rollhauser C. Interleukin 10 and Incidence of Pancreatitis After Therapeutic Endoscopic Retrograde Cholangiopancreatography, 121:232–c
Rollier C, Sunyach C, Barraud L, Madani N, Jamard C, Trepo C, Cova L. Protective and Therapeutic Effect of DNA-Based Immunization Against Hepadnavirus Large Envelope Protein, 116:658
Romagnani P. *See* Bonacchi A
Romagnani S. *See* D'Elios MM
Romagnuolo J, Meier MA, Sadowski DC. Costs of GERD: Facts and Fictions, 125:981–ss
Roman L. *See* Liaw Y-F
Roman RJ. *See* Lu G
Roman RM. *See* Schlenker T
Roman RM, Fitz JG. Emerging Roles of Purinergic Signaling in Gastrointestinal Epithelial and Hepatobiliary Functions, 116:964–srr
Romana S-P. *See* Verkarre V
Romanelli RG
See Caligiuri A
See Failli P
See La Villa G
See Marra F
Romani L. *See* Fiorucci S
Romano M. *See* Fiorucci S
Romans KE. *See* Cruz-Correa M
Rombeau JL. *See* Aberra FN
Rombouts K
See Caligiuri A
See Hellemans K
Romero G. *See* Vorobioff JD
Romero Y. *See* Vazquez-Sequeiros E
Romero-Gómez M, Gutierrez-Tous R, Delgado-Mije D. Anticoagulation Therapy for Recent Portal Vein Thrombosis in a Patient With Liver Cirrhosis Suffering From Variceal Rebleeding, 122:2095–c
Rommens JM. *See* Boocock GR
Ronco A. *See* Ratineau C
Ronco G. *See* Bras-Gonçalves RA
Rong W. *See* Wynn G
Rooijen NV. *See* Selzner N
Rooman I, Lardon J, Flamez D, Schuit D, Bouwens L. Mitogenic Effect of Gastrin and Expression of Gastrin Receptors in Duct-like Cells of Rat Pancreas, 121:940
Roots I. *See* Schwab M
Ropeleski MJ, Tang J, Walsh-Reitz MM, Musch MW, Larson RA, Chang EB. Interleukin-11-Induced Heat Shock Protein 25 Confers Intestinal Epithelial-Specific Cytoprotection From Oxidant Stress, 124:1358
Ros J. *See* Morales-Ruiz M
Ros J, Clària J, To-Figueras J, Planagumà A, Cejudo-Martín P, Fernández-Varo G, Martín-Ruiz R, Arroyo V, Rivera F, Rodés J, Jiménez W. Endogenous Cannabinoids: A New System Involved in the Homeostasis of Arterial Pressure in Experimental Cirrhosis in the Rat, 122:85
Rose C. *See* Chatauret N
Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, Spahr L, Huet P-M, Pomier-Layrargues G. Manganese Deposition in Basal Ganglia Structures Results From Both Portal-Systemic Shunting and Liver Dysfunction, 117:640
Rose-John S
See Neurath MF
See Peters M
Rosen HR. *See* Madoff RD
Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Rabkin J, Corless CL, Bouwer HGA. Association of Multispecific $CD4^+$ Response to Hepatitis C and Severity of Recurrence After Liver Transplantation, 117:926
Rosen HR, Urbarz C, Holzer B, Novi G, Schiessel R. Sacral Nerve Stimulation

as a Treatment for Fecal Incontinence, 121:536
Rosen R, Nurko S, Furuta GT. Impeding Gastroesophageal Refluxate: A New Application of an Old Medication. Comment, 125:984–ss
Rosenau J. *See* Bahr MJ
Rosenberg DW. *See* Girnun GD
Rosenberg IM. *See* Otte J-M
Rosenberg PM. *Therapies for Viral Hepatitis*, 117:506–pmr
Rosenberg WMC. *See* Butterworth JR
Rosenberger JR. *See* van der Schoor SRD
Rosenbloom B. *See* Papadakis KA
Rosenheim M
See Di Martino V
See Lunel F
Rosenstiel P. *See* Waetzig GH
Rosenstiel P, Fantini M, Bräutigam K, Kühbacher T, Waetzig GH, Seegert D, Schreiber S. TNF-α and IFN-γ Regulate the Expression of the NOD2 (CARD15) Gene in Human Intestinal Epithelial Cells, 124:1001
Rosewicz S
See Höcker M
See Marschall ZV
See Scholz A
Rosina F, Conoscitore P, Cuppone R, Rocca G, Giuliani A, Cozzolongo R, Niro G, Smedile A, Saracco G, Andriulli A, Manghisi OG, Rizzetto M. Changing Pattern of Chronic Hepatitis D in Southern Europe, 117:161
Roskams T. *See* Desmet VJ
See Clotman F
See Spirlì C
Rosmawati M. *See* Lai C-L
Rosmorduc O. Differential HFE Allele Expression in Hemochromatosis Heterozygotes. Reply, 123:653–c
Rosmorduc O, Hermelin B, Boelle P-Y, Parc R, Taboury J, Poupon R. *ABCB4* Gene Mutation-Associated Cholelithiasis in Adults, 125:452
Rosmorduc O, Hermelin B, Poupon R. Differential HFE Allele Expression in Hemochromatosis Heterozygotes. Reply, 120:1309–c
Rosmorduc O, Poupon R, Nion I, Wendum D, Feder J, Bérériat G, Hermelin B. A Differential HFE Allele Expression Influences the Iron Overload in Hemochromatosis Heterozygotes, 119:1075
Rosner BA. *See* Giovannucci E
Ross C. *See* Huizinga JD
Rossi A. *See* Primignani M
Rossi E. *See* Gochee PA
Rossi L
See Degen LP
See Hildeand P
See Schneider A
Rössle M. *See* Gerbes A
Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl V, Deibert D, Olschewski M, Reiser M, Gerbes AL. Management of Refractory Ascites: Are Tips or Taps Tops?, 120:311–ss
Rössle M, Siegerstetter V. Duplex Ultrasonography and TIPS, 117:511–c
Rossman H. *See* Jacob P
Rossmann H. *See* Jacob P
Rossmann H, Bachmann O, Vieillard-Baron D, Gregor M, Seidler U. Na^+/HCO_3^- Cotransport and Expression of NBC1 and NBC2 in Rabbit Gastric Parietal and Mucous Cells, 116:1389
Rossol S. *See* Cramp ME
Rost D. *See* Tsujii H
Rost D, König J, Weiss G, Klar E, Stremmel W, Keppler D. Expression and Localization of the Multidrug Resistance Proteins MRP2 and MRP3 in Human Gallbladder Epithelia, 121: 1203–
Rostaing L. *See* Alric L
Roth BE. *Clinical Practice of Gastroenterology*, 116:1009–pmr
Roth M-P. *See* Dupic F
Rothenbacher D, Brenner H. *Helicobacter pylori* Infection in Childhood: Transmission and Role of Antibiotics, 122:1189–c
Rothenberg ME
See Mishra A
See Straumann A
Rothstein R
See Baron JA
See Corley DA
Rothstein RI
See Filipi CJ
See Triadafilopoulos G
Rotondano G. *See* Cipolletta L
Rotter JI
See Abreu MT
See Tountas NA
Rouanet P. *See* Madoff RD
Rouillard D. *See* Janssen K-P
Roukos DH, Paraskevaidis E, Agnantis NJ, Kappas AM. Fruits and Vegetables: Do They Protect From Gastric Cancer?, 124:2006–c
Rouse RW. *See* van Rees BP
Rousseau GQ. *See* Clotman F
Roussomoustakaki M, Koutroubakis I, Vardas EM, Dimoulios P, Kouroumalis EA, Baritaki S, Koutsoudakis G, Krambovitis E. NOD2 Insertion Mutation in a Cretan Crohn's Disease Population, 124: 272–c
Rowland M. *See* Drumm B
Rowland M, Kumar D, Daly L, O'Connor P, Vaughan D, Drumm B. Low Rates of *Helicobacter pylori* Reinfection in Children, 117:336
Roy G. *See* León F
Royo Y. *See* Lanas A
Rozen P, Shomrat R, Strul H, Naiman T, Karminsky N, Legum C, Orr-Urteger A. Prevalence of the I1307K *APC* Gene Variant in Israeli Jews of Differing Ethnic Origin and Risk for Colorectal Cancer, 116:54
R-Pena R. *See* León F
Rubbia-Brandt L. *See* Frossard J-L
Rubin DC. Nutrient Regulation of Intestinal Growth and Adaptation: Role of Glucagon-like Peptide 2 and the Enteroendocrine Cell, 117:261–e
Rubin L, Cole D, Springer J, Heathcote J. Influence of Vitamin D Receptor Gene Polymorphism on Bone Mineral Density in Primary Biliary Cirrhosis. Reply, 119:599–c
Rubin LA. *See* Springer JE
Rubin P. *See* Francella A
Rubin PH. *See* Friedman S
Rubin PH, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J, Waye JD, Present DH. Colonoscopic Polypectomy in Chronic Colitis: Conservative Management After Endoscopic Resection of Dysplastic Polyps, 117:1295
Rubin R
See Sandler RS
See Zhu J
Rubinstein N. *See* Santucci L
Rubio CA, Andersson P, Hanberg A. Gastric Intestinal Metaplasia in Transgenic Mice, 125:996–c
Rubio CA, Befrits R, Jaramillo E, Fisher H, Lindblom A. Mechanism of Diarrhea in Collagenous Colitis, 124: 2000–c
Rubio CA, Befrits R, Jaramillo EJ, Nesi G, Amorosi A. Polypectomy in Chronic Colitis, 119:879–c
Rudi J, Rudy A, Maiwald M, Stremmel W. *Helicobacter* sp. Are Not Detectable in Bile From German Patients With Biliary Disease, 116:1016–c
Rudiger H. *See* Selzner N
Rüdiger HA, Clavien P-A. Tumor Necrosis Factor α, But Not Fas, Mediates Hepatocellular Apoptosis in the Murine Ischemic Liver, 122:202
Rudolph JA, Bezerra J, Alonso M. Image of the Month, 116:788–im
Rudolphu H. *See* Pedowitz SD
Rudy A. *See* Rudi J

Ruebner BH. *See* Sheikh RA
Ruemmele FM. *See* Mention J-J
Ruf A. *See* Vorobioff JD
Rufat P. *See* Malka D
Ruhl CE, Everhart JE
Determinants of the Association of Overweight With Elevated Serum Alanine Aminotransferase Activity in the United States, 124:71
Relation of Elevated Serum Aminotransferase Activity With Iron and Antioxidant Levels in the United States, 124:1821
Ruiz del Arbol L. *See* Ginés P
Ruiz J, Wu GY. *The Basis of Gene Therapy*, 121:1258–pmr
Ruiz P. *See* Smits R
Ruiz-del-Arbol L
See García-Pagán JC
See Sort P
Rullo OJ. *Gastrointestinal Health*, 117:1261–pmr
Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk Factors for the Development of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds, 124:1292
Rungta M, Graham DY. *Drug Therapy for Gastrointestinal and Liver Diseases*, 124:1159–pmr
Runkel N. *See* Schmitz H
Ruoppo E. *See* Mignogna MD
Rusch NJ. *See* Liu X
Ruskone-Fourmestraux A. *See* Liu H
Russel MG
See Boonen A
See Schoon EJ
Russel MGVM. *See* Schoon EJ
Russell R. *See* Boivin GP
Russell RI. *See* Taha AS
Russell RM. *See* Liu C
Russell T. *See* Caplan MS
Russell WE. *See* Carver RS
Russo A
See Bertario L
See Palli D
Russo LL. *See* Mignogna MD
Russo M, Grimm IS. HCV and C282Y: A Sinister Synergism? Comment, 116:495–ss
Russo MP. *See* Weaver SA
Russo MW. *See* Shiva Kumar K
Russo MW, Brown RS Jr. *Advances in Hepatic Encephalopathy & Metabolism in Liver Disease*, 121:1257–pmr
Russo MW, Fried MW. Side Effects of Therapy for Chronic Hepatitis C, 124:1711
Rust C. *See* Miyoshi H
Rustgi AK. *See* Castells A
Rustgi AK
Gastroenterology News, 121:513–gn, 123:3–gn, 123:403–gn, 123:663–gn, 123:965–gn, 123:1424–gn, 123:1759–gn, 124:1724–gn
The Genomic Era: From DNA to Patient and Back to DNA, 118:251–ce
Translational Research: What Is It?, 116:1285–ce
Rusyn I. *See* Wheeler MD
Ruszniewski P
See Attar A
See Cadiot G
See Hammel PR
See Malka D
Rutgeerts P
See Baert F
See D'Haens G
See Fedorak RN
See Ghosh G
See Hanauer SB
See Hellers G
See Joossens S
See Sandborn WJ
See Schreiber S
See Van Assche G
See Vermeire S
Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Efficacy and Safety of Retreatment With Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease, 117:761–rc
Ruth P. *See* Vaandrager AB
Ruuska TH, Karikoski R, Smith VV, Milla PJ. Acquired Myopathic Intestinal Pseudo-Obstruction May Be Due to Autoimmune Enteric Leiomyositis, 122:1132–cr
Ruvoën N. *See* Marionneau S
Ryan BM, Kelleher D. Refractory Celiac Disease, 119:243–srr
Ryan E. *See* Barrett S
Ryan M. *See* van de Wal Y
Ryan MS. *See* Saubermann LJ
Rybicki LA. *See* Ormsby AH
Ryder SD. *See* Vautier G
Ryter SW. *See* Zhang J
Ryu F. *See* Nagao Y

Saab L. *See* Bonen DK
Saab S, Kim M, Wright TL, Han SHB, Martin P, Busuttil RW. Successful Orthotopic Liver Transplantation for Lamivudine-Associated YMDD Mutant Hepatitis B Virus, 119:1382–cr
Saada JI. *See* di Mari JF
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease, 123:745
Sàbat M
See Guarner C
See Villanueva C
Sabattini E. *See* Caletti G
Saberi A. *See* Gill N
Sabin CA. *See* Patch D
Sacchi P. *See* Bruno R
Sachar D. *See* Ullman T
Sachar DB
Genomics and Phenomic in Crohn's Disease, 122:1160–e
Inflammatory Bowel Disease: Clinical Diagnosis and Management, 120:1057–pmr
6-Mercaptopurine Beats a Bum Rap, 125:610–e
Sachar DS. *See* Napierkowski JJ
Sacher-Huvelin S. *See* Piche T
Sachs G
See Scott DR
See Shin JM
Sackett SD. *See* Silberg DG
Sadowski DC. *See* Romagnuolo J
Saeed S. *See* Burdyga G
Saeki T. *See* Boku K
Safdi M. *See* Sandborn WJ
Safdi MA. *See* Sands BE
Sagar M, Tybring G, Dahl M-L, Bertilsson L, Seensalu R. Effects of Omeprazole on Intragastric pH and Plasma Gastrin Are Dependent on the CYP2C19 Polymorphism, 119:670
Sage G le. *See* Alvaro D
Saha S. *See* Pignone M
Sahbatou M. *See* Hugot J-P
Sahel J. *See* Bastid C
Saibil F. *See* Baron JA
Said HM. *See* Dooley S
Saieva C. *See* Palli D
Saigenji K. *See* Boku K
Saiki T. *See* Uwatoku R
Saile B. *See* Knittel T
Sailer M. *See* Timm S
Sáinz R. *See* Lanas A
Sainz S. *See* Villanueva C
Saisho H. *See* Hara T
Saito H. *See* Ethridge RT
Saito M. *See* Kiso S
Saito S. *See* Kawa S
Saitoh K. *See* Dohi T
Saitoh S. *See* Ikeda K
Saitoh Y, Pasricha PJ. On Finding Flat Adenomas: Is the Search Worth the Gain? Reply, 122:840–c
Saji Y. *See* Kamada Y
Sakaguchi T. *See* Brand S
Sakai K. *See* Hwang I-R
Sakai T. *See* Saubermann LJ

Sakai Y, Masamune A, Satoh A, Nishihira J, Yamagiwa T, Shimosegawa T. Macrophage Migration Inhibitory Factor Is a Critical Mediator of Severe Acute Pancreatitis, 124:725
Sakamaki S
See Miyanishi K
See Takayama T
Sakamoto C. *See* Noguchi H
Sakamoto N. *See* Shimoda S
Sakata H. *See* Tsunada S
Sakemi T. *See* Iwakiri R
Sakisaka S. *See* Harada M
Sakiyama Y. *See* Kobayashi I
Sakon M. *See* Yamamoto H
Sakoulas G, Anastopoulos H. Successful Use of Cyclosporine in the Treatment of Glucocorticoid-Resistant Nongranulomatous Chronic Idiopathic Enterocolitis, 117:1258–c
Sakugawa H. *See* Sugauchi F
Sakurada S. *See* Ikeda H
Sala P. *See* Bertario L
Salapatek AMF. *See* Ji J
Salas A. *See* Sans M
Saldinger PF. *See* Michetti P
Saleem RM. *See* Taguchi A
Salen G
See Alberts DS
See Morton DH
Salen G, Knisely AS, Shneider B, Bull L, Morton DH. Abnormal Hepatic Sinusoidal Bile Acid Transport: New Insights Into the Pathogenesis of Cholestasis? Reply, 120:322–c
Salerno F. *See* Marchesini G
Sales D. *See* Levine DS
Salizzoni M. *See* Bugianesi E
Sällberg M. *See* Chen M
Salmerón J-M. *See* Moitinho E
Salmi M. *See* Kurkijärvi R
Salmi M, Alanen K, Grenman S, Briskin M, Butcher EC, Jalkanen S. Immune Cell Trafficking in Uterus and Early Life Is Dominated by the Mucosal Addressin MAdCAM-1 in Humans, 121:853
Saló J. *See* Bessa X
Salomao D. *See* Vazquez-Sequeiros E
Salto-Tellez M, Davidson RD, Price AB. Image of the Month, 120:1076
Saluja A. *See* Frossard J-L
Saluja AK. *See* Lee HS
See Bhagat L
See Singh VP
Saluja AK, Bhagat L. Pancreatitis and Associated Lung Injury: When MIF Miffs, 124:844–e
Saluja AK, Steer M
Early Trpsinogen Activation in Acute Pancreatitis. Reply, 116:772–ss
ICAM-1 in Cerulein-Induced Pancreatitis. Reply, 117:748–c
Salvioli B. *See* Serra J
Salzano R. *See* Galli A
Salzano S. *See* Zarrilli R
Salzberg B. *See* Sands BE
Salzberg BA. *See* Su C
Salzman AL
See Wilson L
See Zingarelli B
Samarasinghe D. *See* Chitturi S
Samarut J. *See* Plateroti M
Sameni M. *See* Marten K
Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, Gruenthal K, Leppert MF, Slattery ML. The Colon Cancer Burden of Genetically Defined Hereditary Nonpolyposis Colon Cancer, 121:830
Sampliner R
See Inadomi JM
See Maltzman T
See Martínez ME
Sampliner RE. *See* Alberts DS
Sampson HA. *See* Beyer K
Samsom M
See Schwartz MP
See van Herwaarden MA
See Verhagen MAMT
Samsom M, Verhagen MAMT, vanBerge Henegouwen GP, Smout AJPM. Abnormal Clearance of Exogenous Acid and Increased Acid Sensitivity of the Proximal Duodenum in Dyspeptic Patients, 116:515
Samson-Bouma M-E. *See* Berriot-Varoqueaux N
Samuel D
See Féray C
See Moreau R
Samuel D, Bizollon T, Feray C, Roche B, Ahmed SNS, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C. Interferon-α 2b Plus Ribavirin in Patients With Chronic Hepatitis C After Liver Transplantation: A Randomized Study, 124:642
Samuel K. *See* Newsome PN
Samuelson LC. *See* Zavros Y
Samulski RJ. *See* Wheeler MD
Sanchez J. *See* Bureau C
Sanchez L. *See* León F
Sánchez L. *See* León F
Sánchez-Lombraña JL. *See* Cabré E
Sánchez-Pozo A. *See* Valdés R
Sanchez-Prieto R. *See* Losa JH
Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of Hepatitis B Virus Genotype on the Long-term Outcome of Chronic Hepatitis B in Western Patients, 123:1848
Sanchez-Tapias JM. Hepatitis B Virus Genotype Distribution in HIV-1 Coinfected Patients. Reply, 125:1560–c
Sanchiz V. *See* Minguez M
Sancho-Bru P. *See* Bataller R
Sandberg-Gertzen H. *See* Bergquist A
Sandberg-Gertzén H. *See* Elmberg M
Sandborn WJ
See Dayharsh GA
See Egan LJ
See Faubion WA
See Faubion WA Jr
See Loftus EV Jr
See Lowry PW
See Mahadevan U
See Panaccione R
See Ricart E
See Schwartz DA
See Silverstein MD
Sandborn WJ
Forecast for Using Metabolite Measurements in the Dosing of Azathioprine or 6-Mercaptopurine for IBD Patients: "Partly Cloudy" Reply, 122:2084–ss
Preventing Antibodies to Infliximab in Patients With Crohn's Disease: Optimize Not Immunize, 124:1140–e
Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA Technical Review on Perianal Crohn's Disease, 125:1508–aga
Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A Review of Activity Indices and Efficacy Endpoints for Clinical Trials of Medical Therapy in Adults With Crohn's Disease, 122:512–srr
Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial, 121:1088–
Sandborn WJ, Loftus EV Jr, Faubion WA. Steroid Dependency in Crohn's Disease. Reply, 123:395–c
Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the Treatment of

Fistulas in Patients With Crohn's Disease: A Randomized, Placebo-Controlled Trial, 125:380
Sandborn WJ, Ricart E, Colombel JF. Successful Closure of Ileal Pouch-Vaginal Fistulas With Infliximab. Reply, 125:633–c
Sandborn WJ, Targan SR. Biologic Therapy of Inflammatory Bowel Disease, 122:1592
Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JWD, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH Jr. Lack of Effect of Intravenous Administration on Time to Respond to Azathioprine for Steroid-Treated Crohn's Disease, 117:527
Sander G, Picon PD, Fuchs FD, Beltrame A, de Souza RR. PEG-Interferon Versus Conventional Interferon and Liver Fibrosis: Do We Have Evidence of Superiority?, 124:584–c
Sanders DS, Carter MJ, Hurlstone DP, Pierce A, Ward AM. Celiac Sprue as a Possible Cause of Symptoms in Presumed Irritable Bowel Syndrome, 122:2086–ss
Sanders KM
See Ördög T
See Porcher C
See Torihashi S
See Ward SM
Sanders KM. Organization of Intestinal Pacemakers, 120:319–c
Sanders KM, Ward SM, Daniel EE. ICC in Neurotransmission: Hard to Swallow a Lack of Involvement, 122:1184–c
Sanders LL. *See* Muir AJ
Sanders TAB. *See* Pufulete M
Sanderson IR. *See* Pollok RCG
Sanderson J. *See* Cuthbert AP
Sandgren EP
See Jamal HZ
See Song SY
Sandkuijl LA. *See* Van Belzen MJ
Sandler RS
See Baron JA
See Martin C
See Sandborn WJ
See Shaheen NJ
Sandler RS
Comment From the Editors, 123:1426–ce
Reporting Randomized Controlled Trials in Gastroenterology: The CONSORT Statement, 121:755–ce
Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The Burden of Selected Digestive Disease in the United States, 122: 1500–srr
Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB Jr, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Preliminary Evaluation of Safety and Activity of Recombinant Human Interleukin 11 in Patients With Active Crohn's Disease, 117:58
Sands BE, Podolsky DK. New Life in a Sleeper: Thalidomide and Crohn's Disease, 117:1485–e
Sanford LP. *See* Bates MD
Sang Park W. *See* Sug Kim H
Sang Q. *See* Hirano I
Sang Q, Goyal RK. Lower Esophageal Sphincter Relaxation and Activation of Medullary Neurons by Subdiaphragmatic Vagal Stimulation in the Mouse, 119:1600
Sangro B
See Lucena JF
See Lucena J-F
See Qian C
Sanmiguel CP. *See* Mintchev MP
Sanna R. *See* van Doorn L-J
Sans M. *See* Panés J
Sans M, Panés J, Ardite E, Elizalde JI, Arce Y, Elena M, Palacán A, Fernández-Checa JC, Anderson DC, Lobb R, Piqué JM. VCAM-1 and ICAM-1 Mediate Leukocyte-Endothelial Cell Adhesion in Rat Experimental Colitis, 116:874
Sans M, Salas A, Soriano A, Prats N, Gironella M, Pizcueta P, Elena M, Anderson DC, Piqué JM, Panés J. Differential Role of Selections in Experimental Colitis, 120:1162
Santantonio T
See Gerlach JT
See Jaeckel E
See Kalinina T
Santella RM. *See* Fontana FJ
Santer R, Hillebrand G, Steinmann B, Schaub J. Intestinal Glucose Transport: Evidence for a Membrane Traffic-Based Pathway in Humans, 124:34
Santiago NA. *See* Fang R
Santorelli G. *See* Valenti L
Santorio R. *See* Mangia A
Santos A. *See* de Magalhães Queiroz DM
Santos J. *See* Pérez-Páramo M
Santos M. *See* Pérez-Páramo M
Santucci L. *See* Fiorucci S
Santucci L, Fiorucci S, Rubinstein N, Mencarelli A, Palazzetti B, Federici B, Rabinovich GA, Morelli A. Galectin-1 Suppresses Experimental Colitis in Mice, 124:1381
Sanyal A. *See* Abouassi S
Sanyal AJ. *See* Shiffman ML
Sanyal AJ
Angiotensin Receptor Blockade and Portal Hypertension: Paradise Gained and Paradise Lost, 121:487–e
Insulin Resistance and Tissue Repair: A "Fato-Logical" Phenomenon, 125:1886–e
Octreotide and Its Effects on Portal Circulation, 120:303–e
Vegetative Infection of TIPS Leading to "Endotipsitis"? Reply, 116:780–c
Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities, 120: 1183
Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T, The Nastra Group. The North American Study for the Treatment of Refractory Ascites, 124: 634
Sanyal R. *See* De BK
Sanz JM. *See* Spirli C
Saotome T. *See* Andoh A
Saperas E. *See* Junquera F
Sapey T. *See* Mendler M-H
Sapone A. *See* de Magistris L
Sappal BS. *See* Wege H
Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B Box Increases the Permeability of Caco-2 Enterocytic Monolayers and Impairs Intestinal Barrier Function in Mice, 123:790
Saracco G. *See* Rosina F
Sardi I. *See* Cianchi F
Sarfeh IJ. *See* Jones MK
Sargent D, Limburg P. *Colorectal Cancer-Multimodality Management*, 125:1551–pmr
Sarkar FH. *See* Marciniak DJ
Sarkar S, Hobson AR, Hughes A, Growcott J, Woolf CJ, Thompson DG, Aziz Q. The Prostaglandin E2 Receptor-1 (EP-1) Mediates Acid-Induced Visceral Pain Hypersensitivity in Humans, 124:18
Sarles J. *See* Cézard JP
Sarna SK
See Ali I
See Liu X

See Lu G
See Shi X-Z
Sarnelli G. *See* De Giorgio R
Sarner M. *See* Vinall LE
Sarosi I. *See* Forbes SJ
Sarr MG
See Chari ST
See Farrugia G
See Holm AN
See Suzuki A
Sarr MG. *Upper Gastrointestinal Surgery: A Comparison to Specialist Surgical Practice*, 122:835–pmr
Sarraf P. *See* Girnun GD
Sartor RB
See Chen F
See Jeffers M
See Rath HC
See Veltkamp C
See Williams KL
Sartor RB
Comment from the Editors, 124:1178–ce
Comments from the Editors, 122:603–ce
Probiotics in Chronic Pouchitis: Restoring Luminal Microbial Balance, 119:584–e
Sasaki H
See Suzuki K
See Yamamoto M
Sasaki I. *See* Shibata C
Sasaki Y
See Kawai N
See Kuzushita N
See Takehara T
Sassolas A. *See* Berriot-Varoqueaux N
Sastre X. *See* Janssen K-P
Sastri B. *See* Lin JL-C
Sata M
See Harada M
See Nagao Y
See Shiratori Y
See Yoshida H
Sato C. *See* Moriguchi H
Sato F. *See* Selaru FM
Sato H
See Ishihara T
See Kazumori H
See Mori N
Sato N
See Enomoto N
See Ikejima K
See Tsune I
Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue CA, Yeo CJ, Cameron JL, Hruban RH, Goggins M. Aberrant Methylation of CpG Islands in Intraductal Papillary Mucinous Neoplasms of the Pancreas, 123:365
Sato T
See Inoue N
See Kanai T
Satoh A. *See* Sakai Y
Satoh A, Shimosegawa T, Satoh K, Ito H, Kohno Y, Masamune A, Fujita M, Toyota T. Activation of Adenosine A1-Receptor Pathway Induces Edema Formation in the Pancreas of Rats, 119:829
Satoh H. *See* Ikeda H
Satoh J. *See* Negoro K
Satoh K. *See* Satoh A
Satoh T. *See* Takayama T
Satoi J. *See* Baumert TF
Satoskar AR. *See* Yu LCH
Satsangi J. *See* Vermeire S
Satsangi J, Chapman RWG, Haldar N, Donaldson P, Mitchell S, Simmons J, Norris S, Marshall SE, Bell JI, Jewell DP, Welsh KI. A Functional Polymorphism of the Stromelysin Gene (MMP-3) Influences Susceptibility to Primary Sclerosing Cholangitis, 121:124
Sattar S. *See* Schneider A
Saubermann LJ
See Mizoguchi A
See Nakajima A
Saubermann LJ, Beck P, de Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka Y, Podolsky DK, Blumberg RS. Activation of Natural Killer T Cells by α-Galactosyl-ceramide in the Presence of CD1d Provides Protection Against Colitis in Mice, 119:119
Sauer PJJ. *See* van Waarde WM
Sauerbruch T
See Heller J
See Schepke M
See Terjung B
See Woitas RP
Sault M-C. *See* Granel B
Saunders MD. *See* Ponec RJ
Saurer L, Reber P, Schaffner T, Büchler MW, Buri C, Kappeler A, Walz A, Friess H, Mueller C. Differential Expression of Chemokines in Normal Pancreas and in Chronic Pancreatitis, 118:356
Saussure P de. *See* Frossard JL
Sauter BV, Parashar B, Showdhury NR, Kadakol A, Ilan Y, Singh H, Milano J, Strayer DS, Chowdhury JR. A Replication-Deficient rSV40 Mediates Liver-Directed Gene Transfer and a Long-term Amelioration of Jaundice in Gunn Rats, 119:1348
Sauter M. *See* Waldegger S
Sauvanet A
See Hammel PR
See Malka D
Sauzeau V. *See* Segain J-P
Savarino V. *See* Zentilin P
Savarino V, Neri M, Vigneri S. PPI-Based Triple Therapy in the Eradication of *H. pylori* Infection, 117:746–c
Savides TJ. *See* Jensen DM
Savides TJ. EUS FNA Staging of Esophageal Cancer, 125:1883–e
Savidge TC. *See* Bush TG
Savidge TC, Pan W-H, Newman P, O'Brien M, Anton PM, Pothoulakis C. *Clostridium difficile* Toxin B Is an Inflammatory Enterotoxin in Human Intestine, 125:413
Sawa A. *See* Watkins CC
Sawai N. *See* Yamaoka Y
Sawai Y. *See* Kiso S
Sawhney H. *See* Kleeff J
Sawhney MS, Nelson DB
An Aspirin a Day Keeps the Cardiologist Away (But What About the Gastroenterologist?) Comment, 124:572–ss
The Winner After 7 Rounds–Fecal Occult Blood Testing! Comment, 122:2081–ss
Yield of Colonoscopy for Non-Acute Rectal Bleeding. Comment, 123:2151–ss
Saxon ML. *See* Troyer KL
Sayer B. *See* Havlik RJ
Scaglione G. *See* Ligresti A
Scapa E. *See* Appleyard M
Scarff KL, Judd LM, Toh B-H, Gleeson PA, van Driel IR. Gastric H^+, K^+-Adenosine Triphosphatase β Subunit Is Required for Normal Function, Development, and Membrane Structure of Mouse Parietal Cells, 117:605
Schachschal G
See Ortner MEJ
See Pirlich M
Schaefer M, Roelofsen H, Wolters H, Hofmann WJ, Müller M, Kuipers F, Stremmel W, Vonk RJ. Localization of the Wilson's Disease Protein in Human Liver, 117:1380
Schaeffeler E. *See* Schwab M
Schaeffer P. *See* Conway EM
Schäfer M. *See* Schmidt W
Schaffalitzky de Muckadell OB
See Lassen A
See Wildner-Christensen M
Schaffer D. *See* Samowitz WS
Schaffner T. *See* Saurer L
Schaible T. *See* D'Haens G
Schaible TF
See Baert FJ
See Rutgeerts P

Schalm SW. *See* Féray C
Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G, Chen D-S, Brouwer JT, Eurohep Study Group for Viral Hepatitis. Interferon-Ribavirin for Chronic Hepatitis C With and Without Cirrhosis: Analysis of Individual Patient Data of Six Controlled Trials, 117:408
Schatzman LC. *See* Bates MD
Schaub J. *See* Santer R
Scheele GA. *See* Freedman SD
Scheffer GL. *See* Hooiveld GJEJ
Schei AJ. *See* Thumshirn M
Schembri JM. *See* Paizis G
Schemmer P. *See* Enomoto N
Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Müller C. Prognostic Significance of the Hepatopulmonary Syndrome in Patients With Cirrhosis, 125:1042
Schepke M. *See* Heller J
Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, Hofer U, Caselmann WH, Sauerbruch T. Hemodynamic Effects of the Angiotensin II Receptor Antagonist Irbesartan in Patients With Cirrhosis and Portal Hypertension, 121:389
Schernick A. *See* van Bömmel F
Scherrer B. *See* Delvaux M
Scherübl H, Sutter AP, Zeitz M. NSAIDs and Esophageal Cancer, 125:1914–c
Scheving LA. *See* Carver RS
Scheving LA. Biological Clocks and the Digestive System, 119:536–srr
Schiano T. *Current Clinical Practic. Disease of the Liver and Bile Ducts. Diagnosis and Treatment*. 116:775–pmr
Schiano TD. *See* Liu LU
Schiedeck THK. *See* Wedel T
Schiedermaier P. *See* Schepke M
Schieferdecker HL. *See* Silberg DG
Schiessel R. *See* Rosen HR
Schiff ER
See Dienstag JL
See Lok ASF
Schillaci A. *See* Laghi A
Schiller J. *See* Rubin PH
Schiller LR. *See* Fine KD
Schilsky ML. *See* Malhi H
Schilsky R. *See* Baron JA
Schiodt FV. *See* Vagquero J
Schirmacher P. *See* Peters M
Schirner M
See Marschall ZV
See Scholz A
Schirren CA. *See* Gerlach JT
Schlaf G. *See* Silberg DG
Schlenker T, Feranchak AP, Schwake L, Stremmel W, Roman RM, Fitz JG. Functional Interactions Between Oxidative Stress, Membrane Na^+ Permeability, and Cell Volume in Rat Hepatoma Cells, 118:395
Schlicht H-J. *See* Diepolder HM
Schlichting J. *See* Leuschner M
Schliebe B. *See* Martin C
Schliess F. *See* Häussinger D
Schloemann SR. *See* Gurtner GJ
Schlueck G. *See* Garcia RT
Schmehl K. *See* Wingler K
Schmid C. *See* Kaplan MM
Schmid P. *See* Lau DT-Y
Schmid RM
See Greten FR
See Paxian S
See Seufferlein T
See Steinle AU
See Wagner M
See Weber CK
Schmid RM. HMG-CoA Reductase Inhibitors for the Treatment of Pancreatic Cancer, 122:565–e
Schmid SW. *See* Läuffer JM
Schmidlin F. *See* Trevisani M
Schmidt A. *See* Bolder U
Schmidt C. *See* Marth T
Schmidt H. *See* Steiner M
Schmidt M. *See* Lügering A
Schmidt W, Wahnschaffe U, Schäfer M, Zippel T, Arvand M, Meyerhans A, Riecken E-O, Ullrich R. Rapid Increase of Mucosal CD4 T Cells Followed by Clearance of Intestinal Cryptosporidiosis in an AIDS Patient Receiving Highly Active Antiretroviral Therapy, 120:984–cr
Schmit A
See Baert F
See Van Gossum A
Schmitt A. *See* Terdiman JP
Schmitt E. *See* Knolle PA
Schmitt K. *See* Dünker N
Schmitt M
See Fischer R
See Kurz AK
Schmitz G. *See* Drobnik W
Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss H-D, Bentzel CJ, Riecken E-O, Schulzke J-D. Altered Tight Junction Structure Contributes to the Impaired Epithelial Barrier Function in Ulcerative Colitis, 116: 301
Schmitz J
See Berriot-Varoqueaux N
See Ritz V
Schneeberber PM. *See* van Doorn L-J
Schneider A, Suman A, Rossi L, Barmada MM, Beglinger C, Parvin S, Sattar S, Ali L, Khan AKA, Gyr N, Whitcomb DC. *SPINK1/PSTI* Mutations Are Associated With Tropical Pancreatitis and Type II Diabetes Mellitus in Bangladesh, 123:1026
Schneider AW, Kalk JF, Klein CP. Angiotensin II Receptor Antagonists in the Pharmacological Therapy of Portal Hypertension: A Caution. Reply, 117:740–ss
Schneider D. *See* Takahashi T
Schneider G. *See* Greten FR
Schneider HT. *See* Benninger J
Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding X-Z, Adrian TE, Pour PM. Prevention of Pancreatic Cancer Induction in Hamsters by Metformin, 120:1263
Schneider M-L. *See* Steiner M
Schneider T
See Kewenig S
See Marth T
Schnekenburger J. *See* Mayerle J
Schnell TG
See Avidan B
See Sontag SJ
Schnettler D. *See* Folwaczny C
Schnitzer TJ. *See* Laine L
Schoelmerich J. *See* Schwab M
Schoenberg JB. *See* El-Omar EM
Schoenfeld P. *See* Laine L
Schoenfeld P, Guyatt F, Hamilton F, Laine L, Cook D, Bjorkman D, Morgan D, Peterson W. An Evidence-Based Approach to Gastroenterology Diagnosis, 116:1230
Schoenfeld P, Lipscomb S, Crook J, Dominguez J, Butler J, Holmes L, Cruess D, Rex D. Accuracy of Polyp Detection by Gastroenterologists and Nurse Endoscopists During Flexible Sigmoidoscopy: A Randomized Trial, 117:312
Schoetz DJ Jr. *Textbook of Anal Diseases*. 116:1011–pmr
Scholl B. *See* Halkic N
Scholle F. *See* Okuda M
Scholmerich J. *See* Merger M
Schölmerich J
See Grossmann J
See Hausmann M
See Leeb SN
See Mühlbauer M
See Rath HC
See Rogler G
See Sandborn WJ
Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, Rosewicz S.

Activated Signal Transducer and Activator of Transcription 3 (STAT3) Supports the Malignant Phenotype of Human Pancreatic Cancer, 125:891
Schomerus P. *See* Backmund M
Schöniger-Hekele M. *See* Schenk P
Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrügger RW, Brummer R-JM. Bone Mineral Density in Patients With Recently Diagnosed Inflammatory Bowel Disease, 119: 1203
Schoon EJ, Russel MGVM, Stockbrügger RW. Osteoporosis in Newly Diagnosed Inflammatory Bowel Disease. Reply, 121:505–c
Schor H. *See* Chowers Y
Schotte L. *See* Steidler L
Schrag D. Defining Optimal Treatment for Stage II Colon Cancer: Does Decision Analysis Help?, 117:1005–e
Schramm W. *See* Spannagl M
Schraut WH
See Kalff JC
See Türler A
Schraut WW. *See* Gerlach JT
Schreiber S
See Croucher PJP
See Cuthbert AP
See Fedorak RN
See Hampe J
See Hanauer SB
See Rosenstiel P
See Swidsinski A
See Waetzig GH
Schreiber S, Fedorak MN, Nielsen OH, Wild G, Williams NC, Nilolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJH, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn's Disease, 119:1461
Schroy PC III, Heeren T, Bliss CM, Bliss CM Jr, Pincus J, Wilson S, Prout M
Implementation of On-Site Screening Sigmoidoscopy Positively Influences Utilization by Primary Care Providers, 117:304
On-Site Screening Sigmoidoscopy Promotes Long-term Utilization but Fails as a Venue for Training Primary Care Endoscopists, 122:1226
Schrump DS. *See* Abou-Saif A
Schteingart CD. *See* Bolder U
Schubert ML
See Abouassi S
See Foody W
See Mogyorósi A
See Zaki M
Schubert ML. *H. pylori* and Nonulcer Dyspepsia: Not Guilty As Charged. Comment, 117:270–ss
Schubert S. *See* Waidmann M
Schuetz JD. *See* Wagner M
Schuetz T. *See* Ockenga J
Schuff-Werner P. *See* Steiner M
Schuit D. *See* Rooman I
Schuit F
See Boushey RP
See Hellemans K
See Reynaert H
Schulte C, Dignass AU, Goebell H, Röher H-D, Schulte K-M. Genetic Factors Determine Extent of Bone Loss in Inflammatory Bowel Disease, 119:909
Schulte K-M
See Schulte C
See Sturm A
Schultsz C, van den Berg FM, ten Kate FW, Tytgat GNJ, Dankert J. The Intestinal Mucous Layer From Patients With Inflammatory Bowel Disease Harbors High Numbers of Bacteria Compared With Controls, 117:1089
Schultz J. *See* Berge KE
Schultz SG. *See* Kozar RA
Schultze-Osthoff K. *See* Bantel H
Schulz S. *See* Park J
Schulze K. *See* Paglia P
Schulzke JD
See Gitter AH
See Wahnschaffe U
Schulzke J-D
See Bürgel N
See Schmitz H
Schuman LM. *See* Mandel JS
Schumann H. *See* Zimmer K-P
Schuppan D. *See* Benninger J
Schuppan D, Hahn EG. Interleukin 10: The Magic Bullet for Liver Fibrosis?, 119:1412–c
Schuppan D. Limitations of Anti-Guinea Pig Liver Transglutaminase IgA in Screening of Celiac Disease. Reply, 120:587–c
Schurmans P. *See* Baert F
Schuster N. *See* Dünker N
Schütz G. *See* Streetz KL
Schutz S. *See* Mulcahy HE
Schwab M. Lack of Association Between the C3435T *MDR1* Gene Polymorphism and Inflammatory Bowel Disease in Two Independent Northern European Populations. Reply, 125:1920–c
Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. Association Between the C3435T *MDR1* Gene Polymorphism and Susceptibility for Ulcerative Colitis, 124:26
Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the Diagnosis of TPMT Deficiency in a Patient With Crohn's Disease Using Phenotyping Only, 121:500–c
Schwake L. *See* Schlenker T
Schwamberger K. *See* Rettenbacher T
Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The Natural History of Fistulizing Crohn's Disease in Olmstead County, Minnesota, 122:874
Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Goardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandborn WJ. A Comparison of Endoscopic Ultrasound, Magnetic Resonance Imaging, and Exam Under Anesthesia for Evaluation of Crohn's Perianal Fistulas, 121:1064–
Schwartz H. *See* Laine L
Schwartz ME. *See* Liu LU
Schwartz MP, Samsom M. Image of the Month, 121:1039–im
Schwartz S, Perucho M. Somatic Mutations in Mitochondria' DNA Do Not Associate With Nuclear Microsatellite Instability in Gastrointestinal Cancer, 119:1906–c
Schwartz S Jr. *See* Brennetot C
Schwartzman JD. *See* Buzoni-Gatel D
Schwarz KB. *See* Jonas MM
Schwarz NT, Engel B, Eskandari MK, Kalff JC, Grandis JR, Bauer AJ. Lipopolysaccharide Preconditioning and Cross-Tolerance: The Induction of Protective Mechanisms for Rat Intestinal Ileus, 123:586
Schwarz NT, Kalff JC, Türler A, Engel BM, Watkins SC, Billiar TR, Bauer AJ. Prostanoid Production via COX-2 as a Causative Mechanism of Rodent Postoperative Ileus, 121:1354
Schwertschlag US. *See* Sands BE
Sciutto A. *See* Hermsen M
Scoazed J-Y. *See* Marion-Audibert A-M
Scoggins CR. *See* Song SY
Scolapio J. *See* Buchman AL
Scolapio JS. Tales From the Crypt, 124: 561–e
Scott DJ, Hull MA, Cartwright EJ, Lam WK, Tisbury A, Poulsom R,

Markham AF, Bonifer C, Coletta PL. Lack of Inducible Nitric Oxide Synthase Promotes Intestinal Tumorigenesis in the *Apc*$^{Min/+}$ Mouse, 121:889
Scott DR, Marcus EA, Weeks DL, Sachs G. Mechanisms of Acid Resistance Due to the Urease System of *Helicobacter pylori*, 123:187
Scott KGE. *See* Buret AG
Scott KG-E, Meddings JB, Kirk DR, Lees-Miller SP, Buret AG. Intestinal Infection With *Giardia* spp. Reduces Epithelial Barrier Function in a Myosin Light Chain Kinase-Dependent Fashion, 123:1179
Scotto B. *See* Bacq Y
Scribe-Outtas M. *See* Moreau R
Scurlock JP. *Ultrasound of Abdominal Transplantation*, 124:1556–pmr
Seal S. *See* Tomlinson I
Sears CL. *See* Wu S
Sebo TJ
See Canbay A
See Krishnadath KK
Secondo A. *See* Canani RB
Secondulfo M. *See* de Magistris L
Secreto P. *See* Fracchia M
Seed B. *See* Beck PL
Seegert D
See Rosenstiel P
See Waetzig GH
Seensalu R. *See* Sagar M
Seery J. *See* Qasim A
Seetharam B. Decreased Affinity of Urinary Intrinsic Factor-Cobalamin Receptor in a Case of Gräsbeck-Imerslund Syndrome. Reply, 116:1275–c
Segain J-P, Raingeard de la Blétière D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche J-P, Loirand G. Rho Kinase Blockade Prevents Inflammation Via Nuclear Factor κB Inhibition: Evidence in Crohn's Disease and Experimental Colitis, 124:1180–rc
Seguy D, Vahedi K, Kapel N, Souberbielle J-C, Messing B. Low-Dose Growth Hormone in Adult Home Parenteral Nutrition-Dependent Short Bowel Syndrome Patients: A Positive Study, 124:293
Seiden M. *See* Chen A
Seidler U
See Jacob P
See Rossmann H
Seidman E. *See* Steinhart AH
Seidman EG. *See* Dubinsky MC
Seidman EG. 6-Mercaptopurine in Maintaining Remission in Crohn's Disease: An Old Friend Becomes a New Hero, 119:1158–e
Seiler M. *See* Wallace MB
Seitz HK. *See* Liu C
Seki M. *See* Kakyo M
Sekihara H
See Osawa E
See Tanaka N
Sekimoto M. *See* Yamamoto H
Selaru FM, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang S, Twigg C, Olaru A, Shustova V, Leytin A, Hytiroglou P, Shibata D, Harpaz N, Meltzer SJ. Artificial Neural Networks Distinguish Among Subtypes of Neoplastic Colorectal Lesions, 606–rc
Selby JV. *See* Levin TR
Selemidis S. *See* Cocks TM
Selinka H-C. *See* Sotlar K
Sellers MT. *See* Meng G
Sellin JH, 125:1569–tmig
This Month in GASTROENTEROLOGY, 123:401–tmig, 123:661–tmig
Selmi C, Zuin M, Meda F, Podda M, Biondi ML, Cecchini F. Common Variants of the Matrix Metalloproteinase-3 (Stromelysin) Gene Promoter in Primary Biliary Cirrhosis, 122:247–c
Selvaggi F. *See* Canani RB
Selves J. *See* Alric L
Selzner M. *See* Selzner N
Selzner M, Graf R, Clavien P-A. IL-6: A Magic Potion for Liver Transplantation?, 125:256–e
Selzner N, Rudiger H, Graf R, Clavien P-A. Protective Strategies Against Ischemic Injury of the Liver, 125:917–srr
Selzner N, Selzner M, Odermatt B, Tian Y, Rooijen NV, Clavien P-A. ICAM-1 Triggers Liver Regeneration Through Leukocyte Recruitement and Kupffer Cell-Dependent Release of TNF-α/IL-6 in Mice, 124:692
Seme K. *See* Poljak M
Semelka RC. *Hepatobiliary Diseases. Pathophysiology and Imaging*, 123:1745–pmr
Sempoux C. *See* Hautekeete ML
Sen S. *See* De BK
Sen SM, Mookerjee RP, Jalan R. Terlipressin-Induced Vasoconstriction Reversed With N-Acetylcysteine: A Case for Combined Use in Hepatorenal Syndrome?, 123:2160–co
Senagore AJ. *See* Lyford GL
Senba M. *See* Mori N
Sendid B
See Joossens S
See Quinton JF
Sepulveda AR. *See* Kim JJ
Serafini M. *See* Ekström AM
Serafini M, Bellocco R, Wolk A, Ekström AM. Total Antioxidant Potential of Fruit and Vegetables and Risk of Gastric Cancer, 123:985
Serfas K. *See* Stern HS
Serra J. *See* Caldarella MP
Serra J, Azpiroz F, Malagelada J-R
Air Apparent: Studies of Gas and Bloating in IBS, 122:576–ss
Air Apparent: Studies of Gas and Bloating in IBS. Reply, 122:577–ss
Serra J, Salvioli B, Azpiroz F, Malagelada J-R. Lipid-Induced Intestinal Gas Retention in Irritable Bowel Syndrome, 123:700
Serrano Y. *See* Degen LP
Serratrice J. *See* Granel B
Seruca R
See Brennetot C
See Huntsman DG
See Machado JC
See Máximo V
See Suraweera N
See Thorstensen L
Sessa WC
See Morales-Ruiz M
See Shah V
See Tsai M-H
Sessler DI. *See* Taguchi A
Setchell KDR
See Kurbegov AC
See Lee J
Setchell KDR, Heubi JE, Bove KE, O'Connell NC, Brewsaugh T, Steinberg SJ, Moser A, Squires RH Jr. Liver Disease Caused by Failure to Racemize Trihydroxycholestanoic Acid: Gene Mutation and Effect of Bile Acid Therapy, 124:217–cr
Seufferlein T. *See* Steinkamp M
Seufferlein T, Van Lint J, Liptay S, Adler G, Schmid RM. Transforming Growth Factor α Activates Ha-Ras in Human Pancreatic Cancer Cells With Ki-*ras* Mutations, 116:1441
Sever MS. *See* Besisik F
Severs N. *See* Deviére J
Seyama Y. *See* Otani T
Seyedsadr M. *See* Taguchi A
Sfiridaki A. *See* Koutroubakis IE
Shaffer HA. *See* Lawrence C
Shah S
See Bitton A
See Sandler RS
Shah SK. *See* Costamagna G
Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC, Groszmann RJ. Impaired

Endothelial Nitric Oxide Synthase Activity Associated With Enhanced Caveolin Binding in Experimental Cirrhosis in the Rat, 117:1222
Shahbazian A, Holzer P. Regulation of Guinea Pig Intestinal Peristalsis by Endogenous Endothelin Acting at ET_B Receptors, 119:80
Shaheen N
Endoscopic Evaluation and Treatment of Swallowing Disorders, 122:585–pmr
Is There a "Barrett's Iceberg?", 123:636–e
Shaheen NF. Separating Bad From Worse in Barrett's Esophagus. Comment, 125:260–ss
Shaheen NJ. *See* Wei JT
Shaheen NJ
The American Gastroenterological Association's Gastroenterology Teaching Project: Pathology and Pathophysiology of the Upper Gastrointestinal Tract, 125: 987–pmr
Awakening the Sleeping Post-Surgical Abdomen. Reply, 122:1178–ss
Can Gastrografin Heal the Obstructed Bowel? Comment, 124:852–ss
Does Surveillance Endoscopy Improve Life Expectancy in Those With Barrett's Esophagus? Comment, 121: 1516–ss
What Is the Right Age Cutoff for Immediate Endoscopic Investigation of Dyspepsia? Comment, 123:2149–ss
Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is There Publication Bias in the Reporting of Cancer Risk in Barrett's Esophagus?, 119:333
Shaheen NJ, Rich M. *Helicobacter pylori* and Nonulcer Dyspepsia: Looking Beyond the Bug. Comment, 121:736–ss
Shaker R
See Kern M
See Kern MK
Shaker R, Easterling C, Kern M, Nitschke T, Massey B, Daniels S, Grande B Kazandjian M, Dikeman K. Rehabilitation of Swallowing by Exercise in Tube-Fed Patients With Pharyngeal Dysphagia Secondary to Abnormal UES Opening, 122:1314
Shaker R. Unsedated Small Caliber Esophagogastroduodenoscopy Versus Conventional Esophagogastroduodenoscopy: A Comparative Study, 117:1492–e
Shakil O. *See* Akriviadis E
Shan B
See Berge KE
See Repa JJ
Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C. Collaboration Is the Key: Identification of a Celiac Protein, 125: 263–ss
Shanahan F
See Collins CG
See O'Sullivan GC
Shanahan F
Inflammatory Bowel Disease: Immunodiagnostics, Immunotherapeutics, and Ecotherapeutics, 120:622
Thrombosis, Factor V Leiden, and Inflammatory Bowel Disease, 116: 778–c
Turbo Probiotics for IBF. Comment, 120:1298–ss
Viral Discrimination and Subversion of Host Defense at the Epithelial Gateway. Comment, 123:947–ss
Shanahan F, Nally K, O'Sullivan GC. Turning on T-Cell Death and Turning Off Crohn's Disease. Comment, 119: 1166–ss
Shanahan F, O'Sullivan GC
Gene Therapy for Food Allergy. Comment, 119:269–ss
Glial Cells, Mucosal Integrity, and Inflammatory Bowel Disease. Comment, 116:493–ss
How Do Intestinal T Cells Sense the Dietary and Microbial Environment? Comment, 118:445–ss
Shannon B. *See* Elsaleh H
Shapiro D. *See* Laine L
Shapiro JA. *See* Levin TR
Shapiro M. *See* Sands BE
Shapiro RA. *See* Jaiswal M
Sharkey K. *See* van Sickle M
Sharma A. *See* Kaplan MM
Sharma MP. *See* Ahuja V
Sharma N. *See* Taguchi A
Sharma R. *See* Cohen P
Sharma S. *See* Yusta B
Sharma T. *See* Mandal M
Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, DuBois RN. Cyclooxygenase 2 Expression Is Increased in the Stroma of Colon Carcinomas From IL-$10^{-/-}$ Mice, 118: 337
Shau W-Y
See Liu C-J
See Yeh S-H
Shaw GM
See Li L
See Meng G
Shaw M. *See* Rex DK
Shaw SK. *See* Shibahara T
Shaw T, Bowden S, Locarnini S. Chemotherapy for Hepatitis B: New Treatment Options Necessitate Reappraisal of Traditional Endpoints, 123:2135–e
Shawcross DL, Jalan R. Delayed Opioid Withdrawal-like Reaction in Primary Biliary Cirrhosis Following Naloxone Therapy, 121:743–c
Shealy D. *See* Baert FJ
Sheehan D. *See* O'Sullivan GC
Sheen I-S. *See* Chen Y-C
Shefer S. *See* Morton DH
Sheikh RA, Yasmeen S, Ruebner BH. Image of the Month, 117:526
Shen B. *See* Bauer WM
Shen B, Achkar J-P, Lashner BA, Ormsby AH, Remzi FH, Bevins CL, Brzezinski A, Petras RE, Fazio VW. Endoscopic and Histologic Evaluation Together With Symptom Assessment Are Required to Diagnose Pouchitis, 121: 261
Shen L. *See* Ward SM
Shen L, Kondo Y, Hamilton SR, Rashid A, Issa J-PJ. p14 Methylation in Human Colon Cancer Is Associated With Microsatellite Instability and Wild-Type p53, 124:626
Shen Y. *See* Sinicrope FA
Shenoy M. *See* Toma H
Sheridan MJ. *See* Saadeh S
Sherman M
See Blendis L
See Capurro M
Sherman NJ. *See* Teitelbaum DH
Sherman PM
See Otley A
See Söderholm JD
Sherman S. *See* Fogel EL
Shermock KM. *See* Vargo JJ
Sherwood AJ. *See* Dunlop SP
Sherwood R
See Bjarnason I
See Thjodleifsson B
Sheth S, Morrin MM, Saldinger P. Image of the Month, 117:1042
Shetler K. *See* Gerson LB
Shewmake K. *See* Souza RF
Shi G
See Hirano I
See Pandolfino JE
Shi W. *See* Capurro M
Shi X-Z, Lindholm PF, Sarna SK. NF-κB Activation by Oxidative Stress and Inflammation Suppresses Contractility in Canine Colonic Circular Smooth Muscle Cells, 124:1369
Shibahara T, Si-Tahar M, Shaw SK, Madara JL. Adhesion Molecules Expressed on Homing Lymphocytes in Model Intestinal Epithelia, 118:289
Shibahara T, Wilcox JN, Couse T, Madara JL. Characterization of Epithelial

Chemoattractants for Human Intestinal Intraepithelial Lymphocytes, 120:60
Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of Inositol 1,4,5-Trisphosphate Receptors From Bile Duct Epithelia Is a Common Event in Cholestasis, 125:1175
Shibata C, Jin X-L, Naito H, Matsuno S, Sasaki I. Intraileal Capsaicin Inhibits Gastrointestinal Contractions Via a Neural Reflex in Conscious Dogs, 123: 1904
Shibata D. *See* Selaru FM
Shibata H. *See* Ohnishi H
Shields SJ. *See* Wallace MB
Shields SJ, Van Dam J. In Pursuit of the Hidden, the Occult, and the Obscure. Comment, 117:273–ss
Shiffman ML. *See* Sanyal AJ
Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, Mills AS, Garret C. A Randomized, Controlled Trial of Maintenance Interferon Therapy for Patients With Chronic Hepatitis C Virus and Persistent Viremia, 117: 1164
Shih JWK. *See* Umemura T
Shimada M
See Andoh A
See Tanaka S
Shimeld C. *See* De Winter H
Shimizu H, Matsuguchi T, Fukuda Y, Nakano I, Hayakawa T, Takeuchi O, Akira S, Umemura M, Suda T, Yoshikai Y. Toll-Like Receptor 2 Contributes to Liver Injury by *Salmonella* Infection Through Fas Ligand Expression on NKT Cells in Mice, 123:1265
Shimizu T, Yarita Y, Haruna H, Kaneko K, Yamashiro Y. Parent-Child Transmission of *Helicobacter pylori* in the Family, 122:2091–c
Shimoda A. *See* Farci P
Shimoda S. *See* Kamihira T
Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N, Matsushita S, Tanaka A, Worman HJ, Gershwin ME, Harada M. Molecular Mimicry of Mitochondrial and Nuclear Autoantigens in Primary Biliary Cirrhosis, 124:1915
Shimosegawa T
See Inoue N
See Masamune A
See Negoro K
See Sakai Y
See Satoh A
Shimoyama T. *See* Inoue N
Shin DM. *See* Kim JY
Shin JM, Sachs G. Restoration of Acid Secretion Following Treatment With Proton Pump Inhibitors, 123:1588
Shin ME. *See* He W
Shin MS. *See* Park WS
Shindo M, Hamada K, Oda Y, Okuno T. Interferon Treatment of HCV: Do We Need A Virological Response?, 122: 237–ss
Shindo M, Okuno T. Interferon Treatment of HCV: Do We Need A Virological Response? Reply, 122:238–ss
Shinomura Y
See Hirota S
See Kamada Y
See Miyazaki Y
Shinomura Y, 120:108
Shintani Y. *See* Andoh A
Shipley GL. *See* Helmer KS
Shipp BK. *See* Atchison CR
Shiraga T, Miyamoto K-I, Tanaka H, Yamamoto H, Taketani Y, Morita K, Tamai I, Tsuji A, Takeda E. Cellular and Molecular Mechanisms of Dietary Regulation on Rat Intestinal H^+/Peptide Transporter PepT1, 116: 354
Shirai N. *See* Furuta T
Shirai T. *See* Kuno A
Shirai Y
See Dohi T
See Yoshida M
Shiraki K, Nakano T, Hisatomi H. Survivin in Liver, 124:1565–c
Shirasawa S. *See* Parisi MA
Shiratori Y
See Hirata Y
See Ijichi M
See Maeda S
See Yoshida H
Shiratori Y, Imazeki F, Moriyama M, Yang M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Is Hepatic Fibrosis Reversible With Therapy in Hepatitis C?, 120:579–ss
Shirin H. *See* Agarwal B
Shirkwadkar S. *See* Kim Y-I
Shirota Y. *See* Honda M
Shirvani VN, Rodica O-L, Baljeet S, Kaur M, Omary B, Triadafilopoulos, 118: 487
Shitoh K. *See* Miyakura Y
Shiva Kumar K, Lefkowitch J, Russo MW, Hesdorffer C, Kinkhabwala M, Kapur S, Emond JC, Brown RS Jr. Successful Sequential Liver and Stem Cell Transplantation for Hepatic Failure Due to Primary AL Amyloidosis, 122: 2026–cr
Shkedy Z. *See* Fischler B
Shneider B
See Chen F
See Morton DH
See Salen G
Shobowale-Bakre EM. *See* McGovern DPB
Shoeb F. *See* Jin X
Shofti R. *See* Appleyard M
Shojamanesh H. *See* Abou-Saif A
Shomrat R. *See* Rozen P
Shorthouse AJ. *See* Carter MJ
Shouval D. *See* Féray C
Showalter LA. *See* Okuda M
Showdhury NR. *See* Sauter BV
Shreiver R. *See* Appleyard M
Shu D. *See* Chadwick VS
Shuber AP. *See* Ahlquist DA
Shull GE. *See* Walker NM
Shumaker H, Soleimani M, Ulrich CD II. Pancreatic Bicarbonate Secretion: Role of CFTR and the Sodium-Bicarbonate Cotransporter. Reply, 117:275–ss
Shuppan D. Current Concepts of Celiac Disease Pathogenesis, 119:234–srr
Shustova V. *See* Selaru FM
Sibley E. *See* Fang R
Sidhu GS. *See* Charney AN
Siegal GP. *See* Yamamoto M
Siegel CA, Robertson DJ. *Gastroenterology and Hepatology for the Primary Care Provider: Principles, Practice and Guidelines for Referral*. 124:1160–pmr
Siegerstetter V. *See* Rössle M
Siegmund B, Lehr HA, Fantuzzi G. Leptin: A Pivotal Mediator of Intestinal Inflammation in Mice, 122:2011
Sierro F. *See* Debard N
Sierro F, Pringault E, Assman PS, Kraehenbuhl J-P, Debard N. Transient Expression of M-Cell Phenotype by Enterocyte-like Cells of the Follicle-Associated Epithelium of Mouse Peyer's Patches, 119:734
SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Duration of Exposure to Gluten and Risk for Autoimmune Disorders in Patients With Celiac Disease, 117:297
Signore A. *See* Annovazzi A
Sigthorsson G
See Bjarnason I
See Thjodleifsson B
See Tibble JA
Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, Intestinal Integrity, and Pathogenesis of Nonsteroidal Anti-inflammatory Drug Enteropathy in Mice, 122:1913

Sikora SS. *See* Bhatia E
Silberg DG. *See* Lynch JP
Silberg DG, Kaestner KH. Morphogenesis and Maintenance of the Gastric Epithelium: A Role for Sonic Hedgehog?, 121:485–e
Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD, Kaestner KH. Cdx2 Ectopic Expression Induces Gastric Intestinal Metaplasia in Transgenic Mice, 122:689
Silberg DG, Swain GP, Suh ER, Traber PG. cdx1 and cdx2 Expression During Intestinal Development, 119:961
Silberhumer G. *See* Schenk P
Silberman SL. *See* Demetri GD
Silbert D. *See* Wagner M
Silen W. Discussion on Appendectomy Is Followed by Increased Risk of Crohn's Disease, 125:997–c
Silini E. *See* Cividini A
Silva M. *See* Brown GR
Silverman D. *See* Deviere J
Silverman LM. *See* Noone PG
Silverman SG. *See* Demetri GD
Silverstein MD, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical Course and Costs of Care for Crohn's Disease: Markov Model Analysis of a Population-Based Cohort, 117:49
Silvia S. *See* Gustavo C
Simeone D
See Chen X
See Ji B
Simeonidis S. *See* Mykoniatis A
Simmang C. *See* Winawer S
Simmonds D. *See* Dahlan Y
Simmons J. *See* Satsangi J
Simmons NL. *See* Thwaites DT
Simmons RL. *See* Kalff JC
Simon H-U. *See* Straumann A
Simon J
See Izzedine H
See Michetti P
Simon PM. *See* Mysore JV
Simon T. *See* Laine L
Simpson AWM. *See* Green AK
Simpson JE. *See* Gawenis LR
Simpson RJ. *See* Sigthorsson G
Sinclair NF. *See* Chen D
Sindram D, Porte RJ, Hoffman MR, Bentley RC, Clavien P-A. Platelets Induce Sinusoidal Endothelial Cell Apoptosis Upon Reperfusion of the Cold Ischemic Rat Liver, 118:183
Singer S. *See* Demetri GD
Singh AB. *See* Means AL
Singh H
See Dubinsky MC
See Sauter BV
Singh KD. *See* Turnbull GK
Singh P. *See* Cobb S
Singh P. Problem of Imbalance in Risk Factors in Clinical Trials: Logistic Regression Is the Answer, 124:1561–c
Singh P, Velasco M, Given R, Varro A, Wang TC. Progastrin Expression Predisposes Mice to Colon Carcinomas and Adenomas in Response to a Chemical Carcinogen, 119:162
Singh S. *See* Geibel JP
Singh VP
See Bhagat L
See Lee HS
Singh VP, Saluja AK, Steer ML. Serine Protease Inhibitors and F-Actin Redistribution. Reply, 122:592–c
Singleton JW. *See* Sands BE
Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced Expression of Cyclooxygenase 2 Proteins in Hereditary Nonpolyposis Colorectal Cancers Relative to Sporadic Cancers, 117:350
Sircar K. *See* Huizinga JD
Sirvent A. *See* Barbier O
Sisk CM, Watkins KT, Hayashi PH. Image of the Month, 122:1200–im
Si-Tahar M. *See* Shibahara T
Sitaraman SV. *See* Painka JD
Sitzmann JV. *See* Theodorakis NG
Sivak MV Jr. *See* Pfau PR
Sivarao DV, Mashimo HL, Thatte HS, Goyal RK
ICC in Neurotransmission: Hard to Swallow a Lack of Involvement. Reply, 122:1185–c
Lower Esophageal Sphincter Is Achalasic in nNOS$^{-/-}$ and Hypotensive in W/W^{v} Mutant Mice, 121:34
Sivula A. *See* Buskens CJ
Sizemore N, Cox AD, Barnard JA, Oldham SM, Reynolds ER, Der CJ, Coffey RJ. Pharmacological Inhibition of Ras-Transformed Epithelial Cell Growth Is Linked to Down-regulation of Epidermal Growth Factor-Related Peptides, 117:567
Sjödahl R. *See* Söderholm JD
Sjölander A. *See* Öhd JF
Sjöqvist A. *See* Fihn B-M
Sjöström H
See Danielsen EM
See Spodsberg N
See Troelsen JT
Skandalis N. *See* Archimandritis A
Skierski JS. *See* Kamiński R
Skill NJ. *See* Theodorakis NG
Skinner M. *See* Spiller RC
Skoletsky JE. *See* Ahlquist DA
Slack JR. *See* Lammers W
Slater E, Owen RJ, Williams M, Pounder RE. Conservation of the *cag* Pathogenicity Island of *Helicobacter pylori*: Associations With Vacuolating Cytotoxin Allele and IS*605* Diversity, 117:1308
Slattery ML. *See* Samowitz WS
Sleisenger MH. *See* Terdiman JP
Slikowski MX, Du Bois R. HER-2/neu Overexpression in Colonic Malignancies. Reply, 122:248–c
Slivka A. *See* Desautels SG
Sloane B. *See* Marten K
Slogoff M. *See* Ethridge RT
Slonim AE, Bulone L, Damore MB, Golberg T, Wingertzahn MA, McKinley MJ. Novel Medical Therapies for Crohn's Disease: Is There Room for Growth?, 120:308–ss
Slors JFM. *See* Brink MA
Slosberg ED. *See* Zhu GH
Sly WS. *See* Parkkila S
Smallwood RA
See Angus PW
See Froomes PRA
Smart DE. *See* Wright MC
Smedile A. *See* Rosina F
Smeeton NC. *See* Thomas LA
Smid SD. *See* Lehmann A
Smith AJ. *See* de Vree JML
Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. HCV and C282Y: A Sinister Synergism?, 116:494–ss
Smith C. *See* West J
Smith J
See Jensen DM
See Rhoads JM
Smith JK. *See* Drossman DA
Smith L. *See* Dahlan Y
Smith MF Jr. *See* Kozaiwa K
Smith NR. *See* Hamlin PJ
Smith PD
See Janoff EN
See Li L
See Meng G
Smith V. *See* Richardson CE
Smith VV
See Pitera JE
See Ruuska TH
Smith WM. *See* Girnun GD
Smits R, Ruiz P, Diaz-Cano S, Luz A, Jagmohan-Changur S, Breukel C, Birchmeier C, Birchmeier W, Fodde R. *E-cadherin* and Adenomatous Polyposis Coli *(Apc)* Mutations Are Synergistic in Intestinal Tumor Initiation in Mice, 119:1045
Smout AJPM
See Samsom M

See van Herwaarden MA
See Verhagen MAMT
Smutney O. *See* Froh M
Smyrk TC
See Chari ST
See Huntsman DG
See Lynch HT
Snapper S. *See* Saubermann LJ
Sninsky CA
See Sandborn WJ
See Sands BE
Snover DC
See Baron JA
See Mandel JS
Snowball M, McMahon BJ. *Living with Hepatitis B. A Survivor's Guide*, 123: 1745–pmr
Snyder J. *Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis and Management*, 119:273–pmr
Snyder SH. *See* Watkins CC
Soares P. *See* Máximo V
Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling The Impact of Interferon Alfa Treatment on Liver Fibrosis Progression in Chronic Hepatitis C: A Dynamic View, 116:378
Sobhani I, Buyse M, Goïot H, Weber N, Laigneau J-P, Henin D, Soulé J-C, Bado A. Vagal Stimulation Rapidly Increases Leptin Secretion in Human Stomach, 122:259–rc
Sobhani I, Vuagnat A, Walker F, Vissuzaine C, Mirin B, Hervatin F, Marmuse J-P, Crémieux A-C, Carbon C, Henin D, Lehy T, Mignon M. Prevalence of High-Grade Dysplasia and Cancer in the Anal Canal in Human Papillomavirus-Infected Individuals, 120:857
Sobrinho-Simoes M
See Máximo V
See Thorstensen L
Sobrinho-Simões M. *See* Machado JC
Socci ND. *See* Cohen P
Söderholm JD, Peterson KH, Olaison G, Franzén LE, Weström B, Magnusson K-E, Sjödahl R. Epithelial Permeability to Proteins in the Noninflamed Ileum of Crohn's Disease?, 117:65
Söderholm JD, Yang P-C, Ceponis P, Vohra A, Riddell R, Sherman PM, Perdue MH. Chronic Stress Induces Mast Cell-Dependent Bacterial Adherence and Initiates Mucosal Inflammation in Rat Intestine, 123: 1099
Sodeyama H. *See* Maeyama H
Soellner S. *See* Wedel T
Soffer E. *See* Lyford GL
Soffer EE. *See* He C-L
Sofroniew MV. *See* Bush TG
Sogawa M. *See* Kuno A
Sogni P
See Pateron D
See Tazi KA
Sogukoglu T. *See* Riegler M
Soh JW. *See* Zhu GH
Sohn N. *Colorectal Disease for Physicians and Surgeons*, 116:501–pmr
Sokal EM
See Jansen PLM
See Jonas MM
Sokol RJ. *See* Kurbegov AC
Sola J. *See* Lucena J-F
Solà R
See García-Pagán JC
See Guarner C
Solary E. *See* Millet A
Solberg C. *See* Hampe J
Solcia E. *See* Rindi G
Solcia E, Bordi C, Capella C, Stolte M, Rindi G. ECL Cell Tumor and Endocrine Carcinoma of the Stomach. Reply, 117:510–c
Soldevila-Pico C. *See* Chu C-J
Soldevilla A. *See* Distrutti E
Solé M
See Bataller R
See Poo J-L
Soleimani M. *See* Shumaker H
Sollid LM
See Arentz-Hansen H
See Molberg Ø
See Shan L
Solnick JV. *See* Mattapallil JJ
Solomon TE. *See* Pandol SJ
Sommer G. *See* Weber CK
Somogyi L, Martin SP, Venkatesan T, Ulrich CD II. Recurrent Acute Pancreatitis: An Algorithmic Approach to Identification and Elimination of Inciting Factors, 120: 708
Somsouk M, Lauer GM, Casson D, Terella A, Day CL, Walker BD, Chung RT. Spontaneous Resolution of Chronic Hepatitis C Virus Disease After Withdrawal of Immunosuppression, 124:1946–cr
Song AM. *See* Bhagat L
Song SY, Gannon M, Washington MK, Scoggins CR, Meszoely IM, Goldenring JR, Marino CR, Sandgren EP, Coffey RJ Jr, Wright CVE, Leach SD. Expansion of Pdx1-Expressing Pancreatic Epithelium and Islet Neogenesis in Transgenic Mice Overexpressing Transforming Growth Factor α, 117:1416
Song Y. *See* Cohen P
Sonnemans MAF. *See* McPhaul LW
Sonnenberg A
See Avidan B
See Inadomi JM
See Suleiman S
Sonnenberg A, Fennerty MB. Medical Decision Analysis of Chemoprevention Against Esophageal Adenocarcinoma, 124:1758
Sönnerborg A. *See* Chen M
Sontag SJ. *See* Avidan B
Sontag SJ, Schnell TG, Chejfec G. Barrett's Esophagus and Neoplasia: Data From the Bayreuth Barrett's Archive. Reply, 122:590–c
Sonzogni A. *See* Spirlì C
Soomro I. *See* Hendrickse MT
Soper P. *See* Madsen K
Sorbi D, Gostout CJ, Henry J, Lindor KD. Unsedated Small-Caliber Esophagogastroduodenoscopy (EGD) Versus Conventional EGD: A Comparative Study, 117:1301
Sorensen HA. *See* Haderslev KV
Soresi M. *See* Carroccio A
Soriano A. *See* Sans M
Soriano G
See Guarner C
See Sort P
See Villanueva C
Soroka CJ. *See* Lee J
Sorrell MF. *Diseases of the Liver and Biliary System*, 124:579–pmr
Sorrentini I. *See* Ligresti A
Sort P. *See* Guevara M
Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, Rodes J. Intravenous Albumin Reduces Mortality in Patients With Spontaneous Bacterial Peritonitis, 118:231–ss
Sort P, Navasa M, Arroyo V, Ginès P. Intravenous Albumin Reduces Mortality in Patients With Spontaneous Bacterial Peritonitis. Reply, 118:233–ss
Soskolne CL. *See* Porter GA
Soslow RA. *See* Zhang F
Sotlar K, Köveker G, Aepinus C, Selinka H-C, Kandolf R, Bültmann B. Human Papillomavirus Type 16-Associated Primary Squamous Cell Carcinoma of the Rectum, 120:988–cr
Sottini A. *See* Umemura T
Souberbielle J-C. *See* Seguy D
Soubeyran P, André F, Lissitzky J-C, Mallo GV, Moucadel V, Roccabianca M,

Rechreche H, Marvaldi J, Dikic I, Dagorn J-C, Iovanna JL. Cdx1 Promotes Differentiation in a Rat Intestinal Epithelial Cell Line, 117:1326
Sougioultzis S
See He D
See Mykoniatis A
Soukas AA. *See* Cohen P
Soulé J-C. *See* Sobhani I
Sousa S. *See* Machado JC
Soussi T. *See* Janssen K-P
Southwell BR, Furness JB. Immunohistochemical Demonstration of the NK_1 Tachykinin Receptor on Muscle and Epithelia in Guinea Pig Intestine, 120:1140
Souza RF, Shewmake K, Terada LS, Jon Spechler S. Acid Exposure Activates the Mitogen-Activated Protein Kinase Pathways in Barrett's Esophagus, 122: 299
Soybel DI
See Cheng I
Soybel DI
Extended Lymphadenectomy for Carcinoma of the Head of the Pancreas. Comment, 116:1500–ss
Surgeon-Related Factors and Outcome in Rectal Cancer. Comment, 116:220–ss
Soza A. *See* Promrat K
Sozzi V. *See* Cocks TM
Spada C. *See* Costamagna G
Spahr L
See Frossard JL
See Rose C
Spahr L, Vingerhoets F, Lazeyras F, Delavelle J, DuPasquier R, Giostra E, Mentha G, Terrier F, Hadengue A. Magnetic Resonance Imaging and Proton Spectroscopic Alterations Correlate With Parkinsonian Signs in Patients With Cirrhosis, 119:774
Spangenberg H. *See* Hoon Ahn S
Spannagl M, Dick A, Folwaczny C, Schramm W, Loeschke K. Factor V Leiden Mutation in Patients With Inflammatory Bowel Disease, 117:280–c
Spaulding AC. *See* Allen SA
Spechler SJ
AGA Technical Review on Treatment of Patients With Dysphagia Caused by Benign Disorders of the Distal Esophagus, 117:233–aga
American Gastroenterological Association Medical Position Statement on Treatment of Patients With Dysphagia Caused by Benign Disorders of the Distal Esophagus, 117:229–aga
Barrett's Esophagus: An Overrated Cancer Risk Factor, 119:587–e
Carcinogenesis at the Gastroesophageal Junction: Free Radicals at the Frontier, 122:1518–e
The Role of Gastric Carditis in Metaplasia and Neoplasia at the Gastroesophageal Junction, 117:218–srr
Speer CA, Ferrentino N. Angiotensin Receptor Antagonists in Portal Hypertension: Fog Over Paradise, 122: 1543–c
Speizer FE. *See* Giovannucci E
Spelta V. *See* Tonini M
Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Distinct Inflammatory Mechanisms Mediate Early Versus Late Colitis in Mice, 122:94
Spengler U
See Heller J
See Streetz K
See Terjung B
See Woitas RP
Spichtin H-P. *See* Straumann A
Spiegel BMR, Eisen G, Gralnek IM. *Evidence-Based Gastroenterology*, 124: 1996–pmr
Spiegel BMR, Vakil NB, Ofman JJ. Dyspepsia Management in Primary Care: A Decision Analysis of Competing Strategies, 122:1270
Spiegelman BM. *See* Girnun GD
Spiegelman D. *See* Leitzmann MF
Spiegler J. *See* Wedel T
Spilde TL. *See* Kobayashi H
Spiller D. *See* Burdyga G
Spiller R. *See* Lind T
Spiller RC. *See* Dunlop SP
Spiller RC
Neuropathology of IBS?, 123:2144–e
Postinfectious Irritable Bowel Syndrome, 124:1662
Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR
Persistent Colonic Inflammation in Postinfectious IBS: Symptom Cause or Curiosity?, 121:493–ss
Persistent Colonic Inflammation in Postinfectious IBS: Symptom Cause or Curiosity? Reply, 121:494–ss
Spinner NB. Alagille Syndrome and the Notch Signaling Pathway: New Insights Into Human Development, 116:1257–e
Spinzi G. *See* Primignani M
Spirli C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, Larusso NF, Sonzogni A, Okolicsanyi L, Strazzabosco M. Cytokine-Stimulated Nitric Oxide Production Inhibits Adenylyl Cyclase and cAMP-Dependent Secretion in Cholangiocytes, 124:737
Spirli C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, Di Virgilio F, Okolicsanyi L, Casagrande F, Strazzabosco M. Proinflammatory Cytokines Inhibit Secretion in Rat Bile Duct Epithelium, 121:156
Spits H. *See* van Montfrans C
Splinter PL
See Chen X-M
See Masyuk TV
Spodsberg N, Troelsen JT, Carlsson P, Enerbäck S, Sjöström H, Norén O. Transcriptional Regulation of Pig Lactase-Phlorizin Hydrolase: Involvement of HNF-1 and FREACs, 116:842
Spöttl T. *See* Hausmann M
Springer J. *See* Rubin L
Springer JE, Cole DEC, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, Peltekova VD, Heathcote EJ. Vitamin D-Receptor Genotypes as Independent Genetic Predictors of Decreased Bone Mineral Density in Primary Biliary Cirrhosis, 118:145
Squires PE. *See* Buchan AMJ
Squires RH Jr. *See* Setchell KDR
Srivastava ED. *See* Gordon FH
Stabler RA. *See* Dorrell N
Staels B
See Barbier O
See Claudel T
See Kok T
Staffieri A. *See* Restivo DA
Stagge V. *See* Wagner M
Stahl GL. *See* Wada K
Stahl-Hennig C. *See* Kewenig S
Staiano A. *See* Clouse RE
Stains J. *See* Berman SM
Stål P. *See* Elmberg M
Stålhammar NO. *See* Myrvold HE
Stallmach A
See Kewenig S
See Marth T
Stallmach A, Wittig B, Giese T, Pfister K, Hoffmann J, Bulfone-Paus S, Kunzendorf U, Meuer SC, Zeitz M. Protection of Trinitrobenzene Sulfonic Acid-Induced Colitis by an Interleukin 2-IgG2b Fusion Protein in Mice, 117: 866
Stals H. *See* Baert F
Stam R, Ekkelenkamp K, Frankhuijzen AC, Bruijnzeel AW, Akkermans LMA, Wiegant VM. Long-Lasting Changes in Central Nervous System Responsivity to Colonic Distention After Stress in Rats, 123:1216
Stambler N. *See* Coulie B

Stamp D. Bile Acids and Esophageal Cancer Cancer, 124:271–c
Stampfer MJ
See Giovannucci E
See Leitzmann MF
Standop J. *See* Schneider MB
Stanford JL. *See* El-Omar EM
Stange E. *See* Schwab M
Stange EF. *See* Sandborn WJ
Stanghellini V
See Barbara G
See De Giorgio R
See Tonini M
Stanley AJ. *See* Lui HF
Stappenbeck TS
See Mills JC
See Wong MH
Starkebaum W. *See* Abell T
Stati T. *See* Alpini G
Staub A. *See* Tomasetto C
Staun M
See Haderslev KV
See Lochs H
Steagall WK, Drumm ML. Stimulation of Cystic Fibrosis Transmembrane Conductance Regulator-Dependent Short-Circuit Currents Across ΔF508 Murine Intestines, 116:1379
Stebel M. *See* Barazzoni R
Steer CJ. *See* Rodrigues CMP
Steer M. *See* Saluja AK
Steer M. Pancreatitis Severity: Who Calls the Shots?, 122:1166–e
Steer ML
See Bhagat L
See Frossard J-L
See Hofbauer B
See Lee HS
See Saluja AK
See Singh VP
Stefan A. *See* Corley DA
Stefano V de. *See* Madonna P
Stefanovic B. *See* Iimuro Y
Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Turbo Probiotics for IBF, 120:1298–ss
Stein RB. *See* Su C
Steinbach G. *See* Baron JA
Steinberg SJ. *See* Setchell KDR
Steinbrecher KA. *See* Bates MD
Steinbrecher KA, Mann EA, Giannella RA, Cohen MB. Increases in Guanylin and Uroguanylin in a Mouse Model of Osmotic Diarrhea Are Guanylate Cyclase C-Independent, 121:1191–
Steindl PE. *See* Kazemi-Shirazi L
Steiner M, Ocran K, Genschel J, Meier P, Gerl H, Ventz M, Schneider M-L, Büttner C, Wadowska K, Kerner W, Schuff-Werner P, Lochs H, Schmidt H. A Homozygous *HFE* Gene Splice Site Mutation (IVS5+1 G/A) in a Hereditary Hemochromatosis Patient of Vietnamese Origin, 122:789–cr
Steiner-Mosonyi M. *See* Conway EM
Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined Budesonide and Antibiotic Therapy for Active Crohn's Disease: A Randomized Controlled Trial, 123:33
Steinkamp M. *See* Reinshagen M
Steinkamp M, Geerling I, Seufferlein T, von Boyen G, Egger B, Grossmann J, Ludwig L, Adler G, Reinshagen M. Glial-Derived Neurotrophic Factor Regulates Apoptosis in Colonic Epithelial Cells, 124:1748
Steinle AU, Weidenbach H, Wagner M, Adler G, Schmid RM. NF-kB/Rel Activation in Cerulein Pancreatitis, 116:420
Steinmann B. *See* Santer R
Stembridge A. *See* Terdiman JP
Stemmermann G. *See* Prior TW
Stengelin S. *See* Meerman L
Stenram U. *See* Nilsson H-O
Stenson WF. *See* Gurtner GJ
Stepankova R. *See* Dvorak B
Stephens W. *See* Hamilton J
Stephenson SL
See Dienstag JL
See Lai C-L
Stepniak DT. *See* Vader LW
Steppan CM. *See* He W
Sterin-Borda L. *See* Goin JC
Sterling RK
See Sanyal AJ
See Shiffman ML
Stern HS, Viertelhausen S, Hunter AGW, O'Rourke K, Cappelli M, Perras H, Serfas K, Blumenthall A, Dewar D, Baumann E, Legarde AE. *APC* I1307K Increases Risk of Transition From Polyp to Colorectal Carcinoma in Ashkenazi Jews, 120:392
Stern J. *See* Heuschen UA
Stern S. *See* Laine L
Sternberg LR. *See* Dudas SP
Sternberg LR, Byrd JC, Yunker CK, Dudas S, Hoon VK, Bresalier RS. Liver Colonization by Human Colon Cancer Cells Is Reduced by Antisense Inhibition of MUC2 Mucin Synthesis, 116:363
Sterneck M. *See* Kalinina T
Sternini C
See Glatzle J
See Tonini M
Sternini C, Wong H, Pham T, De Giorgio R, Miller LJ, Kuntz SM, Reeve JR Jr, Walsh JH, Raybould HE. Expression of Cholecystokinin A Receptors in Neurons Innervating the Rat Stomach and Intestine, 117:1136
Steudel N. *See* Kleber G
Stevens AC. *See* Bitton A
Stevens BR. *See* Maltzman T
Stevenson MC. *See* Carver RS
Stewart ET. *See* Winawer SJ
Stewart S. *See* Barrett S
Stieger B
See Fickert P
See Gerloff T
See Ismair MG
See Kullak-Ublick GA
See Lee JM
See Noé J
See Rahner C
See Reichel C
Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and Estrogen-Induced Cholestasis Through Inhibition of the Hepatocellular Bile Salt Export Pump (Bsep) of Rat Liver, 118:422
Stiegmann GV. *See* Filipi CJ
Stockard CR. *See* Zhang J
Stockbrügger RW
See Boonen A
See Schoon EJ
Stöckel B. *See* Tsujii H
Stoehr JP. *See* Cohen P
Stoffel-Wagner B. *See* Schepke M
Stolar CG. *See* Diwakaran HH
Stoll B
See Guan X
See van der Schoor SRD
Stollman NH
See Garcia RT
See Triadafilopoulos G
Stolte M
See Kiesslich R
See Liu H
See Michetti P
See Miehlke S
See Rindi G
See Solcia E
See Vieth M
Stolte M, Meining A. Lack of Effect of Acid Suppression Therapy on Gastric Atrophy, 118:242–c
Stolte N. *See* Kewenig S
Stone CD, Beejay U, Wolfe MM. Image of the Month, 120:6–im
Stoohs RA. *See* Facchini FS
Storch WB. *See* Kobayashi I
Strada D. *See* Pedowitz SD
Strahl S. *See* Leuschner M
Strain AJ. *See* Crosby HA

Strasberg S. *See* DeLeve LD
Strassburg CP
See Obermayer-Straub P
See Ockenga J
See Vogel A
Strassburg CP, Nguyen N, Manns MP, Tukey RH. UDP-glucuronosyltransferase Activity in Human Liver and Colon, 116:149
Strate LL. *See* Baffy G
Strate U. *See* Fibbe C
Sträter J, Walczak H, Pukrop T, von Müller L, Hasel C, Kornmann M, Mertens T, Möller P. TRAIL and Its Receptors in the Colonic Epithelium: A Putative Role in the Defense of Viral Infections, 122:659
Stratton MR. *See* Tomlinson I
Strauch ED. *See* Li L
Straumann A, Bauer M, Fischer B, Blaser K, Simon H-U, Mishra A, Hogan SP, Brandt EB, Rothenberg ME. More Than Food Traffics Into the Esophagus, 123:946–ss
Straumann A, Spichtin H-P, Grize L, Bucher KA, Beglinger C, Simon H-U. Natural History of Primary Eosinophilic Esophagitis: A Follow-up of 30 Adult Patients for Up to 11.5 Years, 125:1660
Straus D. *See* Musch MW
Strauss AW. *See* Yang Z
Strauss GI, Knudsen GM, Kondrup J, Møller K, Larsen FS. Cerebral Metabolism of Ammonia and Amino Acids in Patients With Fulminant Hepatic Failure, 121:1109–
Strautnieks SS
See Byrne JA
See Jansen PLM
Strayer DS. *See* Sauter BV
Strazzabosco M. *See* Spirlì C
Strazzera A. *See* Farci P
Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns M, Trautwein C. Tumor Necrosis Factor α in the Pathogenesis of Human and Murine Fulminant Hepatic Failure, 119:446
Streetz KL, Wüstefeld T, Klein C, Kallen K-J, Tronche F, Betz UAK, Schütz G, Manns MP, Müller W, Trautwein C. Lack of gp130 Expression in Hepatocytes Promotes Liver Injury, 125:532
Strege P. *See* Holm AN
Stremmel W
See Rost D
See Rudi J
See Schaefer M
See Schlenker T
Stricker BHCh. *See* Eland IA
Striessnig J. *See* Liu X
Strobel S. *See* Zimmer K-P
Strober W
See Boirivant M
See Bouma G
See Fuss IJ
See Marth T
Strocchi A. *See* Di Stefano M
Stroffolini T. *See* Marignani M
Strohmer H. *See* Dejaco C
Strom BL. *See* Lewis JD
Strom S. *See* Radaeva S
Strom S, Fisher R. Hepatocyte Transplantation: New Possibilities for Therapy, 124:568–e
Strong SA
See Danese S
See Lyford GL
See Musso A
Stronkhorst A. *See* De Ridder RJJ
Strowski MZ, Teichgräber U, Rosewicz S. Image of the Month, 123:1427–im
Strul H. *See* Rozen P
Strul H, Pao Y, Konikoff F. Image of the Month, 122:6–im
Stuart R. *See* O'Sullivan GC
Stumptner C. *See* Fickert P
Sturkenboom MJCM. *See* Eland IA
Sturm A. *See* Danese S
Sturm A, Mohr S, Fiocchi C. Critical Role of Caspases in the Regulation of Apoptosis and Proliferation of Mucosal T Cells, 122:1334
Sturm A, Sudermann T, Schulte K-M, Goebell H, Dignass AU. Modulation of Intestinal Epithelial Wound Healing In Vitro and In Vivo by Lysophosphatidic Acid, 117:368
Sturm E. *See* Denson LA
Sturniolo G. *See* Biancone L
Sturrock RD. *See* Taha AS
Stutvoet STD. *See* Blindenbacher A
Stuyver L. *See* Lunel F
Su B, Johansson S, Fällman M, Patarroyo M, Granström M, Normark S. Signal Transduction-Mediated Adherence and Entry of *Helicobacter pylori* Into Cultured Cells, 117:595
Su C, Lewis JD
Treatment of Crohn's Disease: Is Blocking Adhesion the Answer? Comment, 125:1276–ss
Su C, Lichtenstein GR
Challenges in Inflammatory Bowel Disease. 125:269–pmr
Infliximab In Ulcerative Colitis: Is There a Placebo (Effect) in the House? Reply, 124:1991–ss
Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Infliximab In Ulcerative Colitis: Is There a Placebo (Effect) in the House?, 124:1990–ss
Su CG, Lewis JD
Antineoplastic and Anti-Inflammatory Effects of PPAR Ligands in Colitis. Comment, 121:1020–ss
Su CG, Lichtenstein GR
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. Comment, 125:1545–ss
Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. PPAR-γ Ligand Antidiabetic Drugs: Good News for Colitis?, 118: 228–ss
Su X. *See* Julia V
Subbaramaiah K. *See* Zhang F
Subhani J. *See* Gordon FH
Such J. *See* Pascual S
Suchy FJ
See Kim JY
See Young Kim J
Sud A. *See* Hui JM
Suda T. *See* Shimizu H
Sudermann T. *See* Sturm A
Sudhakar A. *See* Yang C
Sudo K. *See* Kurata A
Suematsu M
See Kyokane T
See Uwatoku R
Suen BY. *See* Chan FKL
Suetsugu H. *See* Kazumori H
Sug Kim H, Woo Lee J, Hwa Soung Y, Sang Park W, Young Kim S, Heun Lee J, Young Park J, Gu Cho Y, Jae Kim C, Whan Jeong S, Woo Nam S, Ho Kim S, Young Lee J, Jin Yoo N, Hyung Lee S. Inactivating Mutations of Caspase-8 Gene in Colorectal Carcinomas, 125:708
Sugano K
See Miyakura Y
See Yamamoto H
Suganuma T
See Harada M
See Uwatoku R
Sugauchi F, Miyakawa Y, Mizokami M. Clinical Relevance of Hepatitis B Virus Genotypes Ba and Bj in Taiwan. Reply, 125:1917–c
Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai C-L, Gish RG, Ueda R, Miyakawa Y, Mizokami M. Epidemiologic and Virologic Characteristics of Hepatitis B Virus Genotype B Having the Recombination With Genotype C, 124:925

Sugawara K. *See* Kozaiwa K
Sugi K. *See* Musch MW
Sugi K, Musch MW, Nelson DJ, Chang EB. Oxidants Potentiate Ca^{2+}- and cAMP-Stimulated Cl^- Secretion in Intestinal Epithelial T84 Cells, 120:89
Sugimachi K. *See* Tanaka S
Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, Koide Y. Curcumin Prevents and Ameliorates Trinitrobenzene Sulfonic Acid-Induced Colitis in Mice, 123:1912
Sugimoto Y. *See* Takeuchi K
Sugimura K. *See* Matsuda Y
Sugimurra H. *See* Furuta T
Sugita Y
See Tanaka S
See Yamamoto H
Sugiyama T
See Harada M
See Ohkawara T
Suh ER
See Rings EHHM
See Silberg DG
Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of Colorectal Cancer by Aspirin: A Cost-effectiveness Analysis, 122:78
Sullivan J. *See* Silberg DG
Suman A. *See* Schneider A
Sumanac K. *See* Huang JQ
Sumberaz A. *See* Testino G
Summers RW. *See* Baron JA
Sun A-Q
See Chen F
See Young Kim J
Sun C. *See* Lu G
Sun J
See Collier-Hyams LS
See Lerat H
Sun Z, Klein AS, Radaeva S, Hong F, El-Assal O, Pan H-N, Jaruga B, Batkai S, Hoshino S, Tian Z, Kunos G, Diehl AM, Gao B. In Vitro Interleukin-6 Treatment Prevents Mortality Associated With Fatty Liver Transplants in Rats, 125:202
Sunada K. *See* Yamamoto H
Sunbul M. *See* Hokelek M
Sund NJ. *See* Silberg DG
Sundaram P. *See* Gigliozzi A
Sundback CA, Vacanti JP. Alternatives to Liver Transplantation: From Hepatocyte Transplantation to Tissue-Engineered Organs, 118:438–e
Sung JJY
See Chan FKL
See Leung WK
Sung JJY, Chan FKL, Leung WK, Wu JCY, Lau JYW, Ching J, To KF, Lee YT, Luk YW, Kung NNS, Kwok SPY, Li MKW, Chung SCS. Screening for Colorectal Cancer in Chinese: Comparison of Fecal Occult Blood Test, Flexible Sigmoidoscopy, and Colonoscopy, 124:608
Sung JJY, Lau JYW, Yu LM, To KF. *Helicobacter pylori* Infection and Gastric Cancer. Reply, 120:325–c
Sung JJY, Lin S-R, Ching JYL, Zhou L-Y, To KF, Wang R-T, Leung WK, Ng EKW, Lau JYW, Lee YT, Yeung CK, Chao W, Chung SCS. Atrophy and Intestinal Metaplasia One Year After Cure of *H. pylori* Infection: A Prospective, Randomized Study, 119:7
Sunyach C. *See* Rollier C
Suraweera N. *See* Duval A
Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R. Evaluation of Tumor Microsatellite Instability Using Five Quasimonomorphic Mononucleotide Repeats and Pentaplex PCR, 123:1804
Suri D. *See* Lau GKK
Surrenti C. *See* Galli A
Susini C. *See* Torrisani J
Suter S. *See* Frossard J-L
Sutherland D
See Liebman H
See Liebman HA
Sutherland LR. *See* Sandborn WJ
Mesalamine and Relapse Prevention in Crohn's Disease. Reply, 119:597–c
Mesalamine for the Prevention of Postoperative Recurrence: Is Nearly There the Same as Being There?, 118:436–e
Sutherland RL. *See* Biankin AV
Sutter AP. *See* Scherübl H
Sutton CL. *See* Braun J
Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, Targan SR, Braun J. Identification of a Novel Bacterial Sequence Associated With Crohn's Disease, 119:23
Suyenobu B
See Berman SM
See Naliboff BD
Suzuki A, Mizumoto A, Rerknimitr R, Sarr MG, DiMagno EP. Effect of Bacterial or Porcine Lipase With Low- or High-Fat Diets on Nutrient Absorption in Pancreatic-Insufficient Dogs, 116:431
Suzuki F. *See* Ikeda K
Suzuki H. *See* Nagao Y
Suzuki J. *See* Ueda N
Suzuki K, Ohnami S, Tanabe C, Sasaki H, Yasuda J, Katai H, Yoshimura K, Terada M, Perucho M, Yoshida T. The Genome Damage Estimated by Arbitrarily Primed PCR DNA Fingerprinting Is Useful for the Prognosis of Gastric Cancer, 125:1330
Suzuki M
See Hisamatsu T
See Kakyo M
Suzuki T. *See* Abe T
Suzuki Y
See Akita K
See Ikeda K
Svegliati-Baroni G
See Alvaro D
See Benedetti A
See Galli A
Svennerholm A-M
See Hamlet A
See Mattsson A
Svoboda J. *See* Gut MO
Swain GP. *See* Silberg DG
Swain MG
See Burak KW
See Meddings JB
Swain P
See Appleyard M
See Hong F
See Lewis BS
Swallow DM. *See* Vinall LE
Swanson KM. *See* Inadomi JM
Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal Flora in Inflammatory Bowel Disease, 122:44
Swidsinski A. Mucosal Flora in Inflammatory Bowel Disease: Intraepithelial Bacteria or Endocrine Epithelial Cell Secretory Granules? Reply, 123:956–co
Swidsinski S. *See* Swidsinski A
Sylander ED. *See* Jeffers M
Syngal S, Fox EA, Li C, Dovidio M, Eng C, Kolodner RD, Garber JE. Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer: Are We There Yet?, 118:230–ss
Synnerstad I. *See* Johansson M
Szabó C
See Wilson L
See Zingarelli B
Szabo I. *See* Tarnawski AS
Szabo IL. *See* Baatar D
Szabó IL. *See* Jones MK
Szarka LA. *See* Coulie B
Szumlanski CL. *See* Lowry PW
Szurszewski J. *See* He C-L
Szurszewski JH
See Farrugia G
See He C-L
See Holm AN
See Lyford GL

Taal BG. *See* Liu H
Taboury J. *See* Rosmorduc O
Taché Y
See Luckey A
See Maillot C
Tack J
See Fischler B
See Wilmer A
Tack J, Berghe PV. Neuropeptides and Colonic Motility: It's All in the Little Brain, 119:257–e
Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms Associated With Hypersensitivity to Gastric Distention in Functional Dyspepsia, 121:526
Tack J, Demedts I, Dehondt G, Caenepeel P, Fischler B, Zandecki M, Janssens J. Clinical and Pathophysiological Characteristics of Acute -Onset Functional Dyspepsia, 122:1738
Tack J. Drink Test in Functional Dyspepsia, 122:2093–c
Tacke F. *See* Bock C-T
Tagerud S. *See* Brand SJ
Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A. Awakening the Sleeping Post-Surgical Abdomen, 122:1177–ss
Taha AS, Dahill S, Morran C, Hudson N, Hawkey CJ, Lee FD, Sturrock RD, Russell RI. Neutrophils, *Helicobacter pylori*, and Nonsteroidal Anti-inflammatory Drug Ulcers, 116:254
Tai D-I
See Lai C-L
See Liaw Y-F
Taieb J. *See* Poynard T
Taioli E
See Fracanzani AL
See Valenti L
Takabayashi A
See Hashida H
See Hirota S
Takabayashi K. *See* Rachmilewitz D
Takagi S. *See* Negoro K
Takahashi I. *See* De Winter H
Takahashi M. *See* Iwashita T
Takahashi S
See Inoue N
See Negoro K
Takahashi T. *See* Yazdani A
Takahashi T, Bagnol D, Schneider D, Mizuta Y, Ishiguchi T, Lepard K, Galligan JJ, Watson SJ, Owyang C. Orphanin FQ Causes Contractions via Inhibiting Purinergic Pathway in the Rat Colon, 119:1054
Takahashi T, Mizuta Y, Owyang C. Orphanin FQ, but Not Dynorphin A, Accelerates Colonic Transit in Rats, 119:71
Takasawa S. *See* Kazumori H
Takashima M. *See* Furuta T
Takashima S. *See* Tanaka T
Takaya H. *See* Andoh A
Takayama T
See Dai CY
See Ijichi M
See Mazaki T
See Miyanishi K
See Niitsu Y
Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S, Niitsu Y. Analysis of K-*ras*, *APC*, and β-*Catenin* in Aberrant Crypt Foci in Sporadic Adenoma, Cancer, and Familial Adenomatous Polyposis, 121:599
Takeda E. *See* Shiraga T
Takeda H. *See* Ohkawara T
Takeda K. *See* Kanai T
Takedatsu H. *See* Mizoguchi E
Takehara T. *See* Kuzushita N
Takehara T, Hayashi N, Tatsumi T, Kanto T, Mita E, Sasaki Y, Kasahara A, Hori M. Interleukin 1β Protects Mice From Fas-Mediated Hepatocyte Apoptosis and Death, 117:661
Takei Y
See Enomoto N
See Ikejima K
See Tsune I
Takeoka S. *See* Kyokane T
Taketani Y. *See* Shiraga T
Taketo M. *See* Oshima M
Taketo MM. *See* Aihara T
Takeuchi K, Ukawa H, Kato S, Furukawa O, Araki H, Sugimoto Y, Ichikawa A, Ushikubi F, Narumiya S. Impaired Duodenal Bicarbonate Secretion and Mucosal Integrity in Mice Lacking Prostaglandin E-Receptor Subtype EP_4, 117:1128
Takeuchi O. *See* Shimizu H
Takeuchi T. *See* Kanai M
Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, Kawaguchi R, Tanaka S, Kohara M. Real-Time Detection System for Quantification of Hepatitis C Virus Genome, 116:636
Takikawa H. *See* Matsuzaki Y
Takimoto R
See Miyanishi K
See Takayama T
Takuwa Y. *See* Ikeda H
Tal R
See Chowers MY
See Chowers Y
Talamini G, Bassi C. The "Natural" History of Pain in Chronic Pancreatitis, 118:235–c
Talbot I. *See* Tomlinson I
Talley NJ
See Chitkara D
See Chitkara DK
See Holtmann G
See Katelaris PH
See Levy RL
Talley NJ
Dyspepsia, 125:1219
Dyspepsia Management in the Millennium: The Death of Test and Treat?, 122:1521–e
Talukdar R. *See* Gill N
Talwalkar J. *See* Bambha K
Talwalkar J, Van Dam J. Setback for Systemic Therapy of Esophageal Cancer: Right Concept, Disappointing Result. Comment, 117:1020–ss
Talwalkar JA. Markov Models in Primary Biliary Cirrhosis, 123:1750–co
Tamai I. *See* Shiraga T
Tamboli CP, Richard F, Colombel J-F. Fecal Calprotectin in Crohn's Disease: New Family Ties, 124:1972–e
Taminiau JAJ. *See* van Ginkel R
Taminiau JAJM. *See* van Ginkel R
Tamura K. *See* Inoue N
Tamura S
See Kamada Y
See Kiso S
Tan L-J. *See* Lee H-O
Tan X. *See* Monga SPS
Tanabe C. *See* Suzuki K
Tanabe T. *See* Bonen DK
Tanaka A. *See* Shimoda S
Tanaka H. *See* Shiraga T
Tanaka K
See Nagao Y
See Tanaka N
Tanaka N, Tanaka K, Nagashima Y, Kondo M, Sekihara H. Nitric Oxide Increases Hepatic Arterial Blood Flow in Rats With Carbon Tetrachloride-Induced Acute Hepatic Injury, 117:173
Tanaka S. *See* Takeuchi T
Tanaka S, Hamada K, Yamada N, Sugita Y, Tonai S, Hunyady B, Palkovits M, Falus A, Watanabe T, Okabe S, Ohtsu H, Ichikawa A, Nagy A. Gastric Acid Secretion in L-Histidine Decarboxylase-Deficient Mice, 122:145
Tanaka S, Sugimachi K, Maehara S-I, Shimada M, Maehara Y. A Loss of Function Mutation in *WISP3* Derived From Microsatellite Unstable Gastric Carcinoma, 125:1563–c
Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. Variant

WISPs as Targets for Gastrointestinal Carcinomas, 123:392–c
Tanaka T, Kohno H. Antineoplastic and Anti-Inflammatory Effects of PPAR Ligands in Colitis. Reply, 121:1021–ss
Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Antineoplastic and Anti-Inflammatory Effects of PPAR Ligands in Colitis, 121:1019–ss
Tanaka Y. *See* Umemura T
Tang J. *See* Ropeleski MJ
Tang L. *See* Zhang J
Tang LH
See Läuffer JM
See Peek RM Jr
Tange S. *See* Bolder U
Taniai H. *See* Kyokane T
Taniai M
See Canbay A
See Feldstein AE
Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16^{INK4a} Promoter Mutations Are Frequent in Primary Sclerosing Cholangitis (PSC) and PSC-Associated Cholangiocarcinoma, 123:1090
Taniguchi E. *See* Harada M
Taniguchi K. *See* Krishnadath KK
Taniguchi M. *See* Hirota S
Taniguchi N
See Kiso S
See Miyazaki Y
Tanno H. *See* Vorobioff JD
Tao H. *See* Kim JJ
Tappenden KA. *See* Guan X
Tarantino I. *See* D'Amico G
Tarantino O. *See* Palli D
Tarasova N. *See* Cobb S
Tarek E-H. *See* Ballinger A
Targan S. *See* Rutgeerts P
Targan SR
See Abreu MT
See Braun J
See Dubinsky MC
See Landers CJ
See Papadakis KA
See Papdakis KA
See Quinton JF
See Sandborn WJ
See Sutton CL
See Vasiliauskas EA
Tarnawski AS
See Baatar D
See Jones MK
Tarnawski AS, Szabo I. Apoptosis–Programmed Cell Death and Its Relevance to Gastrointestinal Epothelium: Survival Signal From the Matrix, 120:294–e
Tashiro M. *See* Bragado MJ
Tateishi K. *See* Hirata Y
Tatsuguchi A. *See* Noguchi H
Tatsumi T
See Kuzushita N
See Takehara T
Tatsuta M. *See* Kusama T
Tatum RP. *See* Hirano I
Taupin D, Podolsky DK. Mitogen-Activated Protein Kinase Activation Regulates Intestinal Epithelial Differentiation, 116:1072
Taura P. *See* Lacy AM
Tavernini MM. *See* Madsen KL
Tawil A al. *See* Kamal SM
Taylor CJ. *See* Baugh MD
Taylor IL. Of Mice and Men-The Weight Control of Food Intake And Body Weight, 116:1487–e
Taylor JK. *See* Rings EHHM
Taylor KD. *See* Abreu MT
Taylor LE. *See* Allen SA
Taylor N. *See* Fox JG
Taylor PJS. *See* Goldblatt J
Taylor TH. *See* Theuer CP
Tazi KA. *See* Pateron D
Tazi KA, Barriere E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D. Role of Shear Stress in Aortic eNOS Up-regulation in Rats With Biliary Cirrhosis, 122:1869
Tazi KA, Moreau R, Heller J, Poirel O, Lebrec D. Changes in Protein Kinase C Isoforms in Association With Vascular Hyporeactivity in Cirrhotic Rat Aortas, 119:201
te Elde AA. *See* van Montfrans C
te Velde AA. *See* van Montfrans C
Tearney GJ. *See* Poneros JM
Teich N. *See* Ockenga J
Teich N, Ockenga J, Hoffmeister A, Manns M, Mössner J, Keim V. Chronic Pancreatitis Associated With an Activation Peptide Mutation That Facilitates Trypsin Activation, 119:461
Teitelbaum DH. *See* Yang H
Teitelbaum DH, Cilley RE, Sherman NJ. Single-Stage Operations for Hirschsprung's Disease – Pushing the Envelope, 120:1300–ss
Teitelbaum DH. Single-Stage Operations for Hirschsprung's Disease – Pushing the Envelope. Reply, 120:1302–ss
Teitelbaum DH, Yang H. Enterocyte Apoptosis and TPN-Associated Intestinal Mucosal Atrophy: A View of the Chicken or the Egg? Reply, 125:1274–ss
Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, Badizadegan K, Furuta GT. Eosinophilic Esophagitis in Children: Immunopathological Analysis and Response to Fluticasone Propionate, 122:1216
Tejima K. *See* Ikeda H
Teka T. *See* Rabbani GH
Telega GW, Baumgart DC, Carding SR. Uptake and Presentation of Antigen to T Cells by Primary Colonic Epithelial Cells in Normal and Diseased States, 119:1548
Telford JJ, Ruymann FW. Image of the Month, 121:1274–im
Telford JL. *See* D'Elios MM
Tempero MA. *See* DiMagno EP
Ten Dijke P. *See* Dooley S
Ten Kate FJ. *See* van den Brink GR
ten Kate FJW. *See* van Montfrans C
ten Kate FW. *See* Schultsz C
Tenorio A. *See* Losa JH
ter Beek M-L. *See* de Jonge WJ
Terada K. *See* Harada M
Terada LS. *See* Souza RF
Terada M
See Suzuki K
See Yamamoto H
Terado Y. *See* Kurata A
Terasawa K. *See* Yamamoto M
Terauchi Y. *See* Nakajima A
Terdiman JP, Gum JR Jr, Conrad PG, Miller GA, Weinberg V, Crawley SC, Levin TR, Reeves C, Schmitt A, Hepburn M, Sleisenger MH, Kim YS. Efficient Detection of Hereditary Nonpolyposis Colorectal Cancer Gene Carriers by Screening for Tumor Microsatellite Instability Before Germline Genetic Testing, 120:21
Terdiman JP. HNPCC: An Uncommon but Important Diagnosis, 121:1005–e
Terdiman JP, Levin TR, Allen BA, Gum JR Jr, Fishbach A, Conrad PG, Miller GA, Weinberg V, Bachman R, Bergoffen J, Stembridge A, Toribara NW, Sleisenger MH, Kim YS. Hereditary Nonpolyposis Colorectal Cancer in Young Colorectal Cancer Patients: High-risk Clinic Versus Population-Based Registry, 122:939
Terella A. *See* Somsouk M
Terhorst C
See de Jong YP
See Mizoguchi E
See Saubermann LJ
See Veltkamp C
Terjung B, Spengler U, Sauerbruch T, Worman HJ. "Atypical p-ANCA" in IBD and Hepatobiliary Disorders React With a 50-Kilodalton Nuclear Envelope Protein of Neutrophils and Myeloid Cell Lines, 119:310

Terracciano L
See Blindenbacher A
See Hildeand P
Terrault N
See Chu C-J
See Martino R
Terrazzini N. *See* Paglia P
Terrier F. *See* Spahr L
Terris B. *See* Hammel PR
Terry C. *See* Pufulete M
Terry P, Lagergren J, Ye W, Wolk A, Nyrén O
Inverse Association Between Intake of Cereal Fiber and Risk of Gastric Cardia Cancer, 120:387
Inverse Association Between Intake of Cereal Fiber and Risk of Gastric Cardia Cancer. Reply, 121:1025–c
Tersigni R. *See* Boirivant M
Tersmette AC. *See* Giardiello FM
Tessarollo L. *See* Cobb S
Testa R. *See* Giannini E
Testino G, Sumberaz A, Emilio D, Valentini M, Cornaggia M. Gastric High-Grade Dysplasia, 117:285–c
Tezuka K. *See* Totsuka T
Tham KT. *See* Peek RM Jr
Thasler WE. *See* Mühlbauer M
Thatte HS. *See* Sivarao DV
The FO. *See* de Jonge WJ
Themis M. *See* Forbes SJ
Theodorakis NG, Wang Y-N, Skill NJ, Metz MA, Cahill PA, Redmond EM, Sitzmann JV. The Role of Nitric Oxide Synthase Isoforms in Extrahepatic Portal Hypertension: Studies in Gene-Knockout Mice, 124: 1500
Theodore D. *See* Beavers K
Theodoropoulou A. *See* Koutroubakis IE
Therapondos G. *See* Tripathi D
Therneau TM
See Bambha K
See Kim WR
Theuer CP, Wagner JL, Taylor TH, Brewster WR, Tran D, McLaren CE, Anton-Culver H. Racial and Ethic Colorectal Cancer Patterns Affect the Cost-effectiveness of Colorectal Cancer Screening in the United States, 120: 848
Theurl I. *See* Zoller H
Thevenot T. *See* di Martino V
Thiberge J-M. *See* Touati E
Thibodeau SN. *See* Ahlquist DA
Thiede C. *See* Liu H
Thiéfin G. *See* Cadiot G
Thiele D. *See* Brown GR
Thiim M. *Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment*, 119:1409–pmr
Thijs JC. *See* Van der Wouden E-J
Thiny M, Grimm I. Image of the Month, 124:8–im
Thiny MT. *20 Common Problems Gastroenterology*, 122:2088–pmr
Thiny MT, Shaheen NJ. Is Stretta Ready for Primetime? Comment, 123:644–ss
Thiyagaraja S. *See* Orchard TR
Thjodleifsson B. *See* Bjarnason I
Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Subclinical Intestinal Inflammation: An Inherited Abnormality in Crohn's Disease Relatives?, 124:1728
Thomas G
See Duval A
See Vermeire S
Thomas GAO. *See* Richardson CE
Thomas HC. *See* Paterson M
Thomas HJW. *See* Tomlinson I
Thomas LA
See Dowling RH
See Veysey MJ
Thomas LA, Veysey MJ, Bathgate T, King A, French G, Smeeton NC, Murphy GM, Dowling RH. Mechanism for the Transit-Induced Increase in Colonic Deoxycholic Acid Formation in Cholesterol Cholelithiasis, 119:806
Thomas MG. *See* Lau GKK
Thomas N. *See* Lai C-L
Thomas PD. *See* Biagi F
Thomas R. *See* Friedel D
Thomas T. *See* Liu H
Thomforde G
See Bouras EP
See Prather CM
Thompson C, Brugge W. *Atlas of Cystic Neoplasms of the Pancreas*, 125:988–pmr
Thompson D
See Burdyga G
See Creed F
See Hamilton J
Thompson DG
See Haigh CR
See Higham AD
See McLaughlin J
See Sarkar S
See Turnbull GK
Thompson F. *See* Cummins A
Thompson RJ
See Byrne JA
See Jansen PLM
Thompson RPH. *See* Evans SM
Thompson-Fawcett MW, Marcus V, Redston M, Cohen Z, McLeod RS. Risk of Dysplasia in Long-term Ileal Pouches and Pouches With Chronic Pouchitis, 121:275
Thomsen Ø. A Comparison of Budesonide and Mesalamine for Active Crohn's Disease. Reply, 116:1264–ss
Thomsen Ø, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. A Comparison of Budesonide and Mesalamine for Active Crohn's Disease, 116:1263–ss
Thomson ABR. *See* Lanza FL
Thomson M. *See* Baumert TF
Thomson M, Nascimbeni M, Gonzales S, Murthy KK, Rehermann B, Liang JT. Emergence of a Distinct Pattern of Viral Mutations in Chimpanzees Infected With a Homogeneous Inoculum of Hepatitis C Virus, 121: 1226–
Thomson R Jr. *See* Caplan MS
Thomson TM. *See* Díaz VM
Thor K. *See* Lundell L
Thoreson A-C. *See* Hamlet A
Thorner MO. *See* Rincon JP del
Thornley JP. *See* Spiller RC
Thornstensen L, Diep CB, Meling GI, Aagesen TH, Ahrens CH, Rognum TO, Lothe RA. WNT1 Inducible Signaling Pathway Protein 3, *Wisp-3*, a Novel Target Gene in Colorectal Carcinomas With Microsatellite Instability, 121:1275–rc
Thornton FJ, Nelson RC, O'Connor JB. Image of the Month, 123:968–im
Thorogood P. *See* Pitera JE
Thorstensen L. *See* Duval A
Thorstensen L, Holm R, Lothe RA, Tropé C, Carvalho B, Sobrinho-Simoes M, Seruca R. WNT-Inducible Signaling Pathway Protein 3, WISP-3, Is Mutated in Microsatellite Unstable Gastrointestinal Carcinomas But Not in Endometrial Carcinomas, 124:270–c
Thuille B. *See* Duval A
Thuillier F. *See* Crenn P
Thulesen J. *See* Jeppesen PB
Thumshirn M, Camilleri M, Choi M-G, Zinsmeister AR. Modulation of Gastric Sensory and Motor Functions by Nitrergic and α_2-Adrenergic Agents in Humans, 116:573
Thumshirn M, Camilleri M, Hanson RB, Williams DE, Schei AJ, Kammer PP. New Insights Into the Pathogenesis of Rumination: What's Coming up Next, 116:1006–ss
Thun MJ. NSAIDs and Esophageal Cancer: Ready for Trials but Not Yet Broad Clinical Application, 124:246–e

Thurman RG
See Enomoto N
See Froh M
See Wheeler MD
See Yin M
Thurnheer MC
See He W
See Jiang H-Q
Thwaites DT, Kennedy DJ, Raldua D, Anderson CMH, Mendoza ME, Bladen CL, Simmons NL. H^+/Dipeptide Absorption Across the Human Intestinal Epithelium Is Controlled Indirectly via a Functional Na^+/H^+ Exchanger, 122:1322
Tian H. *See* Berge KE
Tian Y. *See* Selzner N
Tian Z. *See* Sun Z
Tiao G, Warner BW. Transcription Factors and Cholangiocyte Development. Comment, 124:264–ss
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate Markers of Intestinal Inflammation Are Predictive of Relapse in Patients With Inflammatory Bowel Disease, 119:15
Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of Surrogate Markers of Inflammation and Rome Criteria to Distinguish Organic From Nonorganic Intestinal Disease, 123:450
Tie A. *See* Chadwick VS
Tietge UJF. *See* Weissenborn K
Tiethof CHJ, van Es HW. Image of the Month, 117:760
Tigyi G
See Deng W
See Ray RM
Tikellis C. *See* Paizis G
Tillmann HL
See Bock C-T
See Ockenga J
Timm S. *See* Greiner A
Timm S, Sailer M, Fuchs K-H, Greiner A. First Successful Treatment of a Primary High-Grade Gastric MALT Lymphoma by Eradication Therapy for *Helicobacter pylori*. 121:1025–c
Timmer R. *See* Boerma D
Tindberg Y, Bengtsson C, Granath F, Blennow M, Nyrén O, Granström M. *Helicobacter pylori* Infection in Swedish School Children: Lack of Evidence of Child-to-Child Transmission Outside the Family, 121:310
Tindberg Y, Nyrén O. *Helicobacter pylori* Infection in Childhood: Transmission and Role of Antibiotics. Reply, 122: 1189–c
Tinel M. *See* Demeilliers C
Tint GS. *See* Morton DH
Tisbury A. *See* Scott DJ
Titos E
See Bosch-Marcé M
See Graupera M
Titos E, Clària J, Bataller R, Bosch-Marcè M, Ginès P, Jimènez W, Arroyo V, Rivera F, Rodés J. Hepatocytes-Derived Cysteinyl Leukotrienes Modulate Vascular Tone in Experimental Cirrhosis, 119:794
Tjellesen L. *See* Haderslev KV
To KF. *See* Sung JJY
To K-F. *See* Leung WK
Tobi M. *See* Zalewska I
Todd K. *See* Rose C
To-Figueras J. *See* Ros J
Tofteng F. *See* Jeppesen PB
Togliani T. *See* Caletti G
Tognetto M. *See* Trevisani M
Toh B-H
See Marshall ACJ
See Scarff KL
Tokes ZA. *See* DeLeve LD
Tokui T
See Abe T
See Kakyo M
Tokushige K. *See* Kato T
Tokutake Y. *See* Kawa S
Tokutomi Y. *See* Torihashi S
Toledano AY. *See* Johnson CD
Tollenaar RAEM. *See* Liefers G-J
Tom J. *See* Zolotarevsky Y
Toma H, Winston J, Micci M-A, Shenoy M, Pasricha PJ. Nerve Growth Factor Expression Is Up-regulated in the Rat Model of L-Arginine-Induced Acute Pancreatitis, 119:1373
Tomaselli G. *See* Citarda F
Tomasetto C, Karam SM, Ribieras S, Masson R, Lefèbvre O, Staub A, Alexander G, Chenard M-P, Rio M-C. Identification and Characterization of a Novel Gastric Peptide Hormone: The Motilin-Related Peptide, 119:395
Tomasetto C, Masson R, Linares J-L, Wendling C, Lefèbvre O, Chenard M-P, Rio M-C. pS2/TFF1 Interacts Directly With the VWFC Cysteine-Rich Domains of Mucins, 118:70
Tomasetto C, Rio M-C. Identification of Motilin-Related Peptide. Reply, 120: 589–c
Tomé D. *See* Gaudichon C
Tomenson B
See Creed F
See Hamilton J
Tomioka K. *See* Mazaki T
Tomita M, Menconi MJ, Delude RL, Fink MP. Polarized Transport of Hydrophilic Compounds Across Rat Colonic Mucosa From Serosa to Mucosa Is Temperature Dependent, 118:535
Tomiya T. *See* Ikeda H
Tomlinson AD. *See* Collier-Hyams LS
Tomlinson I, Rahman N, Frayling I, Mangion J, Barfoot R, Hamoudi R, Seal S, Northover J, Thomas HJW, Neale K, Hodgson S, Talbot I, Houlston R, Stratton MR. Inherited Susceptibility to Colorectal Adenomas and Carcinomas: Evidence for a New Predisposition Gene on 15q14-q22, 116:789
Tomlinson IPM. *See* Houlston RS
Tonai S. *See* Tanaka S
Toner BB. *See* Drossman DA
Tong S. *See* Hoon Ahn S
Tonini M. *See* De Giorgio R
Tonini M, Spelta V, Ponti F de, Giorgio R de, D'Agostino G, Stanghellini V, Corinaldesi R, Sternini C, Crema F. Tachykinin-Dependent and -Independent Components of Peristalsis in the Guinea Pig Isolated Distal Colon, 120:938
Tonkonogy SL. *See* Veltkamp C
Tonnini C. *See* Benedetti A
Ton-Nu H-T. *See* Bolder U
Tonoki H. *See* Kobayashi I
Toogood GJ. *See* Fenwick SW
Topilow AA. *See* Pedowitz SD
Torella R. *See* Persico M
Torgerson H. *See* Bambha K
Toribara NW. *See* Terdiman JP
Torihashi S, Nishi K, Tokutomi Y, Nishi T, Ward S, Sanders KM. Blockade of Kit Signaling Induces Transdifferentiation of Interstitial Cells of Cajal to a Smooth Muscle Phenotype, 117:140
Törnblom H, Lindberg G, Nyberg B, Veress B. Full-Thickness Biopsy of the Jejunum Reveals Inflammation and Enteric Neuropathy in Irritable Bowel Syndrome, 123:1972
Török HP. *See* Radlmayr M
Török NJ, Larusso EM, McNiven MA. Alterations in Vesicle Transport and Cell Polarity in Rat Hepatocytes Subjected to Mechanical or Chemical Cholestasis, 121:1176–
Torra IP. *See* Barbier O
Torras X. *See* Villanueva C
Torres M, Weppler D, Reddy KR, Tzakis A. Use of Hepatitis C-Infected Donors for Hepatitis C-Positive OLT Recipients, 117:1252–c
Torres VE. *See* Masyuk TV
Torresi J. *See* Bock C-T

Torrisani J, Bouisson M, Puente E, Capellá G, Laurent-Puig P, Berger A, Vaysse N, Susini C, Buscail L. Transcription of SST2 Somatostatin Receptor Gene in Human Pancreatic Cancer Cells Is Altered by Single Nucleotide Promoter Polymorphism, 120:200
Toruner M. *See* Shah V
Toshinai K. *See* Date Y
Toskes PP. It's Time to Bring the Best and Brightest Back to Gastroenterology. Reply, 116:1014–c
Tosti C. *See* Biancone L
Totsuka T. *See* Kanai T
Totsuka T, Kanai T, Iiyama R, Uraushihara K, Yamazaki M, Okamoto R, Hibi T, Tezuka K, Azuma M, Akiba H, Yagita H, Okumura K, Watanabe M. Ameliorating Effect of Anti-inducible Costimulator Monoclonal Antibody in a Murine Model of Chronic Colitis, 124:410
Touati E, Michel V, Thiberge J-M, Wuscher N, Huerre M, Labigne A. Chronic *Helicobacter pylori* Infections Induce Gastric Mutations in Mice, 124:1408
Toubouti Y. *See* Rahme E
Tougas G
See Abell T
See Driman DK
Tounian P. *See* Viola S
Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, Melani L, Pizarro TT, Rotter JI, Cominelli F. Functional and Ethnic Association of Allele 2 of the Interleukin-1 Receptor Antagonist Gene in Ulcerative Colitis, 117:806
Toyota T
See Masamune A
See Negoro K
See Satoh A
Tozawa K. *See* Sugimoto K
Traber PG
See Rings EHHM
See Silberg DG
Tracey KJ. *See* Sappington PL
Trallori G. *See* Palli D
Tran D. *See* Theuer CP
Tran T. *See* Dubinsky MC
Tranberg K-G. *See* Nilsson H-O
Trang H. *See* Faure C
Trang NV. *See* Bolder U
Trauner M
See Fickert P
See Lee JM
Trauner M, Fickert P, Zollner G. Abnormal Hepatic Sinusoidal Bile Acid Transport: New Insights Into the Pathogenesis of Cholestasis?, 120:321–c
Trauner M. When Bile Ducts Say NO: The Good, the Bad, and the Ugly, 124: 847–e
Trautwein C
See Bock C-T
See Jaeckel E
See Klein C
See Streetz K
See Streetz KL
Traverso LW. *Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment*. 116:1268–pmr
Travis SPL. *See* McGovern DPB
Trébéden H. *See* Malassagne B
Treem WR. *See* Eloubeidi MA
Treinen-Moslen M. *See* Atchison CR
Tremaine WJ
See Dayharsh GA
See Loftus EV Jr
See Lowry PW
See Ricart E
See Sandborn WJ
See Schwartz DA
See Silverstein MD
Tremaine WJ. Failure to Yield: Drug Resistance in Inflammatory Bowel Disease, 122:1164–e
Tremblay E, Basque JR, Rivard N, Ménard D. Epidermal Growth Factor and Transforming Growth Factor α Downregulate Human Gastric Lipase Gene Expression, 116:831
Trepo C
See McHutchison JG
See Poynard T
See Rollier C
See Samuel D
Trépo C. *See* Bain C
Trevisani M, Amadesi S, Schmidlin F, Poblete MT, Bardella E, Maggiore B, Harrison S, Figueroa CD, Tognetto M, Navarra G, Turini A, Bunnett NW, Geppetti P, De Giorgio R. Bradykinin B_2 Receptors Mediate Contraction in the Normal and Inflamed Human Gallbladder In Vitro, 125:126
Triadafilopoulos G
See Gerson LB
See Kaur BS
See Ouatu-Lascar R
See Shirvani VN
Triadafilopoulos G
Acid and Bile Reflux in Barrett's Esophagus: A Tale of Two Evils, 121: 1502–e
Is Stretta Ready for Primetime? Reply, 123:644–ss
Triadafilopoulos G, DiBaise JK, Nostrant TT, Stollman NH, Anderson PK, Wolfe MM, Rothstein RI, Wo JM, Corley DA, Patti MG, Antignano LV, Goff JS, Edmundowicz SA, Castell DO, Rabine JC, Kim MS, Utley DS. Is Stretta Ready for Primetime?, 123: 643–ss
Triboulet J-P. *See* Guillem P
Trier JS
Biopsy Is the Gold Standard of Diagnosis of Celiac Sprue. Reply, 116:1273–c
Mucosal Flora in Inflammatory Bowel Disease: Intraepithelial Bacteria or Endocrine Epithelial Cell Secretory Granules?, 123:955–co
Triger DR. *See* Hendrickse MT
Trim N. *See* Wright MC
Trimbath JD. *See* Giardello FM
Trinder D. *See* Frazer DM
Trinh HN. *See* Garcia RT
Tripathi D, Therapondos G, Jackson E, Redhead DN, Hayes PC. Is TIPS Shunt Effective for Secondary Prophylaxis of Gastric Variceal Hemorrhage?, 125:262–ss
Tripathi D, Therapondos G, Redhead DN, Hayes PC. Is TIPS Shunt Effective for Secondary Prophylaxis of Gastric Variceal Hemorrhage? Reply, 125: 263–ss
Tripodi M. *See* Blindenbacher A
Troelsen JT. *See* Spodsberg N
Troelsen JT, Olsen J, Møller J, Sjöström H. An Upstream Polymorphism Associated With Lactase Persistence Has Increased Enhancer Activity, 125: 1686
Trojan J, Zeuzem S, Randolph A, Hemmerle C, Brieger A, Raedle J, Plotz G, Jiricny J, Marra G. Functional Analysis of *hMLH1* Variants and HNPCC-Related Mutations Using a Human Expression System, 122:211
Trolli PA. *See* Vargo JJ
Trombini P. *See* Piperno A
Tromm A. *See* Miehlke S
Tronche F. *See* Streetz KL
Tropé C. *See* Thorstensen L
Trotter JF. *See* McKinsey DS
Troussard X. *See* Hermine O
Troyer KL, Luetteke NC, Saxon ML, Qiu TH, Xian CJ, Lee DC. Growth Retardation, Duodenal Lesions, and Aberrant Ileum Architecture in Triple Null Mice Lacking EGF, Amphiregulin and TGF-α, 121:68
Trozzi L. *See* Galli A
Trueworthy B. *See* Pandolfino JE
Trumpp A. *See* Crone SA
Tsai J. *See* DeLeve LD
Tsai M-H. *See* Wiest R

Tsai M-H, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Vasoconstriction Is Responsible for the Initial eNOS Up-regulation in the Mesenteric Artery of Portal Hypertensive Rats, 125:1452
Tsai S-F. *See* Chen Y-J
Tsai W-L. *See* Lo G-H
Tso P. *See* Richmond BL
Tsubota A. *See* Ikeda K
Tsuchida E. *See* Kyokane T
Tsuchida T
See Ohnishi H
See Ueda N
Tsugawa K. *See* Jones MK
Tsui L-C. *See* Durno C
Tsuiji M. *See* Uwatoku R
Tsuji A. *See* Shiraga T
Tsuji M. *See* Kawai N
Tsuji S. *See* Kawai N
Tsuji T. *See* Yokota K
Tsujii H, König J, Rost D, Stöckel B, Leuschner U, Keppler D. Exon-Intron Organization of the Human Multidrug-Resistance Protein 2 *(MRP2)* Gene Mutated in Dubin-Johnson Syndrome, 117:653
Tsukamoto H. *See* Pandol SJ
Tsukita S. *See* Michl P
Tsukiyama-Kohara K. *See* Takeuchi T
Tsunada S, Iwakiri R, Sakata H, Ogata S, Fujimoto K. Hello, Mr. Clips-Could You Chip In Please? Reply, 125:1898–ss
Tsunada S, Ogata S, Ohyama T, Ootani H, Oda K, Kikkawa A, Ootani A, Sakata H, Iwakiri R, Fujimoto K. Hello, Mr. Clips-Could You Chip In Please?, 125:1896–ss
Tsune I, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Takei Y, Sato N. Dietary Glycine Prevents Chemical-Induced Experimental Colitis in the Rat, 125:775
Tsuneyama K. *See* Kamihira T
Tsutsui S. *See* Miyazaki Y
Tsuyuguchi T. *See* Hara T
Tsuzuki Y. *See* Matsuzaki K
Tsybrovskyy O
See Fickert P
See Wagner M
Tucker LM. *See* McKim SE
Tugues S. *See* Morales-Ruiz M
Tukey RH
See Strassburg CP
See Vogel A
Tulliez M. *See* Malassagne B
Tullis E. *See* Durno C
Tümmler B. *See* Bronsveld I
Tung BY. *See* Emond MJ
Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, Iron Status, and Disease Severity: Relationship With *HFE* Mutations, 124:318
Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA. Ursodiol Prevents UC-Associated CRC, 121:491–ss
Tung C-H. *See* Marten K
Tuo B-G, Isenberg JI. Effect of 5-Hydroxytryptamine on Duodenal Mucosal Bicarbonate Secretion in Mice, 125:805
Turini A. *See* Trevisani M
Türler A
See Moore BA
See Schwarz NT
Türler A, Kalff JC, Heeckt P, Abu-Elmagd KM, Schraut WH, Bond GJ, Moore BA, Brünagel G, Bauer AJ. Molecular and Functional Observations on the Donor Intestinal Muscularis During Human Small Bowel Transplantation, 122:1886
Turley SD. *See* Repa JJ
Turlin B. *See* Mendler M-H
Turnbull GK, Hamdy S, Aziz Q, Singh KD, Thompson DG. The Cortical Topography of Human Anorectal Musculature, 117:32
Turner JR
See Jimenez RE
See Zolotarevsky Y
Turner JR, Jimenez RE. Dialysis-Related Amyloidosis: An Important Cause of Gastrointestinal Symptoms in Patients With End-Stage Renal Disease. Reply, 116:219–ss
Turner M. *See* Church NI
Turner ML. *See* Newsome PN
Turner MW. *See* Kelly P
Turovskaya O. *See* De Winter H
Turunen U, Färkkilä M. Of Ciprofloxacin and Ulcerative Colitis. Reply, 117:281–c
Turunen U, Färkkilä M, Valtonen V. Long-term Treatment of Ulcerative Colitis With Ciprofloxacin, 117:282–c
Turvill J. *See* Ballinger A
Turvill JL, Connor P, Farthing JG. Neurokinin 1 and 2 Receptors Mediate Cholera Toxin Secretion in Rat Jejunum, 119:1037
Tutar E. *See* Hokelek M
Tutuian R. *See* Vela MF
Tuveson DA. *See* Demetri GD
Twarog FJ. *See* Teitelbaum JE
Twigg C. *See* Selaru FM
Tybring G. *See* Sagar M
Tysk C
See Andersson RE
See Halfvarson J
See Hugot J-P
Tytgat G
See Hommes D
See Kuiken S
Tytgat GN. Comment From the Editors, 117:1269
Tytgat GNJ
See Boeckxstaens GE
See Brink MA
See de Jonge WJ
See Schultsz C
See van den Brink GR
See van Rees BP
Tytgat GNJ. Comment From the Editors, 120:787–ce
Tzakis A. *See* Torres M

Uchida K. *See* Ohana M
Uchida T
See Ethridge RT
See Noguchi H
Uchijima M. *See* Sugimoto K
Uchino H. *See* Mizoguchi E
Uchino H, Kataoka H, Itoh H, Hamasuna R, Koono M. Overexpression of Intestinal Trefoil Factor in Human Colon Carcinoma Cells Reduces Cellular Growth In Vitro and In Vivo, 118:60
Ueda N. *See* Ohnishi H
Ueda N, Ohnishi H, Kanamaru C, Suzuki J, Tsuchida T, Mashima H, Yasuda H, Fujita T. Kinesin Is Involved Regulation of Rat Pancreatic Amylase Secretion, 119:1123
Ueda R. *See* Sugauchi F
Ueki T. *See* Sato N
Uemura T. *See* Moriguchi H
Ueno N. *See* Asakawa A
Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki J-I, Kasuga M. Decreased Food Intake and Body Weight in Pancreatic Polypeptide-Overexpressing Mice, 117:1427
Ueno T. *See* Nagao Y
Ueno Y. *See* Alpini G
Uhanova J. *See* Zhang M
Uhlen AK. *See* Molberg Ø
Ukawa H. *See* Takeuchi K
Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of Flat Low-Grade Dysplasia to Advanced Neoplasia in Patients With Ulcerative Colitis, 125:1311
Ullrich R
See Kewenig S
See Schmidt W
See Wahnschaffe U
Ulmer H. *See* Rettenbacher T

Ulrich A. *See* Schneider MB
Ulrich CD II
See Shumaker H
See Somogyi L
Ulsenheimer A. *See* Gerlach JT
Umeki S. *See* Kiso S
Umemura M. *See* Shimizu H
Umemura T, Yeo AET, Sottini A, Moratto D, Tanaka Y, Wang RYH, Shih JWK, Donahue P, Primi D, Alter HJ. A Potential New Hepatitis Agent: Making Sen-se of the Data, 121:734–ss
Umeshita K. *See* Yamamoto H
Underhill JA. *See* Czaja AJ
Underwood JCE
See Gleeson D
See Hendrickse MT
Unge P. *See* Lind T
Ungsunan L. *See* Mykoniatis A
The United Network for Organ Sharing Liver Disease Severity Score Committee. *See* Wiesner R
Unno H. *See* Hamano H
Unno M
See Abe T
See Kakyo M
Unsworth DJ. *See* Porter WM
Uose S
See Ohana M
See Okazaki K
Uraushihara K. *See* Totsuka T
Urbain D. *See* Reynaert H
Urbarz C. *See* Rosen HR
Uribe M. *See* Méndez-Sánchez N
Uring-Lambert B. *See* Chamouard P
Uriz J
See Ginés P
See Ortega R
Urizar NL. *See* Hwang ST
Urrutia R. *See* Camilleri M
U.S. HBV Epidemiology Study Group. *See* Chu C-J
The U.S. Acute Liver Failure Study Group. *See* Vagquero J
Ushikubi F. *See* Takeuchi K
Usuda N. *See* Hamano H
Utermöhlen O. *See* Benz C
Utley DS. *See* Triadafilopoulos G
Uwatoku R, Suematsu M, Ezaki T, Saiki T, Tsuiji M, Irimura T, Kawada N, Suganuma T, Naito M, Ando M, Matsuno K. Kupffer Cell-Mediated Recruitment of Rat Dendritic Cells to the Liver: Roles of *N*-Acetylgalactosamine-Specific Sugar Receptors, 121:1460
Uzel G, Kleiner DE, Kuhns DB, Holland SM. Dysfunctional LAD-1 Neutrophils and Colitis, 121:958–cr
Vaandrager AB, Bot AGM, Ruth P, Pfeifer A, Hofmann F, de Jonge HR. Differential Role of Cyclic GMP-Dependent Protein Kinase II in Ion Transport in Murine Small Intestine and Colon, 118:108
Vacanti JP. *See* Sundback CA
Vaccaro C. *See* Raevaara TE
Vachon F. *See* di Martino V
Vachon PH, Harnois C, Grenier A, Dufour G, Bouchard V, Han J, Landry J, Beaulieu J-F, Vézina A, Dydensborg AB, Gauthier R, Côté A, Drolet J-F, Lareau F. Differentiation State-Selective Roles of p38 Isoforms in Human Intestinal Epithelial Cell Anoikis, 123:1980
Vader LW, Stepniak DT, Bunnik EM, Kooy YMC, De Haan W, Drijfhout JW, Van Veelen PA, Koning F. Characterization of Cereal Toxicity for Celiac Disease Patients Based on Protein Homology in Grains, 125:1105
Vader W, Kooy Y, van Veelen P, de Ru A, Harris D, Benckhuijsen W, Peña S, Mearin L, Wouter Drijfhout J, Koning F. The Gluten Response in Children With Celiac Disease Is Directed Toward Multiple Gliadin and Glutenin Peptides, 122:1729
Vadlamudi RK. *See* Mandal M
Vaeyens F. *See* Reynaert H
Vaezi M. *See* Bauer WM
Vaezi MF
See Fackler WK
See Ormsby AH
Vagquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, Lee WM, Blei AT, The U.S. Acute Liver Failure Study Group. Infection and the Progression of Hepatic Encephalopathy in Acute Liver Failure, 125:755
Vahedi K
See Crenn P
See Seguy D
Vaillant JM. *See* Cézard JP
Vaizey CJ, Kamm MA, Gold DM, Bartram CI, Halligan S, Nicholls RJ. Taking Control of Fecal Incontinence: Early Results of an Artificial Sphincter Device, 116:1005–ss
Vajnik V. *Pathology and Genetics of Tumors of the Digestive System*, 121:1258–pmr
Vakil N
See Canga C
See Inadomi JM
Vakil N. What Is the Right Age Cutoff for Immediate Endoscopic Investigation of Dyspepsia? Reply, 123:2150–ss
Vakil NB. *See* Spiegel BMR
Valayer J. *See* Viola S
Valdés R, Ortega MA, Casado FJ, Felipe A, Gil A, Sánchez-Pozo A, Pastor-Anglada M. Nutritional Regulation of Nucleoside Transporter Expression in Rat Small Intestine, 119:1623
Valdez DT. *See* Beyak MJ
Vale W. *See* Luckey A
Valensi F. *See* Hermine O
Valenti L, Fracanzani AL, Fargion S. Effect of Iron Depletion in Patients With Nonalcoholic Fatty Liver Disease Without Carbohydrate Intolerance, 124:866–c
Valenti L, Ludovica Francanzani A, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S. Tumor Necrosis Factor α Promoter Polymorphisms and Insulin Resistance in Nonalcoholic Fatty Liver Disease, 122:274
Valentini M. *See* Testino G
Valinluck V. *See* Bardag-Gorce F
Valla D
See Colle IO
See Condat B
See di Martino V
See Moreau R
Vallance R. *See* Fletcher J
Valle N della. *See* Ciacci C
Valleix S. *See* Granel B
Valtonen V. *See* Turunen U
van Acker GJD. *See* Bhagat L
Van Assche G
See Baert F
See Vermeire S
Van Assche G, Barbara G, Deng Y, Lovato P, Gauldie J, Collins SM. Neurotransmitters Modulate Cytokine-Stimulated Interleukin 6 Secretion in Rat Intestinal Smooth Muscle Cells, 116:346
Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Randomized, Double-Blind Comparison of 4 mg/kg Versus 2 mg/kg Intravenous Cyclosporine in Severe Ulcerative Colitis, 125:1025
Van Belzen MJ, Meijer JWR, Sandkuijl LA, Bardoel AFJ, Mulder CJJ, Pearson PL, Houwen RHJ, Wijmenga C. A Major Non-HLA Locus in Celiac Disease Maps to Chromosome 19, 125:1032
van Bömmel F, Schernick A, Hopf U, Berg T. Tenofovir Disoproxil Fumarate Exhibits Strong Antiviral Effect in a Patient With Lamivudine-Resistant Severe Hepatitis B Reactivation, 124:586–c

Van Cutsen E. *See* Abell T
Van Dam J
See Jacobson BC
See Shields SJ
See Talwalkar J
van De Velde CJH. *See* Liefers G-J
van de Wal Y, Corazza N, Allez M, Mayer LF, Iijima H, Ryan M, Cornwall S, Kaiserlian D, Hershberg R, Koezuka Y, Colgan SP, Blumberg RS. Delineation of a CD1d-Restricted Antigen Presentation Pathway Associated With Human and Mouse Intestinal Epithelial Cells, 124:1420
Van de Water J
See Bruggraber SFA
See Kita H
Van de Wiele C. *See* Annovazzi A
Van den Abbeele AD. *See* Demetri GD
van den Berg FM. *See* Schultsz C
van den Blink B. *See* Hommes D
van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJH. Infliximab but not Etanercept Induces Apoptosis in Lamina Propria T-Lymphocytes From Patients With Crohn's Disease, 124: 1774
van den Brink GR
See Hardwick JCH
See van den Brande JMH
van den Brink GR, Hardwick JCH, Tytgat GNJ, Brink MA, Ten Kate FJ, Deventer SJH van, Peppelenbosch MP. Sonic Hedgehog Regulates Gastric Gland Morphogenesis in Man and Mouse, 121:317
van den Eertwegh AJM, Hanna MG Jr, Pinedo HM. Giving Cancer Therapy a Shot in the Arm. Reply, 117:1015–ss
van den Elzen B. *See* Kuiken S
van den Elzen BDJ. *See* Boeckxstaens GE
van den Wijngaard RM. *See* de Jonge WJ
van der Dijs B. *See* Lechin F
van der Meer R. *See* Bovee-Oudenhoven IMJ
van der Schoor SRD, Goudoever JB van, Stoll B, Henry JF, Rosenberger JR, Burrin DG, Reeds PJ. The Pattern of Intestinal Substrate Oxidation Is Altered by Protein Restriction in Pigs, 121:1167
van der Schoor SRD, Reeds PJ, Stoll B, Henry JF, Rosenberger JR, Burrin DG, van Goudoever JB. The High Metabolic Cost of a Functional Gut, 123:1931
van der Vliet M. *See* Evans RC
van der Wouden E-J, Thijs JC, van Zwet AA. Metronidazole Susceptibility in *Helicobacter pylori*. 117:1032–c
van Deventer J. *See* de Jonge WJ
van Deventer S
See D'Haens G
See Hommes D
van Deventer SJH
See Hardwick JCH
See Hove TT
See Rutgeerts P
See Schreiber S
See van den Brande JMH
See van den Brink GR
See van Montfrans C
van Deventer SJH. Transmembrane TNF-α, Induction of Apoptosis, and the Efficacy of TNF-Targeting Therapies in Crohn's Disease, 121:1242–e
Van Doesburg W. *See* Bovee-Oudenhoven IMJ
van Doorn L-J. *See* Machado JC
van Doorn L-J, Figueiredo C, Mégraud F, Pena S, Midolo P, de Magalhaes Queiroz DM, Carneiro F, Vanderborght B, da Glória F, Pegado M, Sanna R, de Boer W, Schneeberger PM, Correa P, Ng EKW, Atherton J, Blaser MJ, Quint WGV. Geographic Distribution of *vacA* Allelic Types of *Helicobacter pylori*. 116:823
van Driel IR. *See* Scarff KL
van Es HW. *See* Tiethof CHJ
van Ginkel R, Reitsma JB, Büller HA, van Wijk MP, Taminiau JAJ, Benninga MA. Childhood Constipation: Longitudinal Follow-up Beyond Puberty, 125:357
van Ginkel R, Voskuijl WP, Benninga MA, Taminiau JAJM, Boeckxstaens GE. Alterations in Rectal Sensitivity and Motility in Childhood Irritable Bowel Syndrome, 120:31
van Goor H. *See* Hooiveld GJEJ; Jansen PLM; Meerman L
van Gossum A
See Laharie D
See Vermeire S
van Gossum A, François E, Hittelet A, Schmit A, Devière J. A Prospective, Comparative Study Between Push Enteroscopy and Wireless Video Capsule in Patients With Obscure Digestive Bleeding, 125:276–c
van Goudoever JB. *See* van der Schoor SRD
van Herwaarden MA, Samsom M, Smout AJPM. Excess Gastroesophageal Reflux in Patients With Hiatus Hernia Is Caused by Mechanisms Other Than Transient LES Relaxations, 119:1439
van Hoek A. *See* Chen D
van Hogezand R. *See* D'Haens G
van Hogezand RA. *See* Rutgeerts P
van Ijzendoorn SCD, Mostov KE. Connecting Apical Endocytosis to the Intracellular Traffic Infrastructure in Polarized Hepatocytes, 119:1791–e
van Kleef M. *See* Kemler MA
van Krieken JHJM. *See* Liefers G-J
Van Laethem J-L. *See* Deviére J
van Lanschot JJB
See Buskens CJ
See van Rees BP
van Leeuwen FW. *See* McPhaul LW
Van Lint J. *See* Seufferlein T
van Luyn MJA. *See* Roelofsen H
van Montfoort J. *See* Reichel C
van Montfrans C. *See* van den Brande JMH
van Montfrans C, Hooijberg E, Rodriguez Pena MS, de Jong EC, Spits H, te Velde AA, van Deventer SJH. Generation of Regulatory Gut-Homing Human T Lymphocytes Using Ex Vivo Interleukin 10 Gene Transfer, 123:1877
van Montfrans C, Rodriguez Pena MS, Pronk I, ten Kate FJW, te Elde AA, van Deventer SJH. Prevention of Colitis by Interleukin 10-Transduced T Lymphocytes in the SCID Mice Transfer Model, 123:1865
van Nhieu JT. *See* Li L
van Noesel CJM. *See* van Rees BP
van Noorden S. *See* Arebi N
van Rees BP. *See* Buskens CJ
van Rees BP, Rouse RW, De Wit MJ, van Noesel CJM, Tytgat GNJ, van Lanschot JJB, Offerhaus GJA. Molecular Evidence for the Same Clonal Origin of Both Components of an Adenosquamous Barrett Carcinoma, 122:784–cr
van Schelven LJ. *See* Verhagen MAMT
van Sickle M, Davison J, Sharkey K, Mackie K, Hillard C. Emesis, Appetite, and Endocannabinoids. Reply, 123:655–c
van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA. Cannabinoids Inhibit Emesis Through CB1 Receptors in the Brainstem of the Ferret, 121:767
van Staa T-P, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory Bowel Disease and the Risk of Fracture, 125:1591
Van Steen K
See Joossens S
See Vermeire S
van Stolk RU. *See* Baron JA
van Veelen P. *See* Vader W
van Veelen PA. *See* Vader LW
van Vlierberghe H. *See* Lai C-L

van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, Bloks V, Müller M, Sauer PJJ, Kuipers F. Differential Effects of Streptozotocin-induced Diabetes on Expression of Hepatic ABC-Transporters in Rats, 122:1842
van Waeyenberge C. *See* Hautekeete ML
van Wijk MP. *See* van Ginkel R
van Zwet AA. *See* Van der Wouden E-J
Vanasia M. *See* Caligiuri A
vanBerge Henegouwen GP. *See* Samsom M
Vandenbroucke-Grauls CM. *See* D'Elios MM
Vanderborght B. *See* van Doorn L-J
Vanderschueren S. *See* Wilmer A
Vandervoort M. *See* Steinhart AH
Vandewalle A. *See* Luangsay S
Vandewalle P. *See* Joossens S
Vannacci A. *See* Cianchi F
Vanness DJ. *See* Gluecker TM
Vanni E. *See* Bugianesi E
Vaquero E. *See* Gukovskaya AS
Vaquero EC, Edderkaoui M, Nam KJ, Gukovsky I, Pandol SJ, Gukovskaya AS. Extracellular Matrix Proteins Protect Pancreatic Cancer Cells From Death Via Mitochondrial and Nonmitochondrial Pathways, 125:1188
Varadarajulu S, Cotton PB. Autoimmune Pancreatitis: Is It Relevant in the West?, 125:1557–c
Vardas EM. *See* Roussomoustakaki M
Varesco L. *See* Lowy AM
Varet B. *See* Hermine O
Vargas HE, Laskus T, Wang L-F, Lee R, Radkowski M, Dodson F, Fung JJ, Rakela J. Outcome of Liver Transplantation in Hepatitis C Virus-Infected Patients Who Received Hepatitis C Virus-Infected Grafts, 117:149
Vargas HE, Whitcomb DC. Hepatitis C for Half a Century. Comment, 119:1405–ss
Vargas V. *See* Sort P
Vargo JJ, Zuccaro G Jr, Dumot JA, Shermock KM, Morrow JB, Conwell DL, Trolli PA, Maurer WG. Gastroenterologist-Administered Propofol Versus Meperidine and Midazolam for Advanced Upper Endoscopy: A Prospective, Randomized Trial, 123:8
Varia I, Logue E, O'Connor C, Newby K, Wagner HR, Davenport C, Rathey K, Krishnan KR. Chest Pain and Serotonin: A Possible Link?, 121:495–ss
Varilek GW
See Sands BE
See Shattuck-Brandt RL
Varki NM. *See* Dwinell MB
Varro A
See Burdyga G
See Chen D
See Cobb S
See Haigh CR
See Higham AD
See Ottewell PD
See Singh P
See Wang TC
Varro A, Hemers E, Archer D, Pagliocca A, Haigh C, Ahmed S, Dimaline R, Dockray GJ. Identification of Plasminogen Activator Inhibitor-2 as a Gastrin-Regulated Gene: Role of Rho GTPase and Menin, 123:271
Vasen H
See Bülow C
See Bülow S
Vasen HFA, Watson P, Mecklin J-P, Lynch HT. New Clinical Criteria for Hereditary Nonpolyposis Colorectal Cancer (HNPCC, Lynch Syndrome) Proposed by the International Collaborative Group on HNPCC, 116:1453
Vasiliauskas E. *See* Rutgeerts P
Vasiliauskas EA
See Abreu MT
See Dubinsky MC
See Hassard PV
Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An Open-Label Pilot Study of Low-Dose Thalidomide in Chronically Active, Steroid-Dependent Crohn's Disease, 117:1278
Vasseur S. *See* Malka D
Vasudeva RS. *See* Rex DK
Vatn M
See Hampe J
See Thomsen Ø
Vaughan D. *See* Rowland M
Vaughan JA. *See* Mulcahy HE
Vaughan R. *See* Angus P
Vaughan TL. *See* El-Omar EM
Vaughn DJ. *See* Lewis JD
Vaury C. *See* Suraweera N
Vautier G, Bomford AB, Portmann BC, Metivier E, Williams R, Ryder SD. *p53* Mutations in British Patients With Hepatocellular Carcinoma: Clustering in Genetic Hemochromatosis, 117:154
Vaysse N
See Clerc P
See Torrisani J
Vazquez-Sequeiros E, Wang L, Burgart L, Harmsen W, Zinsmeister A, Allen M, Jondal M, Wiersema M. Occult Lymph Node Metastases as a Predictor of Tumor Relapse in Patients With Node-Negative Esophageal Carcinoma, 122:1815
Vazquez-Sequeiros E, Wiersema MJ, Clain JE, Norton ID, Levy MJ, Romero Y, Salomao D, Dierkhising R, Zinsmeister AR. Impact of Lymph Node Staging on Therapy of Esophageal Carcinoma, 125:1626
Vecchi M
See Cattaneo M
See Tountas NA
Vecchioli A. *See* Costamagna G
Veeze HJ. *See* Bronsveld I
Vehmanen P
See Collin P
See Kaukinen K
Vela MF, Castell DO. Impeding Gastroesophageal Refluxate: A New Application of an Old Medication. Reply, 125:985–ss
Vela MF, Tutuian R, Katz PO, Castell DO. Impeding Gastroesophageal Refluxate: A New Application of an Old Medication, 125:984–ss
Velasco M
See Cobb S
See Singh P
Velcich A. *See* Mariadason JM
Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L. Intestinal Mucin and Colorectal Cancer: It's Not Just Goo, 123:648–ss
Velde AAT. *See* Hove TT
Veldhuyzen Van Zanten S. *See* Lind T
Veldman GM. *See* Spencer DM
Velduyzen van Zanten SJO, Dixon MF, Lee A. The Gastric Transitional Zones: Neglected Links Between Gastroduodenal Pathology and *Helicobacter* Ecology, 116:1217
Veloso FT. *See* Thomsen Ø
Veltkamp C, Tonkonogy SL, Jong YP de, Albright C, Grenther WB, Balish E, Terhorst C, Sartor RB. Continuous Stimulation by Normal Luminal Bacteria Is Essential for the Development and Perpetuation of Colitis in Tg∈26 Mice, 120:900
Veneto G. *See* Di Stefano M
Venihaki M
See Mykoniatis A
See Wlk M
Venkatesan T. *See* Somogyi L
Venook A. *See* Yao FY
Ventura A, Magazzù G, Greco L. Duration of Exposure to Gluten and Risk for

Autoimmune Disorders in Patients With Celiac Disease, 117:297
Venturi A. *See* Gionchetti P
Ventz M. *See* Steiner M
Venzon DJ. *See* Peghini PL
Verbist L. *See* Hautekeete ML
Verburg M, Renes IB, Einerhand AWC, Büller HA, Dekker J. Isolation-Stress Increases Small Intestinal Sensitivity to Chemotherapy in Rats, 124:660
Verdú EF. *See* Berčík P
Verellen-Dumoulin C. *See* Chen J-M
Veress B. *See* Törnblom H
Vergalla J. *See* Baumert TF
Vergani A. *See* Piperno A
Vergani D. *See* Maini MK
Verger R. *See* Carrière F
Vergnolle N
See Coelho A-M
See Wallace JL
Verhagen MAMT. *See* Samsom M
Verhagen MAMT, van Schelven LJ, Samsom M, Smout AJPM. Pitfalls in the Analysis of Electrogastrographic Recordings, 117:453–vidd
Verkade HJ
See van Waarde WM
See Voshol PJ
Verkarre V. *See* Mention J-J
Verkarre V, Romana S-P, Cellier C, Asnafi V, Mention J-J, Barbe U, Nusbaum S, Hermine O, Macintyre E, Brousse N, Cerf-Bensussan N, Radford-Weiss I. Recurrent Partial Trisomy 1q22-q44 in Clonal Intraepithelial Lymphocytes in Refractory Celiac Sprue, 125:40
Verlander JW. *See* Weiner ID
Verma R. *See* Corley DA
Vermeer ITM, Engels LGJB, Pachen DMFA, Dallinga JW, Kleinjans JCS, Maanen JMS van. Intragastric Volatile N-nitrosamines, Nitrite, pH, and *Helicobacter pylori* During Long-term Treatment With Omeprazole, 121:517
Vermeire S
See Baert F
See Joossens S
See Laharie D
See Van Assche G
Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, Groenen P, Vlietinck R, Rutgeerts P. Comparative Study of ASCA (Anti-*Saccharomyces cerevisiae* Antibody) Assays in Inflammatory Bowel Disease, 120:827
Vermeire S, Louis E, Rutgeerts P, de Vos M, van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel J-F, Hugot J-P. NOD2/CARD15 Does Not Influence Response to Infliximab in Crohn's Disease, 123:106
Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity Associated With Anti-Tumor Necrosis Factor α Treatment in Crohn's Disease: A Prospective Cohort Study, 125:32
Vermeire S, Satsangi J, Peeters M, Parkes M, Jewell DP, Vlietinck R, Rutgeerts P. Evidence for Inflammatory Bowel Disease of a Susceptibility Locus on the X Chromosome, 120:834
Verne GN, Hahn AB, Pineau BC, Hoffman BJ, Wojciechowski BW, Wu WC. Association of HLA-DR and -DQ Alleles With Idiopathic Achalasia, 117:26
Vernerová Z. *See* Gut MO
Verrando P. *See* Malka D
Verreet P. *See* Fischbach W
Verrier P. *See* Bouin M
Versteeg HH. *See* van den Brande JMH
Verthier N. *See* Berriot-Varoqueaux N
Verweij CL. *See* Bayley J-P
Vetuschi A. *See* Alvaro D
Veyrac M. *See* Cadiot G
Veyradier A, Balian A, Wolf M, Giraud V, Montembault S, Obert B, Dagher I, Chaput J-C, Meyer D, Naveau S. Abnormal von Willebrand Factor in Bleeding Angiodysplasias of the Digestive Tract, 120:346
Veysey MJ. *See* Thomas LA
Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Murphy GM, Dowling RH. Colonic Transit Influences Deoxycholic Acid Kinetics, 121:812
Vézina A
See Deschênes C
See Vachon PH
Viale J-P. *See* Boillot O
Viani S. *See* Velcich A
Viar MJ. *See* Ray RM
Viarme F. *See* Faure C
Vicari JJ. *See* Goldblum JR
Vickers SM. *See* Yamamoto M
Vidaud M
See Paradis V
See Sobesky R
Videla S. *See* Junquera F
Vidrich A. *See* Rivera-Nieves J
Vieillard-Baron D
See Jacob P
See Rossmann H
Vierling JM
See Dubinsky MC
See Fontana RJ
Viertelhausen S. *See* Stern HS
Vieth M, Stolte M. Barrett's Esophagus and Neoplasia: Data From the Bayreuth Barrett's Archive, 122:590–c
Vig P. *See* Forbes SJ
Viganò M. *See* Piperno A
Vigil JM. *See* Inadomi JM
Vigna SR. Cannabinoids and the Gut, 125: 973–e
Vigneri S. *See* Savarino V
Vila MC
See García-Pagán JC
See Guarner C
Vilde J-L. *See* di Martino V
Vilgrain V. *See* Hammel PR
Villa P. *See* Bras-Gonçalves RA
Villacencio R. *See* Vorobioff JD
Villanueva C. *See* García-Pagán JC
Villanueva C, Miñana J, Balanzó. Prevention of Varices Rebleeding: Are Drugs Better After All? Reply, 122: 833–ss
Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, Boadas J, Cusso X, Guarner C, Balanzo J. Prevention of Varices Rebleeding: Are Drugs Better After All?, 122:832–ss
Villanueva C, Ortiz J, Miñana J, Soriano G, Sàbat M, Boadas J, Balanzó J. Somatostatin Treatment and Risk Stratification by Continuous Portal Pressure Monitoring During Acute Variceal Bleeding, 121:110
Villmow B. *See* Benz C
Vinall LE, King M, Novelli M, Green CA, Daniels G, Hilkens J, Sarner M, Swallow DM. Altered Expression and Allelic Association of the Hypervariable Membrane Mucin MUC1 in *Helicobacter pylori* Gastritis, 123:41
Vincent JP. *See* Martin S
Vinel J-P
See Alric L
See Bureau C
Vingerhoets F. *See* Spahr L
Vingiani AM. *See* Cipolletta L
Vining DJ. *See* Pineau BC
Vío C. *See* Zanlungo A
Viola F. *See* Barbato M
Viola S, Meyer M, Fabre M, Tounian P, Goddon R, Dechelotte P, Valayer J, Gruner M, Bernard O. Ischemic Necrosis of Bile Ducts Complicating Schönlein-Henoch Purpura, 117:211–cr
Viramontes BE. *See* Camilleri M
Visa J. *See* Lacy AM
Vissuzaine C. *See* Sobhani I
Vitali B. *See* Gionchetti P

Vítek L. Etiology of Fasting Hyperbilirubinemia: Genetic Factors Versus Enhanced Enterohepatic Cycling of Bilirubin, 117:1254–c
Vitellas KM. *See* Baillie J
Viûado B. *See* Pérez-Páramo M
Vizzutti F. *See* La Villa G
Vlahcevic ZR, Eggersten G, Björkhem I, Hylemon PB, Redford K, Pandak WM. Regulation of Sterol 12α–Hydroxylase and Cholic Acid Biosynthesis in the Rat, 118:608
Vlietinck R. *See* Vermeire S
Voderholzer W. *See* Ortner MEJ
Voeller G. *See* Abell T
Vogel A. *See* Ockenga J
Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, Strassburg CP. Genetic Link of Hepatocellular Carcinoma With Polymorphisms of the *UDP-Glucuronosyltransferase UGT1A7* Gene, 121:1136–
Vogel JD. *See* Danese S
Vogel W. *See* Zoller H
Vogelsang H
See Joossens S
See Reinisch W
Vogelstein B. *See* Häussinger D
Vogl D. *See* Leeb SN
Vogt B. *See* Berman SM
Vogt BA
See Drossman DA
See Naliboff BD
Vohra A. *See* Söderholm JD
Volenberg I. *See* Malhi H
vom Dahl S. *See* Häussinger D
von Bergmann K
See Drobnik W
See Mitchell SA
von Boyen G. *See* Steinkamp M
von Herbay A. *See* Reinshagen M
Von Mehren M. *See* Demetri GD
von Müller L. *See* Sträter J
von Wasielewski R. *See* Gongoll S
Vonk RJ
See Roelofsen H
See Schaefer M
Vorobioff JD, Gamen M, Kravetz D, Picabea E, Villacencio R, Bordato J, Ruf A, Besone F, Romero G, Palazzi J, Nicora A, Passamonti M, Tanno H. Effects of Long-Term Propanolol and Octreotide on Postprandial Hemodynamics in Cirrhosis: A Randomized, Controlled Trial, 122: 915
Vos TA. *See* Hooiveld GJEJ
Voshol PJ, Minich DM, Havinga R, Oude Elferink RPJ, Verkade HJ, Groen AK, Kuipers F. Postprandial Chylomicron Formation and Fat Absorption in Multidrug Resistance Gene 2 P-Glycoprotein-Deficient Mice, 118:173
Voskuijl WP. *See* van Ginkel R
The VPA Study Group. *See* Gerbes AL
Vuagnat A
See Cadiot G
See Sobhani I
Vuitton DA. *See* Godot V
Vulpe CD. *See* Frazer DM
Vuyyuru L. *See* Zaki M
Vyhnalek P. *See* Ghosh G

Wada A. *See* Mori N
Wada K
See Katayama K
See Nakajima A
See Noguchi H
See Osawa E
Wada K, Montalto MC, Stahl GL. Inhibition of Complement C5 Reduces Local and Remote Organ Injury After Intestinal Ischemia/Reperfusion in the Rat, 120:126
Wada S. *See* Maeyama H
Wadowska K. *See* Steiner M
Wadström T. *See* Nilsson H-O
Waechtler M. *See* Gerlach JT
Waetzig GH. *See* Rosenstiel P
Waetzig GH, Rosenstiel P, Nikolaus S, Seegert D, Schreiber S. Differential p38 Mitogen-Activated Protein Kinase Target Phosphorylation in Responders and Nonresponders to Infliximab, 125: 633–c
Wagner DR
See Imperiale TF
See Lieberman DA
Wagner HR. *See* Varia I
Wagner JL. *See* Theuer CP
Wagner M
See Greten FR
See Steinle AU
Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, Zatloukal K, Guo GL, Schuetz JD, Gonzalez FJ, Marschall H-M, Denk H, Trauner M. Role of Farnesoid X Receptor in Determining Hepatic ABC Transporter Expression and Liver Injury in Bile Duct-Ligated Mice, 125:825
Wagner M, Kunsch S, Duerschmied D, Beil M, Adler G, Mueller F, Gress TM. Transgenic Overexpression of the Oncofetal RNA Binding Protein KOC Leads to Remodeling of the Exocrine Pancreas, 124:1901
Wagner M, Weber CK, Bressau F, Greten FR, Stagge V, Ebert M, Leach SD, Adler G, Schmid RM. Transgenic Overexpression of Amphiregulin Induces a Mitogenic Response Selectively in Pancreatic Duct Cells, 122:1898
Wagner S
See Mix H
See Widjaja A
Waheed A. *See* Parkkila S
Wahli W. *See* Hellemans K
Wahlström J. *See* Björk J
Wahnschaffe U. *See* Schmidt W
Wahnschaffe U. Celiac Disease-like Abnormalities in IBS: Wrong Title or Wrong Disease. Reply, 123:954–co
Wahnschaffe U, Ullrich R, Riecken EO, Schulzke J-D. Celiac Disease-Like Abnormalities in a Subgroup of Patients With Irritable Bowel Syndrome, 121:1329
Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. There Is a Relationship Between Celiac Disease and Patients With Symptoms of Irritable Bowel Syndrome. Reply, 123:1409–co
Waidmann M, Bechtold O, Frick J-S, Lehr H-A, Schubert S, Dobrindt U, Löffler J, Bohn E, Autenrieth IB. *Bacteroides vulgatus* Protects Against *Escherichia coli*-Induced Colitis in Gnotobiotic Interleukin-2-Deficient Mice, 125:162
Wakasa K-I. *See* Yamamoto H
Wakatsuki Y. *See* Yoshida M
Wakefield AJ. *See* Montgomery SM
Wakita T. *See* Kato T
Walczak H. *See* Sträter J
Wald A
See Desautels SG
See Diamant NE
Wald A. Biofeedback for Fecal Incontinence, 125:1533–e
Waldegger S, Klingel K, Barth P, Sauter M, Lanzendörfer M, Kandolf R, Lang F. *h-sgk* Serine-Threonine Protein Kinase Gene as Early Transcriptional Target of Transforming Growth Factor β in Juman Intestine, 116:1081
Waldhoer T. *See* Dejaco C
Waldman SA. *See* Park J
Waldum H, Brenna E. Discussion on the Effect of Chronic Hypergastrinemia on Human Enterochromaffin-Like Cells: Insights From Patients With Sporadic Gastrinomas, 124:1564–c
Waldum HL. ECL Cell Tumor and Endocrine Carcinoma of the Stomach, 117:510–c
Walker AP. *See* Wallace DF
Walker BD. *See* Somsouk M
Walker F. *See* Sobhani I
Walker NM. *See* Gawenis LR
Walker NM, Flagella M, Gawenis LR, Shull GE, Clarke LL. An Alternate

Pathway of cAMP-Stimulated Cl Secretion Across the NKCC1-Null Murine Duodenum, 123:531
Walker S. *See* Schwab M
Wallace DF, Dooley JS, Walker AP. A Novel Mutation of *HFE* Explains the Classical Phenotype of Genetic Hemochromatosis in a C282Y Heterozygote, 116:1409
Wallace JL. *See* Fiorucci S
Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-Induced Gastric Damage in Rats: Requirement for Inhibition of Both Cyclooxygenase 1 and 2, 119:706
Wallace JL, Miller MJS. Nitric Oxide in Mucosal Defense: A Little Goes a Long Way, 119:512–srr
Wallace JL, Vergnolle N, Muscará MN, Asfaha S, Chapman K, McKnight W, Del Soldato P, Morelli A, Fiorucci S. Enhanced Anti-inflammatory Effects of a Nitric Oxide-Releasing Derivative of Mesalamine in Rats, 117:557
Wallace KL. *See* Williams RBH
Wallace M. *See* Mulcahy HE
Wallace M. *Medical Imaging in Gastroenterology and Hepatology*, 125: 626–pmr
Wallace MB, Perelman LT, Backman V, Crawford JM, Fitzmaurice M, Seiler M, Badizadegan K, Shields SJ, Itzkan I, Dasari RR, Dam JV, Feld MS. Endoscopic Detection of Dysplasia in Patients With Barrett's Esophagus Using Light-Scattering Spectroscopy, 119:677
Wallerstedt S. *See* Elmberg M
Walley M. *See* Sigthorsson G
Wallig MA. *See* Frossard J-L
Walsh JH. *See* Sternini C
Walsh JH. Gastroentrology News, 118: 459–gn
Walsh RM. *See* He C-L
Walsh SV, Hopkins AM, Chen J, Narumiya S, Parkos CA, Nusrat A. Rho Kinase Regulates Tight Junction Function and Is Necessary for Tight Junction Assembly in Polarized Intestinal Epithelia, 121:566
Walsh T. *See* O'Sullivan GC
Walsh-Reitz MM. *See* Ropeleski MJ
Walz A. *See* Saurer L
Wandall JH. *See* Thjodleifsson B
Wands J. *See* Hoon Ahn S
Wands JR. *See* Khamzina L
Wang A. *See* Lu J
Wang C
See Ng AY-N
See Riegler M
Wang CC
See Mykoniatis A
See Wlk M
Wang D-A. *See* Deng W
Wang DQ-H. *See* Eckhardt ERM
Wang DQ-H, Afdhal NH. Good Cholesterol, Bad Cholesterol: Role of Oxysterols in Biliary Tract Diseases, 121:216–e
Wang G. *See* Ji J
Wang J
See McPhaul LW
See Zheng H
Wang J-T. *See* Chang C-S
Wang J-Y. *See* Li L
Wang K. Photodynamic Therapy and Genetic Abnormalities, 120:1065–c
Wang KK
See Buttar NS
See Krishnadath KK
See Lin JL-C
Wang L
See He C-L
See Lee J
See Luckey A
See Vazquez-Sequeiros E
Wang LC, Nassir F, Liu Z-Y, Ling L, Kuo F, Crowell T, Olson D, Davidson NO, Burkly LC. Disruption of Hedgehog Signaling Reveals a Novel Role in Intestinal Morphogenesis and Intestinal-Specific Lipid Metabolism in Mice, 122:469
Wang L-F. *See* Vargas HE
Wang M. *See* Yamamoto M
Wang M-L. *See* He W
Wang Q. *See* Kim S
Wang R-T. *See* Sung JJY
Wang RYH. *See* Umemura T
Wang S. *See* Selaru FM
Wang TC
See Boushey RP
See Chen D
See Clerc P
See Farrell JJ
See Fox JG
See Höcker M
See Khan ZE
See Ottewell PD
See Singh P
Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG. Synergistic Interaction Between Hypergastrinemia and *Helicobacter* Infection in a Mouse Model of Gastric Cancer, 118:36
Wang WP. *See* Guo X
Wang X
See Blindenbacher A
See DeLeve LD
Wang X-D. *See* Liu C
Wang Y. *See* Kim Y-I
Wang Y-N. *See* Theodorakis NG
Wanless I. *See* Dahlan Y
Wanless IR. *See* Capurro M
Ward AM. *See* Sanders DS
Ward CA, Liu H, Lee SS. Altered Cellular Calcium Regulatory Systems in a Rat Model of Cirrhotic Cardiomyopathy, 121:1209–
Ward CJ. *See* Masyuk TV
Ward JM. *See* Boivin GP
Ward PA. *See* Lentsch AB
Ward R. *See* Hawkins N
Ward S. *See* Torihashi S
Ward SG. *See* Weaver SA
Ward SJ. *See* Dorrell N
Ward SM
See Porcher C
See Sanders KM
Ward SM, Ördög T, Bayguinov JR, Horowitz B, Epperson A, Shen L, Westphal H, Sanders KM. Development of Interstitial Cells of Cajal and Pacemaking in Mice Lacking Enteric Nerves, 117:584
Warhurst G. *See* Lomax RB
Waring JP. *See* Filipi CJ
Waring P. *See* Ng AY-N
Warley A. *See* Evans SM
Warner BW
See Bates MD
See Erwin CR
See Huang FS
See Robb BW
See Tiao G
Warner BW
Enterocyte Apoptosis and TPN-Associated Intestinal Mucosal Atrophy: A View of the Chicken or the Egg? Comment, 125:1274–ss
GLP-2 as Therapy for the Short-Bowel Syndrome, 120:1041–e
NEC, EGF, Milk and Spit. Comment, 123:383–ss
Peristomal Pyoderma Gangrenosum. Comment, 119:873–ss
Single-Stage Operations for Hirschsprung's Disease – Pushing the Envelope. Comment, 120:1301–ss
Warner RL. *See* Lentsch AB
Warny M. *See* He D
Warren A. *See* Bowen DG
Warshaw AL
See Hartwig W
See Keck T
Warskulat U
See Kubitz R
See Müschen M
Waser B. *See* Reubi JC

Washington K. *See* Boivin GP
Washington MK
See Crawford HC
See DuBois RN
See Means AL
See Shattuck-Brandt RL
See Song SY
Watanabe M
See Inoue N
See Kanai T
See Kazumori H
See Maeyama H
See Nakazawa A
See Totsuka T
Watanabe M, Okazawa A, Sato T, Yamazaki M, Okamoto S, Ishii H, Totsuka T, Iiyama R, Okamoto R, Ikeda M, Kurimoto M, Takeda K, Akira S, Hibi T. Macrophage-Derived IL-18-Mediated Intestinal Inflammation in the Murine Model of Crohn's Disease. *See* Kanai T
Watanabe N. *See* Okazaki K
Watanabe T
See Iwashita T
See Tanaka S
See Yoshida M
Waterfall WE. *See* Abell T
Waterman SA. *See* Goldblatt F
Wathen NC. *See* Monteleone G
Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, Snyder SH, Ferris CD. Are Things Looking Up for the Treatment of Gastroparesis? Sildenafil in Animal Models of Diabetic Gastropathy, 120:576–ss
Watkins KT. *See* Sisk CM
Watkins PB
See Fontana FJ
See Givens RC
Watkins S. *See* Zhao Y
Watkins SC. *See* Schwarz NT
Watson AJM
See Bach SP
See Ottewell PD
Watson JJ. *See* Yao FY
Watson M. *See* Radford-Smith GL
Watson NK. *See* Whitehead RH
Watson PA. *See* Filipi CJ
Watson SJ
See Takahashi T
See Yazdani A
Watts J. *See* Sigthorsson G
Waxman IF. *See* Abou-Saif A
Waye JD. *See* Rubin PH
Weaver AL. *See* Lowry PW
Weaver SA, Russo MP, Wright KL, Kolios G, Jobin C, Robertson DAF, Ward SG. Regulatory Role of Phosphatidylinositol 3-Kinase on TNF-α-Induced Cyclooxygenase 2 Expression in Colonic Epithelial Cells, 120:1117
Webb DJ. *See* Helmy A
Webb G. *See* Hausmann M
Webb PM, Crabtree JE, Forman D, and The Eurogast Study Group. Gastric Cancer, Cytotoxin-Associated Gene A-Positive *Helicobacter pylori*, and Serum Pepsinogens: An International Study, 116:269
Weber CK
See Greten FR
See Wagner M
Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-κB Activity by Sulfasalazine Is Mediated by Direct Inhibition of IκB Kinases α and β, 119:1209
Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, Leder G, Adler G, Gress TM. Biglycan Is Overexpressed in Pancreatic Cancer and Induces G1-Arrest in Pancreatic Cancer Cell Lines, 121:657
Weber J. *See* Swidsinski A
Weber N. *See* Sobhani I
Weber P. *See* Zimmer K-P
Weber TC. *See* Drobnik W
Webster GJM. *See* Maini MK
Wedel T, Spiegler J, Soellner S, Roblick UJ, Schiedeck THK, Bruch H-P, Krammer H-J. Enteric Nerves and Interstitial Cells of Cajal Are Concomitantly Altered in Patients With Slow-Transit Constipation and Megacolon, 123:1459
Wedemeyer H
See Jaeckel E
See Klein C
Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral Immunization With HCV-NS3-Transformed *Salmonella:* Induction of HCV-Specific CTL in a Transgenic Mouse Model, 121:1158–
Wedemeyer H, Pethig K, Manns MP, Böker KHW. Hepatitis B Infection in Heart Transplant Recipients, 120: 1312–c
Weeks DL. *See* Scott DR
Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA. Telomerase Reconstitution Immortalizes Human Fetal Hepatocytes Without Disrupting Their Differentiation Potential, 124: 432
Weglarz TC. *See* Jamal HZ
Wei B
See Braun J
See Sutton CL
Wei JT, Shaheen NJ. Dollars and Sense in Preventing Esophageal Cancer. Comment, 125:1269–ss
Wei JY. *See* Maillot C
Wei X. *See* Meng G
Weich N. *See* Bataller R
Weidenbach H. *See* Steinle AU
Weigle DS. *See* Cummings DE
Weiglein AH. *See* Fickert P
Weihe E. *See* Feurle GE
Weiland O
See Chen M
See Schalm SW
Weill B. *See* Malassagne B
Weiller P-J. *See* Granel B
Weimer M. *See* Weber CK
Weinberg DS. *See* Berman JM
Weinberg V. *See* Terdiman JP
Weiner ID, Miller RT, Verlander JW. Localization of the Ammonium Transporters, Rh B Glycoprotein and Rh C Glycoprotein, in the Mouse Liver, 124:1432
Weinman SA
See Lerat H
See Okuda M
Weinshilboum RM. *See* Lowry PW
Weinstein DH. *Practical Gastroenterology: A Comprehensive Guide*. 123:389–pmr
Weinstein WM. *See* Dulai GS
Weinstin B. *See* Zhu GH
Weinstock JV. *See* Berg DJ
Weir DG. *See* Farrell RJ
Weisbrodt NW. *See* Kozar RA
Weiser J. *See* Rubin PH
Weisiger RA. Carbon Monoxide and Sepsis: Is a Toxic Gas Good For Your Liver?, 120:1289–e
Weiss DG. *See* Lieberman DA
Weiss FU. *See* Mayerle J
Weiss G
See Rost D
See Zoller H
Weiss M. *See* Hermsen M
Weiss NS
See Corley DA
See Ioannou GN
Weiss TS. *See* Mühlbauer M
Weissenborn K, Tietge UJF, Bokemeyer M, Mohammad B, Bode U, Manns MP, Caselitz M. Liver Transplantation Improves Hepatic Myelopathy: Evidence by Three Cases, 124:346
Weissleder R. *See* Marten K
Weizsäcker F von. *See* Geissler M
Welch TJ
See Gluecker TM
See Johnson CD
Weller SG, Klein IK, Penington RC, Karnes WE Jr. Distinct Protein

Kinase C Isozymes Signal Mitogenesis and Apoptosis in Human Colon Cancer Cells, 117:848
Welsh KI
See Ahmad T
See Orchard TR
See Satsangi J
Weltman M. *See* Chitturi S
Welzel M. *See* Scholz A
Wen X. *See* Su CG
Wendling C. *See* Tomasetto C
Wendum D. *See* Rosmorduc O
Wenneberg AK. *See* Pacht ER
Wenzl E. *See* Riegler M
Weppler D. *See* Torres M
Wermke W
See Pirlich M
See Rickes S
Werneburg NW. *See* Yoon J-H
Werner E. *See* Schepke M
Werner J. *See* Hartwig W
West AB. *See* Atchison CR
West GA
See Danese S
See Lawrance IC
See Musso A
West J, Logan RFA, Card TR, Smith C, Hubbard R. Fracture Risk in People With Celiac Disease: A Population-Based Cohort Study, 125:429
West SD. *See* Helmer KS
Westaby D. *See* Miao YM
Westcott JY. *See* Buttar NS
Westland C, Delaney W IV, Yang H, Chen S-S, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B Virus Genotypes and Virologic Response in 694 Patients in Phase III Studies of Adefovir Dipivoxil, 125:107
Westphal H. *See* Ward SM
Weström B. *See* Söderholm JD
Weth R. *See* Geissler M
Wettstein M
See Häussinger D
See Kubitz R
Weuble L. *See* Levine DS
Whan Jeong S. *See* Sug Kim H
Whately-Smith C. *See* Cézard JP
Wheeler MD
See Froh M
See McKim SE
See Yin M
Wheeler MD, Kono H, Yin M, Rusyn I, Froh M, Connor HD, Mason RP, Samulski RJ, Thurman RG. Delivery of the Cu/Zn-Superoxide Dimutase Gene With Adenovirus Reduces Early Alcohol-Induced Liver Injury in Rats, 120:1241
Whitacre CC. New Insights Into Oral Tolerance, 119:260–e
Whitcomb DC
See Etemad B
See Khalid A
See Pfützer R
See Pfützer RH
See Schneider A
See Vargas HE
Whitcomb DC
Early Trypsinogen Activation in Acute Pancreatitis. Comment, 116:771–ss
The Genetics of Shwachman Diamond Syndrome. Comment, 125:1542–ss
Pancreatic Bicarbonate Secretion: Role of CFTR and the Sodium-Bicarbonate Cotransporter. Comment, 117:275–ss
Whitcomb DC, Pogue-Geile KL. A CF Modifier Means Meconium In Mouse and Man. Comment, 119:268–ss
Whitehall VLJ. *See* Jass JR
Whitehead RH
See Fujimoto K
See Means AL
Whitehead RH, Demmler K, Rockman SP, Watson NK. Clonogenic Growth of Epithelial Cells From Normal Colonic Mucosa From Both Mice and Humans, 117:858
Whitehead W. *See* Drossman DA
Whitehead WE
See Diamant NE
See Drossman DA
See Levy RL
See Palsson OS
Whitehead WE
Comment From the Editors, 124:598–ce
Comment from the Editors, 122:5–ce
Whitehead WE, Palsson O, Jones KR. Systematic Review of the Comorbidity of Irritable Bowel Syndrome With Other Disorders: What Are the Causes and Implications?, 122:1139–srr
Whiteley GS. *See* Muralikrishnan VP
Whitington PF. *See* Emerick KM
Whorwell PJ. *See* Calvert EL
Wichlas M. *See* Peck-Radosavljevic M
Widjaja A
See Mix H
See Ockenga J
Widjaja A, Gratz KF, Ockenga J, Wagner S, Manns MP. Octreotide for Therapy of Chylous Ascites in Yellow Nail Syndrome, 116:1017–c
Wiebecke B. *See* Folwaczny C
Wiedenmann B
See Ding W-Q
See Gut MO
See Höcker M
See Marschall ZV
See Scholz A
Wiegant VM. *See* Stam R
Wiener SM. *Textbook of Gastroenterology Self-Assessment Review*, 122:1182–pmr
Wiercinska E. *See* Dooley S
Wiersema M. *See* Vazquez-Sequeiros E
Wiersema MJ
See Chari ST
See Harewood GC
See Schwartz DA
See Vazquez-Sequeiros E
Wiersema MJ
Gastrointestinal Disease-An Endoscopic Approach, 125:989–pmr
Longitudinal Endosonography: Atlas and Manual for Use in the Upper Gastrointestinal Tract, 122:2088–pmr
Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R, The United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End-Stage Liver Disease (MELD) and Allocation of Donor Livers, 124:91
Wiesner RH, Freeman R, Kim WR, Kamath P, Lake J, Kremer W. Utility of the MELD Score for Assessing 3-Month Survival in Patients With Liver Cirrhosis: One More Positive Answer. Reply, 125:994–c
Wiest R, Tsai M-H, Groszmann RJ. Octrotide Potentiates PKC-Dependent Vasoconstrictors in Portal-Hypertensive and Control Rats, 120: 975
Wiggins TM. *See* Gawenis LR
Wigginton T. *See* Mysore JV
Wight NJ. *See* Atherton JC
Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ. Rofecoxib, a COX-2 Inhibitor, Does Not Inhibit Human Gastric Mucosal Prostaglandin Production, 120:867
Wiginton D. *See* Bates MD
Wijmenga C
See Müller T
See Van Belzen MJ
Wikström K. *See* Öhd JF
Wilcox CM. Gastroenterology Fellowship Training: A Generation Lost, 116: 228–c
Wilcox JN. *See* Shibahara T
Wild G
See Bitton A
See Fedorak RN
See Schreiber S
Wilda M. *See* Paxian S
Wildner-Christensen M, Hansen JM, Schaffalitzky de Muckadell OB. Rates

of Dyspepsia One Year After *Helicobacter pylori* Screening and Eradication in a Danish Population, 125:372
Wiley T. *See* Owens CA
Wilhelms G. *See* Miehlke S
Wilkes MM, Navickis RJ
Protein Shakes, 122:582–ss
Protein Shakes. Reply, 122:584–ss
Wilkins SJ. *See* Frazer DM
Wilkinson SP. *See* Dunlop SP
Will H. *See* Kalinina T
Willecke K. *See* Frossard J-L
Willems B. *See* Delage G
Willett WC
See Giovannucci E
See Leitzmann MF
Williams C
See El-Omar EM
See Mowat C
Williams CS
See Callejas NA
See Dvorak B
Williams DE. *See* Thumshirn M
Williams E. *See* Evans RC
Williams G. *See* Ballinger A
Williams GT. *See* Richardson CE
Williams JA. *See* Bragado MJ
Williams JM. *See* Berg CL
Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK. Enhanced Survival and Mucosal Repair After Dextran Sodium Sulfate-Induced Colitis in Transgenic Mice That Overexpress Growth Hormone, 120:925
Williams M. *See* Slater E
Williams MP. *See* Pounder RE
Williams NC. *See* Schreiber S
Williams R
See Cramp ME
See Hermsen M
See Kapoor D
See Lau GKK
See Maini MK
See Vautier G
Williams RBH, Ali GN, Wallace KL, Wilson JS, de Carle DJ, Cook IJ. Esophagopharyngeal Acid Regurgitation: Dual pH Monitoring Criteria for Its Detection and Insights Into Mechanisms, 117:1051
Williams SS. *See* Bates MD
Willis J
See Lawrance IC
See Spencer DM
Wilmer A, Tack J, Frans E, Dits H, Vanderschueren S, Gevers A, Bobbaers H. Duodenogastroesophageal Reflux and Esophageal Mucosal Injury in Mechanically Ventilated Patients, 116: 1293
Wilms K. *See* Fischbach W
Wilson AJ. *See* Mariadason JM
Wilson I. *See* Chadwick VS
Wilson JS. *See* Williams RBH
Wilson KH. *See* Rath HC
Wilson KT
See Fu S
See Gobert AP
Wilson L, Szabó C, Salzman AL. Protein Kinase C-Dependent Activation of NF-κB in Enterocytes Is Independent of IκB Degradation, 117:106
Wilson LA
See Gluecker TM
See Johnson CD
Wilson S. *See* Schroy PC III
Wilson T. *See* Ng AY-N
Wilson-Barnett J. *See* Norton C
Winand D. *See* Reynaert H
Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C. Colorectal Cancer Screening and Surveillance: Clinical Guidelines and Rationale—Update Based on New Evidence, 124:544–aga
Winawer SJ. *See* Zauber AG
Winawer SJ, Zauber AG, Stewart ET. Colonoscopy Versus Double-Contrast Barium Enema. Reply, 119:1402–ss
Wingertzahn MA. *See* Slonim AE
Wingler K, Müller C, Schmehl K, Florian S, Brigelius-Flohé. Gastrointestinal Glutathione Peroxidase Prevents Transport of Lipid Hydroperoxides in CaCo-2 Cells, 119:420
Winston J. *See* Toma H
Winter HS. *Hepatobiliary, Splenic & Pancreatic Disease in Children, Medical & Surgical Treatment*, 116:775–pmr
Winter T. *See* Thomsen Ø
Winther KV. *See* Jess T
Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and Cause-Specific Mortality in Ulcerative Colitis: Follow-up of a Population-Based Cohort in Copenhagen County, 125:1576
Wirth H-P
See Dubois A
See Peek RM Jr
Wirth T. *See* Weber CK
Wirz A
See El-Omar EM
See Fletcher J
See Iijima K
See Mowat C
Wirz AA. *See* Gillen D
Wisniewski R. *See* Balaban DH
Witt H. *See* Bhatia E
Witt H, Hennies HC, Becker M. *SPINK1* Mutations in Chronic Pancreatitis, 120:1060–c
Witt H, Luck W, Becker M
The A16V Signal Peptide Cleavage Site Mutation in the Cationic Trypsinogen Gene and Chronic Pancreatitis. Reply, 117:1509–c
A Signal Peptide Cleavage Site Mutation in the Cationic Trypsinogen Gene Is Strongly Associated With Chronic Pancreatitis, 117:7–rc
Witteman BJM. *See* Bovee-Oudenhoven IMJ
Wittenburg H, Lyons MA, Li R, Churchill GA, Carey MC, Paigen B. FXR and ABCG5/ABCG8 as Determinants of Cholesterol Gallstone Formation From Quantitative Trait Locus Mapping in Mice, 125:868
Wittig B. *See* Stallmach A
Wittig BM. *See* May E
Witzig TE. *See* Dayharsh GA
Wlk M
See Morteau O
See Mykoniatis A
See Riegler M
Wlk M, Wang CC, Venihaki M, Liu J, Zhao D, Anton PM, Mykoniatis A, Pan A, Zacks J, Karalis K, Pothoulakis C. Corticotropin-Releasing Hormone Antagonists Possess Anti-inflammatory Effects in the Mouse Ileum, 123:505
Wo JM
See Corley DA
See Triadafilopoulos G
Woessner M. *See* Dienstag JL
Wogen J. *See* Laine L
Woitas RP, Ahlenstiehl G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offergeld R, Sauerbruch T, Spengler U. Frequency of the HIV-Protective CC Chemokine Receptor 5-Δ32/Δ32 Genotype Is Increased in Hepatitis C, 122:1721–rc
Woitas RP, Ahlenstiehl G, Sauerbruch T, Spengler U. Frequency of the 32-Base Pair Deletion in the Chemokine Receptor CCR5 Gene Is Not Increased in Hepatitis C Patients. Reply, 124: 1560–c
Woitas RP, Ahlenstiel G, Sauerbruch T, Spengler U. HCV Chronic Infection and CCR5-Δ32/Δ32. Reply, 124:869–c
Wojciechowski BW. *See* Verne GN
Wojcikiewicz RJH, Ernst SA, Yule DI. Secretagogues Cause Ubiquitination and Down-regulation of Inositol 1,4,5-

Trisphosphate Receptors in Rat Pancreatic Acinar Cells, 116:1194
Wolf DC
See Hanauer SB
See Sandborn WJ
Wolf DG. *See* Sandborn WJ
Wolf JL. The Impact of Surgery for Ulcerative Colitis on Fertility and Sexual Function in Women, 122:226–e
Wolf M. *See* Veyradier A
Wolfe MM
See Beejay U
See Corley DA
See Stone CD
See Triadafilopoulos G
Wolfe RA. *See* Wiesner R
Wolff BG. *See* Schwartz DA
Wolff G. *See* Yusta B
Wolk A
See Ekström AM
See Serafini M
See Terry P
Wolkersdörfer GW. *See* Franchimont D
Wolters H
See Kok T
See Roelofsen H
See Schaefer M
See van Waarde WM
Wolthers BG. *See* Meerman L
Wong A. *See* Fu S
Wong BCY. *See* Lai KC
Wong CJ. *See* Steinhart AH
Wong CYW. *See* Zhu GH
Wong F
See Benjaminov F
See Blendis L
See Sanyal AJ
Wong H
See Glatzle J
See Sternini C
Wong J. *See* Lai KC
Wong JB. *See* Cheng SJ
Wong MH, Stappenbeck TS, Gordon JI. Living and Commuting in Intestinal Crypts, 116:208–e
Wong P. *See* Wight NJ
Wong RCW, Phan TG, Adelstein S, Basten A. Image of the Month, 116: 514–im
Wong RKH
See Hirota WK
See Napierkowski JJ
See Rex DK
Wong WM. *See* Lai KC
Wong Y. *See* Huang XR
Wonnacott S. *See* Richardson CE
Woo Lee J. *See* Sug Kim H
Woo Nam S. *See* Sug Kim H
Wood G. *See* Cook D
Wood GM. *See* Butterworth JR
Wood JD. *See* Gao C
Wood S. *See* Zoli G
Wood T. *See* Cobb S
Woodruff A. *Positive Options for Living with Your Ostomy: Self-Help and Treatment*, 123:952–pmr
Woolf CJ. *See* Sarkar S
Woolf S. *See* Winawer S
Woosley JT. *See* Martin C
Woosley JT. *Pathology of the Pancreas, Gallbladder, Extrahepatic Biliary Tract, and Ampullary Region*, 125:1553–pmr
Wordsworth BP. *See* Orchard TR
Worman HJ
See Shimoda S
See Terjung B
Wotherspoon AC. *See* Isaacson PG
Wouter Drijfhout J. *See* Vader W
Wrangstadh M. *See* Lind T
Wren BW. *See* Dorrell N
Wright CVE
See Means AL
See Song SY
Wright JP. *See* Thomsen Ø
Wright KL. *See* Weaver SA
Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJP, Iredale JP, Mann DA. Gliotoxin Stimulates the Apoptosis of Human and Rat Hepatic Stellate Cells and Enhances the Resolution of Liver Fibrosis in Rats, 121:685
Wright NA. *See* Forbes SJ
Wright T
See Fontana RJ
See Spiller RC
Wright TL. *See* Saab S
Wu AKL. *See* Leung WK
Wu C-C. *See* Chen Y-J
Wu F. *See* Lawrance IC
Wu GD
See He W
See Su CG
Wu GD. Is There a Role for PPARγ in IBD? Yes, No, Maybe, 124:1538–e
Wu GD, Murthy S, Lazar MA. PPAR-γ Ligand Antidiabetic Drugs: Good News for Colitis? Reply, 118:230–ss
Wu GY. *See* Ruiz J
Wu H-L. *See* Liu C-J
Wu J
See Wege H
See Zhu J
Wu J-C. *See* Huo T-I
Wu JCY
See Chan FKL
See Sung JJY
Wu P-C. *See* Lai C-L
Wu S, Morin PJ, Maouyo D, Sears CL. *Bacteroides fragilis* Enterotoxin Induces c-Myc Expression and Cellular Proliferation, 124:392
Wu T-T. *See* Kim SG
Wu WC. *See* Verne GN
Wu X. *See* Meng G
Wu Y-C. *See* Zhang F
Wulf A. *See* Benz C
Wullstein F. *See* Gitter AH
Wündisch T. *See* Liu H
Wuscher N. *See* Touati E
Wüstefeld T
See Klein C
See Streetz KL
Wustinger M. *See* Guéant J-L
Wyllie R. *See* Ogunmola NA
Wynn G, Rong W, Xiang Z, Burnstock G. Purinergic Mechanisms Contribute to Mechanosensory Transduction in the Rat Colorectum, 125:1398

Xavier R. *See* Beck PL
Xavier RJ. *See* Mizoguchi E
Xi L. *See* Sinicrope FA
Xia Y. *See* Gao C
Xian CJ. *See* Troyer KL
Xiang Z. *See* Wynn G
Xiao F. *See* Furuta T
Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the Intestinotropic Hormone Glucagon-like Peptide 2 Is Differentially Regulated by Nutrients in Humans, 117:99
Xiao S-Y. *See* Lerat H
Xiao Y. *See* Caplan MS
Xiao Yuan Q. *See* McPhaul LW
Xiao Z-L. *See* Amaral J
Xiao Z-L, Chen Q, Biancani P, Behar J. Mechanisms of Gallbladder Hypomotility in Pregnant Guinea Pigs, 116:411
Xiol X. *See* Guardiola J
Xiong H. *See* Chen F
Xiong S
See Angus P
See Westland C
Xu B. *See* Lin X
Xu C. *See* Hommes D
Xu L. *See* Yang C
Xu Y. *See* Selaru FM
Xue S. *See* Beyak MJ

Yachimec C. *See* Madsen K
Yacyshyn BR, Pilarsky LM. Discussion on the Safety of 6-Mercaptopurine for Childbearing Patients With Inflammatory Bowel Disease: A Retrospective Cohort Study, 125:1562–c
Yadav D. *See* Chari ST

Yadav D, Hughes J, Pitchumoni CS. Image of the Month, 120:787–im
Yagita H. *See* Totsuka T
Yahagi N. *See* Ikeda H
Yajima T. *See* Nakazawa A
Yakimets WW. *See* Porter GA
Yamada A. *See* Kiso S
Yamada G
See Shiratori Y
See Yoshida H
Yamada J. *See* Yang Z
Yamada M. *See* Kobayashi I
Yamada N. *See* Tanaka S
Yamada T. *See* Kuno A
Yamada Y. *See* Kishibe K
Yamagata N. *See* Adachi Y
Yamagiwa T. *See* Sakai Y
Yamaguchi T
See Hara T
See Kyokane T
Yamaji Y. *See* Maeda S
Yamamoto H
See Malkhosyan SR
See Shiraga T
Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K-I, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M. JTE-522, a Cyclooxygenase-2 Inhibitor, Is an Effective Chemopreventive Agent Against Rat Experimental Liver Fibrosis, 125:556
Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M. Gastric Cancers of the Microsatellite Mutator Phenotype Display Characteristic Genetic and Clinical Features, 116:1348
Yamamoto H, Yano T, Kita H, Sunada K, Ido K, Sugano K. New System of Double-Balloon Enteroscopy for Diagnosis and Treatment of Small Intestinal Disorders, 125:1556–c
Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT. Infectivity Enhanced, Cyclooxygenase-2 Promoter-Based Conditionally Replicative Adenovirus for Pancreatic Cancer, 125:1203
Yamamoto M, Miura N, Ohtake N, Amagaya S, Ishige A, Sasaki H, Komatsu Y, Fukuda K, Ito T, Terasawa K. Genipin, a Metabolite Derived From the Herbal Medicine Inchin-ko-to, and Suppression of Fas-Induced Lethal Liver Apoptosis in Mice, 118:380
Yamamoto N. *See* Mori N
Yamamoto Y. *See* Balaban DH
Yamane A
See Braun J
See Sutton CL
Yamaoka Y
See Hashida H
See Hwang I-R
See Iimuro Y
Yamaoka Y, El-Zimaity HMT, Gutierrez O, Figura N, Kim JG, Kodama T, Kashima K, Graham DY. Relationship Between the *cagA* 3′ Repeat Region of *Helicobacter pylori*, Gastric Histology, and Susceptibility to Low pH, 117:342
Yamaoka Y, Graham DY. CagA Status and Gastric Cancer: Unreliable Serological Tests Produce Unreliable Data, 117:745–c
Yamaoka Y, Kikuchi S, El-Zimaity HMT, Gutierrez O, Osato MS, Graham DY. Importance of *Helicobacter pylori oipA* in Clinical Presentation, Gastric Inflammation, and Mucosal Interleukin 8 Production, 123:414
Yamaoka Y, Kita M, Kodama T, Imamura S, Ohno T, Sawai N, Ishimaru A, Imanishi J, Graham DY. *Helicobacter pylori* Infection in Mice: Role of Outer Membrane Proteins in Colonization and Inflammation, 123:1992
Yamashina S
See Enomoto N
See Ikejima K
Yamashiro Y. *See* Shimizu T
Yamashita K. *See* Ougolkov AV
Yamata T, 118:497
Yamazaki M
See Inoue N
See Kanai T
See Nakazawa A
See Totsuka T
Yamori M. *See* Yoshida M
Yamschikov V. *See* Kozaiwa K
Yan F. *See* Kaiser GC
Yanagihara K, 118:497
Yanai A. *See* Hirata Y
Yanase M. *See* Ikeda H
Yandell BS. *See* Cohen P
Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, Xu L, Eng F, Afdhal N, Kalluri R. Liver Fibrosis: Insights Into Migration of Hepatic Stellate Cells in Response to Extracellular Matrix and Growth Factors, 124:147
Yang F. *See* Shattuck-Brandt RL
Yang H
See Abreu MT
See Angus P
See Dubinsky MC
See Landers CJ
See Sappington PL
See Teitelbaum DH
See Tountas NA
See Vasiliauskas EA
See Westland C
Yang H, Fan Y, Teitelbaum DH. Enterocyte Apoptosis and TPN-Associated Intestinal Mucosal Atrophy: A View of the Chicken or the Egg?, 125:1273–ss
Yang J-C. *See* Chang C-S
Yang K
See Boivin GP
See Holt PR
See Velcich A
Yang M
See Dubois A
See Jeffers M
See Peek RM Jr
See Shiratori Y
Yang P-C
See Söderholm JD
See Yu LCH
Yang Q. *See* Fischbach W
Yang R. *See* Sappington PL
Yang S
See Arruda SMB de
See Li Z
Yang SQ. *See* Cortez-Pinto H
Yang VW. *See* Giardello FM
Yang VW. *APC* as a Checkpoint Gene: The Beginning or the End?, 123:935–e
Yang W. *See* Velcich A
Yang Y. *See* Lerat H
Yang Z, Yamada J, Zhao Y, Strauss AW, Ibdah JA. Is It HELLPFUL to Consider the Hanging LCHAD in Pregnancy-Associated Liver Disease?, 124:1548–ss
Yano M. *See* Yoshida H
Yano T. *See* Yamamoto H
Yao F. Expansion of Criteria for Liver Transplantation in HCC: A Slippery Slope? Reply, 122:582–ss
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Expansion of Criteria for Liver Transplantation in HCC: A Slippery Slope?, 122:579–ss
Yao G-B. *See* Lok ASF
Yao N, Hong Z, Lau JYN. Application of Structural Biology Tools in the Study of Viral Hepatitis and the Design of Antiviral Therapy, 123:1350–srr
Yao R. *See* McHutchison JG
Yao X. *See* Karvar S
Yap PSH. *See* Hautekeete ML
Yarita Y. *See* Shimizu T
Yasmeen S. *See* Sheikh RA
Yasuda H. *See* Ueda N

Yasuda J. *See* Suzuki K
Yasumaru M. *See* Kawai N
Yatomi Y. *See* Ikeda H
Yawn BP
See Bambha K
See Kim WR
Yawo H. *See* Kakyo M
Yazdani A, Takahashi T, Bagnol D, Watson SJ, Owyang C. Functional Significance of a Newly Discovered Neuropeptide, Orphanin FQ, in Rat Gastrointestinal Motility, 116:108
Ye H. *See* Liu H
Ye J. *See* Huizinga JD
Ye W
See Freedman J
See Lagergren J
See Terry P
Ye W, Chow W-H, Lagergren J, Yin L, Nyrén O. Risk of Adenocarcinomas of the Esophagus and Gastric Cardia in Patients With Gastroesophageal Reflux Diseases and After Antireflux Surgery, 121:1286
Yee J. *See* Johnson CD
Yegutkin GG. *See* Kurkijärvi R
Yeh K-Y, Yeh M, Glass J, Granger DN. Rapid Activation of NF-κB and AP-1 and Target Gene Expression in Postischemic Rat Intestine, 118:515
Yeh M. *See* Yeh K-Y
Yeh S-H. *See* Chen Y-J
Yeh S-H, Chen P-J, Shau W-Y, Chen Y-W, Lee P-H, Chen J-T, Chen D-S. Chromosomal Allelic Imbalance Evolving From Liver Cirrhosis to Hepatocellular Carcinoma, 121:699
Yeo AET. *See* Umemura T
Yeo CJ. *See* Sato N
Yerramalla U. *See* Yang C
Yeung CK. *See* Sung JJY
Yin J
See Chen JDZ
See Selaru FM
Yin L. *See* Ye W
Yin M. *See* Wheeler MD
Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG. Essential Role of Tumor Necrosis Factor α in Alcohol-Induced Liver Injury in Mice, 117:942
Yin X-M. *See* Zhao Y
Yiu HHY. *See* Lau GKK
Yokohata K. *See* Jin C
Yokosuka O
See Shiratori Y
See Yoshida H
Yokota K, Kobayashi K, Kawahara Y, Hayashi S, Hirai Y, Mizuno M, Okada H, Akagi T, Tsuji T, Oguma K. Gastric Ulcers in SCID Mice Induced by *Helicobacter pylori* Infection After Transplanting Lymphocytes From Patients With Gastric Lymphoma, 117:893
Yoo NJ. *See* Park WS
Yoo NM. *See* Park WS
Yoon J-H, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile Acids Induce Cyclooxygenase-2 Expression via the Epidermal Growth Factor Receptor in a Human Cholangiocarcinoma Cell Line, 122:984
Yoon S. *See* Bardag-Gorce F
Yoshida H
See Hirata Y
See Maeda S
See Shiratori Y
Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon Therapy Prolonged Life Expectancy Among Chronic Hepatitis C Patients, 123:483
Yoshida M, Shirai Y, Watanabe T, Yamori M, Iwakura Y, Chiba T, Kita T, Wakatsuki Y. Differential Localization of Colitogenic Th1 and Th2 Cells Monospecific to a Microflora-Associated Antigen in Mice, 123:1949
Yoshida T
See Matsuzaki Y
See Suzuki K
See Yamamoto H
Yoshida Y. *See* Kiso S
See Kamada Y
See Matsuzaki K
Yoshidome H. *See* Lentsch AB
Yoshikai Y. *See* Shimizu H
Yoshikawa M
See Ikejima K
See Tsune I
Yoshimura K. *See* Suzuki K
Yoshitani S. *See* Tanaka T
Yoshizawa K. *See* Kawa S
Younes M. Can Proton Pump Inhibitors Be Blamed for the Rising Incidence of Esophageal Cancer?, 125:1912–c
Younes M, Lechago J, Ertan A. Photodynamic Therapy and Genetic Abnormalities, 120:1065–c
Young J
See Fletcher J
See Jass JR
Young Kim J, Hwan Kim K, Lee JA, Namkung W, Sun A-Q, Ananthanarayanan M, Suchy FJ, Min Shin D, Muallem S, Lee MG. Transporter-Mediated Bile Acid Uptake Causes Ca^{2+}-Dependent Cell Death in Rat Pancreatic Acinar Cells, 122:1941
Young Kim S. *See* Sug Kim H
Young L. *See* Moayyedi P
Young Lee J. *See* Sug Kim H
Young Park J. *See* Sug Kim H
Young-Fadok T
See He C-L
See Lyford GL
Young-Fadok TM. *See* Schwartz DA
Younossi ZM
See Matteoni CA
See Ong JP
See Saadeh S
Younossi ZM. Chronic Liver Disease and Health-Related Quality of Life, 120:305–e
Yu H. *See* Laine L
Yu J-R. *See* Lin JL-C
Yu L. *See* Berge KE
Yu LCH, Yang P-C, Berin MC, Di Leo V, Conrad DH, McKay DM, Satoskar AR, Perdue MH. Enhanced Transepithelial Antigen Transport in Intestine of Allergic Mice is Mediated by IgE/CD23 and Regulated by Interleukin-4, 121:370
Yu LM. *See* Sung JJY
Yu P. *See* Amaral J
Yu Q. *See* Laine L
Yu Y. *See* Marciniak DJ
Yuan D. *See* Masyuk TV
Yuan Q, Furura GT. Insights Into Milk Protein Allergy: Microenvironment Matters. Comment, 124:260–ss
Yuan QX. *See* Bardag-Gorce F
Yuen KY. *See* Leung WK
Yuen MF. *See* Lai KC
Yuen ST. *See* Zhu GH
Yuen S-T. *See* Lau GKK
Yule DI. *See* Wojcikiewicz RJH
Yunker CK
See Dudas SP
See Sternberg LR
Yusim K. *See* Lyra AC
Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ. Enteroendocrine Localization of GLP-2 Receptor Expression in Humans and Rodents, 119:744
Yusuff T. *See* Raju GS
Yuzuriha H. *See* Asakawa A

Zabalegui N. *See* Lucena J-F
Zachoval R. *See* Gerlach JT
Zacks J
See Morteau O
See Mykoniatis A
See Wlk M
Zadorova Z. *See* Ghosh G
Zafrani ES. *See* Mathieu D
Zagorodnyuk V. *See* Lynn PA

Zaki M, Koduru S, McCuen R, Vuyyuru L, Schubert ML. Amylin, Released From the Gastric Fundus, Stimulates Somatostatin and Thus Inhibits Histamine and Acid Secretion in Mice, 123:247
Zalewska I, Tobi M. The "Innocent Colon" and K-*ras* Mutation-Guilty By (ACF) Association?, 124:274–c
Zalis M. *See* Johnson CD
Zaman B. *See* Rabbani GH
Zandecki M. *See* Tack J
Zanetti M. *See* Barazzoni R
Zanger U. *See* Schwab M
Zaninovic V
See Gukovskaya AS
See Pandol SJ
Zankel M. *See* Jaeckel E
Zanlungo A, Amigo L, Mendoza H, Miquel JF, Vío C, Glick JM, Rodríguez A, Kozarsky K, Quiñones V, Rigotti A, Nervi F. Sterol Carrier Protein 2 Gene Transfer Changes Lipid Metabolism and Enterohepatic Sterol Circulation in Mice, 119:1708
Zaret KS. *See* Lin X
Zaretsky A. *See* Appleyard M
Zarrilli R, Pignata S, Apicella A, Di Popolo A, Memoli A, Ricchi P, Salzano S, Acquaviva AM. Cell Cycle Block at G_1-S or G_2-M Phase Correlates With Differentiation of Caco-2 Cells: Effect of Constitutive Insulin-like Growth Factor II Expression, 116:1358
Zarski J-P. *See* Bain C
Zatloukal K
See Fickert P
See Wagner M
Zauber AG. *See* Winawer SJ
Zauber AG, O'Brien MJ, Winawer SJ. On Finding Flat Adenomas: Is the Search Worth the Gain?, 122:839–c
Závada J. *See* Gut MO
Závadová Z. *See* Gut MO
Zavros Y. *See* Rathinavelu S
Zavros Y, Rieder G, Ferguson A, Merchant JL. New Insights Into Microbially Initiated Gastric Malignancies: Beyond the Usual Suspects, 123:1739–ss
Zavros Y, Rieder G, Ferguson A, Samuelson LC, Merchant JL. Genetic or Chemical Hypochlorhydria Is Associated With Inflammation That Modulates Parietal and G-Cell Populations in Mice, 122:119
Zavzavadjian J. *See* Jin X
Zayed J. *See* Rose C
Zehender G, De Maddalena C, Milazzo L, Piazza M, Galli M. Hepatitis B Virus Genotype Distribution in HIV-1 Coinfected Patients, 125:1559–c
Zeijlon L. *See* Lind T
Zein CO. *See* Metwally MA
Zein NN. *See* Metwally MA
Zein NN, Li H, Persing DH. Humoral Immunity in Acute and Chronic Hepatitis C Infection, 117:510–c
Zeisberg M. *See* Yang C
Zeitoun G. *See* Condat B
Zeitz M
See Bürgel N
See Kewenig S
See Marth T
See May E
See Scherübl H
See Stallmach A
Zeldis JB. *See* Vasiliauskas EA
Zeldis JB. *Drug Development: Molecular Targets for GI Disease*, 121:498–pmr
Zender L, Köck R, Eckhard M, Frericks B, Gösling T, Gebhardt T, Drobek S, Galanski M, Kühnel F, Manns M, Kubicka S. Gene Therapy by Intrahepatic and Intratumoral Trafficking of p53-VP22 Induces Regression of Liver Tumors, 123:608
Zeng bH. *See* Collier-Hyams LS
Zentilin P, Savarino V, Garnero A, Accardo S, Seriolo B. Is *Helicobacter pylori* Infection a Risk Factor for Disease Severity in Rheumatoid Arthritis?, 116:503–c
Zenz R. *See* Fickert P
Zern MA
See Wege H
See Zhu J
Zeuzem S. *See* Trojan J
Zhang F, Altorki NK, Wu Y-C, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal Reflux Induces Cyclooxygenase 2 in the Esophageal Mucosa of Rats: Evidence for Involvement of Bile Acids, 121:1391
Zhang H-Y. *See* Lau GKK
Zhang J. *See* Berg DJ
Zhang J, Ling Y, Luo B, Tang L, Ryter SW, Stockard CR, Grizzle WE, Fallon MB. Analysis of Pulmonary Heme Oxygenase-1 and Nitric Oxide Synthase Alterations in Experimental Hepatopulmonary Syndrome, 125: 1441
Zhang L. *See* Cao W
Zhang M, Goedert JJ, O'Brien TR. High Frequency of *CCR5*-Δ*32* Homozygosity in HCV-Infected, HIV-1-Uninfected Hemophiliacs Results From Resistance to HIV-1, 124:867–c
Zhang M, Gong Y, Corbin I, Mellon A, Choy P, Uhanova J, Minuk GY. Light Ethanol Consumption Enhances Liver Regeneration After Partial Hepatectomy in Rats, 119:1333
Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Baclofen Effects on Esophageal Function: A Possible Therapy for GERD?, 123:1736–ss
Zhang T
See Läuffer JM
See Peek RM Jr
Zhang Y-J. *See* Ikejima K
Zhang Z-F. *See* Kurtz RC
Zhang ZW. *See* Dorrell N
Zhao C-M. *See* Chen D
Zhao D
See Mykoniatis A
See Wlk M
Zhao Y. *See* Yang Z
Zhao Y, Ding W-X, Qian T, Watkins S, Lemasters JJ, Yin X-M. Bid Activates Multiple Mitochondrial Apoptotic Mechanisms in Primary Hepatocytes After Death Receptor Engagement, 125:854
Zheng GF. *See* Huang JQ
Zheng H, Wang J, Koteliansky VE, Gotwals PJ, Hauer-Jensen M. Recombinant Soluble Transforming Growth Factor β Type II Receptor Ameliorates Radiation Enteropathy in Mice, 119:1286
Zheng S. *See* Richmond BL
Zheng S-X. *See* Mathews CJ
Zheng Y. *See* Ray RM
Zhong Z
See Enomoto N
See Froh M
Zhou L-Y. *See* Sung JJY
Zhou Z. *See* Noone PG
Zhu G. *See* Chen X-M
Zhu GH, Wong CYW, Slosberg ED, Eggo MC, Ching CK, Yuen ST, Lai CL, Soh JW, Weinstein B, Lam SK. Overexpression of Protein Kinase C-β1 Isoenzyme Suppresses Indomethacin-Induced Apoptosis in Gastric Epithelial Cells, 118:507
Zhu J, Wu J, Frizell E, Liu S-L, Bashey R, Rubin R, Norton P, Zern MA. Rapamycin Inhibits Hepatic Stellate Cell Proliferation In Vitro and Limits Fibrogenesis in an In Vivo Model of Liver Fibrosis, 117:1198
Zhu Y. *See* Huizinga JD
Zhu Y, Richardson JA, Parada LF, Graff M. Escape from the *Smad* World by Colon Cancer, 116:1496–ss
Zhuo M, Gebhart GF. Facilitation and Attenuation of a Visceral Nociceptive Reflex From the Rostroventral Medulla in the Rat, 122:1006

Ziegler TR. *See* Fernandez-Estivariz C
Ziegler TR, Fernández-Estívariz C, Gu LH, Fried MW, Leader LM. Severe Villus Atrophy and Chronic Malabsorption Induced by Azathioprine, 124:1950–cr
Zielenski J. *See* Durno C
Zimmer D. *See* Brenner DA
Zimmer K-P
See Mayerle J
See Ritz V
Zimmer K-P, Büning J, Weber P, Kaiserlian D, Strobel S. Modulation of Antigen Trafficking to MHC Class II-Positive Late Endosomes of Enterocytes, 118:128
Zimmer K-P, Schumann H, Mecklenbeck S, Bruckner-Tuderman L. Esophageal Stenosis in Childhood: Dystrophic Epidermolysis Bullosa Without Skin Blistering Due to Collagen VII Mutations, 122:220–cr
Zimmerman A. *See* Dufour J-F
Zimmerman TL. *See* Denson LA
Zimmermann A. *See* Liao Q
Zingarelli B, Szabó CC, Salzman AL. Blockade of Poly(ADP-ribose) Synthetase Inhibits Neutrophil Recruitment, Oxidant Generation, and Mucosal Injury in Murine Colitis, 116:335
Zinke J. *See* Huster D
Zinsmeister AR
See Bouras EP
See Dayharsh GA
See Faubion WA Jr
See Prather CM
See Sandborn WJ
See Schwartz DA
See Silverstein MD
See Thumshirn M
See Vazquez-Sequeiros E
Zinzani PL. *See* Liu H
Zinzindohoué F. *See* Laurent-Puig P
Zippel T. *See* Schmidt W
Zipprich A. *See* Kleber G
Zitoun C. *See* Rajas F
Zittel TT. *See* Glatzle J
Zoghbi H. *See* Lin X
Zoli G, Corazza GR, Wood S, Bartoli R, Gasbarrini G, Farthing MJG. Why Patients on Long-Term Intravenous Hyperalimentation Are Prone to Infections, 116:1495–ss
Zolle O. *See* Green AK
Zoller H. Another Link in the Iron Chain? Comment, 118:632–ss
Zoller H, Theurl I, Koch RO, McKie AT, Vogel W, Weiss G. Duodenal Cytochrome b and Hephaestin Expression in Patients With Iron Deficiency and Hemochromatosis, 125:746
Zollner G
See Fickert P
See Trauner M
See Wagner M
Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, Mrsny RJ, Turner JR. A Membrane-Permeant Peptide That Inhibits MLC Kinase Restores Barrier Function in In Vitro Models of Intestinal Disease, 123:163
Zong Y. *See* Pandol SJ
Zopf D
See Dubois A
See Mysore JV
Zornig C
See Fibbe C
See Layer P
Zou T. *See* Selaru FM
Zouali H
See Hugot J-P
See Vermeire S
Zoulim F. *See* Bain C
Zuccaro G Jr. *See* Vargo JJ
Zucker SD
See Chauchan SS
See Morelli MS
Zucker SD
All *Kid*ding Aside With the Use of Lamivudine in Children With Chronic Hepatitis. Comment, 123:1742–ss
Diet and Colon Cancer: Strike Out the Bran. Comment, 119:590–ss
Is It HELLPFUL to Consider the Hanging LCHAD in Pregnancy-Associated Liver Disease? Comment, 124:1549–ss
Management of Refractory Ascites: Are Tips or Taps Tops? Comment, 120:311–ss
A Potential New Hepatitis Agent: Making Sen-se of the Data. Comment, 121:734–ss
Some Tips for the Prevention of Recurrent Variceal Hemorrhage? Comment, 123:385–ss
Whomsoever Ignores the Natural History of the Hepatitis C Virus is Doomed to Treat It. Comment, 122:578–ss
Zuckerman GR, Prakash C, Askin MP, Lewis BS. AGA Technical Review on the Evaluation and Management of Occult and Obscure Gastrointestinal Bleeding, 118:201–aga
Zucman-Rossi J
See Bacq Y
See Laurent-Puig P
Zuezem S. *See* Poynard T
Zuin M
See Longo M
See Selmi C
zur Nedden D. *See* Rettenbacher T
Zushi S. *See* Miyazaki Y
Zwingmann C. *See* Chatauret N

SUBJECT INDEX TO VOLUMES 116–125

Abacavir, GI toxicity and GI-associated drug interactions of, 120:607

***ABCB4* gene,** mutation, cholelithiasis associated with, in adults, 125:452

Abcc2. *See* **Multidrug resistance-associated protein 2**

ABCG5/ABCG8, in genetic susceptibility to and pathogenesis of cholesterol gallstones (mice), 125:868

ABC transporter, hepatic expression of in biliary obstruction, farnesoid X receptor and (mice), 125:825
in PPAR-α-mediated metabolic response to fasting (mice), 124:160, 124:254-e

Abdomen, plain film of, in acute mesenteric ischemia, 118:954

Aberrant crypt foci
analysis of K-*ras*, *APC*, and β-*catenin* in, 121:599
dysplastic vs. nondysplastic, 123:862-srr
formation, inhibition by PPAR ligands, 121:1019-ss
K-*ras* mutation and, 124:274-c

Abetalipoproteinemia, apolipoprotein B48 glycosylation in, 121:1101

Ablation therapy
for Barrett's esophagus, 122:1569
in hepatocellular carcinoma, 122:1609

Abscess
gastric wall, 124:599-im
hepatic, pyogenic, complicated by bronchial fistula, 123:666-im
perianal, in Crohn's disease, 125:1503-aga, 125:1508-aga

ABT 378, GI toxicity and GI-associated drug interactions of, 120:607

Abuse
drug. *See* **Drugs, abuse of**
history-taking in, 122:1701
physical, and irritable bowel syndrome and comorbid conditions, 122:1139-srr, 122:1701
sexual, and irritable bowel syndrome and comorbid conditions, 122:1139-srr, 122:1701, 122:2032-srr

Academic medicine, evolution of, 122:1719-ce

Acanthosis nigricans, clinical characteristics of, 124:1595

Acetaldehyde, regulation of mitochondrial glutathione transport, 124:708

Acetaminophen
gastrointestinal complications of, relative risk of, 122:1535-ss
oxidative metabolism of, in cirrhosis, 116:915, 117:1025-c

Acetylcholine (ACh) receptor
muscarinic, autoantibodies to, and chagasic achalasia, 117:798
nicotinic, α3-subunit, absence of, in megacystis-microcolon-intestinal hypoperistalsis syndrome, 121:350

***N*-Acetylcysteine,** with terlipressin, in hepatorenal syndrome, 123:2160-c

Achalasia
chagasic, muscarinic cholinergic receptor, autoantibodies in, 117:798
chest pain in
age and, 117:1259-c
patient characteristics and course of, 116:1281-tmig, 116:1300
defective belch reflex secondary to, 123:7-im
diagnosis of, 117:233-aga
esophageal manometry for, 120:783-tmig, 120:789
fine-needle injection for, endoscopic ultrasound guidance for, 122:1631
HLA phenotypes and, 117:1-tmig, 117:26
sildenafil and, 118:247-tmig, 118:253
treatment of, 117:229-aga, 117:233-aga

Acid. *See also* **Gastric acid**
esophagopharyngeal regurgitation
abrupt occurrence of, 117:1037-tmig, 117:1051
detection of, 117:1037-tmig, 117:1051
dual pH monitoring in, 117:1037-tmig, 117:1051
erect position and, 117:1037-tmig, 117:1051
exogenous
abnormal clearance in functional dyspepsia, 116:509-tmig, 116:515, 116:761-e
sensitivity to, in normal versus inflamed stomach (rat), 125:1410
secretion
H^+,K^+-ATPase β subunit and, 117:513-c
rebound, after omeprazole therapy, 116:233-tmig, 116:239, 116:479-e, 117:513-c

Acid channels, in gastric mucus (rat), 119:1297, 119:1397-e

Acid-peptic disease, gastroenterologist training in, 124:1065-aga

Acid suppression therapy
and differentiation and proliferation in Barrett's esophagus, 117:327, 117:1510-c
long-term
effect on gastric atrophy, 117:291-tmig, 117:319, 118:239-c, 118:242-c, 118:453-c
effect on intestinal metaplasia, 117:291-tmig, 117:319
efficacy and safety of, 118:649-tmig, 118:661, 118:795-e, 119:1176-c, 119:1177-c
and gastric cancer risk, 119:1176-c
in GERD, efficacy and safety of, 118:649-tmig, 118:661, 118:795-e
in Zollinger-Ellison syndrome, 118:649-tmig, 118:696

Acinar cells
F-actin redistribution in, serine protease inhibitors and, 122:591-c
pancreatic
bile- and calcium-dependent cell death in (rat), 122:1941
calcium waves in, inositol triphosphate receptor and ryanodine receptor activation and (rat), 122:415
CCK2/gastrin receptor expression and (transgenic mice), 122:428
ethanol metabolites and (rat), 122:106

Acinetobacter lwoffi, and gastritis and hypergastrinemia (mice), 123:1739-ss

Acinus/acini, pancreatic
inositol trisphosphate receptor down-regulation in (rat), 116:1194
Rab4 and regulated exocytosis in (rat), 116:943

Acquired immunodeficiency syndrome (AIDS). *See also* **HIV-infected (AIDS) patients; Human immunodeficiency virus (HIV-1)**
anal fissure in, 124:235-aga

KEY TO ABBREVIATIONS

aga—American Gastroenterological Association
c—Correspondence
ce—Comment From the Editors
cr—Case Reports
gn—Gastroenterology News
e—Editorials
im—Image of the Month
pmr—Print and Media Reviews
rc—Rapid Communications
ss—Selected Summaries
srr—Special Reports and Reviews
tmig—This Month in Gastroenterology
vidd—Viewpoints in Digestive Diseases

cryptosporidiosis in, nonimmune defense against, 119:1236
esophageal pathology in, 117:296-im
lamivudine-resistant hepatitis B in, 122:244-c, 124:586-c
parenteral nutrition in, 121:966-aga, 121:970-aga
Acrodermatitis enteropathica, clinical features of, 124:1595
Actin, redistribution in acinar cells, serine protease inhibitors and, 122:591-c
***Actinomyces* infection,** esophageal, in HIV-infected (AIDS) patients, 117:296-im
Activation peptide, mutation of, trypsin activation induced by, in chronic pancreatitis, 119:288-tmig, 119:461
Activation protein 1 (AP-1)
activation, in postischemic intestine (rat), 118:525
and butyric acid-induced apoptosis in colon cancer cells, 120:71
Acute fatty liver of pregnancy, long-chain hydroxyacyl coenzyme A dehydrogenase (LCHAD) and, 124:1548-ss
Acute necrotizing esophagitis, 118:252-im
Acute-phase response, NF-κB/Rel in, 118:1208-srr
Acute respiratory distress syndrome
nutritional attenuation of, 119:592-ss
pancreatitis-associated, matrix metalloproteinase and (rat), 122:2-tmig, 122:188
Adaptive cytoprotection, in gastric mucosa, PGI_2 and CGRP in, 120:134
Adefovir dipivoxil
GI toxicity and GI-associated drug interactions of, 120:607
for hepatitis B, 120:1828-srr
efficacy of, HBV genotypes and, 125:107
resistance to, HBV polymerase mutation and, 125:292-rc
Adenocarcinoma
of gastric cardia, risk stratification for, 117:293-gn
pancreatic ductal, epidemiology, diagnosis, and treatment of
AGA medical position statement on, 117:1463-aga
AGA technical review on, 117:1464-aga
Adenoma-like lesion or mass (ALM)
dysplasia-associated. *See* **Dysplasia-associated lesion or mass (DALM)**
in ulcerative colitis, management of, 117:1488-e, 118:1277-c
Adenomas. *See also* **Familial adenomatous polyposis (FAP)**
characteristics of, and risk of recurrence, 120:1071-tmig, 120:1077
colonic
aberrant crypt foci in, analysis of K-*ras*, *APC*, and β-*catenin* in, 121:599
in Bloom's syndrome, 121:435-cr
detection of, in signoidoscopy, by RNs vs. MDs, 117:291-tmig, 117:312, 117:486-e
exophytic, aberrant expression of G1-phase cell cycle regulators in, 120:1680
progastrin expression and (mice), 119:2-tmig, 119:162
recurrence of, diet and, 119:590-ss
sporadic, distinguished by artificial neural networks, 122:606-rc
colorectal
apoptosis and, 123:1770
biologically distinct, with similar appearance, 123:862-srr
flat
aberrant expression of G1-phase cell cycle regulators in, 120:1680
dye spraying for, efficacy of, 122:839-c
prevalence and biologic characteristics of, 120:1671, 122:842-c
initiation of, *APC* mutation and, 123:862-srr
Ki-*ras* mutations in, 121:302
NSAIDs and, 123:1770, 125:285-tmig, 125:328, 125:404
prevention of, aspirin and, 124:1176-gn, 125:328, 125:612-e, 125:1539-ss
progression of
APC mutation and, 123:862-srr
chromosomal instability and, 123:1109
susceptibility gene on chromosome 15q14-q22, 116:783-tmig, 116:789
intestinal, dysplastic, molecular imaging of (mice), 122:254-tmig, 122:406, 122:571-e
periampullary, in familial adenomatous polyposis, risk stratification for, 121:1127, 121:1246-e
serrated, in hyperplastic polyposis, 119:323
Adenomatous polyposis coli gene *(APC)*
cell cycle regulation by, and colorectal carcinogenesis, 123:751, 123:935-e
and familial adenomatous polyposis, 124:1574
I1307K variant, 121:198-aga
in colorectal cancer, 116:54, 116:58, 116:210-e
and colorectal cancer risk, 121:282
in Ashkenazi Jews, 120:331-tmig, 120:392
in Israeli Jews, 116:54, 116:210-e
mutations of
in aberrant crypt foci from FAP and non-FAP cases, 121:599
in colorectal adenoma initiation and progression, 123:862-srr
and development of colitis-associated dysplasia and neoplasia (mice), 121:1407
and *E-cadherin* mutations, synergistic effects in intestinal tumorigenesis (mice), 119:1045, 119:1161-e
genetic testing for, 124:1574
and periampullary lesions in familial adenomatous polyposis, 121:1127, 121:1246-e
Adenomatous polyposis coli gene *(APC)*/β-catenin pathway, in colon carcinogenesis, 119:854-srr, 125:619-ss
Adenosine
agonists, in protection against hepatic ischemic injury, 125:917-srr
infusion, in assessment of hepatic artery flow reserve in cirrhosis, 116:906
and neurotensin stimulation of chloride secretion in human colon, 119:348
Adenosine A1-receptor pathway, and pathogenesis of pancreatitis (rat), 119:610-tmig, 119:829
Adenosine triphosphatase, H^+,K^+-, β subunit, and parietal cell function, development and membrane structure (mice), 117:605
Adenosine triphosphate, and mechanosensory transduction in colorectum (rat), 125:1398
Adenosquamous carcinoma, in Barrett's esophagus, clonal origin of both components of, 122:784-cr
S-Adenosylmethionine, down-regulation by nitric oxide, and HGF-induced proliferation of hepatocytes, 122:1355
Adenovirus, infectivity-enhanced COX2 promoter-based conditional replicative, for pancreatic cancer, 125:1006-tmig, 125:1203
Adhesion molecules
in colitis, 121:958, 121:1008-e

expression on homing lymphocytes in intestinal epithelia, 118:289
and inflammatory response in murine model of Crohn's disease, 121:1428
in lymphocyte-endothelial recognition, 122:1592
in lymphocyte trafficking, 121:853, 121:1008-e

Adhesion protein, $p120^{ctn}$, in pancreatic cancer, 124:949

Adiponectin, and hepatic fibrosis (mice), 125:1796, 125:1889-e

Adipose tissue, mesenteric, inflammatory changes in, in Crohn's disease, 117:2-tmig, 117:73

ADL 8-2698, for postoperative ileus, 122:1177-ss

Adolescents
dieting by, and weight gain, 125:1572-gn
obesity in, 125:1908-pmr

Adrenal glands, activation of, in colitis (mice), 119:1560

α_2-Adrenergic agents, effects on gastric sensorimotor function, 116:510-tmig, 116:573

Adrenergic agonists, for anal fissure, 124:235-aga

Adrenergic antagonists, for anal fissure, 124:235-aga

β-Adrenergic blockers, in prevention of variceal bleeding, 123:963-tmig, 123:1013, 123:1388-e

Adrenoceptor, β3, agonist, and LES pressure (opossum), 123:1508

Adverse events, reporting, 119:1429-ce

Affymetrix Inc., human genome scans on glass chips, 119:1427-gn

African Americans
hepatitis C in, 119:1385-srr
hepatocellular carcinoma in, 119:1385-srr

Age
and chest pain in achalasia, 117:1259-c
and enteric nervous system changes, 117:1438-srr
and familial pancreatic cancer, 124:1292

Agenerase. *See* Amprenavir

Aggresomes, 121:1264-c

Aging. *See also* Elderly
and ethanol-induced mitochondrial dysfunction, 122:2049-srr
gastrointestinal changes related to, 122:1688

Agriculture, Department of (USDA), Elsa A. Murano as Under-Secretary for Food Safety for, 121:1272-gn

AIE-75 autoantigen, in autoimmune enteropathy, 117:823

Akt, in cirrhotic liver, and portal hypertension (rat), 125:522

Alagille syndrome
JAGGED1 gene mutations in, 116:1141, 116:1257-e
partial external biliary diversion in, 124:1155-ss

Alanine aminotransferase, serum levels of
abnormalities of, evaluation of, 123:1367-aga, 125:279-c
elevation of, etiology of, 123:1367-aga, 125:279-c
in nonalcoholic fatty liver disease, iron depletion and, 122:930
and overweight, 124:71, 124:248-e
persistently normal, in mild chronic hepatitis C, clinical significance of, 118:649-tmig, 118:760, 121:1526-c
and serum iron and antioxidant levels, 124:1821

Alanine transaminase, serum levels of, in hepatitis C
persistently normal, 123:1748-c
testing, 123:2082

Albendazole, for strongyloidosis, 119:1805-c

Albumin
administration of, patient survival after, 122:582-ss
intravenous, beneficial effects in spontaneous bacterial peritonitis, 118:231-ss
serum levels of, evaluation of, 123:1367-aga

Alcohol. *See also* Ethanol
abuse, in hepatitis C patients, 123:402-tmig, 123:476
blood levels, cycling of, and alcoholic liver disease (rat), 123:325
gastric injury from, gastric NOS expression and (rat), 123:173
and hepatitis C, 123:2082
liver injury caused by
inducible NOS and (mice), 125:1834
in obesity (rat), 125:1818
oxidants and antioxidants in, 124:778-srr
reduction by betaine (mice), 124:1488
suppression by thalidomide, mechanisms in (rat), 123:291
and mitochondrial DNA depletion (mice), 123:1278

Alcoholic pancreatitis, chronic, pain patterns in, 116:1023-tmig, 116:1132, 116:1252-e, 117:1026-c, 118:235-c

Alcoholic steatosis, Kupffer cell in (rat), 120:581-ss

Alcoholism, hepatic mitochondrial DNA damage in (mice), 117:181, 117:265-e

Aldosterone antagonists, antifibrogenic effects on hepatic stellate cells, 124:504

Alendronate
for Crohn's disease, and lumbar spine bone mineral density, 119:609-tmig, 119:639, 119:866-e
for osteoporosis, gastroesophageal effects of, 119:609-tmig, 119:631, 119:866-e

Alkaline phosphatase, serum levels of, abnormalities, evaluation of, 123:1367-aga

Allopurinol, for pouchitis, 124:1636

Alosetron
adverse effects and side effects of, 120:557-cr, 120:652
deactivation of brain regions by, 123:969
for irritable bowel syndrome, 120:652
response to, molecular mechanisms of, 123:401-tmig, 123:425
ischemic colitis caused by, 120:557-cr
mechanism of, 121:231-c
mechanism of action of, 123:969

Alpha-fetoprotein
DNA, immunotherapy based on
and autoimmune liver disease (mice), 121:931
for hepatocellular carcinoma (mice), 119:1104
serum level of
measurement of, in hepatocellular carcinoma, 122:1609
and postsurgical recurrence of hepatocellular carcinoma, 123:2152-ss

Alport syndrome, pathology of, 120:216-cr

Alternative medicine, 117:1041-ce
and conventional medicine, in digestive health, 121:498-pmr
credibility of, 119:1189-ce
in irritable bowel syndrome, 120:652

Alveolar disease, interferon-related, 124:1711

American Digestive Health Foundation (ADHF), website, 117:1029-c

American Gastroenterological Association
abstracts presented at DDW 2003, 125:605
advocacy for IBD act, 123:403-gn
colorectal cancer screening and surveillance guidelines, 124:544
committees, 123:2104

deceased members, 121:1029, 123:1415, 125:1291
acknowledgment of, 125:1291
Digestive Health and Nutrition, popularity of, 122:255-gn
focus on nutrition and obesity, 123:967-ce
Foundation for Digestive Health and Nutrition, Carol M. Dreher as executive vice president of, 123:3-gn
Foundation for Digestive Heath and Nutrition, 121:753-gn
future of gastroenterology and hepatology (abstract), 116:1244
gastroenterology core curriculum, 124:1055
Gastroenterology Teaching Project publications
on inflammatory bowel disease—pathology, 125:990-pmr
on irritable bowel syndrome, 125:990-pmr
on pancreatitis, 125:991-pmr
on pathology and pathophysiology of upper gastrointestinal tract, 125:987-pmr
on viral hepatitis, 125:991-pmr
GI Coding and Billing AnswerLine, 125:4-gn
and HCFA policy effects on gastroenterologists and Medicare patients, 120:3-gn
joint statement on missions and submission of papers to AGA journals, 123:877
Emmet B. Keefe elected vice-president, 122:601-gn
Loren Laine as new chair of Council, 123:966-gn
Manpower and Training Committee, list of available training programs in gastroenterology, 121:444
medical position statement
on anorectal testing techniques, 116:732
on celiac sprue, 120:1522
on constipation, 119:1761
on diagnosis and care of patients with anal fissure, 124:233
on epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma, 117:1463-aga
on evaluation and management of chronic diarrhea, 116:1461
on evaluation and management of occult and obscure gastrointestinal bleeding, 118:197
on evaluation of food allergies, 120:1023
on evaluation of liver chemistry tests, 123:1364
on hereditary colorectal cancer and genetic testing, 121:195
on impact of dietary fiber on colon cancer occurrence, 118:1233
on intestinal ischemia, 118:951, 119:280 *correction*
on irritable bowel syndrome, 123:2105
on management of oropharyngeal dysphagia, 116:452
on nausea and vomiting, 120:261
on nonalcoholic fatty liver disease, 123:1702
on obesity, 123:879
on osteoporosis in gastrointestinal diseases, 124:791
on osteoporosis in hepatic disorders, 125:937
on parenteral nutrition, 121:966
on perianal Crohn's disease, 125:1503
on short bowel syndrome and intestinal transplantation, 124:1105
on treatment of dysphagia caused by benign disorders of distal esophagus, 117:229
national office of, functions of, 121:242-gn
new clinical journal published by, 123:965-gn
policy statement, on precertification of pharmaceuticals, 121:965
presentation of Julius M. Friedenwald Medal
to Sidney Cohen, 122:2064
to Don W. Powell, M.D., 120:1854
to Howard M. Spiro, M.D., 118:1229
to Jerry S. Trier, M.D., 116:1457
to Tadataka Yamada, M.D., 124:1965
president
Thomas A. Brasitus, M.D., 118:945
Martin Brotman, M.D., 122:1197-gn, 122:1512
Presidential Address, 125:1878-aga
Donald O. Castell, M.D., Presidential Address, 117:1459
Ralph A. Giannella, M.D., 116:1238
Jon I. Isenberg, M.D.
goals of, 120:786-gn, 120:1518, 120:1519
Presidential Address, 123:2100
Daniel K. Podolsky, M.D., 124:1524, 124:1724-gn
research policy initiatives of, 123:664-gn
and Senate committee passage of colorectal cancer screening expansion, 123:663-gn
standards for office-based gastrointestinal endoscopy studies, 121:440
strategic planning task force, 125:1008-gn
technical review
on anorectal testing techniques, 116:735
on celiac sprue, 120:1526
on constipation, 119:1766
on diagnosis and care of patients with anal fissure, 124:235, 125:995-c
on epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma, 117:1464
on evaluation and management of chronic diarrhea, 116:1464
on evaluation and management of occult and obscure gastrointestinal bleeding, 118:201
on evaluation of food allergy in gastrointestinal disorders, 120:1026
on evaluation of liver chemistry tests, 123:1367, 125:279-c
on hereditary colorectal cancer and genetic testing, 121:198
on impact of dietary fiber on colon cancer occurrence, 118:1235
on intestinal ischemia, 118:953
on irritable bowel syndrome, 123:2108
on management of oropharyngeal dysphagia, 116:455
on nausea and vomiting, 120:263
on nonalcoholic fatty liver disease, 123:1705
on obesity, 123:882
on osteoporosis in gastrointestinal diseases, 124:795
on osteoporosis in hepatic disorders, 125:941
on parenteral nutrition, 121:970
on perianal Crohn's disease, 125:1508-aga
on short bowel syndrome and intestinal transplantation, 124:1111
on treatment of dysphagia caused by benign disorders of distal esophagus, 117:233

Amino acids
dietary, bioavailability of, functional gut and, 123:1931
ileal losses of, and assessment of amino acid requirements, 123:50
intestinal recycling of, 123:1931
metabolism of
in acute liver failure, 118:1131
cerebral, in fulminant hepatic failure, 121:1109
intestinal, protein restriction and (pig), 121:1167
requirements, assessment of, ileal losses of nitrogen and amino acids and, 123:50

Aminopeptidase N, in colon cancer, 122:376

Aminosalicylates, for Crohn's disease with fistulous complications, 119:1132-srr
5-Aminosalicylic acid (5-ASA)
and azathioprine or 6-mercaptopurine, drug interactions, 117:1514-c, 119:276-c
plasma levels, after single oral dose, 117:1514-c
Ammonia, metabolism of
in acute liver failure, 118:1131
cerebral, in fulminant hepatic failure, 121:1109
Ammonium transporters, hepatic expression of (mice), 124:1432
Amoxicillin-clavulanate
for diarrhea caused by small intestinal bacterial overgrowth, 117:755-tmig, 117:794
immunoallergic hepatitis induced by, HLA association in, 117:1038-tmig, 117:1181
Amphiregulin
in gastrointestinal development and mucosal integrity (mice), 121:68
overexpression in pancreas, and proliferation of pancreatic duct cells (transgenic mice), 122:1898
Amprenavir, GI toxicity and GI-associated drug interactions of, 120:607
Ampulla of Vater
adenomas, in familial adenomatous polyposis, risk stratification for, 121:1127, 121:1246-e
carcinoma
epigenetic and genetic alterations in, 124:1300
in familial adenomatous polyposis, risk stratification for, 121:1127, 121:1246-e
pathology of, 125:1553-pmr
Amylin, and gastric secretion (mice), 123:247
Amyloidosis
dialysis-related, and gastrointestinal symptoms, 116:217-ss
hepatic failure in, liver/stem cell transplantation for, 122:2026-cr
primary, of duodenum, 125:1302-im
systemic, complicating Crohn's disease, renal dysfunction caused by, dimethylsulfoxide for, 117:1031-c
variant lysozyme and, 123:1346-cr
Amyotrophic lateral sclerosis, percutaneous endoscopic gastrostomy in, botulinum toxin for masseter muscle spasticity and, 123:1749-c
Anal canal, cancer of, risk of, HPV and, 120:784-mig, 120:857, 120:1046-e
Anal canal sensation testing
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
Anal dilatation, for anal fissure, 124:235-aga
Anal disease, textbook on, 116:1011-pmr
Anal fissure
botulinum toxin for, 116:221-ss, 117:516-c, 124:233-aga, 124:235-aga, 124:1165-c
long-term follow-up of, 123:112
in Crohn's disease, 124:235-aga
diagnosis and care of patients with
AGA medical position statement on, 124:233-aga
AGA technical review on, 124:235-aga, 125:995-c
etiology of, 124:235-aga
in HIV-infected (AIDS) patients, 124:235-aga
in perianal Crohn's disease, 125:1503-aga, 125:1508-aga
Anal fistula, in Crohn's disease, initial medical management for, cost-utility of, 120:1640
Anal incontinence. *See also* Incontinence
anal sphincter and, 124:1672
artificial anal sphincter for, 116:1005-ss
dynamic muscle plasty for, 116:549
levator ani function in, assessment of, 123:1421-tmig, 123:1441
manometry in, 124:1672
pelvic floor muscles in, 123:1421-tmig, 123:1441
Anal manometry, in fecal incontinence, 124:1672
Anal reconstruction, dynamic muscle plasty in, 116:549
Anal sphincter
artificial device, for fecal incontinence, 116:1005-ss
and fecal incontinence, 124:1672
internal, heme oxygenase activity in (opossum), 118:477
Anal ulcer, in perianal Crohn's disease, 125:1508-aga
Anandamide, and arterial hypotension in cirrhosis (rat), 122:85
Anaphylatoxin C5a receptor, induction in hepatocytes, by lipopolysaccharide (rat), 122:697
Anaphylaxis, intestinal, afferent nerve sensitivity to (rat), 119:1267
Anderson's disease, apolipoprotein B48 glycosylation in, 121:1101
Anemia
duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404
with pegylated interferon, for hepatitis C, 124:1711
Aneurysm, splenic artery, 123:1427-im
Angina, intestinal. *See* Mesenteric ischemia, chronic
Angiodysplasia
bleeding
abnormal von Willebrand factor in, 120:346
prevention of, hormonal therapy in, 121:1033-tmig, 121:1073
colonic, diagnosis of, imaging modality for, 119:287-tmig, 119:293, 119:581-e
hormonal therapy in, 121:1033-tmig, 121:1073, 123:2156-c
rebleeding from, prevention of, hormonal therapy in, 121:1033-tmig, 121:1073
Angiogenesis
aminopeptidase N in, 122:376
in colorectal cancer, COX-2 up-regulation and, 121:1339
in pancreatic tumors, promotion by t-PA, 122:806-vidd
stimulation of, by VEGF and angiopoietin-1 gene therapy, 121:1040-rc
Angiography. *See also* Computed tomographic angiography
in acute mesenteric ischemia, 118:954
for diagnosis of bleeding colonic angiomas, 119:581-e
in obscure gastrointestinal bleeding, 118:201-aga
Angiopoietin-1, gene therapy, for gastric ulcers, 121:1040-rc
Angiopoietins, in focal nodular hyperplasia, 124:594-tmig, 124:651
Angiotensin-converting enzyme (ACE) inhibition/inhibitor
attenuation of hepatic fibrosis (rat), 121:148
attenuation of pancreatic inflammation and fibrosis, in male Wistar Bonn/Kobori rats, 124:1010
intestinal angioedema caused by, 119:1190-im
Angiotensin II
mitogenic effect on hepatic stellate cells, 118:996-tmig, 118:1149, 118:1261-e
in regulation of vascular tone in cirrhosis, 118:565
synthesis of, in hepatic stellate cells, 125:117
vasoconstrictive effect on hepatic stellate cells, 118:996-tmig, 118:1149, 118:1261-e

Angiotensin II receptor antagonists, for portal hypertension, 117:740-ss, 122:1543-c
in cirrhosis, 121:240-tmig, 121:382, 121:389, 121:487-e
Angiotherapy, for gastrointestinal bleeding, 118:201-aga
Anion secretion, intestinal, 118:101, 118:1282-c
Ankylosing spondylitis, intestinal inflammation in relatives of patients with, 125:1598
Anoikis, enterocytic, p38 isoforms in, 123:1980
Anorectal function, and fecal continence, 124:1672
Anorectal manometry
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
in constipation, 119:1766-aga
Anorectal strictures, in perianal Crohn's disease, 125:1503-aga, 125:1508-aga
Anorectal testing techniques
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
Anorectum
aging-related changes in, 122:1688
musculature of, cortical representation of, 117:1-tmig, 117:32
Anorexia
of aging, 122:1688
drug treatment for, 122:1688
evaluation of, 122:1688
treatment of, 122:1688
in inflammatory bowel disease, serotonin and (rat), 118:457-tmig, 118:544, 118:625-e
Anthraquinones, for constipation, 119:1766-aga
Anthrax, gastrointestinal, 121:1272-gn
Antiadhesion agent, for *H. pylori* infection (rhesus monkey), 117:1265-tmig, 117:1316
Antiapoptotic molecules, in protection against hepatic ischemic injury, 125:917-srr
Antibiotic resistance, in *Salmonella*, from antibiotic-treated cattle, 119:3-gn
Antibiotics
and budesonide, combined, for Crohn's disease, 123:33
for colitis in IL-10 gene-deficient mice, 118:995-tmig, 118:1094
in colonic ischemia, 118:954
for Crohn's disease, with fistulous complications, 119:1132-srr
for Crohn's fistula, 124:1595
for *H. pylori* infection in childhood, 122:1189-c
for perianal Crohn's disease, 125:1503-aga
for pouchitis, 124:1636
prescribing practices for, and *C. difficile* epidemic, 118:249-gn
for small intestinal bacterial overgrowth, 117:755-tmig, 117:794
Anticoagulation
in acute mesenteric ischemia, 118:954
for mesenteric vein thrombosis, 120:578-ss
for portal vein thrombosis, 120:490, 120:578-ss
in cirrhotic patient with variceal rebleeding, 122:2095-c
for superior mesenteric venous thrombosis, 118:954
Antidepressants
for functional bowel disorders, 125:19, 125:249-e
for irritable bowel syndrome, 120:652, 123:2108-aga, 124:303, 125:1554-c
Antidiarrheal agents, in treatment of irritable bowel syndrome, 120:652
Antiemetic agents, for nausea and vomiting, 120:263-aga, 125:1860
Anti-endomysial antibody, in detection of celiac disease, 122:246-c
Anti-HuD antibodies, enteric neuronal apoptosis evoked by, and paraneoplastic gut dysmotility, 125:70
Antihypertensive drugs, and gastrointestinal hemorrhage, 119:1416-c
Anti-inflammatory agents. *See also* Nonsteroidal anti-inflammatory drugs (NSAIDs)
for colonic epithelial cells, 117:1039-gn
Antimitochondrial antibody, in liver disease, 120:239-srr
Antineutrophil cytoplasmic antibody (ANCA)
and LTA haplotype, and responses to infliximab in Crohn's disease, 120:1347
perinuclear (p-ANCA)
atypical, antigen reacting with, 119:310
in indeterminate colitis, 122:1195-tmig, 122:1242, 125:999-c
response to, in Crohn's disease, 123:689
Antinuclear antibodies
and infliximab in Crohn's disease, 117:1433-cr
in liver disease, 120:239-srr
Antioxidant-responsive element, and inducible NOS expression in hepatocytes (rat), 118:608
Antioxidants
in alcohol-induced liver disease, 124:778-srr
dietary
in fruit and vegetables, and risk of gastric cancer, 123:985
intake of, and risk of gastric cancer, 124:2006-c
gene expression, hepatitis C virus core protein-induced, 122:366, 122:568-e
for nonalcoholic fatty liver disease, 122:1649
in protection against hepatic ischemic injury, 125:917-srr
serum levels of, elevated serum alanine aminotransferase and, 124:1821
Antireflux surgery
in Barrett's esophagus, 122:1569
cancer risk after, 121:1270-tmig, 121:1286, 121:1506-e
esophageal manometry before, 121:5, 121:214-e
versus medical management, cost analysis of, 122:1178-ss
outcomes, effect of esophageal dysmotility on, 122:1183-c
Antiretroviral therapy, for HIV-1 infection
adverse effects and side effects of, 120:607
efficacy of, 120:607
Anti-*Saccharomyces cerevisiae* antibodies (ASCA)
assays, in inflammatory bowel disease, comparative study of, 120:827
in indeterminate colitis, 122:1195-tmig, 122:1242, 125:999-c
Antisense ICAM-1, in treatment of chronic active Crohn's disease, 120:1317-tmig, 120:1339
α1-Antitrypsin, gene polymorphisms, and chronic pancreatitis, 120:682
Antiviral agents, for viral hepatitis, 117:525-ce
Anus
neoplasms of, 119:1803-pmr
surgery of, 119:1173-pmr
Anxiety, and postinfectious IBS, 125:1651
Aortic thrombosis, IBD-associated, with splenic and renal embolization, 118:637-c
Aortoenteric fistula, 121:756-im
***APC* gene.** *See* Adenomatous polyposis coli gene *(APC)*

Apical sodium-dependent bile acid transporter (ASBT), cytokine-mediated repression of (rat), 123:2005
Apolipoprotein-A4, for obesity treatment, 124:877-gn
Apolipoprotein B48, glycosylation, in hereditary lipid malabsorption, 121:1101
Apolipoprotein CIII, expression in liver, farnesoid X receptor agonists and (mice), 125:544
Apolipoprotein E, in regulation of biliary cholesterol secretion and cholesterol gallstone formation (mice), 118:650-tmig, 118:772
Apoptosis
acinar cell, and severity of acute pancreatitis (mice), 124:481
after hepatic ischemia/reperfusion, 125:1246-srr
butyric acid-induced, JNK/AP1 pathway in, 120:71
of $CD8^+$ T cells, in liver, 120:250-srr
cholangiocyte, effects of vagotomy on, 117:191
in colon cancer cells
butyric acid–induced, 120:71
resistance to, during spontaneous Caco-2 cell differentiation, 120:889
glyceryl trinitrate and, 123:235
colonic epithelial cell, regulation by glial-derived neurotrophic factor, 124:1721-tmig, 124:1748
and colorectal adenomas, 123:1770
dysregulation, in gastric cancer, 121:1219
enteric neuronal, anti-HuD–evoked, and paraneoplastic gut dysmotility, 125:70
enterocyte, with parenteral nutrition (mice), 125:1273-ss
in epithelial cells
leukotrienes and, 119:890-tmig, 119:1007
prevention of, *Cryptosporidium parvum*-activated factor κB and, 120:1774
regulation by glial-derived neurotrophic factor, 124:1721-tmig, 124:1748
signal transduction during, 120:79, 120:294-e
ethanol-induced mitochondrial dysfunction and, 122:2049-srr
Fas-mediated
in cholestasis (mice), 117:669, 117:732-e
and fibrosis, link between, in hepatocytes (mice), 123:1323
IL-1β and (mice), 117:661
inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810
modulation by survivin deficiency, via mitochondrial pathways (mice), 123:619
prevention by genipen (mice), 118:380
prevention by SOD mimetic (mice), 121:1451
of Th1 T cells, in experimental colitis, anti-IL-12 treatment and, 117:1078, 117:1238-e
in gastric pit cells, inhibition by transforming growth factor-α, nuclear factor κB and (mice), 121:56
in gastrointestinal inflammatory states, 116:509-tmig, 116:557
in hepatic stellate cells
peripheral-type benzodiazepine receptor expression and, 120:1212, 120:1285-e
stimulation of, and inhibition of hepatic fibrosis (humans, rats), 121:512-tmig, 121:685
in tissue injury, 120:1212, 120:1285-e
hepatocellular
Bid-mediated activation of mitochondrial apoptotic mechanisms in, 125:854
bile salt–induced, EGF-R/CD95 and, 125:839
Fas-mediated
in cholestasis (mice), 117:669, 117:732-e
IL-1β and (mice), 117:661
inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810
prevention by genipen (mice), 118:380
prevention by SOD mimetic (mice), 121:1451
and fibrosis, Fas-mediated mechanistic link between (mice), 123:1323
in ischemic liver, TNF-α-induced (mice), 122:202
mitochondrial permeability transition and (rat), 124:494
in nonalcoholic steatohepatitis, 125:437
TNF-α- and Fas-mediated, NF-κB stimulation of inducible nitric oxide synthase and (mice), 120:1251
IFN-γ-induced, Kupffer cells and (rat), 116:666
IL-1β-induced, in enterochromaffin-like cells, mediation by iNOS, NF-κB, and Bax protein (rat), 118:457-tmig, 118:515
induction, death receptors in, 121:1242-e
inhibition by Stat3 and NF-κB, in pancreatic cancer, 123:2052
in intestinal cells
chemotherapy-induced, LPA-induced rescue from, 123:206
NAG-1 gene and (mouse, human), 122:1388
radiation-induced, LPA-induced rescue from, 123:206
in intestinal epithelial cells, leukotrienes and, 119:890-tmig, 119:1007
in intestinal macrophages, dietary microparticles and calcium in, 123:1543
in intestinal mucosa, TGF-β2 and TGF-β3 in (mice), 122:1364
in ischemic liver injury, calpain and (rat), 116:2-tmig, 116:168
of lamina propria T cells, in gastrointestinal inflammatory states, 116:509-tmig, 116:557
in liver development, β-catenin and, 124:202
modulation of epithelial barrier function during, 119:1425-tmig, 119:1524, 119:1783-e
monocyte, induction by infliximab, 121:1034-tmig, 121:1145, 121:1242-e
of mucosal T cells, caspases and, 122:1334
NF-κB/Rel activity and, 118:1208-srr
nitrogen oxides and, 119:512-srr
NSAID-induced, 118:1012
in gastric epithelial cells, suppression by protein kinase C β1 overexpression, 118:457-tmig, 118:507
in pancreatic cells, role of TNF-α and pancreatitis-associated protein I in (rat), 119:816
PKC-δ and, in Caco-2 cells, 120:1700, 120:1868-e
prevention of, during liver development, NF-κB/Rel activity and, 118:1208-srr
sinusoidal endothelial cell, platelet-induced, after reperfusion of liver graft (rat), 118:183
sulindac-induced, in colon cancer cells, lovastatin and, 117:755-tmig, 117:838
taurolithocholic acid-3 sulfate-induced, in hepatocytes, mechanisms of (rat), 122:1411
T-cell
caspases and, 122:1334
in Crohn's disease, 119:1166-ss
in experimental colitis, anti-IL-12 treatment and, 117:1078, 117:1238-e

in lamina propria, in gastrointestinal inflammatory states, 116:509-tmig, 116:557

Apoptosis [term], pronunciation of, 119:1805-c

Appendectomy
Crohn's disease risk after, 124:40, 125:997-c, 125:1562-c
laparoscopic, in patients with refractory ulcerative colitis, 120:1562-c
protective effect against inflammatory bowel disease, 125:1270-ss
ulcerative colitis improvement after, 119:502-cr

Appendicitis, diagnosis of
accuracy of, 123:381-ss, 125:272-c
imaging in, 123:992, 125:272-c

Appendix
complete invagination of, progressing to ileocecocolic intussusception, 123:1762-im
mucinous tumor of, 122:1200-im
in ulcerative colitis, 117:272-ss, 119:502-cr, 120:1562-c, 121:730-ss

Appetite
regulation, ghrelin in, 120:337-rc
stimulation, by endocannabinoids, 123:655-c
suppression, long-chain fatty acids and, 119:889-tmig, 119:943

Aquaporins, in transcellular water transport, 122:545-srr

Arachidonic acid, as second messenger in colonic circular muscle contraction, 119:1-tmig, 119:62

Arteriovenous malformations, hepatic, 120:1579-im

Arthritis, in inflammatory bowel disease, 123:714

Arthropathy, in inflammatory bowel disease, genotype-phenotype relationship in, 118:279

Artificial neural networks, discrimination among subtypes of colorectal neoplasia, 122:606-rc

ASCA. *See* Anti-*Saccharomyces cerevisiae* antibodies (ASCA)

Ascariasis, imaging in, 124:879-im

Aschoff, Carl Albert Ludwig, 120:1598

Ascites
in cirrhosis
albumin therapy for, 125:1283-c
TIPS for, 123:1757-tmig, 123:1839, 124:594-tmig, 124:634, 124:1700, 125:997-c
current management of, 120:726
new-onset, treatment of, 120:726
refractory
management of, 120:311-ss, 120:726
treatment of, 124:594-tmig, 124:634

Ashkenazim
risk for colorectal adenomas, susceptibility gene on chromosome 15q14-q22 and, 116:783-tmig, 116:789
risk for colorectal cancer
I1307K *APC* gene variant and, 116:54, 116:210-e, 120:331-tmig, 120:392
susceptibility gene on chromosome 15q14-q22 and, 116:783-tmig, 116:789

Aspartate aminotransferase, serum levels of
abnormalities of, evaluation of, 123:1367-aga, 125:279-c
elevation of, etiology of, 123:1367-aga, 125:279-c

Aspirin. *See also* NO-aspirin
and colorectal adenoma, 124:1176-gn
dyspepsia development with, visceral sensory function and, 123:1451
gastric resistance to, COX-2-derived lipoxin A_4 and, 123:1598
gastric toxicity of, 117:1-tmig, 117:17, 117:1506-c
gastrointestinal complications of, *Helicobacter pylori* elimination and, 122:238-ss
gastrointestinal effects of, 119:521-srr
low-dose
safety of, 117:1-tmig, 117:17, 117:1506-c
ulcer complications from, 124:572-ss
nitric oxide-releasing, inhibition of caspases, 116:1089
in prevention of colonic adenomas, 124:1176-gn, 125:328, 125:612-e, 125:1539-ss
in prevention of colorectal cancer, 125:1539-ss
cost-effectiveness of, 122:1-tmig, 122:78, 122:230-e
in prevention of esophageal cancer, 124:47, 124:246-e, 125:1912-c

Asthma, acid reflux in
in children without neurological deficits, 121:1294
coughing or wheezing and, 123:1398-ss

ATPase. *See* Adenosine triphosphatase

ATP-binding cassette (ABC) transporter
A1 (ABCA1), and cholesterol metabolism, 120:1203
mutations, and cholesterol accumulation in sitosterolemia, 121:1255-ss

ATP7B (Wilson disease) protein
copper-induced apical trafficking of, in hepatic cells, 119:782
localization of, 125:1911-c
mutants
as aggresomes, 121:1264-c
localization of, 120:784-tmig, 120:967, 125:1911-c
properties of, 120:784-tmig, 120:967, 121:1264-c

Atrial natriuretic peptide, attenuation of oscillatory calcium signaling in hepatocytes (rat), 123:1291

Atrophic gastritis
cancer risk with, 116:1217-vodd
fundic endocrinopathy in, 125:827-c
H. pylori and, 118:239-c, 118:242-c, 118:453-c
IL-1β polymorphisms and, 123:92
long-term omeprazole therapy and, 118:239-c, 118:242-c, 118:453-c
risk, genetic profile and, 125:364

Attractin, and weight regulation (mice), 117:294-gn

Autism, secretin therapy for, 117:524-gn, 118:250-gn

Autoantibodies
in APECED hepatitis, 121:668
in autoimmune hepatitis, 120:1502-srr
in liver disease, 120:239-srr

Autoantigens, response to, in Crohn's disease, 123:689

Autoimmune enteric leiomyositis, and intestinal pseudo-obstruction, 122:1132-cr

Autoimmune enteropathy, AIE-75 autoantigen in, 117:823

Autoimmune gastritis, proton pump as target autoantigen of Th1-type cytotoxic T cells in, 120:377

Autoimmune hepatitis (AIH)
anti-SLA-positive, glutathione *S*-transferase as autoantigen in, 116:1015-c
atypical p-ANCA antigen in, 119:310
autoantibodies in, 120:1502-srr
cholestatic disease and, 120:1502-srr
clinical presentation of, 120:1502-srr
cytokine polymorphisms in, 117:522-tmig, 117:645, 117:728-e
definition of, 120:1502-srr
diagnostic criteria for, 120:1502-srr
differential diagnosis of, 120:1502-srr
genetic heterogeneity of, 120:1502-srr
histology of, 120:1502-srr
immunoserological heterogeneity of, 120:1502-srr
liver cytosol antigen in, 116:643
liver transplantation for, 120:1502-srr
natural history of, 120:1502-srr
prognosis for, 120:1502-srr
treatment-dependent, budesonide for, 119:1185-tmig, 119:1312
treatment of, 120:1502-srr

Autoimmune injury, hepatic, mechanisms of, 120:1485-srr
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), hepatic autoantigens in, 121:668
Autoimmunity
in celiac disease, 119:234-srr, 119:243-srr
duration of exposure to gluten and, 117:291-tmig, 117:297
induced by DNA vaccination against α-fetoprotein (mice), 121:931
and infliximab in Crohn's disease, 117:1433-cr
redefinition of, 125:1574-ce
Autonomic nervous system
dysfunction, in irritable bowel syndrome and comorbid conditions, 122:1139-srr
in health, gender differences in, 123:1686-srr
in irritable bowel syndrome, 123:2108-aga
gender differences in, 123:1686-srr
Azathioprine (AZA)
and 5-aminosalicylic acid agents, drug interactions, 119:276-c
for autoimmune hepatitis, 120:1502-srr
and balsalazide, drug interactions, 116:1505-c, 117:1514-c
in Crohn's disease
combined with infliximab (abstract), 125:606-aga
with fistulous complications, 119:1132-srr, 124:1595
intravenous administration of, 117:521-tmig, 117:527
steroid therapy and, 118:1281-c
and lymphoma risk, 121:1034-tmig, 121:1080, 121:1239-e
for maintenance of remission, 118:995-tmig, 118:1018
myelosuppression during, 118:995-tmig, 118:1025
steroid therapy and, 118:1281-c
for inflammatory bowel disease, 120:622
dosage of, metabolite measurements and, 122:2082-ss
and male fertility, 121:1048
and postoperative infections, 125:320, 125:610-e
and risk of EBV-positive lymphoma, 122:72
intolerance, in inflammatory bowel disease, 122:838-c
and 6-mercaptopurine, for refractory microscopic colitis, 120:1483-cr
metabolism of, 122:838-c, 122:848-tmig, 122:2082-ss
for perianal Crohn's disease, 125:1503-aga, 125:1508-aga
villus atrophy and chronic malabsorption induced by, 124:1950-cr
Azoxymethane, induction of colon carcinogenesis (mice), 119:2-tmig, 119:162
AZT. *See* Zidovudine

Babcock, William Wayne, 121:244
Backwash ileitis, and colorectal cancer in ulcerative colitis, 120:783-tmig, 120:841, 122:245-c
Baclofen
and esophageal function, 123:1736-ss
for gastroesophageal reflux disease, 118:1-tmig, 118:7, 125:984-ss
inhibition of transient lower esophageal sphincter relaxation (dog), 117:1037-tmig, 117:1147
Bacteria. *See also* Flora, enteric
cecal load, in experimental colitis and gastritis, 116:310
and colitis
in IL-10 gene-deficient mice, 118:995-tmig, 118:1094
in Tgε26 mice, 120:900
colonic, 119:1410-pmr
superantigens from, and colitis (mice), 125:1785
commensal, associated with Crohn's disease, 119:23, 119:254-e
as drug delivery systems, 119:1187-gn
enteroinvasive, and barrier and transport properties of intestinal epithelium, 122:1069
gene expression, in human tissue, global analysis of, 123:1637
interactions with host, in inflammatory bowel disease, 122:44, 122:228-e, 123:955-c, 125:1288-c
intestinal, provocation of inflammatory bowel disease (mice), 122:1346
in intestinal mucus layer, in inflammatory bowel disease, 117:1037-tmig, 117:1089
in irritable bowel syndrome, 125:1898-ss
N-nitrosation, omeprazole for *H. pylori* and, 119:287-tmig, 119:339
normal enteric, regulation of goblet cell–specific protein RELMβ/FIZZ2, 125:1296-tmig, 125:1388
and pathogenesis of colonic inflammation, 116:1107, 116:1246-e
probiotic, 119:291-ce
and intestinal epithelial function, 123:391-c
and small intestinal barrier function, zonulin release and, 123:1607
Bacterial antigens, response to, in Crohn's disease, 123:689
Bacterial overgrowth
in elderly, 122:1688
evaluation for, 122:1688, 122:1701
in patients with gallstones, 120:1310-c
treatment of, 117:755-tmig, 117:794, 122:1688
Bacterial translocation, in cirrhosis, prokinetics and, 120:314-ss
Bacteroides fragilis, enterotoxin and β-catenin nuclear signaling in intestinal epithelial cells, 124:392
and oncogenic potential in intestinal epithelial cells, 124:392
Bacteroides vulgatus, prevention of *E. coli*-induced colitis (mice), 125:1-tmig, 125:162
Bag-1, in protection against hepatic ischemic injury, 125:917-srr
Balloon expulsion test
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
in constipation, 119:1766-aga
Balsalazide
and azathioprine or 6-mercaptopurine, drug interactions, 116:1505-c, 117:1514-c, 119:276-c
plasma levels, after single oral dose, 117:1514-c
Bananas, green, in management of persistent diarrhea in children, 121:554
Bangladesh, posttherapeutic recurrence of *Helicobacter pylori* in, 121:792, 123:653-c
Bariatric surgery, for obesity, 120:669
Barium enema
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
diagnostic use of, 119:612-gn
double-contrast
versus colonoscopy, 119:1402-ss
recommendations for, 124:544-aga
Barrett's esophagus
ablation therapy for, 122:1569
acid-related MAP kinase activation in, and carcinogenesis, 122:253-tmig, 122:299
biopsy, optical techniques, 122:1569
and cancer of esophagus and esophagogastric junction, 116:277
chemoprevention in, 122:1569
cost-effectiveness of, 124:1758
cyclooxygenase 2 expression in, 118:457-tmig, 118:487, 121:1391, 121:1502-e
diagnosis of, 122:1569
differentiation and proliferation in, acid suppression therapy and, 117:327, 117:1510-c

dysplasia in
and cancer risk, 122:1569
evaluation of, 125:260-ss
fluorescence, reflectance, and light-scattering spectroscopy for, 120:1607, 120:1864-e
high-grade
diagnosis of, interobserver variability in, 125:260-ss
long-term nonsurgical management of, 120:1617, 120:1864-e
and risk of carcinoma, 120:1630, 120:1864-e
prevention of, rofecoxib for, 123:1-tmig, 123:50
endoscopic mucosal resection in, 122:1569
for early cancer and high-grade dysplasia, 118:649-tmig, 118:670
epidemiology of, 122:1569
esophageal cancer in
adenocarcinoma, DNA copy number in, 121:592, 121:726-e
adenosquamous, clonal origin of both components of, 122:784-cr
biology of, 122:1569
biomarkers of increased risk in, 122:1569
data on, from Bayreuth Barrett's archive, 122:590-c
diagnosis of, 125:260-ss
epidemiology of, 122:1569
and outcomes, 122:26
preoperative prevalence of, 122:26, 123:955-c
prevention by COX-2 inhibitors (rat), 122:1100, 122:1171-e
regional variation in, 122:588-c
risk factors for, 122:1569
risk of, 119:333, 119:587-e, 119:1165-ss, 120:1617, 120:1630
in individual patient, 122:1569
expert panel on, 124:876-gn
lack of association with gastric surgery, 121:1281, 121:1502-e, 123:954-c
neoplastic progression in, CDKN2A/p16 methylation in, 122:1112
pathogenesis of, 121:1281, 121:1391, 121:1502-e
pathophysiology of, 122:1569
photodynamic therapy for, 120:785-gn, 122:1569
persistent genetic abnormalities after, 119:624-rc, 120:1064-c, 120:1065-c
prevalence of
in asymptomatic individuals, 123:402-tmig, 123:461, 123:636-e
clinical impact of, 123:636-e
in general population, 123:636-e
risk stratification in, 122:1569
rofecoxib for, 123:1-tmig, 123:50
screening, 125:1569-tmig, 125:1670
cost-utility of, 125:1268-ss
strategies for, 122:1569
segment length in, and risk for neoplastic progression, 119:1165-ss
short-segment, 118:987-c, 125:1569-tmig, 125:1670
cytokeratin immunoreactivity in, 119:609-tmig, 119:683
spectroscopic detection of dysplasia in, 119:609-tmig, 119:677
surveillance endoscopy in
cost-utility of, 125:1268-ss
and patient survival, 122:633, 122:820-e
value of, 121:1516-ss
surveillance strategies for, 122:1569, 123:402-tmig, 123:461, 123:636-e
treatment of
heater probe for, 124:2008-c
medical, 122:1569
surgical, 122:1569. *See also* **Antireflux surgery**

Barrett's metaplasia, gastrin-induced proliferation in, and CCK_2 receptor, 124:615, 125:1912-c, 125:1921-c

Basalazide, for ulcerative colitis, 124:574-ss

Basal ganglia, alterations, in cirrhosis, correlation with Parkinsonian signs, 119:774

Basiliximab, for inflammatory bowel disease, 122:1592, 124:2005-c

Bax gene, and butyric acid-induced apoptosis in colon cancer cells, 120:71

Bax protein, and IL-1β-induced apoptosis in enterochromaffin-like cells (rat), 118:457-tmig, 118:515

B cells. *See* **B lymphocytes (B cells)**

Bcl-2
expression and distribution in intestinal epithelial cells, leukotrienes and, 119:890-tmig, 119:1007
in protection against hepatic ischemic injury, 125:917-srr
regulation of, TGF-β2 and TGF-β3 in (mice), 122:1364

Bcl-3, and Peyer's patch organogenesis (mice), 122:1853

Bcl-xL, regulation of, TGF-β2 and TGF-β3 in (mice), 122:1364

Beaumont, William, 116:14

Beckwith-Wiedemann syndrome, colonic polyps in, 118:637-c

Behavior therapy, for obesity, 120:669

Behçet's disease
acute pancreatitis and pericardial effusion in, 117:286-c
Budd-Chiari syndrome in, 117:526-im
gastrointestinal, anti-tumor necrosis factor monoclonal antibody therapy for, 120:995-cr

Benzodiazepine receptor, peripheral type, and apoptosis induction in hepatic stellate cells, 120:1212, 120:1285-e

Bernard, Claude, 119:828

Beta-blockers, in prevention of variceal bleeding, 123:963-tmig, 123:1013, 123:1388-e

Betaine, reduction of alcoholic liver injury by (mice), 124:1488

Bethanechol, for anal fissure, 124:235-aga

Bezafibrate, therapeutic potential in colitis, 121:1019-ss

BF-5, for inflammatory bowel disease, 122:1592

Bicarbonate
duodenal mucosal secretion of, 5-HT and (mice), 125:805
excretion, biliary, cholangiocytes and (rat), 121:396
inhibition of cystic fibrosis transmembrane conductance regulator in pancreatic duct cells (guinea pig), 118:1187
secretion of
biliary, in humans, positron emission tomography of, 117:167
cAMP-stimulated, in NKCC1-null murine duodenum, 123:531
in colonic crypt, chloride secretion and (rat), 118:101, 118:1282-c
cystic fibrosis transmembrane conductance regulator and, 118:1051, 118:1187, 118:1258-e
duodenal, prostaglandin E-receptor subtype EP, and (mice), 117:1037-tmig, 117:1128
intestinal (rabbit, rat, human), 122:600-tmig, 122:709
pancreatic, role of CFTR and sodium-bicarbonate cotransporter, 117:275-ss
pancreatic ductal (guinea pig), 118:1187
transport, in duodenum (rabbit), 119:406

Bid, activation of mitochondrial apoptotic mechanisms in hepatocytes, 125:854

Bifidobacteria
in prevention of neonatal necrotizing enterocolitis (rat), 117:521-tmig, 117:577, 118:1280-c
therapy with, 119:291-ce
for pouchitis, 119:287-tmig, 119:305, 119:584-e
Biglycan, and pancreatic cancer, 121:657
Bile
and biliary chemokine production, 118:1157
cholesterol solubility in, gallbladder epithelial dysfunction and, 118:912
composition of, in biliary microlithiasis, 121:1014-ss
flow, cholangiocytes and (rat), 121:396
formation, ductal, microperfused IBDU model for study of (rat), 119:1672
gallbladder, in Crohn's disease, 116:1282-tmig, 116:1420, 116:1491-e
gastric injury from, gastric NOS expression and (rat), 123:173
intestinal exposure to, and carcinogenesis, 121:542
oxysterols in, 121:118, 121:216-e
reflux, and esophageal carcinogenesis, 121:548
secretion, vasoactive intestinal polypeptide and (rat), 117:420
Bile acids
bile acid transporter regulation by (rat), 121:140, 121:218-e
book on, 125:1280-pmr
and cholesterol, gallstone calcification, and enterohepatic circulation of bilirubin, 116:1276-c
composition, sterol 12α-hydroxylase expression and (rat), 120:1801
COX-2 induction mediated by, in cholangiocarcinoma, 122:984
and duodenal reflux, in COX-2 induction in esophageal mucosa (rat), 121:1391, 121:1502-e
and esophageal cancer, 124:271-c
and hepatic signal transduction, 117:433-srr
and hepatocellular transporter expression (mice), 121:170
hydrophobic, in regulation of sterol 12α-hydroxylase (rat), 118:599
jejunal absorption of, neurotensin and (rat), 120:151
kinetics, intestinal transit and, 121:812
metabolism
manipulation of, by activation of deorphanized nuclear receptors, 120:1054-ss
sterol carrier protein 2 and (mice), 119:1708
modulation of cholangiocyte secretion and growth (rat), 123:1226
mucosal protection against, biliary phospholipids in (rat), 118:1179, 118:1265-e
pool, composition, regulation of (rat), 118:599
regulation of ductal secretion and cholangiocyte proliferation, 116:179
regulation of ileal bile acid binding protein expression (rat), 122:1483
replacement therapy, for short-bowel syndrome, 116:1-tmig, 116:15
secretion of, canalicular, tauroursodesoxycholate-induced, mechanisms of, 121:407
synthesis
defect in, and neonatal liver disease, 124:217-cr
feedback regulation of, 120:1557-ss
nuclear receptors and, 120:1557-ss
transport
hepatobiliary, 117:433-srr
in ileitis (rat), 123:2005
transporter-mediated uptake of, and calcium-dependent cell death in pancreatic acinar cells (rat), 122:1941
Bile acid transporters
hepatocellular, bile acids and (mice), 121:170
ntcp, negative feedback regulation of, by bile acid-activated induction of *shp* (rat), 121:140, 121:218-e
preservation of, in endotoxemia, heat stress and (rat), 122:962
Bile ducts
disease of, diagnosis and treatment of, book on, 122:2089-pmr
epithelia, and biliary bicarbonate excretion (rat), 121:396
extrahepatic, carcinoma of, epigenetic and genetic alterations in, 124:1300
intrahepatic
microperfusion of (rat), 119:1672
tumors, pathology of, atlas of, 122:586-pmr
ischemic necrosis of, in Schönlein-Henoch purpura, 117:211-cr
leaks, ERCP with, 124:1686
obstruction of
and biliary chemokine production, 118:1157
magnetic resonance cholangiography in, 124:1686
and pancreatitis, 124:863-c
postoperative strictures, endoscopic management of, long-term results of, 122:1533-ss
secretory activity
bile acid-regulated, 116:179
nitric oxide and, 124:737, 124:847-e
stones in. *See* **Choledocholithiasis**
Bile flow, gap junctions and, in perfused liver (rat), 116:1024-tmig, 116:1176
Bile salt-dependent lipase
intestinal transcytosis of, 124:470
pancreatic origin of, 124:470
Bile salt export pump
in experimentally induced diabetes (rat), 122:1842
expression of, after chronic cholestasis (rat), 118:163
human
characterization of, 123:1649, 123:1659, 123:1733-e
expression of, 123:1649, 123:1733-e
functional expression of, 123:1659, 123:1733-e
inhibitors of, identification of, 123:1649, 123:1733-e
substrate specificity, characterization of, 123:1649, 123:1733-e
inhibition of, in drug- and estrogen-induced cholestasis (rat), 118:422
translocation, and tauroursodesoxycholate-induced choleresis (rat), 121:407
Bile salt receptor FXR, in genetic susceptibility to and pathogenesis of cholesterol gallstones (mice), 125:868
Bile salts
cyclooxygenase 2 expression induced by, ex vivo, 118:457-tmig, 118:487
excretion, in chronic cholestasis (rat), 118:163
hepatocyte apoptosis induced by, EGF-R-dependent CD95 tyrosine phosphorylation in, 125:839
malabsorption of, in postinfectious irritable bowel syndrome, 124:1662
secretion of
in progressive familial intrahepatic cholestasis, 117:1370, 117:1496-e
in STZ-diabetic rats, 122:1842
Bile salt transporters, adaptive regulation of, in obstructive cholestasis (rat), 121:1270-tmig, 121:1473
Biliary dyskinesia, ERCP in, 124:1686
Biliary fibrosis, in erythropoietic protoporphyria (mice), 117:688
Biliary strictures
ERCP in, 124:1686
magnetic resonance cholangiography in, 124:1686

Biliary tract
barraging, for postoperative bile duct strictures, long-term results with, 122:1533-ss
development of, transcription factors and, 124:263-ss
disease
book on, 124:579-pmr
gastroenterologist training in, 124:1067-aga
oxysterols in, 121:118, 121:216-e
epithelium
barrier function of, impairment by proinflammatory cytokines (rat), 121:156
Cryptosporidium parvum infection of, 118:248-tmig, 118:368
extrahepatic, pathology of, 125:1553-pmr
imaging of, 124:1686, 125:1565 *correction*
obstruction
farnesoid X receptor in (mice), 125:825
ursodeoxycholic acid in (mice), 123:1238
pathophysiology of, nitric oxide and, 124:737, 124:847-e
surgery of, 121:1524-pmr
tumors
endoscopic ultrasound of, 122:1631
FDG positron emission tomography in, 125:1235-srr
Bilio-pancreatic diseases, textbook on, 116:776-pmr
Biliopancreatic diversion, for obesity, 120:669, 123:882-aga
with duodenal switch, 123:882-aga
Bilirubin
enterohepatic cycling of
and bile acids, cholesterol, and gallstone calcification, 116:1276-c
evidence for, 116:1420, 116:1491-e
and fasting hyperbilirubinemia, 117:1255-c
serum levels of, abnormalities of, evaluation of, 123:1367-aga
BIM26226, and gastrointestinal motility, 120:331-tmig, 120:361
Binge eating, and obesity, 123:882-aga
Biofeedback training
in anorectal disorders
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
for fecal incontinence, 124:1672, 125:1320, 125:1533-e
Biological clocks, and digestive system, 119:536-srr
Biologic therapy
definition of, 122:1592
delivery vehicles for, 122:1592
for inflammatory bowel disease, 122:1592
Biotechnology, roles of academia and dedicated biotechnology companies in, 119:5-ce
Bisacodyl, for constipation, 119:1766-aga
Bismuth
for pouchitis, 124:1636
quadruple therapy, for *Helicobacter pylori* eradication, 123:1763, 125:639-c
triple therapy, for *Helicobacter pylori* eradication, 123:1763
Bisphosphonates, for osteoporosis, 124:795-aga
gastroesophageal effects of, 119:609-tmig, 119:631, 119:866-e
Blacks, colorectal cancer screening in, cost-effectiveness of, 120:848, 120:1043-e
Bleeding, gastrointestinal. *See also* **Hemorrhage, gastrointestinal; Variceal bleeding**
acute
diagnosis and treatment of, 125:1279-pmr
diverticular, urgent endoscopy with endoscopic therapy for, 118:978-ss
upper tract, erythromycin for, 123:1-tmig, 123:17
from angiodysplasia
abnormal von Willebrand factor in, 120:346
prevention of, hormonal therapy in, 121:1033-tmig, 121:1073
lower, urgent endoscopy with endoscopic therapy for, 118:978-ss
obscure
evaluation and management of, 118:197-aga, 118:201-aga
sources of, 118:201-aga
occult. *See also* **Fecal occult blood testing**
etiology of, 118:201-aga
evaluation and management of, 118:197-aga, 118:201-aga
in peptic ulcer disease, management of, hemoclips versus heater probe for, 123:1399-ss
rectal, colonoscopy for, yield of, 123:2151-ss
refractory, from ruptured gastric varices, TIPS for, 118:1270-ss
Bloating, in irritable bowel syndrome, 122:576-ss
Blood donors, hepatitis C virus infection in, risk factors for, 116:784-tmig, 116:893
Blood group antigen-binding adhesin (BabA), as *H. pylori* virulence factor, 118:3-gn
Blood pressure, in cirrhosis, 122:1658
Blood transfusion, requirements, in critical care, 117:1017-ss
Bloom's syndrome, colonic adenomas in, 121:435-crr
Blue rubber bleb nevus syndrome, 118:462-im, 124:1595
Blumer, George, 118:30
B lymphocytes (B cells)
clonally expanded, in human colon, 119:1253
impaired T-cell regulation of, in *H. pylori*-related gastric MALToma, 117:1105
Boas, Izmar Isidor, 119:299
Bochdalek, Vincent Alexander, 122:680
Body fat
distribution of, as health risk, 123:882-aga
in obesity, 123:882-aga
regulation of, plasma leptin and plasma ghrelin in (rat), 124:1188-rc, 124:1532-e
Body mass index (BMI)
assessment of, 122:1677
classification of, and disease risk, 122:1677
and liver fibrosis, 118:996-tmig, 118:1117
and mortality, relationship between, 123:882-aga
in obesity, 123:882-aga
Body weight
attractin and (mice), 117:294-gn
decreased, in pancreatic polypeptide transgenic mice, 117:1427
gain, dieting by adolescents and, 125:1572-gn
and liver fibrosis, 118:996-tmig, 118:1117
loss of, plasma ghrelin levels after, 124:575-ss
regulation of
pancreatic polypeptide and, 124:1325, 124:1542-e
plasma leptin and plasma ghrelin in (rat), 124:1188-rc, 124:1532-e
urocortin and (mice), 116:1281-tmig, 116:1287-rc, 116:1487-e
BON cells, serotonin (5-HT) release, D-glucose and, 121:1400
Bone densitometry
clinical applications of, 124:795-aga
in gastrointestinal disease, 124:795-aga
in liver disease, 125:936-aga, 125:941-aga

in osteoporosis, 124:795-aga
technical aspects of, 124:795-aga
Bone density
after liver transplantation, longitudinal studies of, 125:941-aga
in liver disease, longitudinal studies of, 125:941-aga
measurement of, in liver disease, 125:936-aga, 125:941-aga
Bone loss, in inflammatory bowel disease, 119:1203
genetic factors and, 119:889-tmig, 119:909
Bone marrow cells
as alternative to liver transplantation, 119:891-gn
fusion with liver, brain, and heart cells, 125:1572-gn
Bone mass, peak, lactose malabsorption and intolerance and, 122:1793
Bone mineral density
alendronate therapy and, in Crohn's disease, 119:609-tmig, 119:639, 119:866-e
in primary biliary cirrhosis, vitamin D receptor genotype as predictor of, 118:145, 119:599-c, 119:1805-c
in recently diagnosed IBD, 119:1203, 121:504-c
Bone morphogenetic protein 2
effects on cell growth in vitro, 116:1202
expression in human pancreatic cancer, 116:1202
Botulinum toxin
for anal fissure, 124:233-aga, 124:235-aga, 124:1165-c
long-term follow-up of, 123:112
for chronic anal fissures, 116:221-ss, 117:516-c
for dysphagia in oculopharyngeal muscular dystrophy, 119:1416-c
for masseter muscle spasticity in amyotrophic lateral sclerosis, and PEG placement, 123:1749-c
Bradykinin receptors, B_2, and gallbladder contraction, 125:126
Brain
activity, in irritable bowel syndrome and clinical status, 124:754-cr
gender differences in, 124:1738, 124:1975-e
cortical and subcortical regions in, activation of, by gastric distention, 120:369
edema, ammonia-induced, prevention by hypothermia (rat), 116:686
glucose metabolism, in acute liver failure, hypothermia and, 125:815, 125:976-e
manganese deposition in, in liver disease, 117:640
Brain-derived neurotrophic factor, recombinant human, and colonic transit, 119:1-tmig, 119:41, 119:257-e
Brain-gut axis
pain sensitivity of, in IBS, 119:1418-c
and response to subliminal visceral stimulation, 122:290
Branched-chain amino acids, supplements, in cirrhosis, 124:1723-tmig, 124:1792, 124:1980-e
Brasitus, Thomas A., president of AGA, 118:945
Breast cancer, risk, in CDH1 mutation carriers, 121:1348
Breath testing, for lactose malabsorption, 122:1701
Brenner, David A., 121:241-gn
Bromfenac, hepatotoxicity of, 117:759-ce
Bronchiectasis, and gastroesophageal reflux disease, in children without neurological deficits, 121:1294
Brotman, Martin, 96th president of American Gastroenterological Association, 122:1197-gn, 122:1512
Presidential Address, 125:1878-aga
***BSEP* gene mutations,** and hepatocanalicular bile salt export pump deficiency, 117:1370, 117:1496-e
Budd, George, 118:1050
Budd-Chiari syndrome
in Behçet's disease, 117:526-im
G20210A prothrombin gene mutation and, 120:1059-c
hepatopulmonary syndrome in, 122:896
survival with, factors affecting, 120:578-ss
Budesonide
and antibiotics, combined, for Crohn's disease, 123:33
in autoimmune hepatitis, 120:1502-srr
for collagenous colitis, 122:1-tmig, 122:20, 123:964-tmig, 123:978
versus mesalamine, for active Crohn's disease, 116:1263-ss
prophylaxis, for postsurgical recurrence of Crohn's disease, 116:294
for treatment-dependent autoimmune hepatitis, 119:1185-tmig, 119:1312
and ursodeoxycholic acid, combined, for primary biliary cirrhosis, 117:756-tmig, 117:918
Buerger's disease, intestinal ulcers in, 125:911-cr
Bulimia nervosa, ondansetron therapy for, 119:271-ss
Bupropion, Crohn's disease remission with, 121:1260-c, 125:1290-c
Burks, Thomas Franklin III, 121:2-gn
Burnett, Charles Hoyt, 119:1202
Burn injury, parenteral nutrition in, 121:966-aga, 121:970-aga
Butyrate
cell differentiation and apoptosis induced by, resistance to, during spontaneous Caco-2 cell differentiation, 120:889
and 5-fluorouracil, antitumor synergy of, in human colorectal cancer xenografts, 120:874
and nuclear factor κB activity in colonic epithelial cells, 118:724, 118:798-e
in ulcerative colitis, 117:745-c

Caco-2 cells, differentiation of, cell cycle arrest and, 116:1358
Caffeine plus ephedrine, for obesity, 120:669
Calcification, vascular, in chronic renal failure, 122:495-cr
Calcitonin, for osteoporosis treatment, 124:795-aga
Calcitonin gene-related peptide (CGRP), and adaptive cytoprotection in gastric mucosa, 120:134
Calcium
and apoptosis in intestinal macrophages, 123:1543
cardiomyocyte regulatory system for, alteration in cirrhosis, 121:1209
and chemoprevention, 116:1261-ss
deficiency of, treatment of, 122:1677
dietary, and host resistance to infectious diarrheal disease, 125:286-tmig, 125:469
influx, and mechanical tone in colon from dystrophic *(mdx)* mice, 120:1430
intercellular, HBx-triggered release of, 122:255-gn
for osteoporosis treatment, 124:795-aga
and regulation of hepatocellular bile acid transport, 117:433-srr
signaling
oscillatory, in hepatocytes, attenuation by ANP (rat), 123:1291
in pancreatic acinar cells, transporter-mediated bile acid uptake and (rat), 122:1941
Calcium-binding protein s100A4, in colorectal cancer, prognostic significance of, 123:1425-tmig, 123:1478

Calcium-channel blockers, and gastrointestinal hemorrhage, 119:1416-c
Calcium channels
L-type
in enterochromaffin cells from duodenal crypts (guinea pig, human), 117:1363
in inflamed circular smooth muscle cells of colon (dog), 120:331-tmig, 120:480
M_2 muscarinic receptor coupling to, in colonic circular smooth muscle (rabbit), 123:827
mechanosensitive, in intestinal smooth muscle cells, 117:900
Calcium receptor
expression in stomach (rat), 116:118
in human antral gastrin cells, mechanism of action of, 120:1128, 120:1279-e
Calcium waves
in hepatocytes, type II inositol 1,4,5-trisphosphate receptor and (rat), 122:1087
in pancreatic acinar cells, inositol triphosphate receptor and ryanodine receptor activation and (rat), 122:415
in small intestine, propagation and neural regulation of (guinea pig), 118:892
Calot, Jean-François, 123:–
Calpain, in ischemic liver injury (rat), 116:2-tmig, 116:168
Calprotectin, fecal
in differentiation between organic and nonorganic intestinal disease, 123:401-tmig, 123:450
as predictive marker for IBD relapse, 119:1-tmig, 119:15
Camostat mesilate, in prevention of hepatic fibrosis (rat), 120:1784
Cancer. *See also* Malignancy
anal. *See* Anal canal, cancer of
celiac disease and, 120:636, 120:1526-aga
colon. *See* Colorectal cancer
colorectal. *See* Colorectal cancer
esophageal. *See* Esophageal cancer
esophagogastric, micrometastases, detection in resected rib, 116:509-tmig, 116:543
gastric. *See* Gastric cancer
gastrointestinal
microsatellite unstable, WISP-3 mutations in, 124:270-c
treatment of, 124:265-pmr
hepatic. *See also* Hepatocellular carcinoma (HCC)
treatment of, 119:877-pmr
I1307K *APC* gene variant as risk factor for, in Israeli Jews, 116:54, 116:210-e
intestinal, mouse models of, 124:762-srr
lung. *See* Lung cancer
obesity and, 123:882-aga
pancreatic. *See* Pancreatic cancer
parenteral nutrition in, 121:966-aga, 121:970-aga
perianal Crohn's disease and, 125:1503-aga, 125:1508-aga
rectal. *See* Colorectal cancer
risk
in CDH1 mutation carriers, 121:1348
in celiac disease, 123:1428, 123:1726-e
in Peutz-Jeghers syndrome, 119:1425-tmig, 119:1447
screening for
book on, 125:271-pmr
needed improvement in, presidential panel's report on, 122:3-gn
targeted chemotherapy for, LST-2 and, 120:1689
treatment of, needed improvement in, presidential panel's report on, 122:3-gn
upper gastrointestinal
book on, 125:987-pmr
endoscopic detection of, 119:872-ss
Cancer Genome Project, 119:1427-gn
Cannabinoids
antiemetic action of, 123:655-c
mediation by CB1 receptors in brainstem (ferret), 121:767-rc
and appetite, 123:655-c
endogenous
and cholera (mice), 125:765, 125:973-e
in cirrhosis (rat), 122:85
and colorectal cancer, 125:677, 125:973-e
inhibition of gastroesophageal reflux (dog), 123:1129
Canrenone, antifibrogenic effects on hepatic stellate cells, 124:504
Capsaicin, intraileal, and gut motility (dog), 123:1904
Capsule endoscopy, in small bowel, 124:1150-ss
Captopril, attenuation of hepatic fibrosis by (rat), 121:148
Carbohydrate
absorption, in pancreatic insufficiency (dog), 116:431
colonic fermentation of, and LES function in gastroesophageal reflux disease, 124:894
dietary
requirements for, 122:1677
in parenteral nutrition, 121:970-aga
restriction of, effects of, 125:650-gn
Carbon dioxide (CO_2), and colonic sodium absorption (rat), 122:318
Carbonic anhydrase, in duodenal bicarbonate secretion (rabbit), 119:406
Carbonic anhydrase II, autoantibodies against, in autoimmune pancreatitis, 118:458-tmig, 118:573, 118:626-e
Carbonic anhydrase IX, gene for *(Car9),* mutations of, and gastric hyperplasia (mice), 123:1889
Carbon monoxide
from heme catabolism, protective effect against hepatobiliary dysfunction (rat), 120:1227, 120:1288-e
inhalation, in prevention of postoperative ileus (mice), 124:377
role in internal anal sphincter smooth muscle (opossum), 118:477
therapeutic potential, in IBD, 119:612-gn
Carcinogenesis
in Caco-2 cells, PKC-δ and, 120:1700, 120:1868-e
c-K-*ras* mutations in, 118:995-tmig, 118:1045
hepatic, pathways of, genetic alterations and, 120:1763
NF-κB/Rel/IκB in, 118:1208-srr
Ras-induced transformation in, NF-κB/Rel activity and, 118:1208-srr
Carcinoid tumors, in hypergastrinemic patients, *Reg* gene mutation and, 116:1310, 116:1489-e
Cardiomyopathy, cirrhotic
cellular calcium regulatory system alteration in (rat), 121:1209
pathogenesis of, nitric oxide in (rat), 118:937
Cardiotrophin-1, up-regulation in regenerating liver, and cytoprotective effects (rat), 125:3-tmig, 125:192
Cardiovascular disease, obesity and, 123:882-aga
Caroli, Jacques, 118:486
Carvedilol, effects on portal hypertension, 118:802-ss
Case Reports
Acquired myopathic intestinal pseudo-obstruction may be due to autoimmune enteric leiomyositis, 122:1132
Acute hepatitis induced by greater celandine *(Chelidonium majus),* 117:1234
Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome, 124:754

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report, 120:995
Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile, 125:1227
Consecutive regression of concurrent laryngeal and gastric MALT lymphoma after anti-*Helicobacter pylori* therapy, 124:537
Covert transmission of hepatitis C virus during bloody fisticuffs, 119:507
Development of interstitial cells of Cajal in a full-term infant without an enteric nervous system, 120:561
Diffuse esophageal leiomyomatosis with perirectal involvement mimicking Hirschsprung disease, 120:216
Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma, 122:500
Dysfunctional LAD-1 neutrophils and colitis, 121:958
Dysphagia in a patient with lateral medullary syndrome: insight into the central control of swallowing, 121:420
Esophageal stenosis in childhood: dystrophic epidermolysis bullosa without skin blistering due to collagen VII mutations, 122:220
Evolution of acute cytomegalovirus gastritis to chronic gastrointestinal dysmotility in a nonimmunocompromised adult, 116:953
Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene, 122:1493
Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene, 120:210
Familial liver adenomatosis associated with hepatocyte nuclear factor 1α inactivation, 125:1470
A family with gastrointestinal amyloidosis associated with variant lysozyme, 123:1346
Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis, 118:431
Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty, 118:192
A homozygous *HFE* gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin, 122:789
Human papillomavirus type 16-associated primary squamous cell carcinoma of the rectum, 120:988
Intestinal ischemia and peripheral gangrene in a patient with chronic renal failure, 122:495
Ischemic colitis during treatment with alosetron, 120:557
Ischemic necrosis of bile ducts complicating Schönlein-Henoch purpura, 117:211
Liver and kidney foreign bodies granulomatosis in a patient with malocclusion, bruxism, and worn dental prostheses, 121:1234
Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy, 124:217
Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement, 116:187
Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes, 121:427
Mesenteric inflammatory veno-occlusive disorder: a rare entity mimicking inflammatory bowel disorder, 125:236
Mitochondrial neurogastrointestinal encephalomyopathy: manometric and diagnostic features, 116:959
Molecular evidence for the same clonal origin of both components of an adenosquamous Barrett carcinoma, 122:784
A multidrug resistance gene 3 mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis, 124:1037
Multiple ulcers with perforation of the small intestine in Buerger's disease: a case report, 125:911
A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer, 120:1271
Numerous colonic adenomas in an individual with Bloom's syndrome, 121:435
Pain as a complication of use of opiate antagonists for symptom control in cholestasis, 125:591
A patient with improvement of ulcerative colitis after appendectomy, 119:502
Pediatric-onset primary biliary cirrhosis, 125:1476
Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy, 120:984
Relapsing ulcerative colitis associated with spinal cord stimulation, 117:215
The relationship between infliximab treatment and lymphoma in Crohn's disease, 117:1433
Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy, 117:1229
Severe villus atrophy and chronic malabsorption induced by azathioprine, 124:1950
Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression, 124:1946
Successful infliximab treatment for steroid-refractory celiac disease: a case report, 122:800
Successful management of Crohn's disease of the ileoanal pouch with infliximab, 117:429, 125:631-c
Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus, 119:1382
Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis, 122:2026
A syndrome of hereditary pancreatic adenocarcinoma and cysts of the liver and kidneys, 122:796
Syngeneic living-donor liver transplantation without the use of immunosuppression, 123:1341
Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine, 120:1483
Treatment of vitamin D deficiency due to Crohn's disease with tanning bed ultraviolet B radiation, 121:1485

Caspase
inhibition
by nitric oxide-releasing aspirin, 116:1089
by NO-aspirin derivative, in concanavalin A-induced hepatitis, 118:404
in mucosal immunity, 122:1334

Caspase-8, mutations, in colorectal cancer, 125:708

Caspase 9, and killing of hepatic stellate cells by activated Kupffer cells, 123:845

Caspase recruitment domain (CARD) motifs, in Crohn's disease, 122:847-tmig, 122:853-rc, 122:1160-e
Castell, Donald O., Presidential Address (1999), 117:1459-aga
Cataracts, obesity and, 123:882-aga
β-Catenin
in clinical late-stage colon cancer, 122:60
gene mutations, in aberrant crypt foci from FAP and non-FAP cases, 121:599
in intestinal epithelial cells, leukotrienes and, 119:890-tmig, 119:1007
in liver development, 124:202
nuclear signaling, in intestinal epithelial cells, *Bacteroides fragilis* enterotoxin and, 124:392
oncogenic, and APC-induced cell cycle arrest, 123:751, 123:935-e
PPARγ and, 125:619-ss
Caveolin, enhanced expression and interaction with eNOS, in cirrhotic liver (rat), 117:1222
***CCR5*-Δ32**
and HCV infection, 124:352, 124:867-c, 124:868-c, 124:1558-c
and resistance to HIV-1, 124:352, 124:867-c, 124:1558-c
CD (cluster of differentiation)
CD4
antibodies to, therapy with, for inflammatory bowel disease, 122:1592
HCV-specific, and hepatitis C recurrence, 117:756-tmig, 117:933, 117:1012-e, 118:807-c
after liver transplantation, 117:756-tmig
T cells expressing
in experimental pancreatitis (mice), 118:458-tmig, 118:582, 118:626-e, 119:881-c
in gastric mucosa, in acute *H. pylori* infection (Rhesus macaque), 118:247-tmig, 118:307
CD8, HBV-specific
direct ex vivo analysis of, 117:1386
pathogenetic role of, in hepatitis B, 117:1386
CD18
dysfunction, in leukocyte adhesion deficiency 1, 121:958, 121:1008-e
phagocytes expressing, in extraintestinal dissemination of *S. typhimurium,* 118:803-ss
CD23, and transepithelial antigen transport in sensitized intestine (mice), 121:370
CD34, in human biliary epithelial progenitor cells, 120:534
CD58
as costimulatory molecule for IEC-induced T-cell proliferation, 116:1023-tmig, 116:1054
polarized expression and function in intestinal epithelial cells, 116:1023-tmig, 116:1054
CD86, expression on epithelial cells, in inflamed colonic mucosa, 117:521-tmig, 117:536, 117:726-e
CD94, intraepithelial lymphocytes expressing, in celiac disease, 118:816-tmig, 118:867
CD95, ligand-independent surface trafficking of, and bile acid-induced apoptosis in hepatocytes (rat), 122:1411
CD154/CD40 pathway
in chronic murine colitis, 119:715
in development of acute ileitis (mice), 122:762
CDC2 kinase, activity, IFN-α inhibition of neuroendocrine tumor cell growth and, 118:650-tmig, 118:735
CD1d, as antigen-presenting molecule on intestinal epithelial cells (human, mouse), 124:1420
CDH1 mutation carriers, risk of gastric and breast cancer in, 121:1348
CD40 ligand
in inflammatory response in IBD, platelets and, 124:1249
in pancreatitis and pancreatitis-associated lung injury (mice), 121:184
CDP571
for active Crohn's disease, 120:1317-tmig, 120:1330
biologic therapy with, for inflammatory bowel disease, 122:1592
for Crohn's disease with fistulous complications, 119:1132-srr
CDP870, clinical response to, in Crohn's disease (abstract), 125:606-aga
CD95 (Apo-1/Fas) receptor/ligand system, in hepatic immunoregulation (rat), 116:666
Cdx1, protein product, and differentiation of intestinal epithelial cells (rat), 117:1266-tmig, 117:1316
CDX2, regulation of liver intestine-cadherin, 123:1565
Cdx-2, expression in colonic epithelium, *PTEN* and TNF-α regulation of, 123:1163, 123:1395-e
Ceftriaxone, resistance, in *Salmonella* from antibiotic-treated cattle, 119:3-gn
Celebrex, gastrointestinal effects of, 117:4-gn
Celecoxib
gastrointestinal safety of, 119:521-srr
and NSAID-induced gastric damage (rat), 119:610-tmig, 119:706
in prevention of colorectal neoplasia, 125:404
in prevention of familial adenomatous polyposis, 119:1797-ss
in prevention of intestinal polyposis, 122:234-ss
Celiac disease
AGA medical position statement on, 120:1522-aga
AGA technical review on, 120:1526-aga
associated diseases, 120:636, 120:1526-aga
and autoimmune disease, 120:636
autoimmunity in, 119:234-srr, 119:243-srr
duration of exposure to gluten and, 117:291-tmig, 117:297
bone disease in, 124:791-aga, 124:795-aga
cancer risk in, 123:1428, 123:1726-e
$CD94^+$ intraepithelial lymphocytes in, 118:816-tmig, 118:867
cereal toxicity for, 125:1105, 125:1264-e
childhood, cytokines in intestinal T cells in, 123:667, 125:1560-c
clinical features of, 120:636, 120:1526-aga
complications of, 120:1526-aga
definition of, 120:1526-aga
detection of, anti-endomysial antibody in, 122:246-c
diagnosis of, 116:1273-c, 120:636, 120:1526-aga, 125:279-c
epidemiology of, 116:237-ce, 120:636, 120:1526-aga
epithelial changes in, IL-15 and, 119:996
evaluation for, 122:1701
as food allergy, 120:1026-aga
fracture risk in, 125:429
genetics of, 119:234-srr, 120:1526-aga
gliadin peptide transport and absorption in, 125:647-tmig, 125:696
gluten-free diet in, and reversal of liver failure, 122:880, 123:2158-c
gluten intolerance in
protein homology in grains and, 125:1105, 125:1264-e
structural basis for, 125:268-ss
gluten response in, diversity of, 122:1729, 122:2072-e
handbook on, 119:595-pmr
HFE gene mutations in, protective effect against iron deficiency, 123:444
histopathology of, 119:234-srr

historical perspective on, 120:1526-aga
intraepithelial lymphocyte homeostasis in, IL-15 and, 125:648-tmig, 125:730
iron deficiency in, *HFE* gene mutation and, 124:1562-c, 124:1563-c
and irritable bowel syndrome, differentiation of, 122:2086-ss
latent/potential, in irritable bowel syndrome, 121:1329, 121:1512-e, 123:954-c, 123:1408-c
major non-HLA locus in, on chromosome 19, 125:1032
and malignancy, 120:636, 120:1526-aga, 125:40
microscopic and collagenous colitis in, 116:778-c
oligosymptomatic or silent, screening for, 119:234-srr
pathogenesis of, 116:1277-c, 119:234-srr, 120:1526-aga
gliadin T-cell epitopes and, 123:803, 123:939-e
pathology of, 120:1526-aga
refractory, 119:243-srr, 120:636
chromosomal abnormalities in, 125:40
screening for, 120:636
in chronic liver disease, 125:1289-c
limitations of anti-guinea pig liver transglutaminase IgA in, 120:586-c
serologic tests for, 124:585-c
serum IgA from patients with, inhibition of human T84 intestinal crypt epithelial cell differentiation, 116:510-tmig, 116:566
steroid-refractory, infliximab for, 122:800-cr
T-cell recognition of high-molecular-weight glutenins in, 125:337
TNF-α production in intestinal T cells in, 125:1560-c
treatment of, 120:636, 120:1526-aga
types of, 120:1526-aga

Celiac plexus block, endoscopic ultrasound-guided, 122:1631

Cell adhesion molecules, and leukocyte recruitment in colon cancer, 122:1121

Cell cycle
arrest, and Caco-2 cell differentiation, 116:1358
G_1/S progression, regulation by *APC* gene, and colorectal carcinogenesis, 123:751, 123:935-e
and intestinal cell differentiation, 120:423

Cell migration, polyamines and RhoA in, 123:196

Cell motility, aminopeptidase N in, 122:376

Cell proliferation
in liver development, β-catenin and, 124:202
rhythms of, in cornea and digestive system, 119:536-srr

Cellular physiology, gastrointestinal, gastroenterologist training in, 124:1095-aga

Centers for Disease Control and Prevention (CDC), study of rotavirus vaccine, 117:758-gn

Central hypoventilation syndrome, congenital, esophageal dysmotility in, 122:1258

Central nervous system (CNS), in irritable bowel syndrome, 123:2108-aga

Central pattern generator, in control of swallowing, 121:420-cr

Ceramide, and *H. pylori*-induced IL-8 production in gastric cancer cell lines, 116:1330

Cerebral blood flow, alosetron and, 123:969

Cerebral cortex, and response to subliminal visceral stimulation, 122:290

Cerebral edema, in liver failure, 125:815, 125:976-e

Cerebrovascular disease, obesity and, 123:882-aga

Cerivastatin, cytotoxic activity of, in pancreatic cancer, 123:1747-c

Cerulein pancreatitis, NF-κB/Rel activation in, 116:420, 116:489-e

Chagas, Carlos Justiniano Ribeiro, 125:1031

Chagas' disease, achalasia with, muscarinic cholinergic receptor autoantibodies in, 117:798

Chelidonium majus, acute hepatitis induced by, 117:1234-cr

Chemoattractants, epithelial
characterization of, 120:60, 120:291-e
interferon-inducible, production of, 120:49, 120:291-e

Chemoembolization, in hepatocellular carcinoma, 122:1609

Chemokine receptor
CCR1, deficiency, reduction of *C. difficile* toxin A effects in (mice), 122:600-tmig, 122:725
CCR5
and $CD8^+$ T-cell migration in inflamed small intestine, 125:491
decreased expression in intestinal macrophages, and impaired permissiveness to HIV-1, 116:1043
in pathobiology of hepatitis C, 122:1721-rc, 122:2069-e, 124:867-c, 124:868-c
CCR9, in small intestinal Crohn's disease, 121:246-rc
expression on intestinal epithelial cells, 117:359

Chemokines
biliary production of, obstruction and (rat), 118:1157
CCL21, and inflammation and fibrosis in hepatitis C, 125:1060
expression of
CCK-8-induced, ethanol diet and (rat), 117:706
in chronic pancreatitis, 118:356
in normal pancreas, 118:356
in regulation of lymphocyte homing to intestinal mucosa, 120:49, 120:60, 120:291-e
secretion, in human pancreas, cytokine regulation of, 119:211
thymus-expressed, in small intestinal Crohn's disease, 121:246-rc

Chemonociception, and gastric injury (rat), 125:1410

Chemoprevention
calcium and, 116:1261-ss
of colorectal cancer, 116:1003-ss, 119:267-ss
NAG-1 gene and (mouse, human), 122:1388
NSAIDs in, 125:285-tmig, 125:328, 125:404
by PPAR-γ ligands (mice), 124:281-tmig, 124:361, 124:564-e
of familial adenomatous polyposis
COX-2 inhibition in, 119:1797-ss
with sulindac, 123:379-ss

Chemotherapy
delayed emesis after, treatment of, 117:737-ss
epithelial sensitivity to, stress and (rat), 124:660
hepatitis B reactivation after, preemptive lamivudine therapy for, 125:1742
for hepatocellular carcinoma, 122:1609
nausea and vomiting caused by, 120:263-aga
for pancreatic cancer, AGA technical review on, 117:1464-aga
targeted, in gastrointestinal cancer, LST-2 and, 120:1689

Chest pain
in achalasia
age and, 117:1259-c
patient characteristics and course of, 116:1281-tmig, 116:1300
esophageal contraction and, 116:29
noncardiac, high-dose omeprazole in, 116:226-c
serotonin and, 121:495-ss

Child, Charles Gardner III, 119:928

Children. *See also* Pediatrics
constipation in, follow-up of, 125:357
electrogastrography in, 117:453-vidd
Helicobacter pylori reinfection in, 117:291-tmig, 117:336
obesity in, 125:1908-pmr
paramyxovirus infections in, and subsequent inflammatory bowel disease, 116:783-tmig, 116:796, 116:988-e, 117:1253-c
primary biliary cirrhosis in, 125:1476-cr
urease-based test for *H. pylori* in, sensitivity of, 116:1506-c
Child-Turcotte-Pugh classification, of candidates for liver transplantation, 120:749
Chinese
colorectal cancer incidence in, 125:1913-c
colorectal cancer screening in, 124:608
Chinese herbal medicine, for irritable bowel syndrome, 123:2108-aga
Chloride, secretion
cAMP-stimulated, in NKCC1-null murine duodenum, 123:531
CFTR-mediated, 119:32
and colonic crypt bicarbonate secretion (rat), 118:101, 118:1282-c
in colonic epithelial cells, growth hormone and, 125:1114
from homozygous ΔF508 murine intestines, CFTR activation and, 116:1379
in human colon, stimulation by neurotensin, 119:348
in intestinal epithelial T84 cells, potentiation of, by oxidants, 120:2-tmig, 120:89
Chloride/bicarbonate exchanger, duodenal apical (rabbit, rat, human), 122:600-tmig, 122:709
Chloride channels
CFTR, in crypt cells, inhibitory effect of boiled rice on, 116:1282-tmig, 116:1342
epithelial cAMP-dependent, sucrase-isomaltase as, 120:117, 120:299-e, 121:741-c
high-conductance, and pacemaker currents in interstitial cells of Cajal, 123:1627
Cholangiocarcinoma
bile acid-mediated COX-2 expression in, 122:984
FDG positron emission tomography in, 125:1235-srr
Helicobacter sp. in liver and, 120:323-c
magnetic resonance cholangiography in, 124:1686
photodynamic therapy for, 125:1295-tmig, 125:1355, 125:1536-e
PSC-associated, $p16^{INK4a}$ promoter mutations and, 123:1090
Cholangiocytes
in bile flow and biliary bicarbonate excretion (rat), 121:396
development of, transcription factors and, 124:263-ss
fibrocystin expression, and ciliary structure, in PCK rat, 125:1303-rc
growth of, bile acid modulation of (rat), 123:1226
Mdr1a in, molecular identification and functional characterization of (rat), 119:1113
oxidative DNA damage in, 120:190
proliferation
bile acid-regulated, 116:179
cholinergic modulation of (rat), 117:191
estrogens and (rat), 119:1681, 123:336
secretory activities
bile acid modulation of (rat), 123:1226
cholinergic modulation of (rat), 117:191
corticosteroids and (rat), 122:1057
inhibition by proinflammatory cytokines (rat), 121:156
nitric oxide and, 124:737, 124:847-e
vasoactive intestinal polypeptide and (rat), 117:420
Cholangiopancreatography, endoscopic ultrasound guidance for, 122:1631
Cholangiopathy, ischemic, in Schönlein-Henoch purpura, 117:211-cr
Cholangitis. *See also* Primary sclerosing cholangitis
acute, 121:1039-im
Cholecystectomy
after treatment of choledocholithiasis, 125:617-ss
and esophageal adenocarcinoma, 121:548
and intestinal cancer, 121:542
Cholecystokinin (CCK)
CCK-8
hepatic uptake of, by Oatp4 (rat) and OATP8 (human), 121:1185
lack of response to, in human pancreatic acinar cells, 121:1380
pancreatitis caused by, ethanol diet and (rat), 117:706
regulation of pancreatic digestive enzyme protein synthesis (rat), 119:1731
regulation of Rab4, 116:943
secretion, fatty acid chain length and, 116:46
Cholecystokinin (CCK) A receptors
expression in neurons of gastrointestinal tract (rat), 117:1136
lack of, in human pancreas, 121:1380
Cholecystokinin (CCK) B receptors
lack of, in human pancreas, 121:1380
in pancreatic duct-like cells (rat), 121:940
Cholecystokinin (CCK)/gastrin receptors, pancreatic function of (transgenic mice), 122:428
Cholecystokinin (CCK) receptors
CCK_1, distribution in human pancreatic tissues, 125:98
CCK_2
in differentiation and function of gastric ECL cells (mice), 123:577
distribution in human pancreatic tissues, 125:98
and gastrin-induced proliferation in Barrett's metaplasia, 124:615, 125:1912-c, 125:1921-c
Choledocholithiasis
diagnosis of, ERCP in, 124:1686
endoscopic ultrasound in, 122:1631
magnetic resonance cholangiography in, 124:1686
treatment of
cholecystectomy after, 125:617-ss
ERCP in, 124:1686
Cholelithiasis
ABCB4 gene mutation-associated, in adults, 125:452
cholesterol, 121:1014-ss
colonic deoxycholic acid formation in, 119:610-tmig, 119:806, 120:1310-c
genetic susceptibility to and pathogenesis of (mice), 125:868
MDR3 gene defect in, 120:1459, 120:1549-e
MDR3 mutation and, 120:1459, 120:1549-e, 124:1037-cr, 125:1922-c
Cholera
epidemic, 123:403-gn
vaccine, development of, 123:403-gn
Cholera toxin, secretion induced by endogenous cannabinoid and (mice), 125:765, 125:973-e
tachykinins and (rat), 119:890-tmig, 119:1037
Choleresis, TUDC- and hypo-osmolarity-induced, integrins and Src in, 124:1476
Cholestasis. *See also* Progressive familial intrahepatic cholestasis
bile salt export pump expression in (rat), 118:163

chronic, opioid withdrawal-like reaction precipitated by naltrexone in, 118:431-cr
drug- and estrogen-induced, inhibition of bile salt export pump in (rat), 118:422
estrogens and (rat), 123:336
Fas-mediated hepatocyte apoptosis in (mice), 117:669, 117:732-e
with home parenteral nutrition, management of, 124:1651
inositol 1,4,5-trisphosphate receptor in bile duct epithelia and, 125:1175
neonatal, bile acid synthetic defect and, 124:217-cr
obstructive
adaptive regulation of hepatic and renal bile salt transporters in (rat), 121:1270-tmig, 121:1473
Mrp2 expression in, regulation of (rat), 123:599
opiate antagonists for, pain with, 125:591-cr
pathogenesis of, 120:321-c
of pregnancy, MDR3 mutation and, 124:1037-cr, 125:1922-c
and sensitivity to locomotor-activating effects of corticotropin-releasing hormone (rat), 122:681
septic
early events in, 116:401, 116:486-e
prevention of, heat stress and (rat), 122:962
sulindac-induced, pathophysiology of, 117:962
and vesicular trafficking and cell polarity in hepatocytes (rat), 121:1033-tmig, 121:1176

Cholesterol
absorption
dietary sphingomyelin and, 122:947
pancreatic phospholipase A_2 and (mice), 120:1193
sterol carrier protein 2 and (mice), 119:1708
and bile acids, gallstone calcification, and enterohepatic circulation of bilirubin, 116:1276-c
crystal nucleation and growth, recombinant gallbladder mucin polypeptide and, 116:784-tmig, 116:936
dietary
accumulation in sitosterolemia, ABC transporter mutations and, 121:1255-ss
biliary secretion of, apolipoprotein E and (mice), 118:650-tmig, 118:772
hepatic synthesis and storage of, sterol carrier protein 2 and (mice), 119:1708
metabolism
ATP-binding cassette transporter A1 (ABCA1) and, 120:1203
manipulation of, by activation of deorphanized nuclear receptors, 120:1054-ss
plasma membrane, effects on gallbladder muscle contractility and membrane fluidity, 116:678
in regulation of sterol 12α-hydroxylase (rat), 118:599
solubility in bile, gallbladder epithelial dysfunction and, 118:912

Cholesterol gallstones
diet-induced formation of, apolipoprotein E and (mice), 118:650-tmig, 118:772
formation of, 121:1014-ss
chromosomal organization of candidate genes involved in (mice), 120:221-srr
colonic deoxycholic acid formation in, 120:1310-c
gallbladder lipid absorption and, 118:912
genetic susceptibility to and pathogenesis of (mice), 125:868
MDR3 gene defect and, 120:1459, 120:1549-e
mucin and, 116:784-tmig, 116:936

Cholic acid
biosynthesis, regulation of (rat), 118:599
and hepatocellular transporter expression (mice), 121:170

Cholinergic system, and cholangiocyte proliferation and secretion, 117:191

Chromoendoscopy, 120:749
in Barrett's esophagus, 122:1569

Chromogranin A-luciferase fusion gene, expression
gastrin-dependent, in transgenic mouse, 121:43
neuroendocrine-specific, in transgenic mouse, 121:43

Chromosome 1, abnormalities, in refractory sprue, 125:40

Chromosome 19, major non-HLA locus on, in celiac disease, 125:1032

Chromosome 22, allelic loss on, in colorectal cancer, 117:831

Chromosome 12q, candidate genes for IBD susceptibility on, 117:1029-c

Chromosomes, changes in, and colorectal cancer progression, 123:1109

Chronic fatigue syndrome, comorbidity with irritable bowel syndrome, 122:1139-srr

Chylomicrons, postprandial formation of, absorption, biliary lipids and, in *Mdr2*$^{-/-}$ mice, 118:173, 118:225-e

Chylous ascites, in yellow nail syndrome, octreotide for, 116:1017-c

Chymotrypsinogen system, molecular genetics of, 119:277-c

Cigarette smoke, and inflammatory bowel disease (rat), 117:756-tmig, 117:877, 117:884, 117:1008-e

Cilansetron, for irritable bowel syndrome, 123:2108-aga

Ciprofloxacin
and budesonide, combined, for Crohn's disease, 123:33
for Crohn's disease with fistulous complications, 119:1132-srr
and ulcerative colitis, 117:280-c, 117:282-c

Circadian rhythms
and digestive system, 119:536-srr
traditional explanation for, 119:536-srr

Circular muscle
colonic, inflammation of
arachidonic acid and (dog), 119:1-tmig, 119:62
PKC isozymes in (dog), 122:483
jejunal, sodium channel in, 122:178
sigmoid, contraction, NK_2 receptors and, 119:51
of small intestine, propagation and neural regulation of calcium waves in (guinea pig), 118:892

Circulation, hyperdynamic, in cirrhosis, 122:1658

Cirrhosis. *See also* Primary biliary cirrhosis (PBC)
advanced, TIPS placement in, predictors of outcome with, 118:2-tmig, 118:138
antifibrinolytic factor deficiency in, 121:131
aortic eNOS in (rat), 122:1869
arterial vasodilation in, site and mechanism of, 122:1658
ascitic
regional sympathetic nerve activity in, 122:1538-ss
TIPS for, 124:1700
bacterial translocation in, prokinetics and, 120:314-ss
biliary
in adulthood, MDR3 mutation and, 124:1037-cr
in Schönlein-Henoch purpura, 117:211-cr
blood pressure in, 122:1658

branched-chain amino acid supplements in, 124:1723-tmig, 124:1792, 124:1980-e
cardiocirculatory dysfunction in, 122:1658
cardiomyopathy in
cellular calcium regulatory system alteration in (rat), 121:1209
pathogenesis of, nitric oxide in (rat), 118:937
with coagulopathy, liver biopsy in, safety and efficacy of recombinant factor VIIa in, 123:118
complications of, current management of, 120:726
cryptogenic
and diagnosis of nonalcoholic fatty liver disease, 123:1705-aga
nonalcoholic steatohepatitis and, 123:134, 123:375-e
development of, in UDCA-treated patients with primary biliary cirrhosis, 122:599-tmig, 122:652
endogenous cannabinoids in (rat), 122:85
endothelin receptor blockade in (rat), 116:161
energy expenditure and malnutrition in, leptins and, 119:1425-tmig, 119:1656
esophageal varices in
and anticoagulation therapy for portal vein thrombosis, 122:2095-c
endoscopic screening for, 122:1620
cost-effectiveness of, 122:1620
recommendations for, 122:1620
health-related quality of life in, 120:170, 120:305-e
hepatic
genetic aberrations in, hepatocellular carcinogenesis, 121:699
hepatopulmonary syndrome in, prognostic significance of, 125:1042, 125:1261-e
nitric oxide and (rat), 117:1222
portopulmonary hypertension with, 125:622-ss
vascular tone in, cysteinyl leukotrienes and (rat), 119:794
hepatic arterial contraction in, selective alteration of, 118:765
hepatic artery flow change and hepatocyte oxygenation in, 117:1257-c
hepatic artery flow volume and reserve in, assessment of, 116:906
in hepatitis C, reversibility of, after medical treatment, 122:1195-tmig, 122:1303, 122:1525-e, 124:584-c, 124:1561-c, 125:629-c
hepatorenal syndrome in, terlipressin and, 122:922
in hereditary hemochromatosis, alcohol and, 122:281, 122:563-e
with high risk for esophageal varices
endoscopic screening in
cost-effectiveness of, 122:1620
recommendations for, 122:1620
endoscopic therapy in, cost-effectiveness of, 122:1620
medical therapy in, cost-effectiveness of, 122:1620
hyponatremia in, treatment with vasopressin receptor antagonist, 124:933
intrahepatic vascular resistance in, 5-lipoxygenase inhibition and (rat), 122:387
obesity and, 125:1053
oxidative drug metabolism in, 116:915
parkinsonian signs in, correlation with basal ganglia alteration detected on MRI and MRS, 119:774
portal and mesenteric venous thrombosis in, 123:1409-c
portal hypertension in
Akt signaling in (rat), 125:522
angiotensin II receptor antagonists for, 121:240-tmig, 121:382, 121:389, 121:487-e
portal hypertensive gastropathy in
natural history of, 119:181
TIPS for, 118:816-tmig, 118:905
portal pressure in, response to long-term losartan versus propranolol, 122:1543-c, 122:1544-c
postprandial hemodynamics in, effects of long-term propranolol and octreotide on, 122:915
preascitic
regional sympathetic nerve activity in, 122:1538-ss
sodium retention in, pathogenesis of, 124:858-ss
profibrinolytic factor levels in, 121:131
protein kinase C isoforms and aortic hyporeactivity in (rat), 119:2-tmig, 119:201
refractory ascites in
albumin therapy for, 125:1283-c
TIPS for, 123:1757-tmig, 123:1839, 125:997-c
renal function in, 122:1658
cyclooxygenase 2 inhibition and (rat), 116:1024-tmig, 116:1167
spontaneous bacterial peritonitis in, risk of, 117:292-tmig, 117:414, 117:495-e
treatment of
hepatic oxygen supplementation in, 117:1025-c
hepatocyte xenotransplantation for (rat), 124:282-tmig, 124:422, 124:568-e
variceal bleeding in
emergency sclerotherapy versus vasoactive drugs for, 124:1174-tmig, 124:1277
prevention, β-blocker plus nitrate for, 119:1170-ss
vascular responsiveness in, alterations of, 116:387
vascular tone in, regulation of, angiotensin II and, 118:565
Cisapride, 119:1766-aga
and bacterial translocation in cirrhosis, 120:314-ss
gastrointestinal use of, surveillance of, 119:1429-ce
Citation analysis, 122:257-ce
Citrulline, plasma level of
as marker for intestinal failure in short-bowel syndrome, 119:1425-tmig, 119:1496
in villous atrophy-associated small bowel disease, 124:1210
c-Jun N-terminal kinase (JNK)
and bile acid-induced apoptosis in hepatocytes (rat), 122:1411
and butyric acid-induced apoptosis in colon cancer cells, 120:71
c-*kit* gene
germline mutation of, and familial gastrointestinal stromal tumor with hyperpigmentation, 120:210-cr
in human biliary epithelial progenitor cells, 120:534
Claudin-4, as target for pancreatic cancer treatment, 121:512-tmig, 121:678
Claudins
expression and subcellular localization of, in gastrointestinal tract, heterogeneity in (rat), 120:411
expression in human intestinal epithelial cells, 118:1001-rc
Clevudine, for hepatitis B, 120:1828-srr
Clinical Gastroenterology and Hepatology, mission of, 123:877-aga, 123:965-gn
Clinical practice guidelines, quality of, 123:1426-ce
Clinical trials
data analysis in, logistic regression and, 124:1561-c
pharmaceutical supported, reporting of, 125:639-c
published in GASTROENTEROLOGY from 1994 to 2000, validity of, 122:1156-srr
safety of, 123:1761-ce
VIRAHEP-C, 122:1198-gn

Clock genes, emerging findings on, 119:536-srr
Clonidine, and gastric sensorimotor function, 116:510-tmig, 116:573
Clostridium difficile
diarrhea caused by, epidemics of, antibiotic-prescribing practices and, 118:249-gn
probiotic therapy for, 119:291-ce
toxin A
and colonocyte IL-8 release, 122:1047
effects of, chemokine receptor CCR1 deficiency and (mice), 122:600-tmig, 122:725
enteritis caused by, leptin and (mice), 124:683
mitochondrial damage caused by (CHO cells), 119:139
toxin B, as enterotoxin, 125:413
***Clostridium perfringens* enterotoxin,** claudin-4 as target for, in pancreatic cancer treatment, 121:512-tmig, 121:678
c-Met, down-regulation by IFN-α, in human hepatocytes, 122:1019
cM-T412, therapy with, for inflammatory bowel disease, 122:1592
c-MYC, and APC-induced cell cycle arrest, 123:751, 123:935-e
CNI-1493, biologic therapy with, for inflammatory bowel disease, 122:1592
CNT1 nucleoside transporter, expression in small intestine, nutritional regulation of (rat), 119:1623
Coffee, and gallstone disease in women, 123:1823
Cohen, Sidney, Julius M. Friedenwald Medal presented to, 122:2064-aga
***COL7A1* gene,** mutations, esophageal stenosis due to, 122:220-cr
Colchicine, 119:1766-aga
for primary biliary cirrhosis, 117:1038-tmig, 117:1173
Colectomy
for adenoma-like lesion or mass (ALMs), in ulcerative colitis, 117:1488-e, 118:1277-c
for cancer
in chronic ulcerative colitis or Crohn's colitis, 118:1277-c
laparoscopy-assisted versus open, 124:1991-ss
Colitis. *See also* **Ulcerative colitis (UC)**
adhesion molecules in, 121:958, 121:1008-e
adrenal cortical activation in (mice), 119:1560
caused by CD4 cells monospecific to microflora-associated antigen (mice), 123:1949
cecal bacterial load and, in HLA-B27 transgenic rats, 116:310
chronic
adenoma-like dysplasia-associated lesion or mass (DALM) in, treatment of, 117:1265-tmig, 117:1295, 117:1488-e, 118:1277-c
colonoscopic polypectomy in, 118:1277-c
Crohn's, screening and surveillance colonoscopy in, 120:783-tmig, 120:820
ICOS/B7RP-1 in (mice), 124:410
macrophage-derived IL-18 in (mice), 121:875
polypectomy in, 119:879-c
collagenous. *See* **Collagenous colitis**
colonic bacterial superantigens and (mice), 125:1785
cytomegalovirus, 125:8-im
dextran sulfate sodium-induced
development of dysplasia and neoplasia in, germline mutation in Apc and (mice), 121:1407
impaired nNOS expression in (rat), 118:714
prevention, by dietary glycine (rat), 125:775
recovery from, in transgenic mice overexpressing growth hormone, 120:925
early versus late, inflammatory mechanisms in (mice), 122:94
enteric flora species and, 125:1-tmig, 125:162
epithelial alteration in, 125:148
experimental
abrogation by IL-2-IgG2b fusion protein (mice), 117:858
aggravation by cigarette smoke (rat), 117:877, 117:1008-e
apoptosis of Th1 T cells in, anti-IL-12 treatment and, 117:1078, 117:1238-e
CD154/CD40 pathway in (mice), 119:715
differential role of selectins in, 120:1072-tmig, 120:1162
epithelial alteration in, 125:148
genetic susceptibility to (mice), 123:554
neurotrophins and (rat), 119:368
prevention
by curcumin (mice), 123:1912
by dietary glycine (rat), 125:775
reduction of food intake in, mechanisms of (rat), 118:457-tmig, 118:544, 118:625-e
Rho kinase in (rat), 124:1180-rc
suppression by galectin-1 (mice), 124:1381
therapeutic effects of vasoactive intestinal polypeptide in (mice), 124:961
treatment of, by curcumin (mice), 123:1912
hapten-induced
IL-16 in (mice), 119:972
Th1 and Th2 cytokine responses in (mice), 119:724
in IL-10 gene-deficient mice, antibiotic therapy for, 118:995-tmig, 118:1094
indeterminate, serologic markers in, 122:1195-tmig, 122:1242, 125:999-c
interleukin 4 in, in T-cell receptor α mutant mice, 116:233-tmig, 116:320
leukocyte adhesion deficiency 1 and, 121:958, 121:1008-e
leukocyte-endothelial cell adhesion in, VCAM-1 and ICAM-1 in (rat), 116:874
microscopic
in treated celiac disease, 116:778-c
treatment with azathioprine and 6-mercaptopurine, 120:1483-cr
modulation by immunostimulatory DNA (mice), 122:1428
normal luminal bacteria and, in Tgε26 mice, 120:900
in NSAID-treated IL-10-deficient mice, 123:1527
poly(ADP-ribose) synthetase in (mice), 116:233-tmig, 116:335
PPAR ligands in, antineoplastic and anti-inflammatory effects of, 121:1019-ss
prevention
by anti-MIF antibody (mice), 123:256
by IL-10-transduced T cells, in SCID mice, 123:1865, 123:2140-e
by *Lactobacillus* species, in IL-10 gene-deficient mice, 116:1107, 116:1246-e
protection against, by natural killer cells activated by α-galactosylceramide in presence of CD1d (mice), 119:119
T cells in, characterization of, in TCRα$^{-/-}$ mice, 119:983
TNBS-induced
abrogation by IL-2-IgG2b fusion protein (mice), 117:858
amelioration by IL-18 blockade (mice), 121:1270-tmig, 121:1372

indoleamine 2,3-dioxygenase and (mice), 125:1762
prevention, by dietary glycine (rat), 125:775
treatment of, PPAR-γ ligands for, 118: 228-ss

Collagenous colitis
budesonide for, 122:1-tmig, 122:20, 123:964-tmig, 123:978
diarrhea in, 124:2000-c
pathophysiology of, 123:401-tmig, 123:433
in treated celiac disease, 116:778-c

Colography, CT, 121:221-ss. *See also* **Computed tomography (CT) colonography**

Colon
adenomas. *See* **Adenomas**
angiodysplasia of, diagnosis of, imaging modality for, 119:287-tmig, 119: 293, 119:581-e
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
clonally expanded B cells in, in humans, 119:1253
development of, 116:702-srr
distal, findings in, and risk of proximal neoplasms, 120:1049-ss
distention of. *See also* **Rectal distention**
hypersensitivity to, in irritable bowel syndrome, fedotozine and, 116:1-tmig, 116:38
sensitivity to, neurokinin 3 receptors and (rat), 116:1124, 116:1250-e
epithelial cells
leptin as growth factor for (humans, mice), 121:79
mitosis in, stimulation by progastrin (mice), 124:1348
water transport by, 122:545-srr
EP_4 receptor-mediated mucin exocytosis, prostaglandin E_2 and (rat), 117: 1352
fluid homeostasis in, cGMP-dependent protein kinase II and (mice), 118: 108
gene expression in, regulation of, by normal enteric bacteria, 125:1296-tmig, 125:1388
IgA and IgM V_H repertoires in, in humans, 119:1253
inflammation of
L-type calcium channels in (dog), 120: 331-tmig, 120:480
persistent, in postinfectious irritable bowel syndrome, 121:493-ss
PKC isozymes in (dog), 122:483
intraepithelial neoplasia in, in ulcerative colitis, detection of, chromoendoscopy for, 124:873-tmig, 124: 880-rc, 124:1135-e
microbial flora of, 119:1410-pmr
and development versus inhibition of colitis, 125:1-tmig, 125:162
motor function of, aging-related changes in, 122:1688
mucosal progenitor cells, clonal growth of (human, mouse), 117:858
muscle contractions, orphanin FQ-induced, 119:1-tmig, 119:71
mechanism of, 119:890-tmig, 119: 1054
muscle in, tachykinin receptor NK1 on, immunohistochemical demonstration of (guinea pig), 120:1140
neoplasms of, 119:1803-pmr
subtypes of, distinguished by artificial neural networks, 122:606-rc
NSAIDs and, 117:755-tmig, 117:838
peristalsis in, tachykinin-dependent and -independent components of (guinea pig), 120:938
polarized transmucosal transport of hydrophilic compounds in, temperature dependence of (rat), 118: 535
polyps. *See* **Polyps**
proximal, from dystrophic *(mdx)* mice, mechanical tone of, calcium influx and, 120:1430
sodium absorption in, carbon dioxide and (rat), 122:318
sporadic neoplasms of, subtypes of, distinguished by artificial neural networks, 122:606-rc
surgery of, 119:1173-pmr
TRAIL and its receptors in, 122:659
transit time, tegaserod and, in constipation-predominant IBS, 118:463
tumor-suppressing pathway in, transforming growth factor β and, 117:500-ss
UDP-glucuronosyltransferase activity in, 116:149
in vivo absorption of medium-chain fatty acids versus short-chain fatty acids (rat), 120:1152

Colon cancer. *See* **Colorectal cancer**

Colonic crypts
bicarbonate secretion in, chloride secretion and (rat), 118:101, 118: 1282-c
Na^+-dependent fluid absorption in (rat), 120:144

Colonic ischemia
acquired and hereditary thrombotic risk factors in, 121:561, 121:724-e
AGA guidelines on, 118:951, 119:280 *correction*
AGA technical review on, 118:954
alosetron-induced, mechanism of, 121: 231-c

Colonic motility, in stress, peripheral CRF in (rat), 119:1569

Colonic pseudo-obstruction, acute, neostigmine for, 118:443-ss

Colonic transit
and bile acid kinetics, 121:812
and deoxycholic acid metabolism in cholesterol cholelithiasis, 119:610-tmig, 119:806, 120:1310-c
dynorphin A and (rat), 119:1-tmig, 119:71
measurement of, in constipation, 119: 1766-aga
orphanin FQ and (rat), 119:1-tmig, 119:71
recombinant human neurotrophic factors and, 119:1-tmig, 119:41, 119: 257-e

Colonocytes
antigen uptake and presentation by, in normal and diseased states (mice), 119:1548
IL-8 release, mitochondrial oxygen radical generation and, 122:1047

Colonoscopy
in colorectal cancer screening, in Chinese, 124:608
in Crohn's disease, 120:783-tmig, 120: 820
for diagnosis of bleeding colonic angiomas, 119:581-e
versus double-contrast barium enema, 119:1402-ss
in irritable bowel syndrome, 122:1701
in non-acute rectal bleeding, diagnostic yield of, 123:2151-ss
in prevention of colorectal cancer, effectiveness of, 121:1521-ss
recommendations for, 124:544-aga
screening, efficacy of, 122:839-c
virtual, 121:221-ss
as screening tool, 120:1073-gn, 125: 285-tmig, 125:304, 125:311, 125:608-e

Colon transit studies
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga

Colorectal adenomas. *See* **Adenomas**

Colorectal cancer. *See also* **Colon cancer**
allelic loss on chromosome 22 in, 117: 831
aminopeptidase N expression in, 122:376
angiogenesis in, COX-2 up-regulation and, 121:1339
antitumor synergy of 5-fluorouracil and 3*n*-butyrate in, 120:874

APC-dependent suppression of, by PPARγ, 125:619-ss
APC-mediated cell cycle regulation and, 123:751, 123:935-e
azoxymethanine-induced, in gastrin gene knockout mice, 123:516
Caco-2 cells
  differentiation of, phosphatidylinositol 3-kinase and, 120:1317-tmig, 120:1381, 120:1543-e
  partial reversion of malignant phenotype in, PKC-δ and, 120:1700, 120:1868-e
  resistance to butyrate-induced cell differentiation and apoptosis, 120:889
calcium-binding protein s100A4 in, prognostic significance of, 123:1423-tmig, 123:1478
caspase-8 gene mutations in, 125:708
cells
  apoptosis in
    protein kinase C and, 117:848
    sulindac-induced, lovastatin and, 117:755-tmig, 117:838
  growth of, inhibition by intestinal trefoil factor, 118:1-tmig, 118:60
  mitogenesis in, protein kinase C and, 117:848
cell survival factors in, 124:57
chemoprevention, 116:1003-ss, 119:267-ss
  NAG-1 gene and (mouse, human), 122:1388
  NSAIDs in, 125:285-tmig, 125:328, 125:404
  by PPAR-γ ligands (mice), 124:281-tmig, 124:361, 124:564-e
chemotherapy for, microsatellite instability as prognostic indicator in, 119:889-tmig, 119:921, 120:1309-c
chromosomal instability in, 123:1109
circulating tumor cells in peripheral blood of patients with, prognostic significance of, 120:1071-tmig, 120:1084
clinical late-stage, β-catenin and MMP-7 in, 122:60
common familial, 124:1574
cyclooxygenase 2 expression in, 121:1339, 125:285-tmig, 125:328, 125:404
  in HNPCC, 117:291-tmig, 117:350
  in IL-10$^{-/-}$ mice, 118:248-tmig, 118:337, 119:600-c
$CysLT_1$ expression in, 124:57
detection of, 125:1549-pmr
diet and, 122:1715-tmig, 122:1784
distinguished by artificial neural networks, 122:606-rc
early onset, in hereditary nonpolyposis colorectal cancer, 122:939
economic and social costs of, in United States, 122:1500-srr
endocannabinoid system and, 125:677, 125:973-e
endoscopic surveillance for, efficacy of, 122:839-c
endoscopic ultrasound in, 122:1631
epidemiology of, dietary fiber and, 118:1233-aga, 118:1235-aga
epidermal growth factor receptor-related protein (ERRP) in, 124:1337
familial risk for, screening of persons with, 119:837-srr
family history of, and recommendations for cancer screening, 124:544-aga
FDG positron emission tomography in, 125:1235-srr
fiber and, 116:785-gn
5-fluorouracil and pyrrolidinedithiocarbamate combination for, effects on therapeutic-to-toxic ratio (mice), 118:2-tmig, 118:81
folate as foiler of, 116:3-gn
folate deficiency and (rat), 119:1-tmig, 119:151
genes methylated in, 123:862-srr
in genetically defined hereditary nonpolyposis colorectal cancer, 121:830, 121:1005-e
genetic basis of, 119:854-srr, 121:1275-rc, 121:1497-e, 125:4-gn
genetic mouse models of, 119:854-srr
glutathione *S*-transferase P1-1 in, 121:865, 121:1010-e
growth
  COX-2 and HER-2/*neu* inhibitors and, 120:1721, 120:1872-e, 125:1915-c
  inhibition of, by MAP kinase, 117:523-gn
  SRC mutation and, 116:1025-gn
hepatic metastases
  angiogenesis in, rofecoxib and, 125:647-tmig, 125:716
  molecular genetics of, 122:3-gn
HER-2/*neu* oncogene and, 120:1721, 120:1872-e, 125:1915-c
high microsatellite instability (MSI-H), serrated pathway to, 123:862-srr
high-risk groups for, genetic testing in, 124:1574
history of, surveillance after, recommendations for, 124:544-aga
of HNPCC, cyclooxygenase-2 expression in, 117:291-tmig, 117:350
IGF-I receptor blockade in, anti-tumor effects of, 123:1191
I1307K *APC* gene in, 116:54, 116:58, 116:210-e
incidence of
  in ethnic Chinese, 125:1913-c
  fecal occult blood testing and, 121:752-ss
individuals at risk for, identification of, 120:1317-tmig, 120:1356
inflammatory bowel disease and, 120:783-tmig, 120:820, 120:841, 120:1317-tmig, 120:1356
inherited syndromes of, and genetic testing, 119:837-srr, 121:195-aga
initiation of, 123:862-srr
intestinal mucin in, 123:648-ss
  expression of, modulation by galectin-3, 123:817
JC virus and, 124:268-c
K-*ras* mutations and *p16* methylation in, 116:1063
leukocyte recruitment in, 122:1121
liver intestine-cadherin expression in, regulation by CDX2, 123:1565
low microsatellite instability (MSI-L), serrated pathway to, 123:862-srr
metastasis, MUC2 gene and, 116:363
with microsatellite instability
  evaluation for, 121:198-aga
  hepatocyte nuclear factor 1 and, 124:1311
  methylation of h*MLH1* promoter region and, 121:1300, 121:1497-e
  p14 methylation and, 124:626
  prognostic significance of, 118:459-gn
  promoter methylation pattern of hMLH1 and p16 in, gender difference in, 124:1165-c
  site, sex, and age differences in, 121:230-c
  and *WISP-3* mutations, 121:1275-rc, 121:1497-e, 124:270-c
microsatellite mutator phenotype with hypermethylated *hMLH1* gene, in women, 119:597-c
mismatch repair deficiency in, gender difference for, 121:1026-c
molecular markers in, 122:248-c
molecular staging of, 116:769-ss
novel tropomyosin isoform (TC22) associated with, 123:2-tmig, 123:152
obesity and, biological basis of (humans, mice), 121:79
pathogenesis
  colonic luminal contents and, 120:332-tmig, 120:401
  lectin/galactose hypothesis of, 122:1715-tmig, 122:1784
p14 methylation in, 124:626
precursors identified by magnifying endoscopy, 116:235-gn
preoperative staging of, 123:24

prevention, 119:267-ss, 125:1549-pmr
advances in (future directions for), 120:3-gn
aspirin in, 125:1539-ss
cost-effectiveness of, 122:1-tmig, 122:78, 122:230-e
colonoscopy in, effectiveness of, 121:1521-ss
progastrin expression and (mice), 119:2-tmig, 119:162
progression of, 123:862-srr
protection against, amidated gastrins in, 123:516
recurrence of, diet and, 119:590-ss
regulation of Par-4 gene in, by NSAIDs, 118:1012
resection
follow-up, 117:784, 117:1005-e
surveillance after, 119:1403-ss
risk
with *APC* I1307K mutation in Ashkenazi Jews, 120:331-tmig, 120:392
in first-degree relatives of patients, 117:747-c
folate status and genomic DNA hypomethylation and, 124:1240
polymorphisms and, 121:282
risk stratification, 124:544-aga
screening, 119:837-srr, 120:333-gn
action plan for, 119:893-ce
in Chinese, 124:608
in chronic Crohn's colitis, 120:783-tmig, 120:820
clinical guidelines and rationale for, 124:544-aga
colonoscopic, 120:1049-ss, 120:1051-ss
in first-degree relatives of patients, 117:747-c
cost-effectiveness of, 124:856-ss, 125:1645
by detection of altered DNA in stool, 119:1219
distal colonic findings in, and risk of proximal neoplasms, 120:1049-ss
efficacy of, 122:839-c
evidence for, 119:837-srr
fecal occult blood testing in, 122:236-ss, 122:2081-ss
frequency of missed polyps in, by RNs vs. MDs, 117:291-tmig, 117:312, 117:486-e
in hereditary nonpolyposis colorectal cancer, efficacy of, 118:815-tmig, 118:829, 118:969-e
methods, efficacy of, 122:236-ss
racial/ethnic patterns of disease and, 120:848, 120:1043-e
signoidoscopy utilization in, 117:291-tmig, 117:304, 117:486-e
virtual colonoscopy in, 120:1073-gn, 124:258-ss, 125:285-tmig, 125:304, 125:311, 125:608-e
second primary, surveillance for, 123:1401-ss
Smad gene and (mice), 116:1496-ss
sporadic
aberrant crypt foci in, analysis of K-*ras*, *APC*, and β-*catenin* in, 121:599
DNA methylation in, 122:1196-tmig, 122:1376
microsatellite instability in, 122:1196-tmig, 122:1376
Src activation in, and intestinal epithelial response to TNF-α (rat), 122:331
stage II/III
active specific immunotherapy for, 117:1015-ss
postoperative management of, 117:784, 117:1005-e
surgeon-related factors and outcome in, 116:220-ss
surveillance
clinical guidelines and rationale for, 124:544-aga
colonoscopic, in chronic Crohn's colitis, 120:783-tmig, 120:820
susceptibility gene on chromosome 15q14-q22, 116:783-tmig, 116:789
TCF1 gene mutations in, 124:1311
top-down and bottom-up models of, 123:862-srr
treatment of, 125:1549-pmr, 125:1551-pmr
in chronic ulcerative colitis or Crohn's colitis, 118:1277-c
colectomy for, laparoscopy-assisted versus open, 124:1991-ss
tumorigenesis in
cell proliferation in, $p16^{INK4a}$ and, 119:929
critical pathways of, 119:854-srr
epigenetic mechanisms in, 119:854-srr
glutathione *S*-transferase-π overexpression in, K-*ras* mutation and, 121:865, 121:1010-e
$p16^{INK4a}$ expression in, 119:929
telomeres and, 119:891-gn
tyrosine kinase genes and, 125:4-gn
in ulcerative colitis
backwash ileitis and, 120:783-tmig, 120:841, 122:245-c
detection of, chromoendoscopy for, 124:873-tmig, 124:880-rc, 124:1135-e
p53 gene and, 120:1877-ss
prevention of, by ursodiol, 121:491-ss
Wnt/APC/β-catenin signal transduction pathway in, protein kinase C β_{II} isozyme and, 117:1499-ss
Colorectal distention, visceral pain caused by, kappa opioid agonists and, 117:292-tmig, 117:388
Colorectum, mechanosensory transduction in, ATP and (rat), 125:1398
Combivir. *See* ZDV-3TC
Comment from the Editors, 121:3
Avoiding hepatic injury from drugs, 117:759
The best and the brightest, 122:851
Bringing new therapies to patients-what is the proper physician-industry relationship?, 125:7
Challenges in GI drug approval and surveillance programs, 119:1429
Challenges in the physician-patient relationship: feeling "drained," 121:1037
Clinical research: at the crossroads, 121:515
Complementary and alternative medicine: the roots of healing, 117:1041
David and Goliath: discovery in the industrial age of science, 119:5
Digestive disease centers: it's not about the money, 118:461
Discordant research opportunities and human resources: can we meet the challenge?, 122:603
Discovery-based research and fishing, 125:290
Does irritable bowel syndrome really exist? Reactions to the proposed motility-based classification system, 124:598
Editorial transition, 120:1577
Endangered species, 117:5
Entangled in a Web(site)?, 120:1321
Evidence-based medicine: clinical judgment is required, 124:1726
The evolution of modern academic medicine continues, 122:1719
Fecal incontinence: a neglected area of gastroenterology, 122:5
50 ways to lose your lover or 10 secrets for development of better drugs for functional gastrointestinal diseases, 118:653
The flexible Ph.D., 125:1301
Follow the money, 118:819
Gastro-Central, one year later, 123:5
Gastroenterology 2000: the perfect storm, 118:5
Gender equity in biomedical science: comments from a lone female associate editor, 121:243

The genomic era: from DNA to patient and back to DNA, 118:251
GERD remains an intriguing enigma, 120:787
The GI core curriculum: five years later, 118:999
Guidelines for the gastroenterologist, 123:1426
Having an impact: GASTROENTEROLOGY–the journal, 116:1027
Human investigations: answering to an ever higher authority, 123:1761
Impact factors-a good thing?, 124:286
The leadership of innovation, 116:787
Lessons from Mendel about data analysis, 124:878
MELD and the practicing gastroenterologist, 125:1009
Minimally invasive surgery: how goes the revolution?, 116:513
More attention to functional disorders, 117:1269
New antiviral agents for viral hepatitis: our cup runneth over but is only half full, 117:525
The "organification" of functional GI disorders: implications for research, 124:6
Patient competence, 119:613
The physician-scientist in gastroenterology, 125:652
Physiological mouse genomics, 123:405
Postapproval drug surveillance and the first principle of medicine, 120:5
Pump up the volume: a sound policy?, 120:1075
Putting the spotlight on our most important discoveries, 122:257
The real meaning of translational research, 123:665
Redefining autoimmunity, 125:1574
Remembering John Walsh: One of the prophets of GI, 120:335
The Renaissance of probiotics and prebiotics, 119:291
Reporting randomized controlled trials in gastroenterology: the CONSORT statement, 121:755
Research opportunity at the interface of molecular biology and clinical epidemiology, 122:1199
Seeing is believing: a revolution in imaging, 121:1273
So, where are all the celiacs?, 116:237
Striking up the match, 117:295
On the threshold of translating basic enteric neuroscience advances, 116:5
Translational research: bridging the widening gap between basic and clinical research, 124:1178
Translational research: what is it?, 116:1285
Why should gastroenterologists be interested in nutrition and obesity?, 123:967
Winning the war and losing the peace?, 119:893

Comparative genomic hybridization, in detection of hepatoma relapse, 119:288-tmig, 119:431

Compensation, litigation against Health Care Financing Administration (HCFA) about, 116:3-gn

Complement
activation of, induced by *Helicobacter pylori,* 120:1108
C5, inhibition of, effect on local and remote organ injury after intestinal ischemia-reperfusion (rat), 120:126
resistance to, by protectin-bound *Helicobacter pylori,* 120:332-tmig, 120:470

Complementary medicine, 117:1041-ce

Computed tomographic angiography, helical, for diagnosis of colonic angiodysplasia, 119:287-tmig, 119:293, 119:581-e

Computed tomography (CT). *See also* **Multidetector helical CT (MDCT) cholangiography**
in acute mesenteric ischemia, 118:954
anorectal
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
of biliary tract, 124:1686
colography, 121:221-ss
of pancreas, in diagnosis of pancreatitis, 120:682
in preoperative staging of rectal cancer, 123:24

Computed tomography (CT) colonography, 121:221-ss
for detection of colorectal polyps, 125:311, 125:608-e
extracolonic findings at, 124:911
performance evaluation, retrospective multicenter study, 125:688

Computer modeling, in structural biology, 123:1350-srr

Congenital disorders, multisystem, Notch signaling pathway and, 116:1257-e

Congenital sodium diarrhea, genetics of, 119:1506

Connective tissue disease, skin signs of, 124:1595

Connexin, and severity of acute pancreatitis (mice), 124:481

Consolidated Standards of Reporting Trials, 121:755-ce

CONSORT statement, 121:755-ce

Constipation
AGA guidelines on, 119:1761-aga
AGA technical review on, 119:1766-aga
anorectal manometry in, AGA technical review on, 116:735-aga
childhood, follow-up of, 125:357
clinical evaluation in, 119:1761-aga, 119:1766-aga
clinical features of, 119:1766-aga
clinical subtypes of, 119:1761-aga
combination syndromes of, 119:1761-aga
definition of, 116:735-aga, 119:1761-aga
diagnostic testing in, 119:1761-aga, 119:1766-aga
economic effects of, 119:1766-aga
in elderly, 122:1688
enteric nerves and interstitial cells of Cajal in, 123:1422-tmig, 123:1459
epidemiology of, 119:1766-aga
evaluation of, 122:1688
functional, prucalopride for, 120:331-tmig, 120:354
gut motility in, recombinant human neurotrophic factors and, 119:1-tmig, 119:41, 119:257-e
historical perspective on, 120:317-pmr
interstitial cells of Cajal in, 118:1-tmig, 118:14, 125:264-ss
medical management of, 119:1761-aga, 119:1766-aga
pathogenesis of, 118:1-tmig, 118:14
pathophysiology of, 119:1766-aga
with pelvic floor dysfunction, 119:1761-aga
pelvic floor retraining in, 119:1761-aga
rectal sensation testing in, AGA technical review on, 116:735-aga
referral consultations for, 119:1766-aga
risk factors for, 119:1766-aga
slow-transit, 119:1761-aga
pathophysiology of, 118:1-tmig, 118:14, 125:264-ss
tests for diagnosis or management of
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
treatment of, 122:1688
surgical, 119:1761-aga, 119:1766-aga

Continuous Professional Development, recertification via, 121:754-gn

Contrast media, 121:1022-pmr

Copper
biliary excretion of
ATPB7 in (human, rat), 118:921
mechanism for, 119:782
cellular uptake of, 125:1868-srr
metabolism of, 125:1868-srr
Coprology, 119:1174-pmr
Coronary heart disease, obesity and, 123:882-aga
Coronavirus, associated with SARS outbreak, 124:1724-gn
Correction, 116:506, 116:1019, 116:1507, 117:286, 117:754, 117:1033, 117:1260, 117:1516, 118:453, 121:234, 121:1531, 122:250, 122:1548, 123:396, 123:656, 123:957, 123:1412, 123:1752, 123:2162, 123:2164, 124:275, 124:588, 124:1168, 124:1568, 125:281, 125:1565
Correspondence
Abnormal hepatic sinusoidal bile acid transport: new insights into the pathogenesis of cholestasis?, 120:321
Acute pancreatitis and pericardial effusion in Behçet's disease, 117:286
Albumin for refractory ascites, 125:1283
Angiotensin receptor antagonists in portal hypertension: fog over paradise, 122:1543
Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease, 124:583
Anticoagulation therapy for recurrent portal vein thrombosis in a patient with liver cirrhosis suffering from variceal rebleeding, 122:2094
Antihypertensive drugs and gastrointestinal hemorrhage: causation or confounding?, 119:1416
Aortic thrombosis with splenic and renal embolization, 118:637
API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of *H. pylori* eradication treatment in low-grade gastric MALT lymphoma, 120:1884
Apoptosis, 119:1805
Appendicectomy and Crohn's disease: clinical and genetic associations, 125:1562, 125:1563
Autoimmune pancreatitis: is it relevant in the west?, 125:1557
Autoimmune pancreatitis is increasing in Japan, 125:1557
The A16V signal peptide cleavage site mutation in the cationic trypsinogen gene and chronic pancreatitis, 117:1508
Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity, 122:838
Balloon endoscopic sclerotherapy, a novel treatment for high-risk gastric fundal varices: a pilot study, 117:515
Balsalazide and azathioprine or 6-mercaptopurine: evidence for a potentially serious drug interaction, 116:1505
Barrett's esophagus and heater probe, 124:2008
Barrett's esophagus and neoplasia: data from the Bayreuth Barrett's archive, 122:590
Bifidobacteria in necrotizing enterocolitis, 118:1280
Bile acids, cholesterol, gallstone calcification, and the enterohepatic circulation of bilirubin, 116:1276
Bile acids and esophageal cancer, 124:271
Biopsychosocial treatment of irritable bowel syndrome, 125:1554
Biopsy is the gold standard of diagnosis of celiac sprue, 116:1273
Bone marrow-derived liver stem cells: their therapeutic potential, 123:654
Brain-gut interactions in ulcerative colitis, 118:807
CagA status and gastric cancer: unreliable serological tests produce unreliable data, 117:745
Can proton pump inhibitors be blamed for the rising incidence of esophageal cancer?, 125:1912
A case of infective endotipsitis, 117:514
$CD4^+$ T cells in cerulein-induced pancreatitis, 119:881
Celiac disease-like abnormalities in IBS: wrong title or wrong disease?, 123:954
Cerebral activation in inflammatory bowel syndrome, 119:1418
Chest pain in achalasia is an age-dependent phenomenon, 117:1258
Chronic anal fissure: advances and insights in pathophysiology and treatment, 125:995
The c-insertion mutation of the *NOD2* gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease, 122:2091
Of ciprofloxacin and ulcerative colitis, 117:281
Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan, 125:1916
The clinical role of COX-2 inhibitors, 118:639
Colonoscopic polypectomy in chronic colitis, 118:1277
Colonoscopic screening of first-degree relatives of patients with colorectal cancer, 117:747
Colon polyps in Beckwith-Wiedemann syndrome: role of imprinted genes, 118:637
Colorectal cancer incidence differs within ethnic Chinese, 125:1913
Comments on experimental use of intravenous cyclosporine (CsA) alone to treat severe ulcerative colitis, 121:1530
Comments regarding article comparing small bowel radiographs and video capsule endoscopy, 125:276
Common variants of the matrix metalloproteinase-3 (stromelysin) gene promoter in primary biliary cirrhosis, 122:247
Controversies about the histological features of chronic HCV patients with persistently normal alanine aminotransferase levels: what can be done about the present definition?, 123:1748
Cost-utility of initial medical management for Crohn's disease perianal fistula, 122:1186
COX-2 in murine intestinal tumors, 119:600
COX-2 selectivity and lack of gastrointestinal toxicity: true, true and unrelated?, 118:640
Crohn's disease remission on bupropion, 125:1290
Decreased affinity of urinary intrinsic factor–cobalamin receptor in a case of Gräsbeck-Imerslund syndrome, 116:1274
Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy, 121:743
Development of a tensostat for gastric perception studies, 118:641
Diagnosing appendicitis, 125:272
Differential HFE allele expression in hemochromatosis heterozygotes, 120:1308, 123:652
Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab, 125:633

Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn's disease, 117:1031
Discussion of "Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis," 122:245
Discussion on appendectomy is followed by increased risk of Crohn's disease, 125:997
Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure, 123:2158
Discussion on "cutting the cord" for capsule endoscopy, 125:998
Discussion on frequency of the HIV-protective chemokine receptor 5-D32/D32 genotype is increased in hepatitis C, 124:1558
Discussion on genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis, 125: 1286
Discussion on 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis, 123:1747
Discussion on inflammatory bowel disease is not associated with an increased risk of lymphoma, 123: 653
Discussion on predictors of response to infliximab in patients with Crohn's disease, 124:2002
Discussion on preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systemic review, 123:955
Discussion on probiotic bacteria enhance murine and human intestinal epithelial function, 123:391
Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis, 122:1544
Discussion on simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole, 122:1545
Discussion on the association between hepatitis C infection and survival after orthotopic liver transplantation, 123:2160
Discussion on the biologic therapy of inflammatory bowel disease, 124: 2005
Discussion on the effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas, 124:1564
Discussion on the effects of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas, 125:627
Discussion on the role of hemochromatosis susceptibility gene mutation in protecting against iron deficiency in celiac disease, 124:1562
Discussion on the safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study, 125: 1562
Discussion on the true impact of fatigue in primary biliary cirrhosis: a population study, 124:582
Does ursodeoxycholic acid cause lichenoid eruption?, 122:1547
Drink test in functional dyspepsia, 122: 2093
Duplex ultrasonography and TIPS, 117: 511
Duplex ultrasonography of TIPS: how useful is it?, 116:1272
E-cadherin germline mutations and risk of gastric cancer, 123:1406
ECL cell tumor and endocrine carcinoma of the stomach, 117:510
Effect of esophageal dysmotility on surgical outcomes, 122:1183
Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance, 124:866
Effect of long-term lamivudine therapy on histological outcome in chronic hepatitis B, 125:1286
Efficacy and safety of long-term omeprazole treatment, 119:1177
Elevated serum transaminases and celiac disease: possible modifications of a diagnostic algorithm, 125:280
Emesis, appetite, and endocannabinoids, 123:655
Endoscopic ultrasonography for gallbladder disease, 116:1018
An enormous ventral (epigastric) hernia as a cause of acute pancreatitis: Pfeffer's closed duodenal loop model in the animal, first seen in a human, 124:865
Enterokinase in cerulein pancreatitis, 118:452
The epidemiology of Crohn's disease, 116:1503
Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West., 122:589
Esophageal mucosa resistance: the "Cinderella" of GERD pathophysiological research, 125:1558
Etiology of fasting hyperbilirubinemia: genetic factors vs. enhanced enterohepatic cycling of bilirubin, 117:1254
Evidence for pooling of gastric secretions in the proximal stomach in humans using single photon emission computed tomography, 123: 2157
Expression of leptin and its receptor in the human stomach, 117:509
Factor V Leiden mutation in patients with inflammatory bowel disease, 117:280
On finding flat adenomas: is the search worth the gain?, 122:839
First, do not harm: power, oppression, and violence of liver biopsy, 125: 272
Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increased in hepatitis C patients, 124:1558
Frequent Ki-*ras* mutations in gastric tumors of the MSI phenotype, 125:1282
Fruits and vegetables: do they protect from gastric cancer?, 124:2006
Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV, 122:244
Gallbladder disease: acalculous or not?, 121:1529
Gallbladder muscle dysfunction and neuroanatomic disorders, 123:1407
G20210A prothrombin gene mutation and other thrombophilic polymorphisms in patients with portal or hepatic venous thrombosis, 120:1059
Gastric high-grade dysplasia, 117:285
Gastric intestinal metaplasia in transgenic mice, 125:996
Gastric surgery and Barrett's esophagus, 123:954
Gastrin-induced hyperproliferation in Barrett's esophagus, 125:1921
Gastroenterologists of the new millennium, 117:1028
Gastroenterology fellowship training: a generation lost, 116:228
Gastrointestinal effects of low-dose aspirin, 117:1505

Gender difference for mismatch repair deficiency in human colorectal cancer, 121:1027
Gender difference for promoter methylation pattern of hMLH1 and p16 in sporadic MSI colorectal cancer, 124:1165
Genetic basis of fasting hyperbilirubinemia, 116:1272
A "G insertion" at nucleic acids 481 of the *H. pylori fldA* gene is not associated with gastric MALT lymphoma, 118:988
Glutathione *S*-transferase as a major autoantigen in anti-SLA-positive autoimmune hepatitis, 116:1015
H. pylori adhesion and Lewis X, 119:1414
H. pylori and risk of ulcer bleeding among users of NSAIDs, 118:451
HCV chronic infection and CCR5-Δ32/Δ32, 124:868
Helicobacter pylori eradication therapy in primary high-grade gastric MALT lymphoma, 123:393-c
Helicobacter pylori infection and gastric cancer, 120:324
Helicobacter pylori infection in childhood: transmission and role of antibiotics, 122:1189
Helicobacter sp. are not detectable in bile from German patients with biliary disease, 116:1016
Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma, 120:323
Heparin therapy for ulcerative colitis, 120:1307
Hepatic artery flow change and hepatocyte oxygenation in human cirrhosis, 117:1256
Hepatic deficiency of interleukin 10 in chronic hepatitis C, 119:1411
Hepatic oxygen supplementation as therapy in cirrhotic liver disease, 117:1025
Hepatitis B infection in heart transplant recipients, 120:1311
Hepatitis B virus genotype distribution in HIV-1 coinfected patients, 125:1559
Hepatitis B virus genotypes and hepatocellular carcinoma in Japan, 120:1564
HER-2/neu overexpression in colonic malignancies, 122:248
High-dose omeprazole in patients with noncardiac chest pain, 116:226
Higher or lower doses of botulinum toxin for the treatment of chronic anal fissure?, 124:1165
High frequency of *CCR5*-Δ*32* homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1, 124:867
"High-grade MALT" vs. diffuse large B cell lymphoma, 123:956, 123:1410
High incidence of oral lichen planus in an HCV hyperendemic area, 119:883
High recurrence rate of *Helicobacter pylori* infection in developing countries, 123:653
Histological improvement of oral lichen planus in patients with chronic hepatitis C treated with interferon, 117:283
Hormonal therapy in angiodysplasia: should we completely abandon its use?, 123:2156
The human hepatocyte-specific organic anion transporter encoded by the SLC21A8 gene, 122:1545
Humoral immunity in acute and chronic hepatitis C infection, 117:510
Hypnotherapy for functional dyspepsia: do the results add up?, 125:636
ICAM-1 in cerulein-induced pancreatitis, 117:748
ICC in neurotransmission: hard to swallow a lack of involvement, 122:1184
Identification of motilin-related peptide, 120:588
Identification of multiple candidate genes for IBD susceptibility using high-density transcript mapping in the IBD2 locus on chromosome 12q, 117:1029
Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis, 121:503
Ileorectal anastomosis in patients with familial adenomatous polyposis, 121:502
IL-10 in post ERCP pancreatitis, 121:233
Immune activation in irritable bowel syndrome: wrong title or wrong disease? Part 2, 124:1163
Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection, 122:593
Importance of adequate acid suppression in the management of Barrett's esophagus, 117:1509
Improvement of masseter spasticity by botulinum toxin facilitates PEG placement in amyotrophic lateral sclerosis, 123:1749
Increased levels of factor VIII:C as a possible risk factor for portal, splenic, and mesenteric vein thrombosis, 120:1563
Infection with *Giardia* and intestinal permeability in humans, 125:277
Inflammation of the gastric cardia, 116:228
Inflammatory bowel disease and the risk of thrombosis, 117:280
Influence of vitamin D receptor gene polymorphism on bone mineral density in primary biliary cirrhosis, 119:599
The "innocent colon" and K-*ras* mutation-guilty by (ACF) association?, 124:274
Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes, 118:986
Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents, 119:276
The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection, 125:1284
Interleukin10: the magic bullet for liver fibrosis?, 119:1412
Interleukin 10 and incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography, 121:232
Intestinal motility and bacterial overgrowth in patients with gallstones, 120:1310
Intractable insomnia after cessation of treatment with thalidomide, 120:1567
Inverse association between intake of cereal fiber and risk of gastric cardia cancer, 121:1024
Is *Helicobacter pylori* infection a risk factor for disease severity in rheumatoid arthritis?, 116:503
Is intrahepatic cholestasis of pregnancy an MDR3-related disease?, 125:1921
Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign?, 121:1526
Isolation of a *Helicobacter* strain from the human liver, 121:1023
Is small-caliber esophagogastroduodenoscopy more tolerable that conventional one in unsedated patients?, 119:878
It's time to bring the best and brightest back to gastroenterology, 116:1014

JC virus and human colon carcinoma: an intriguing and inconclusive association, 124:268
Lack of association between the C3435T *MDR1* gene polymorphism and inflammatory bowel disease in two independent Northern European populations, 125:1919
Lack of effect of acid suppression therapy on gastric atrophy, 118:242, 118:453
The lack of HER-2/Neu oncogene amplification in colorectal malignancies, 125:1915
Laparoscopic appendectomy in patients with refractory ulcerative colitis, 120:1562
Late onset and high incidence of colon cancer of the mutator phenotype with hypermethylated *hMLH1* gene in women, 119:598
Leptin and gastric neuroendocrine system, 123:1751
Lichenoid eruptions due to ursodeoxycholic acid administration, 121:501
Limitations of anti-guinea pig liver transglutaminase IgA in screening of celiac disease, 120:586
Long-term effects of omeprazole on the gastric mucosa, 119:1176
Long-term follow-up of gastric MALT lymphoma treated by eradication of *H. pylori* with antibiotics, 117:750
Long-term omeprazole treatment and risk of gastric cancer, 119:1176
Long-term treatment of ulcerative colitis with ciprofloxacin, 117:282
A loss of function mutation in *WISP3* derived from microsatellite unstable gastric carcinoma, 125:1563
Low-dose aspirin may or may not damage the gastric mucosa, 117:1505
Low-dose methotrexate in primary biliary cirrhosis, 117:1510
The magic bullet for liver fibrosis?, 119:1412
Mallory bodies, like the mutant of ATP7B seen in Wilson's disease, are aggresomes, 121:1264
Management of the irritable bowel syndrome, 121:1527
Markov models in primary biliary cirrhosis, 123:1750
Mechanism of diarrhea in collagenous colitis, 124:2000
Mesalamine and relapse prevention in Crohn's disease, 119:597
Mesalamine maintenance therapy for Crohn's disease, 120:585
Mesenteric venous thrombosis revealing both factor II 620210A mutation and hyperhomocysteinemia related to pernicious anemia, 118:237
Metronidazole susceptibility in *Helicobacter pylori*, 117:1032
Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapy, 120:1309
The microsatellite instability phenotype in human colorectal carcinoma: relationship to sex, age, and tumor site, 121:230
Microscopic and collagenous colitis in treated celiac disease due to food allergy?, 116:778
Mimicry of blood group antigen A by *Helicobacter mustelae* and *H. pylori*, 116:504
Molecular mechanisms of glucocorticoid resistance, 119:1178
Motilin-related peptide and ghrelin: lessons from molecular techniques, peptide chemistry, and receptor biology, 120:587
Mucosal flora in inflammatory bowel disease: intraepithelial bacteria or endocrine epithelial cell secretory granules?, 123:955
Multiple focal nodular hyperplasia in Klippel-Trénaunay syndrome, 117:284
Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis, 120:1061
National resident matching program, 117:509
The "natural" history of pain in chronic pancreatitis, 118:235
Neuroendocrine cell secretory granules are not bacteria in inflammatory bowel disease, 125:1288
A new model for the pathogenesis of celiac disease, 116:1277
New system of double-balloon enteroscopy for diagnosis and treatment of small intestinal disorders, 125:1556
NF-κB in IBD: does binding to DNA imply transcriptional activity?, 116:1504
No-aspirin (NCX 4016), 125:1918
NOD2 insertion mutation in a Cretan Crohn's disease population, 124:272
Nonsurgical treatment modalitites for chronic anal fissure using botulinum toxin, 117:516
NSAIDs and esophageal cancer, 125:1914
Octreotide for therapy of chylous ascites in yellow nail syndrome, 116:1017
Omeprazole and accelerated onset of atrophic gastritis, 118:238
Omeprazole and ultrastructural modifications occurring in reflux esophagitis, 122:837
Omeprazole test and 24-hour esophageal pH monitoring in diagnosing GERD, 116:1012
Optimal cases and sites to search for primary microbial agents in Crohn's disease, 120:1066
Optimal IFN therapy for 40-year-old patients with severe HCV-1b infection, 124:1166
Optimal medical therapy with proton pump inhibitor infusion to prevent recurrent ulcer hemorrhage in patients with adherent clots, 125:276
Optimal use of propranolol, 124:2005
Organic anion-transporting polypeptides: expression cloning and functional tests, 120:1887
Organization of intestinal pacemakers, 120:319
Osteoporosis in newly diagnosed inflammatory bowel disease, 121:504
Outcomes of patients with seroclearance of HBsAg: different facets of a truth, 125:274
Pain in alcoholic chronic pancreatitis, 117:1026
Pancreatic stenting after biliary sphincterotomy in patients with sphincter of Oddi dysfunction, 117:283
Pancreatitis from bile reflux-again?, 124:863
Parent-child transmission of *Helicobacter pylori* in the family, 122:2091
Pathogenesis of diclofenac enteropathy, 120:1885
PEG-interferon versus conventional interferon and liver fibrosis: do we have evidence of superiority?, 124:584
Percutaneous ethanol injection therapy of large hepatic tumors: a stereotaxic echo-guided approach, 116:504
Photodynamic therapy and genetic abnormalities, 120:1065
Polypectomy in chronic colitis, 119:879

Portal and mesenteric venous thrombosis in cirrhotic patients, 123:1409
Possible mechanisms for ischemic colitis during alosetron therapy, 121: 231
Postsurgical recurrence in Crohn's disease, 116:1013
Posttraumatic stress disorder, 116:227
PPI-based triple therapy in the eradication of *H. pylori* infection, 117: 746
The predictive parameters for relapse in ulcerative colitis, 121:1261
Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population, 122:842
Problem of imbalance in risk factors in clinical trials: logistic regression is the answer, 124:1561
The prognosis for life in an HCV hyperendemic area, 125:628
Propofol for endoscopy sedation, 124: 1162
A prospective, comparative study between push enteroscopy and wireless video capsule in patients with obscure digestive bleeding, 125:276
Psychotherapy and paroxetine: cost effective for severe IBS, or a waste of resources, 125:1555
The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials, 125: 639
Rebound hypersecretion after omeprazole, 117:513
Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy, 124:1561
Regression of MALT lymphoma of the rectum after anti-*H. pylori* therapy in a patient negative for *H. pylori*, 117:514
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation?, 117:1255
Remission of Crohn's disease on bupropion, 121:1260
Renovascular hypertension consequent to giant cyst of the liver, 121:745
Reversal of cirrhosis: evidence-based medicine?, 125:629
Rofecoxib versus placebo ulcer rates, 118:638
The role of cytomegalovirus in inflammatory bowel disease and gastrointestinal lymphoma, 123:390
Role of fecal calprotectin test in the work-up of IBS patients, 124: 1164
The role of polymorphism in manganese superoxide dismutase in susceptibility to alcoholic liver disease, 124:2000
Screening for celiac disease in patients with chronic liver disease, 125: 1289
Search for mumps virus genome in intestinal biopsy specimens of patients with IBD, 117:1252
Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease, 125:637
Sensitivity of anti-endomysial antibody in detecting celiac disease, 122: 246
Sensitivity of cold-preserved rat liver to single-pass reperfusion, 118:450
Sensitivity of urease-based test on diagnosis of *Helicobacter pylori* in children and the elderly, 116:1506
Serine protease inhibitors and F-actin redistribution, 122:591
Serine protease inhibitors cause F-actin redistribution in pancreatic acini?, 124:583
Serologic tests for celiac disease, 124:585
Serum HBV-DNA levels in inactive hepatitis B virus carriers, 122:2092
Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only, 121:500
Short-segment Barrett's: a significant lesion, 118:987
Should patients with IBS be submitted to painful rectal distention in clinical practice?, 124:863
Significance of genetic abnormalities after photodynamic therapy, 120:1064
A significant advance in the understanding of intestinal anion secretion, 118:1282
Slow waves, spike patches, and "propagating contractions," 121:742
Somatic mutation of the β_2-microglobulin gene associates with unfavorable prognosis in gastrointestinal cancer of the microsatellite mutator phenotype, 120:1565
SPINK1 mutations in chronic pancreatitis, 120:1060
Steroid dependency in Crohn's disease, 123:393
Steroids may prevent leukopenia, hastening response to IV azathioprine in treatment of Crohn's disease, 118:1281
Successful botulinum toxin treatment of dysphagia in oculopharyngeal muscular dystrophy, 119:1416
Successful closure of ileal pouch-vaginal fistulas with infliximab, 125:631
Successful orthotopic liver transplantation, 120:1561
Successful use of cyclosporine in the treatment of glucocorticoid-resistant nongranulomatous chronic idiopathic enterocolitis, 117:1258
Sucrase-isomaltase: an epithelial chloride channel?, 121:741
Survivin in liver, 124:1565
Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation, 124:586
Terlipressin-induced vasoconstriction reversed with *N*-acetylcysteine: a case for combined use in hepatorenal syndrome?, 123:2160
Thalidomide therapy for Crohn's disease, 119:596
There is a relationship between celiac disease and patients with symptoms of irritable bowel syndrome, 123:1408
Thrombosis, factor V Leiden, and inflammatory bowel disease, 116:778
TIPS in refractory ascites in cirrhosis: not only survival is the clue, 125: 997
Tissue transglutaminase antibodies in dermatitis herpetiformis, 117:749
TNF-α production by intra-epithelial T cells in celiac disease, 125:1560
Treatment of patients with dysphagia caused by benign disorders of the distal esophagus, 118:235
Treatment of *Strongyloides* infections, 119: 1805
Trypsinogen mutations in chronic pancreatitis, 117:1507
Unexpected low incidence of oral lichen planus in an HCV hyperendemic area of southern Italy, 121:1528
Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients, 117:1252
The use of serum tTG-ab assay in patients on gluten-free diet as a measure of dietetic compliance, 122:588
Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer, 125:992
The value of serologic markers in indeterminate colitis: a prospective follow-up study, 125:999

Variability of serologic testing for *H. pylori* using U.S. and Peruvian antigens, 120:325
Variant WISPs as targets for gastrointestinal carcinomas, 123:392
Vegetative infection of TIPS leading to "endotipsitis"?, 116:779
Vitamin D receptor gene analysis in primary biliary cirrhosis, 119:1805
In vivo colonic butyrate metabolism and colonic permeability in extensive ulcerative colitis, 117:745
Wanted: a consensus nomenclature for cationic trypsinogen mutations, 119:278
Water immersion stress induces heat shock protein expression and protects against pancreatitis, 121:744
Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence, 124:2003
What is the risk of biliary pancreatitis in patients with gallstones?, 119:879
When can unfractionated heparin really be useful in the treatment of ulcerative colitis?, 120:1306
When enthusiasm is infectious, 119:274
When should endoscopic screening in familial adenomatous polyposis be started?, 118:808
Where is the site that ATP7B transports copper within hepatocytes?, 125:1911
Which is the hen and which is the egg?, 118:807
Why the mesenteric margin?, 120:1885
A wider view on diagnostic criteria of nonalcoholic steatohepatitis, 122:840
WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas, 124:270
YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient, 121:1027

Cortactin, in invasion of biliary epithelia by *Cryptosporidium parvum*, 125:216

Corticosteroids
bone loss caused by, 124:795-aga
and cholangiocyte secretory activities (rat), 122:1057
in colonic ischemia, 118:954
for Crohn's disease
in children, 119:889-tmig, 119:895, 119:1158-e
with fistulous complications, 119:1132-srr, 124:1595
and postoperative infections in IBD patients, 125:320, 125:610-e
for pouchitis, 124:1636

Corticotropin-releasing factor (CRF)
and colonic motor activity in stress (rat), 119:1569
gene expression
developmental stressors and, 122:2032-srr
genetically induced changes in, animal models of, 122:2032-srr
repeated stressors and, 122:2032-srr

Corticotropin-releasing factor (CRF) receptors, CRF_1
and colonic motor activity in stress (rat), 119:1569
and postoperative gastric ileus (mice), 125:654-rc

Corticotropin-releasing hormone
antagonists, anti-inflammatory effects in intestine (mice), 123:505
locomotor-activating effects of, sensitivity to, in cholestasis (rat), 122:681

Costs and cost analysis. *See* Economics

Couric, Katie, and CRC screening, 120:333-gn

Cowden syndrome, genetic testing in, 119:837-srr

Cow's milk allergy
disorders associated with, 120:1026-aga
gastroesophageal reflux disease associated with, in infants, 120:1026-aga

Coxibs. *See* Cyclooxygenase-2 (COX-2), inhibitors

***CRAC1* gene,** and colorectal carcinoma and adenoma susceptibility, 116:783-tmig, 116:789

Critical care
nutrition in, 117:1500-ss
transfusion requirements in, 117:1017-ss

Critical illness, parenteral nutrition in, 121:966-aga, 121:970-aga

Crixivan. *See* Indinavir

Crohn, Burrill Bernard, 116:1034

Crohn's disease (CD). *See also* Inflammatory bowel disease (IBD)
alendronate for, and lumbar spine bone mineral density, 119:609-tmig, 119:639, 119:866-e
anal fissure in, 124:235-aga
antibodies to infliximab in, 125:32
prevention of, by intravenous premedication with hydrocortisone, 124:874-tmig, 124:917, 124:1140-e
anti-TNF antibody for
ANCA pattern and LTA haplotype and, 120:1347
immunohistological effects of, 116:1-tmig, 116:22
using engineered human antibody (CDP571), 120:1317-tmig, 120:1330
ASCA (anti-*Saccharomyces cerevisiae* antibody) assays in, comparative study of, 120:827
bacterial I2 sequence associated with, 119:23, 119:254-e
budesonide for
and antibiotic, combined, 123:33
versus mesalamine, 116:1263-ss
clinical trials in, endpoints for, 122:512-srr
costs of care for, 117:2-tmig, 117:49
course of, 117:2-tmig, 117:49
smoking cessation and, 120:1071-tmig, 120:1093
defective apoptosis of lamina propria T cells in, 116:509-tmig, 116:557
disease activity in, measurement of, 122:512-srr
epidemiology of, 116:1503-c
etanercept for, initial results with, 121:1033-tmig, 121:1088, 121:1242-e
extraintestinal manifestations of, 123:661-tmig
fibrostenotic, *NOD2* gene mutation and, 122:2091-c, 123:661-tmig, 123:679
fistulas in
enteroenteric, 119:1132-srr
enterovesical, 119:1132-srr
external, 119:1132-srr
infliximab for, 117:1247-ss
internal, 119:1132-srr, 124:1629
perianal, 119:1132-srr
diagnosis of, 124:1629
imaging of, 121:1064
incidence of, 124:1629
initial medical management of, cost-utility of, 120:1640, 122:1186-c
medical therapy for, 124:1595
pathogenesis of, 124:1629
surgical management of, 124:1595
peri-ileostomy, 119:1132-srr
postoperative, 119:1132-srr
rectovaginal, 119:1132-srr
fistulizing/fistulous
natural history of, in Olmstead County, MN, 122:874
NOD2 gene mutation and, 122:2091-c
treatment of, 119:1132-srr
fracture risk in, population-based study of, 123:468

gastrointestinal permeability in, stress and, 119:1019
gene therapy for, advances in, 123:1758-tmig
genetics of, 117:755-tmig, 117:806, 124:521-srr
hepatitis B or C infection in, immunomodulatory drugs and, 122:593-c
HLA associations in, 123:661-tmig, 123:714
ileal, epithelial permeability to proteins in, 117:65
of ileoanal pouch, infliximab for, 117:429-cr, 125:631-c
IL-10 for, bacterial delivery system for, 119:1187-gn
IL-16 up-regulation in, 119:972
immune-mediated thrombocytopenia associated with, rituximab for, 124:583-c
immunopathogenesis of, 119:23, 119:254-e
inflammatory changes in, mesenteric adipose tissue and, 117:2-tmig, 117:73
inflammatory response in, ICAM-1 and VCAM-1 blockade and (mice), 121:1428
infliximab for, 117:429-cr, 117:755-tmig, 117:761-rc, 117:1247-ss, 125:631-c
clinical experience with, at 5 years, 125:1902-ss
intravenous azathioprine for, steroid therapy and, 118:1281-c
long-term efficacy of, immunogenicity and, 125:1544-ss
and lymphoma, 117:1433-cr
maintenance regimen for, 124:1988-ss
mechanism of action of, 121:1034-tmig, 121:1145, 121:1242-e
mechanism of efficacy of, 124:1722-tmig, 124:1774
response to
NOD2/CARD15 and, 123:1-tmig, 123:106
predictors of, 123:661-tmig, 123:707, 124:2002-c
inhibition of stress-activated MAP kinases in, 122:7-rc, 125:633-c
intestinal mucosal lymphocyte proliferation in, IL-18 and, 119:1514
intravenous azathioprine for, 117:521-tmig, 117:527
lesion healing in, with infliximab treatment, 116:1023-tmig, 116:1029
lymphoma risk in, 121:1034-tmig, 121:1080, 121:1239-e, 123:653-c
macrophage-derived IL-18 in (mice), 121:875
mesalamine for, 116:509-tmig, 116:521
maintenance therapy with, 120:585-c
postoperative, 118:247-tmig, 118:264, 118:436-e
molecular classification of, 122:847-tmig, 122:853-rc, 122:1160-e
mortality and causes of death in, population-based study of, 122:1808
natalizumab for, 121:268, 125:1276-ss
newly diagnosed, guide for patient with, 123:953-pmr
NOD2 gene and, 122:826-ss, 123:1-tmig, 123:86, 123:106, 123:661-tmig, 123:679, 123:2148-ss, 125:1-tmig, 125:47
NOD2 insertion mutation in, 124:272-c
NOD2 variants in
genetic and functional significance of, 124:2-tmig, 124:140
lack of, in Japanese patients, 123:1-tmig, 123:86
novel polymorphisms of TNF gene 5′ flanking region in, 117:1037-tmig, 117:1062
novel therapies for, 120:308-ss
onset of
increased intestinal permeability preceding, 119:1740-cr
linkage heterogeneity for *IBD1* locus and, 119:1483
osteoporosis in, and fracture risk, population-based study of, 123:468
patient education about, 120:317-pmr
pediatric, assessment of, activity index for, 116:509-tmig, 116:527
perianal
AGA position statement on, 125:1503-aga
AGA technical review on, 125:1508-aga
classification of, 125:1508-aga
diagnosis of, 125:1503-aga, 125:1508-aga
epidemiology of, 125:1503-aga, 125:1508-aga
etiology of, 125:1508-aga
lesions in, definitions of, 125:1508-aga
medical treatment of, 125:1503-aga
surgical treatment of, 125:1503-aga, 125:1508-aga
pigment gallstones in, 116:1282-tmig, 116:1420, 116:1491-e
polypectomy in, 119:879-c
postsurgical recurrence, 116:1013-c
prevention, budesonide for, 116:294
pouchitis caused by, 124:1636
primary chronic interstitial nephritis in, 123:1436
primary microbial agents in, optimal cases and sites to search for, 120:1066-c
recombinant human IL-10 for, 119:1425-tmig, 119:1461, 119:1473, 119:1781-e
recombinant human IL-11 in, safety and activity of, 117:2-tmig, 117:58
relapse
predictive markers of, 119:1-tmig, 119:15
prevention of, 118:247-tmig, 118:264, 118:436-e
mesalamine and, 119:597-c
stress and, 119:1019
relatives of patients with, subclinical intestinal inflammation in, 124:1721-tmig, 124:1728, 124:1972-e
remission in
azathioprine for maintenance of, 118:995-tmig, 118:1018
myelosuppression during, 118:995-tmig, 118:1025
steroid therapy and, 118:1281-c
bupropion and, 121:1260-c, 125:1290-c
definition and maintenance of, 122:512-srr
methotrexate for maintenance of, 120:1553-ss
response to CDP870 in (abstract), 125:606-aga
Rho kinase in, 124:1180-rc
risk
after appendectomy, 124:40, 125:997-c, 125:1562-c
gene mutations and, 121:1-gn
NOD2 gene mutations and, 122:866-rc, 122:1160-e
screening and surveillance colonoscopy in, 120:783-tmig, 120:820
selected loss of tolerance in, 123:689
severity of, linkage heterogeneity for *IBD1* locus and, 119:1483
sites of involvement in, *NOD2* gene mutations and, 122:866-rc, 122:1160-e
skin lesions in, 124:1595
small intestinal
relapse, predictive marker for, 119:1-tmig, 119:15
thymus-expressed chemokine and $CCR9^+$ lymphocytes in, 121:246-rc
spontaneous mouse model of, quantitative trait locus for ileitis in, 125:477
steroid-dependent, 123:393-c
infliximab combined with azathioprine or 6-mercaptopurine for (abstract), 125:606-aga
management of, 125:906

steroid therapy for, natural history of, 121:239-tmig, 121:255
subcutaneous antisense ICAM-1 for, absence of efficacy of, 120:1317-tmig, 120:1339
susceptibility, *NOD2* gene and, 123:1-tmig, 123:86, 125:1-tmig, 125:47
systemic amyloidosis complicating, renal dysfunction caused by, dimethylsulfoxide for, 117:1031-c
T-cell apoptosis in, 119:1166-ss
T cells and IL-10 in, 123:1865, 123:1877, 123:2140-e
thalidomide for, 119:596-c
open-label trials of, 117:1265-tmig, 117:1271, 117:1278, 117:1485-e
thiopurine *S*-methyltransferase deficiency in, diagnosis of, 121:500-c
treatment of, 120:317-pmr
in children, 119:889-tmig, 119:895, 119:1158-e
trinitrobenzene sulfonic acid model of, therapeutic effects of vasoactive intestinal polypeptide in (mice), 124:961
vitamin D deficiency in, treatment by tanning bed UV B radiation, 121:1485-cr

Crohn's Disease Activity Index (CDAI)
in pediatric patients, 116:509-tmig, 116:527
in perianal disease, 125:1508-aga

Cronkhite-Canada syndrome, clinical characteristics of, 124:1595

CRST syndrome, clinical characteristics of, 124:1595

Crypt(s)
epithelial renewal in, 116:7-rc, 116:208-e
hyperplasia, in SIV-infected Rhesus macaques, 116:650

Cryptosporidiosis (*Cryptosporidium parvum* infection)
of biliary and intestinal epithelia, 118:248-tmig, 118:368
enterocyte resistance against, IFN-γ–mediated, 120:99
in HIV-infected (AIDS) patient, HAART-related resolution of, 120:984-cr
invasion of biliary epithelia, c-Src and cortactin in, 125:216
and NF-κB activation in biliary epithelia, and prevention of epithelial cell apoptosis, 120:1774
nonimmune defense against, in HIV-infected (AIDS) patients, 119:1236

c-Src kinase, in invasion of biliary epithelia by *Cryptosporidium parvum*, 125:216

c-src kinase, in coupling of L-type calcium channels to M_2 muscarinic receptors, in colonic circular smooth muscle (rabbit), 123:827

Cullen, Thomas Steven, 122:280

Cullen's sign, 124:1595

Curcumin, in prevention and treatment of experimental colitis (mice), 123:1912

Curriculum, core, in gastroenterology, 118:999-ce

Cushing, Harvey Williams, 119:22

Cutis laxa, 119:1430-im

Cyclic adenosine monophosphate (cAMP)
effects on glutamine-stimulated proliferation in enterocytes, 118:90
and hepatocellular bile acid transport, 117:433-srr
inhibition of extracellular signal-related kinase, in enterocytes, 118:90

Cyclin B, expression of, IFN-α inhibition of neuroendocrine tumor cell growth and, 118:650-tmig, 118:735

Cyclin D, and APC-induced cell cycle arrest, 123:751, 123:935-e

Cyclin D1
APC-induced cell cycle arrest and, 123:751, 123:935-e
and progression of pancreatic intraepithelial neoplasia, 123:645-ss

Cyclooxygenase-1 (COX-1)
deficiency/inhibition, and intestinal integrity (mice), 122:1913, 125:637-c
inhibition
by aspirin, 117:17
and NSAID-induced gastric damage (rat), 119:610-tmig, 119:706

Cyclooxygenase-2 (COX-2)
in acute pancreatitis (mice), 123:1311
bile acid-mediated induction of, in cholangiocarcinoma, 122:984
elevated, in esophageal cancer, prognostic significance of, 122:1715-tmig, 122:1800
expression
in adenocarcinoma, 118:457-tmig, 118:487
in Barrett's esophagus, 118:457-tmig, 118:487
and cellular localization in *H. pylori* gastritis, 116:1281-tmig, 116:1319
in colorectal cancer, 121:1339, 124:57
in IL-10$^{-/-}$ mice, 118:248-tmig, 118:337, 119:600-c
ex vivo induction by bile salts and acid exposure, 118:457-tmig, 118:487
and function of, in gastric muscle (mice), 122:1442
in hepatocytes, regulation by CCAAT/enhancer-binding proteins, 119:493
in hereditary nonpolyposis colorectal cancer, 117:291-tmig, 117:350
in intestinal myofibroblasts, IL-1α-induced, PKCz-ROS pathway in, 124:1855
in murine intestinal tumors, 119:600-c
and gastroprotective prostaglandins, 121:1262-c
induction in esophageal mucosa, duodenal reflux and bile acids in (rat), 121:1391, 121:1502-e
in infectious diarrhea, 122:1069
inhibition
for Barrett's esophagus, 123:1-tmig, 123:50
and NSAID-induced gastric damage (rat), 119:610-tmig, 119:706
and prevention of Barrett's-related esophageal adenocarcinoma (rat), 122:1100, 122:1171-e
and prevention of colorectal cancer, 119:267-ss
and prevention of colorectal neoplasia, 125:404
and prevention of colorectal polyps, 125:285-tmig, 125:328, 125:404
and prevention of familial adenomatous polyposis, 119:1797-ss
and prevention of hepatic fibrosis (rat), 125:286-tmig, 125:556
and prevention of intestinal polyposis, 122:234-ss
and renal function in cirrhosis (rat), 116:1024-tmig, 116:1167
inhibitors, 118:457-tmig, 118:487, 119:521-srr
in arthritis management, 119:521-srr, 125:637-c
chronic therapy with, GI resource use with, 125:389
effects on gastroduodenal mucosa, 117:776, 117:1002-e, 118:638-c, 118:639-c, 118:640-c
gastrointestinal effects of, 116:512-gn, 117:4-gn
gastrointestinal safety of, 119:521-srr
and NSAID-induced gastric damage (rat), 119:610-tmig, 119:706
and relapse of inflammatory bowel disease, 125:637-c
and risk of lower GI events, 124:281-tmig, 124:288

therapeutic roles of, 122:241-pmr
therapy with, during NSAID use, 120:594
in intestinal epithelial cells, leukotrienes and, 119:890-tmig, 119:1007
and intestinal integrity (mice), 122:1913, 125:637-c
in pancreatitis-associated lung injury (mice), 123:1311
prostanoid production via, and postoperative ileus (mice, rats), 121:1269-tmig, 121:1354
and tumor angiogenesis in colorectal cancer, 121:1339

Cyclooxygenase-3 (COX-3), and colorectal carcinoma growth, 120:1721, 120:1872-e

Cyclooxygenase-4 (COX-4), and gastroprotective prostaglandins, 120:784-tmig, 120:867

Cyclooxygenase-5 (COX-5), inhibitor, therapy with, during NSAID use, 120:594

Cyclooxygenase-6 (COX-6), and persistent postinfective enteric muscle dysfunction (mice), 120:1713

Cyclooxygenase-7 (COX-7), TNF-α-induced expression of, in colonic epithelial cells, phosphatidylinositol 3-kinase and, 120:1117

Cyclooxygenase-8 (COX-8), transcription in human colon carcinoma cells, colonic luminal contents and, 120:332-tmig, 120:401

Cyclophosphamide, for autoimmune hepatitis, 120:1502-srr

Cyclosporin A
for Crohn's disease with fistulous complications, 119:1132-srr, 124:1595
effects on hepatic immunoregulation, CD95 (Apo-1/Fas) ligand and (rat), 116:666

Cyclosporine
for autoimmune hepatitis, 120:1502-srr
for glucocorticoid-resistant nongranulomatous chronic idiopathic enterocolitis, 117:1259-c
intravenous, in ulcerative colitis, 125:1025
for perianal Crohn's disease, 125:1503-aga, 125:1508-aga
as single therapy for acute ulcerative colitis, 120:1317-tmig, 120:1323, 120:1541-e, 121:1530-c

CYP8b1. *See* Sterol 12α-hydroxylase

CYP2C19 polymorphism, and effects of omeprazole on intragastric pH and plasma gastrin, 119:609-tmig, 119:670

Cysteinyl-leukotrienes, and intrahepatic vascular resistance in cirrhosis (rat), 122:387

Cystic fibrosis
meconium ileus in, molecular genetics of, 119:268-ss
pancreatic acinar cell dysfunction in (mice), 121:752-tmig, 121:950
pancreatitis in, genotype and phenotype correlations in, 123:1857, 125:1286-c

Cystic fibrosis transmembrane conductance regulator
activation, and chloride secretion from homozygous ΔF508 murine intestines, 116:1379
and alternative chloride conductances in gut, 119:32
and bicarbonate secretion, 118:1051, 118:1187, 118:1258-e
chloride channels, in crypt cells, inhibitory effect of boiled rice on, 116:1282-tmig, 116:1342
DF508, as chloride channel, 119:32
gene *(CFTR),* mutations, and chronic pancreatitis, 121:1310, 121:1509-e
inhibition of intestinal Na^+/H^+ exchange (mice), 125:1148
knockout mice, pancreatic dysfunction in, 121:752-tmig, 121:950
mutations, and chronic pancreatitis, 120:682
in pancreatic bicarbonate secretion, 117:275-ss
in pancreatic duct cells, inhibition by bicarbonate (guinea pig), 118:1187

Cysts
hepatic, and renovascular hypertension, 121:745-c
pancreatic, endoscopic ultrasound of, 122:1631

Cytochrome b, duodenal, in iron disorders, 125:746

Cytochrome P-450
CYP1A, expression, chargrilled meat diet and, 117:89
CYP3A
and drug therapy, 125:240-srr
expression, chargrilled meat diet and, 117:89
CYP2C19, polymorphism, and drug therapy, 125:240-srr
CYP2D6, polymorphism, and drug therapy, 125:240-srr
hepatic, impairment of, by indomethacin (rat), 122:774

Cytochrome P-451, CYP8b1, and regulation of bile acid pool composition (rat), 120:1801

Cytochrome P-452, CYP4502E1, ethanol-induced, and retinoic acid metabolism (rat), 120:179

Cytokeratin, immunoreactivity, in diagnosis of short-segment Barrett's esophagus, 119:609-tmig, 119:683

Cytokines
in acute *H. pylori* infection (Rhesus macaque), 118:247-tmig, 118:307
and aortic eNOS up-regulation in cirrhosis (rat), 122:1869
and bystander hepatitis (mice), 123:1252
CCK-8-induced expression of, ethanol diet and (rat), 117:706
in colitis, in T-cell receptor α mutant mice, 116:233-tmig, 116:320
and colitogenic CD4 T cells, 123:1949
and ductular secretion, 124:737, 124:847-e
in gastrointestinal function and disease, 123:2064-srr
and heat shock protein expression in colonic epithelial cells (mice), 124:1175-tmig, 124:1395
in intestinal T cells, in childhood celiac disease, 123:667, 125:1560-c
Kupffer cell production of, leptin deficiency and (mice), 123:1304
in mucosal immune response (mice), 122:1829
and NOD2/CARD15 gene expression in epithelial cells, 124:875-tmig, 124:1001, 124:1145-e
and nuclear RARα:RXRα levels, in obstructive cholestasis, and regulation of Mrp2 expression (rat), 123:599
polymorphisms, in autoimmune hepatitis, 117:522-tmig, 117:645, 117:728-e
proinflammatory
gene polymorphisms, and risk of gastric cancer, 124:1193
inhibition of cholangiocyte functions (rat), 121:156
regulation of chemokine secretion in human pancreas, 119:211
release in intestinal smooth muscle cells, neurotransmitters and (rat), 116:346
Th1- and Th2-type, in hapten-induced colitis (mice), 119:724
T helper (Th)1-like, in concanavalin A-induced hepatitis, inhibition by NO-aspirin derivative, 118:404
therapy with, for hepatitis B, 120:1828-srr

Cytology, in Barrett's esophagus, 122:1569

Cytomegalovirus (CMV)
colitis caused by, 125:8-im
gastritis, evolution to chronic gastrointestinal dysmotility in nonimmunocompromised adult, 116:953-cr
in gastrointestinal lymphoma, 123:390-c
immune reaction to, in liver transplant patients, 122:1201
in inflammatory bowel disease, 123:390-c
Cytotoxin associated gene product A (CagA), as marker for *Helicobacter pylori* exposure, 121:751-tmig, 121:784

Daclizumab, for inflammatory bowel disease, 122:1592, 124:2005-c
Data analysis
in clinical trials, logistic regression and, 124:1561-c
methods for, 124:878-ce
D-cells, gastric, regulation by nitric oxide (rabbit), 123:566
ddC. *See* Zalcitabine
ddI. *See* Didanosine
Death receptor, apoptosis induction through, 121:1242-e
Death receptor 5 gene (*DR5*), inactivating mutations, in gastric cancer, 121:1219
Defecation, impaired, tests for diagnosis or management of
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
Defecography
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
in constipation, 119:1766-aga
in evaluation of pelvic floor, 122:1701
in fecal incontinence, 124:1672
Degos' disease, cutaneous features of, 124:1595
Delavirdine, GI toxicity and GI-associated drug interactions of, 120:607
Dendritic cells
impaired allostimulatory function of, in chronic hepatitis C, 120:512
recruitment to liver, Kupffer cell-mediated, mechanisms for (rat), 121:1460
Dental prosthesis, worn, and systemic foreign body granulomatosis, 121:1234-cr
Deoxycholic acid
colonic formation of, and cholesterol cholelithiasis, 119:610-tmig, 119:806, 120:1310-c
kinetics, intestinal transit and, 121:812

Depression
in hepatitis C, 124:1711
with pegylated interferon, for hepatitis C, 124:1711
and postinfectious IBS, 125:1651
Dermatitis herpetiformis, 120:1526-aga
cancer risk in, 123:1428, 123:1726-e
clinical features of, 124:1595
tissue transglutaminase antibodies in, 117:749-c
Dermatomyositis, clinical characteristics of, 124:1595
Descending perineum syndrome, constipation in, 119:1766-aga
Desipramine, for functional bowel disorders, 125:19, 125:249-e
Developing nations, posttherapeutic recurrence of *Helicobacter pylori* in, 123:653-c
Development, of human gastrointestinal tract, 116:702-srr
Developmental biology, of gastrointestinal tract, 120:1883-pmr
Dextran sulfate, effect on *H. pylori* urease adherence to mucin and lipopolysaccharides, 119:287-tmig, 119:358
Dextran sulfate sodium, colitis induced by
development of dysplasia and neoplasia in, germline mutation in Apc and (mice), 121:1407
impaired nNOS expression in (rat), 118:714
prevention, by dietary glycine (rat), 125:775
recovery from, in transgenic mice overexpressing growth hormone, 120:925
Diabetes mellitus
and acute hepatic failure in, 122:1822
in chronic pancreatitis, risk factors for, 119:1186-tmig, 119:1324
emphysematous gastritis in, 118:1000-im
fibrocalculous pancreatic, *SPINK1* gene mutations and, 123:1026
hepatogenous, pathogenesis of, 119:1800-ss
in pancreatic cancer, 121:640
small intestinal mucosal protein synthesis in, 118:299
streptozotocin-induced, hepatic ABC-transporter expression in (rat), 122:1842
type 2
glycemic control in, dietary fiber and, 119:1168-ss
iron metabolism and hepatic steatosis in, 118:986-c
and nonalcoholic fatty liver disease, 122:1649
obesity and, 123:882-aga
SPINK1 gene mutations and, 123:1026
Diabetic gastropathy, sildenafil therapy in animal models of, 120:576-ss
Diagnosis, evidence-based approach to, 116:1230-srr
Dialysis-related amyloidosis, and gastrointestinal symptoms, 116:217-ss
Diarrhea. *See also* Congenital sodium diarrhea
acute, in children, management of, 120:783-tmig, 120:799
bacterial, multidrug-resistant, 117:3-gn
chronic, evaluation and management of
AGA medical position statement on, 116:1461-aga
AGA technical review on, 116:1464-aga
in collagenous colitis, 124:2000-c
mechanisms of, 123:401-tmig, 123:433
enteropathogenic *Escherichia coli*-induced, molecular mechanisms of, 121:496-ss
enterotoxigenic *Escherichia coli*-induced, resistance to, dietary calcium and, 125:286-tmig, 125:469
in giardiasis, pathogenesis of, mechanisms of, 123:964-tmig, 123:1179, 125:277-c
in HIV-infected (AIDS) patients, pathophysiology of, 124:282-tmig, 124:368
infectious
resistance to, dietary calcium and, 125:286-tmig, 125:469
role of iNOS and COX-2 in, 122:1069
neural mechanisms in, 118:651-gn
osmotic, guanylin and uroguanylin in (mice), 121:1191
persistent, in children, treatment of, green banana and pectin in, 121:554
in SARS-coronavirus infection, 125:1011-rc
with small intestinal bacterial overgrowth, antibiotic therapy for, 117:755-tmig, 117:794
Diclofenac
enteropathy induced by, drug-enterocyte adducts in (rat), 119:1537
prevention of post-ERCP pancreatitis, 124:1722-tmig, 124:1786, 124:1977-e

Didanosine, GI toxicity and GI-associated drug interactions of, 120:607
Diet(s)
for attenuation of ARDS, 119:592-ss
carbohydrate-restricted, effects of, 125:650-gn
and colorectal cancer, 119:590-ss, 122:1715-tmig, 122:1784
defined-formula, 122:1677
gluten-free, for irritable bowel syndrome patients with latent/potential celiac disease, 121:1329, 121:1512-e
hospital, 122:1677
and risk of gastric cancer, 124:2006-c
weight loss, for adolescents, and weight gain, 125:1572-gn
Diet therapy, for obesity, 120:669
Dieulafoy's lesion, 118:820-im
Digestive disease, economic and social costs of, in United States, 122:1500-srr
Digestive disease centers, economics of, 118:461-ce
Digestive Disease Week 2002, online abstract submissions for, 121:1271-gn
Digestive system. *See also* Gastrointestinal tract
cell proliferation in, rhythms of, 119:536-srr
function, circadian variations in, 119:536-srr
ultrastructure of, circadian variation in, 119:536-srr
Dihydropyrimidine dehydrogenase, and 5-fluorouracil therapy, 125:240-srr
Dimethylsulfoxide, for renal dysfunction caused by systemic amyloidosis in Crohn's disease, 117:1031-c
Dinitrobenzene sulfonic acid, colitis induced by, aggravation by cigarette smoke (rat), 117:877, 117:1008-e
Dipeptides, intestinal absorption of, apical NHE3 activity and, 122:1314
Disaccharides, and IL-8 and IL-1b secretion by intestinal epithelial cells, 120:449
Divalent metal transporter 2, expression of, in iron deficiency and iron overload, 120:1317-tmig, 120:1412
Divalent metal transporter 3, intestinal iron uptake determined by, in HFE-deficient mice with hemochromatosis, 120:1420
Diverticular bleeding, acute, urgent endoscopy with endoscopic therapy for, 118:978-ss
Diverticular disease, gastroenterologist training in, 124:1062-aga
DMP 777, reversible oxyntic atrophy caused by (rat), 118:1080
DNA (deoxyribonucleic acid)
abnormalities, in stool, in colorectal cancer screening, 124:544-aga
base excision repair, nitric oxide-mediated inhibition of, 120:190
hepatitis B virus, serum levels of, in inactive HBV carriers, 122:2092-c
hypomethylation of, low folate status and, and risk of colorectal neoplasia, 124:1240
immunostimulatory, modulation of experimental colitis (mice), 122:1428
JC virus, in human gastrointestinal tract, 119:1228
methylation
in duodenal carcinoma, 124:1300
in intraductal papillary mucinous neoplasms of pancreas, 123:365
in sporadic colorectal cancer, 122:1196-tmig, 122:1376
microsatellite instability, in colorectal cancer, 123:862-srr
mismatch repair
in colon carcinogenesis, 119:854-srr
in gastric epithelial cells, *Helicobacter pylori* and, 123:542
mitochondrial
alcohol-induced degradation of, in liver (mice), 117:181, 117:265-e
alcohol-induced depletion of (mice), 123:1278
ethanol-induced oxidative stress and, 122:2049-srr
mutation, in gastric cancer, 118:835
nuclear, mutation, in gastric cancer, 118:835
oxidative damage, in cholangiocytes, 120:190
repair genes, inactivation of, in colorectal cancer, 123:862-srr
stool screening for, in colorectal cancer detection, 119:1219
Doppler, Christian Johann, 125:1590
Doppler ultrasound
in acute mesenteric ischemia, 118:954
intravascular, in assessment of hepatic artery flow volume in cirrhosis, 116:906
DPC4, and progression of pancreatic intraepithelial neoplasia, 123:645-ss
DRA (down-regulated in adenoma), and intestinal bicarbonate secretion (rabbit, rat, human), 122:600-tmig, 122:709
Dreher, Carol M., as executive vice president of FDHN, 123:3-gn
Drinking tests, in functional dyspepsia, 122:2093-c
Drugs
abuse of, in hepatitis C patients, 123:402-tmig, 123:476
approval and surveillance programs for, challenges in, 119:1429-ce
design of, structural biology and, 123:1350-srr
development
in gastroenterology, 118:460-gn, 118:653-ce
review of, 121:498-pmr
and patient care, principles of, 125:7-ce
postapproval surveillance in, and interests of patients, 120:5-ce
expedited review of, 125:289-gn
and liver chemistry tests, 123:1367-aga
metabolism of, in cirrhosis, oxygen supplementation and, 116:915, 117:1025-c
pharmacogenetics of, and clinical gastroenterology, 125:240-srr
Drug therapy, review of, 124:1159-pmr
d4T. *See* Stavudine
Dubin-Johnson syndrome, *MRP2* gene mutations in, exon-intron organization of, 117:653
Duck hepatitis B virus (DHBV), large envelope protein, DNA-based immunization against, 116:658
Dukes, Cuthbert Esquire, 118:828
Duodenal metal transporter (DMT-1), in hereditary hemochromatosis, 118:632-ss
Duodenal switch, for obesity, 120:669
Duodenal ulcers
acid output and, 116:1217-vodd
gastritis and, 116:1217-vodd
H. pylori cagA genotype and, 116:233-tmig, 116:259
location of, in relation to antroduodenal transitional zone, 116:1217-vodd
Duodeno-gastroesophageal reflux
and COX-2 induction in esophageal mucosa (rat), 121:1391, 121:1502-e
and esophageal mucosal injury during mechanical ventilation, 116:1281-tmig, 116:1293
Duodenum
bicarbonate secretion in (rabbit, rat, human), 122:600-tmig, 122:709
bicarbonate transport in (rabbit), 119:406
carcinoma of, epigenetic and genetic alterations in, 124:1300

defects of, in AR/EGF/TGF-α triple null mice, 121:68
H. pylori infection of, 116:233-tmig, 116:259
hyperalgesia, in sphincter of Oddi dysfunction type III, 116:900, 116:996-e
hypersensitivity to acid infusion, in dyspepsia, 116:509-tmig, 116:515, 116:761-e
mucosal bicarbonate secretion, 5-HT and (mice), 125:805
pain and biomechanical responses to distention in, in systemic sclerosis, 124:1230
primary amyloidosis of, 125:1302-im
wind sock web deformity of, 119:292-im

Dwarfism, nutritional, clinical features of, 122:1677

Dynorphin A, and colonic transit (rat), 119:1-tmig, 119:71

Dyslipidemia
and nonalcoholic fatty liver disease, 122:1649
obesity and, 123:882-aga

Dysmotility
antibody-mediated, in scleroderma, 123:1144
paraneoplastic, anti-HuD–induced apoptosis in enteric neurons and, 125:70
skin signs of, 124:1595
in small intestine, intestinal failure caused by, 124:1615

Dyspepsia. *See also* **Heartburn**
aspirin-related, visceral sensory function and, 123:1451
causes of, 125:1219
chemical stimulation and, 125:1410
clinical management of, 125:1219
definition of, 125:1219
diagnosis of, research needs in, 117:1269-ce
effect of population screening and treatment of *H. pylori* on, 119:1795-ss
in elderly, 122:1688
endoscopy in, age cutoff for, 123:2149-ss
epidemiology of, 125:1219
evaluation of, 122:1688
functional
acute-onset
clinical features of, 122:1738
pathophysiology of, 122:1738
antro-fundic dysfunctions in, 124:1220
differential diagnosis of, 122:1701
drinking capacity in, noninvasive assessment of, 121:1054
drink tests in, 122:2093-c
fundic capacity in, noninvasive assessment of, 121:1054
heterogeneity of, 124:903
hypersensitivity to gastric distention in, 121:526
noninvasive assessment of, 121:1054
hypnotherapy for, 123:1778, 123:2132-e, 125:636-c
proximal stomach motor function in, noninvasive assessment of, 121:1054
psychological treatment of, 119:609-tmig, 119:661, 119:869-e
and visceral afferent nervous system, 116:495-ss
management, 120:1298-ss
in primary care, 122:1270, 122:1521-e
natural history of, 125:1219
nausea in, duodenal acid sensitivity and, 116:509-tmig, 116:515, 116:761-e
nonulcer, *Helicobacter pylori* and, 117:270-ss, 121:735-ss
rates of, after *H. pylori* screening and eradication, 125:372
test-and-treat for, 122:1270, 122:1521-e
treatment of, 122:1688
research needs in, 117:1269-ce

Dysphagia
with benign disorders of distal esophagus
barium swallow in, 117:233-aga
diagnosis of, 117:233-aga
endoscopy in, 117:233-aga
esophageal manometry in, 117:233-aga
esophageal transit scintigraphy in, 117:233-aga
physical findings in, 117:233-aga
treatment of, 117:229-aga, 118:235-c
videofluoroscopy in, 117:233-aga
due to abnormal UES opening, rehabilitative exercise for, 122:1314
in elderly, 122:1688
esophageal, 122:1688
evaluation of, 122:1688
familial gastrointestinal stromal tumors with, 122:1493-cr
neuromyogenic, self-report symptom inventory in, 118:649-tmig, 118:678
in oculopharyngeal muscular dystrophy, botulinum toxin treatment of, 119:1416-c
oropharyngeal, 122:1688
quantitative assessment of, 118:649-tmig, 118:678
in patient with lateral medullary syndrome, 121:420-cr
syndromes associated with, skin signs of, 124:1595
treatment of, 122:1688
vascular anomalies and, 117:1270-im

Dysplasia
in Barrett's esophagus
and cancer risk, 122:1569
diagnosis of, interobserver variability in, 125:260-ss
and cancer of esophagus and esophagogastric junction, 116:277
flat low-grade, in ulcerative colitis, progression to advanced neoplasia, 125:1311, 125:1531-e
in pouch, 124:1636
risk of, in ileal pouch and pouches with chronic pouchitis, 121:268

Dysplasia-associated lesion or mass (DALM)
adenoma-like, in chronic ulcerative colitis, treatment of, 117:1265-tmig, 117:1288, 117:1295, 117:1488-e, 118:1277-c
colonoscopic treatment of, 118:1277-c
in IBD, 119:879-c

Dysrhythmias, gastric electrical, gastric electrical stimulation and (dog), 124:401

Eating disorders, ghrelin and, 125:1492-srr

Eberth, Karl Joseph, 122:852

E-biomed, and peer-reviewed publication, 117:293-gn, 117:1040-gn

***E-cadherin* mutations**
and *Apc* mutations, synergistic effects in intestinal tumorigenesis (mice), 119:1045, 119:1161-e
carriers, gastric and breast cancer risk in, 121:1348
germline
and gastric cancer risk, 123:1406-c
in hereditary diffuse gastric cancer, 122:830-ss

Echinococcosis
cystic, percutaneous ivermectin therapy for (sheep), 122:956
hepatic alveolar, interferon α-2a and (mice), 124:1441
hepatic involvement in, 117:1042-im

Economics
of antireflux surgery versus medical management, 122:1178-ss
of aspirin for prevention of colorectal cancer, 122:1-tmig, 122:78, 122:230-e
of colorectal cancer screening, 124:856-ss, 125:1645
racial/ethnic patterns of disease and, in U.S., 120:848, 120:1043-e
of COX-2 inhibitors versus NSAIDs, 125:389
of CT colonography, 124:911
of digestive disease centers, 118:461-ce

of esophageal cancer prevention, 124: 1758, 125:1268-ss
of gastroesophageal reflux disease, 125: 981-ss
of gastrointestinal and liver disease, in United States, 122:1500-srr
of HCFA policy, effects on gastroenterologists and Medicare patients, 120:3-gn
and health-care restructuring, 118:461-ce
of hepatitis C treatment, 118:1268-ss
of inflammatory bowel disease, 125:982-ss
of initial medical management for Crohn's disease perianal fistulae, 120:1640
of managing GI risk in patients taking NSAIDs, 120:594
of medical management of perianal fistula in Crohn's disease, 122:1186-c
of Medicare cuts to physicians, 124:877-gn
of NIH Clinical Research Loan Repayment Program, 121:1035-gn
of precertification of pharmaceuticals, 121:965-aga
of propofol for advanced upper endoscopy, 123:8, 123:373-e
of psychotherapy and paroxetine for IBS, 125:1554-c
of reimbursement for ambulatory endoscopy, 122:849-gn
of research funding initiative in Germany, 120:334-gn
of screening endoscopy in cirrhosis, 122: 1620
of screening for Barrett's esophagus, 125: 1268-ss
of step-down therapy for gastroesophageal reflux disease, 121:1034-tmig, 121:1095

Editorials

Acid and bile reflux in Barrett's esophagus: a tale of two evils, 121: 1502
Adhesion molecules in lymphocyte trafficking and colitis, 121:1008
Alagille syndrome and the notch signaling pathway: new insights into human development, 116:1257
ALM vs. DALMs in ulcerative colitis: polypectomy or colectomy?, 117: 1488
Alternatives to liver transplantation: from hepatocyte transplantation to tissue-engineered organs, 118: 438
Angiotensin receptor blockade and portal hypertension: paradise gained and paradise lost, 121:487
Antireflux surgery and adenocarcinoma of the esophagus: let the truth be told, 121:1506
APC as checkpoint gene: the beginning or the end?, 123:935
Apoptosis–programmed cell death and its relevance to gastrointestinal epithelium: survival signal from the matrix, 120:294
Barrett's esophagus: an overrated cancer risk factor, 119:587
Barrett's-related esophageal cancer: has the final hurdle been cleared, now paving the way for human chemoprevention trials?, 122:1171
Bicarbonate secretion and CFTR: continuing the paradigm shift, 118:1258
Bile acids and hepatocyte apoptosis: living/leaving life in the Fas lane, 117:732
Bile-ology 101, 121:218
Biliary lipid secretion, membrane pumps, and the metabolic response to fasting: distinct PPAR-ts of a common regulatory pathway, 124:254
A biliary milestone: functional expression of the human bile salt export pump, 123:1733
Biofeedback for fecal incontinence, 125: 1533
Branched-chain amino acid-enriched supplemnents as therapy for liver disease: Rasputin lives, 124:1980
The brute force approach to electrical stimulation of gastric emptying: a future treatment for refractory gastroparesis?, 118:433
Cancer, crash sites, and the new genetics of neoplasia, 116:210
Cancer risk in celiac disease, 123:1726
Cannabinoids and the gut, 125:973
Carbon monoxide and sepsis: is a toxic gas good for your liver?, 120: 1288
Carcinogenesis at the gastroesophageal junction: free radicals at the frontier, 122:1518
A case for an immunological basis for irritable bowel syndrome, 122: 2078
Celiac disease: a future without gluten-free diet??, 125:1264
Celiac disease pathogenesis: the plot thickens, 123:939
Chemokines regulate lymphocyte homing to the intestinal mucosa, 120:291
Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints, 123:2135
Chronic liver disease and health-related quality of life, 120:305
Colorectal cancer: not an equal opportunity cancer, 120:1043
The color of dysplasia in ulcerative colitis, 124:1135
Combining T cells and IL-10: a new therapy for Crohn's disease?, 123: 2140
Commensal bacteria as targets in Crohn's disease, 119:254
Connecting apical endocytosis to the intracellular traffic infrastructure in polarized hepatocytes, 119: 1791
The cost-effectiveness of aspirin for chemoprevention of colorectal cancer, 122:230
"Cutting the cord" for capsule endoscopy, 123:1385, 125:998-c
Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?, 117: 1002
Defining nonalcoholic fatty liver disease: implications for epidemiologic studies, 124:248
Defining optimal treatment for stage II colon cancer: does decision analysis help?, 117:1005
Deflating postoperative ileus, 117:489
Disputing dysplasia, 120:1864
Do mucosal T cells prevent intestinal inflammation?, 118:974
Do we need to perform rectal distention tests to diagnose IBS in clinical practice?, 122:2075
Dyspepsia management in the millennium: the death of test and treat?, 122:1521
Early events in sepsis-associated cholestasis, 116:486
Early virus infections and IBD: back to the drawing board?, 116:988
Effects of alcohol on hepatic mitochondrial function and DNA, 117: 265
Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal hemorrhage: what makes the difference?, 123:1388
Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology, 120:1872
Esophageal manometry prior to antireflux surgery: required, preferred, or even needed?, 121:214
Esophagogastric junction opening: does it explain the difference between

normal subjects and patients with reflux disease?, 125:1258
EUS FNA staging of esophageal cancer, 125:1883
Experimental colitis and reduction of food intake: what are the mechanisms?, 118:625
Failure to yield: drug resistance in inflammatory bowel disease, 122:1164
The fall and rise of the hiatal hernia, 119:1779
Fecal calprotectin in Crohn's disease: new family ties, 124:1972
Functional dyspepsia: a case of indecision, 116:761
Further characterization of human brain processing of viscero-sensation: the role of gender and a word of caution, 124:1975
Gastric cancer and *H. pylori*: host genetics open the way, 121:1002
Gastric cardia cancer and dietary fiber, 120:568
Gastroenterologists and choosing the right bisphosphonate, 119:866
Gene mutations and idiopathic chronic pancreatitis: clinical implications and testing, 121:1506
Genomics and phenomics in Crohn's disease, 122:1160
Ghrelin-leptin tango in body-weight regulation, 124:1532
GISTs: the revolution continues, 125:967
GLP-2 as therapy for the short-bowel syndrome, 120:1041
Glucose-derived osmolytes and energy impairment in brain edema accompanying liver failure: the role of glutamine reevaluated, 125:976
Good cholesterol, bad cholesterol: role of oxysterols in biliary tract diseases, 121:216
The growing case for hypnosis as adjunctive therapy for functional gastrointestinal disorders, 123:2132
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion, 116:479
Helicobacter pylori acquisition and transmission: where does it all begin?, 121:483
Helicobacter pylori factors associated with disease, 117:257
Hepatitis C virus in solid organ transplantation: not always a bad thing, 123:1729
Hepatitis C virus proteins: direct link to hepatic oxidative stress, steatosis, carcinogenesis and more, 122:568
Hepatitis C virus replicons finally get to second base, 125:1892
Hepatitis C virus-specific $CD4^+$ T cells: do they help or damage?, 117:1012
Hepatocyte transplantation: new possibilities for therapy, 124:568
Hepatopulmonary syndrome: a good relationship gone bad, 125:1261
Hereditary hemochromatosis and alcohol: a fibrogenic cocktail, 122:563
A hitchhiker's guide to the galaxy-an *H. pylori* travel guide, 124:1983
HMG-CoA reductase inhibitors for the treatment of pancreatic cancer, 122:565
HNPCC: an uncommon but important diagnosis, 121:1005
How can mathematics help us understand HCV?, 120:1546
Human papillomavirus infection: an emerging problem in anal and other squamous cell cancers, 120:1046
Identification of a new chloride channel: a sweet story?, 120:299
Identifying new risk factors for spontaneous bacterial peritonitis: how important is it?, 117:495
If aggressive surveillance in hereditary nonpolyposis colorectal cancer is now state of the art, are there any challenges left?, 118:969
IL-6: a magic potion for liver transplantation?, 125:256
From immune activation to gut tissue injury: the pieces of the puzzle are coming together, 117:1238
The impact of surgery for ulcerative colitis on fertility and sexual function in women, 122:226
Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue, 120:1281
Insulin resistance and tissue repair: a "fato-logical" phenomenon, 125:1889
Intestinal epithelial cells and innate immunity in the intestine: is CARD15/NOD2 another player?, 124:1145
Intrahepatic cholestasis: order out of chaos, 117:1496
Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone?, 120:1541
Irritable bowel syndrome: how far do you go in the workup?, 121:1512
Irritable bowel syndrome in childhood, 120:287
Is EXO1 a colon cancer predisposition gene?, 120:1860
Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?, 123:375
Is there a "Barrett's iceberg?", 123:636
Is there a role for PPARg in IBD? Yes, no, maybe, 124:1538
Is virtual colonoscopy ready for widespread application?, 125:608
Lamivudine therapy for chronic hepatitis B: is longer duration of treatment better?, 119:263
Leptin and liver fibrosis: a matter of fat, 122:1529
Less degradation, more shock, please, 116:994
Liver fibrosis and Na^+/H^+ exchange, 120:572
Living and commuting in intestinal crypts, 116:208
Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy, 121:1239
Maintaining a defense as the injured leave the field: apoptosis and barrier function in the intestine, 119:1783
Management of ulcers with adherent clots, 123:632
Managing functional bowel disorders from the top down: lessons from a well-designed treatment trial, 125:249
Mandate to modify a medicinal mantra: maybe not yet?, 124:842
The many faces of low-grade dysplasia, 125:1531
MDR3 mutations: a glimpse into Pandora's box and the future of canalicular pathophysiology, 120:1549
MELD: the answer or just more questions?, 124:251
6-Mercaptopurine beats a bum rap, 125:610
6-mercaptopurine in maintaining remission in Crohn's disease: an old friend becomes a new hero, 119:1158
Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there?, 118:436
Methotrexate in the treatment of primary biliary cirrhosis: the hype and the hope, 117:492
Moderate alcohol drinking: effects on the heart and liver, 119:1399

More clues to the relationship between hepatic iron and steatosis: an association with insulin resistance?, 117:1241
Morphogenesis and maintenance of the gastric epithelium: a role for sonic hedgehog?, 121:485
Mortality in inflammatory bowel disease: peril and promise, 125:1881
A mouse model of intestinal fibrosis?, 125:1886
Much to do about gas, 123:933
Multistep progression of colorectal cancer in the setting of microsatellite instability: new details and novel insights, 121:1497
Neurokinin 3 receptors in the gut: a new target for the treatment of visceral pain, 116:1250
Neuropathology of IBS?, 123:2144
Neuropeptides and colonic motility: it's all in the little brain, 119:257
New insights into acute hepatitis C, 125:253
New insights into oral tolerance, 119:260
New life in a sleeper: thalidomide and Crohn's disease, 117:1485
A new model system to study Norwalk virus immunity, 117:255
New strategies to enhance gene therapy efficacy, 123:639
NF-κB activation in acute pancreatitis: protective, detrimental, or inconsequential?, 116:489
NSAIDs and esophageal cancer: ready for trials but not yet broad clinical application, 124:246
Nutrient regulation of intestinal growth and adaptation: role of glucagon-like peptide 2 and the enteroendocrine cell, 117:261
Octreotide and its effects on portal circulation, 120:303
Optical biopsies, "bioendoscopy," and why the sky is blue: the coming revolution in gastrointestinal imaging, 122:571
Pancreatic polypeptide: more than just another gut hormone?, 124:1542
Pancreatic severity: who calls the shots?, 122:1166
Pancreatitis and associated lung injury: when MIF miffs, 124:844
Patient and graft survival following liver transplantation for hepatitis C: much ado about something, 122:1161
Pentoxifylline and alcoholic hepatitis, 119:1787
Phospholipid flippase, low HDL levels, and intestinal fat absorption: a new look at the ABCs of enterohepatic lipid flux, 118:225
p16^{INK4}: involvement early and often in gastrointestinal malignancies, 116:483
(Post) inflammatory visceral hyperalgesia: don't we believe what we don't see?, 122:823
Potential roles for chemokine receptor CCR5 in the pathobiology of hepatitis C infection, 122:2069
PPARg ligands: taking ppart in chemoprevention, 124:564
Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize, 124:1140
Prevention is the best defense: probiotic prophylaxis of pouchitis, 124:1535
Prevention of post-ERCP pancreatitis: pharmacologic solution of patient selection and pancreatic stents?, 124:1977
Primary biliary cirrhosis: past, present, and future, 123:1392
Probiotics in chronic pouchitis: restoring luminal microbial balance, 119:584
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?, 116:1246
Progress in understanding acalculous gallbladder disease, 120:570
Propofol for conscious sedation?, 123:373
Protein kinase C isozymes in colon carcinogenesis: guilt by omission, 120:1868
The prothrombin G20210A mutation: a new high-prevalence congenital risk factor for thrombosis, 116:213
Radiofrequency energy treatment of GERD, 125:970
"Real-time" polymerase chain reaction, 116:763
Recombinant interleukin 10 for the treatment of active Crohn's disease: lessons in biologic therapy, 119:1781
Rectal distention: from sensation to feeling, 118:972
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C, 122:1525
Risk stratification for periampullary carcinoma in patients with familial adenomatous polyposis: does Theodore know what to do now?, 121:1246
The role of glutathione *S*-transferase P1-1 in colorectal cancer: friend or foe, 121:1010
The role of immunocytes in acute and chronic pancreatitis: when friends turn into enemies, 118:626
Screening flexible sigmoidoscopy: effectiveness is not enough, 117:486
Searching for the needle in the haystack: another candidate needle in autoimmune hepatitis?, 117:728
Significance of biliary phospholipids for maintenance of the gastrointestinal mucosal barrier and hepatocellular integrity, 118:1265
On smoking, rats, and inflammatory bowel disease, 117:1008
Sphincter of Oddi dysfunction type III: another manifestation of visceral hyperalgesia?, 116:996
A spotlight on cholangiocarcinoma, 125:1536
Spreading and focusing of gluten epitopes in celiac disease, 122:2072
Sugar pills for pancreatic cancer: the benefits of becoming (insulin) sensitive, 120:1291
Surveying the case for surveillance, 122:820
Tales from the crypt, 124:561
Thrombophilia and colon ischemia: *Aura Popularis?*, 121:724
To differentiate or proliferate? The interaction between PI3K/PTEN and Cdx2, 123:1395
Touch and go: mediating cell-to-cell interactions and Wnt signaling in gastrointestinal tumor formation, 119:1161
Toward understanding (and management) of painful chronic pancreatitis, 116:1252
Transepithelial signaling: making sense of stomach contents, 120:1279
Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease, 121:1242
Tumor genomics vs. tumor genetics: a paradigm shift?, 121:726
Unlocking the secrets of the porcelain vase, 119:1397
Unsettling facts of life: bacterial commensalism, epithelial adherence, and inflammatory bowel disease, 122:228

The up-and-down of hepatic stellate cells in tissue injury: apoptosis restores cellular homeostasis, 120:1285
Ursodiol: good drug makes good, 124:1135
Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy, 118:1261
The virtuosity of hepatic stellate cells, 117:1244
A Wake-up Call? Unsedated versus conventional esophagogastroduodenoscopy, 117:1992
What's so (co)stimulating about the intestinal epithelium?, 117:726
What to choose for diagnosis of bleeding colonic angiomas: colonoscopy, angiography, of helical computed tomography angiography?, 119:581
When bile ducts say NO: the good, the bad, and the ugly, 124:847
When heredity is infectious, 118:222
Why should psychotherapy be a useful approach to management of patients with nonulcer dyspepsia?, 119:869
Will an aspirin a day keep the endoscopy away?, 125:612
Will impedance testing rewrite the book on GERD?, 120:1862
Will transplantation of a hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients?, 117:263
Working toward a *Helicobacter pylori* vaccine, 116:990
A year in the life of the gastric mucosa, 119:252
The Yin and Yang of intestinal differentiation: key roles for lipid signaling, 120:1543

Education and training, 116:228-c, 116:1014-c, 116:1283-gn. *See also* **American Gastroenterological Association, Gastroenterology Teaching Project publications**
and flexible career choices, 125:1301-ce
of gastroenterologists of next century, 117:1028-c
in gastroenterology, 118:459-gn, 118:999-ce
and clinical research, 121:515-ce
programs available for, 121:444-aga
gastroenterology core curriculum for, 124:1055-aga
gastroenterology fellowship training: a generation lost, 116:228-c
Gastroenterology Match in, 117:295-ce, 117:509-c
on management of common digestive and liver disorders, AGA's Spring Postgraduate course at DDW and, 124:1176-gn
postgraduate programs available, 117:461, 117:972

Efavirenz, GI toxicity and GI-associated drug interactions of, 120:607

Einhorn, Max, 117:10

Elderly. *See also* **Aging**
anorexia in, 122:1688. *See also* **Anorexia, of aging**
bacterial overgrowth in, 122:1688
constipation in, 122:1688
dyspepsia in, 122:1688
fecal impaction in, 122:1688
fecal incontinence in, 122:1688
gastrointestinal motility problems in, 122:1688
urease-based test for *H. pylori* in, sensitivity of, 116:1506-c
weight loss in
causes of, 122:1688
drugs causing, 122:1688
mnemonic for, 122:1688

Electrical stimulation
gastric, effects on vomiting and gastric dysrhythmias (dog), 124:401
of stomach (dog), 118:247-tmig, 118:258, 118:433-e

Electrogastrography
analysis of
computerized, 117:453-vidd
pitfalls in, 117:453-vidd
in children, 117:453-vidd
in clinical practice, 117:453-vidd
frequency spectra, interpretation of, 117:453-vidd
in research, 117:453-vidd

Electrolyte transport, CFTR-mediated, restoration through pharmacologic manipulation (mice), 116:1379

Electromyography, anorectal
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga

Electrophysiology, cardiac, in cirrhosis, 121:1209

Emesis. *See also* **Nausea and vomiting**
chemotherapy-related, neurokinin-1-receptor antagonist for, 117:737-ss
control of, cannabinoids for, 123:655-c

Emtricitabine, therapy with, for hepatitis B, 120:1828-srr

Endocannabinoids
and appetite, 123:655-c
and cholera (mice), 125:765, 125:973-e
and colonic motility (mice), 123:227
and colorectal cancer, 125:677, 125:973-e
in control of emesis, 121:767-rc, 123:655-c

Endocrine carcinoma, gastric, 117:510-c

Endocrine tumors
gastric, prognosis for, 116:532
pancreatic, microvessel density in, histoprognostic significance of, 125:1094

Endocytosis, apical, in hepatocytes, in situ (rat), 119:1692, 119:1791-e

Endoplasmic reticulum stress
and acetaldehyde regulation of mitochondrial glutathione transport, 124:708
homocysteine-induced, betaine and (mice), 124:1488

Endoscopic diagnostics, 120:763, 120:1304-pmr

Endoscopic mucosal resection, of gastric cancer, soft prelooped cap for, 125:621-ss

Endoscopic retrograde cholangiography (ERC), clinical applications of, 124:1686

Endoscopic retrograde cholangiopancreatography (ERCP)
clinical applications of, 124:1686
complications of, 124:1686
NIH panel's recommendations on, 122:601-gn
pancreatitis after
interleukin 10 and, 120:332-tmig, 120:498, 121:232-c, 121:233-c
prevention of
by diclofenac, 124:1722-tmig, 124:1786, 124:1977-e
by pancreatic duct stenting, 125:1274-ss
by secretin (abstract), 125:605-aga
protection against, by IL-10, 120:332-tmig, 120:498
propofol for, cost-effectiveness of, 123:8, 123:373-e

Endoscopic retrograde pancreatography (ERP), in diagnosis of pancreatitis, 120:682

Endoscopic ultrasound (EUS), 118:234-pmr, 122:1631
in acute pancreatitis, 122:1631
advances in (future directions for), 122:1631
of anomalous pancreaticobiliary union, 122:1631
in biliary tract, 124:1686
of biliary tumors, 122:1631
for cancer staging, 122:1631
in choledocholithiasis, 122:1631
in chronic pancreatitis, 122:1631

in diagnosis of pancreatitis, 120:682
in esophageal cancer, 122:1631
with fine-needle aspiration, for staging of esophageal cancer, effect on treatment, 125:1883-e, 1225:1626
of gallbladder, 116:1018-e, 122:1631
in gastric cancer, 122:1631
of gastroesophageal masses, 122:1631
guidance
for celiac plexus block, 122:1631
for fine-needle aspiration biopsy, 122:1631
for fine-needle aspiration of esophageal cancer, 125:1883-e, 1225:1626
for fine-needle injection of achalasia, 122:1631
for fine-needle injection therapy of tumors, 122:1631
for paracentesis, 122:1631
for pseudocyst drainage, 122:1631
for sclerotherapy, 122:1631
of gut wall, 122:1631
indications for, 122:1631
in inflammatory bowel disease, 122:1631
instrumentation for, 122:1631
interventional, 122:1631
intraductal, of pancreatic intraductal papillary-mucinous tumor, 122:34
of large bowel, 122:1631
of lymph nodes, 122:1631
of mediastinal masses, 122:1631
in neuroendocrine pancreatic tumors, 122:1631
of pancreas divisum, 122:1631
of pancreatic ampullary tumors, 122:1631
in pancreatic cancer, 122:1631
of pancreatic cysts, 122:1631
of pancreaticobiliary system, 122:1631
of perianal fistulas in Crohn's disease, 121:1064
in portal hypertension, 122:1631
principles of, 122:1631
propofol for, cost-effectiveness of, 123:8, 123:373-e
in rectal cancer, 122:1631
for preoperative staging, 123:24
of submucosal tumors, 122:1631
use of, atlas and manual for, 122:2088-pmr

Endoscopists, primary care, training of, 122:1226

Endoscopy
in acute biliary pancreatitis, 125:229
advances in, 122:242-pmr
in anorectal disorders
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
of Barrett's esophagus
in follow-up of high-grade dysplasia, 120:1617
spectroscopic detection of dysplasia in, 119:609-tmig, 119:677
bidirectional, in occult gastrointestinal bleeding, 118:201-aga
book on, 125:270-pmr, 125:989-pmr
in dyspepsia, age cutoff for, 123:2149-ss
erythromycin infusion before, 123:1-tmig, 123:17
esophageal mucosal resection using, in Barrett's esophagus with early cancer and high-grade dysplasia, 118:649-tmig, 118:670
in fecal incontinence, 124:1672
and gastric intestinal metaplasia, 125:586
for gastric mucosal resection, perforations caused by, endoscopic closure using clips, 125:1896-ss
gastroenterologist training in, 124:1080-aga
gastrointestinal, 120:1304-pmr
history of, 121:738-pmr
of leiomyosarcoma, 122:605-im
in management of postoperative bile duct strictures, long-term results with, 122:1533-ss
nursing in, book on, 124:579-pmr
in occult gastrointestinal bleeding, 118:201-aga
office-based, standards for, 121:440-aga
patterns of use, in United States, 118:619-srr
in pouchitis, 121:239-tmig, 121:261
screening
in familial adenomatous polyposis, schedule for, 118:808-c
for varices in cirrhosis, 122:1620
recommendations for, 122:1620
sedation for, propofol for, 124:1162-c
surveillance
in Barrett's esophagus, 122:1569
and patient survival, 122:633, 122:820-e
value of, 121:1516-ss
for colorectal cancer, 119:1403-ss
for esophageal cancer, 122:26, 123:955-c
in swallowing disorders, 122:585-pmr
therapeutic
for acute diverticular bleeding, 118:978-ss
for bleeding peptic ulcer, with heater probe plus thrombin versus heater probe plus placebo, 125:396
book on, 121:227-pmr
in chronic ulcerative colitis or Crohn's colitis, 118:1277-c
for esophageal varices, 123:728, 123:735, 123:1388-e
cost-effectiveness of, 122:1620
in gastroesophageal reflux disease, 119:611-gn, 121:1249-ss
for gastrointestinal bleeding, 118:201-aga
for ulcers with adherent clots, 123:407, 123:632-e, 125:276-c
upper GI
propofol for, cost-effectiveness of, 123:8, 123:373-e
timing of, 119:872-ss
urgent, for acute diverticular bleeding, 118:978-ss
video capsule, in small bowel disease, 123:963-tmig, 123:999, 123:1385-e, 125:276-c, 125:998-c
wireless, 122:828-ss
wireless capsule, versus push enteroscopy, for detection of small-bowel lesions, 119:1431-rc

Endothelial cells, lymphocyte adhesion to, mucosal addressin cell adhesion molecule 1 and, 121:853, 121:1008-e

Endothelin
hepatic stellate cell contraction induced by, suppression by somatostatin (rat), 121:915
regulation of intestinal peristalsis (guinea pig), 119:1-tmig, 119:80

Endothelin-A receptor antagonists, as antifibrotic agents in chronic liver disease, 118:996-tmig, 118:1169, 118:1261-e

Endothelin receptors
blockade, in cirrhosis (rat), 116:161
ET_B, in peristaltic motor regulation, 119:1-tmig, 119:80

Endothelium, microvascular dysfunction in, in inflammatory bowel disease, 125:58

Endotoxemia
bile acid transport in, heat stress and (rat), 122:962
gastric NOS expression in (rat), 123:173
NF-κB activity during, regulation of, 124:118

Endotoxin, effects on multidrug resistance protein 2 in liver (rat), 116:401, 116:486-e

End-stage renal disease, dialysis-related amyloidosis and gastrointestinal symptoms in, 116:217-ss

Energy
endogenous stores of, 122:1677
metabolism
amino acid contribution to, low-protein feeding and (pig), 121:1167
and obesity, 123:882-aga

requirements, 122:1677
in parenteral nutrition, 121:970-aga
Energy balance
and obesity, 123:882-aga
regulation of, pancreatic polypeptide in, 124:1325, 124:1542-e
Energy expenditure, 122:1677
Entecavir, for hepatitis B, 123:1831, 123:2135-e
Enteral nutrition
for alcoholic hepatitis, 120:1053-ss
in critical care, 117:1500-ss
formulas for, 122:1677
postoperative, versus parenteral nutrition, for gastrointestinal cancer patients, 122:1536-ss
principles of, 122:1677
Enteric disease, gastroenterologist training in, 124:1071-aga
Enteric nervous system
abnormalities, diseases associated with, 117:1438-srr
adaptive changes in, 117:1438-srr
age-related changes in, 117:1438-srr
book on, 125:1907-pmr
colonic epithelial expression of ErbB2 and, 125:1900-ss
in constipation and megacolon, 123:1422-tmig, 123:1459
degeneration, in pathogenesis of irritable bowel syndrome, 123:1972, 123:2144-e
development of
cell lineages in, 117:1438-srr
neurotrophic factors in, 117:1438-srr
and development of interstitial cells of Cajal, in human small intestine, 120:561-cr
impairment, and paraneoplastic gut dysmotility, 125:70
plasticity in, 117:1438-srr
Enteric neuroscience, advances in, 116:5-ce
Enteritis, *C. difficile* toxin A-induced, CCR1 deficiency and (mice), 122:600-tmig, 122:725
Enterochromaffin cells
from duodenal crypts, L-type calcium channels in (guinea pig, human), 117:1363
hyperplasia, and postinfectious IBS, 125:1651
serotonin (5-HT) release, D-glucose and, 121:1400
Enterochromaffin-like (ECL) cells
chronic hypergastrinemia and, 124:1564-c
gastric
differentiation of, in CCK_2 receptor deficiency (mice), 123:577
proliferation
pituitary adenylate cyclase–activating polypeptide and (rat), 116:623
vasoactive intestinal polypeptide and (rat), 116:623
IL-1β-induced apoptosis in, mediation by iNOS, NF-κB, and Bax protein (rat), 118:457-tmig, 118:515
in Zollinger-Ellison syndrome, 123:68, 125:827-c
Enterochromaffin-like (ECL) cell tumor
development of, *Reg* gene mutation and, 116:1310, 116:1489-e
and endocrine carcinoma of stomach, 117:510-c
gastric, prognosis for, 116:532
Enteroclysis, in obscure gastrointestinal bleeding, 118:201-aga
Enterocolitis, nongranulomatous chronic idiopathic, glucocorticoid-resistant, cyclosporine for, 117:1259-c
Enterocolitis syndrome, dietary (food) protein–induced, 120:1026-aga
Enterocytes
antigen targeting to late endosomes of, in induction of oral tolerance, 118:2-tmig, 118:128
apoptosis, with parenteral nutrition (mice), 125:1273-ss
differentiation, lactase transcription during, homeodomain protein Cdx2 and, 118:115
of follicle-associated epithelium of murine Peyer's patches, transient M-cell features in, 119:734
high-affinity basolateral glycine uptake in, GLYT1 and, 120:439
nuclear factor κB activation in, IκB-independent, mediated by protein kinase C, 117:89, 117:261-e
Enteroendocrine cells, response to feeding, effects on intestinal growth and adaptation, 117:89, 117:261-e
Enterokinase, in cerulein pancreatitis (rat), 118:452-c
Enteropathy
autoimmune, AIE-75 autoantigen in, 117:823
diclofenac
drug-enterocyte adducts in (rat), 119:1537
pathogenesis of, 120:1885-c
dietary (food) protein–induced, 120:1026-aga
NSAID-induced, pathogenesis of (mice), 122:1913, 125:637-c
radiation, amelioration by recombinant soluble TGF-β type II receptor (mice), 119:1185-tmig, 119:1286
in SIV-infected Rhesus macaques, 116:650
Enteroscopy
diagnostic value of, 117:273-ss
double-balloon, in small intestinal disorders, 125:1556-c
intraoperative, in obscure gastrointestinal bleeding, 118:201-aga
peroral, in obscure gastrointestinal bleeding, 118:201-aga
retrograde, in obscure gastrointestinal bleeding, 118:201-aga
transnasal, in obscure gastrointestinal bleeding, 118:201-aga
Enterotoxins
Clostridium difficile toxin B as, 125:413
enteritis caused by, CCR1 deficiency and (mice), 122:600-tmig, 122:725
secretion induced by, tachykinins and (rat), 119:890-tmig, 119:1037
Enterovesical fistulas, 125:291-im
Enteryx, for gastroesophageal reflux disease, 124:1725-gn
Enzyme, functioning as ion channel, 120:117, 120:299-e
Eosinophilic esophagitis. *See* Esophagitis
Eosinophilic gastroenteritis, 120:1026-aga
Eosinophils, in concanavalin A-induced hepatitis (mice), 122:2001
Eotaxin-1, in eosinophilic esophagitis induced by intratracheal IL-13, 125:1419
Epidemiology, gastrointestinal, future of, 123:966-gn
Epidermal growth factor (EGF)
and gastric lipase gene expression, 116:831
in gastrointestinal development and mucosal integrity (mice), 121:68
heparin-binding, gastrin-induced (rat), 116:78
in prevention of necrotizing enterocolitis (rat), 123:383-ss
therapy with, for inflammatory bowel disease, 122:1592
Epidermal growth factor (EGF) receptor
activation by bile acids
and CD95 tyrosine phosphorylation, in hepatocyte apoptosis, 125:839
and COX-2 expression in cholangiocarcinoma, 122:984
blockade
and colorectal carcinoma growth, 120:1721, 120:1872-e

therapeutic applications of, 120:1721, 120:1872-e
and growth hormone–related reduction of chloride secretion in colonic epithelial cells, 125:1114
ligands
in gastrointestinal development and mucosal integrity (mice), 121:68
in Ras-transformed epithelial cell growth, farnesyl transferase inhibitor and, 117:521-tmig, 117:567
and stress-induced expression of EGF-like growth factors in gastric epithelial cells (rat), 120:108

Epidermal growth factor receptor-related protein (ERRP), antitumor properties of, 124:1337

Epidermolysis bullosa
clinical characteristics of, 124:1595
esophageal stenosis in, in childhood, 122:220-cr

Epilepsy, abdominal, 120:263-aga

Epithelial barrier function
defects, in ulcerative colitis, 116:233-tmig, 116:301, 121:1269-tmig, 121:1320
effects of HMG1 B box (mice), 123:662-tmig, 123:790
enteroinvasive bacteria and, 122:1069
membrane-permeant inhibitor of MLC kinase (PIK) and, 123:163
modulation during apoptosis, 119:1425-tmig, 119:1524, 119:1783-e
probiotics and, 121:511-tmig, 121:580
protection by heatshock protein 72, 117:115
stress-induced disruption of, interferon-γ and myosin light chain kinase in (mice), 125:795

Epithelial cells
biliary, invasion by *Cryptosporidium parvum,* c-Src and cortactin in, 125:216
colonic
alteration, in colitis, 125:148
antigen uptake and presentation by, in normal and diseased states (mice), 119:1548
anti-inflammatory agents for, 117:1039-gn
apoptosis in, regulation by glial-derived neurotrophic factor, 124:1721-tmig, 124:1748
EP_4 receptor-mediated mucin exocytosis, prostaglandin E_2 and, 117:1352
heat shock protein expression in, modulation by enteric flora and cytokines (mice), 124:1175-tmig, 124:1395
leptin as growth factor for (humans, mice), 121:79
migration, IGF-I signaling pathway for, 116:64
stress-induced disruption of, interferon-γ and myosin light chain kinase in (mice), 125:795
differentiation, celiac disease IgA and, 116:510-tmig, 116:566
duct-like pancreatic
gastrin/CCK B receptor expression in (rat), 121:940
mitogenic effects of gastrin in (rat), 121:940
gastric
calcium receptor expression in (rat), 116:118
DNA mismatch repair in, *Helicobacter pylori* and, 123:542
NBC1 and NBC2 Na^+/HCO_3^- co-transporters in (rabbit), 116:1389
progenitors, molecular characterization of (mice), 125:266-ss
proliferation
gastrin and, 116:78
heregulin α and, 117:1119
intestinal. *See also* **Enterochromaffin cells**
anti-apoptotic effects of LPA in, 123:206
apoptosis, leukotrienes and, 119:890-tmig, 119:1007
barrier function
protection by heatshock protein 72, 117:115
stress-induced disruption of, interferon-γ and myosin light chain kinase in (mice), 125:795
β-catenin nuclear signaling in, *Bacteroides fragilis* enterotoxin and, 124:392
and CD1d-restricted antigen presentation pathway (human, mouse), 124:1420
chemokine receptor expression by, 117:359
clonal growth of (human, mouse), 117:858
CX3CR1 signaling in, 122:166
cytoplasmic phospholipase A_2 expression, glucocorticoid-dependent inhibition of (rat), 116:783-e, 116:855
differentiation
Cdx1 and (rat), 117:1266-tmig, 117:1316
Elf3 in (mice), 122:1455
mitogen-activated protein kinase and, 116:1072
effects of HIV-1 Tat protein on, 124:282-tmig, 124:368
exosome secretion by, 121:337
and expansion of regulatory $CD8^+$ T cells, 123:1516
expression of CD86 on, in inflamed colonic mucosa, 117:521-tmig, 117:536, 117:726-e
growth inhibition, JunD expression and, 123:764
HIV-1 transfer in, 123:946-ss
H-Ras-transformed, growth inhibition by farnesyl transferase inhibitors, 117:521-tmig, 117:567
in immune responses, 116:783-e, 116:855, 116:1023-tmig, 116:1054
malignant transformation of, leukotrienes and, 119:890-tmig, 119:1007
morphogenesis of, *Elf3* in (mice), 122:1455
nuclear factor κB activation in, 117:89, 117:261-e
polarized expression and function of CD58 on, 116:1023-tmig, 116:1054
progenitors
clonal analysis of (mice), 116:7-rc, 116:208-e
molecular characterization of (mice), 125:266-ss
proliferation, mesalamine and (mice), 116:509-tmig, 116:602
protection against oxidant injury, by short-chain fatty acids, 121:631
response to TNF-α, Src activation and (rat), 122:331
NOD2/CARD15 as antibacterial factor in, 124:875-tmig, 124:993, 124:1145-e
NOD2/CARD15 gene expression in, regulation of, 124:875-tmig, 124:1001, 124:1145-e
secretory granules, 123:955-c
T84, differentiation, celiac disease IgA and, 116:510-tmig, 116:566

Epithelium
apoptosis in, signal transduction during, 120:79, 120:294-e
bile duct, and biliary bicarbonate excretion (rat), 121:396
biliary
Cryptosporidium parvum and NF-κB activation in, and prevention of epithelial cell apoptosis, 120:1774
Cryptosporidium parvum infection of, 118:248-tmig, 118:368
intrahepatic, proliferation of, estrogens and (rat), 119:1681
progenitor cells of, 120:534
cell biology in, keratin 19 promoter in, 120:1728

colonic
absorption of medium-chain fatty acids (rat), 120:1152
Cdx-2 expression in, *PTEN* and TNF-α regulation of, 123:1163, 123:1395-e
defense against viral infection, TRAIL and its receptors in, 122:659
hyperplasia, tumor necrosis factor receptor 2 in (mice), 122:134
liver intestine-cadherin expression in, regulation by CDX2, 123:1565
mitosis in, stimulation by progastrin (mice), 124:1348
NF-κB activity in, butyrate and, 118:724, 118:798-e
resistance to butyrate-induced cell differentiation and apoptosis, 120:889
TNF-α-induced COX-2 expression in, phosphatidylinositol 3-kinase and, 120:1117
follicle-associated
lymphocyte-dependent development of, in Peyer's patches (mice), 120:1173
of murine Peyer's patches, transient M-cell features in, 119:734
gallbladder
dysfunction, and cholesterol gallstone disease, 118:912
MRP2 and MRP3 expression and localization in, 121:1203
gastric
H. pylori adherence and entry into, signal transduction and, 117:595
hyperplasia, in carbonic anhydrase IX-deficient mice, 123:1889
macrophage migration inhibitory factor expression in, 122:667
morphogenesis and maintenance, sonic hedgehog and (humans, mice), 121:240-tmig, 121:317, 121:485-e
NSAID-induced apoptosis in, suppression by protein kinase C β1 overexpression, 118:457-tmig, 118:507
stress-induced expression of EGF-like growth factors, EGFR-mediated (rat), 120:108
gastrointestinal, water transport by, 122:545-srr
intestinal
cell differentiation in, cell cycle and, 120:423
chloride secretion in, potentiation of, by oxidants, 120:2-tmig, 120:89
Cryptosporidium parvum infection of, 118:248-tmig, 118:368
dipeptide transport, apical NHE3 activity and, 122:1314
dysfunction, caused by inhibition of Na^+,K^+-ATPase by interferon γ, 120:1393
effects of HMG1 B box (mice), 123:662-tmig, 123:790
enteroinvasive bacteria and, 122:1069
function of, probiotic bacteria and, 123:391-c
homing lymphocytes in, phenotypic analysis of, 118:289
hPepT1 expression in, in inflammatory bowel disease, 120:1657
IL-8 and IL-1β secretion by, disaccharides and, 120:449
K-*ras* expression in, and tumorigenesis (mice), 123:492
macrophage migration inhibitory factor expression in, 122:667
membrane-permeant inhibitor of MLC kinase (PIK) and, 123:163
natural killer cells in, 125:345
p53 mutations in, and tumorigenesis (mice), 123:492
probiotics and, 121:511-tmig, 121:580
protection of, from inflammatory cells, digestive enzymes, and microbes, 118:996-tmig, 118:1061
secretion of secretory leukocyte proteinase inhibitor by, 118:996-tmig, 118:1061
tight junction assembly in, Rho kinase and, 121:566
wound healing, lysophosphatidic acid and, 117:359
intrahepatic biliary, secretory activities of, corticosteroids and (rat), 122:1057
lymphocyte chemoattractants produced by
characterization of, 120:60, 120:291-e
production of, 120:49, 120:291-e
pancreatic, Pdx1-expressing, expansion of, TGF-αoverexpression and (mice), 117:1416
protection from oxidant stress, by IL-11-induced hsp25 expression, 124:1358
small intestinal
atrophic changes, Th2 cell dysregulation and (mice), 124:672
goblet cell transformation in, Th2 cell dysregulation and (mice), 124:672
sensitivity to chemotherapy, stress and (rat), 124:660
tachykinin receptor NK_1 on, immunohistochemical demonstration of (guinea pig), 120:1140

Epivir. *See* Lamivudine
Epstein-Barr virus (EBV)
and gastric cancer, 118:1031, 121:612
infection, 116:788-im
ErbB2, colonic epithelial expression of, and enteric nervous system, 125:1900-ss
ErbB receptor
expression, during liver development and regeneration (rat), 123:2017
HER-2/*neu*, and colorectal carcinoma growth, 120:1721, 120:1872-e
erbB receptor family
expression in gastrointestinal cell lines, 117:1119
and gastric epithelial cell proliferation, 117:1119
Erythema nodosum, in inflammatory bowel disease, 123:714
Erythromycin, for acute upper gastrointestinal bleeding, 123:1-tmig, 123:17
Erythropoietic protoporphyria, biliary fibrosis in (mice), 117:688
Escherich, Theodore, 122:54
Escherichia coli
amyloid fiber formation in, 122:849-gn
enteropathogenic, diarrhea caused by, molecular mechanisms of, 121:496-ss
enterotoxigenic, diarrhea caused by, resistance to, dietary calcium and, 125:286-tmig, 125:469
heat-stable enterotoxin, effects on intestinal fluid homeostasis, cGMP-dependent protein kinase II and (mice), 118:108
nonpathogenic, for treatment of ulcerative colitis, 118:630-ss
E-selectin, and NF-κB activity during sepsis, 124:118
Esophageal cancer
acid-related MAP kinase activation in Barrett's esophagus and, 122:253-tmig, 122:299
in Barrett's esophagus, 116:277
data on, from Bayreuth Barrett's archive, 122:590-c
diagnosis of, interobserver variability in, 125:260-ss
metaplasia-dysplasia-carcinoma sequence and, 123:636-e
and outcomes, 122:26
preoperative prevalence of, 122:26, 123:955-c
prevention
by COX-2 inhibitors (rat), 122:1100, 122:1171-e
rofecoxib for, 123:1-tmig, 123:50
regional variation in, 122:588-c
risk of, 123:636-e

bile acids and, 124:271-c
cholecystectomy and, 121:548
c-K-*ras* mutations in, 118:995-tmig, 118:1045
cyclooxygenase 2 expression in, 118:457-tmig, 118:487
prognostic significance of, 122:1715-tmig, 122:1800
endoscopic surveillance for, 122:26, 123:955-c
endoscopic ultrasound in, 122:1631
for fine-needle aspiration staging, effect on treatment, 125:1883-e, 1225:1626
FDG positron emission tomography in, 125:1235-srr
and gastric cancer, molecular differences between, 121:592, 121:726-e
GERD-associated, risk of, 121:1270-tmig, 121:1286
Helicobacter pylori and, 116:277, 125:605-aga (abstract)
lack of association with gastric surgery, 121:1281, 121:1502-e, 123:954-c
node-negative, tumor relapse in, prediction of, 122:1815
NSAIDs and, 125:1912-c
occult lymph node metastases in, prognostic significance of, 122:1815
photodynamic therapy for, 120:785-gn
prevention of
cost-effectiveness of, 124:1758
cost-utility of, 125:1268-ss
protective association of aspirin/NSAIDs and, 124:47, 124:246-e, 125:1912-c
proton pump inhibitor therapy and, 125:1912-c
risk
in celiac disease, 123:1428, 123:1726-e
high-grade dysplasia in Barrett's esophagus and, 120:1617, 120:1630
risk stratification for, 117:293-gn
specialized intestinal metaplasia and, 116:277
survival with, relapse-free, predictors of, 122:1815
systemic therapy for, 117:1020-ss

Esophageal manometry, for diagnosis of achalasia, 120:783-tmig, 120:789

Esophageal motility, in gastroesophageal reflux disease
fundoplication and, 121:5, 121:214-e
preoperative, effect on antireflux surgery outcomes, 122:1183-c

Esophageal obstruction, incomplete, by vascular anomaly, 117:1270-im

Esophageal stricture
benign
diagnosis of, 117:233-aga
treatment of, 117:229-aga, 117:233-aga
treatment of, 118:235-c

Esophageal varices. *See also* Variceal bleeding
endoscopic screening for, in cirrhosis, 122:1620
first hemorrhage with
prophylaxis for, 122:1620, 123:735
risk for, 122:1620
risk stratification for
based on independent determinants, 122:1620
recommendations for, 122:1620
incidence of, 122:1620
prevalence of, 122:1620
prophylaxis, 118:802-ss
rebleeding, prevention of, 123:728, 123:1388-e
risk for hemorrhage with, endoscopic grading of, 122:1620
size of
change in, 122:1620
endoscopic grading of, 122:1620
stigmata of, endoscopic grading of, 122:1620

Esophagitis
acute necrotizing, 118:252-im
eosinophilic, 123:946-ss
in children, 122:1216
and GER, in adults and children, 120:1026-aga
induced by intratracheal IL-13, 125:1419
natural history of, 125:1660
reflux. *See also* Gastroesophageal reflux disease (GERD)
acid- and pepsin-induced (rabbit), 116:1-tmig, 116:97
healing of, *Helicobacter pylori* and, 117:1-tmig, 117:11
during mechanical ventilation, 116:1281-tmig, 116:1293
rabbit model for, 116:1-tmig, 116:97

Esophagogastric junction
cancer
Barrett's esophagus and, 116:277
H. pylori infection and, 116:277
micrometastases, detection in resected rib, 116:509-tmig, 116:543
opening, in gastroesophageal reflux disease, 125:1018, 125:1258-e

Esophagogastroduodenoscopy, unsedated, 117:1265-tmig, 117:1301, 117:1492-e, 118:987-c
small-caliber, 119:878-c
ultrathin, 125:1569-tmig, 125:1606

Esophagus. *See also* Barrett's esophagus
aging-related changes in, 122:1688
contraction, and chest pain, 116:29
development of, 116:702-srr
diffuse leiomyomatosis of, 120:216-cr
dilatation
for benign disorders, 117:229-aga, 117:233-aga
techniques for, 118:235-c
distal and deglutitive inhibition in, neural mechanisms of (rat), 118:328
double-peaked waves in, topography of, 118:457-tmig, 118:469
dysmotility, in children with congenital central hypoventilation syndrome, 122:1258
eosinophil trafficking in, 123:946-ss
epithelium of, water transport by, 122:545-srr
foreign body in, 118:5-im, 125:1575-im
function, CNS nitric oxide in, 119:287-tmig, 119:377
high-grade dysplasia in, photodynamic therapy for, 120:785-gn
motility, sildenafil and, in achalasia, 118:247-tmig, 118:253
mucosal injury, by duodenogastroesophageal reflux, during mechanical ventilation, 116:1281-tmig, 116:1293
mucosal resistance, in GERD, 125:1558-c
nerve-mediated contractions in, tachykinins and, 120:1-tmig, 120:39
smooth muscle of, potassium channels in, inhibition by SNAP-25, 122:993
stenosis of, in childhood, in dystrophic epidermolysis bullosa, 122:220-cr
surgery of, 119:1173-pmr, 125:625-pmr
ulcers, healing of, keratinocyte growth factor and, 122:254-tmig, 122:458

EspF protein, from enteropathogenic *Escherichia coli*, disruption of host intestinal barrier function, 121:496-ss

Estrogen
and cholangiocyte proliferation (rat), 119:1681, 123:336
for osteoporosis treatment, 124:795-aga

Estrogen-progestagen treatment, for prevention of rebleeding from angiodysplasia, 121:1033-tmig, 121:1073

Etanercept
for Crohn's disease, initial results with, 121:1033-tmig, 121:1088, 121:1242-e
for inflammatory bowel disease, 122:1592
mechanism of action of, 124:1722-tmig, 124:1774

Ethanol. *See also* Alcohol
acute intoxication, cysteinyl leukotrienes in, 118:1140
binge, in obesity, hepatic effects of (rat), 125:1818
and chronic pancreatitis, 120:682
and cirrhosis, in hereditary hemochromatosis, 122:281, 122:563-e
effects on hepatic mitochondrial function and DNA, 117:181, 117:265-e
induction of CYP4502E1, and retinoic acid metabolism (rat), 120:179
intestinal production of, in obesity (mice), 119: 1186-tmig, 119: 1340, 119:1399-e
light consumption of, and hepatic regenerative activity (rat), 119:1333, 119:1399-e
liver disease caused by, risk of, homozygosity for alanine in mitochondrial targeting sequence of SOD and, 120:1318-tmig, 120:1468
liver injury caused by
reduction of, by superoxide dismutase (rat), 120:1241
TNF-α and (mice), 117:942
long-term enteral feeding with, mouse model for, 117:942
metabolites, and extracellular matrix protein content in pancreas (rat), 125:1845
and mitochondrial function, 122:2049-srr
and pancreatic acinar cells (rat), 122:106
pancreatic fibrosis stimulated by, stellate cells and (rat), 118:650-tmig, 118:780
Ethanol diet, and pancreatitis caused by CCK-8 (rat), 117:706
Ethics, of professionals evaluating drugs and/or products, 118:819-ce
Ethnicity
and BMI-related risk, 123:882-aga
and gallbladder disease, in United States, 117:522-tmig, 117:632
and ulcerative colitis, genetic and pathogenetic factors in, 117:806
Etodolac, gastrointestinal events related to, risk of, 120:594
European Cooperative Crohn's Disease Study VI, 118:247-tmig, 118:264, 118:436-e
Evacuation proctography, in fecal incontinence, 124:1672
Evidence-based gastroenterology, 124:861-pmr, 124:1726-ce, 124: 1996-pmr
Ewald, Karl Anton, 123:1803
Exercise therapy, for obesity, 120:669
***EXO1* gene,** germline variants of, in hereditary nonpolyposis colorectal cancer, 120:1580-rc, 120:1860-e
Exosomes, secretion of, by intestinal epithelial cells, 121:337
Experimental therapeutics, review of, 124:1159-pmr
Extracellular matrix (ECM)
and hepatic stellate cell migration in fibrosis, 124:147
in intestinal fibrosis (mice), 125:1570-tmig, 125:1750, 125:1886-e
proteins
in pancreas, ethanol metabolites and (rat), 125:1845
protection of pancreatic cancer cells from death, 125:1188
remodeling of, leptin and leptin receptors in (rat), 122:1399, 122:1529-e
Extracellular regulated kinase, and growth hormone–related reduction of chloride secretion in colonic epithelial cells, 125:1114
Extracellular signal-related kinase
inhibition of, in enterocytes, 118:90
in regulation of intestinal barrier, 118: 1001-rc

Factor II, G20210A gene mutation in idiopathic portal vein thrombosis, 116:2-tmig, 116:144, 116:213-e, 118:237-c
in mesenteric venous thrombosis, 118: 237-c
Factor VII, recombinant, activated, safety and efficacy of, for cirrhotic patient with coagulopathy undergoing liver biopsy, 123:118
Factor V Leiden
mutation
in idiopathic portal vein thrombosis, 116:2-tmig, 116:144
in inflammatory bowel disease, 117: 280-c
and thrombosis, and inflammatory bowel disease, 116:778-c
Familial adenomatous polyposis (FAP)
aberrant crypt foci in, analysis of K-*ras*, *APC*, and β-*catenin* in, 121: 599
attenuated, 121:198-aga, 125:1462
chemoprevention of
COX-2 inhibition in, 119:1797-ss
with sulindac, 123:379-ss
clinical features of, 121:198-aga, 124: 1574
colorectal cancer screening in, recommendations for, 124:544-aga
endoscopic screening in, schedule for, 118:808-c
extracolonic features in, 121:198-aga
genetic defect in, 121:198-aga
genetic testing for, 119:837-srr, 121: 195-aga, 124:1574
technical review on, 121:198-aga
ileorectal anastomosis in, 119:1454, 121: 502-c, 121:503-c
long-term sulindac treatment in, 122: 641
molecular basis for, 119:854-srr
mouse model of
inducible nitric oxide synthase in, antineoplastic role of, 121:889
tumorigenesis in, inducible nitric oxide synthase and, 121:889
periampullary adenomas in, risk stratification for, 121:1127, 121:1246-e
periampullary carcinoma in, risk stratification for, 121:1127, 121:1246-e
postoperative follow-up in, 121:198-aga
screening for, 121:198-aga
skin signs of, 124:1595
treatment of, 121:198-aga, 122:641
surgical, 118:1275-pmr
Familial liver adenomatosis, HNF-1α inactivation and, 125: 1470-cr
Familial Mediterranean fever, clinical features of, 124:1595
Familial polyposis coli, surgery for, 118:1275-pmr
Farnesoid X receptor (FXR)
activity, feedback control of, 124:1926
agonists, and hepatic apolipoprotein CIII expression (mice), 125:544
and cholesterol and bile acid metabolism, 120:1054-ss
in hepatic ABC transporter expression and liver injury in biliary obstruction (mice), 125:825
and ontogenic expression of ileal bile acid binding protein (rat), 122: 1483
and regulation of human OATP8 gene promoter, 122:1954
regulation of UGT2B4 in hepatocytes, 124:1926
Farnesyl transferase inhibitors, effect on Ras-transformed epithelial cell growth, reduced EGRF ligand production and, 117:521-tmig, 117:567
Fas-associated death domain (FADD), as molecular target to prevent hepatocyte death (mice), 119:446
Fas protein
acute liver failure caused by, reactive oxygen species in, 121:1451
apoptosis mediated by, inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810

in autoimmune gastritis (mice), 123:780
in colon cancer cell apoptosis, 123:235
expression, in nonalcoholic steatohepatitis, 125:437
in hepatocellular apoptosis and fibrosis (mice), 123:1323
hepatocyte apoptosis mediated by
in cholestasis (mice), 117:669, 117:732-e
IL-1β and (mice), 117:661
prevention
by genipen (mice), 118:380
by superoxide dismutase mimetic MnTBAP (mice), 121:1451
Th1 T cell apoptosis mediated by, in experimental colitis, anti-IL-12 treatment and, 117:1078, 117:1238-e

Fasting, metabolic response to, PPAR-α-mediated (mice), 124:160, 124:254-e

Fat
absorption
biliary lipids and, in *Mdr2*$^{-/-}$ mice, 118:173, 118:225-e
in pancreatic insufficiency (dog), 116:431
digestion, and modulation of gastrointestinal sensations in gastric distention, 120:1071-tmig, 120:1100
and gut function, 123:700, 123:933-e

Fatigue, in primary biliary cirrhosis, 122:1235, 124:582-c

Fatty acid ethyl esters, and extracellular matrix protein content in pancreas (rat), 125:1845

Fatty acids
chain length, mediation of CCK secretion and gastric motility, 116:46
long-chain, effects on appetite, 119:889-tmig, 119:943
medium-chain, colonic absorption of (rat), 120:1152
short-chain, 118:1235-aga

Fatty liver disease. *See also* Liver, steatotic
alcoholic vs. nonalcoholic, 123:1705-aga
diagnosis of, histologic criteria for, 123:1705-aga
nomenclature for, 123:1705-aga
nonalcoholic. *See* Nonalcoholic fatty liver disease
pathogenesis of, intestinal ethanol production in obesity and (mice), 119:1186-tmig, 119:1340, 119:1399-e
and uncoupling proteins, 116:1024-tmig, 116:1184

Fecal calprotectin test
in irritable bowel syndrome, 124:1164-c
in relatives of patients with Crohn's disease, 124:1721-tmig, 124:1728, 124:1972-e

Fecal impaction
in elderly, 122:1688
evaluation of, 122:1688
treatment of, 122:1688

Fecal incontinence. *See* Incontinence

Fecal occult blood testing
in colorectal cancer screening, 119:837-srr
in Chinese, 124:608
diagnostic testing after, compliance and, 118:980-ss
effect on incidence of colorectal cancer, 121:732-ss
efficacy of, in screening for colon cancer, 122:236-ss, 122:2081-ss
recommendations for, 124:544-aga

Fedotozine
and perception of colonic distention in irritable bowel syndrome, 116:1-tmig, 116:38
and visceral pain, 117:292-tmig, 117:388

Fellowships
gastroenterology fellowship training: a generation lost, 116:228-c
in gastrointestinal pathology, in United States and Canada, 117:972
postgraduate, availability of, by state, 117:461

Fenfluramine plus phentermine, for obesity, 120:669

Ferroportin 1, expression of, in iron deficiency and iron overload, 120:1317-tmig, 120:1412

Fertility
female, ulcerative colitis and, 122:15, 122:226-e
male, azathioprine therapy and, in inflammatory bowel disease, 121:1048

Fiber, dietary
and colorectal cancer, 116:785-gn, 118:1233-aga, 118:1235-aga
for constipation, 119:1766-aga
consumption of, 118:1235-aga
definition of, 118:1235-aga
and glycemic control in type 2 diabetes, 119:1168-ss
intake of, and risk of gastric cardia cancer, 120:331-tmig, 120:387, 120:568-e, 121:1024-c
for pouchitis, 124:1636
sources of, 118:1235-aga
in treatment of irritable bowel syndrome, 120:652

Fibrinolytic system, in cirrhosis, 121:131

Fibroblast growth factor (FGF)
FGF-7. *See* Keratinocyte growth factor
FGF-20, therapeutic activity in intestinal inflammation, 123:1151

Fibroblast growth factor receptor, FGFR-1, IIIc isoform, in pancreatic cancer, 123:301

Fibroblasts, reduced migration of, in inflammatory bowel disease, 125:1295-tmig, 125:1341

Fibrocystin, expression in cholangiocyte cilia (rat), 125:1303-rc

Fibrogenesis, NF-κB/Rel in, 118:1208-srr

Fibromyalgia, comorbidity with irritable bowel syndrome, 122:1139-srr

Fibrosis
hepatocellular
and apoptosis, Fas-mediated mechanistic link between (mice), 123:1323
in hepatitis C
effect of renal transplantation on, 123:1494, 123:1729-e
insulin resistance and, 125:1570-tmig, 125:1695, 125:1889-e
noninvasive tests of, 123:2082
susceptibility gene *Hfib1* (mice), 123:2041
tissue renin-angiotensin system and (rat), 123:1667
intestinal, mouse model of, 125:1570-tmig, 125:1750, 125:1886-e

***FIC1* gene,** mutation, in Amish kindred, 119:188, 120:321-c

Filgrastim, for inflammatory bowel disease, 122:1592

Financial disclosure, by professionals evaluating drugs and/or products, 118:819-ce

Fine-needle aspiration biopsy, endoscopic ultrasound guidance for, 122:1631
in preoperative staging of rectal cancer, 123:24
for staging of esophageal cancer, effect on treatment, 125:1883-e, 1225:1626

Fine-needle injection therapy, EUS-guided
for achalasia, 122:1631
for tumors, 122:1631

Fistula-in-ano
classification of, 125:1508-aga
etiology of, 125:1508-aga

Fistulas
Crohn's
community study of, 122:874
infliximab for, 117:1247-ss
perianal, 125:1503-aga
disease activity, measurement of, 125:1508-aga

high, 125:1508-aga
initial medical management of, cost-utility of, 122:1186-c
low, 125:1508-aga
medical treatment of, 125:1508-aga
rectovaginal, 125:1503-aga, 125:1508-aga
tacrolimus for, 125:380
enterovesical, 125:291-im
Fitness, aerobic, health benefits of, 123:882-aga
FK506. *See* Tacrolimus
Flexible sigmoidoscopy
in irritable bowel syndrome, 122:1701
screening, complications of, 123:1786
Flora, enteric
and colitis, 125:1-tmig, 125:162
ecology of, book on, 124:1998-pmr
and heat shock protein expression in colonic epithelial cells (mice), 124:1175-tmig, 124:1395
and PPAR-γ gene expression in colonic epithelium, 124:1174-tmig, 124:1265, 124:1538-e
Fluorescence imaging, of intestinal adenomas (mice), 122:254-tmig, 122:406, 122:571-e
5-Fluorouracil
in vitro response to, mismatch repair proficiency and, 117:123
and 3*n*-butyrate, antitumor synergy of, in human colorectal cancer xenografts, 120:874
and pyrrolidinedithiocarbamate, combination of, effects on therapeutic-to-toxic ratio (mice), 118:2-tmig, 118:81
therapy with, dihydropyrimidine dehydrogenase and, 125:240-srr
Fluticasone propionate, for eosinophilic esophagitis in children, 122:1216
Fluvastatin, antimetastatic effect of, in pancreatic cancer, 122:253-tmig, 122:308, 122:565-e
Focal adhesion kinase
cleavage of, during apoptosis, 120:79, 120:294-e
phosphorylation, reduced, in inflammatory bowel disease, 125:1295-tmig, 125:1341
Focal nodular hyperplasia
in Klippel-Trénaunay syndrome, 117:284-c
of liver, gene expression in, 124:594-tmig, 124:651
Folate
deficiency of, and colon carcinogenesis (rat), 119:1-tmig, 119:151
as foiler of colon cancer, 116:3-gn
intake, and risk of colorectal cancer, 124:1240
Food allergy
clinical manifestations of, 120:1026-aga
diagnostic criteria for, 120:1026-aga
epidemiology of, 120:1026-aga
evaluation of
AGA technical review on, 120:1026-aga
guidelines for, AGA medical position statement on, 120:1023-aga
gene therapy for, 119:269-ss
and microscopic and collagenous colitis in treated celiac disease, 116:778-c
pathophysiology of, 120:1026-aga
Food and Drug Administration (FDA)
drug approval and surveillance by, 119:1429-ce
Gastrointestinal Drug Advisory Committee, and expedited review of drugs, 125:289-gn
new rules, effects on pediatric research and drug companies, 116:1025-gn
proposal to increase public access to information on xenotransplantation and gene therapy trials, 120:786-gn
Food intake
decreased, in pancreatic polypeptide transgenic mice, 117:1427
regulation of, melanin concentrating hormone receptor and, 117:524-gn
urocortin and (mice), 116:1281-tmig, 116:1287-rc, 116:1487-e
Food protein, immediate (IgE-mediated) gastrointestinal reactions to, 120:1026-aga
Foreign body
esophageal, 118:5-im, 125:1575-im
tubular, 122:6-im
Foreign body granulomatosis, systemic, worn dental prosthesis and, 121:1234-cr
Forkhead-related activator (FREAC), in transcriptional regulation of lactase-phlorizin hydrolase (pig), 116:842
Formiminotransferase cyclodeaminase, as liver-specific antigen, in autoimmune hepatitis, 116:643
Fortovase. *See* Saquinavir
Fosinopril, intestinal angioedema caused by, 119:1190-im
Foundation for Digestive Heath and Nutrition (FDHN), mission of, 121:753-gn
Fractalkine receptor CX3CR1, signaling, in intestinal epithelial cells, 122:166
Fractures
incidence of
after liver transplantation, 125:941-aga
in chronic liver disease, 125:941-aga
prevalence of
after liver transplantation, 125:941-aga
in chronic liver disease, 125:941-aga
risk of
in celiac disease, population-based study of, 125:429
in Crohn's disease, population-based study of, 123:468
in inflammatory bowel disease, 125:1591
Free radicals, and effects of passive smoking in inflammatory bowel disease, 117:756-tmig, 117:884, 117:1008-e
Friedenwald, Julius, 122:1737
Functional disorders, 121:1523-pmr
cognitive-behavioral therapy for, 125:19, 125:249-e
desipramine for, 125:19, 125:249-e
diagnosis of, research needs in, 117:1269-ce
gastroenterologist training in, 124:1062-aga
pathophysiologic models of, 122:2032-srr
research on, 124:6-ce
treatment of
research needs in, 117:1269-ce
strategies for, 125:19, 125:249-e
Fundoplication, and esophageal motility, in gastroesophageal reflux disease, 121:5, 121:214-e

$GABA_A$ receptors, in esophageal distal inhibition (rat), 118:328
$GABA_B$ agonists, for gastroesophageal reflux disease, 118:1-tmig, 118:7
$GABA_B$ receptors
activation, inhibition of transient lower esophageal sphincter relaxation (dog), 117:1037-tmig, 117:1147
and vagal motor control of lower esophageal sphincter, 120:1749
Galactose, dietary, effect on colorectal cancer risk, 122:1715-tmig, 122:1784
Galectin-1, suppression of experimental colitis (mice), 124:1381
Galectin-3, modulation of intestinal mucin expression in colon cancer, 123:817
Gallbladder
chronic acalculous disease of, 121:1529-c
muscle dysfunction in, 120:506, 120:570-e

contraction
bradykinin B_2 receptors and, 125:126
GRP receptor blockade and, 120:331-tmig, 120:361
disease
diagnosis and treatment of, book on, 122:2089-pmr
economic and social costs of, in United States, 122:1500-srr
endoscopic ultrasonography for, 116:1018-c
in obesity, 123:882-aga
in United States, 117:522-tmig, 117:632
endoscopic ultrasound of, 122:1631
epithelia, MRP2 and MRP3 expression and localization in, 121:1203
hypomotility, in pregnancy (guinea pig), 116:234-tmig, 116:411
motility
and chronic acalculous disease, 120:506, 120:570-e, 121:1529-c
disorders of, as neuroautonomic dysfunction, 123:1407-c
opioid effects on (guinea pig), 122:340
in pregnancy (guinea pig), 116:234-tmig, 116:411
muscle contractility and membrane fluidity in, membrane cholesterol and, 116:678
pathology of, 125:1553-pmr
porcelain, 117:760-im

Gallstones
and bile acids, cholesterol, and enterohepatic circulation of bilirubin, 116:1276-c
cholesterol
diet-induced formation of, apolipoprotein E and (mice), 118:650-tmig, 118:772
formation of, chromosomal organization of candidate genes involved in (mice), 120:221-srr
gallbladder lipid absorption and, 118:912
genetic susceptibility to and pathogenesis of (mice), 125:868
pathogenesis of, mucin in, 116:784-tmig, 116:936
octreotide-induced, pathogenesis of, 121:812
pancreatitis caused by
diagnosis of, 125:229
endoscopic management of, 125:229
outcome of, 125:229
pancreatitis risk with, 119:879-c
pathogenesis of, oxysterols in, 121:118, 121:216-e
pigment
in Crohn's disease, 116:1282-tmig, 116:1420, 116:1491-e
oxysterols in, 121:118, 121:216-e
prevention of, in women, coffee and, 123:1823

Gamna-Gandy bodies, 125:1010-im

Gangrene, peripheral, in chronic renal failure, 122:495-cr

Gap junctional communication, acinar cell, and severity of acute pancreatitis (mice), 124:481

Gap junctions, and bile flow, in perfused liver (rat), 116:1024-tmig, 116:1176

Gardner's syndrome
molecular basis for, 119:854-srr
skin signs of, 124:1595

Garlic breath, origin of odor in, 117:1248-ss

Gas, intestinal
clearance, in patients with retention, 122:1748
in irritable bowel syndrome, 122:576-ss, 123:700, 123:933-e

Gas transit test, 122:1748

Gastrectomy
bone disease after, 124:791-aga, 124:795-aga
partial, lack of association with Barrett's esophagus, 121:1281, 121:1502-e, 123:954-c

Gastric acid
cyclooxygenase 2 expression induced by, ex vivo, 118:457-tmig, 118:487
mucosal diseases related to, book on, 122:1181-pmr. *See also* **Nocturnal gastric acid breakthrough**
resistance to, in *Helicobacter pylori*, urease and, 123:187
secretion
amylin and (mice), 123:247
ghrelin and, 125:1492-srr
in L-histidine decarboxylase deficiency (mice), 122:145
KCNQ1 in, 120:1363
M_3 muscarinic receptors and (mice), 125:1774
restoration of, after proton pump inhibitor therapy, 123:1588
synergistic effect of glycine-extended gastrin and gastrin 17 in (mice), 119:756
suppression
and differentiation and proliferation in Barrett's esophagus, 117:327, 117:1510-c
long-term
effect on gastric atrophy, 118:239-c, 118:242-c, 118:453-c
lack of effect on gastric atrophy, 117:291-tmig, 117:319
lack of effect on intestinal metaplasia, 117:291-tmig, 117:319
unbuffered, at gastroesophageal junction, after meal, 121:775

Gastric antral vascular ectasia, TIPS for, 124:1700

Gastric antrum
epithelial cell turnover in, *H. pylori* infection and, 118:1-tmig, 118:48
in *H. pylori* infection, response to oral immunization, 116:497-ss

Gastric banding, for obesity, 120:669, 123:882-aga

Gastric bypass, for obesity, 120:669, 123:882-aga

Gastric cancer. *See also* **Lymphoma**
of cardia
cereal fiber intake and, 120:331-tmig, 120:387, 120:568-e, 121:1024-c
GERD-associated, risk of, 121:1270-tmig, 121:1286
cell proliferation, heregulin α and, 117:1119
cells
indomethacin-induced apoptosis in, regulation by differential expression of PKC isoforms, 118:457-tmig, 118:507
nuclear factor κB activation by *H. pylori* in, mechanisms of, 119:97
c-K-*ras* mutations in, 118:995-tmig, 118:1045
development of, *H. pylori* eradication and, 119:1-tmig, 119:7, 119:252-e
differentiation phenotype, 121:839
DNA copy number in, 121:592, 121:726-e
endoscopic mucosal resection of, soft prelooped cap for, 125:621-ss
endoscopic ultrasound in, 122:1631
Epstein-Barr virus-associated, 118:1031
genetic changes in, 121:612
and esophageal cancer, molecular differences between, 121:592, 121:726-e
familial, *H. pylori* and, 118:1-tmig, 118:22, 118:31, 118:222-e
FDG positron emission tomography in, 125:1235-srr
genomic damage in, estimated by arbitrarily primed PCR DNA fingerprinting, 125:1330
GERD-associated, risk of, 121:1270-tmig, 121:1286
growth pattern, 121:839
Helicobacter pylori and, 118:1-tmig, 118:22, 118:31, 118:36, 118:48, 118:1031, 119:274-c, 120:324-c, 121:751-tmig, 121:784, 121:823, 121:1002-e
cagA genotype and pepsinogen levels in, 116:269

cagA status and, 117:745-c, 125:1005-tmig, 125:1125, 125:1569-tmig, 125:1636
and gastrin (rodents), 118:1-tmig, 118:36, 118:48
gender difference in (mice), 124:1879
IL-1β in (mice), 124:1879
hereditary diffuse, 122:830-ss
families, CDH1 mutation carriers from, cancer risk in, 121:1348
hypergastrinemia and *Helicobacter* infection in (mice), 118:1-tmig, 118:36
inactivating mutations of *KILLER/DR5* genes in, 121:1219
Ki-*ras* mutations in, 125:1282-c
microbially initiated, 123:1739-ss
microsatellite mutator phenotype, genetic and clinical features of, 116:1348
microsatellite unstable
WISP3 in, 125:1563-c
and mitochondrial and nuclear DNA mutation in, 118:835
noncardia
Helicobacter pylori and, 121:751-tmig, 121:784
risk of, proinflammatory cytokine gene polymorphisms and, 124:1193
pathogenesis of, 116:1217-vodd
peritoneal dissemination, integrin α6β4 as suppressor and predictive marker for, 118:497
p53 exon 4 in, 118:995-tmig, 118:1039
prognosis for, genomic damage and, 125:1330
proinflammatory *IL-1* genotypes and, 121:823, 121:1002-e
risk
antioxidant potential of fruit and vegetables and, 123:985
in CDH1 mutation carriers, 121:1348
dietary intake and, 124:2006-c
E-cadherin germline mutations and, 123:1406-c
genetic profile and, 125:364
long-term omeprazole therapy and, 119:1176-c
risk factors for, 116:813, 116:1217-vodd
trefoil factor family 1 gene mutations in, 119:609-tmig, 119:691

Gastric cancer spheroids, multicellular, recapitulation of human gastric cancer, 121:839

Gastric cardia
adenocarcinoma of, 117:218-srr
risk stratification for, 117:293-gn
anatomy of, 117:218-srr
histology of, 117:218-srr
inflammation of, 116:228-c
and metaplasia and neoplasia at gastroesophageal junction, 117:218-srr

Gastric distention
cortical and subcortical regions activated by, 120:369
gastrointestinal sensations induced by, fat digestion and, 120:1071-tmig, 120:1100
hypersensitivity to, and dyspeptic symptoms, 121:526
perception of
gastric wall tension and, 116:1035
studies, tensostat for, 118:641-c

Gastric dysplasia, high-grade, 117:285-c

Gastric electric stimulation, for medically refractory gastroparesis, 125:421

Gastric emptying
delayed, in nNOS$^{-/-}$ mice, 119:766
GRP receptor blockade and, 120:331-tmig, 120:361
in pancreatic polypeptide transgenic mice, 117:514-c
of solids, microprocessor-controlled (dog), 118:247-tmig, 118:258, 118:433-e
urocortin and (mice), 116:1281-tmig, 116:1287-rc, 116:1487-e

Gastric glands, morphogenesis, sonic hedgehog and (humans, mice), 121:240-tmig, 121:317, 121:485-e

Gastric histology, *H. pylori cagA* 3′ repeat region and, 117:342

Gastric intestinal metaplasia. *See* Intestinal metaplasia, gastric

Gastric juice, ascorbate/nitrite ratio in dietary nitrate and, 116:813
omeprazole and, 116:813

Gastric lipase, human, specific activity of, measurement of, 119:949

Gastric motility, fatty acid chain length and, 116:46

Gastric pit cells, antiapoptotic role of TGF-α in, nuclear factor κB and (mice), 121:56

Gastric secretions, leptin and (rat), 121:1417

Gastric transitional zones
anatomy of, 116:1217-vodd
antral-body, 116:1217-vodd
cardia-body, 116:1217-vodd
and *Helicobacter pylori* ecology, 116:1217-vodd
location of, 116:1217-vodd
migrating, *H. pylori* and, 116:1217-vodd
in proximal gastric ulcers, 116:1217-vodd

Gastric ulcers
development, with MALToma, immune response to *H. pylori* and (mice), 117:893
transitional zones in, 116:1217-vodd

Gastric varices
bleeding from
refractory, response to TIPS, 118:1270-ss
secondary prophylaxis with TIPS, 125:262-ss
fundal, balloon endoscopic sclerotherapy for, 117:514-c
management of, histoacryl in, 120:1875-ss
prevalence of, 122:1620
risk for first hemorrhage with, 122:1620

Gastric vascular ectasia, in portal hypertension, response to TIPS, 118:816-tmig, 118:905

Gastric wall tension, and perception of gastric distention, 116:1035

Gastrin
amidated, and colon carcinogenesis (mice), 119:2-tmig, 119:162
and CCK_2 receptor in Barrett's metaplasia, 124:615, 125:1912-c, 125:1921-c
in development of ECL carcinoids, *Reg* gene mutation and, 116:1310, 116:1489-e
gene
and islet development (mice), 125:1164
knockout mice, colon carcinogenesis in, 123:516
in glucose homeostasis, 125:1164
glycine-extended, and gastrin 17, synergistic effect on acid secretion in glycine-deficient mice, 119:756
and *Helicobacter* infection, in gastric cancer (rodents), 118:1-tmig, 118:36, 118:48
human, as *H. pylori*-specific growth factor, 117:1113
induction of heparin-binding epidermal growth factor-like growth factor (rat), 116:78
lack of response to, in human pancreatic acinar cells, 121:1380
nonamidated, and colon carcinogenesis (mice), 119:2-tmig, 119:162
and PAI-2 expression, 123:271
and pancreatic duct-like cells (rat), 121:940
plasma, effects of omeprazole on, CYP2C19 polymorphism and, 119:609-tmig, 119:670
regulation of trefoil factor TFF1 expression, 125:510
secretory response to, M_3 muscarinic receptors and (mice), 125:1774
trophic response to, in oxyntic mucosa,

M$_1$ muscarinic receptors and (mice), 125:1774

Gastrinoma
abnormal secretin receptor in, 122:500-cr
resection, in Zollinger-Ellison syndrome, 117:758-gn

Gastrin receptors, in pancreatic duct-like cells (rat), 121:940

Gastrin-releasing peptide (GRP) receptors, in gastric emptying, gallbladder contraction, and small intestinal transit, 120:331-tmig, 120:361

Gastritis
Acinetobacter lwoffi and (mice), 123:1739-ss
atrophic. *See* Atrophic gastritis
autoimmune
Fas in (mice), 123:780
proton pump as target autoantigen of Th1-type cytotoxic T cells in, 120:377
cecal bacterial load and, in HLA-B27 transgenic rats, 116:310
comprehensive textbook on, 119:1409-pmr
cytomegalovirus, evolution to chronic gastrointestinal dysmotility in nonimmunocompromised adult, 116:953-cr
and duodenal ulcers, 116:1217-vodd
emphysematous, 118:1000-im
Helicobacter felis-induced, development of, IL-7R signaling in (mice), 121:329
Helicobacter pylori
clinical presentation of, virulence factors and, 123:414
inducible NOS and cyclooxygenase 2 in, 116:1281-tmig, 116:1319
MUC1 in, 123:41
outcome in, virulence factors and, 123:414
pathogenesis of, virulence factors and, 123:414
somatostatin suppression in (rabbit), 123:566
and transitional zones, 116:1217-vodd
and sodium currents in gastric sensory neurons (rat), 122:752, 122:823-e

Gastro-Central, functioning of, 123:5-ce

Gastroenteritis
eosinophilic, 120:1026-aga
non-food-borne, economic and social costs of, in United States, 122:1500-srr
viral, 123:651-pmr
acute, outbreaks on cruise ships, 124:284-gn

Gastroenterologists
numbers of, and need for, 118:459-gn
in physician-patient interaction, 121:1037-ce
training of, 122:851-ce

GASTROENTEROLOGY
David Brenner, editor, 121:241-gn
and CONSORT statement, 121:755-ce
editorial transition, 120:1577-ce
impact on gastroenterology, 116:1027-ce
mission of, 123:877-aga
new editors for, 121:3-ce
randomized clinical trials published in, from 1994 to 2000, validity of, 122:1156-srr
reviewers, 121:1532
acknowledgment of, 123:2166, 125:1925
special issue on therapeutics and diagnostics, introduction to, 120:593

Gastroenterology
advances in (future directions for), 118:5-ce
British and American, relationship between, 123:965-gn
clinical essentials of, 123:389-pmr
common problems in, book on, 122:2088-pmr
evidence-based, 120:1559-pmr
fellowships in, attracting candidates for, 122:851-ce
future of (abstract), 116:1244-aga
history of, 121:738-pmr
textbook of, 118:984-pmr, 118:1275-pmr
self-assessment review for, 122:1182-pmr
women in, demand for, 122:256-gn

Gastroenterology Match, 117:295-ce, 117:509-c

Gastroenterology News
Acute gastroenteritis outbreaks on cruise ships linked to Norwalk-like viruses, 124:284
ADHF to FDHN spells new opportunities for AGA, 121:753
AGA advocacy helps prompt IBD act, 123:403
AGA a key to HELP committee passage of colorectal cancer screening passage, 123:663
AGA national office is available to help you!, 121:242
AGA panel achieves GERD consensus, 124:4
AGA research policy initiatives, 123:664
AGA's DH&N proving popular with the public, 122:255
AGA's Spring Postgraduate course at DDW offers latest management for common digestive and liver disorders, 124:1176
Amyloid fiber formation in *E. coli*, 122:849
Another possible target for antiobesity drugs, 116:511
Approval of Enteryx for GERD recommended by FDA panel, 124:1725
Aspirin and colorectal adenoma prevention, 124:1176
Attractin more interest in weight regulation, 117:294
BabA cries for attention as *Helicobacter pylori* pathogenesis factor, 118:3
Barrett's esophagus issues reviewed by expert panel, 124:876
Bill seeks to reform, educate on Medicare regulations, 120:1320
Bio-containable, recombinant organism for IBD therapy, 125:1007
Biomedical research funding on the rise in Japan, 120:1074
Bone marrow cells spontaneously fuse with liver, brain, and heart cells, 125:1572
Bone marrow instead of liver transplantation?, 119:891
British and American gastroenterology: some seek closer ties, 123:965
Budget bickering is bad news for NIH, 117:4
Thomas Franklin Burks, III, Ph.D. (1940-2001), 121:2
C. difficile epidemic raises difficult questions about antibiotic-prescribing practices, 118:249
Ceftriaxone-resistant *Salmonella* infection from antibiotic-treated cattle, 119:3
Chips ahoy!, 119:1427
Cholera primed by gut transit, 123:403
Colon tumor precursors identified by magnifying endoscopy, 116:235
Congress approves bill with language that prevents Medicare cuts to physicians, 124:877
Couric, Tartikoff to push CRC screening message in March, 120:333
David Brenner, new *Gastroenterology* editor, sees basic/clinical combination as a plus for journal, 121:241
Death knell for barium enema as a diagnostic?, 119:611
Demand increasing for women in gastroenterology, 122:256
Dr. Roger Haggit, 119:611
Early negative results not the last word on secretin/autism story, 118:250
E-biomed: improving access or a threat to peer review?, 117:293
Epidemiologic evidence underscores role for folate as foiler of colon cancer, 116:3

Erythromycin-responsive motilin receptor regulates upper gastrointestinal motility, 117:524
Fat-free zebrafish, 121:1
FDA seeks to increase access to information on xenotransplantation, gene therapy trials, 120:786
Fiber and colorectal cancer: poor relations?, 116:785
Frequent dieting by adolescents may actually promote weight gain, 125:1572
The future of colon cancer prevention, 120:03:00
Future of GI epidemiology, 123:966
Future of rotavirus vaccine may hinge on results of CDC study, 117:758
Gastrointestinal effects of new Cox-2-inhibiting drugs are debated, 116:512
Gene family analysis uncovers new therapeutic targets for colorectal cancers, 125:4
Gene mutations implicated in Crohn's disease risk, 121:1
Gene therapy: back to the drawing board?, 118:651
Genomes of two *H. pylori* strains reveal few clues, 116:786
GI coding and billing AnswerLine in second year, 125:4
GI groups join with other subspecialties in challenging HCFA in court, 116:3
Glaxo/SmithKline merger has AGA overtones, 118:460
GLP-2 cloning may lead to therapy for intestinal deficiency diseases, 116:786
Glut? Gastroenterologists finding heavy demand for their service, 118:459
Gorden steps down from NIDDK post, 116:236
Griffin P. Rodgers, NIDDK deputy director, outlines institute's goals, 121:241
H. pylori gets hydrogen boost, 124:284
H. pylori in nonulcer dyspepsia: to treat or not to treat?, 116:511
HCFA policy hurts gastroenterologists and Medicare patients, AGA charges, 120:03:00
HCV issues begin to come into focus, 117:757
Hepatitis B "X" gene linked to cellular calcium release, 122:255
Hepatitis drugs win approval, 116:236
HIPAA privacy guidelines effective in April, 124:4
House and Senate pass versions of Medicare prescription drug legislation, 125:650
How *Helicobacter pylori* defends its turf, 117:3
Incontinence considered at interdisciplinary conference, 124:597
Increased funding doesn't add up to more GI grants in 2000, 118:652
Increased need for PhDs in gastrointestinal research, 123:664
Inhibitor of MAP kinase activation blocks colon cancer growth, 117:523
Intravenous omeprazole as adjuvant therapy for bleeding peptic ulcers, 119:1428
Irradiation of meat is approved, but will it be used?, 116:785
Jon Isenberg (1937–2003), 125:1571
A key role for FDA GI drug advisory committee in expedited reviews, 125:289
Lamivudine for hepatitis B: an alternative to interferon, 118:3
Latest multidrug-resistant bacterial diarrheas raise questions, 117:3
Loren Laine, the new chair of the AGA Council, 123:966
Major funding initiative in Germany enhances research efforts, 120:334
Manpower issue remains murky, 116:1283
Melanin concentrating hormone receptor regulates food intake, 117:524
Melanocortin reverses obesity in POMC-deficient mice, 117:1039
MELD and the practicing gastroenterologist, 125:1009
In memoriam John H. Walsh, 119:289
Microsatellite instability: a general marker for improved colon cancer prognosis, 118:459
Molecular clue to colon cancer liver metastasis, 122:3
More room for clinical perspectives in new journal, 123:965
Mutation in human bile salt exporter pump causes progressive familial intrahepatic cholestasis, 116:4
National gnotobiotic rodent resource, 124:285
Nervous elements influencing intestinal inflammation and rotavirus diarrhea may lead to new treatments, 118:651
New activating mutation in GI stromal tumors, 124:596
New AGA president outlines goals, 120:786, 124:1724
New AGA president takes multi-focus approach, 122:1197
New class of anti-inflammatory agents for colonic epithelial cells, 117:1039
New COX-2 inhibitors look for the GI-safe label, 117:4
New endoscopic strategies offer middle ground for treating GERD, 119:611
New executive vice president at FDHN, 123:3
New fat-preventing pill likely to yield slim benefits, 117:4
New FDA rules a boon to pediatric research–and some drug companies, 116:1025
New leadership in Washington: implications for gastroenterology, 120:333
New mechanism reported for hepatitis C resistance to interferon, 117:757
New NIDDK director hopes to forge links between basic, clinical science, 118:4
New study: HCV and racial disparities in response to antiviral therapy, 122:1198
New tools to study motility and satiety from the receptor orphanage, 117:524
New VP elect for AGA, 122:601
NIDDK director outlines program, 119:1427
NIH announces clinical research loan repayment program, 121:1035
NIH budget boon: the sequel, 118:4
NIH Consensus Development Conference updates HCV management, 123:404
NIH gets record raise for FY2002, 122:602
NIH looks to parlay budget boon toward more patient-oriented research, 116:3
NIH set to expand digestive diseases study section, 123:663
Nissen of the Nissen fundoplication, 125:6
Novel coronavirus associated with SARS outbreak, 124:1724
Nutrition and obesity, xenotransplantation among topics to be covered at DDW 2001, 120:1073
Nutrition moves beyond weighty issues, 120:1319
Obesity drugs in the pipeline include GI hormones, 124:877
Olestra hard to digest, critic charges, 116:1026
Panel issues ERCP recommendations, 122:601
Patient's Bill of Rights remains in Congress, 121:514
Pediatric gastroenterology evolves rapidly, 123:3

Pegylated interferon for treatment of hepatitis C, 120:03:00
Photo finish for Barrett's esophagus, other digestive tract lesions?, 120:785
A pH-sensitive channel regulates urea access to *Helicobacter pylori* urease, 118:249
Physical and chemical cooperation between somatostatin and dopamine receptors, 119:3
Presidential panel urges improvements in nation's cancer-care delivery, 122:3
Presidential politics not expected to derail NIH from 5-year doubling track, 119:891
Promising cancer drug may be de-TRAILed by liver toxicity concerns, 119:3
PubMed Central: A boon to information access, a bane to quality control, or neither?, 117:1040
Radiologist sees a future for virtual colonoscopy as screening tool, 120:1073
Recertification via CPD, 121:754
Reimbursement issues surround ambulatory endoscopy centers, 122:849
Report of hepatitis A outbreak raises concerns, 116:1283
Researchers fret as NIH budget is squeezed, 116:1025
Results pending on secretin's benefits to autism, but many aren't willing to wait, 117:524
Revising theories of colon carcinogenesis: telomeres and colon cancer models, 119:891
Ronald G. Thurman, Ph.D. (1941-2001), 121:513
Senate amendment aims to hike NIH funding, 125:1007
Snapshot of GI medicine in Japan, 124:876
Solving the African enigma: parasites may have their place, 119:611
SRC mutation enhances colon cancer growth, 116:1025
Stem cell research to be funded on limited basis, 121:753
Strategic planning taskforce tackles AGA priorities, 125:1008
Student loan burden may be eased, 120:1320
Studies explore effects of carbohydrate restriction in obesity, 125:650
Successful gastrinoma resection in Zollinger-Ellison syndrome, 117:758
Survey highlights myths surrounding HCV, 125:289
Taste receptor breakthrough is bittersweet, 116:1284
This month at the NIH: NIDDK forms hepatotoxicity clinical research network, 125:1008
This month at the NIH: NIDDK special emphasis program announcements, 125:5
This month at the NIH: redesign of digestive sciences integrated review group, 125:651
Toxic gas may have a therapeutic future, 119:611
Trends in digestive disease science in Spain, 121:1035
Two more studies weigh in on interferon-ribavirin combination for hepatitis C, 116:4
Malcolm P. Tyor, M.D., (1923-2003) AGA President 1981-1982, 125:288
United States Senate set to debate medical malpractice legislation, 124:1176
UNOS, feds continue to wrestle over liver allocation, 117:523
When does heartburn warrant more concern?, 117:293
Yet another drug company merger proposed, 116:236

Gastroesophageal junction
carcinogenesis at, dietary nitrate and nitric oxide in, 122:1248, 122:1518-e
metaplasia and neoplasia at, gastric carditis and, 117:218-srr
unbuffered acid at, after meal, 121:775

Gastroesophageal masses, endoscopic ultrasound of, 122:1631

Gastroesophageal reflux disease (GERD), 120:583-pmr. *See also* Barrett's esophagus
acid, nonacid, and gas, during 24-hour pH-impedance recordings, 120:583-pmr, 120:1596, 120:1862-e
acid and nonacid, simultaneous intraesophageal impedance and pH measurement of, 122:1545-c
effect of omeprazole, 120:583-pmr, 120:1588, 120:1862-e
antireflux surgery for, cancer risk after, 121:1270-tmig, 121:1286, 121:1506-e
associated with cow's milk allergy, in infants, 120:583-pmr, 120:1026-aga
in asthma, 123:1398-ss
baclofen in, 123:1736-ss, 125:984-ss
and Barrett's metaplasia, 121:1281, 121:1502-e
cannabinoids and (dog), 123:1129
in children without neurological deficits, extra-esophageal associations in, 121:1294
costs of, 125:981-ss
diagnosis, 120:583-pmr, 120:787-ce
omeprazole test and 24-hour esophageal pH monitoring in, 116:1012-c
economic and social costs of, in United States, 122:1500-srr
in elderly, 122:1688
endoscopic treatment of LES in, 123:944-ss
endotherapies for, 123:643-ss
eosinophilic esophagitis and, in adults and children, 120:583-pmr, 120:1026-aga
esophageal cancer risk in, 121:1270-tmig, 121:1286
esophageal motility in
effect on surgical outcomes, 122:1183-c
fundoplication and, 121:5, 121:214-e
esophageal mucosal resistance in, 125:1558-c
esophagogastric junction opening in, 125:1018, 125:1258-e
evaluation of, 122:1688
$GABA_B$ agonists for, 118:1-tmig, 118:7
gastric cardia cancer risk in, 121:1270-tmig, 121:1286
genetics of, 122:55
healing of, *Helicobacter pylori* and, 117:1-tmig, 117:11
hiatal hernia and, 118:650-tmig, 118:688
excess reflux in, 119:1439, 119:1779-e
long-term omeprazole therapy for, efficacy and safety of, 118:649-tmig, 118:661, 118:795-e, 119:1176-c, 119:1177-c
lower esophageal sphincter function in, colonic fermentation and, 124:894
management of, 124:4-gn, 124:860-pmr, 124:1941
nocturnal gastric acid breakthrough in, histamine receptor blockade and, 122:599-tmig, 122:625
in obesity, 123:882-aga
pathogenesis of, 120:583-pmr, 120:787-ce
pathophysiology of, 125:1558-c
postprandial refluxate in, pH of, 121:775
radiofrequency energy for, 125:668, 125:970-e
relapse rates in, *Helicobacter pylori* eradication and, 121:1120

treatment of, 120:583-pmr, 120:787-ce, 122:1688
endoscopy in, 119:611-gn, 121:1249-ss, 123:944-ss
Enteryx approved for, 124:1725-gn
possible approach to (dog), 117:1037-tmig, 117:1147
step-down management in, 121:1034-tmig, 121:1095
Stretta device in, 123:643-ss
surgical, 121:5, 121:214-e
surgical versus medical, cost analysis of, 122:1178-ss
in twins, 122:55
ultrastructural modifications in, omeprazole and, 122:837-c

Gastrografin, therapeutic effect in small bowel obstruction, 124:852-ss

Gastrointestinal disease
diagnosis of, 125:1549-pmr
drug therapy for, review of, 124:1159-pmr
pathophysiology of, 125:1549-pmr
treatment of, 125:1549-pmr

Gastrointestinal motility. *See* Motility

Gastrointestinal permeability
along villus-crypt axis (rat), 119:1029
increased, preceding onset of Crohn's disease, 119:1740-cr
stress and (rat), 119:1019

Gastrointestinal rhythmicity, development of (mice), 117:522-tmig, 117:584

Gastrointestinal stromal tumor, familial, with hyperpigmentation, c-*kit* gene mutation and, 120:210-cr

Gastrointestinal tract. *See also* Digestive system
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
human, development of, 116:702-srr
infections of, 125:1550-pmr
innervation of, 125:1907-pmr
orphanin FQ in (rat), 116:2-tmig, 116:108
pathophysiology of, 118:636-pmr

Gastrointestinal transit
GRP receptor blockade and, 120:331-tmig, 120:361
prucalopride and, in functional constipation, 120:331-tmig, 120:354

Gastroparesis
gastric neurostimulation for, 125:979-ss
intractable nausea and vomiting with, 120:263-aga
medically refractory, gastric electrical stimulation for, 125:421
potential treatment for, 118:247-tmig, 118:258, 118:433-e
treatment of, 118:247-tmig, 118:258, 118:433-e, 120:576-ss, 125:1860

Gastropathy. *See also* Portal hypertensive gastropathy
indomethacin-induced, role of proteasome in, 116:865, 116:994-e
NSAID-related
COX-1 and COX-2 inhibition and (rat), 119:610-tmig, 119:706
cysteine endoproteinases in, 116:1089
management of, 119:521-srr
mechanisms of (mice), 119:610-tmig, 119:699
pathogenesis of, 119:521-srr
role of proteasome in, 116:865

Gastroplasty, for obesity, 120:669, 123:882-aga

G cells
calcium-sensing receptor on, mechanism of action of, 120:1128, 120:1279-e
in hypochlorhydria-associated inflammation (mice), 122:119

Gender difference
in central processing of visceral stimuli, in IBS, 124:1738, 124:1975-e
in familial pancreatic cancer, 124:1292
in *Helicobacter pylori*-induced gastric cancer (mice), 124:1879
in irritable bowel syndrome, 123:1686-srr
animal models for, 122:2032-srr
for mismatch repair deficiency, in human colorectal cancer, 121:1026-c
for promoter methylation pattern of hMLH1 and p16 in MSI colorectal cancer, 124:1165-c

Gender role, and gender differences in IBS, 123:1686-srr

Gene expression, along anterior-posterior axis of gastrointestinal tract, microarray-based analysis of (mice), 122:1467

Gene polymorphisms, and colorectal cancer risk, 121:282

Gene therapy
credibility of, 119:1189-ce
for Crohn's disease, advances in, 123:1758-tmig
efficiency of, improvement of, 123:608, 123:639-e
for food allergy, 119:269-ss
future directions for, 118:651-gn
liver-directed, recombinant replication-deficient simian virus 40 in (Gunn rat), 119:1348
for liver disease, Kupffer cell transplantation in (rat), 124:3-tmig, 124:173
mutant *Salmonella* as vectors for, 121:224-ss
PPAR-γ, for IBD (mice), 124:1315, 124:1538-e
principles and practice of, 121:1258-pmr
in protection against hepatic ischemic injury, 125:917-srr
and regression of liver tumors, 123:608, 123:639-e
trials of, information on, FDA seeks to increase access to, 120:786-gn
VEGF and angiopoietin-1, for gastric ulcers, 121:1040-rc

Genetic counseling
in hereditary diffuse gastric cancer families, 121:1348
in pancreatic cancer-prone families, 119:1756-cr

Genetics
of colorectal cancer, 121:1275-rc, 121:1497-e
of gastric cancer, 121:1219
of gastrointestinal tumors, 121:1258-pmr
of hepatocellular carcinoma, 121:1136
of irritable bowel syndrome, 121:751-tmig, 121:799
of nonalcoholic pancreatitis, 121:1310, 121:1509-e
of periampullary lesions in familial adenomatous polyposis, 121:1127, 121:1246-e

Genetic testing
for familial adenomatous polyposis (FAP), 124:1574
for hereditary nonpolyposis colorectal cancer, 117:1502-ss, 118:230-ss
microsatellite instability and, 120:1-tmig, 120:21
in heritable colorectal cancer syndromes, 119:837-srr, 121:195-aga
indications for, 121:198-aga
strategy for, 121:198-aga
technical review on, 121:198-aga
for high-risk colon cancer patients, 124:1574
for *p16* mutations, in pancreatic cancer-prone families, 119:1756-cr
principles of, 124:1574

Gene transfer, using retroviral vectors, during growth factor-stimulated liver hyperplasia (rat), 118:591

Genipen, prevention of Fas-mediated hepatic apoptosis (mice), 118:380

Genomics
advances in (future directions for), and clinical medicine, 118:251-ce
physiological, in mouse, 123:405-ce

Geriatric gastroenterology, gastroenterologist training in, 124:1098-aga

Ghrelin
and appetite regulation, 120:337-rc
cardiovascular and other effects of, 125: 1492-srr
distribution of, 125:1492-srr
and eating disorders, 125:1492-srr
effects on feeding and energy homeostasis, 125:1492-srr
expression, pancreatic polypeptide and, 124:1325, 124:1542-e
functions of, gastric afferent vagal nerve and (rat), 123:1120
and gastric acid secretion, 125:1492-srr
and gastric motility, 125:1492-srr
and growth hormone secretion, 125:1492-srr
localization of, 125:1492-srr
and motilin-related peptide, 120:587-c, 120:588-c
and obesity, 125:1492-srr
for obesity treatment, 124:877-gn
plasma levels of
after weight loss, 124:575-ss
plasma leptin and (rat), 124:1188-rc, 124:1532-e
structure of, 120:337-rc
therapeutic potential of, 125:1492-srr
Giannella, Ralph A., 116:1238
Giardia, diarrhea caused by, pathogenesis of, mechanisms of, 123:964-tmig, 123:1179, 125:277-c
Glaxo/SmithKline merger, effects on gastroenterology, 118:460-gn
Gliadin
DQ2-restricted T-cell epitopes, and celiac disease, 123:803, 123:939-e
peptides, transport and absorption of, in celiac disease, 125:647-tmig, 125:696
Glial cells
enteric, 117:1438-srr
and mucosal integrity, in inflammatory bowel disease, 116:493-ss
Glial-derived neurotrophic factor, regulation of apoptosis in colonic epithelial cells, 124:1721-tmig, 124:1748
Gliotoxin, stimulation of hepatic stellate cell apoptosis, and inhibition of hepatic fibrosis (humans, rats), 121:512-tmig, 121:685
Glisson, Francis, 120:1362
Glomerular filtration rate (GFR), in cirrhosis, 122:1658
Glucagon
and MKP-1 expression in hepatocytes (rat), 118:929
modulation of bile flow, gap-junctional communication in, 116:1024-tmig, 116:1176
Glucagon-like peptide
biological actions of, 122:531-srr
GLP1, for obesity treatment, 124:877-gn
GLP2
metabolic effects of (piglet), 125:136
secretion, nutrient regulation of, 117: 89, 117:261-e
and therapy for intestinal deficiency diseases, 116:786-gn
in treatment of short-bowel syndrome, 120:783-tmig, 120:806, 120: 1041-e
therapeutic potential of, 122:531-srr
Glucagon-like peptide 2 receptor
enteroendocrine localization of, in humans and rodents, 119:744
function, nitric oxide and (piglet), 125: 136
Glucagonoma syndrome, 116:1286-im
Glucocorticoid receptor β, expression
in glucocorticoid-resistant ulcerative colitis, 119:1177-c
in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis, 118:816-tmig, 118:859
Glucocorticoids
for inflammatory bowel disease, response to, constitutive high MDR expression and, 118:247-tmig, 118: 279
resistance to, molecular mechanisms of, 119:1177-c
responsiveness to, in ulcerative colitis, predictor of, 118:816-tmig, 118: 859, 119:1177-c
Glucose
homeostasis, gastrin and (mice), 125: 1164
intestinal transport of, membrane trafficbased pathway for, 124:34
oxidation, intestinal, protein restriction and (pig), 121:1167
transport, and permeability characteristics along villus-crypt axis (rat), 119:1029
uptake, GLP2 and (piglet), 125:136
D-Glucose, and serotonin (5-HT) release from enterochromaffin cells, 121: 1400
Glucose-6 phosphatase, expression, in small intestine (fasted and diabetic, rat), 117:132
Glucose-6-phosphate dehydrogenase deficiency, *UGT1A1* gene, and neonatal hyperbilirubinemia, 123:127
Glucuronidation, in human liver and colon, 116:149
Glutamine
and cerebral edema in liver failure, 125: 815, 125:976-e
efflux, cerebral, in fulminant hepatic failure, 121:1109
metabolism, stimulation of intestinal cell mitogen-activated protein kinases, 118:90
for pouchitis, 124:1636
and proliferation of starved intestinal cells, 118:90
signaling, in enterocytes, Raf-independent mechanism for, 118:90
Glutathione
mitochondrial transport of, regulation of, by acetaldehyde, 124:708
protective effect against reperfusion injury, in cold-preserved liver (rat), 117:200, 118:450-c
Glutathione peroxidase, intestinal, as barrier against hydroperoxide absorption (CaCo-2 cells), 119: 420
Glutathione *S*-transferase
as autoantigen in anti-SLA-positive autoimmune hepatitis, 116:1015-c
overexpression in colon carcinogenesis, K-*ras* mutations and, 121:865, 121:1010-e
Gluten
duration of exposure to, and autoimmune disorders in celiac disease, 117: 291-tmig, 117:297
immunoreactive motif of
protein homology in grains and, 125: 1105, 125:1264-e
sequence and functional characterization of, 125:268-ss
in medications, 120:636
total avoidance of, in treatment of celiac disease, 120:636, 120:1526-aga
as trigger of celiac disease, 119:234-srr
Gluten-free diet
in celiac disease, and reversal of liver failure, 122:880, 123:2158-c
compliance with, measurement of, 122: 588-c
for irritable bowel syndrome patients with latent/potential celiac disease, 121:1329, 121:1512-e
Glutenins, T-cell recognition of, 125: 337
Gluten-sensitive enteropathy. *See* Celiac disease
Glyceryl trinitrate
for anal fissure, 124:233-aga, 124:235-aga
and apoptosis in colon cancer cells, 123: 235
Glycine
dietary, prevention of experimental colitis (rat), 125:775

high-affinity basolateral uptake of, in enterocytes, GLYT1 and, 120:439
Glycolipid rafts, and IgA transcytosis in small intestine (mice), 116:610
Glypican-3, as marker for hepatocellular carcinoma, 125:89
Gnotobiotic rodents, resource for, 124:285-gn
Goblet cells
differentiation of, regulation by keratinocyte growth factor, 120:1372
transgenic ablation of, and susceptibility to colonic injury, 118:1272-ss
Goblet cell-specific protein RELMβ/FIZZ2, regulation of, by normal enteric bacteria, 125:1296-tmig, 125:1388
Gonadal steroid replacement therapy, for corticosteroid-dependent patients with bone loss, 124:795-aga
Gorden, Phillip, 116:236-gn
Gottron's sign, 124:1595
Gout, in obesity, 123:882-aga
gp130, in hepatocellular protection (mice), 125:532
G-protein-coupled receptors, interactions of, 119:4-gn
Graft-versus-host disease, intestinal, tumor necrosis factor in (mice), 116:510-tmig, 116:593
Granulocyte colony-stimulating factor (G-CSF), for inflammatory bowel disease, 122:1592
Granulocyte-macrophage colony-stimulating factor (GM-CSF), for inflammatory bowel disease, 122:1592
Granulomatosis, foreign body, systemic, worn dental prosthesis and, 121:1234-cr
Gräsbeck-Imerslund syndrome, decreased affinity of urinary intrinsic factor–cobalamin receptor in, 116:1274-c
Greater celandine, acute hepatitis induced by, 117:1234-cr
Grey-Turner's sign, 124:1595
Growth factors
and hepatic stellate cell migration in fibrosis, 124:147
therapy with, for inflammatory bowel disease, 122:1592
vascular, expression in focal nodular hyperplasia of liver, 124:594-tmig, 124:651
Growth hormone (GH)
and chloride secretion in colonic epithelial cells, 125:1114
human, for inflammatory bowel disease, 122:1592
low-dose, for parenteral nutrition-dependent short bowel syndrome patients, 124:293, 124:561-e
and recovery from dextran sodium sulfate-induced colitis (mice), 120:925
secretion of, ghrelin-induced, gastric afferent vagal nerve and (rat), 123:1120
therapy with
in critically ill adults, increased morbidity and mortality with, 118:633-ss
for Crohn's disease, 120:308-ss
Growth retardation, in AR/EGF/TGF-α triple null mice, 121:68
Guanylin, increased, in osmotic diarrhea (mice), 121:1191
Guanylyl cyclase C, intestine-specific activity of, regulation by Cdx2, 119:89
Gut. *See also* Digestive system; Gastrointestinal tract
conditioned responses in, 117:1438-srr
neuromusculature of, embryonic development of, *Hox* code and (mice), 117:1266-tmig, 117:1339

Haggitt, Roger, 119:612-gn
Halsted, William Stewart, 120:386
Hamartomatous polyposis, genetic testing in, 119:837-srr
Harris-Benedict equation, 122:1677
Hartmann, Henri, 124:888
Harvey ras-1 variable number tandem repeat polymorphism, and colorectal cancer risk, 121:282
HBcAg, antigen-processing pathway for, 116:650, 116:765-e
HBeAg, antigen-processing pathway for, 116:650, 116:765-e
Health Care Financing Administration (HCFA)
litigation against, 116:3-gn
policy, effects on gastroenterologists and Medicare patients, 120:3-gn
Health care quality, volume/outcome relationship in, 120:1075-ce
Health Insurance Portability and Accountability Act (HIPAA), implementation of, 124:4-gn
Health-related quality of life, in chronic liver disease, 120:170, 120:305-e
Heartburn
and Barrett's esophagus, 125:1569-tmig, 125:1670
and cancer risk stratification, 117:293-gn
refractory, management of, 124:1941
Heart transplantation, recipients
hepatitis B in, 120:1311-c
viral hepatitis in, 119:890-tmig, 119:1064, 120:1561-c
Heat shock protein
expression in colonic epithelial cells
cytokines and (mice), 124:1175-tmig, 124:1395
enteric flora and (mice), 124:1175-tmig, 124:1395
hsp25
expression in colonic epithelial cells, modulation by enteric flora and cytokines (mice), 124:1175-tmig, 124:1395
expression in colonic mucosa, short-chain fatty acids and, 121:511-tmig, 121:631
induction by IL-11, and epithelium-specific cytoprotection from oxidant stress, 124:1358
Hsp60, in protection against pancreatitis (rat), 119:220, 121:744-c
HSP70, protective effect in acute pancreatitis (rat), 122:2-tmig, 122:156
hsp72
expression in colonic epithelial cells, modulation by enteric flora and cytokines (mice), 124:1175-tmig, 124:1395
protection of Caco2 cell barrier function, 117:115
Heat stress, in prevention of septic cholestasis (rat), 122:962
Hedgehog signaling pathway, in intestinal morphogenesis and intestinal lipid metabolism (mice), 122:438
Heidenhain, Rudolf, 120:1083
***Helicobacter* spp.**
in liver from patients with cholangiocarcinoma and hepatocellular carcinoma, 120:323-c
not detectable in bile from German patients with biliary disease, 116:1016-c
Helicobacter felis
gastritis caused by, development of, IL-7R signaling in (mice), 121:329
and hypergastrinemia, in gastric cancer (mice), 118:1-tmig, 118:36
Helicobacter heilmannii, gastric MALToma associated with, remission after treatment, 118:815-tmig, 118:821
***Helicobacter* infection,** immune protection against, $\alpha_4\beta_7$-integrin-positive lymphocytes and (mice), 119:109

Helicobacter muridarum, provocation of inflammatory bowel disease (mice), 122:1346
Helicobacter mustelae, mimicry of blood group antigen A, 116:504-c
Helicobacter pylori
and acid-inhibitory effect of omeprazole, 116:233-tmig, 116:239, 116:479-e
and acid tolerance, 116:1217-vodd
acquisition of, in childhood, 121:239-tmig, 121:310, 121:483-e
activation of NF-κB, mechanism of, in gastric cancer cells, 119:97
adaptation to human host, gastrin and, 117:1113
adherence and entry into cells, signal transduction and, 117:595
adhesion, and Lewis X, 119:1414-c
binding to gastric MUC5AC glycoforms, 123:1923
cag$^+$, and MMP-7, 125:1005-tmig, 125:1125
cagA genotype
and duodenal ulcers, 116:253-tmig, 116:259
and pepsinogen levels, in gastric cancer, 116:269
CagA protein
and phosphorylation-dependent cytoskeletal rearrangement, 123:1962
transcriptional activation by, 123:1962
cagA 3′ repeat region
and gastric hitology, 117:342
and susceptibility to low pH, 117:342
cagA status
and gastric cancer, 117:745-c, 125:1005-tmig, 125:1125, 125:1569-tmig, 125:1636
serological detection of, 117:745-c
cag pathogenicity island of, associations with vacuolating cytotoxin allele and IS*605* diversity, 117:1308
and cancer of esophagus and esophagogastric junction, 116:277
in children
antibiotics for, 122:1189-c
transmission of, 122:1189-c, 122:2091-c
colonization
in nonhuman primates, 116:1-tmig, 116:90
outer membrane proteins and (mice), 123:1992
complement activation induced by, 120:1108
defenses of
antacid, 117:3-gn
against other bacteria, 117:3-gn
and disease severity in rheumatoid arthritis, 116:503-c
and DNA mismatch repair in gastric epithelial cells, 123:542
elimination of, in high-risk aspirin or NSAID users, 122:238-ss
eradication
and development of gastric cancer, 119:1-tmig, 119:7, 119:252-e
dyspepsia rates one year after, 125:372
effectiveness of, 122:1270, 122:1521-e
in gastric MALT lymphoma, API2-MALT1 chimeric transcript as predictive marker for responsiveness to, 120:1884-c
omeprazole in, 116:248, 116:479-e, 117:746-c
PPI-based triple therapy in, 117:746-c
in primary high-grade gastric MALT lymphoma, 123:393-c
versus prompt endoscopy, for dyspepsia, 120:1298-ss
QUADRATE study of, 123:1763, 125:639-c
quadruple and triple therapies for, 123:1763, 125:639-c
recrudescence and reinfection after, 121:792, 123:653-c
and regression of rectal MALT lymphoma, 117:514-c
and relapse rates in gastroesophageal reflux disease, 121:1120
resistance to, by t(11;18) gastric MALT lymphomas, 122:1286
and esophageal cancer (abstract), 125:605-aga
exposure, cytotoxin associated gene product A (CagA) as marker for, 121:751-tmig, 121:784
FldA protein, and gastric MALToma, 117:2-tmig, 117:82, 117:257-e, 118:988-c
and gastric atrophy, 118:239-c, 118:242-c, 118:453-c, 121:823, 121:1002-e
gastric cancer related to, 118:1-tmig, 118:22, 118:31, 118:36, 118:48, 118:222-e, 118:1031, 119:1-tmig, 119:7, 119:252-e, 119:274-c, 120:324-c, 121:823, 121:1002-e, 123:1739-ss
genetic predisposition and, 123:1406-c
regression after *H. pylori* treatment, 124:537-cr
risk of, proinflammatory cytokine gene polymorphisms and, 124:1193
and gastric cell turnover and gastrin secretion (rodents), 118:1-tmig, 118:48
and gastric MALToma, 117:2-tmig, 117:82, 117:257-e, 117:750-c, 118:988-c
impaired T-cell regulation of B-cell growth in, 117:1105
and gastric mutations (mice), 124:1408
and gastric neuromuscular function (mice), 123:1205
at gastric transitional zones, 116:1217-vodd
gastritis, 119:1-tmig, 119:7, 119:252-e
attenuation by helminthic infestation, 119:611-gn
inducible NOS and cyclooxygenase 2 in, 116:1281-tmig, 116:1319
MUC1 in, 123:41
gene expression, in gastric mucosa, 123:1637
genomes of two strains, 116:786-gn
genotypes, global distribution of, 116:783-tmig, 116:823
and healing of reflux esophagitis, 117:1-tmig, 117:11
host-bacterium interactions, in nonhuman primates, 116:1-tmig, 116:90
host defense against, LL-37 and, 125:1613
human gastrin as specific growth factor for, 117:1113
in human liver, 121:1023-c
hydrogen use by, 124:284-gn
IL-8 production induced by, in gastric cancer cell lines, sphingomyelin-ceramide pathway in, 116:1330
immune response to, and gastric ulcer development with MALToma (mice), 117:893
infection
acute, immune responses in (Rhesus macaque), 118:247-tmig, 118:307
familial clustering of, 118:1-tmig, 118:22, 118:31, 118:222-e
host-microbial interactions in, 122:2084-ss
IL-1β production in, IL-1 polymorphisms and, 123:1793
inflammation caused by, outer membrane proteins and (mice), 123:1992
inhibition of gastric mucin synthesis by, 118:1072
local acid production and, 116:1217-vodd
metronidazole susceptibility in, 117:1032-c
mimicry of blood group antigen A, 116:504-c
MMP-9 expression induced by, NF-κB activation and, 124:983
molecular and cellular biology of, review of, 121:740-pmr

mucosal colonization in suckling mice, genetic analysis of, 124:577-ss
and mucosal vaccination, 116:497-ss
NF-κB/Rel induction in, 118:1208-srr
and noncardiac gastric cancer, 121:751-tmig, 121:784
and nonulcer dyspepsia, 116:511-gn, 117:270-ss, 121:735-ss
novel treatment for, using antiadhesion compound (rhesus monkey), 117:1265-tmig, 117:1316
and NSAID-related peptic ulcers, 116:254
NSAIDs and, 119:521-srr, 120:594
oipA, as predictor of gastric inflammation and clinical outcome, 123:414
omeprazole for, and alteration of intragastric milieu, 119:287-tmig, 119:339, 121:517
oral vaccination to, role of saliva in (mice), 118:749
outer membrane proteins, role of (mice), 123:1992
parent-child transmission of, 122:2091-c
phospholipase (PldA)
characterization of, 117:1098
in colonization of gastric mucosa, 117:1098
pH-sensitive urea channel of, 118:249-gn
and platelets, 124:1846, 124:1983-e
population screening and treatment of, 119:1795-ss
protectin-bound, complement-induced lysis prevented by, 120:332-tmig, 120:470
recurrence, posttherapeutic, 121:792, 123:653-c
reinfection, in children, 117:291-tmig, 117:336
screening, dyspepsia rates one year after, 125:372
serologic testing for, using U.S. and Peruvian antigens, 120:325-c
test-and-treat for, in dyspepsia management, 122:1270, 122:1521-e, 125:1219
transmission
in children, 121:239-tmig, 121:310, 121:483-e
parent-child, 122:2091-c
treatment of, 119:1795-ss
effect on gastric intestinal metaplasia, 125:586
regression of gastric and laryngeal MALT lymphoma after, 124:537-cr
using antiadhesion compound (rhesus monkey), 117:1265-tmig, 117:1316
and ulcer bleeding in NSAID users, 116:1281-tmig, 116:1305, 118:451-c
urease
acid-dependent adherence to polysaccharides, 119:287-tmig, 119:358
and *E. coli* heat-labile enterotoxin, oral immunization with, 116:783-tmig, 116:804, 116:990-e
and gastric acid resistance, 123:187
urea access to, regulation of, 118:249-gn
urease-based test for, sensitivity in children and elderly, 116:1506-c
vacA allelic types of, geographic distribution of, 116:783-tmig, 116:823
vaccine, development of, 116:783-tmig, 116:804, 116:990-e
virulence, strain population structure and, 117:1308
virulence factor, blood group antigen-binding adhesin (BabA) as, 118:3-gn

HELLP syndrome, long-chain hydroxyacyl coenzyme A dehydrogenase (LCHAD) and, 124:1548-ss

Helminths
and attenuation of *H. pylori*-related gastritis, 119:611-gn
hepatic infection, interferon α-2a and (mice), 124:1441

Helper T cells
Th1 phenotype
in chronic murine colitis dependent on CD154/CD40 pathway, 119:715
cytokine responses, in hapten-induced colitis (mice), 119:724
Th2 phenotype
and colitis in TCRα$^{-/-}$ mice, 119:983
cytokine responses, in hapten-induced colitis (mice), 119:724

Hematopoiesis, IFN-α therapy and, 123:141

Heme catabolism, carbon monoxide from, and protection against hepatobiliary dysfunction (rat), 120:1227, 120:1288-e

Heme oxygenase
activity, in internal anal sphincter smooth muscle (opossum), 118:477
inhibitor of, 118:477

Heme oxygenase-1
as antifibrogenic protein, in hepatic myofibroblasts, 125:460
in experimental hepatopulmonary syndrome (rat), 125:1441

Hemobilia, diagnosis of, 122:1720-im

Hemochromatosis
cancer risk in, 121:1251-ss, 125:1733
classic, novel mutation of *HFE* in, 116:1282-tmig, 116:1409
clinical features of, 120:718
diagnosis of, 120:718
differential HFE allele expression in, 119:1075, 120:1308-c, 123:652-c
duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404
duodenal iron accumulation in, pathophysiology of, 125:746
duodenal metal transporter (DMT-1) in, 118:632-ss
epidemiology of, 116:198
first-degree relatives of patients with, cancer risk in, 125:1733
genetic
and hepatocellular carcinoma, *p53* mutations in, 117:154
and iron status in chronic hepatitis C, 116:2-tmig, 116:127
genetics of, 119:1409-pmr, 120:718
genotype and phenotype in, 116:199
H63D mutation in, 122:599-tmig, 122:646
in HFE-deficient mice, and intestinal iron uptake determined by divalent metal transporter 1, 120:1420
HFE expression in, 121:1489-srr
HFE function in, 121:1489-srr
homozygous *HFE* gene splice site mutation in, 122:789-cr
iron, alcohol, and cirrhosis in, 122:281, 122:563-e
iron absorption in, 121:1489-srr
and iron metabolism, 116:194
knockout mouse model, transcript levels of iron-related genes in, 122:745
and liver disease, clinical issues in, 116:201
management, 120:718
controversies in, 116:202
molecular medicine and (meeting report), 116:193
novel nonsense mutations of *HFE* gene in, in Italian patients, 119:441
oxidoreductase expression in, 125:746
pathophysiology of, 119:1409-pmr, 120:718
screening for
family, 120:718
population, 120:718
susceptibility gene. *See HFE* gene
treatment of, 119:1409-pmr
type 3, transferrin receptor 2 gene mutation in, 122:1295

Hemodialysis, for hepatorenal syndrome, 122:1658

Hemofiltration, for hepatorenal syndrome, 122:1658

Hemorrhage, gastrointestinal
antihypertensive drugs and, 119:1416-c
skin signs of, 124:1595
Hemorrhoids, in perianal Crohn's disease, 125:1503-aga, 125:1508-aga
Hepadnavirus, large envelope protein, DNA-based immunization against, 116:658
Heparan sulfate, disaccharides derived from, and IL-8 and IL-1β secretion by intestinal epithelial cells, 120:449
Heparin
disaccharides derived from, and IL-8 and IL-1β secretion by intestinal epithelial cells, 120:449
unfractionated
for moderate and severe ulcerative colitis, comparison with methylprednisolone, 119:889-tmig, 119:8903
for ulcerative colitis, comparison with methylprednisolone, 120:1306-c, 120:1307-c
Heparin-binding EGF-like growth factor, overexpression of, and pancreatic disease (mice), 124:1020
Heparin-binding epidermal growth factor (HB-EGF), transgenic expression of, and liver regeneration (mice), 124:701
Hepatic artery(ies)
blood flow in
and hepatocyte oxygenation in human cirrhosis, 117:1257-c
nitric oxide and, in acute hepatic injury (rat), 117:173
endothelium-free, adrenergic responsiveness in cirrhosis, 116:387
flow volume and reserve in cirrhosis, assessment of, 116:906
receptor-mediated contraction, in cirrhosis, 118:765
Hepatic cells, copper homeostasis in, ligand-induced apical sorting and, 119:782
Hepatic encephalopathy, 121:1257-pmr
progression, in acute liver failure, infection and, 125:755
with TIPS, 124:1700
Hepatic myelopathy, improvement, by liver transplantation, 124:346
Hepatic osteodystrophy
pathophysiology of, 125:941-aga
prevalence of, 125:941-aga
Hepatic portal venous gas, computed tomography of, 119:6-im
Hepatic vein, thrombosis, G20210A prothrombin gene mutation and, 120:1059-c
Hepatitis
acute
alcoholic, pentoxifylline and, 119:1426-tmig, 119:1637, 119:1787-e
drug-induced, 117:1234-cr
induced by greater celandine *(Chelidonium majus)*, 117:1234-cr
alcoholic
nutritional therapy for, 120:1053-ss
pentoxifylline and, 119:1426-tmig, 119:1637, 119:1787-e
APECED, autoantibodies in, 121:668
autoimmune. *See* **Autoimmune hepatitis (AIH)**
bystander, cytokine-dependent (mice), 123:1252
concanavalin A-induced, role of IL-5 and eosinophils in (mice), 122:2001
drug-induced immunoallergic, HLA association in, 117:1038-tmig, 117:1181
SEN virus and, 121:734-ss
treatment of, new drugs for, 116:236-gn, 117:525-ce
viral. *See also* **Hepatitis A/Hepatitis A virus (HAV); Hepatitis B/Hepatitis B virus (HBV); Hepatitis C/Hepatitis C virus (HCV)**
AGA Gastroenterology Teaching Project publication on, 125:991-pmr
chronic
diagnosis and treatment of, 125:1278-pmr
management of, 123:2154-pmr
in heart transplant recipients, 119:890-tmig, 119:1064, 120:1311-c, 120:1561-c
serologic tests for, interpretation of, 123:1367-aga
structural biology and, 123:1350-srr
Hepatitis A/Hepatitis A virus (HAV), report of outbreak, 116:1283-gn
Hepatitis B/Hepatitis B virus (HBV)
adefovir dipivoxil for, 120:1828-srr
efficacy of, HBV genotype and, 125:107
resistance to, HBV polymerase mutation and, 125:292-rc
advanced, antiviral therapy for, 120:1828-srr
animal models of, 120:1828-srr
antiviral agents for, 117:525-ce
book on, 124:1997-pmr
carriers, serum HBV-DNA levels in, 122:2092-c
chronic
acute flares of, 120:1009-srr
in children, 120:1828-srr
clinical outcome in, HBV genotype and, 118:458-tmig, 118:554, 125:1916-c
decompensated, lamivudine for, determinants of early mortality in, 123:714
gene expression in, cDNA microarray analysis of, 120:955, 121:1263-c
HBeAg-negative
interferon α therapy in, 120:1828-srr
interferon α treatment and retreatment in, 121:101
lamivudine therapy for, 120:1828-srr
HBeAg-positive
interferon α therapy in, 120:1828-srr
lamivudine therapy for, 120:1828-srr
lamivudine for, 116:1498-ss, 119:2-tmig, 119:172, 119:263-e
in children, 123:1741-ss
long-term safety of, 125:1714
liver histology in, 120:1828-srr
liver transplantation in, 123:714
long-term outcome in, HBV genotype and, 123:1848
patients' guide to, 123:1745-pmr
resolution, by adoptive transfer of immunity to HBcAg, 122:614
treatment of, endpoints for, 123:1831, 123:2135-e
core antigen, immunity to, and resolution of chronic hepatitis B, 122:614
core gene deletions, after kidney transplantation, 124:1809
core promoter mutations, and risk of hepatocellular carcinoma, 124:327
in Crohn's disease, immunomodulatory therapy and, 122:593-c
DNA, tests for, 120:1828-srr
drug resistance
molecular anatomy and pathophysiologic implications of, 120:1000-srr
structural biology and, 123:1350-srr
epidemiology of, 120:1828-srr
in United States, 125:444
exacerbations of, HBV variants and, 124:80
flares of
antiviral therapy-induced, 120:1009-srr

HBV genotypic variation and, 120:1009-srr
lamivudine therapy and, 120:1000-srr
other viral infection and, 120:1009-srr
genotypes
B, and hepatocellular carcinoma, 118:458-tmig, 118:554, 125:1916-c
Ba and Bj, clinical relevance of, in Taiwan, 125:1916-c
B and C, recombination of, epidemiologic and virologic characteristics of, 124:925
and clinical outcome in chronic hepatitis B, 118:458-tmig, 118:554, 125:1916-c
and efficacy of adefovir dipivoxil therapy, 125:107
and HBeAg seroconversion, 122:1756
and hepatocellular carcinoma, in Japan, 120:1564-c
in HIV-coinfected patients, 125:1559-c
and long-term outcome in chronic hepatitis B, 123:1848
and progression of liver disease, 122:1756
in United States, 125:444
HBcAg, antigen-processing pathway for, 116:650, 116:765-e
HBeAg
antigen-processing pathway for, 116:650, 116:765-e
variants, with reduced expression, 125:1370
in heart transplant recipients, 119:890-tmig, 119:1064, 120:1311-c, 120:1561-c
and hepatocellular carcinoma, surveillance for, 120:1828-srr
in HIV-infected (AIDS) patients
lamivudine-resistant, 122:244-c, 124:586-c
long-term outcome in, 123:1812
response to interferon therapy in, 123:1812
treatment of, 120:1828-srr
viral genotypes in, 125:1559-c
immunopathogenesis of, 120:1828-srr
lamivudine-associated YMDD mutant, liver transplantation for, 119:1382-cr
lamivudine for, 117:525-ce, 118:3-gn, 121:222-ss
lamivudine-resistant, 120:1828-srr
in HIV-infected (AIDS) patient, 122:244-c, 124:586-c
tenofovir disoproxil fumarate for, 124:586-c
molecular diagnosis of, 122:1554
natural history of, 120:1828-srr
and NF-κB/Rel activation, 118:1208-srr
occult infection with, 125:1903-ss
pathogenesis of, HBV-specific CD8⁺ T cells in, 117:1386
patient education about, 123:1745-pmr
polymerase, 120:1000-srr
postchemotherapy reactivation of, preemptive lamivudine for, 125:1742
recurrence after liver transplantation
prevention of
combination therapy for, 120:1828-srr
HBIg for, 120:1828-srr
treatment of, 120:1828-srr
replication, enhanced, during lamivudine therapy, 122:264
replication in vivo, inhibition by nucleoside analogues and siRNA (mice), 125:9-rc
secretion-defective variant of, 125:1077
spontaneous HBsAg seroclearance in, prognosis after, 123:1084, 125:274-c
stages of, levels of circulating HBV-specific CD8⁺ T cells during, 117:1386
treatment of
book on, 122:1181-pmr
endpoints for, 123:1831, 123:2135-e
in HIV-infected (AIDS) patients, 120:1828-srr, 123:1812
lamivudine for, histological outcome during, 124:1-tmig, 124:105, 125:1286-c
molecular approaches to, 120:1828-srr
nucleoside analogs for, 120:1828-srr
nucleoside analogues and siRNA in (mice), 125:9-rc
recommendations for, 120:1828-srr
vaccine against, 120:1828-srr
and multiple sclerosis, 120:1880-ss
variants and mutants of, 120:1828-srr
virology of, 120:1828-srr
X gene, and cellular calcium release, 122:255-gn
YMDD-mutant, and liver failure in HIV-infected (AIDS) patient, 121:1027-c

Hepatitis C/Hepatitis C virus (HCV)

acute, 123:2082
asymptomatic, management of, 125:80, 125:253-e
course of, 125:80, 125:253-e
humoral immunity in, 117:510-c
management of, 123:2082
treatment of, 122:1175-ss
strategies for, 125:80, 125:253-e
viral clearance in, 125:80, 125:253-e
in African Americans, 119:1385-srr
alcohol and, 123:2082
antiviral agents for, 117:525-ce
in blood donors, risk factors for, 116:784-tmig, 116:893
book on, 121:227-pmr, 124:1996-pmr
carriers, with persistently normal aminotransferase levels
management of, 118:649-tmig, 118:760
natural history of, 121:1526-c
CCR5-Δ32 in, 122:1721-rc, 122:2069-e, 124:352, 124:867-c, 124:868-c, 124:1558-c
in children, management of, 123:2082
chronic, 123:2082
adherence to therapy and response in, 123:1061, 123:2082, 125:1284-c
after liver transplantation, IFN-α2b plus ribavirin for, 124:642
allostimulatory defect of dendritic cells in, 120:512
fibrosis in
CCL21 and, 125:1060
HFE gene mutations and, 124:318
insulin resistance and, 125:1570-tmig, 125:1695, 125:1889-e
interferon alfa treatment and, 116:234-tmig, 116:378
progression of, 124:1-tmig, 124:97, 124:318, 125:1570-tmig, 125:1695, 125:1889-e
gene expression in, cDNA microarray analysis of, 120:955, 121:1263-c
hepatic deficiency of IL-10 in, 119:1411-c
hepatocellular carcinoma prevention in, interferon therapy and, 117:738-ss, 117:757-gn, 118:446-ss
HFE gene mutations in, 116:2-tmig, 116:127, 124:318
humoral immunity in, 117:510-c
interferon for, maintenance therapy, 117:1038-tmig, 117:1164
interferon-ribavirin treatment for, 117:292-tmig, 117:408
interleukin 10 treatment for, 118:649-tmig, 118:655-rc, 119:1411-c, 119:1412-c
lymphocyte recruitment in, CCL21 and, 125:1060
MCP-1 gene polymorphism in, 125:1085
medical treatment of, effectiveness of, 122:1195-tmig, 122:1303, 122:1525-e, 124:584-c, 125:629-c
oral lichen planus in, interferon therapy and, 117:283-c
with persistently normal ALT levels, 123:1748-c

core protein, oxidative stress induced by, 122:366, 122:568-e
course of
hemochromatosis gene and, 124:318, 124:1509-srr
long-term cohort study of, 124:261-ss
predictors of, 124:1-tmig, 124:97
in Crohn's disease, immunomodulatory therapy and, 122:593-c
and C282Y, 116:494-ss
diagnosis of, 123:2082
epidemiology of, 123:2082, 125:628-c
extrahepatic manifestations of, 123:2082
45-year follow-up of, 119:1405-ss
genome, quantification, real-time detection system for, 116:636, 116:763-e
genotype 1b
response to therapy in, interferon sensitivity determining region and, 125:1284-c
treatment of, interferon for, 124:1166-c
genotype 2a, replicons, development of, 125:1808, 125:1892-e
HCV-specific T-cell response to, induction by oral immunization with *Salmonella* carrier for HCV DNA (mice), 121:1158
in heart transplant recipients, 119:890-tmig, 119:1064, 120:1561-c
and hepatic fibrosis
effect of renal transplantation on, 123:1494, 123:1729-e
response to interferon therapy, 120:579-ss
in HIV-infected (AIDS) patients, management of, 120:607, 123:2082
humoral immunity in, 116:2-tmig, 116:135, 125:597-srr
hyperendemic area for
mortality rates due to HCC and cirrhosis in, 125:628-c
oral lichen planus incidence in, 119:883-c, 121:1528-c
immune responses in, 117:756-tmig, 117:926, 117:933, 117:1012-e, 118:807-c, 118:1124, 121:646
immunoglobulin, 125:597-srr
infectious clone of, molecular evolution of (chimpanzee), 121:1226
information on, for children, 120:1056-pmr
in injection drug users, management of, 123:2082
interference with interferon signaling (mice), 124:1465
interferon for
adherence to therapy and response to, 123:1061, 125:1284-c
biochemical response to, outcomes with, 122:237-ss
and improved survival, 123:402-tmig, 123:483
monotherapy, 116:1266-ss
pegylated, 120:3-gn
viral kinetics with, 120:1318-tmig, 120:1438, 120:1546-e
and T-cell responses, 123:1070
interferon/ribavirin treatment for, 116:4-gn, 116:1266-ss, 117:525-ce, 121:1017-ss
cost-effectiveness of, 118:1268-ss
T-cell reactivity in, 118:248-tmig, 118:346
internal ribosome entry site, translation directed by, cell cycle regulation of, 118:2-tmig, 118:152
life expectancy in, improvement, by interferon therapy, 123:402-tmig, 123:483
liver infected with, transplantation into HCV-infected recipient, 117:2-tmig, 117:149, 117:263-e, 117:1253-c
liver transplantation for, 117:502-ss
European experience with, 117:522-tmig, 117:619
recurrence after, 120:749
HCV-specific CD4$^+$ response and, 117:756-tmig, 117:926, 117:1012-e
molecular diagnosis of, 122:1554
mother-to-child transmission of, prevention of, 120:1555-ss
mutations, patterns of (chimpanzee), 121:1226
natural history of, 122:578-ss, 123:2082
neutralizing antibodies in, 125:597-srr
and nonalcoholic fatty liver disease, 123:1705-aga
NS5A protein, inhibition of interferon antiviral activity, 117:1187
outcome
HCV-specific T-cell responses and, 121:646
HLA and, 118:1124
prediction of, 120:312-ss
and patient and allograft survival after liver transplantation, 122:848-tmig, 122:888, 122:1161-e, 123:2160-c
patients' guide to, 123:650-pmr
PKR inhibitor proteins, correlation with IFN responsiveness, 119:1649
prevalence of, 117:757-gn
in B-cell non-Hodgkin's lymphoma, 125:1723
prognosis for, 120:1878-ss
and psychiatric disorders, 123:402-tmig, 123:476
public misunderstanding of, 125:289-gn
quasispecies
evolution of, after liver transplantation, 123:1422-tmig, 123:1485
prognostic significance of, 120:312-ss
recurrence
after liver transplantation, 120:749
HCV-specific CD4$^+$ response and, 117:756-tmig, 117:926, 117:1012-e
HCV-specific CD4$^+$ response and, 117:756-tmig, 117:933, 117:1012-e, 118:807-c
replication of, hepatic cell cycle and, 118:2-tmig, 118:152
replicons, 125:1808, 125:1892-e
research on
advances in (future directions for), 123:2082
racial and ethnic issues in, 119:1385-srr
resistance to interferon, mechanism for, 117:757-gn
RNA
qualitative assays for, 123:2082
quantitative assays for, 123:2082
RNA interference in, 125:1546-ss
with schistosomiasis, outcome of, 121:646
serologic assays for, 123:2082
skin ulcers in, 121:245-im
spontaneous resolution of, after withdrawal of immunosuppression, 124:1946-cr
structural biology of, 123:1350-srr
TAP2 gene polymorphisms and, 116:1023-tmig, 116:1149
transgenic mice expressing proteins of, liver injury in, 122:352, 122:568-e
transmission of, 117:757-gn
during bloody fisticuffs, 119:507-cr
mother-to-child, prevention of, 120:1555-ss
prevention of, 123:2082
treatment of, 120:1878-ss
adherence to therapy and response to, 123:1061, 123:2082, 125:1284-c
adverse effects and side effects of, 124:1711
frequency of, 124:1711
hematologic, 124:1711
management of, 124:1711
neurologic, 124:1711
neuropsychiatric, 124:1711
pulmonary, 124:1711
book on, 122:1181-pmr
efficacy of, adherence and, 124:1711

NIH Consensus Development Conference statement on, 123:2082
NIH Consensus Development Conference update on, 123:404-gn
in prisoners, 125:1543-ss
racial differences in response to, 122:1198-gn
regression of splenic lymphoma after, 124:1157-ss
response to, race and, 119:1186-tmig, 119:1317
vaccine for, development of, 117:1266-tmig, 117:1397, 125:597-srr
virus-like particles
characterization of, 117:1266-tmig, 117:1397
as potential vaccine candidate, 117:1266-tmig, 117:1397
synthesized in insect cells, 117:1266-tmig, 117:1397

Hepatitis D/Hepatitis D (delta) virus (HDV), chronic
epidemiology of, 117:154
interferon for, 117:1229-cr
natural history of, 117:154

Hepatobiliary disease
imaging in, 123:1745-pmr
pathophysiology of, 123:1745-pmr

Hepatobiliary system
cancer of, risk for, with primary sclerosing cholangitis, 123:647-ss
epithelium of, water transport by, 122:545-srr
pathophysiology of, 118:636-pmr

Hepatobiliary transport, of sulindac, 117:755-tmig, 117:962

Hepatocellular carcinoma (HCC)
ablation therapy for, 122:1609
in African Americans, 119:1385-srr
chemoembolization for, 122:1609
chemotherapy for, 122:1609
in chronic hepatitis C, prevention of, interferon therapy and, 117:738-ss, 117:757-gn, 118:446-ss
clinical features of, 122:1609
CpG methylation of *p16* in, 116:234-tmig, 116:394
development of
chromosomal allelic imbalance in liver cirrhosis and, 121:699
in chronic hepatitis B, HBV genotype and, 118:458-tmig, 118:554, 125:1916-c
diagnosis of, 122:1609
α-fetoprotein-specific immunotherapy for (mice), 119:1104
genetic alterations in, 120:1763
glypican-3 as marker for, 125:89
HBV genotypes and, in Japan, 120:1564-c
Helicobacter sp. in liver and, 120:323-c
in hereditary hemochromatosis, 121:1251-ss
incidence of, in HCV hyperendemic area, 125:628-c
liver resection in, 122:1609
liver transplantation in, 122:1609
criteria for, 122:579-ss
mortality from, reduction, by interferon therapy for hepatitis C, 123:402-tmig, 123:483
nerve growth factor production by (mice), 122:1978
nonalcoholic steatohepatitis and, 123:134, 123:375-e
pathogenesis of, 118:2-tmig, 118:152
p53 mutations in, 117:154
prevention
in chronic hepatitis C, interferon therapy for, 117:738-ss, 117:757-gn, 118:446-ss
by interferon, 120:1301-ss
primary and recurrent, chromosomal changes and clonality relationship between, 119:288-tmig, 119:431
radiologic features of, 122:1609
recurrence, postsurgical, circulation AFP mRNA as marker for, 123:2152-ss
risk, HBV core promoter mutations and, 124:327
screening for, in hepatitis C, 123:2082
staging of, 122:1609
surveillance for, in hepatitis B, 120:1828-srr
survival with, by stage at diagnosis, 122:1609
UGT1A7 and *UGT1A9* polymorphisms and, 121:1136

Hepatocyte nuclear factor 1 (HNF1)
and colorectal cancer with microsatellite instability, 124:1311
in transcriptional regulation of lactase-phlorizin hydrolase (pig), 116:842

Hepatocyte nuclear factor 1α (HNF-1α), inactivation, and familial liver adenomatosis, 125:1470-cr

Hepatocytes
anaphylatoxin C5a receptor induction in, by lipopolysaccharide (rat), 122:697
apical endocytosis and intracellular traffic infrastructure in (rat), 119:1692, 119:1791-e
apoptosis
Bid-mediated activation of mitochondrial apoptotic mechanisms in, 125:854
bile salt–induced, EGF-R/CD95 and, 125:839
Fas-mediated
in cholestasis (mice), 117:669, 117:732-e
IL-1β and (mice), 117:661
inhibition by bile acid-activated phosphatidylinositol 3-kinase (rodent), 120:1810
prevention by genipen (mice), 118:380
prevention by SOD mimetic (mice), 121:1451
and fibrosis, Fas-mediated mechanistic link between (mice), 123:1323
mitochondrial permeability transition and (rat), 124:494
in nonalcoholic steatohepatitis, 125:437
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and, 119:3-gn
ATPB7 localization in (rat), 118:921
calcium waves in, type II inositol 1,4,5-trisphosphate receptor and (rat), 122:1087
cholestatic, altered vesicular trafficking and cell polarity in (rat), 121:1033-tmig, 121:1176
COX-2 expression in, C/EBP-α and, 119:493
cryopreserved, regenerative capacity of (mice), 118:248-tmig, 118:390, 118:438-e
derived from bone marrow, 119:891-gn
fetal, telomerase-immortalized, 124:283-tmig, 124:432, 124:568-e
glucagon-induced MKP-1 expression in (rat), 118:929
growth inhibition of, by sphingosine 1-phosphate (rat), 124:459
HGF-induced proliferation of, S-adenosylmethionine down-regulation by nitric oxide and, 122:1355
human cord blood cell differentiation into (mice), 124:1891
IFN-α signal pathway in, 122:1019
inducible NOS expression in, oxidative stress and (rat), 118:608
lipid-induced uncoupling protein 2 expression in (rat), 116:1024-tmig, 116:1184
maturation of, β-catenin and, 124:202
necrotic cell death in, mitochondrial permeability transition in (rat), 124:494
organic anion transporter specific to, encoded by SLC21A8 gene, 122:1545-c
oxygenation, hepatic artery flow change and, in human cirrhosis, 117:1257-c

proliferation
growth factor-stimulated (rat), 118:591
ICAM-1 and (mice), 124:692
protection of, in regenerating liver, cardiotrophin-1 and (rat), 125:3-tmig, 125:192
proteolytic activity of, regulation by cell hydration, $p38^{MAPK}$ in, 116:921
syngeneic, transplanted, Kupffer cells and (rat), 123:1677
taurolithocholic acid-3 sulfate-induced apoptosis in, mechanisms of (rat), 122:1411
TNF-α and Fas-mediated apoptosis in, NF-κB activation and iNOS in (mice), 120:1251
transplantation, 120:749
benefits of, in Wilson's disease (rat), 122:438
in mouse model of progressive familial intrahepatic cholestasis, 119:1720
xenotransplantation, for liver failure and cirrhosis (rat), 124:282-tmig, 124:422, 124:568-e

Hepatology
clinical science of, 118:449-pmr
evidence-based, 120:1559-pmr
future of (abstract), 116:1244-aga
gastroenterologist training in, 124:1077-aga

Hepatoma cells. *See also* Hepatocellular carcinoma (HCC)
cellular localization of mutant ATP7B in, 124:335, 125:1911-c
functional interactions among oxidative stress, cell volume recovery, and membrane sodium permeability in (rat), 118:395
proliferation, methionine adenosyltransferase II β subunit in, 124:940

Hepatoportal thrombosis, causes of, 119:874-ss

Hepatopulmonary syndrome
in Budd-Chiari syndrome, 122:896
in cirrhosis, prognostic significance of, 125:1042, 125:1261-e
heme oxygenase-1 and NOS alterations in (rat), 125:1441
in inferior vena cava obstruction, 118:192
pathogenesis of, 118:192

Hepatorenal syndrome
cardiovascular function in, 122:1658
in cirrhotic patients, 122:1658
clinical features of, 122:1658
development of, 122:1658
diagnosis of, 122:1658
terlipressin and, 122:922
types of, 122:1658
historical perspective on, 122:1658
prevention of, 122:1658
terlipressin and *N*-acetylcysteine in, 123:2160-c
therapy for, 116:1264-ss
TIPS for, 124:1700
treatment of, 120:726, 122:1658
molecular adsorbent and recirculating system (MARS) for, 119:1799-ss
terlipressin with and without albumin for, 124:1552-ss

Hepatotoxicity
of drugs and chemicals, 117:759-ce, 118:984-pmr
NIDDK Clinical Research Network on, 125:1008-gn

Hepcidin
and iron absorption (rat), 123:835
and iron transporter expression in duodenum (rat), 123:835

Hephaestin, duodenal, in iron disorders, 125:746

Herbal remedies, for liver disease, 117:1250-ss

Herbs, and liver chemistry tests, 123:1367-aga

Hereditary angioedema, 116:514-im

Hereditary diffuse gastric cancer families, CDH1 mutation carriers from, cancer risk in, 121:1348

Hereditary hemochromatosis (HHC). *See* Hemochromatosis

Hereditary hemorrhagic telangiectasia (HHT)
clinical characteristics of, 124:1595
hyperdynamic circulation in, liver transplantation and, 116:187-cr

Hereditary mixed polyposis syndrome
clinical characteristics of, 124:1574
genetic testing for, 124:1574

Hereditary nonpolyposis colorectal cancer (HNPCC)
atypical, germline variants of *EXO1* gene in, 120:1580-rc, 120:1860-e
clinical criteria for, 121:1005-e
proposed by International Collaborative Group on HNPCC, 116:1453-srr
clinical features of, 121:198-aga, 124:1574
colorectal cancer screening in, efficacy of, 118:815-tmig, 118:829, 118:969-e
cyclooxygenase-2 expression in, vs. sporadic colorectal cancer, 117:291-tmig, 117:350
detection of, by screening for tumor microsatellite instability before germline genetic testing, 120:1-tmig, 120:21
diagnosis of, 121:1005-e
frequency of, 121:830, 121:1005-e
genetically defined, colon cancer burden in, 121:830, 121:1005-e
genetic defect in, 121:198-aga
genetic testing for, 118:230-ss, 119:837-srr, 121:195-aga, 124:1574
technical review on, 121:198-aga
hMLH1 del616 in, functional analysis of, 125:501
hMLH1 mutations in, functional analysis of, 122:211
microsatellite instability in, 121:198-aga
mismatch repair gene testing in, 121:198-aga
molecular basis for, 119:854-srr
population-based screening for, 121:1005-e
recommendations for cancer screening in, 124:544-aga
screening for, 121:198-aga
treatment of, 121:198-aga
in young colorectal cancer patients, 122:939

Heregulin α, and gastric epithelial cell proliferation, 117:1119

Hering, Karl Ewald Konstantin, 121:1347

HER-2/*neu*
and colorectal carcinoma growth, 120:1721, 120:1872-e, 125:1915-c
overexpression of, in colonic malignancy, 122:248-c, 125:1915-c

Hernia, ventral (epigastric), and pancreatitis, 124:865-c

***HFE* gene,** 116:195
and course of hepatitis C, 124:318, 124:1509-srr
C282Y mutation
penetrance of, in general US population, 123:948-ss
and protection against iron deficiency in celiac disease, 123:444
differential allelic expression of, in hemochromatosis, 119:1075, 120:1308-c, 123:652-c
H63D mutation, 122:599-tmig, 122:646
and protection against iron deficiency in celiac disease, 123:444
and hepatic fibrosis in hepatitis C, 124:318
and iron deficiency in celiac disease, 124:1562-c, 124:1563-c
and iron overload, 121:1489-srr
knockout models of, 120:718, 121:1489-srr
mutations
analysis of, in liver disease, 120:718
in chronic hepatitis C, 116:2-tmig, 116:127

in classic hemochromatosis, 116:1282-tmig, 116:1409
and nonalcoholic steatohepatitis, 125:615-ss
phenotypic expression of, 116:233-tmig, 116:372
novel nonsense mutations of, in Italian patients with hemochromatosis, 119:441
splice site mutation, homozygous, 122:789-cr

***Hfe* gene,** knockout mice, iron-related mRNAs in, 122:745

HFE protein
cellular and tissue distribution of, 121:1489-srr
expression, molecular aspects of, 121:1489-srr
function, 121:1489-srr

***HFib1* gene,** as hepatic fibrosis susceptibility gene (mice), 123:2041

Hiatal hernia
excess reflux with, in GERD, 119:1439, 119:1779-e
and gastroesophageal reflux disease, 118:650-tmig, 118:688

Highly active antiretroviral therapy (HAART)
GI-associated drug interactions of, 120:607
for HIV-1 infection
adverse effects and side effects of, 120:607
efficacy of, 120:607
and mucosal immunity, 120:984-cr

High mobility group (HMG) B1, B box, effects on intestinal permeability and barrier function (mice), 123:662-tmig, 123:790

Hirschsprung disease
differential diagnosis of, 120:216-cr
ErbB2 in, 125:1900-ss
kinase domain mutations of RET in, 121:24
single-stage operations for, 120:1299-ss

Histamine
amylin and (mice), 123:247
and other gastric secretagogues, correlation of (mice), 122:145

Histamine (H_2) antagonists
effects on nocturnal gastric acid breakthrough, 122:599-tmig, 122:625
for NSAID gastropathy, 119:521-srr

Histamine (H_1) receptors, and afferent nerve sensitivity to intestinal anaphylaxis (rat), 119:1267

L-Histidine decarboxylase, deficiency, gastric acid secretion in (mice), 122:145

Histoacryl, in management of gastric varices, 120:1875-ss

Histo-blood group antigens, Norwalk virus binding to, on gastroduodenal epithelial cells of secretor individuals, 122:1967

Histology, in pouchitis, 121:239-tmig, 121:261

History
of endoscopy, 121:738-pmr
of gastroenterology, 121:738-pmr

HIVID. *See* Zalcitabine

HIV-infected (AIDS) patients. *See also* Human immunodeficiency virus (HIV-1)
hepatitis B in. *See* Hepatitis B/Hepatitis B virus (HBV), in HIV-infected (AIDS) patients
hepatitis C in, management of, 120:607, 123:2082

H^+,K^+-ATPase. *See* Proton pump

hMLH1
promoter methylation
and microsatellite instability in colorectal cancer, 121:1300, 121:1497-e
pattern of, in sporadic MSI colorectal cancer, 124:1165-c
variants, functional analysis of, 122:211

***hMLH1* del616,** pathogenicity of, linked to shortage of functional protein, 125:501

Hodgkin's disease, risk, in ulcerative colitis, 119:647

Homeobox *(Hox)* genes
Cdx1, and differentiation of intestinal epithelial cells (rat), 117:1266-tmig, 117:1316
3′, coordinated expression of, during embryonal gut development (mice), 117:1266-tmig, 117:1339

Homeobox transcription factors, and intestinal pseudo-obstruction (mice), 125:1297-tmig, 125:1428

Homeodomain protein Cdx2. *See* Transcription factor Cdx2

Home parenteral nutrition, 121:966-aga, 121:970-aga

Hormonal therapy, for prevention of rebleeding from angiodysplasia, 121:1033-tmig, 121:1073

Hormones, and gender differences in IBS, 123:1686-srr

Host response
to bacteria, in inflammatory bowel disease, 122:44, 122:228-e, 123:955-c, 125:1288-c
CX3CR1 signaling in intestinal epithelial cells and, 122:166

hPepT1, colonic epithelial expression of, in inflammatory bowel disease, 120:1657

H-Ras, intestinal epithelial cells transformed by, growth inhibition by farnesyl transferase inhibitors, 117:521-tmig, 117:567

***h-sgk* serine-threonine protein kinase gene,** transcriptional regulation by TGF-β in human intestine, 116:1081

Human cationic antimicrobial peptide 18 (hCAP18). *See* LL-37

Human genome, 119:1427-gn

Human immunodeficiency virus (HIV). *See also* HIV-infected (AIDS) patients
and hepatitis C, co-infection with, management of, 123:2082
infection
and chronic hepatitis B, 123:1812. *See also* Hepatitis B/Hepatitis B virus (HBV), in HIV-infected (AIDS) patients
cryptosporidiosis in, nonimmune defense against, 119:1236
liver failure in, caused by YMDD-mutant hepatitis B virus, 121:1027-c
management of, gastrointestinal aspects of, 120:607
pathogenesis of, gastrointestinal aspects of, 120:607
reduced levels in intestinal macrophages, 116:1043
resistance to
CC chemokine receptor 5-Δ32/Δ32 genotype and, 124:352, 124:867-c, 124:868-c, 124:1558-c
in *CCR5*-*Δ32* homozygotes, 124:867-c
screening for, in hepatitis C, 123:2082
Tat protein, effects on intestinal epithelial cells, 124:282-tmig, 124:368
transfer across intestinal epithelial cells, 123:946-ss
transmission of, gastrointestinal mucosa and, 120:607

Human leukocyte antigen(s) (HLA)
in autoimmune pancreatitis, in Japanese population, 122:1264
class II, in drug-induced immunoallergic hepatitis, 117:1038-tmig, 117:1181
and disease outcome in hepatitis C, 118:1124
genotype, and clinical phenotype of arthropathy in IBD, 118:279
HLA-DQ1, and achalasia, 117:1-tmig, 117:26

HLA-DQ2, in irritable bowel syndrome patients with latent/potential celiac disease, 121:1329, 121:1512-e
HLA-DR, and achalasia, 117:1-tmig, 117:26
in inflammatory bowel disease, 123:661-tmig, 123:714, 124:521-srr
Human papilloma virus (HPV)
and high-grade dysplasia in anal canal, 120:784-tmig, 120:857, 120:1046-e
and risk of anal canal cancer, 120:784-tmig, 120:857, 120:1046-e
type 16, and primary squamous cell carcinoma of rectum, 120:988-cr, 120:1046-e
Humoral immunity, in hepatitis C, 116:2-tmig, 116:135, 117:510-c, 125:597-srr
Hydatid disease, in liver, ivermectin treatment for (sheep), 122:956
Hydrocortisone, intravenous premedication with, and reduction of antibodies to infliximab in Crohn's disease, 124:874-tmig, 124:917, 124:1140-e
Hydroperoxides, dietary, absorption of, intestinal glutathione peroxidase as barrier against (CaCo-2 cells), 119:420
Hydrophilic compounds, polarized transport across colonic mucosa (rat), 118:535
Hydrothorax, hepatic, TIPS for, 124:1700
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. *See* Statins
5-Hydroxytryptamine, and duodenal mucosal bicarbonate secretion (mice), 125:805
5-Hydroxytryptamine receptors
5-HT_3
antagonist, for irritable bowel syndrome, 123:2108-aga
expression in gastrointestinal tract (rat), 123:217
5-HT_4, agonist, for irritable bowel syndrome, 123:2108-aga
Hydroxyurea, therapy with, GI toxicity and GI-associated drug interactions of, 120:607
Hyperalgesia, visceral, new rat model of, 119:1185-tmig, 119:1276
Hyperbilirubinemia
conjugated
and elevated hepatic alkaline phosphatase, evaluation of, 123:1367-aga
etiology of, 123:1367-aga
etiology of, 117:1255-c
fasting
enterohepatic cycling of bilirubin in, 117:1255-c
genetic basis of, 116:1272-c
genetic basis of, 117:1255-c
neonatal, *UGT1A1* gene and G6PD deficiency and, 123:127
unconjugated, isolated, evaluation of, 123:1367-aga
Hypercalcemia, and chronic pancreatitis, 120:682
Hypercholesterolemia, in primary biliary cirrhosis, 124:854-ss
Hypergastrinemia
Acinetobacter lwoffi and (mice), 123:1739-ss
chronic, effects on enterochromaffin-like (ECL) cells, 123:68, 124:1564-c, 125:827-c
and *Helicobacter* infection, in gastric cancer (mice), 118:1-tmig, 118:36
Hyperhomocysteinemia
alcohol-induced, betaine and (mice), 124:1488
in mesenteric venous thrombosis, related to pernicious anemia, 118:237-c
Hyperinsulinemia, and association of overweight and elevated serum ALT activity, 124:71, 124:248-e
Hyperleptinemia, and association of overweight and elevated serum ALT activity, 124:71, 124:248-e
Hyperlipidemia
and chronic pancreatitis, 120:682
in primary biliary cirrhosis, 124:854-ss
Hyperpigmentation, familial gastrointestinal stromal tumor with, 120:210-cr
Hyperplastic polyposis
molecular characteristics of, 119:323
phenotypic characteristics of, 119:323
Hypersensitivity angiitis, gastrointestinal involvement in, 124:1595
Hypertension
and nonalcoholic fatty liver disease, 121:91
obesity and, 123:882-aga
portal. *See* Portal hypertension
Hyperthyroidism, with pegylated interferon, for hepatitis C, 124:1711
Hyperventilation, mechanical, cerebral metabolism of ammonia and amino acids during, 121:1109
Hypnotherapy
as adjunctive therapy, for functional gastrointestinal disorders, 123:2132-e
for functional dyspepsia, 123:1778, 123:2132-e, 125:636-c
in irritable bowel syndrome, 120:652
Hypochlorhydria
IL-1β polymorphisms and, 123:92
inflammation in, effects on parietal and G cells (mice), 122:119
Hyponatremia, in cirrhosis, treatment with vasopressin receptor antagonist, 124:933
Hypo-osmolarity, choleresis induced by, integrins and Src in, 124:1476
Hypotension, arterial, in cirrhosis, endogenous cannabinoids in (rat), 122:85
Hypothalamic-pituitary-adrenocortical axis, in health, gender differences in, 123:1686-srr
Hypothermia
cerebroprotective effect in acute liver failure, 125:815, 125:976-e
prevention of ammonia-induced brain edema (rat), 116:686
Hypothyroidism, with pegylated interferon, for hepatitis C, 124:1711
Hypoventilation, in obesity, 123:882-aga
Hypoxia, hepatic, blood alcohol cycling and (rat), 123:325

IBD1, pedigrees at high risk for, identification using disease onset and severity, 119:1483
Ibuprofen
effects on gastroduodenal mucosa, 117:776, 117:1002-e, 118:638-c, 118:639-c, 118:640-c
gastrointestinal events related to, risk of, 120:594
ICAM. *See* Intercellular adhesion molecule
Idiopathic intracranial hypertension, in obesity, 123:882-aga
IkB kinases, inhibition by sulfasalazine, 119:1209
IkB proteins
in gastrointestinal diseases, 118:1208-srr
phosphorylation by IκB kinase complex, 118:1208-srr
Ileal bile acid binding protein, ontogenic expression of, regulation by bile acids (rat), 122:1483
Ileal pouch, risk of dysplasia in, 121:268
Ileal pouch-anal anastomosis
dysplasia in, 124:1636
quality of life after, 124:1173-tmig, 124:1202, 124:1535-e, 124:1636
for ulcerative colitis, health-related quality of life after, 122:1179-ss

Ileitis
acute, development of, CD154/CD40 pathway in (mice), 122:752, 122: 823-e
after intracellular parasite infection, regulation by TGF-β-producing intraepithelial lymphocytes (mice), 120:914
bile acid transport in (rat), 123:2005
Crohn's
epithelial permeability to proteins in, 117:65
mesalamine therapy for, 116:509-tmig, 116:521
quantitative trait locus for, in spontaneous mouse model of Crohn's disease, 125:477
SAMP1/YitFc mouse model of, perianal fistulizing disease in, 124:972
Ileoanal pouch, Crohn's disease of, infliximab for, 117:429-cr, 125: 631-c
Ileorectal anastomosis, in familial adenomatous polyposis, 119:1454, 121:502-c, 121:503-c
Ileum
defects of, in AR/EGF/TGF-α triple null mice, 121:68
nitrogen and amino acid losses in, and assessment of amino acid requirements, 123:50
Ileus, postoperative
ADL 8-2698 for, 122:1177-ss
attenuation by inhaled carbon monoxide (mice), 124:377
cause of (mice, rats), 121:1269-tmig, 121:1354
CRF receptors and (mice), 125:654-rc
cross-tolerance to, after LPS preconditioning (rat), 123:586
intestinal immune infiltrates and (mice), 125:1005-tmig, 125:1137
leukocytic inflammatory response in intestinal muscularis externa and (rat), 117:378, 117:489-e
nitric oxide in (rodent), 118:247-tmig, 118:316
prevention of (mice, rats), 121:1269-tmig, 121:1354
prostanoid production via COX-2 and (mice, rats), 121:1269-tmig, 121: 1354
Image of the Month, 117:752
ACE inhibitor angioedema of intestine, 119:1190
acute cholangitis, 121:1039
acute necrotizing esophagitis, 118:252
aortoenteric fistula, 121:756
appendiceal mucinous tumor, 122:1200
ascariasis, 124:879
blue rubber bleb nevus syndrome, 118: 462
Budd-Chiari syndrome in Behçet's disease, 117:526
complete invagination of appendix progressing to ileocecocolic intussusception, 123:1762
complications of endoscopic variceal sclerotherapy, 120:336
cutis laxa, 119:1430
cytomegalovirus colitis, 125:8
defective belch reflex secondary to achalasia, 123:7
Dieulafoy's lesion, 118:820
emphysematous gastritis, 118:1000
enterovesical fistulas, 125:291
Epstein-Barr virus (EBV) infection, 116: 788
esophageal foreign body, 118:5, 125: 1575
esophageal obstruction by vascular anomaly, 117:1270
esophageal pathology in HIV-infected (AIDS) patients, 117:296
Gamna-Gandy bodies, 125:1010
gastric mucosal metastatic calcification, 119:894
gastric wall abscess, 124:599
giant fibrovascular polyp, 124:8
glucagonoma syndrome, 116:1286
hemobilia, 122:1720
hepatic arteriovenous malformations, 120:1579
hepatic involvement in echinococcosis, 117:1042
hepatic portal venous gas, 119:6
hepatitis C, skin ulcers in, 121:245
hereditary angioedema, 116:514
hide-bound bowel sign in scleroderma, 124:1179
ileocecal tuberculosis, 120:1076
intraductal papillary mucinous neoplasm of pancreas, 123:406
leiomyosarcoma, 122:605
malignant lymphomatous polyposis, 121: 1530
mantle cell lymphoma, 122:852
Menetrier disease with premalignant transformation, 123:968
nodular fatty infiltration of liver in Wilson's disease, 122:258
Ormond's disease, 116:1028
pancreatic bladder, 121:4
pheochromocytoma, 120:06:00
pneumatosis intestinalis, 116:6
pneumobilia, 116:238
porcelain gallbladder, 117:760
primary amyloidosis of duodenum, 125: 1302
pseudomyxoma peritonei, 124:1727
pyoderma gangrenosum, 118:654
pyogenic hepatic abscess complicated by bronchial fistula, 123:666
Salmonella aortitis, 120:1322
splenic artery aneurysms, 123:1427
superior mesenteric arteriovenous fistula and portal hypertension, 125:653
superior mesenteric artery syndrome, 121:516
Sweet's syndrome, 124:287
syringohydromyelia, 119:614
tubular foreign body, 122:6
vascular complications of portal hypertension, 117:6
von Hippel-Lindau (VHL) disease, 120: 788
wind sock web deformity of duodenum, 119:292
Imaging
advances in, 121:1273-ce
in anorectal disorders
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
biliary, 124:1686, 125:1565 *correction*
book on, 125:626-pmr
diagnostic, in appendicitis, 123:992, 125:272-c
gastrointestinal
advances in (future directions for), 122:254-tmig, 122:406, 122: 571-e
case review of, 121:228-pmr
case reviews of, 122:1541-pmr
in hepatobiliary disease, 123:1745-pmr
in irritable bowel syndrome, 122:1701
in nonalcoholic fatty liver disease, 123: 662-tmig, 123:745
of perianal fistulas in Crohn's disease, 121:1064
of small intestine, 123:388-pmr
Immune cells, hepatic, 120:250-srr
Immune response
in acute *H. pylori* infection (Rhesus macaque), 118:247-tmig, 118:307
cellular, defective, in Whipple's disease, 123:1468
in CMV-induced liver-restricted complications of liver transplantation, 122:1201
to *H. pylori* oral vaccination, role of saliva in (mice), 118:749
in hepatitis C, 116:2-tmig, 116:135, 117:510-c
intestinal epithelial cells in, 116:783-e, 116:855, 116:1023-tmig, 116: 1054
mucosal
caspases and, 122:1334
and IL-10 (mice), 122:1829

Th1-like, in concanavalin A-induced hepatitis, inhibition by nitric oxide-aspirin derivative, 118:404
Th1/Th2-type, in autoimmune pancreatitis, 118:458-tmig, 118:573, 118:626-e

Immune system, dysfunction, in irritable bowel syndrome and comorbid conditions, 122:1139-srr, 122:1778, 122:2078-e

Immunization, DNA-based, against hepadnavirus large envelope protein, 116:658

Immunocytes, in acute and chronic pancreatitis, 118:458-tmig, 118:573, 118:582, 118:626-e, 119:881-c

Immunodiagnostics, in inflammatory bowel disease, 120:622

Immunogens, mucosal delivery of, 117:40, 117:255-e

Immunoglobulin
heavy chain, variable (V_H) region, gene for, in ulcerative colitis, 121:15
hepatitis C, 125:597-srr
IgA
anti-guinea pig liver transglutaminase, in screening for celiac disease, limitations of, 120:586-c
heavy-chain diversity, in human colon, 119:1253
serum, in celiac disease, effects on mesenchymal-epithelial cell crosstalk, 116:510-tmig, 116:566
transcytosis in small intestine (mice), 116:610
IgE, and transepithelial antigen transport in sensitized intestine (mice), 121:370
IgM, heavy-chain diversity, in human colon, 119:1253

Immunology, of irritable bowel syndrome with latent/potential celiac disease, 121:1329, 121:1512-e, 123:954-c, 123:1408-c

Immunomodulators
for Crohn's disease, with fistulous complications, 119:1132-srr
effect on course of hepatitis B or C, in Crohn's disease, 122:593-c
for inflammatory bowel disease, 120:622
and postoperative infections, 125:320, 125:610-e

Immunonutrition, preoperative, in gastrointestinal cancer patients, 122:1763

Immunosuppression
for autoimmune hepatitis, 120:1502-srr
evolving strategies for, 120:749
historical perspective on, 120:749
for inflammatory bowel disease, 120:622
for pouchitis, 124:1636
for refractory sprue, 119:243-srr
and response to infliximab for Crohn's disease, 123:661-tmig, 123:707

Immunotherapy, for stage II/III colon cancer, 117:1015-ss

Impedance testing, in gastroesophageal reflux disease, 120:1588, 120:1596, 120:1862-e

Inchin-ko-to, therapeutic effect of, mechanism for, 118:380

Incidence density ratio method, 119:895

Incontinence, fecal, 124:1672
anorectal manometry in, AGA technical review on, 116:735-aga
artificial sphincter device for, 116:1005-ss
biofeedback for, 125:1320, 125:1533-e
clinical evaluation of, 124:1672
definition of, 116:735-aga
diagnostic testing in, 124:1672
dynamic muscle plasty for, 116:549
in elderly, 122:1688
epidemiology of, 124:1672
etiology of, 124:1672
evaluation of, 122:1688
as neglected area of gastroenterology, 122:5-ce
pathophysiology of, 124:1672
rectal sensation testing in, AGA technical review on, 116:735-aga
sacral nerve stimulation for, 121:511-tmig, 121:536
tests for diagnosis or management of
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
treatment, 122:1688, 124:1672
research on, 124:597-gn

Indinavir, GI toxicity and GI-associated drug interactions of, 120:607

Indoleamine 2,3-dioxygenase, and TNBS-induced colitis (mice), 125:1762

Indomethacin
apoptosis induced by, in gastric epithelial cells, suppression by protein kinase C β1 overexpression, 118:457-tmig, 118:507
gastric injury caused by, role of proteasome in, 116:865, 116:994-e
gastrointestinal events related to, risk of, 120:594
impairment of P450 enzymes by (rat), 122:774
inflammation induced by, vascular anatomy in, 120:1885-c

Inducible costimulator (ICOS)/B7RP-1, in chronic colitis (mice), 124:410

Infection
enteropathogenic, NF-κB/Rel and, 118:1208-srr
gastrointestinal, 125:1550-pmr
and progression of hepatic encephalopathy in acute liver failure, 125:755

Infectious disease, gastroenterologist training in, 124:1071-aga

Inferior vena cava, obstruction, hepatopulmonary syndrome in, 118:192

Inflammation
colonic
circular smooth muscle slow wave alterations in (dog), 116:884
down-regulation of L-type calcium channels in (dog), 120:331-tmig, 120:480
and open-state probability of large-conductance calcium-activated potassium channels (dog), 116:884
peroxisome proliferator-activated receptor γ-activating drugs and, 117:1039-gn
colonic circular muscle, PKC isozymes in (dog), 122:483
in Crohn's disease, 117:2-tmig, 117:73
enterotoxin-mediated, leptin and (mice), 124:683
gastric, and sodium currents in gastric sensory neurons (rat), 122:394
of gastric cardia, 116:228-c
in hypochlorhydria, effects on parietal and G cells (mice), 122:119
ileal, development of, CD154/CD40 pathway in (mice), 122:752, 122:823-e
intestinal
chronic stress and (rat), 123:1099
corticotropin-releasing hormone and (mice), 123:505
curcumin and (mice), 123:1912
defective apoptosis of lamina propria T cells in, 116:509-tmig, 116:557
gastroenterologist training in, 124:1071-aga
IL-1β release in, 123:1543
in irritable bowel syndrome, 123:2108-aga
leptin in (mice), 122:2011
macrophage-derived IL-18 in (mice), 121:875
mucosal T cells and (mice), 118:880, 118:974-e
neonatal, models of, 122:2032-srr
neural mechanisms in, 118:651-gn

neurogenic, 117:1256-c
noninfectious, in adult, models of, 122:2032-srr
in pathogenesis of irritable bowel syndrome, 123:1972, 123:2144-e
postinfectious, models of, 122:2032-srr
regulation by natural killer cells activated by α-galactosylceramide in presence of CD1d (mice), 119:119
in relatives of patients with ankylosing spondylitis, 125:1598
resolution of, lipoxins and, 124:1043-srr
Rho kinase in, 124:1180-rc
subclinical, in relatives of patients with Crohn's disease, 124:1721-tmig, 124:1728, 124:1972-e
toll-like receptor up-regulation in, 122:1716-tmig, 122:1987
treatment of, with fibroblast growth factor, 123:1151
tumor necrosis factor receptor 2 in (mice), 122:134
in ischemia-reperfusion injury, PPARγ and (mice), 120:332-tmig, 120:460
mucosal, normal luminal bacteria and, in Tgε26 mice, 120:900
in murine model of Crohn's disease, ICAM-1 and VCAM-1 in, 121:1428
NF-κB activation by, and contractility of colonic circular smooth muscle cells (dog), 124:1369
NF-κB in (rat), 122:438
NF-κB/Rel in, 118:1208-srr
in small bowel transplantation, graft muscularis and, 122:1886

Inflammatory bowel disease (IBD). *See also* **Crohn's disease (CD); Ulcerative colitis (UC)**
anorexia in, serotonin and (rat), 118:457-tmig, 118:544, 118:625-e
antibody testing for, clinical usefulness of, 116:1001-ss
aortic thrombosis with splenic and renal embolization in, 118:637-c
arthropathy in, genotype-phenotype relationship in, 118:279
ASCA (anti-*Saccharomyces cerevisiae* antibody) assays in, 120:827
atypical p-ANCA antigen in, 119:310
azathioprine for
dosage of, metabolite measurements and, 122:2082-ss
and male fertility, 121:1048
azathioprine intolerance in, 122:838-c
bacteria in intestinal mucus in, 117:1037-tmig, 117:1089
biologic therapy for, 122:1592, 124:2005-c
bone disease in, 124:791-aga, 124:795-aga
bone loss in, genetic factors and, 119:889-tmig, 119:909
bone mineral density in, at diagnosis, 119:1203
book on, 118:1276-pmr, 125:269-pmr
candidate susceptibility genes, on chromosome 12q, 117:1029-c
CD86 expression on epithelial cells in, 117:521-tmig, 117:536, 117:726-e
cigarette smoke and (rat), 117:756-tmig
clinical care for, 124:860-pmr
colonic epithelial hPepT1 expression in, 120:1657
and colorectal cancer risk, 120:783-tmig, 120:816, 120:820, 120:841
family history and, 120:816, 120:1317-tmig, 120:1356
colorectal cancer screening and surveillance in, recommendations for, 124:544-aga
complications of, 116:233-tmig, 116:301
costs of, 125:982-ss
cytomegalovirus and, 123:390-c
diagnosis of, 120:622, 120:1057-pmr, 125:269-pmr
drug therapy for, adverse effects and side effects of, 124:1986
dysplasia or cancer related to, subtypes of, distinguished by artificial neural networks, 122:606-rc
EBV-positive lymphoma in, 122:72
ecotherapeutics for, 120:622
endoscopic ultrasound in, 122:1631
erythema nodosum in, 123:714
factor V Leiden mutation in, 117:280-c
familial, 124:521-srr
with fibrosis, mouse model of, 125:1570-tmig, 125:1750, 125:1886-e
fracture risk in, 125:1591
genetics of, 123:661-tmig, 124:521-srr
glial cells and mucosal integrity in, 116:493-ss
glucocorticoids for, response to, constitutive high MDR expression and, 118:247-tmig, 118:279
guide for patient with, 123:953-pmr
historical perspective on, 124:861-pmr
HLA associations in, 123:661-tmig, 123:714
IL-1 receptor antagonist gene in, 117:755-tmig, 117:806
immune intervention in, 117:521-tmig, 117:536, 117:546, 117:726-e
immunodiagnostics of, 120:622
immunotherapeutics for, 120:622
intestinal biopsy specimens of patients with, search for mumps virus genome in, 117:1253-c
lymphoma risk in, 121:1034-tmig, 121:1080, 121:1239-e, 123:653-c
management, 120:622, 120:1057-pmr
new modalities for, 120:1317-tmig, 120:1323, 120:1330, 120:1339, 121:1530-c
matrix metalloproteinase levels in, 117:755-tmig, 117:814
6-mercaptopurine for
dosage of, metabolite measurements and, 122:2082-ss
pharmacogenomics and metabolite measurement for, 118:705
safety of, for childbearing patients, 124:1-tmig, 124:9, 125:1562-c
6-mercaptopurine resistance in, causes of, identification of, 122:848-tmig, 122:903, 122:1164-e
mesenteric inflammatory veno-occlusive disorder mimicking, 125:236-cr
methotrexate for, 123:1737-ss
microvascular dysfunction in, 125:58
mortality in, 125:1576, 125:1583, 125:1881-e
mucosal flora in, 122:44, 122:228-e, 123:955-c, 125:1288-c
neuroendocrine cell secretory granules in, 125:1288-c
newly diagnosed, osteoporosis in, 121:504-c
NF-κB in, binding to DNA and transcriptional activity, 116:1504-c
nitric oxide in, 119:512-srr
NOD2 gene mutations and, 122:866-rc, 122:1160-e, 123:661-tmig, 123:679
nutritional information for, 119:876-pmr
paramyxovirus infection in childhood and, 116:783-tmig, 116:796, 116:988-e, 117:1253-c
parenteral nutrition in, 121:966-aga, 121:970-aga
pathogenesis of, 116:233-tmig, 116:320, 116:335, 116:1107, 116:1246-e, 121:1270-tmig, 121:1372
pathology of, AGA Gastroenterology Teaching Project publication on, 125:990-pmr
and peristomal pyoderma gangrenosum, 119:873-ss
platelets and CD40-dependent inflammatory response in, 124:1249
polypectomy in, 119:879-c
postoperative infections in, corticosteroids and immunomodulators and, 125:320, 125:610-e
PPAR-γ gene therapy for (mice), 124:1315, 124:1538-e

probiotic therapy in, 116:1107, 116:1246-e, 120:622, 120:1297-ss
protection against, appendectomy and, 125:1270-ss
provocation of, by *H. muridarum* (mice), 122:1346
reduced fibroblast migration in, and wound-healing response, 125:1295-tmig, 125:1341
relapse
COX-2 inhibitor therapy and, 125:637-c
predictive markers of, 119:1-tmig, 119:15
research on, advances in, 119:876-pmr
role of goblet cells in, study using targeted transgenic ablation, 118:1272-ss
SAMP1/YitFc mouse model of, perianal fistulizing disease in, 124:972
in spouses and their offspring, 120:816
steroid therapy for, natural history of, 121:239-tmig, 121:255
susceptibility
locus for, on X chromosome, evidence for, 120:834
MDR1 C3435T polymorphism and, 124:26, 125:1919-c
NOD2/CARD15 polymorphism and, 124:521-srr
in Swedish twin cohort, long-term follow-up of, 124:1767
6-thioguanine for, liver injury caused by, 125:298-rc
thrombosis and factor V Leiden and, 116:778-c
thrombosis risk in, 117:280-c
toll-like receptors in, 122:1716-tmig, 122:1987
treatment, 118:247-tmig, 118:264, 118:279, 118:436-e, 122:585-pmr, 125:269-pmr
advances in (future directions for), 118:651-gn, 121:1270-tmig, 121:1372
biocontainable recombinant organism for, 125:1007-gn
carbon monoxide in, 119:612-gn
in children, 119:889-tmig, 119:895, 119:1158-e
galectin-1 and, 124:1381
growth hormone as potential agent in, 120:925
inhibition of NF-κB/Rel activation and, 118:1208-srr
and tumor necrosis factor receptor 2 expression in colonic epithelial cells (mice), 122:134
uveitis in, 123:714

Inflammatory Bowel Disease Act, AGA advocacy of, 123:403-gn

Infliximab
antibodies to, in Crohn's disease, 125:32
prevention of, by intravenous premedication with hydrocortisone, 124:874-tmig, 124:917, 124:1140-e
anti-inflammatory effects of, mechanism of action of, 121:1034-tmig, 121:1145, 121:1242-e
for Crohn's disease, 117:755-tmig, 117:761-rc
and autoimmunity, 125:32
clinical experience with, at 5 years, 125:1902-ss
efficacy of, mechanism of, 124:1722-tmig, 124:1774
endoscopic and histological healing with, 116:1023-tmig, 116:1029
with fistulous complications, 119:1132-srr, 124:1595
in initial medical management, cost-utility of, 120:1640
of ileoanal pouch, 117:429-cr, 125:631-c
immunohistological effects, 116:1-tmig, 116:22
long-term efficacy of, immunogenicity and, 125:1544-ss
maintenance regimen for, 124:1988-ss
mechanism of action of, 121:1034-tmig, 121:1145, 121:1242-e
response to
effect of ANCA pattern and LTA haplotype on, 120:1347
NOD2/CARD15 and, 123:1-tmig, 123:106
predictors of, 123:661-tmig, 123:707, 124:2002-c
for fistulas, 117:1247-ss
for gastrointestinal Behçet's disease, 120:995-cr
for inflammatory bowel disease, 122:1592
and lymphoma, 117:1433-cr
for perianal Crohn's disease, 125:1503-aga, 125:1508-aga
proapoptotic effects in monocytes, mechanism of action of, 121:1034-tmig, 121:1145, 121:1242-e
in steroid-dependent Crohn's disease, combined with azathioprine or 6-mercaptopurine (abstract), 125:606-aga
in steroid-refractory celiac disease, 122:800-cr
for ulcerative colitis, 124:1990-ss

Information access, PubMed Central (E-biomed) and, 117:293-gn, 117:1040-gn

Infrared imaging, 120:749

Inhibitor of κB-like gene *(IKBL)*, polymorphism, and susceptibility to ulcerative colitis, 119:1491

INK4A, in pancreatic intraductal neoplasia, 124:1958-srr

Innate immunity, intestinal, intestinal myofibroblasts in, 124:1866

Inositol trisphosphate receptors
activation, and calcium waves in pancreatic acinar cells (rat), 122:415
in bile duct epithelia, and cholestasis, 125:1175
type II, and calcium waves in hepatocytes (rat), 122:1087

Insomnia, intractable, after cessation of thalidomide therapy, 120:1567-c

Insulin
effects on small intestinal mucosal protein synthesis, 118:299
in nonalcoholic fatty liver disease, 122:930, 123:1705-aga
secretion, reduced, in pathogenesis of hepatogenous diabetes, 119:1800-ss
sensitivity, decreased, in pathogenesis of hepatogenous diabetes, 119:1800-ss
signaling, in liver development (rat), 125:572

Insulin-dependent diabetes mellitus (IDDM)
inhibitory innervation in, decrease in, 121:240-tmig, 121:427
interstitial cells of Cajal in, decrease in, 121:240-tmig, 121:427

Insulin-like growth factor-I, signaling pathway for colonic epithelial cell migration, 116:64

Insulin-like growth factor-II, effects on Caco-2 cell differentiation, 116:1358

Insulin-like growth factor receptor, genetic blockade of, antitumor effects of, in colon cancer cells, 123:1191

Insulin receptor substrate, in liver development (rat), 125:572

Insulin resistance
and fibrosis progression in hepatitis C, 125:1570-tmig, 125:1695, 125:1889-e
hepatic iron overload associated with, 117:1038-tmig, 117:1155, 117:1241-e, 118:986-c
and nonalcoholic fatty liver disease, 121:91, 122:1649, 123:1705-aga
and obesity, in pancreatic carcinogenesis, 120:1072-tmig, 120:1263, 120:1291-e
and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281-e

Insurers, use of medication precertification criteria, 121:965-aga

Integrins
α_1
humanized monoclonal antibody to, in Crohn's disease, 121:268
and inflammatory response in murine model of Crohn's disease, 121:1428
$\alpha_1\beta$-, and lymphocytic protection of gastric mucosa against *H. felis* (mice), 119:109
$\alpha6\beta4$, as suppressor and predictive marker for peritoneal dissemination of gastric cancer, 118:497
$\alpha E\beta7$, expression, on homing lymphocytes in intestinal epithelia, 118:289
$\alpha X\beta2$, expression, on homing lymphocytes in intestinal epithelia, 118:289
β_2, dysfunction, in leukocyte adhesion deficiency 1, and colitis, 121:958, 121:1008-e
expression in colonic epithelium, identification and isolation of colonic stem cells based on, 123:1941
and hepatic stellate cell migration in fibrosis, 124:147
in TUDC- and hypo-osmolarity-induced choleresis, 124:1476
Intercellular adhesion molecule-1 (ICAM-1)
antisense to, therapy with, for inflammatory bowel disease, 122:1592
blockade, and inflammatory response in murine model of Crohn's disease, 121:1428
in cerulein-induced pancreatitis, 117:748-c
in experimental colitis (rat), 116:874
expression
in colon, poly(ADP-ribose) synthetase and (mice), 116:233-tmig, 116:335
on homing lymphocytes in intestinal epithelia, 118:289
and fibroblast-T cell interaction in mucosal immunity, 117:521-tmig, 117:546
and liver regeneration (mice), 124:692
in pancreatitis and pancreatitis-associated lung injury, 116:510-tmig, 116:694
Intercellular adhesion molecule (ICAM)
expression in indomethacin-induced gastropathy, proteasome and, 116:865, 116:994-e
and leukocyte recruitment in colon cancer, 122:1121
Interferon
antiviral activity, inhibition by HCV NS5A protein and, 117:1187
for chronic delta hepatitis, 117:1229-cr
for chronic hepatitis C
clinical response to, HCV NS5A protein and, 117:1187
effects on oral lichen planus, 117:283-c
maintenance therapy, 117:1038-tmig, 117:1164
and prevention of hepatocellular carcinoma, 117:738-ssm, 117:757-gn, 120:1301-ss
contraindications to, 124:1711
effect on hepatic fibrosis in hepatitis C, 116:234-tmig, 116:378, 120:579-ss
HCV responsiveness to, viral PKR inhibitor proteins and, 119:1649
for hepatitis C, 116:1266-ss, 121:1017-ss. *See also* **Interferon alfa-2b**
adverse effects and side effects of, 124:1711
in African Americans, 119:1385-srr
biochemical response to, outcomes with, 122:237-ss
effectiveness of, 122:1195-tmig, 122:1303, 122:1525-e, 124:584-c
response to, race and, 119:1186-tmig, 119:1317
hepatitis C resistance to, mechanism for, 117:757-gn
IFN-α
activation of STAT signals in hepatocytes, 122:1019
for chronic hepatitis B
in children, 120:1828-srr
effect on natural history, 120:1828-srr
in HIV-infected (AIDS) patients, 123:1812
plus lamivudine, 120:1828-srr
for HBeAg-negative chronic hepatitis B, 120:1828-srr
treatment and retreatment with, 121:101
for HBeAg-positive chronic hepatitis B, 120:1828-srr
and hematopoiesis, 123:141
for inflammatory bowel disease, 122:1592
inhibition of neuroendocrine tumor cell growth, molecular mechanism of, 118:650-tmig, 118:735
structure of, 123:1350-srr
IFN-α-2a, immunoregulatory properties of, and hepatic alveolar echinococcosis (mice), 124:1441
IFN-β, and prevention of hepatocellular carcinoma in hepatitis C, 120:1301-ss
IFN-β-1a, for inflammatory bowel disease, 122:1592
IFN-γ
and colitis in T-cell receptor α mutant mice, 116:233-tmig, 116:320
and enterocyte resistance against *Cryptosporidium parvum*, 120:99
expression, IL-12 enhancement of T cell responses and, 117:1069, 117:1238-e
in hepatic immunoregulation, CD95 (Apo-1/Fas) ligand and (rat), 116:666
for inflammatory bowel disease, 122:1592
and intestinal epithelial transport and barrier function, 120:1393
monoclonal antibodies to, therapy with, for inflammatory bowel disease, 122:1592
and NOD2/CARD15 gene expression in epithelial cells, 124:875-tmig, 124:1001, 124:1145-e
and reduced fibroblast migration in inflammatory bowel disease, 125:1295-tmig, 125:1341
and reduced T-cell migration in oral tolerance, 119:129, 119:260-e
in stress-induced disruption of colonic epithelial barrier (mice), 125:795
intracellular signaling induced by, HCV interference with (mice), 124:1465
pegylated
adverse effects and side effects of, 123:2082
and hematopoiesis, 123:141
for hepatitis C, 120:3-gn
adherence to therapy and response in, 124:1711
adverse effects and side effects of, 124:1711
constitutional symptoms with, 124:1711
discontinuation of, 124:1711
dose modifications with, 124:1711
effectiveness of, 122:1195-tmig, 122:1303, 122:1525-e, 124:584-c
hematologic effects of, 124:1711
neurologic effects of, 124:1711
ocular effects of, 124:1711
optimal regimen for, 124:1166-c
psychiatric effects of, 124:1711
pulmonary effects of, 124:1711
regression of hepatic fibrosis and cirrhosis with, 124:1561-c
viral kinetics with, 120:1318-tmig, 120:1438, 120:1546-e
plus ribavirin, for hepatitis C, 123:1061, 123:2082, 125:1284-c

adherence to therapy and response in, 123:1061, 125:1284-c
and T-cell responses, 123:1070
plus ribavirin, for hepatitis C, 116:4-gn, 116:1266-ss, 117:292-tmig, 117:408, 117:525-ce, 121:1017-ss, 123:1061, 123:2082, 125:1284-c
in African Americans, 119:1385-srr
cost-effectiveness of, 118:1268-ss
response to
adherence to therapy and, 123:1061
race and, 119:1186-tmig, 119:1317
and T-cell responses, 118:248-tmig, 118:346, 123:1070

Interferon alfa-2b
acute pancreatitis attributed to, 119:230-cr
for hepatitis C, 122:1175-ss
plus ribavirin, for hepatitis C
adherence to therapy and response in, 123:1061, 124:1711, 125:1284-c
adverse effects and side effects of, 124:1711
for chronic disease in liver transplant recipients, 124:642
optimal regimen for, 124:1166-c
regression of hepatic fibrosis and cirrhosis with, 124:1561-c
weight-based regimen for, 124:2003-c

Interferon sensitivity determining region (ISDR), and response to therapy in HCV-1b infection, 125:1284-c

Interleukin(s)
in early versus late colitis (mice), 122:94
IL-1
IL-1B and *IL-1RN* polymorphisms, and gastric cancer, 121:823, 121:1002-e
polymorphisms, and IL-1β production in *H. pylori* infection, 123:1793
proinflammatory polymorphisms, and gastric cancer, 121:823, 121:1002-e
receptor antagonist, gene polymorphism, in inflammatory bowel disease, 117:755-tmig, 117:806
receptor antagonist gene allele 2, as predictor of pouchitis in ulcerative colitis, 121:751-tmig, 121:805
IL-1α, COX-2 expression induced by, in intestinal myofibroblasts, PKCz-ROS pathway in, 124:1855
IL-1β
apoptosis induced by, in enterochromaffin-like cells, mediation by iNOS, NF-κB, and Bax protein (rat), 118:457-tmig, 118:515
gene polymorphisms, and risk of gastric cancer, 124:1193
in *Helicobacter pylori*-induced gastric cancer (mice), 124:1879
and inducible NOS expression in hepatocytes, enhancement by superoxide (rat), 118:608
polymorphisms
and atrophic gastritis, 123:92
and hypochlorhydria, 123:92
and risk of duodenal ulcer recurrence, 123:92
production
in *H. pylori* infection, IL-1 polymorphisms and, 123:1793
by intestinal epithelial cells, disaccharides and, 120:449
in intestinal inflammation, 123:1543
IL-1ra, genetic variations in, and bone loss in IBD, 119:889-tmig, 119:909
IL-2
receptor, antibodies to, for inflammatory bowel disease, 122:1592
therapy with, GI toxicity and GI-associated drug interactions of, 120:607
IL-4
in colitis, in T-cell receptor α mutant mice, 116:233-tmig, 116:320
and transepithelial antigen transport in sensitized intestine (mice), 121:370
IL-5
in concanavalin A-induced hepatitis (mice), 122:2001
in eosinophilic esophagitis induced by intratracheal IL-13, 125:1419
IL-6
genetic variations in, and bone loss in IBD, 119:889-tmig, 119:909
and ICAM-1-triggered liver regeneration (mice), 124:692
and IL-6R, combination of, and liver regeneration, 119:1663
from Kupffer cells, and LPS-induced C5a receptor induction in hepatocytes (rat), 122:697
protection of steatotic liver transplants (rat), 125:202, 125:256-e
release in intestinal smooth muscle cells, neurotransmitters and (rat), 116:346
IL-7, receptor, and development of *Helicobacter felis*-induced gastritis (mice), 121:329
IL-8
gastric levels of, *Helicobacter pylori* virulence factors and, 123:414
H. pylori-induced production of, in gastric cancer cell lines, sphingomyelin-ceramide pathway in, 116:1330
NF-κB-mediated gene expression, inhibition by soluble factor from *Saccharomyces boulardii* (abstract), 125:606-aga
release in colonocytes, mitochondrial oxygen radical generation and, 122:1047
secretion
in human pancreas, cytokine regulation of, 119:211
by intestinal epithelial cells, disaccharides and, 120:449
IL-10
for chronic hepatitis C, 118:649-tmig, 118:655-rc, 119:1411-c, 119:1412-c
for Crohn's disease, bacterial delivery system for, 119:1187-gn
gene, ex vivo transfer to gut-homing T cells, 123:1877, 123:2140-e
hepatic deficiency of, in chronic hepatitis C, 119:1411-c
for inflammatory bowel disease, 122:1592
biocontainable recombinant organism secreting, 125:1007-gn
intestinal immune response and (mice), 122:1829
and liver fibrosis, 119:1412-c
and post-ERCP pancreatitis, 121:232-c, 121:233-c
and prevention of colitis in SCID mice, 123:1865, 123:2140-e
recombinant human, for Crohn's disease, 119:1425-tmig, 119:1461, 119:1473, 119:1781-e
IL-11
hsp25 expression induced by, and epithelium-specific cytoprotection from oxidant stress, 124:1358
for inflammatory bowel disease, 122:1592
protection against ERCP-induced pancreatitis, 120:332-tmig, 120:498
recombinant human, in Crohn's disease, safety and activity of, 117:2-tmig, 117:58
IL-12
enhancement of T cell responses with, tissue injury caused by, 117:1069, 117:1238-e
in genetic susceptibility to experimental colitis (mice), 123:554
hepatic, leptin deficiency and (mice), 123:1304
for inflammatory bowel disease, 120:1297-ss
monoclonal antibodies to, therapy with, for inflammatory bowel disease, 122:1592

monoclonal antibody against, effects on Fas-mediated Th1 T cell apoptosis in experimental colitis, 117:1078, 117:1238-e
IL-13, intratracheal, eosinophilic esophagitis induced by, 125:1419
IL-15
and epithelial changes in celiac disease, 119:996
hepatic, leptin deficiency and (mice), 123:1304
and intraepithelial lymphocyte homeostasis in celiac disease, 125:648-tmig, 125:730
IL-16
in hapten-induced colitis (mice), 119:972
up-regulation of, in Crohn's disease (CD), 119:972
IL-17, and claudin expression in human intestinal epithelial cells, 118:1001-rc
IL-18
antibodies to, therapy with, for inflammatory bowel disease, 122:1592
blockade, in treatment of TNBS-induced colitis (mice), 121:1270-tmig, 121:1372
and intestinal mucosal lymphocyte proliferation in Crohn's disease, 119:1514
macrophage-derived, in Crohn's disease (mice), 121:875
IL-1β, and Fas-mediated hepatocyte apoptosis (mice), 117:661
IL-2/IL-2R, in gut T lymphopoiesis (mice), 118:880, 118:974-e
Interleukin 2-IgGb2 fusion protein, abrogation of experimental colitis (mice), 117:858
Internet
medical information on, 120:1321-ce
patients' use of, to gain medical information, 119:613-ce
publication on, 117:293-gn117:1040-gn
Interstitial cells of Cajal (ICC)
in constipation, 118:1-tmig, 118:14, 125:264-ss
in constipation and megacolon, 123:1422-tmig, 123:1459
development of (mice), 117:522-tmig, 117:584
development of, enteric nervous system and, in human small intestine, 120:561-cr
in inflammation-induced small-bowel motor disturbances (mice), 119:1590
intramuscular, and lower esophageal sphincter function (mice), 121:34
loss of, in insulin-dependent diabetes mellitus, 121:240-tmig, 121:427
in neurotransmission, 122:1184-c
pacemaker currents in
and gastric dysrhythmias (mice), 123:2028
high-conductance chloride channels and, 123:1627
and smooth muscle cells, plasticity between, regulated by Kit-dependent cell signaling, 117:140
Interstitial lung disease, interferon-related, 124:1711
Interstitial nephritis, in Crohn's disease, 123:1436
Intestinal angina. *See* Mesenteric ischemia, chronic
Intestinal blood flow, GLP2 and (piglet), 125:136
Intestinal bypass, for obesity, rheumatic and cutaneous sequelae of, 124:1595
Intestinal cancer, cholecystectomy and, 121:542
Intestinal cells. *See* Epithelial cells
Intestinal disease, organic and nonorganic, differentiation between, 123:401-tmig, 123:450
Intestinal failure
book on, 123:2154-pmr
centers with expertise in, referral to, indications for, 124:1651
definition of, 124:1615
disease states causing, 124:1615
intestinal transplantation for, 124:1615
plasma citrulline as marker for, 119:1425-tmig, 119:1496
rational approach to, 124:1615
Intestinal ischemia, AGA guidelines on, 118:951, 119:280 *correction*
Intestinal metaplasia
diagnosis of, optical coherence tomography in, 120:1-tmig, 120:7
in esophagus, 117:218-srr
gastric
clinical management of, 125:586
in distal stomach, 117:218-srr
induced by Cdx2 ectopic expression (transgenic mice), 122:689, 125:996-c
gastric carditis and, 117:218-srr
liver intestine-cadherin expression in, regulation by CDX2, 123:1565
pathophysiology of, 116:1217-vodd
Intestinal permeability
after bacterial exposure, zonulin and, 123:1607
in differentiation between organic and nonorganic intestinal disease, 123:401-tmig, 123:450
in giardiasis, myosin light-chain kinase and, 123:964-tmig, 123:1179, 125:277-c
Intestinal pseudo-obstruction
autoimmune enteric leiomyositis and, 122:1132-1138-cr
genetic modifiers in (mice), 125:1297-tmig, 125:1428
Intestinal smooth muscle cells, IL-6 production, neuropeptide and sympathetic modulation of (rat), 116:346
Intestinal transit, and bile acid kinetics, 121:812
Intestinal transplantation
complications of, 124:1615
follow-up for, 124:1615
for gut failure, 124:1615
indications for, 124:1105-aga, 124:1111-aga, 124:1615
infection in, 124:1615
isolated, 124:1615
management after, 124:1615
outcomes of, 124:1615
rejection of, 124:1615
in short-bowel syndrome
AGA medical position statement on, 124:1105-aga
AGA technical review on, 124:1111-aga
types of, 124:1615
Intestinal trefoil factor, suppression of colon cancer cell growth, 118:1-tmig, 118:60
Intestine. *See also* Small intestine; Colon
circadian-regulated genes in, 119:536-srr
damage to, in SIV infection (Rhesus macaque), 116:1023-tmig, 116:1115
development, 116:702-srr
Cdx1 and Cdx2 expression in, 119:961
in triiodothyronine knockout mice, 116:1367
epithelium, *Cryptosporidium parvum* infection of, 118:248-tmig, 118:368
glucose transport in, membrane traffic-based pathway for, 124:34
growth and adaptation of, glucagon-like peptide 2 and, 117:89, 117:261-e
morphogenesis, hedgehog signaling in (mice), 122:438
muscularis externa, LPS preconditioning, and cross-tolerance to intestinal manipulation (rat), 123:586
substrate oxidation in, low-protein feeding and (pig), 121:1167
wound healing in, lysophosphatidic acid and, 117:359
Intracranial pressure, increased, cerebral metabolism of ammonia

and amino acids during hepatic failure and, 121:1109
Intragastric balloon therapy, for obesity, 123:882-aga
Intravenous hyperalimentation, long-term, infection risk with, 116:1495-ss
Intravital microscopy, of lamina propria lymphocyte adhesion to microvessels of small intestine (mice), 122:734
Intussusception, ileocecocolic, complete invagination of appendix and, 123:1762-im
Invirase. *See* Saquinavir
Irbesartan
for portal hypertension in cirrhosis, 121:240-tmig, 121:389, 121:487-e
portal pressure response to, 122:1543-c
Iron. *See also* Stimulator of Fe transport (SFT)
absorption
hepcidin expression and (rat), 123:835
in hereditary hemochromatosis, 118:632-ss, 121:1489-srr
and carcinogenesis, 121:1251-ss
deficiency
in celiac disease
HFE gene mutation and, 124:1562-c, 124:1563-c
protection against, HFE mutations in, 123:444
duodenal expression of stimulator of Fe transport and transferrin receptor in, 120:1404
expression of divalent-metal transporter 1 and ferroportin 1 in, 120:1317-tmig, 120:1412
oxidoreductase expression in, 125:746
depletion
in nonalcoholic fatty liver disease, insulin-sparing effect of, 122:930
in nonalcoholic fatty liver disease without carbohydrate intolerance, 124:866-c
duodenal absorption of, effect on iron homeostasis, 120:1317-tmig, 120:1412
hepatic, and nonalcoholic fatty liver disease, 118:981-ss
homeostasis, in humans, transferrin receptor 2 gene in, 122:1295
intestinal uptake of, by divalent metal transporter 1, in HFE-deficient mice with hemochromatosis, 120:1420
loading, in hepatitis C, *HFE* gene mutations and, 124:318
metabolism, proteins of, 125:1906-pmr
in nonalcoholic fatty liver disease, 122:930
and nonalcoholic steatohepatitis, 125:615-ss
overload. *See also* Hemochromatosis
in classic hemochromatosis, in C282Y heterozygote with novel mutation of *HFE*, 116:1282-tmig, 116:1409
classification of, 120:718
expression of divalent-metal transporter 1 and ferroportin 1 in, 120:1317-tmig, 120:1412
hepatic, insulin resistance-associated, 117:1038-tmig, 117:1155, 117:1241-e, 118:986-c
HFE genotype and, 116:233-tmig, 116:372
and nonalcoholic steatohepatitis, 123:1705-aga
serum levels of, elevated serum alanine aminotransferase and, 124:1821
Iron status, *HFE* gene mutations and, in chronic hepatitis C, 116:2-tmig, 116:127
Iron transporter, expression, hepcidin expression and (rat), 123:835
Irradiation, of meat, 116:785-gn
Irritable bowel syndrome (IBS), 120:1559-pmr
AGA Gastroenterology Teaching Project publication on, 125:990-pmr
AGA medical position statement on, 123:2105-aga
AGA technical review on, 123:2108-aga
alosetron for
mechanism of action of, 123:969
response to, molecular mechanisms of, 123:401-tmig, 123:425
animal models of, 122:2032-srr
acute versus chronic, 122:2032-srr
face and construct validity of, 122:2032-srr
gender differences and, 122:2032-srr
lessons from other systems and, 122:2032-srr
and miniaturization of readout instrumentation, 122:2032-srr
predictive validity of, 122:2032-srr
species used for, 122:2032-srr
autonomic activity in, 123:2108-aga
bacteria in, 125:1898-ss
biopsychosocial treatment for, 125:1554-c
book on, 125:625-pmr
and celiac disease, differentiation of, 122:2086-ss
celiac disease-like abnormalities in, 121:1329, 121:1512-e, 123:954-c, 123:1408-c
central processing of visceral stimuli in, gender differences in, 124:1738, 124:1975-e
in children, 120:1-tmig, 120:31, 120:287-e, 120:1559-pmr
classification of, 123:2108-aga
clinical features of, pathophysiologic mechanisms of, animal models for, 122:2032-srr
CNS modulation in, 123:2108-aga
cognitive-behavioral therapy for, 125:19, 125:249-e
comorbidity with other disorders, 122:1139-srr
conceptual models of, 122:2032-srr
constipation-predominant, orocecal transit in, tegaserod and, 118:463
costs of, 123:2108-aga
definition of, 123:2108-aga
desipramine for, 125:19, 125:249-e
diagnosis of, 122:1701, 123:2105-aga, 123:2108-aga
approach for, 122:1701
rectal barostat testing for, 122:1771, 122:2075-e
rectal distention in, 124:863-c
tests used in, 122:1701
diagnostic criteria for, 120:652, 120:1559-pmr, 122:1701, 123:1686-srr, 123:2105-aga, 123:2108-aga
diarrhea-predominant, serotonin transporter polymorphism in, 123:401-tmig, 123:425
differentiation of, from other functional anorectal disorders, 122:1701
dual-etiology hypothesis for, 122:1139-srr
dysmotility in, 123:2108-aga
economic and social costs of, in United States, 122:1500-srr
emotional distress and pain in, altered brain activity with, 124:754-cr
epidemiology of, 120:652, 120:1559-pmr, 122:1701, 123:1686-srr, 123:2108-aga, 124:1662
extracolonic manifestations of, gender differences in, 123:1686-srr
fecal calprotectin test in, 124:1164-c
gender differences in, 123:1686-srr
and health care utilization, 123:2108-aga
heredity and social learning in, 121:751-tmig, 121:799
heterogeneity of, 122:1139-srr, 122:2032-srr
histopathology of, 123:1972, 123:2144-e
immune activation in, 124:1163-c
inflammation in, 123:2108-aga
intestinal gas and bloating in, 122:576-ss
lactulose breath testing in, 125:1898-ss
natural history of, 120:652, 120:1559-pmr
neuropathology of, 123:1972, 123:2144-e

new rat model of, 119:1185-tmig, 119:1276
pathogenesis of
CNS-directed
animal models of, 122:2032-srr
conceptual model of, 122:2032-srr
gut-directed
animal models of, 122:2032-srr
conceptual model of, 122:2032-srr
mucosal immune system in, 122:1778, 122:2078-e
pathophysiology of, 120:652, 120:1559-pmr, 123:2105-aga, 123:2108-aga
animal models of, 122:2032-srr
in patients on remission from inflammatory bowel disease, 122:2032-srr
perception of colonic distention in, fedotozine and, 116:1-tmig, 116:38
physical examination in, 122:1701
postinfectious, 122:2032-srr, 124:1662
clinical features of, 124:1662
depression and, 125:1651
diagnosis of, 124:1662
differential diagnosis of, 124:1662
enterochromaffin cell hyperplasia and, 125:1651
mucosal abnormalities in, 124:1662
persistent colonic inflammation in, 121:493-ss
prognosis for, 124:1662
risk factors for, 124:1662
serotonin in, 124:1662
treatment of, 124:1662
prevalence of, 123:1686-srr, 123:2108-aga
proposed motility-based classification system for, 124:598-ce
psychological treatment for, 123:2105-aga, 123:2108-aga, 124:303, 125:1554-c
psychosocial evaluation in, 122:1701
psychosocial factors in, 123:2105-aga, 123:2108-aga
and quality of life, 119:654, 123:1686-srr, 123:2108-aga
regional cerebral activation in, 118:815-tmig, 118:842, 118:972-e, 119:1418-c
and sexual dysfunction, gender differences in, 123:1686-srr
signs and symptoms of, 123:1686-srr, 123:2108-aga
and sleep, gender differences in, 123:1686-srr
tests for diagnosis or management of
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
treatment, 120:652, 120:1559-pmr, 121:1527-c, 123:2105-aga, 123:2108-aga
investigational, 123:2108-aga
novel and experimental therapies for, 120:652, 120:1559-pmr
pharmacogenomics and, 123:401-tmig, 123:425
response to, gender differences in, 123:1686-srr
strategies for, 125:19, 125:249-e
twin study of, 121:799
variants of, 120:652, 120:1559-pmr
visceral hypersensitivity in, 123:2108-aga
work-up for, 121:1329, 121:1512-e

Ischemia
colonic
AGA guidelines on, 118:951, 119:280 *correction*
AGA technical review on, 118:954
intestinal
AGA guidelines on, 118:951, 119:280 *correction*
in chronic renal failure, 122:495-cr
mesenteric
AGA guidelines on, 118:951, 119:280 *correction*
AGA technical review on, 118:954

Ischemia-reperfusion injury
anti-inflammatory activity in, PPARγ and (mice), 120:332-tmig, 120:460
in graft muscularis, in small bowel transplantation, 122:1886
gut function after, modulation by sodium-coupled solute (rat), 123:810
hepatic
calpain proteases and (rat), 116:2-tmig, 116:168
inflammatory injury induced by, secretory leukocyte protease inhibitor and (mice), 117:953
prevention, preconditioning for, 125:1480-srr
protective strategies against, 125:917-srr
intestinal
activation of NF-κB and AP-1 in (rat), 118:525
complement C5 inhibition and (rat), 120:126
remote organ injury after, complement C5 inhibition and (rat), 120:126
target gene expression in damage-repair processes after (rat), 118:525
in liver graft, platelet-induced sinusoidal endothelial cell apoptosis and (rat), 118:183
protection against
in cold-preserved liver (rat), 118:450-c
by glutathione, in cold-preserved liver (rat), 117:200
tyrosine phosphorylation of IκB in, 118:1208-srr

Ischemic colitis, during alosetron therapy, 120:557-cr

Ischemic preconditioning, in protection against hepatic ischemic injury, 125:917-srr

Isenberg, Jon I., President of AGA, 120:1518-aga, 123:2100-aga, 125:1571-gn
goals of, 120:786-gn

ISIS 2302, for inflammatory bowel disease, 122:1592

Islet amyloid polypeptide, in pancreatic cancer, 121:640

Isosorbide-5-mononitrate
and first variceal bleed, in β-blocker intolerant patients, 121:752-tmig, 121:908
in prevention of recurrent variceal bleeding, 122:832-ss
in prevention of variceal bleeding, 123:728, 123:735

Ivermectin, for liver hydatid disease (sheep), 122:956

***JAGGED1* gene,** mutations, in Alagille syndrome, 116:1141, 116:1257-e

Japan
biomedical research funding in, 120:1074-gn
GI medicine in, 124:876-gn
HBV genotypes and hepatocellular carcinoma in, 120:1564-c

JC virus
and colon cancer, 124:268-c
DNA, in human gastrointestinal tract, 119:1228

Jeghers, Harold J., 117:1068

Jejunoileal bypass, for obesity, 120:669, 123:882-aga

Jejunum
afferent firing in, PGE_2 and (rat), 119:1580
afferent nerves of, somatostatin sst_2 receptor-mediated inhibition of (rat), 121:358
bile acid absorption in, neurotensin and (rat), 120:151

Journals, professional, impact factors and, 124:286-ce

JTE-522, prevention of hepatic fibrosis (rat), 125:286-tmig, 125:556

Julius M. Friedenwald Medal
presentation to Don W. Powell, 120:1854-aga
presentation to Howard M. Spiro, M.D., 118:1229-aga

presentation to Sidney Cohen, 122:2064-aga
JunD, gene expression, and growth inhibition in intestinal epithelial cells, 123:764
Juvenile polyposis
clinical characteristics of, 124:1574
genetic testing for, 119:837-srr, 124:1574

Kaletra. *See* ABT 378
Kallikrein, in LPS-related impairment of liver regeneration (mice), 123:352
Kaposi, Moriz, 125:327
Kaposi's sarcoma, and gastrointestinal bleeding, 124:1595
Keefe, Emmet B., elected vice-president of AGA, 122:601-gn
Keratinocyte growth factor
and esophageal ulcer healing, 122:254-tmig, 122:458
and goblet cell differentiation, 120:1372
therapy with, for inflammatory bowel disease, 122:1592
and triiodothyronine, synergistic enhancement of liver hyperplasia (rat), 118:591
Keratin 19 promoter, and cell-specific targeting of genes in transgenic mice, 120:1728
Ketorolac, gastrointestinal events related to, risk of, 120:594
Kidney
bile salt transporters, adaptive regulation of, in obstructive cholestasis (rat), 121:1270-tmig, 121:1473
cysts, in syndrome of hereditary pancreatic cancer, 122:796-cr
dysfunction, in cirrhosis, 122:1658
foreign body granulomatosis, worn dental prosthesis and, 121:1234-cr
function, cyclooxygenase 2 inhibition and, in cirrhosis (rat), 116:1024-tmig, 116:1167
Kidney disease. *See also* Renal failure
intestinal ischemia and peripheral gangrene in, 122:495-cr
parenteral nutrition in, 121:966-aga
Kidney transplantation
effect on hepatic fibrosis in hepatitis C, 123:1494, 123:1729-e
HBV core gene deletions after, molecular analysis of, 124:1809
***KILLER/DR5* genes,** inactivating mutations of, in gastric cancer, 121:1219
Kinesin, in pancreatic amylase secretion (rat), 119:1123
Ki-*ras*, mutation
in colorectal adenomas, 121:302
in gastric tumors of MSI phenotype, 125:1282-c
in pancreatic cancer, and TGF-α activation of Ha-Ras–ERK cascade, 116:1441
KIT, expression, in gastrointestinal stromal tumors, 124:596-gn, 125:967-e
KIT gene, germline mutation of, familial gastrointestinal stromal tumors with, 122:1493-cr
Kit signaling, and plasticity between interstitial cells of Cajal and smooth muscle cells, 117:140
Klatskin, Gerald, 116:1309
Klippel-Trénaunay syndrome, multiple focal nodular hyperplasia in, 117:284-c
KOC, transgenic reexpression of, and remodeling of exocrine pancreas (mice), 124:1901
Kocher, Emil Theodor, 121:14
K-*ras*
mutation
in aberrant crypt foci, 124:274-c
from FAP and non-FAP cases, 121:599
and glutathione *S*-transferase-π overexpression, in colon carcinogenesis, 121:865, 121:1010-e
in human gastrointestinal tumors, 118:995-tmig, 118:1045
in hyperplastic polyposis, 119:323
in pancreatic intraductal neoplasia, 124:1958-srr
p16 methylation and, in colonic adenomas and cancers, 116:1063
oncogenic, expression in intestinal epithelium, and tumorigenesis (mice), 123:492
Kupffer cells
activated, killing of hepatic stellate cells, 123:845
in alcoholic steatosis (rat), 120:581-ss
CD95 (Apo-1/Fas) ligand expression, in hepatic immunoregulation (rat), 116:666
and clearance of transplanted hepatocytes (rat), 123:1677
in dendritic cell recruitment to liver (rat), 121:1460
gene-altered, transplantation of (rat), 124:3-tmig, 124:173
sensitization, suppression by thalidomide, in prevention of alcoholic liver injury (rat), 123:291
Kussmaul, Adolf, 121:1038
Kwashiorkor, clinical features of, 122:1677

Lactase, persistence, upstream polymorphism associated with, increased enhancer activity of, 125:1686
Lactase gene, promoter, and homeodomain protein Cdx2, interaction of, 118:115
Lactase-phlorizin hydrolase, transcriptional regulation of, involvement of HNF-1 and FREACs (pig), 116:842
***Lactobacillus* spp.**
prevention of colitis in IL-10 gene-deficient mice, 116:1107, 116:1246-e
as probiotic agents, 119:291-ce
for pouchitis, 119:287-tmig, 119:305, 119:584-e
Lactoferrin, autoantibodies against, in autoimmune pancreatitis, 118:458-tmig, 118:573, 118:626-e
Lactose
intolerance, and peak bone mass, 122:1793
malabsorption
breath testing for, 122:1701
and peak bone mass, 122:1793
Lactulose, for constipation, 119:1766-aga
Lactulose breath testing, in irritable bowel syndrome, 125:1898-ss
Laine, Loren, as new chair of AGA Council, 123:966-gn
Lamina propria, lymphocytes from, adhesion to microvessels of small intestine (mice), 122:734
Laminin-1, mesenchymal, in pancreatic exocrine linkage selection (mice), 123:1331
Lamivudine
for decompensated chronic hepatitis B, early mortality in, determinants of, 123:714
and enhanced HBV replication, 122:264
GI toxicity and GI-associated drug interactions of, 120:607
for hepatitis B, 116:1498-ss, 117:525-ce, 118:3-gn, 119:2-tmig, 119:172, 119:263-e, 121:222-ss, 123:1831, 123:2135-e
in children, 123:1741-ss
and development of YMDD mutant virus, 120:1000-srr, 120:1561-c
in HBeAg-negative disease, 120:1828-srr
in HBeAg-positive disease, 120:1828-srr
long-term safety of, 125:1714
long-term therapy with, histological outcome during, 124:1-tmig, 124:105, 125:1286-c

plus IFN-α, therapy with, in chronic hepatitis B, 120:1828-srr
for postchemotherapy reactivation of hepatitis B, preemptive therapy with, 125:1742
resistance, in hepatitis B, 120:1000-srr, 120:1828-srr
in HIV-infected (AIDS) patient, 122:244-c, 124:586-c
tenofovir disoproxil fumarate for, 124:586-c
and YMDD mutant hepatitis B, 119:1382-cr

Lansoprazole
for NSAID gastropathy, 119:521-srr
for ulcer complications from low-dose aspirin, 124:572-ss

Laparoscopic colectomy, for colon cancer, 124:1991-ss

Laparoscopic colorectal surgery, 118:806-pmr

Laparoscopy, miniaturization of, monograph on, 121:228-pmr

Laparotomy, exploratory, in obscure gastrointestinal bleeding, 118:201-aga

Large intestine, tumors of, c-K-*ras* mutations in, 118:995-tmig, 118:1045

Laryngitis, and gastroesophageal reflux disease, in children without neurological deficits, 121:1294

Lateral medullary syndrome, dysphagia in, 121:420-cr

Laxative, for constipation
saline, 119:1766-aga
stimulant, 119:1766-aga

Lectin, mannose-binding, in nonimmune defense against cryptosporidiosis, 119:1236

Leiomyomatosis, diffuse esophageal, 120:216-cr

Leiomyosarcoma, endoscopic appearance of, 122:605-im

Leiomyositis, autoimmune enteric, 122:1132-cr
and intestinal pseudo-obstruction, 122:1132-cr

Leptin
and *C. difficile* toxin A-induced enteritis (mice), 124:683
in cirrhotic patients, 119:1426-tmig, 119:1656
deficiency of, and Kupffer cell production of cytokines (mice), 123:1304
expression in human stomach, 117:509-c
and gastric neuroendocrine system, 123:1751-c
gastric secretion of, vagal stimulation and, 122:259-rc
and gastric secretions (rat), 121:1417
as growth factor in colonic epithelial cells (humans, mice), 121:79
in intestinal inflammation (mice), 122:2011
in liver fibrogenesis (rat), 122:1399, 122:1529-e
and liver regeneration after toxic injury in *ob/ob* mice, 124:1451
plasma levels of, effects on plasma ghrelin (rat), 124:1188-rc, 124:1532-e
signaling, and obesity, 124:1546-ss

Leptin receptors
expression in human stomach, 117:509-c
in liver fibrogenesis (rat), 122:1399, 122:1529-e

Leukocyte adhesion deficiency, type 1 (LAD-1), and colitis, 121:958, 121:1008-e

Leukocytes
in intestinal muscularis externa, and postoperative ileus (rat), 117:378, 117:489-e
recruitment
in colitis, VCAM-1 and ICAM-1 in (rat), 116:874
in colon cancer, 122:1121

Leukocytoclastic vasculitis, gastrointestinal involvement in, 124:1595

Leukotrienes
and cell survival factors in intestinal epithelial cells, 119:890-tmig, 119:1007
in colorectal cancer, 124:57
cysteinyl
in acute alcohol intoxication, 118:1140
and intrahepatic vascular resistance in cirrhosis (rat), 122:387
and vascular tone in hepatic cirrhosis (rat), 119:794

Levator ani, function of, assessment of, in anal incontinence, 123:1421-tmig, 123:1441

Levator ani syndrome
definition of, 116:735-aga
differential diagnosis of, 122:1701
tests for diagnosis or management of
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga

Lewis antigens, and *H. pylori* adhesion, 119:1414-c

LI-cadherin, expression, regulation by CDX2, 123:1565

Lichenoid eruptions, ursodeoxycholic acid and, 121:501-c, 122:1547-c

Lichen planus
incidence of, in HCV hyperendemic area, 119:883-c, 121:1528-c
oral, in chronic hepatitis C, interferon therapy and, 117:283-c

Lieberkühn, Johann Nathanael, 124:7

Light-induced fluorescence spectroscopy, 120:749

Light-scattering spectroscopy, 120:749

Lipase(s)
and diet, effect on nutrient absorption in pancreatic insufficiency (dog), 116:431
digestive, specific activities of, measurement of, 119:949
gastric, gene expression, down-regulation by EGF and TGF-α, 116:831

Lipid-lowering therapy, for nonalcoholic fatty liver disease, 122:1649

Lipids
biliary
binding by recombinant gallbladder mucin polypeptide, 116:784-tmig, 116:936
in postprandial chylomicron formation, in *Mdr2*$^{-/-}$ mice, 118:173, 118:225-e
biliary secretion of, sterol carrier protein 2 and (mice), 119:1708
dietary, requirements for, 122:1677
in parenteral nutrition, 121:970-aga
duodenal, gastrointestinal sensations induced by, fat digestion and, 120:1071-tmig, 120:1100
gallbladder absorption of, in cholesterol gallstone disease, 118:912
and intestinal gas retention in irritable bowel syndrome, 123:700, 123:933-e
intestinal metabolism of, hedgehog signaling in (mice), 122:469
malabsorption, hereditary, apolipoprotein B48 glycosylation in, 121:1101
metabolism, in zebrafish, 121:1-gn
and reactive oxygen species production in hepatocytes (rat), 116:1024-tmig, 116:1184
and uncoupling protein 2 expression in hepatocytes (rat), 116:1024-tmig, 116:1184

Lipoate, antibodies against, in primary biliary cirrhosis, 125:1705

Lipopolysaccharide. *See also* Endotoxin
impairment of liver regeneration, via TGF-β (mice), 123:352
induction of C5a receptors in hepatocytes (rat), 122:697

preconditioning, and cross-tolerance to postoperative ileus (rat), 123:586
radioprotective effect in intestine (mice), 118:1106
response to, NOD2 variants and, 124:2-tmig, 124:140
Lipoproteins, hepatic metabolism of, sterol carrier protein 2 and (mice), 119:1708
Lipoxin A_4, COX-2-derived, and gastric mucosal defense against aspirin, 123:1598
Lipoxins, and resolution of intestinal inflammation, 124:1043-srr
5-Lipoxygenase, inhibition, and intrahepatic vascular resistance in cirrhosis (rat), 122:387
Lisinopril, attenuation of pancreatic inflammation and fibrosis, in male Wistar Bonn/Kobori rats, 124:1010
Liver. *See also* **Nonalcoholic fatty liver disease**
abscess, pyogenic, complicated by bronchial fistula, 123:666-im
adverse effects of drugs and chemicals on, 118:984-pmr
alcoholic disease of, risk of, homozygosity for alanine in mitochondrial targeting sequence of SOD and, 120:1318-tmig, 120:1468
alcoholic steatosis in, Kupffer cell and (rat), 120:581-ss
alcohol-induced injury
inducible NOS in (mice), 125:1834
in obesity (rat), 125:1818
reduction of
by betaine (mice), 124:1488
by superoxide dismutase (rat), 120:1241
TNF-α and (mice), 117:942
ammonium transporter expression in (mice), 124:1432
anatomy of, 120:1304-pmr
arteriovenous malformations in, 120:1579-im
autoimmune injury of, mechanisms of, 120:1485-srr
bile salt secretory capacity of, in STZ-diabetic rats, 122:1842
bile salt transporters, adaptive regulation of, in obstructive cholestasis (rat), 121:1270-tmig, 121:1473
biology and pathobiology of, 125:1909-pmr
biopsy
in diagnosis of nonalcoholic fatty liver disease, 123:1705-aga
in hepatitis C, 123:2082
in hepatocellular carcinoma, 122:1609
indications for, evaluation of, 123:1367-aga, 125:272-c
laparoscopic, in cirrhotic patients with coagulopathy, safety and efficacy of recombinant factor VIIa in, 123:118
circadian-regulated genes in, 119:536-srr
cirrhotic, nitric oxide and (rat), 117:1222
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
colorectal cancer metastases to
angiogenesis in, rofecoxib and, 125:647-tmig, 125:716
molecular genetics of, 122:3-gn
cooling, in protection against ischemic injury, 125:917-srr
cysts, in syndrome of hereditary pancreatic cancer, 122:796-cr
dendritic cell recruitment to, Kupffer cell-mediated, mechanisms for (rat), 121:1460
development of
apoptosis prevention during, NF-κB/Rel activity and, 118:1208-srr
β-catenin in, 124:202
ErbB receptor protein expression during (rat), 123:2017
insulin signaling in (rat), 125:572
prenylcysteine carboxymethyltransferase in (mice), 123:345
diseases of. *See* **Liver disease**
drug-induced damage to, avoiding, 117:759-ce
dysfunction of, with home parenteral nutrition, management of, 124:1651
echinococcal cyst of, 117:1042-im
failure
acute
amino acid metabolism in, 118:1131
ammonia metabolism in, 118:1131
brain metabolic pathways in, hypothermia and, 125:815, 125:976-e
diabetes mellitus and, 122:1822
Fas-induced, prevention by superoxide dismutase mimetic MnTBAP (mice), 121:1451
hepatic encephalopathy in, infection and, 125:755
in amyloidosis, liver/stem cell transplantation for, 122:2026-cr
fulminant
cerebral metabolism of ammonia and amino acids in, 121:1109
TNF-α in, 119:446
in HIV-infected (AIDS) patient, caused by YMDD-mutant hepatitis B virus, 121:1027-c
prevention
in celiac disease, gluten-free diet and, 122:880, 123:2158-c
in cirrhosis, branched-chain amino acid supplements in, 124:1723-tmig, 124:1792, 124:1980-e
treatment of, hepatocyte xenotransplantation for (rat), 124:282-tmig, 124:422, 124:568-e
fibrogenesis in
Fas-mediated (mice), 123:1323
heme oxygenase-1 and, 125:460
leptin and leptin receptors in (rat), 122:1399, 122:1529-e
Smad7 and (rat), 125:2-tmig, 125:178
fibrosis
alltenuation by MMP-1 (rat), 124:445
antialdosteronic drugs and, 124:504
and apoptosis, Fas-mediated mechanistic link between (mice), 123:1323
attenuation by adiponectin (mice), 125:1796, 125:1889-e
attenuation by angiotensin-converting enzyme inhibition (rat), 121:148
cell types of fibroblast lineage and, 117:1038-tmig, 117:1205, 117:1244-e
in chronic hepatitis C
CCL21 and, 125:1060
IL-10 treatment for, 118:655, 119:1411-c, 119:1412-c
interferon therapy and, 118:446
endothelin-A receptor blockade for, 118:996-tmig, 118:1169, 118:1261-e
in hepatitis B, reversibility of, after medical treatment, 124:1-tmig, 124:105, 125:1286-c
in hepatitis C
effect of renal transplantation on, 123:1494, 123:1729-e
HFE gene mutations and, 124:318
insulin resistance and, 125:1570-tmig, 125:1695, 125:1889-e
noninvasive tests of, 123:2082
response to interferon therapy, 120:579-ss
reversibility of, after medical treatment, 122:1195-tmig, 122:1303, 122:1525-e, 124:584-c, 124:1561-c, 125:629-c
herbal remedies for, 117:1250-ss
inhibition
by stimulation of apoptosis in hepatic stellate cells (humans, rats), 121:512-tmig, 121:685
by thiazolidinediones (rat), 122:1924
Na^+/H^+ exchanger and (rat), 120:545, 120:572-e
nitrovasodilator action and, 119:288-tmig, 119:479
in obesity, predictors of, 121:91

in overweight patients, 118:996-tmig, 118:1117
prevention
by COX-2 inhibition (rat), 125:286-tmig, 125:556
PPAR-γ ligands and, 119:288-tmig, 119:466
by protease inhibitor (rat), 120:1784
progression, in hepatitis C, 124:1-tmig, 124:97
HFE gene mutations and, 124:318
interferon and, 116:234-tmig, 116:378
rapamycin and, in vivo model for (rat), 117:1038-tmig, 117:1198, 117:1244-e
stellate cell migration in, 124:147
susceptibility gene *Hfib1* (mice), 123:2041
tissue renin-angiotensin system and (rat), 123:1667
focal nodular hyperplasia of
gene expression in, 124:594-tmig, 124:651
oral contraceptives and, 118:458-tmig, 118:560, 119:280 *correction*
foreign body granulomatosis, worn dental prosthesis and, 121:1234-cr
giant cyst of, renovascular hypertension with, 121:745-c
healthy, immunology of, 120:250-srr
Helicobacter sp. in, 120:323-c
herbal remedies for, 117:1250-ss
hydatid disease, ivermectin treatment for (sheep), 122:956
hyperplasia, growth factor-stimulated (rat), 118:591
hypothermic preservation of
protection against reperfusion injury after (rat), 118:450-c
by glutathione, 117:200
reperfusion after, platelet-mediated sinusoidal endothelial cell apoptosis in (rat), 118:183
single-pass reperfusion for (rat), 118:450-c
IFN-α in, antiviral and antitumor activities of, 122:1019
immunoregulation, CD95 (Apo-1/Fas) receptor/ligand system in (rat), 116:666
injury
in biliary obstruction, farnesoid X receptor and (mice), 125:825
in hepatitis C transgenic mice, 122:352, 122:568-e
hepatocyte gp130 and (mice), 125:532
by 6-thioguanine, in inflammatory bowel disease, 125:298-rc
iron overload, insulin resistance-associated, 117:1038-tmig, 117:1155, 117:1241-e, 118:986-c
ischemia-reperfusion injury
inflammatory injury induced by, secretory leukocyte protease inhibitor and (mice), 117:953
mode of cell death after, 125:1246-srr
prevention, preconditioning for, 125:1480-srr
protective strategies against, 125:917-srr
ischemic
calpain in (rat), 116:2-tmig, 116:168
hepatocellular apoptosis in, TNF-α-induced (mice), 122:202
isolation of *Helicobacter* strain from, 121:1023-c
lipid metabolism in, sterol carrier protein 2 and (mice), 119:1708
malignant tumors of, treatment of, 119:877-pmr
microsomal monooxygenase activities in, impairment of, by indomethacin (rat), 122:774
mitochondrial function and DNA in, alcohol and, 117:181, 117:265-e
nodular fatty infiltration of, in Wilson's disease, 122:258-im
NSAIDs and, 117:755-tmig, 117:962
organic anion transporter rlst-1, molecular characterization and functional regulation of (rat), 117:770-rc
organic anion-transporting polypeptide Oatp2 in, localization and function of (rat), 117:688
organic anion-transporting polypeptides (OATPs) of, functional comparison of, 120:525
pancreatic cancer metastases to, effect of statins on, 122:253-tmig, 122:308
paracrine endothelin system, in cirrhosis, 116:161
preconditioning, mechanisms of, 125:1480-srr
preservation solutions, in protection against ischemic injury, 125:917-srr
regeneration
after partial hepatectomy, light ethanol use and (rat), 119:1333, 119:1399-e
after toxic injury, leptin and (*ob/ob* mice), 124:1451
autoimmunity against, induced by DNA vaccination against α-fetoprotein (mice), 121:931
cardiotrophin-1 up-regulation in, and cytoprotective effects (rat), 125:3-tmig, 125:192
differential expression of basolateral and canalicular organic anion transporters during (rat), 117:1266-tmig, 117:1408
ErbB receptor protein expression during (rat), 123:2017
ICAM-1 and (mice), 124:692
IL-6 and soluble IL-6R in (mice), 119:1663
NF-κB/Rel activity in, 118:1208-srr
sphingosine 1-phosphate and (rat), 124:459
suppression by LPS, via TGF-β (mice), 123:352
transgenic expression of heparin-binding epidermal growth factor and (mice), 124:701
resection, in hepatocellular carcinoma, 122:1609
retinoic acid metabolism, ethanol-induced CYP4502E1 and (rat), 120:179
in Schönlein-Henoch purpura, 117:211-cr
sinusoidal bile acid uptake, impaired, in Amish kindred, 119:188, 120:321-c
sinusoidal endothelial cells, priming of naive $CD4^+$ T cells (mice), 116:1428
steatotic transplant, protection by IL-6 (rat), 125:202, 125:256-e
surgery of, 121:1524-pmr
survivin in, 124:1565-c
transplantation. *See* **Liver transplantation**
tumors
FDG positron emission tomography in, 125:1235-srr
pathology of, atlas of, 122:586-pmr
percutaneous ethanol injection therapy of, stereotaxic echo-guided approach for, 116:504-c
UDP-glucuronosyltransferase activity in, 116:149
vascular resistance in, in cirrhosis, 5-lipoxygenase inhibition and (rat), 122:387
Wilson's disease protein in, localization of, 117:1266-tmig, 117:1380

Liver chemistry tests
biologic basis of, 123:1367-aga
evaluation of
AGA medical position statement on, 123:1364-aga, 125:272-c
AGA technical review on, 123:1367-aga, 125:272-c, 125:279-c

Liver cytosol antigen, in autoimmune hepatitis, 116:643

Liver disease. *See also* **Fatty liver disease; Nonalcoholic fatty liver disease**

alcohol-induced
oxidants and antioxidants in, 124:778-srr
susceptibility to, MnSOD polymorphism and, 124:2000-c
autoantibodies in, 120:239-srr
bone density in
longitudinal studies of, 125:941-aga
testing, 125:936-aga
book on, 118:449-pmr, 124:579-pmr
cancer risk assessment in, *UGT1A7* gene as marker for, 121:1136
in children, 121:1523-pmr
chronic
bone disease in, 125:936-aga, 125:941-aga
circulating soluble vascular adhesion protein 1 in, 119:1096
endothelin-A receptor blockade in, antifibrotic effects of, 118:996-tmig, 118:1169, 118:1261-e
and health-related quality of life, 120:170, 120:305-e
increased intrahepatic vascular resistance in, 118:996-tmig, 118:1149, 118:1261-e
screening for celiac disease in, 125:1289-c
diagnosis and management of, 120:584-pmr
diagnosis of, 125:1549-pmr
drug therapy for, review of, 124:1159-pmr
economic and social costs of, in United States, 122:1500-srr
ethanol-induced mitochondrial dysfunction and, 122:2049-srr
gastroenterologist training in, 124:1077-aga
gene therapy for, Kupffer cell transplantation in (rat), 124:3-tmig, 124:173
HCV-related, severity of, MCP-1 gene polymorphism and, 125:1085
Helicobacter in, 121:1023-c
herbal remedies for, 117:1250-ss
HFE gene mutation analysis in, 120:718
incidence of, in HCV hyperendemic area, 125:628-c
and manganese deposition in brain, 117:640
metabolism in, 121:1257-pmr
neonatal, bile acid synthetic defect and, 124:217-cr
in obesity, 123:882-aga
osteoporosis in
AGA medical position statement on, 125:936-aga
AGA technical review on, 125:941-aga
treatment of, 125:936-aga, 125:941-aga
parenteral nutrition in, 121:966-aga, 121:970-aga
pathophysiology of, 125:1549-pmr
pregnancy-associated, long-chain hydroxyacyl coenzyme A dehydrogenase (LCHAD) and, 124:1548-ss
treatment of, 125:1549-pmr
Liver intestine-cadherin, expression, regulation by CDX2, 123:1565
Liver-intestine transplantation, 124:1615
Liver/kidney microsome type 1, antibody to, in liver disease, 120:239-srr
Liver transplantation
alternatives to, 118:248-tmig, 118:368, 118:438-e
atlas of, 124:1556-pmr
for autoimmune hepatitis, 120:1502-srr
bone density after, longitudinal studies of, 125:941-aga
bone disease after, 125:936-aga, 125:941-aga
pathogenesis of, 125:941-aga
prevalence of, 125:941-aga
treatment of, 125:941-aga
bone marrow as alternative to, 119:891-gn
in chronic hepatitis B, 123:714
chronic hepatitis C after, IFN-α2b plus ribavirin for, 124:642
contraindications to, 120:749
current status of, 120:749
donor organ allocation in, Model for End-Stage Liver Disease (MELD) score and, 124:91, 124:251-e, 125:992-c, 125:993-c, 125:1009-ce
evolution of HCV quasispecies after, 123:1422-tmig, 123:1485
of HCV-positive organ, into HCV-infected recipient, 117:2-tmig, 117:149, 117:263-e, 117:1253-c
in hepatic myelopathy, 124:346
for hepatitis C, 117:502-ss
in African Americans, 119:1385-srr
European experience with, 117:522-tmig, 117:619
hepatitis C recurrence after, HCV-specific $CD4^+$ response and, 117:756-tmig, 117:926, 117:1012-e
in hepatocellular carcinoma, 122:1609
criteria for, 122:579-ss
for hepatorenal syndrome, 122:1658
historical perspective on, 120:749
indications for, 120:749
for lamivudine-associated YMDD mutant hepatitis B, 119:1382-cr
listing criteria for, 120:749
living donor, 120:749
and nonalcoholic fatty liver disease, 123:1705-aga
novel approaches to, 120:749
organ allocation for, 117:523-gn
organ shortage and, 120:749
patient and allograft survival after, hepatitis C and, 122:848-tmig, 122:888, 122:1161-e, 123:2160-c
in primary AL amyloidosis, 122:2026-cr
recipients, CMV immune reactions in, 122:1201
recurrent disease after, 120:749
reperfusion injury in, platelet-induced sinusoidal endothelial cell apoptosis and (rat), 118:183
and resolution of hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement, 116:187-cr
selection criteria for, 120:749
split, 120:749
of steatotic graft, protection by IL-6 (rat), 125:202, 125:256-e
syngeneic living-donor, without immunosuppression, 123:1341-cr
xenotransplantation for, 120:749
Liver X receptors, and cholesterol and bile acid metabolism, 120:1054-ss
LL-37, expression in human gastric epithelial cells, and host defense against *Helicobacter pylori*, 125:1613
Long-chain hydroxyacyl coenzyme A dehydrogenase (LCHAD), and pregnancy-associated liver disease, 124:1548-ss
Longitudinal muscle, of small intestine, propagation and neural regulation of calcium waves in (guinea pig), 118:892
Loperamide, in treatment of irritable bowel syndrome, 120:652
Lopinavir-ritonavir, therapy with, GI toxicity and GI-associated drug interactions of, 120:607
Losartan
for portal hypertension, 117:740-ss
in cirrhosis, 121:240-tmig, 121:382, 121:487-e
portal pressure response to, 122:1543-c, 122:1544-c
Lovastatin, and sulindac-induced apoptosis in colon cancer cells, 117:755-tmig, 117:838
Low-birth-weight infants, parenteral nutrition for, 121:966-aga
Lower esophageal ring
diagnosis of, 117:233-aga
treatment of, 117:229-aga, 117:233-aga

Lower esophageal sphincter (LES)
endoscopic implantation of biopolymer in, in gastroesophageal reflux disease, 123:944-ss
and excess reflux in GERD with hiatal hernia, 119:1439, 119:1779-e
function, in gastroesophageal reflux disease, colonic fermentation and, 124:894
hypertensive, in nNOS$^{-/-}$ mice, 121:34
hypotensive, in W/W^{v} mutant mice, 121:34
inhibition by β3 adrenergic stimulation (opossum), 123:1508
relaxation, 122:1184-c
brain stem neurons in (mice), 119:1600
inhibition by cannabinoids (dog), 123:1129
tone, maintenance of, group I secreted phospholipase 2 in, 119:1243
transient relaxations
baclofen and, 117:1037-tmig, 117:1147, 118:1-tmig, 118:7
in GERD patients with hiatal hernia, 118:650-tmig, 118:688
vagal motor control of, site of action of $GABA_B$ receptor for, 120:1749
LPD-02, for inflammatory bowel disease, 122:1592
LPS (lipopolysaccharide). *See* Endotoxin
LST-2, and targeted chemotherapy for gastrointestinal cancer, 120:1689
Lung cancer, and Zollinger-Ellison syndrome, 120:1271-cr
Lung disease
obesity and, 123:882-aga
parenteral nutrition in, 121:966-aga
Lung function, in obesity, 123:882-aga
Lung injury
after intestinal ischemia-reperfusion, anti-C5 therapy and (rat), 120:126
in pancreatitis, 124:595-tmig, 124:725, 124:844-e
CD40 ligand and (mice), 121:184
COX-2 and (mice), 123:1311
intercellular adhesion molecule-1 and neutropenia in, 116:510-tmig, 116:694
matrix metalloproteinase and (rat), 122:2-tmig, 122:188
Lymphocytes
endothelial cell adhesion, mucosal addressin cell adhesion molecule 1 and, 121:853, 121:1008-e
intestinal epithelial, homing, phenotypic analysis of, 118:289
intraepithelial
CD94^{+}, in celiac disease, 118:816-tmig, 118:867
γδ, activation and peripheral expansion (mice), 116:327
lamina propria
adhesion to microvessels of small intestine, intravital observation of (mice), 122:734
defective apoptosis in gastrointestinal inflammatory states, 116:509-tmig, 116:557
migration
age and, 121:853, 121:1008-e
molecular mechanisms of, 121:853, 121:1008-e
mucosal
and heat shock protein expression in colonic epithelial cells (mice), 124:1175-tmig, 124:1395
proliferation, in Crohn's disease, IL-18 and, 119:1514
Lymphocyte trafficking, inhibitors of, therapy with, for inflammatory bowel disease, 122:1592
Lymphoepithelioma-like carcinomas (LELCs), Epstein-Barr virus and, 118:1031
Lymphoma
in Crohn's disease, infliximab treatment and, 117:1433-cr
cytomegalovirus and, 123:390-c
diffuse large B cell, vs. high-grade MALT, 123:956-c, 123:1410-c
EBV-positive, in inflammatory bowel disease, 122:72
esophageal involvement, in HIV-infected (AIDS) patients, 117:296-im
of gastric mucosa-associated lymphoid tissue (MALToma), 120:1884-c
gastric ulcer development with, *H. pylori* and, 117:893
H. heilmannii-associated, remission after treatment, 118:815-tmig, 118:821
H. pylori and, 118:988-c, 121:1025-c
high-grade, 123:956-c, 123:1410-c
H. pylori eradication therapy in, 123:393-c
regression after *H. pylori* treatment, 124:537-cr
t(11;18)-positive, resistance to *H. pylori* eradication, 122:1286
treatment of, by *H. pylori* eradication, 121:1025-c
H. pylori and, 117:2-tmig, 117:82, 117:257-e, 117:750-c, 117:1105
laryngeal MALT, regression after *H. pylori* treatment, 124:537-cr
non-Hodgkin's, B-cell, hepatitis C and, 125:1723
primary gastric B-cell, 119:1185-tmig, 119:1191
of rectal mucosa-associated lymphoid tissue (MALToma), *H. pylori* and, 117:514-c
risk
azathioprine and, 118:995-tmig, 118:1018, 121:1034-tmig, 121:1080, 121:1239-e
in celiac disease, 123:1428, 123:1726-e, 125:40
inflammatory bowel disease and, 121:1034-tmig, 121:1080, 121:1239-e, 123:653-c
6-mercaptopurine and, 121:1034-tmig, 121:1080, 121:1239-e
splenic, regression of, after treatment of hepatitis C, 124:1157-ss
Lymphomatous polyposis, 121:1530-im
Lymphotoxin
alpha (LTA), haplotype, and response to infliximab in Crohn's disease, 120:1347
and M cell development, in Peyer's patches (mice), 120:1173
Lysophosphatidic acid
anti-apoptotic effects of, in intestinal epithelial cells, 123:206
and intestinal epithelial wound healing in vitro and in vivo, 117:359
Lysosome-associated membrane proteins (LAMP-1), in induction of oral tolerance, 118:2-tmig, 118:128
Lysozyme, variant, and familial amyloidosis, 123:1346-cr

Macrophage migration inhibitory factor (MIF)
antibody against, prevention of colitis by (mice), 123:256
expression, in gastric and intestinal epithelium, 122:667
in pathogenesis of gastric inflammation (rat), 121:619
in severe acute pancreatitis, 124:595-tmig, 124:725, 124:844-e
Macrophages
IL-18 derived from, in Crohn's disease (mice), 121:875
intestinal
decreased expression of surface CCR5 and reduced levels of HIV-1 in, 116:1043
reduced permissiveness to HIV-1, 116:1043
Magnesium, deficiency of, treatment of, 122:1677
Magnetic resonance cholangiography
contrast-enhanced, 124:1686
indications for, 124:1686
technical aspects of, 124:1686

Magnetic resonance cholangiopancreatography (MRCP), clinical applications of, 124:1686
Magnetic resonance colonography, for detection of polyps, 119:287-tmig, 119:300
Magnetic resonance imaging (MRI)
in acute mesenteric ischemia, 118:954
anorectal
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
in diagnosis of pancreatitis, 120:682
and parkinsonian signs in cirrhotic patients, 119:774
pelvic, in fecal incontinence, 124:1672
of perianal fistulas in Crohn's disease, 121:1064
Magnetic resonance spectroscopy, and parkinsonian signs in cirrhotic patients, 119:774
Magnification endoscopy, 120:749
***mahogany* gene product,** and weight regulation (mice), 117:294-gn
Major histocompatibility complex (MHC)
class II molecules
and disease outcome in hepatitis C, 118:1124
in induction of oral tolerance, 118:2-tmig, 118:128
class I molecules, expression of, intestinal epithelial transport of bacterial peptides and, 120:1657
Malabsorption
azathioprine-induced, 124:1950-cr
in giardiasis, pathogenesis of, mechanisms of, 123:964-tmig, 123:1179, 125:277-c
lipid, hereditary, apolipoprotein B48 glycosylation in, 121:1101
Malabsorption syndrome, skin lesions in, 124:1595
Male fertility, azathioprine therapy and, in inflammatory bowel disease, 121:1048
Malignancy. *See also* Cancer
gastrointestinal, gastroenterologist training in, 124:1073-aga
hepatic, treatment of, 119:877-pmr
intestinal, initiation of, synergy between *E-cadherin* and *Apc* mutations in (mice), 119:1045, 119:1161-e
Malignant lymphomatous polyposis, 121:1530-im
Mall, Franklin Paine, 121:791
Mallory, Frank Burr, 117:769
Mallory, George Kenneth, 121:541
Mallory bodies
as aggresomes, 121:1264-c
formation of, causes of, 122:1715-tmig, 122:1878
Malnutrition
parenteral nutrition in, 121:966-aga
refeeding in, 121:966-aga, 121:970-aga
risk for, in elderly, screening for, 122:1688
Malpractice, legislation on, before United States Senate, 124:1176-gn
Managed care organizations, use of medication precertification criteria, 121:965-aga
Manganese, deposition in brain, in liver disease, 117:640
Manometry
anorectal, in constipation, 119:1766-aga
esophageal
before antireflux surgery, 121:5, 121:214-e
double-peaked waves in, 118:457-tmig, 118:469
Mantle cell lymphoma, intestinal involvement in, 122:852-im
MAPK. *See* Mitogen-activated protein kinase (MAPK)
MAP kinase. *See* Mitogen-activated protein kinase (MAPK)
MAPK kinase phosphatase, MKP-1, in pancreatic cancer, 124:1830
Marasmus, clinical features of, 122:1677
Mast cells, in stress-induced intestinal inflammation (rat), 123:1099
Mastocytosis, clinical characteristics of, 124:1595
Matrilysin, in clinical late-stage colon cancer, 122:60
Matrix metalloproteinase (MMP)
in inflammatory bowel disease, 117:755-tmig, 117:814, 120:622
inhibition
and prevention of sinusoidal obstruction syndrome (rat), 125:882
in protection against hepatic ischemic injury, 125:917-srr
MMP-1, attenuation of liver fibrosis by (rat), 124:445
MMP-3, gene promoter, variants, in primary biliary cirrhosis, 122:247-c
MMP-7
in clinical late-stage colon cancer, 122:60
in inflamed gastric mucosa, *H. pylori cag*$^+$ strains and, 125:1005-tmig, 125:1125
MMP-9
Helicobacter pylori-induced expression of, NF-κB activation and, 124:983
in pancreatitis-associated acute respiratory distress syndrome (rat), 122:2-tmig, 122:188
MAX.16H5, therapy with, for inflammatory bowel disease, 122:1592
M cells
human intestinal, model for, 121:1520-ss
mature lymphocyte-independent development of, in Peyer's patches (mice), 120:1173
transient expression of, in follicle-associated epithelium of murine Peyer's patches, 119:734
McKinley, William, assassination of, 124:266-pmr
***mdr* gene expression,** induction, in statin-treated rats, 117:678
Meal supplements, therapy with, 122:1677
Meat, chargrilled, effects on CYP1A expression, 117:89
Mechanical ventilation, duodenogastroesophageal reflux and esophageal mucosal injury during, 116:1281-tmig, 116:1293
Mechanoreceptors, with intraganglionic laminar endings, in rectum (guinea pig), 125:786
Mechanosensory transduction, in colorectum, ATP and (rat), 125:1398
Meconium ileus, in cystic fibrosis, molecular genetics of, 119:268-ss
Mediastinal masses, endoscopic ultrasound of, 122:1631
Medicare
HCFA policy and, 120:3-gn
regulations, legislation aimed at reform of, and education on, 120:1320-gn
Medicare Prescription Drug and Modernization Act, 125:650-gn
Medication precertification criteria, AGA policy statement on, 121:965-aga
Megacolon, enteric nerves and interstitial cells of Cajal in, 123:1422-tmig, 123:1459
Megacystis-microcolon-intestinal hypoperistalsis syndrome
absence of nicotinic acetylcholine receptor α3-subunit in, 121:350
pathogenesis of, 121:350

Meigs, Joe Vincent, 123:699
Meissner, George, 116:247
Melanin concentrating hormone receptor, in regulation of food intake, 117:524-gn
Melanocortin, reversal of obesity in POMC-deficient mice, 117:1039-gn
Meloxicam, gastrointestinal events related to, risk of, 120:594
Membrane-permeant inhibitor of MLC kinase (PIK), and barrier function in intestinal disease, 123:163
Memory B cells, intestinal, 119:1253
Ménétrier, Pierre Eugene, 123:1414
Ménétrier's disease, with premalignant transformation, 123:968-im
Menin, and gastrin-regulated expression of PAI-2, 123:271
Menopause, and gender differences in IBS, 123:1686-srr
Menstrual cycle, and gender differences in IBS, 123:1686-srr
6-Mercaptopurine (6-MP)
and 5-aminosalicylic acid agents, drug interactions, 119:276-c
and azathioprine, for refractory microscopic colitis, 120:1483-cr
and azathioprine-intolerant patients, with inflammatory bowel disease, 122:838-c
and balsalazide, drug interactions, 116:1505-c, 117:1514-c
for Crohn's disease
in children, 119:889-tmig, 119:895, 119:1158-e
combined with infliximab (abstract), 125:606-aga
with fistulous complications, 119:1132-srr, 124:1595
and lymphoma risk, 121:1034-tmig, 121:1080, 121:1239-e
for inflammatory bowel disease, 120:622
dosage of, metabolite measurements and, 122:2082-ss
metabolite levels in, 118:705
and risk of EBV-positive lymphoma, 122:72
thiopurine methyltransferase genotype and, 118:705
metabolism of, 122:848-tmig, 122:903, 122:1164-e, 122:2082-ss
for perianal Crohn's disease, 125:1503-aga, 125:1508-aga
and postoperative infections in IBD patients, 125:320, 125:610-e
resistance, in inflammatory bowel disease, causes of, identification of, 122:848-tmig, 122:903, 122:1164-e
safety of, for childbearing patients, 124:1-tmig, 124:9, 125:1562-c
Mergers, proposed Zeneca Group PLC and Astra AB, 116:236-gn
Mesalamine
adverse effects and side effects of, 124:1986-ss
and chronic interstitial nephritis, 123:1436
for Crohn's disease
versus budesonide, 116:1263-ss
with fistulous complications, 124:1595
as maintenance therapy, 120:585-c
postoperative therapy with, 118:247-tmig, 118:264, 118:436-e
and prevention of relapse, 119:597-c
for Crohn's ileitis, 116:509-tmig, 116:521
and intestinal epithelial cell proliferation (mice), 116:509-tmig, 116:602
nitric oxide-releasing, anti-inflammatory effects of (rat), 117:557
for pouchitis, 124:1636
and TNF-α-regulated signal transduction in colonocytes (mice), 116:509-tmig, 116:602
for ulcerative colitis, 118:630-ss, 124:574-ss
Mesenteric artery, eNOS up-regulation in, in portal hypertension (rat), 125:1452
Mesenteric inflammatory veno-occlusive disorder, diagnosis and management of, 125:236-cr
Mesenteric ischemia
acute
AGA guidelines on, 118:951, 119:280 *correction*
AGA technical review on, 118:954
AGA technical review on, 118:954
chronic
AGA guidelines on, 118:951, 119:280 *correction*
AGA technical review on, 118:954
nonocclusive, management of, 118:954
Mesenteric venous thrombosis
anticoagulant therapy for, 120:578-ss
in cirrhosis, 123:1409-c
factor II G20210A gene mutation in, 118:237-c
hyperhomocysteinemia in, related to pernicious anemia, 118:237-c
increased levels of factor VIII:C as risk factor for, 120:1563-c
management of, 118:954
Meta-analysis, of *Helicobacter pylori cagA* status and gastric cancer, 125:1569-tmig, 125:1636
Metabolic syndrome, in obesity, 123:882-aga
Metformin, prevention of pancreatic cancer induction (hamster), 120:1072-tmig, 120:1263, 120:1291-e
Methionine adenosyltransferase II, β subunit, in hepatoma proliferation, 124:940
Methotrexate
for Crohn's disease
with fistulous complications, 119:1132-srr, 124:1595
for maintenance of remission, 120:1553-ss
in inflammatory bowel disease, 123:1737-ss
for primary biliary cirrhosis, 117:292-tmig, 117:395, 117:400, 117:492-e, 117:1038-tmig, 117:1173, 117:1511-c
sensitivity, in gastrointestinal cancer, LST-2 and, 120:1689
***N*-Methyl-D-aspartate (NMDA) receptors,** peripheral, in visceral nociception (rat), 120:1737
Methylenetetrahydrofolate reductase, gene polymorphism, and colorectal cancer risk, 121:282
Methylprednisolone, for ulcerative colitis, comparison with unfractionated heparin, 119:889-tmig, 119:8903, 120:1306-c, 120:1307-c
Metronidazole
and budesonide, combined, for Crohn's disease, 123:33
for Crohn's disease, with fistulous complications, 119:1132-srr
susceptibility, in *H. pylori,* 117:1032-c
***MICA* alleles,** and primary sclerosing cholangitis, 120:1475
Microarray-based genomics, in study of gastrointestinal tract, 122:1196-tmig, 122:1467
Microbial antigens, response to, in Crohn's disease, 123:689
Microflora
in intestinal mucus, in inflammatory bowel disease, 117:1037-tmig, 117:1089
and pathogenesis of colonic inflammation, 116:1107, 116:1246-e
β_2-Microglobulin gene, somatic mutation of, and unfavorable prognosis in GI cancer of microsatellite mutator phenotype, 120:1565-c

Microlaparoscopy, monograph on, 121:228-pmr
Microlithiasis
biliary, 121:1014-ss
pigment, 121:1529-c
Micronutrients, requirements, in parenteral nutrition, 121:970-aga
Microparticles, and apoptosis in intestinal macrophages, 123:1543
Microsatellite instability
in colon carcinogenesis, 119:854-srr
in colorectal cancer, 122:1196-tmig, 122:1376
hepatocyte nuclear factor 1 and, 124:1311
methylation of h*MLH1* promoter region and, 121:1300, 121:1497-e
p14 methylation and, 124:626
as prognostic indicator in chemotherapy, 119:889-tmig, 119:921, 120:1309-c
prognostic significance of, 118:459-gn
promoter methylation pattern of hMLH1 and p16 in, gender difference in, 124:1165-c
site, sex, and age differences in, 121:230-c
WISP-3 mutations with, 121:1275-rc, 121:1497-e, 124:270-c
in duodenal carcinoma, 124:1300
evaluation of, 123:1804
in gastric cancer
Ki-*ras* mutations and, 125:1282-c
and loss-of-function mutation in *WISP3*, 125:1563-c
in hereditary nonpolyposis colorectal cancer (HNPCC), 124:1574
in hyperplastic polyposis, 119:323
and mitochondrial and nuclear DNA mutation, in gastric cancer, 118:835
screening for, in detection of hereditary nonpolyposis colorectal cancer, 120:1-tmig, 120:21
testing for, in colorectal tumors, 121:198-aga
Microsatellite mutator phenotype
gastric cancer of, genetic and clinical features of, 116:1348
gastrointestinal cancer with, somatic mutation of β_2-microglobulin gene and unfavorable prognosis in, 120:1565-c
with hypermethylated *hMLH1* gene, in colon cancer, in women, 119:597-c
Migraine, abdominal, 120:263-aga
Migratory necrolytic erythema, clinical features of, 124:1595
Milk, maternal, in prevention of necrotizing enterocolitis (rat), 123:383-ss
Milk protein allergy, pathogenesis of, immunohistochemical considerations in, 124:259-ss
Minerals
deficiencies of, treatment of, 122:1677
nutritional use of, 122:834-pmr
requirements, in parenteral nutrition, 121:970-aga
Mismatch repair
deficiency, in human colorectal cancer, gender difference in, 121:1026-c
gene
hMLH1
HNPCC-related mutations, functional analysis of, 122:211
variants, functional analysis of, 122:211
testing for, in hereditary nonpolyposis colorectal cancer, 121:198-aga
proficiency, and in vitro response to 5-fluorouracil, 117:123
Misoprostol, for NSAID gastropathy, 119:521-srr
Mitochondria
abnormalities of, and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281-e
damage to
by *C. difficile* toxin A (CHO cells), 119:139
hepatitis C virus core protein-induced, 122:366, 122:568-e
ethanol and, 122:2049-srr, 123:1278
hepatocyte, apoptotic mechanisms in, Bid-mediated activation of, 125:854
Mitochondrial neurogastrointestinal encephalomyopathy, manometric and diagnostic features, 116:959-cr
Mitochondrial permeability transition
ethanol and, 122:2049-srr
and necrotic cell death in hepatocytes (rat), 124:494
Mitogen-activated protein kinase (MAPK)
activation
by acid exposure, in Barrett's esophagus, and carcinogenesis, 122:253-tmig, 122:299
in colonocytes, mesalamine and (mice), 116:509-tmig, 116:602
and intestinal epithelial cell differentiation, 116:1072
inhibition of, in Crohn's disease, 122:7-rc, 125:633-c
p38, activation, and taurioursodesoxycholate-induced choleresis (rat), 121:407
in regulation of intestinal barrier, 118:1001-rc
in regulation of proteolysis by hepatocyte hydration, 116:921
stimulation of, by glutamine metabolism, in enterocytes, 118:90
Mitogen-activated protein kinase (MAPK) kinase, inhibitor of, inhibition of colon cancer growth, 117:523-gn
Mitogen-activated protein kinase (MAPK) phosphatase MKP-1, glucagon-induced expression in hepatocytes (rat), 118:929
MnTBAP, prevention of Fas-induced acute liver failure (mice), 121:1451
Model for End-Stage Liver Disease (MELD) score, and donor organ allocation in liver transplantation, 124:91, 124:251-e, 125:992-c, 125:993-c, 125:1009-ce
Molecular adsorbent and recirculating system (MARS), for hepatorenal syndrome, 119:1799-ss
Molecular biology
and clinical epidemiology, research opportunity at interface of, 122:1199-ce
at interface of molecular biology and clinical epidemiology, 122:1199-ce
of viral hepatitis, 122:1554
Molecular genetics, of colorectal cancer metastases, 122:3-gn
Molecular imaging, of premalignant mucosal lesions (mice), 122:254-tmig, 122:406, 122:571-e
Molecular mimicry, of mitochondrial and nuclear autoantigens, in primary biliary cirrhosis, 124:1915
Molecular physiology, gastrointestinal, gastroenterologist training in, 124:1095-aga
Monoamine oxidase, activity, in chronic liver disease, circulating soluble vascular adhesion protein 1 and, 119:1096
Monocyte chemoattractant protein-1, secretion, in human pancreas, cytokine regulation of, 119:211
Monocyte chemotactic protein-1 (MCP-1), gene polymorphism, in chronic hepatitis C, 125:1085

Monocytes, apoptosis, induction by infliximab, 121:1034-tmig, 121:1145, 121:1242-e
Morgagni, Giovanni Batista, 123:424
Motilin, regulation of interdigestive gastric blood flow (dog), 123:1578
Motilin receptor
erythromycin-responsive, and upper GI motility, 117:524-gn
in human GI system, 117:1504-ss
identification of, 117:524-gn
Motilin-related peptide
and ghrelin, 120:587-c, 120:588-c
identification and characterization of, 119:288-tmig, 119:395, 120:587-c, 120:588-c
Motility, 120:1056-pmr
abnormalities of, in irritable bowel syndrome, 123:2108-aga
atlas of, 125:1906-pmr
clinical disorders of, in elderly, 122:1688
colonic
endocannabinoids and (mice), 123:227
recombinant human neurotrophic factors and, 119:1-tmig, 119:41, 119:257-e
cytomegalovirus gastritis and, 116:953-cr
disorder of, antibody-mediated, in scleroderma, 123:1144
disturbances of, skin signs of, 124:1595
esophageal, sildenafil and, in achalasia, 118:247-tmig, 118:253
gastric, ghrelin and, 125:1492-srr
gastroenterologist training in, 124:1062-aga
in health, gender differences in, 123:1686-srr
intraileal capsaicin and (dog), 123:1904
in irritable bowel syndrome, gender differences in, 123:1686-srr
mechanisms for, 120:331-tmig, 120:361, 120:480
ontogeny of, 116:702-srr
orphanin FQ in (rat), 116:2-tmig, 116:108
in peritoneal infection or tissue damage, protease-activated receptors and, 116:586
in pregnancy, 123:1686-srr
problems, in elderly, 122:1688
small bowel, propagation and neural regulation of calcium waves in (guinea pig), 118:892
studies of, orphan receptor in, 117:524-gn
tachynergic and cholinergic transmission in, 120:938
upper gastrointestinal, erythromycin-responsive motilin receptor and, 117:524-gn
Motor cortex, representation of anorectal musculature in, 117:1-tmig, 117:32
Moynihan, Berkeley George Andrew, 123:32, 123:1413
***MRP2* gene,** mutations, in Dubin-Johnson syndrome, exon-intron organization of, 117:653
Mucin
and colon cancer metastasis, 116:363
exocytosis, EP_3 receptor-mediated, prostaglandin E_2 and, 117:1352
gallbladder, and cholesterol gallstones, 116:784-tmig, 116:936
gastric
MUC5AC, *Helicobacter pylori* binding to, 123:1923
MUC5AC and MUC6, expression in pancreatic intraepithelial neoplasms, 123:1052
synthesis of, inhibition by *H. pylori,* 118:1072
hypervariable membrane-bound, MUC1, in *Helicobacter pylori* gastritis, 123:41
intestinal, in colorectal cancer, 123:648-ss
modulation by galectin-3, 123:817
and trefoil factors, interaction of, 118:70
Mucinous tumor, appendiceal, 122:1200-im
Mucosa
antral, leptin receptors and STAT-3 in (rat), 121:1417
colonic
polarized transport of hydrophilic compounds across, temperature dependence of (rat), 118:535
progenitor cells, clonal growth of (human, mouse), 117:858
protective effect of short-chain fatty acids in, 121:511-tmig, 121:631
duodenal
aspirin and, 117:1-tmig, 117:17
prostaglandin levels, aspirin and, 117:1-tmig, 117:17, 117:1506-c
flora of, in inflammatory bowel disease, 122:44, 122:228-e, 123:955-c, 125:1288-c
gastric
adaptive cytoprotection in, PGI_2 and CGRP in, 120:134
aspirin and, 117:1-tmig, 117:17, 117:1506-c
biological action of heregulin α in, 117:1119
colonization by *H. pylori,* phospholipase (PldA) in, 117:1098
damaged, CINC-2β and *Reg* gene expression in (rat), 119:1610
development and cellular homeostasis in, H^+,K^+-ATPase β subunit and (mice), 117:605
Helicobacter pylori gene expression in, 123:1637
histology of, *Helicobacter pylori* virulence factors and, 123:414
metastatic calcification in, 119:894-im
prostaglandin levels, aspirin and, 117:1-tmig, 117:17, 117:1506-c
prostaglandin production in, COX-2 inhibitors and, 120:784-tmig, 120:867, 121:1262-c
response to TIPS for portal hypertensive gastropathy in cirrhosis, 118:816-tmig, 118:905
gastroduodenal
effects of rofecoxib on, 118:638-c, 118:640-c
effects of rofecoxib vs. ibuprofen on, 117:776, 117:1002-e
gastrointestinal
defense, nitric oxide in, 119:512-srr
diseases of, book on, 122:1181-pmr
in HIV-1 infection, 120:607
ileal, permeability to proteins, in Crohn's disease, 117:65
immune response in
caspases and, 122:1334
in colitis (mice), 122:94
and IL-10 (mice), 122:1829
in pathogenesis of irritable bowel syndrome, 122:1778, 122:2078-e
intestinal
apoptosis in, TGF-β2 and TGF-β3 in (mice), 122:1364
integrity, prostaglandin E-receptor subtype EP_3 and (mice), 117:1037-tmig, 117:1128
protection against bile acids, biliary phospholipids in (rat), 118:1179, 118:1265-e
leakiness, in ulcerative colitis, pathogenesis of, 121:1269-tmig, 121:1320
rectal, prostaglandin levels, aspirin and, 117:1-tmig, 117:17, 117:1506-c
repair of, 124:1159-pmr
Mucosa-associated lymphoid tissue (MALT)
gastric, lymphoma of (MALToma)
gastric ulcer development with, *H. pylori* and, 117:893
H. heilmannii-associated, remission after treatment, 118:815-tmig, 118:821
H. pylori and, 118:988-c, 121:1025-c
high-grade, 123:956-c, 123:1410-c
H. pylori eradication therapy in, 123:393-c

low-grade, 120:1884-c
regression after *H. pylori* treatment, 124:537-cr
t(11;18)-positive, resistance to *H. pylori* eradication, 122:1286
treatment of, by *H. pylori* eradication, 121:1025-c
H. pylori and, 117:2-tmig, 117:82, 117:257-e, 117:750-c, 117:1105
laryngeal, lymphoma of, regression after *H. pylori* treatment, 124:537-cr
rectal, lymphoma of (MALToma), *H. pylori* and, 117:514-c

Mucosal addressin cell adhesion molecule 1 (MAdCAM-1), in immune cell trafficking, 121:853, 121:1008-e

Mucosal immunity
fibroblast-T cell interaction in, ICAM-1 in, 117:521-tmig, 117:546
In *H. pylori* infection, 116:497-ss
HAART and, 120:984-cr
and inflammatory bowel disease, 124:521-srr
in irritable bowel syndrome, 124:1163-c

Mucus
gastric, acid channels in (rat), 119:1297, 119:1397-e
intestinal, bacteria in, in inflammatory bowel disease, 117:1037-tmig, 117:1089

Multidetector helical CT (MDCT) cholangiography, clinical applications of, 124:1686

Multidrug resistance
in bacterial diarrhea, 117:3-gn
expression, in inflammatory bowel disease, and response to glucocorticoid therapy, 118:247-tmig, 118:279

Multidrug resistance-associated protein 2
and bile salt secretion in STZ-diabetic rats, 122:1842
regulation of, in obstructive cholestasis (rat), 123:599

Multidrug resistance gene
MDR1, C3435T polymorphism, and ulcerative colitis, 124:26, 125:1919-c
Mdr2, expression, fasting and (mice), 124:160, 124:254-e
MDR3
defect
and cholesterol cholelithiasis, 120:1459, 120:1549-e
in progressive familial intrahepatic cholestasis type 3, 120:1448, 120:1549-e
mutation, and cholelithiasis, cholestasis of pregnancy, and biliary cirrhosis in adulthood, 124:1037-cr, 125:1922-c

Multidrug resistance P-glycoprotein gene product Mdr1a, in cholangiocytes, molecular identification and functional characterization of (rat), 119:1113

Multidrug resistance protein(s)
MRP2
gene mutations, in Dubin-Johnson syndrome, exon-intron organization of, 117:653
in liver, regulation by lipopolysaccharide and dexamethasone (rat), 116:401, 116:486-e
MRP2 and MRP3, expression and localization in gallbladder epithelia, 121:1203

Multiple endocrine neoplasia, type 1, with Zollinger-Ellison syndrome, prognostic factors in, 116:233-tmig, 116:286

Multiple sclerosis (MS), hepatitis B vaccine and, 120:1880-ss

Multivisceral transplantation, 124:1615

Mumps virus genome, search for, in intestinal biopsy specimens of patients with IBD, 117:1253-c

Murano, Elsa A., as Under-Secretary for Food Safety, USDA, 121:1272-gn

Murphy, John Benjamin, 124:292

Muscarinic receptors
M_2, coupling to calcium channels, in colonic circular smooth muscle (rabbit), 123:827
M_3, knockout mice, impaired gastric secretion and lack of trophic responses to gastrin in, 125:1774

Muscle, smooth. *See* Smooth muscle

Muscle tone, in anorectal disorders, AGA technical review on, 116:735-aga

Muscular dystrophy
mdx mouse model of, mechanical tone of colon in, calcium influx and, 120:1430
oculopharyngeal, dysphagia in, botulinum toxin treatment of, 119:1416-c

Muscularis externa, intestinal, leukocytes in, and postoperative ileus (rat), 117:378, 117:489-e

Mycophenolate mofetil
for autoimmune hepatitis, 120:1502-srr
for Crohn's disease, with fistulous complications, 119:1132-srr

Myelosuppression, with azathioprine therapy for Crohn's disease, 118:995-tmig, 118:1025
steroid therapy and, 118:1281-c

Myenteric neurons
degeneration, in pathogenesis of irritable bowel syndrome, 123: 1972, 123:2144-e
in small intestine, excitation by serine proteases (guinea pig), 123:1554

Myocardial infarction, after screening flexible sigmoidoscopy, 123:1786

Myocytes, enteric, plasticity, 117:1438-srr

Myofibroblasts
hepatic, phenotypic and functional properties of (rat), 117:1038-tmig, 117:1205, 117:1244-e
intestinal
IL-1α-induced COX-2 expression in, PKCz-ROS pathway in, 124:1855
in innate immunity, 124:1866

Myosin light chain kinase
inhibition by membrane-permeant peptide, 123:163
in stress-induced disruption of colonic epithelial barrier (mice), 125:795

Nabumetone, gastrointestinal events related to, risk of, 120:594

Nadolol
plus nitrate, for prevention of variceal bleeding, 119:1170-ss
in prevention of recurrent variceal bleeding, 122:832-ss, 123:728

NADPH oxidase, and intrapancreatic trypsin activation, in acute pancreatitis (mice), 122:973, 122:1166-e

NAG-1 gene, expression and regulation of (mouse, human), 122:1388

Na^+/HCO_3^- cotransporters, NBC1 and NBC2, in gastric cells (rabbit), 116:1389

Na^+/H^+ exchanger. *See* Sodium/hydrogen antiporter (sodium/hydrogen exchanger)

Naloxone, delayed opioid withdrawal-like reaction precipitated by, in primary biliary cirrhosis, 121:743-c

Naltrexone, florid opioid withdrawal-like reaction precipitated by, in chronic cholestasis, 118:431-cr

Naproxen, gastrointestinal events related to
H. pylori elimination and, 122:238-ss
lower GI, risk of, 124:281-tmig, 124:288
risk of, 120:594
upper GI, risk of, 123:1006

Natalizumab
for Crohn's disease, 121:268, 125:1276-ss
for inflammatory bowel disease, 122:1592

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
goals for, 121:241-gn
Hepatotoxicity Clinical Research Network, 125:1008-gn
planned initiatives for 2001, 119:1427-gn
Griffin P. Rodgers, deputy director, 121:241-gn
Special Emphasis Program announcements, 125:5-gn
Allen M. Spiegel, director, 118:4-gn
support for basic research, 118:4-gn
National Institutes of Health (NIH)
Clinical Research Loan Repayment Program, 121:1035-gn
Consensus Development Conference statement on management of hepatitis C, 123:2082
Consensus Development Conference update of HCV management, 123:404-gn
digestive diseases study section, expansion of, 123:663-gn
Digestive Sciences Integrated Review Group, 125:651-gn
funding for, 117:4-gn, 118:4-gn, 118:652-gn, 122:602-gn
2004, 125:1007-gn
politics and, 119:892-gn
research funding opportunities from, 122:603-ce, 124:1995
roadmap for medical research in 21st century, 125:1573-gn
National Residency Matching Program, 122:851-ce
National Resident Matching Program, 117:294-ce, 117:509-c
Natural killer cells
activated by α-galactosylceramide in presence of CD1d, and protection against colitis (mice), 119:119
hepatic, depletion of, leptin deficiency and (mice), 123:1304
intestinal intraepithelial, 125:345
in primary biliary cirrhosis, quantitation and phenotypic analysis of, 123:1031
toll-like receptors on, in liver injury by *Salmonella* (mice), 123:1265
Natural killer receptor CD94, intraepithelial lymphocytes expressing, in celiac disease, 118:816-tmig, 118:867
Nausea and vomiting. *See also* Emesis
AGA medical position statement on, 120:261-aga
AGA technical review on, 120:263-aga
chemotherapy-related, 120:263-aga
clinical approach to, 120:263-aga, 125:1860
differential diagnosis of, 120:263-aga, 125:1860
in dyspepsia, duodenal acid sensitivity and, 116:509-tmig, 116:515, 116:761-e
functional, 120:263-aga
intractable, with gastroparesis, 120:263-aga
management of, 120:263-aga
postoperative, 120:263-aga
radiation-related, 120:263-aga
socioeconomic effects of, 120:263-aga
NCX-4016
gastrointestinal safety of, 124:593-tmig, 124:600, 124:842-e, 125:1918-c
inhibition of Th1-like response in concanavalin A-induced hepatitis, 118:404
Near-infrared imaging, 120:749
Necrapoptosis, after hepatic ischemia/reperfusion, 125:1246-srr
Necrosis
ethanol-induced mitochondrial dysfunction and, 122:2049-srr
in ischemic liver injury, calpain and (rat), 116:2-tmig, 116:168
oncotic, after hepatic ischemia/reperfusion, 125:1246-srr
Necrotizing enterocolitis (NEC)
biology of, 121:1016-ss
neonatal, prevention of (rat), 117:521-tmig, 117:577, 118:1280-c
EGF in, 123:383-ss
risk factors for, 121:1016-ss
Needle electromyography, of external sphincter, in fecal incontinence, 124:1672
Nelfinavir, GI toxicity and GI-associated drug interactions of, 120:607
Neoplasia
anal, 119:1803-pmr
colonic, 119:1803-pmr
at gastroesophageal junction, dietary nitrate-derived nitric oxide in, 122:1248, 122:1518-e
induction in secretin-expressing cells, early region of simian virus 40 in (mice), 119:1305
intraductal papillary mucinous, of pancreas, 123:406-im
aberrant DNA methylation in, 123:365
recurrence after surgical resection, 123:1500
rectal, 119:1803-pmr
and refractory sprue, 119:243-srr
Neostigmine
for acute colonic pseudo-obstruction, 118:443-ss
effect on gas transit, 122:1748
Nerve growth factor (NGF)
effects in experimental colitis (rat), 119:368
production, by hepatocellular carcinoma (mice), 122:1978
up-regulation, in L-arginine-induced acute pancreatitis (rat), 119:1373
Nerve latency measurements, anorectal
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
Nerves, and IL-6 production in intestinal smooth muscle cells (rat), 116:346
Neuroautonomic disorder, gallbladder muscle dysfunction as, 123:1407-c
Neuroendocrine gastroenteropancreatic tumors, treatment of, 118:650-tmig, 118:735
Neuroendocrine pancreatic tumors, endoscopic ultrasound in, 122:1631
Neuroendocrine response
in health, gender differences in, 123:1686-srr
In irritable bowel syndrome, gender differences in, 123:1686-srr
Neuroendocrine tumor cells, interferon alfa-mediated growth inhibition in, molecular mechanism of, 118:650-tmig, 118:735
Neuroendocrine tumors, xenin in, 123:1616
Neurokinin A, in human sigmoid circular muscle contraction, 119:51
Neurokinin-1-receptor antagonist, for chemotherapy-related emesis, 117:737-ss
Neurokinin 3 receptors
and colorectal sensitivity to distention (rat), 116:1124, 116:1250-e
in gastrointestinal disorders (rat), 116:1124, 116:1250-e
and visceral nociception (rat), 116:1124, 116:1250-e
Neuronal plasticity, in enteric nervous system
chemistry of, 117:1438-srr
clinical aspects of, 117:1438-srr
investigation of, 117:1438-srr
molecular mechanisms involved din, 117:1438-srr
pathophysiology of, 117:1438-srr
pharmacology of, 117:1438-srr
repetitive stimulation and, 117:1438-srr
Neurons, enteric, 117:1438-srr
apoptosis, anti-HuD–induced, and paraneoplastic gut dysmotility, 125:70

Neuropathy
associated with cryoglobulinemia and hepatitis C, 124:1711
interferon-related, 124:1711
Neuropeptides
and colonic motility, 119:1-tmig, 119:257-e
in gastrointestinal motility (rat), 116:2-tmig, 116:108
Neuropsychiatric symptoms, with pegylated interferon, for hepatitis C, 124:1711
Neurotensin
and jejunal bile acid absorption (rat), 120:151
stimulation of chloride secretion in human colon, mechanisms of, 119:348
Neurotensin receptors, heterodimerization of, 123:1135
Neurotransmission, in esophageal distal and deglutitive inhibition (rat), 118:328
Neurotransmitters, and IL-6 production in intestinal smooth muscle cells (rat), 116:346
Neurotrophic factor 3, recombinant human, and colonic transit, 119:1-tmig, 119:41, 119:257-e
Neurotrophin-3, effects of, in experimental colitis (rat), 119:368
Neurotrophins, enteric, 117:1438-srr
Neutropenia
in pancreatitis and pancreatitis-associated lung injury, 116:510-tmig, 116:694
with pegylated interferon, for hepatitis C, 124:1711
Neutrophil chemoattractant 2β, regulation of *Reg* gene expression in injured gastric mucosa (rat), 119:1610
Neutrophil chemoattractants, biliary production of, 118:1157
Neutrophils
dysfunctional, in leukocyte adhesion deficiency 1, and colitis, 121:958, 121:1008-e
and effects of passive smoking in inflammatory bowel disease, 117:756-tmig, 117:884, 117:1008-e
gastric, and ulceration in NSAID users, 116:254
and intrapancreatic trypsin activation, in acute pancreatitis (mice), 122:973, 122:1166-e
and lung injury in pancreatitis (rat), 122:2-tmig, 122:188
recruitment, in colonic inflammation, poly(ADP-ribose) synthetase and (mice), 116:233-tmig, 116:335
Nevirapine, GI toxicity and GI-associated drug interactions of, 120:607
Night-eating syndrome, and obesity, 123:882-aga
Nissen, Rudolph, 125:6
Nitrates
dietary
and ascorbate/nitrite ratio in gastric juice, 116:813
and generation of nitric oxide at gastroesophageal junction, 122:1248, 122:1518-e
in prevention of variceal bleeding, 123:963-tmig, 123:1013, 123:1388-e
topical, for anal fissure, 124:233-aga, 124:235-aga
Nitric oxide (NO)
and acute metabolic effects of GLP2 (piglet), 125:136
biology
in inflammatory bowel disease, 119:512-srr
in portal hypertensive gastropathy, 119:512-srr
cellular sources of, 119:512-srr
central nervous system, and swallowing (cat), 119:287-tmig, 119:377
and cirrhotic cardiomyopathy (rat), 118:937
in cirrhotic liver (rat), 117:1222
coupled to NSAID, 119:521-srr
dietary nitrate-derived, in carcinogenesis at gastroesophageal junction, 122:1248, 122:1518-e
donors, in protection against hepatic ischemic injury, 125:917-srr
down-regulation of S-adenosylmethionine, and HGF-induced proliferation of hepatocytes, 122:1355
effect on hepatic arterial blood flow in acute hepatic injury (rat), 117:173
and gastric sensorimotor function, 116:510-tmig, 116:573
and leukocyte recruitment in colon cancer, 122:1121
and lower esophageal sphincter function (mice), 121:34
mesalamine derivative releasing, anti-inflammatory effects of (rat), 117:557
in mucosal defense, 119:512-srr
and oxidative DNA damage in cholangiocytes, 120:190
in postoperative ileus (rodent), 118:247-tmig, 118:316
production, by neural stem cells, 121:757-rc
regulation of somatostatin release from gastric D-cells (rabbit), 123:566
and secretion in cholangiocytes, 124:737, 124:847-e
spinal, in visceral hyperalgesia (rat), 116:1282-tmig, 116:1399
therapeutic potential of, 119:512-srr
vasodilation mediated by, loss of, in inflammatory bowel disease, 125:58
Nitric oxide-aspirin derivative
gastrointestinal safety of, 124:593-tmig, 124:600, 124:842-e, 125:1918-c
inhibition of Th1-like response in concanavalin A-induced hepatitis, 118:404
Nitric oxide synthase (NOS)
aortic NOS3, in systemic vasodilation of portal hypertension (rat), 119:2-tmig, 119:196
endothelial
in biliary cirrhosis (rat), 122:1869
impaired activity, in cirrhotic liver (rat), 117:1222
in portal hypertension (rat), 125:1452
in experimental hepatopulmonary syndrome (rat), 125:1441
and gastric mucosal defense (rat), 123:173
inducible
and alcohol-induced liver injury (mice), 125:1834
antineoplastic role in $Apc^{Min/+}$ mouse, 121:889
cytokine-induced stimulation of, in cirrhotic cardiomyopathy (rat), 118:937
expression in hepatocytes, oxidative stress and (rat), 118:608
gene expression and cellular localization in *H. pylori* gastritis, 116:1281-tmig, 116:1319
and hepatic arterial blood flow in acute hepatic injury (rat), 117:173
and IL-1β-induced apoptosis in enterochromaffin-like cells (rat), 118:457-tmig, 118:515
in infectious diarrhea, 122:1069
in intestinal tumorigenesis (mice), 121:889
and postoperative ileus (rodent), 118:247-tmig, 118:316
stimulation by NF-κB, and protection against TNF-α and Fas-mediated apoptosis in hepatocytes (mice), 120:1251
isoforms, and portal hypertension (mice), 124:1500
neuronal
deficiency, gastric stasis with (mice), 119:766

expression
in dextran sulfate sodium-induced colitis (rat), 118:714
in neural stem cells, 121:757-rc
splice variants of, in human gut, 118:849
Nitric oxide synthase (eNOS)-interacting protein (NOSIP), in gastrointestinal tract, organ distribution of (rat), 123:314
Nitrite, intragastric
long-term use of omeprazole and, 121:517
omeprazole for *H. pylori* and, 119:287-tmig, 119:339
Nitrogen, ileal losses of, and assessment of amino acid requirements, 123:50
Nitrogen oxides, and apoptosis, 119:512-srr
Nitroglycerin, effects on gastric sensorimotor function, 116:510-tmig, 116:573
***N*-Nitrosamines,** intragastric, long-term use of omeprazole and, 121:517
Nitrovasodilators, action in human hepatic stellate cells, 119:288-tmig, 119:479
Nociception, visceral
kappa opioids and, 117:292-tmig, 117:388
neurokinin 3 receptors and (rat), 116:1124, 116:1250-e
peripheral NMDA receptors in (rat), 120:1737
Nocturnal gastric acid breakthrough, histamine receptor blockade and, 122:599-tmig, 122:625
NOD2/CARD15
as antibacterial factor in epithelial cells, 124:875-tmig, 124:993, 124:1145-e
in chronic inflammatory disorders, 124:521-srr
gene expression
in epithelial cells, regulation of, 124:875-tmig, 124:1001, 124:1145-e
in Paneth cells, 125:1-tmig, 125:47
polymorphisms, and Crohn's disease, 124:521-srr
***NOD2* gene**
and Crohn's disease, 122:826-ss, 122:847-tmig, 122:853-rc, 122:866-rc, 122:1160-e, 122:2091-c, 123:1-tmig, 123:86, 123:106, 123:661-tmig, 123:679, 123:2148-ss, 125:1-tmig, 125:47
insertion mutation of, in Crohn's disease, 124:272-c
mutations
and fibrostenotic Crohn's disease, 123:661-tmig, 123:679
and fistulizing and fibrostenotic phenotypes in Crohn's disease, 122:2091-c
genetic and functional significance of, in Crohn's disease, 124:2-tmig, 124:140
and inflammatory bowel disease, 122:866-rc, 122:1160-e
and risk of Crohn's disease, 121:1-gn, 125:1-tmig, 125:47
Nonadrenergic, noncholinergic relaxation, in distal colon, impairment in dextran sulfate sodium-induced colitis (rat), 118:714
Nonalcoholic fatty liver disease
AGA medical position statement on, 123:1702-aga
AGA technical review on, 123:1705-aga
and alcoholic fatty liver disease, differentiation between, 123:1705-aga
antioxidants for, 122:1649
associated conditions, 122:1649
in children, 123:1705-aga
clinical impact of, 122:1649
clinical spectrum of, 116:1282-tmig, 116:1413, 123:1705-aga
demographics of, 123:1705-aga
diagnosis of, 122:1649, 123:1705-aga
diagnostic criteria for, 123:1705-aga
dyslipidemia and, 122:1649
epidemiology of, 122:1649, 123:1705-aga
evaluation for, 123:1702-aga
familial clustering of, 123:1705-aga
hepatic iron and, 118:981-ss
and hepatitis C, 123:1705-aga
imaging in, 123:662-tmig, 123:745
incidence of, 123:1705-aga
insulin resistance and, 122:1649, 123:1705-aga
insulin-sensitizing medications for, 122:1649
iron depletion in, insulin-sparing effect of, 122:930
laboratory findings in, 122:1649, 123:1705-aga
lifestyle modification for, 122:1649
lipid-lowering therapy for, 122:1649
and liver transplantation, 123:1705-aga
in morbid obesity, 123:1705-aga
natural history of, 123:1705-aga
in obesity, 122:1649
predictors of, 121:91
pathologic spectrum of, 116:1282-tmig, 116:1413
prevalence of, 122:1649, 123:1705-aga
profiling for, 122:1649
prognosis for, 123:1702-aga
research on, 124:71, 124:248-e
advances in (future directions for), 122:1649
risk factors for, 123:1702-aga
treatment of, 123:1705-aga
signs and symptoms of, 123:1705-aga
susceptibility for, TNF-α polymorphisms and, 122:253-tmig, 122:274
treatment of, 122:1649, 123:1702-aga, 123:1705-aga
type 2 diabetes mellitus and, 122:1649
ursodeoxycholic acid for, 122:1649
without carbohydrate intolerance, iron depletion and, 124:866-c
Nonalcoholic steatohepatitis
hepatocyte apoptosis and Fas expression in, 125:437
iron and *HFE* mutations in, 125:615-ss
Noncardiac chest pain, high-dose omeprazole in, 116:226-c
Non-Hodgkin's lymphoma, B-cell, hepatitis C and, 125:1723
Non-nucleoside reverse transcriptase inhibitors, GI toxicity and GI-associated drug interactions of, 120:607
Nonsteroidal anti-inflammatory drugs (NSAIDs)
apoptosis induced by, in gastric epithelial cells, suppression by protein kinase C β1 overexpression, 118:457-tmig, 118:507
cancer chemoprevention by, NAG-1 gene and (mouse, human), 122:1388
chemopreventive effects of, 117:755-tmig, 117:838, 125:285-tmig, 125:328, 125:404
chronic therapy with, GI resource use with, 125:389
colitis caused by, in IL-10-deficient mice, 123:1527
and colorectal adenomas, 123:1770
effects on colon, 117:755-tmig, 117:838
effects on liver, 117:755-tmig, 117:962
enteropathy caused by, pathogenesis of (mice), 122:1913, 125:637-c
for esophageal cancer prevention, cost-effectiveness of, 124:1758
gastrointestinal complications of
COX inhibition and (rat), 119:610-tmig, 119:706
Helicobacter pylori elimination and, 122:238-ss
mechanisms of (mice), 119:610-tmig, 119:699
relative risk of, 122:1535-ss
risk factors for, 120:594
serious lower GI, 124:281-tmig, 124:288
strategies for decreasing, 120:594

upper GI, risk stratification for, 123:1006
gastropathy caused by
cysteine endoproteinases in, 116:1089
management of, 119:521-srr
pathogenesis of, 119:521-srr
role of proteasome in, 116:865, 116:994-e
and *H. pylori*, 116:254, 116:1281-tmig, 116:1305, 118:451-c, 119:521-srr, 120:594, 122:238-ss
hepatobiliary transport of, 117:755-tmig, 117:962
inflammation induced by, vascular anatomy in, 120:1885-c
nitric oxide coupled to, 119:521-srr
nonselective, in prevention of colorectal neoplasia, 125:404
peptic ulcers related to, neutrophils and *H. pylori* status and, 116:254
in prevention of colorectal cancer, cost-effectiveness of, 122:1-tmig, 122:78, 122:230-e
in prevention of colorectal polyps, 125:285-tmig, 125:328, 125:404
protection of ileal mucosa against, biliary phospholipids in (rat), 118:1179, 118:1265-e
protective effect against esophageal cancer, 124:47, 124:246-e, 125:1912-c
regulation of Par-4 gene by, 118:1012
and risk of ulcer bleeding in *H. pylori* infection, 116:1281-tmig, 116:1305, 118:451-c
safer, 119:521-srr
use in high-risk patients, 120:594

Nonulcer dyspepsia, *H. pylori* in, 116:511-gn

Norfloxacin, for diarrhea caused by small intestinal bacterial overgrowth, 117:755-tmig, 117:794

Norvir. *See* Ritonavir

Norwalk-like virus, and acute gastroenteritis outbreaks on cruise ships, 124:284-gn

Norwalk virus
binding to histo-blood group antigens on gastroduodenal epithelial cells of secretor individuals, 122:1967
immunity to, studies of, 117:40, 117:255-e
recombinant virus-like particles, oral delivery of, 117:40, 117:255-e

Notch signaling pathway
Alagille syndrome and, 116:1141, 116:1257-e
and human development, 116:1257-e

NS-398, inhibition of cyclooxygenase 2 expression, 118:457-tmig, 118:487

Nuclear factor κB
activation
in colonic epithelial cells, drugs affecting, 117:1039-gn
by *Cryptosporidium parvum*, in biliary epithelia, and prevention of epithelial cell apoptosis, 120:1774
and *H. pylori*-induced expression of MMP-9, 124:983
and *H. pylori*-induced IL-8 production in gastric cancer cell lines, 116:1330
by *H. pylori*, mechanism of, in gastric cancer cells, 119:97
IKB-independent, mediated by protein kinase C, 117:89, 117:261-e
and IL-1β-induced apoptosis in enterochromaffin-like cells (rat), 118:457-tmig, 118:515
and iNOS, in TNF-α and Fas-mediated apoptosis in hepatocytes (mice), 120:1251
in postischemic intestine (rat), 118:525
activity
in colonic epithelial cells, butyrate and, 118:724, 118:798-e
during sepsis, regulation of, 124:118
antiapoptotic signaling by, in pancreatic cancer, 123:2052
and contractility of colonic circular smooth muscle cells (dog), 124:1369
in gastrointestinal diseases, 118:1208-srr
in inflammatory bowel disease, 116:1504-c
inhibition by sulfasalazine, molecular mechanism of, 119:1209
inhibitors, therapy with, for inflammatory bowel disease, 122:1592
in mouse model of intestinal fibrosis, 125:1570-tmig, 125:1750, 125:1886-e
NF-κB1 and NF-κB2, and Peyer's patch organogenesis (mice), 122:1853
Salmonella AvrA effector and, 124:1550-ss
and TGF-α inhibition of apoptosis in gastric pit cells, 121:56

Nuclear factor κB/Rel, activation in acute pancreatitis, 116:420, 116:489-e
in colonocytes, mesalamine and (mice), 116:509-tmig, 116:602

Nuclear magnetic resonance spectroscopy, in structural biology, 123:1350-srr

Nuclear receptor fxr, and bile acid transporter regulation by bile acids (rat), 121:140, 121:218-e

Nuclear receptors, orphan, and cholesterol and bile acid metabolism, 120:1054-ss

Nuclear scans, in obscure gastrointestinal bleeding, 118:201-aga

Nucleoside analogs
GI toxicity and GI-associated drug interactions of, 120:607
inhibition of hepatitis B virus replication in vivo (mice), 125:9-rc
therapy with, for hepatitis B, 120:1828-srr

Nucleoside reverse transcriptase inhibitors, GI toxicity and GI-associated drug interactions of, 120:607

Nucleoside transporters, expression in small intestine, nutritional regulation of (rat), 119:1623

Nucleus tractus solitarii, and esophageal distal and deglutitive inhibition (rat), 118:328

Nurse endoscopists, screening flexible sigmoidoscopy performed by, 117:291-tmig, 117:312

Nutrients
deficiencies of, assessment for, 122:1677
requirements for, 122:1677

Nutrition
advances in (future directions for), 120:1319-gn
in critical care, 117:1500-ss
gastroenterologists' interest in, 123:967-ce
gastroenterologist training in, 124:1085-aga
in infants, 122:241-pmr
oral, 122:1677
pediatric, book on, 123:2155-pmr
postoperative, enteral versus parenteral, for gastrointestinal cancer patients, 122:1536-ss
preoperative, with specialized supplementation, in gastrointestinal cancer patients, 122:1763
in short-bowel syndrome, GLP-2 administration and, 120:783-tmig, 120:806, 120:1041-e

Nutritional support, 122:1677
in clinical practice, 123:1744-pmr
enteral, principles of, 122:1677
in ICU, 119:592-ss
metabolic principles of, 122:1677
for mineral deficiencies, 122:1677
oral, 122:1677
parenteral, principles of, 122:1677

Obesity
AGA medical position statement on, 123:879-aga
AGA technical review on, 123:882-aga

bariatric surgery for, 123:879-aga, 123:882-aga
cancer risk in, 123:882-aga
carbohydrate restriction and, 125:650-gn
child and adolescent, 125:1908-pmr
and cirrhosis, 125:1053
classification of, 120:669
and colon cancer, biological basis of (humans, mice), 121:79
comorbidities in, 120:669
definition of, 123:882-aga
environmental factors and, 123:882-aga
ethanol binge and liver injury in (rat), 125:1818
gastroenterologists' interest in, 123:967-ce
genetics of, 123:882-aga
ghrelin and, 125:1492-srr
and insulin resistance, in pancreatic carcinogenesis, 120:1072-tmig, 120:1263, 120:1291-e
intestinal bypass for, rheumatic and cutaneous sequelae of, 124:1595
intestinal ethanol production in, and fatty liver (mice), 119: 1186-tmig, 119:1340, 119:1399-e
leptin signaling and, 124:1546-ss
liver fibrosis in, 118:996-tmig, 118:1117
predictors of, 121:91
medical complications of, 123:882-aga
mesenteric, in Crohn's disease, 117:2-tmig, 117:72
morbid, nonalcoholic fatty liver disease in, 123:1705-aga
and nonalcoholic fatty liver disease, 122:1649, 123:1705-aga
nonalcoholic steatohepatitis in, 123:1705-aga
predictors of, 121:91
pathogenesis of, 123:882-aga
pharmacotherapy for, 116:1287-rc, 116:1487-e, 123:879-aga, 123:882-aga
prevalence of, 123:882-aga
research on, advances in (future directions for), 123:882-aga
treatment of, 123:879-aga, 123:882-aga
advances in (future directions for), 120:1319-gn, 123:882-aga
behavior modification in, 123:879-aga, 123:882-aga
dietary intervention in, 123:879-aga, 123:882-aga
drugs for, 116:511-gn
exercise in, 123:879-aga, 123:882-aga
GI hormones for, 124:877-gn
guidelines for, 123:882-aga
medical, 120:669
pancreatic polypeptide in (mice), 124:1325, 124:1542-e
surgical, 120:669
weight management after, 123:882-aga
weight loss in, health benefits of, 123:882-aga

Obstetrics. *See also* **Pregnancy**
hepatitis C and, 120:1555-ss
perianal Crohn's disease and, 125:1503-aga, 125:1508-aga

Obstructive sleep apnea, in obesity, 123:882-aga

Octreotide
for acute variceal bleeding, meta-analysis of, 120:946
for chylous ascites in yellow nail syndrome, 116:1017-c
effects on portal hypertension, 120:2-tmig, 120:161, 120:303-e, 120:975
effects on postprandial hemodynamics in cirrhosis, 122:915
gallstones caused by, pathogenesis of, 121:812
for variceal bleeding in cirrhosis, comparison with emergency sclerotherapy, 124:1174-tmig, 124:1277

Oddi, Ruggero, 116:542

Oldfield's syndrome, clinical characteristics of, 124:1595

Olestra, digestibility of, 116:1026-gn

Olsalazine, plasma levels, after single oral dose, 117:1514-c

Omeprazole
acid-inhibitory effect, *H. pylori* status and, 116:233-tmig, 116:239, 116:479-e
and ascorbate/nitrite ratio in gastric juice, 116:813
effect on simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux, 122:1545-c
effects on intragastric pH and plasma gastrin, CYP2C19 polymorphism and, 119:609-tmig, 119:670
for *H. pylori,* 116:248, 116:479-e, 117:746-c
and alteration of intragastric milieu, 119:287-tmig, 119:339, 121:517
high-dose, in noncardiac chest pain, 116:226-c
intravenous, as adjuvant therapy for bleeding peptic ulcers, 119:1428-gn
long-term therapy with
carcinogenic risk with, 121:517
effect on gastric atrophy, 118:239-c, 118:242-c, 118:453-c
efficacy and safety of, 119:1176-c, 119:1177-c
and gastric cancer risk, 119:1176-c
in GERD, efficacy and safety of, 118:649-tmig, 118:661, 118:795-e
lack of effect on gastric atrophy, 117:291-tmig, 117:319
lack of effect on intestinal metaplasia, 117:291-tmig, 117:319
and nonacid GERD, 120:1588
for NSAID gastropathy, 119:521-srr
rebound acid secretion after, 116:233-tmig, 116:239, 116:479-e, 117:513-c
restoration of gastric acid secretion after therapy with, 123:1588
for ulcers with adherent clots, 125:276-c
and ultrastructural modifications in reflux esophagitis, 122:837-c

Oncology
clinical, 120:583-pmr
parenteral nutrition in, 121:966-aga, 121:970-aga

Ondansetron, for bulimia nervosa, 119:271-ss

Onercept, for inflammatory bowel disease, 122:1592

Opiate antagonists, for cholestasis, pain with, 125:591-cr

Opiates, for postinfectious irritable bowel syndrome, 124:1662

Opioid agonist, and perception of colonic distention in irritable bowel syndrome, 116:1-tmig, 116:38

κ-Opioid receptor agonists, and visceral pain, 117:292-tmig, 117:388

Opioids, and gallbladder motility (guinea pig), 122:340

Opioid withdrawal-like reaction
precipitated by naloxone, in primary biliary cirrhosis, 121:743-c
precipitated by naltrexone, in chronic cholestasis, 118:431-cr

Optical coherence tomography, 120:749
in diagnosis of specialized intestinal metaplasia, 120:1-tmig, 120:7

Oral contraceptives, and focal nodular hyperplasia of liver, 118:458-tmig, 118:560, 119:280 *correction*

Oral rehydration solutions
characteristics of, 122:1677
improvement of, 119:590-ss
therapy with, 122:1677

Oral tolerance, induction of, 118:2-tmig, 118:128

Orexin, and gut-brain signaling (human, rat), 124:129

Organic anion transporters
hepatic basolateral and canalicular, differential expression during hepatic regeneration (rat), 117:1266-tmig, 117:1408

human hepatocyte-specific, encoded by SLC21A8 gene, 122:1545-c
rlst-1, molecular characterization and functional regulation of (rat), 117:770-rc
Organic anion-transporting polypeptides
expression cloning and functional tests of, 120:1887-c
Oatp2, hepatic localization and function of (rat), 117:688
OATP8 (human), gene promoter, regulation by farnesoid X receptor, 122:1954
Oatp4 (rat) and OATP8 (human), hepatic uptake of CCK-8 by, 121:1185
OATP-B, functional comparison with other OATPs of human liver, 120:525
Organ transplantation. *See also* Kidney transplantation; Liver transplantation; Intestinal transplantation
abdominal, ultrasound of, 124:1556-pmr
book on, 124:580-pmr
liver-intestine, 124:1615
multivisceral, 124:1615
Orlistat
adverse effects and side effects of, 123:882-aga
concerns about safety and efficacy of, 117:4-gn
for obesity, 120:669, 123:879-aga, 123:882-aga, 124:877-gn
Ormond's disease, 116:1028-im
Orocecal transit time, tegaserod and, in constipation-predominant IBS, 118:463
Orphanin FQ
and colonic purinergic pathway (rat), 119:890-tmig, 119:1054
and colonic transit (rat), 119:1-tmig, 119:71
in gastrointestinal motility (rat), 116:2-tmig, 116:108
Orphan nuclear receptors
and cholesterol and bile acid metabolism, 120:1054-ss
shp, bile acid-activated induction of, and negative feedback regulation of *ntcp* bile acid transporter (rat), 121:140, 121:218-e
Orphan receptors, in studies of motility and satiety, 117:524-gn
Osteoarthritis
in obesity, 123:882-aga
treatment, effects on gastroduodenal mucosa, 117:776, 117:1002-e, 118:638-c, 118:639-c, 118:640-c
Osteomalacia, in chronic liver disease, 125:941-aga
Osteoporosis
bisphosphonates for, gastroesophageal effects of, 119:609-tmig, 119:631, 119:866-e
in celiac disease, population-based study of, 125:429
in Crohn's disease, and fracture risk, population-based study of, 123:468
in gastrointestinal diseases
AGA medical position statement on, 124:791-aga
AGA technical review on, 124:795-aga
in hepatic disorders, AGA medical position statement on, 125:936-aga
in inflammatory bowel disease, 119:1203, 121:504-c, 125:1591
in liver disease, AGA technical review on, 125:941-aga
pathophysiology of, 124:795-aga
in primary biliary cirrhosis, vitamin D receptor genotype as predictor of, 118:145, 119:599-c, 119:1805-c
treatment of, 124:795-aga
Ostomy, guide for patient with, 123:952-pmr
Outcomes, in surgical disease, 119:273-pmr
Ovalbumin, targeting to late endosomes of enterocytes, in induction of oral tolerance, 118:2-tmig, 118:128
Overweight. *See also* Obesity
and elevated alanine aminotransferase activity, 124:71, 124:248-e
treatment of, guidelines for, 123:882-aga
Oxidants
in alcohol-induced liver disease, 124:778-srr
and Cl^- secretion in intestinal epithelial T84 cells, 120:2-tmig, 120:89
generation in colonic inflammation, poly-(ADP-ribose) synthetase and (mice), 116:233-tmig, 116:335
Oxidative drug metabolism, in cirrhosis, 116:915, 117:1025-c
Oxidative stress
in alcohol-induced liver disease, 124:778-srr
carcinogenesis caused by, dietary antioxidants and, 123:985
and digestive disease, 125:1279-pmr
ethanol-induced mitochondrial dysfunction and, 122:2049-srr
hepatitis C virus core protein-induced, 122:366, 122:568-e
and inducible NOS expression in hepatocytes (rat), 118:608
on intestinal epithelial barrier, protection against
by heat-shock protein 72, 117:115
IL-11-induced hsp25 expression and, 124:1358
modulation of membrane sodium permeability and cell volume recovery in hepatoma cells (rat), 118:395
NF-κB activation by, and contractility of colonic circular smooth muscle cells (dog), 124:1369
and pathogenesis of nonalcoholic steatohepatitis, 120:1183, 120:1281-e
Oxidoreductases, in iron disorders, 125:746
Oxygen supplementation
effects on oxidative drug metabolism in cirrhosis, 116:915
hepatic, in cirrhosis, 117:1025-c
Oxyntic atrophy, reversible drug-induced (rat), 118:1080
Oxysterols, in biliary tract disease, 121:118, 121:216-e

$p38^{MAPK}$, in regulation of proteolysis by hepatocyte hydration, 116:921
Pacemakers, intestinal
nonneural, organization of (rat), 119:386
organization of, 120:319-c, 121:742-c
Pain. *See also* Pelvic pain; Visceral pain
abdominal, in sphincter of Oddi dysfunction type III, 116:900, 116:996-e
in alcoholic chronic pancreatitis, 116:1023-tmig, 116:1132, 116:1252-e, 117:1026-c, 118:235-c
with opiate antagonist therapy in cholestasis, 125:591-cr
perception, gender differences in, 123:1686-srr
postcholecystectomy, pathophysiology of, 116:900, 116:996-e
Pain sensitivity, of brain-gut axis, in irritable bowel syndrome, 118:815-tmig, 118:842, 118:972-e, 119:1418-c
pANCA. *See* Antineutrophil cytoplasmic antibody (ANCA), perinuclear
Pancreas
acinar cells
apoptosis, and severity of acute pancreatitis (mice), 124:481
bile- and calcium-dependent cell death in (rat), 122:1941
calcium waves in, inositol triphosphate receptor and ryanodine receptor activation and (rat), 122:415
CCK2/gastrin receptor expression and (transgenic mice), 122:428
digestive enzyme secretion by, apical actin and, 120:1818

dysfunction in cystic fibrosis, 121:752-tmig, 121:950
ethanol and (rat), 122:106
lack of functional responses to cholecystokinin and gastrin (humans), 121:1380
acini
F-actin in, serine protease inhibitors and, 124:583-c
inositol trisphosphate receptor down-regulation in (rat), 116:1194
Rab4 and regulated exocytosis in (rat), 116:943
alcoholic fibrogenesis in, stellate cells in (rat), 118:650-tmig, 118:780
amphiregulin overexpression in, and proliferation of pancreatic duct cells (transgenic mice), 122:1898
ampullary tumors of, endoscopic ultrasound of, 122:1631
bicarbonate secretion, role of CFTR and sodium-bicarbonate cotransporter, 117:275-ss
CCK receptor distribution in, 125:98
chemokine expression in, 118:356
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
cystic neoplasms of, 125:988-pmr
development of, 116:702-srr
digestive enzyme protein synthesis, regulation by CCK (rat), 119:1731
diseases of, textbook on, 116:776-pmr
duct cells
mitogenic response to amphiregulin overexpression (transgenic mice), 122:1898
response to FGFR-1 IIIc (hamster), 123:301
duct-like cells
gastrin/CCK B receptor expression in (rat), 121:940
mitogenic effects of gastrin in (rat), 121:940
epithelium of, water transport by, 122:545-srr
exocrine, development of, retinoids in (mice), 123:1331
extracellular matrix protein content, fatty acid ethyl esters and (rat), 125:1845
fibrosis
attenuation by ACE inhibitor, in male Wistar Bonn/Kobori rats, 124:1010
heparin-binding EGF-like growth factor and (mice), 124:1020
gastrin and (mice), 125:1164
inflammation of, attenuation by ACE inhibitor, in male Wistar Bonn/Kobori rats, 124:1010
intraductal papillary-mucinous tumor of, 123:406-im
aberrant DNA methylation in, 123:365
diagnosis of, 122:34
management of, 122:34
recurrence after surgical resection, 123:1500
intraepithelial neoplasms of
MUC5AC and MUC6 gastric mucin expression in, 123:1052
progression of, genetic abnormalities and, 123:645-ss
sialyl Tn expression in, 123:1052
pathology of, 125:1553-pmr
Pdx1-expressing epithelium, expansion of, TGF-α overexpression and (mice), 117:1416
phenotype, transgenic reexpression of KOC and (mice), 124:1901
secretion, luminal factor-stimulated, serotonin and (rat), 118:1197
structural imaging of, in diagnosis of pancreatitis, 120:682
tumors, progression, promotion by t-PA, 122:806-vidd
in von Hippel-Lindau disease, 119:1087
Pancreas divisum, endoscopic ultrasound of, 122:1631
Pancreatic amylase, secretion, regulation of, kinesin in (rat), 119:1123
Pancreatic bladder, 4-im
Pancreatic cancer
antiapoptotic signaling by Stat3 and NF-κB in, 123:2052
association with obesity and insulin resistance, 120:1072-tmig, 120:1263, 120:1291-e
autocrine/paracrine mitogenic loop in, 119: 1186-tmig, 119:1358
biglycan and, 121:657
bone morphogenetic protein 2 expression in, 116:1202
book on, 125:1552-pmr
CCK2/gastrin receptor expression and (transgenic mice), 122:428
CCK receptor distribution in, 125:98
cell lines, G1-arrest in, biglycan and, 121:657
diabetes of, 121:640
diagnosis of, 121:640
AGA medical position statement on, 117:1463-aga
AGA technical review on, 117:1464-aga
dual-specificity phosphatase MKP-1 in, 124:1830
endoscopic ultrasound in, 122:1631
epidemiology of
AGA medical position statement on, 117:1463-aga
AGA technical review on, 117:1464-aga
extracellular matrix proteins and, 125:1188
familial, risk factors for, 124:1292
FDG positron emission tomography in, 125:1235-srr
FGFR-1 IIIc in, 123:301
of head of pancreas, extended lymphadenectomy for, 116:1499-ss
hepatic metastases of, effect of statins on, 122:253-tmig, 122:308, 122:565-e
hereditary, 122:796-cr
as incidental finding, 124:1958-srr
induction of, prevention of, by metformin (hamster), 120:1072-tmig, 120:1263, 120:1291-e
invasiveness, statins and, 123:1747-c
islet amyloid polypeptide in, 121:640
with Ki-*ras* mutations, Ha-Ras activation by TGF-α in, 116:1441
malignant phenotype in, activated STAT3 and, 125:649-tmig, 125:891
metastases, statins and, 123:1747-c
$p120^{ctn}$ in, 124:949
preneoplastic lesions and, 123:645-ss, 124:1958-srr
progression of, "catastrophic hypothesis" for, 124:1958-srr
risk of
in celiac disease, 123:1428, 123:1726-e
UGT1A7 gene polymorphisms and, 124:1802
SST2 gene polymorphism and, 120:200
treatment of
AGA medical position statement on, 117:1463-aga
AGA technical review on, 117:1464-aga
claudin-4 as target for, 121:512-tmig, 121:678
infectivity-enhanced COX2 promoter-based conditional replicative adenovirus for, 125:1006-tmig, 125:1203
VEGF and VEGF receptors in, 119: 1186-tmig, 119:1358
Pancreatic cancer-prone families, genetic counseling and testing for *p16* mutations in, 119:1756-cr
Pancreatic cysts, endoscopic ultrasound of, 122:1631
Pancreatic disease
gastroenterologist training in, 124:1067-aga

heparin-binding EGF-like growth factor and (mice), 124:1020
UGT1A7 gene polymorphisms in, 124:1802
Pancreatic insufficiency, nutrient absorption in, effect of bacterial or porcine lipase and diet on (dog), 116:431
Pancreatic lipase, human, specific activity of, measurement of, 119:949
Pancreaticobiliary union, anomalous, endoscopic ultrasound of, 122:1631
Pancreatic polypeptide (PP)
as antiobesity treatment (mice), 124:1325, 124:1542-e
overexpression of, and decreased food intake and body weight (mice), 117:1427
in regulation of energy balance, 124:1325, 124:1542-e
Pancreatic secretory trypsin inhibitor, mutations
and chronic pancreatitis, 120:682
in idiopathic chronic pancreatitis, 120:1061-c
Pancreatic stenting, after biliary sphincterotomy for sphincter of Oddi dysfunction, 117:283-c
Pancreatitis
acute
acute respiratory distress syndrome in, matrix metalloproteinase and (rat), 122:2-tmig, 122:188
biliary, endoscopic management of, 125:229
CD40 ligand and (mice), 121:184
COX-2 and (mice), 123:1311
early trypsinogen activation in, 116:770-ss
endoscopic ultrasound in, 122:1631
immunocytes in, 118:458-tmig, 118:573, 118:582, 118:626-e, 119:881-c
initial episode of, evaluation during, 120:708
interferon alfa-associated, 119:230-cr
L-arginine-induced, NGF up-regulation in (rat), 119:1373
parenteral nutrition in, 121:966-aga, 121:970-aga
pathogenesis of
adenosine in, 119:610-tmig, 119:829
TNF-α in, 119:610-tmig, 119:816
peritoneal dialysis-related, 119:1407-ss
protective effect of HSP70 in (rat), 122:2-tmig, 122:156
recurrent, 120:682
causes of, 120:708
inciting factors, identification and elimination of, 120:708
severe, 120:682
MIF in, 124:595-tmig, 124:725, 124:844-e
severity of, connexin and (mice), 124:481
AGA Gastroenterology Teaching Project publication on, 125:991-pmr
alcoholic. *See* **Alcoholic pancreatitis**
autoimmune, 120:682, 121:1518-ss
autoantibodies and Th1/Th2-type cellular immune response in, 118:458-tmig, 118:573, 118:626-e
epidemiology of, 125:1557-c
HLA analysis of, in Japanese population, 122:1264
in Japan, 125:1557-c
bile duct obstruction and, 124:863-c
biliary, risk of, with gallstones, 119:879-c
CCK-8-induced, ethanol diet and (rat), 117:706
cerulein-induced
$CD4^+$ T cells in, 119:881-c
enterokinase in (rat), 118:452-c
ICAM-1 in, 117:748-c
chronic
autoimmune, 120:682
CFTR mutations and, 121:1310, 121:1509-e
chemokine expression in, 118:356
classification of, 120:682
clinical manifestations of, 120:682
diagnosis of, 120:682, 120:708
endoscopic ultrasound in, 122:1631
epidemiology of, 120:682
etiology of, 120:682
genetic predispositions to, 120:682
idiopathic, 120:682
PTSI gene mutations in, 120:1061-c
immunocytes in, 118:458-tmig, 118:573, 118:582, 118:626-e, 119:881-c
lisinopril and, in male Wistar Bonn/Kobori rats, 124:1010
minimum change, 120:682
obstructive, 120:682
pain patterns in, 116:1023-tmig, 116:1132, 116:1252-e, 117:1026-c, 118:235-c
risk factors for, 120:682
risk of, UGT1A7 gene polymorphisms and, 124:1802
risk of diabetes mellitus in, 119:1186-tmig, 119:1324
SPINK1 mutations in, 120:1060-c
staging of, 120:682
surgical pain relief in, 116:1023-tmig, 116:1132, 116:1252-e, 117:1026-c, 118:235-c
tropical, 120:682
trypsin activation in, 119:288-tmig, 119:461
trypsin inhibitor gene *(PSTI)* mutations and, 121:1310, 121:1509-e
trypsinogen mutations in, 117:1-tmig, 117:7-rc, 117:1508-c, 117:1509-c, 119:277-c
in cystic fibrosis, genotype and phenotype correlations in, 123:1857, 125:1286-c
experimental, $CD4^+$ T cells in (mice), 118:458-tmig, 118:582, 118:626-e, 119:881-c
gallstone, endoscopic management of, 125:229
intercellular adhesion molecule-1 and neutropenia in, 116:510-tmig, 116:694
lung injury associated with, COX-2 and (mice), 123:1311
necrotizing, interstitial trypsinogen and (rat), 117:717, 118:452-c
NF-κB/Rel in, 118:1208-srr
nuclear factor κB in (rat), 122:438
in obesity, 123:882-aga
pathogenesis of, immune responses in, 118:458-tmig, 118:573, 118:582, 118:626-e, 119:881-c
pathologic activation of digestive enzymes in, neutrophils and (mice), 122:973, 122:1166-e
and pericardial effusion, in Behçet's disease, 117:286-c
phases of, 122:1166-e
post-ERCP
interleukin 10 and, 121:232-c, 121:233-c
prevention of
by diclofenac, 124:1722-tmig, 124:1786, 124:1977-e
by IL-10, 120:332-tmig, 120:498
by pancreatic duct stenting, 125:1274-ss
by secretin (abstract), 125:605-aga
protection against, by water immersion stress and induction of Hsp60 expression (rat), 119:220, 121:744-c
reduced CFTR-mediated ion transport in, 121:1310, 121:1509-e
secretagogue-induced, NF-κB/Rel activation in, 116:420, 116:489-e
severity of, determinants of, 122:1166-e
skin lesions in, 124:1595
SPINK1/PST1 polymorphisms as disease modifiers in, 119:615-rc

tropical calcific, *SPINK1* trypsin inhibitor mutations and, 123:1020, 123:1026
ventral (epigastric) hernia and, 124:865-c
Pancreatitis-associated protein I, activation, and TNF-α-triggered antiapoptotic mechanisms in pancreatic cells (rat), 119:816
Pancreatoscopy, peroral, of intraductal papillary-mucinous tumor, 122:34
Paneth cells, NOD2/CARD15 gene expression in, 125:1-tmig, 125:47
Pantoprazole
efficacy of, *Helicobacter pylori* and, 117:1-tmig, 117:11
intravenous, in Zollinger-Ellison syndrome, efficacy of, 118:649-tmig, 118:696
restoration of gastric acid secretion after therapy with, 123:1588
Paracentesis
for ascites, rationale for, 120:726
endoscopic ultrasound guidance for, 122:1631
for refractory ascites, 120:311-ss, 120:726
in cirrhosis, 123:1839
Paramyxovirus infection, in childhood, and subsequent inflammatory bowel disease, 116:783-tmig, 116:796, 116:988-e, 117:1253-c
Parathyroid hormone (PTH), for osteoporosis treatment, 124:795-aga
Parenchymal cells, liver, IFN-γ-induced apoptosis, Kupffer cells and (rat), 116:666
Parenteral nutrition
advances in (future directions for), 121:970-aga
AGA medical position statement on, 121:966-aga
AGA technical review on, 121:970-aga
central, 122:1677
complications of, 122:1677
clinical use of, 121:970-aga
complications of, 121:970-aga
dependence, in short bowel syndrome, 117:1037-tmig, 117:1043
enterocyte apoptosis with (mice), 125:1273-ss
failure of, 124:1615
formulas for, 121:970-aga
home, 121:966-aga, 121:970-aga
complications of, 124:1111-aga
infectious, 124:1651
management of, 124:1651
mechanical, 124:1651
metabolic, 124:1651
financial considerations in, 124:1111-aga
low-dose growth hormone in, 124:293, 124:561-e
psychosocial issues with, 124:1651
and quality of life, 124:1111-aga
indications for, 121:966-aga, 121:970-aga
initiation of, 121:970-aga
long-term
complications of, 124:1105-aga, 124:1111-aga
infection risk with, 116:1495-ss
meta-analysis of, 121:970-aga
monitoring in, 121:970-aga
nutrient requirements in, 121:970-aga
postoperative, versus enteral nutrition, for gastrointestinal cancer patients, 122:1536-ss
principles of, 122:1677
randomized controlled trials of, 121:970-aga
recommendations for, 121:966-aga, 121:970-aga
in short-bowel syndrome, 124:1105-aga, 124:1111-aga
solutions for, 122:1677
venous access for, 121:970-aga
Parietal cells
H^+,K^+-ATPase β subunit and (mice), 117:605
in hypochlorhydria-associated inflammation (mice), 122:119
reversible drug-induced oxyntic atrophy of (rat), 118:1080
VAMP-2 in, 123:281
Parkinsonism, in cirrhotic patients, correlation with basal ganglia alteration detected on MRI and MRS, 119:774
Paroxetine, for irritable bowel syndrome, 124:303, 125:1554-c
Partial external biliary diversion (PEBD)
in Alagille syndrome, 124:1155-ss
in progressive familial intrahepatic cholestasis, 125:1227-cr
Paterson-Brown-Kelly-Plummer-Vinson syndrome, skin signs of, 124:1595
Pathology
gastrointestinal, gastroenterologist training in, 124:1088-aga
hepatic, gastroenterologist training in, 124:1088-aga
Pathophysiology
gastrointestinal, 118:636-pmr
hepatobiliary, 118:636-pmr
Patient-physician relationship, 121:1037-ce
Patients' bill of rights, 121:514-gn
PD 184352, inhibition of colon cancer growth, 117:523-gn
Pdx1 gene expression, in normal and metaplastic pancreatic epithelium (mice), 117:1416
Pectin, in management of persistent diarrhea in children, 121:554
Pediatric Crohn's Disease Activity Index (PCDAI), and assessment of activity in pediatric Crohn's disease, 116:509-tmig, 116:527
Pediatric gastroenterology
advances in, 123:3-gn
book on, 123:2155-pmr
gastroenterologist training in, 124:1088-aga
Pediatrics
acute diarrhea in, management of, 120:783-tmig, 120:799
celiac disease in
cytokines in intestinal T cells in, 123:667, 125:1560-c
gluten-specific T-cell responses in, 122:1729, 122:2072-e
congenital central hypoventilation syndrome in, esophageal dysmotility and, 122:1258
eosinophilic esophagitis in, 122:1216
esophageal stenosis in, dystrophic epidermolysis bullosa and, 122:220-cr
gastroesophageal reflux disease in, extra-esophageal associations in, in children without neurological deficits, 121:1294
gastrointestinal disease in, book on, 121:739-pmr
H. pylori infection in
antibiotics for, 122:1189-c
transmission of, 122:1189-c, 122:2091-c
H. pylori transmission in, 121:239-tmig, 121:310, 121:483-e
hepatitis B in, lamivudine for, 123:1741-ss
hepatitis C in, 123:2082
inflammatory bowel disease treatment in, 119:889-tmig, 119:895, 119:1158-e
irritable bowel syndrome in, 120:1-tmig, 120:31, 120:287-e
liver disease in, 121:1523-pmr
nonalcoholic fatty liver disease in, 123:1705-aga
nutrition in, 122:241-pmr
parenteral nutrition in, 121:966-aga, 121:970-aga

pathophysiology, diagnosis, and management of gastrointestinal disease in, 119:273-pmr
persistent diarrhea in, treatment of, green bananas and pectin in, 121:554
protein-energy malnutrition in, 122:1677

Pelvic floor dyssynergia
diagnostic criteria for, 122:1701
differential diagnosis of, 122:1701

Pelvic pain, chronic, comorbidity with irritable bowel syndrome, 122:1139-srr

Penrose, Charles Bingham, 122:1215

Pentoxifylline
and acute alcoholic hepatitis, 119:1426-tmig, 119:1637, 119:1787-e
in protection against hepatic ischemic injury, 125:917-srr

Pepsinogen, and CagA-positive *H. pylori* infection, in gastric cancer, 116:269

Peptic ulcer disease
bleeding
heater probe plus thrombin versus heater probe plus placebo for, 125:396
intravenous omeprazole as adjuvant therapy for, 119:1428-gn
management of, hemoclips versus heater probe for, 123:1399-ss
in NSAID users with *H. pylori* infection, 116:1281-tmig, 116:1305, 118:451-c
economic and social costs of, in United States, 122:1500-srr
epidemiology of, 116:1217-vodd
H. pylori-associated, pathogenesis of, 124:1846, 124:1983-e
NSAID-associated
H. pylori elimination and, 122:238-ss
with *H. pylori* infection, bleeding in, 116:1281-tmig, 116:1305
neutrophils and *H. pylori* status and, 116:254
ulcers with adherent clots in, medical or endoscopic therapy for, 123:407, 123:632-e, 125:276-c

Peptide transporter PepT1, dietary regulation of (rat), 116:354

Peptidoglycan, response to, NOD2 variants and, 124:2-tmig, 124:140

Percutaneous endoscopic gastrostomy, in amyotrophic lateral sclerosis, botulinum toxin for masseter muscle spasticity and, 123:1749-c

Percutaneous transluminal mesenteric angioplasty, for chronic mesenteric ischemia, 118:954

Perianal fistulas, in Crohn's disease, imaging of, 121:1064

Pericardial effusion, and pancreatitis, in Behçet's disease, 117:286-c

Perioperative period, parenteral nutrition in, 121:966-aga, 121:970-aga

Peripheral lymph node addressin (PNAd), in lymphocyte trafficking, 121:853, 121:1008-e

Peristalsis
esophageal, CNS nitric oxide in, 119:287-tmig, 119:377
intestinal, regulation of, by endothelin (guinea pig), 119:1-tmig, 119:80
in small intestine, propagation and neural regulation of calcium waves in (guinea pig), 118:892

Peritoneal dialysis, acute pancreatitis caused by, 119:1407-ss

Peritonitis, spontaneous bacterial, community-acquired, risk of, 117:292-tmig, 117:414, 117:495-e

Pernicious anemia, hyperhomocysteinemia related to, and mesenteric venous thrombosis, 118:237-c

Peroxisome proliferator-activated receptor(s) (PPAR)
ligands, antineoplastic and anti-inflammatory effects of, 121:1019-ss
PPAR-α, and metabolic response to fasting (mice), 124:160, 124:254-e
PPAR-β, and stellate cell proliferation, 124:184
PPAR-γ
activation in hepatic stellate cells, and inhibition of hepatic fibrosis by thiazolidinediones (rat), 122:1924
and anti-inflammatory activity in ischemia-reperfusion injury (mice), 120:332-tmig, 120:460
APC-dependent suppression of colon carcinogenesis, 125:619-ss
in Crohn's disease, 117:2-tmig, 117:73
drugs activating, anti-inflammatory effects of, 117:1039-gn
gene expression
impairment of, in ulcerative colitis, 124:1174-tmig, 124:1265, 124:1538-e
intestinal flora and, 124:1174-tmig, 124:1265, 124:1538-e
gene therapy, for IBD (mice), 124:1315, 124:1538-e
ligands, suppression of colon carcinogenesis (mice), 124:281-tmig, 124:361, 124:564-e
and profibrogenic and proinflammatory actions in hepatic stellate cells, 119:288-tmig, 119:466
therapeutic potential in colitis, 118:228-ss

Peroxynitrite, and regulation of NF-κB activity during sepsis, 124:118

Peutz-Jeghers syndrome
cancer risk in, 119:1425-tmig, 119:1447
clinical characteristics of, 124:1574, 124:1595
genetic testing for, 119:837-srr, 124:1574
skin signs of, 124:1595

Peyer's patches, abnormal, in NF-κB and Bcl-3-deficient mice, 122:1853

Pfeffer's closed duodenal loop model, first seen in human, 124:865-c

***p14* gene,** methylation, in colorectal cancer, 124:626

***p16* gene**
inactivation, by methylation of CDKN2A promoter, during neoplastic progression in Barrett's esophagus, 122:1112
methylation in colonic adenomas and cancers, and association with K-*ras* mutations, 116:1063
mutations, genetic testing for, in pancreatic cancer-prone families, 119:1756-cr
promoter methylation pattern of, in sporadic MSI colorectal cancer, 124:1165-c

***p21* gene**
expression, in polyamine-deficient intestinal epithelial cells, JunD and, 123:764
and progression of pancreatic intraepithelial neoplasia, 123:645-ss

***p53* gene**
and hepatocarcinogenesis, 120:1763
mutations
and gastric cancer, 118:995-tmig, 118:1039
in hepatocellular carcinoma, 117:154
and intestinal tumorigenesis (mice), 123:492
overexpression, in hyperplastic polyposis, 119:323
and progression of pancreatic intraepithelial neoplasia, 123:645-ss
strand breaks, folate and, in colon (rat), 119:1-tmig, 119:151
in ulcerative colitis, and cancer, 120:1877-ss

PG-I. *See* Biglycan
P-glycoprotein, expression, chargrilled meat diet and, 117:89
P-glycoprotein 170, expression of, in inflammatory bowel disease, and response to glucocorticoid therapy, 118:247-tmig, 118:279
pH, intragastric, long-term use of omeprazole and, 121:517
Phagocytes, CD18-expressing, in extraintestinal dissemination of *S. typhimurium,* 118:803-ss
Pharmacogenetics, and clinical gastroenterology, 125:240-srr
Pharmacotherapy, for gastrointestinal bleeding, 118:201-aga
Pharmacy benefit managers, use of medication precertification criteria, 121:965-aga
Phentermine
adverse effects and side effects of, 123:882-aga
in obesity treatment, 123:882-aga
Phenylephrine, for fecal incontinence, 124:1672
Pheochromocytoma, radiologic appearance of, 120:6-im
Phosphatidylinositol 3-kinase
bile acid-activated pathway, inhibition of Fas-mediated apoptosis in rodent hepatocytes, 120:1810
and HT29 and Caco-2 intestinal cell differentiation, 120:1317-tmig, 120:1381, 120:1543-e
and TNF-α-induced COX-2 expression in colonic epithelial cells, 120:1117
Phosphodiesterase inhibitor, and CFTR activation, effects on chloride secretion from homozygous ΔF508 murine intestines, 116:1379
Phospholipase A_2 (PLA_2)
and cholesterol absorption (mice), 120:1193
cytoplasmic, glucocorticoid-dependent inhibition of (rat), 116:8565
expression and activation of, colonic inflammation and, 119:1-tmig, 119:62
expression in intestinal epithelial cells, glucocorticoid-dependent inhibition of (rat), 116:783-e, 116:855
group I secreted, in maintenance of human LES tone, 119:1243
Phospholipids, biliary
and hepatocellular integrity, 118:1179, 118:1265-e
in intestinal fat absorption, in *Mdr2*$^{-/-}$ mice, 118:173, 118:225-e
in maintenance of mucosal barrier (rat), 118:1179, 118:1265-e
Phosphorus, deficiency of, treatment of, 122:1677
Photodynamic diagnosis, 120:749
Photodynamic therapy
for Barrett's esophagus, 120:785-gn, 122:1569
persistent genetic abnormalities after, 119:624-rc, 120:1064-c, 120:1065-c
for cholangiocarcinoma, 125:1295-tmig, 125:1355, 125:1536-e
Physical examination, in anorectal disorders, AGA technical review on, 116:735-aga
Physician-patient relationship, 121:1037-ce
Physician-scientist
future of, 125:652-ce
importance of, and prospects for, 117:5-ce
Phytosterols, in sitosterolemia, ABC transporter mutations and, 121:1255-ss
Pioglitazone, suppression of colon carcinogenesis (mice), 124:281-tmig, 124:361, 124:564-e
Piroxicam, gastrointestinal events related to, risk of, 120:594
Pituitary adenylate cyclase-activating polypeptide (PACAP), effects on gastric enterochromaffin-like cell proliferation (rat), 116:623
$p27^{Kip1}$, in human intestinal cell differentiation, 120:423
Placebo effect, 121:1253-ss
Placebo therapy, efficacy of, 121:1253-ss
Plasminogen activator inhibitor-2, expression, gastrin-regulated, 123:271
Platelet-activating factor, and ICAM-1, in cerulein-induced pancreatitis, 117:748-c
Platelet-derived growth factor, and Na^+/H^+ exchange, in hepatic stellate cells (rat), 116:1024-tmig, 116:1155
Platelet-derived growth factor-alpha (PDGFRA), mutations, in gastrointestinal stromal tumors, 124:596-gn
Platelet-derived growth factor receptor α (PDGFRA), gain-of-function mutations, in gastrointestinal stromal tumors, 125:660-rc, 125:967-e
Platelet glycoprotein Ib, *Helicobacter pylori* and, 124:1846, 124:1983-e
Platelets
effects of *Helicobacter pylori* on, 124:1846, 124:1983-e
and mucosal inflammation in IBD, 124:1249
sinusoidal endothelial cell apoptosis induced by, after reperfusion of liver graft (rat), 118:183
Plummer, Henry S., 117:1526
Pneumatosis intestinalis, 116:6-im
computed tomography of, 119:6-im
Pneumobilia, 116:238-im
Pneumocolon, CT, 121:221-ss
Pneumonia, and gastroesophageal reflux disease, in children without neurological deficits, 121:1294
Podolsky, Daniel K., president of American Gastroenterological Association, 124:1524-aga, 124:1724-gn
Politics and publishing
Bush administration and gastroenterology, 120:333-gn
FDA seeks to increase access to information on xenotransplantation, gene therapy trials, 120:786-gn
and Medicare regulations, 120:1320-gn
and student loan burden, 120:1320-gn
Polyamine depletion, in intestinal epithelial cells
effects on cell cycle-related proteins and cell growth, 123:764
and JunD gene expression, 123:764
Polyethylene glycol, for constipation, 119:1766-aga
Polymerase chain reaction
pentaplex system, for evaluation of tumor microsatellite instability, 123:1804
real-time detection, for hepatitis C virus genome detection, 116:636, 116:763-e
Polypectomy
for adenoma-like dysplasia-associated lesion or mass (DALM), in ulcerative colitis, 117:1265-tmig, 117:1288, 117:1295, 117:1488-e, 118:1277-c
colonoscopic, in chronic colitis, 118:1277-c
Polyposis. *See also* **Juvenile polyposis; Peutz-Jeghers syndrome; Hereditary mixed polyposis syndrome**
hyperplastic, and colorectal cancer, 123:862-srr
intestinal, prevention of, inhibition of COX-2 in, 122:234-ss
malignant lymphomatous, 121:1530-im
retinal pigment epithelium in, 124:1595
skin signs in, 124:1595

Polyps. *See also* Familial adenomatous polyposis (FAP); Hyperplastic polyposis
adenomatous, and recommendations for cancer screening, 124:544-aga
admixed hyperplastic-adenomatous, in hyperplastic polyposis, 119:323
book on, 124:266-pmr
colonic
in Beckwith-Wiedemann syndrome, 118:637-c
detection of, magnetic resonance colonography for, 119:287-tmig, 119:300
colorectal
chemoprevention of, NSAIDs in, 125:285-tmig, 125:328, 125:404
detection of, CT colonography for, 125:311, 125:608-e
serrated, 123:862-srr
transition to colorectal carcinoma, *APC* gene I1307K mutation and, 120:331-tmig, 120:392
gastric fundal, clinical management of, 125:1462
giant fibrovascular, 124:8-im
Polysaccharides, competitive blockage of *H. pylori* urease adherence to mucin and lipopolysaccharides, 119:287-tmig, 119:358
Poly(ADP-ribose) synthetase, in colitis (mice), 116:233-tmig, 116:335
Porcelain gallbladder, 117:760-im
Portal hypertension
and acute variceal bleeding, 117:522-tmig, 117:626
Akt signaling in (rat), 125:522
angiotensin receptor antagonists in, 122:1543-c
in cirrhosis, 122:1538-ss
angiotensin II receptor antagonists for, 121:240-tmig, 121:382, 121:389, 121:487-e
hepatic paracrine endothelin system and, 116:161
complications of, current management of, 120:726
effects of octreotide on, 120:2-tmig, 120:161, 120:303-e, 120:975
endoscopic ultrasound in, 122:1631
and eNOS up-regulation in mesenteric artery (rat), 125:1452
gastric mucosal lesions in, TIPS for, 118:816-tmig, 118:905
intrahepatic, vasoactive agents in, 118:996-tmig, 118:1149, 118:1261-e
NOS isoforms and (mice), 124:1500
protein kinase C isoforms and aortic hyporeactivity in (rat), 119:2-tmig, 119:201
superior mesenteric arteriovenous fistula and, 125:653-im
and systemic hemodynamics, 122:1658
systemic vasodilation of, aortic eNOS in (rat), 119:2-tmig, 119:196
treatment of
advance in, 118:802-ss
angiotensin II blockade in, 117:740-ss
medical, 124:1993-ss
vascular complications of, 117:6-im
Portal hypertensive gastropathy
in cirrhosis, natural history of, 119:181
nitric oxide in, 119:512-srr
TIPS for, 124:1700
Portal pressure
during acute variceal bleeding, prognostic significance of, 121:110
postprandial increase in, effects of long-term octreotide and propranolol on, 122:915
Portal-systemic shunting, and manganese deposition in brain, 117:640
Portal thrombosis, causes of, 119:874-ss
Portal vein
endothelium-free, adrenergic responsiveness in cirrhosis, 116:387
thrombosis
anticoagulant therapy for, 120:490, 120:578-ss
anticoagulation therapy for, in cirrhotic patient with variceal rebleeding, 122:2095-c
in cirrhosis, 123:1409-c
factor II G20210A gene mutation in, 118:237-c
factor V Leiden mutation and, 116:2-tmig, 116:144
increased levels of factor VIII:C as risk factor for, 120:1563-c
prothrombin gene mutation and, 116:2-tmig, 116:144, 116:213-e
Portopulmonary hypertension, with cirrhosis, 125:622-ss
Positron emission tomography
of biliary bicarbonate secretion in humans, 117:167
in biliary tract, 124:1686
F-18 fluorodeoxyglucose, in nonendocrine gastrointestinal neoplasia, 125:1235-srr
Posttraumatic stress disorder, 116:227-c
Potassium, deficiency of, treatment of, 122:1677
Potassium channels, 116:216-ss
calcium-activated
in colonic circular smooth muscle cells, inflammatory modulation of (dog), 116:884
in intestinal smooth muscle, effects of monchloramine on (rabbit), 117:906
in esophageal smooth muscle, inhibition by SNAP-25, 122:993
KCNQ1, in gastric acid secretion, 120:1363
Pouchitis
after pouch-anal anastomosis in ulcerative colitis, IL-1ra allele 2 as predictor of, 121:751-tmig, 121:805
chronic, risk of dysplasia in, 121:268
complications of, 124:1636
Crohn's, 124:1636
definition of, 124:1636
diagnosis of, 121:239-tmig, 121:261, 124:1636
endoscopy in, 121:239-tmig, 121:261
etiology of, 124:1636
frequency of, 124:1636
histology of, 121:239-tmig, 121:261
management of, 124:1636
pouch excision for, 124:1636
predictive factors for, 124:1636
prevention of, probiotics in, 124:1173-tmig, 124:1202, 124:1535-e
probiotic therapy in, 119:287-tmig, 119:305, 119:584-e
treatment of, 124:1636
Pouchitis Activity Score, 124:1636
Pouchitis Disease Activity Index, 121:239-tmig, 121:261, 124:1636
Powell, Don W., presentation of Julius M. Friedenwald Medal to, 120:1854-aga
p38 protein kinase, isoforms, in enterocytic anoikis, 123:1980
Pre-ascites, sympathetic hyperactivity in, 122:1538-ss
Prebiotic agents
applications of, 119:291-ce
for inflammatory bowel disease, 120:622
Prednisone, for Crohn's disease, in children, 119:889-tmig, 119:895, 119:1158-e
Pregnancy. *See also* Obstetrics
cholestasis of, MDR3 mutation and, 124:1037-cr, 125:1922-c
and gallbladder hypomotility (guinea pig), 116:234-tmig, 116:411
gastrointestinal motility in, 123:1686-srr
and irritable bowel syndrome, 123:1686-srr
liver disease in, long-chain hydroxyacyl coenzyme A dehydrogenase (LCHAD) and, 124:1548-ss
6-mercaptopurine therapy in, safety of, 124:1-tmig, 124:9, 125:1562-c
Prenylcysteine carboxymethyltransferase, in early liver formation (mice), 123:345

Preveon. *See* Adefovir dipivoxil
Primary biliary cirrhosis (PBC)
autoreactive T-cell clones in, 125:1379
bone mineral density in, vitamin D receptor genotype as predictor of, 118:145, 119:599-c, 119:1805-c
colchicine for, 117:1038-tmig, 117:1173
combination therapy for, 117:756-tmig, 117:918
epidemiology of, in United States, 119:1425-tmig, 119:1631
fatigue in, 122:1235, 124:582-c
hypercholesterolemia in, 124:854-ss
lipoate autoantibodies in, 125:1705
Markov models in, 123:1750-c
methotrexate for, 117:292-tmig, 117:395, 117:400, 117:492-e, 117:1038-tmig, 117:1173, 117:1511-c
MMP-3 gene promoter variants in, 122:247-c
molecular mimicry of mitochondrial and nuclear autoantigens in, 124:1915
naloxone therapy in, and delayed opioid withdrawal-like reaction, 121:743-c
natural history of, 119:1425-tmig, 119:1631
natural killer T cells in, quantitation and phenotypic analysis of, 123:1031
pediatric-onset, 125:1476-cr
survival in, 123:1044, 123:1392-e
symptom progression in, 123:1044, 123:1392-e
treatment of, 123:1392-e
UDCA-treated patients with, cirrhosis development in, 122:599-tmig, 122:652
Primary care, gastrointestinal disorders seen in, 119:1803-pmr
Primary care providers, gastroenterology and hepatology for, review of, 124:1160-pmr
Primary sclerosing cholangitis (PSC)
atypical p-ANCA antigen in, 119:310
clinical spectrum of, 125:1364
colon cancer in, chemoprevention of, ursodeoxycholic acid in, 124:873-tmig, 124:889, 124:1139-e
high-dose ursodeoxycholic acid therapy in, 121:752-tmig, 121:900
incidence of, 125:1364
MICA polymorphism in, 120:1475
outcomes of, 125:1364
$p16^{INK4a}$ promoter mutations in, and cholangiocarcinoma, 123:1090
as premalignant condition, 123:647-ss
stromelysin gene polymorphism in, 121:124
Primum non nocere, postapproval drug surveillance and, 120:5-ce
Print and Media Reviews
Abdominal Ultrasound, 123:388
Acid Related Disease: Biology and Treatment, 117:743
Acute Gastrointestinal Bleeding. Diagnosis and Treatment, 125:1279
Advanced Therapy of Inflammatory Bowel Disease, 122:585
Advances in Gastrointestinal Endoscopy, 122:242
Advances in Hepatic Encephalopathy & Metabolism in Liver Disease, 121:1257
The American Gastroenterological Association's Gastroenterology Teaching Project: Pathology and Pathophysiology of the Upper Gastrointestinal Tract, 125:987
Artificial Nutrition Support in Clinical Practice. 2nd Edition, 123:1744
Ascites and Renal Disorders in Liver Disease, 117:1023
Atlas of Cystic Neoplasms of the Pancreas, 125:988
Atlas of Gastrointestinal Endoscopy & Endoscopic Biopsies, 120:1304
Atlas of Liver Transplantation, 124:1556
Atlas of the Liver, 120:1304
Atlas of Tumor Pathology: Tumors of the Esophagus and Stomach, 117:508
Atlas of Tumor Pathology: Tumors of the Liver and Intrahepatic Bile Ducts, 122:586
The Basis of Gene Therapy, 121:1258
Bile Acids: From Genomics to Disease and Therapy, 125:1280
Biomedical Research Reports: Hepatitis C, 121:227
A Brief History of Endoscopy, 121:738
Cancer of the Upper Gastrointestinal Tract, 125:987
Cancer Screening: A Practical Guide for Physicians, 125:271
Case Studies in Gastroenterology, 116:501
Challenges in Inflammatory Bowel Disease, 125:269
Child and Adolescent Obesity: Causes and Consequences, Prevention and Management, 125:1908
Cholelithiasis: Causes and Treatment, 116:1010
Chronic Viral Hepatitis Diagnosis and Therapeutics, 125:1278
Clinical and Pediatric Gastroenterology, 116:1269
Clinical Imaging of the Small Intestine, Second Edition, 123:388
Clinical Nutrition of the Essential Trace Elements and Minerals. The Guide for Health Professionals., 122:834
Clinical Practice of ERCP, 117:507
Clinical Practice of Gastroenterology, 116:1009
Colonic Microbiota, Nutrition and Health, 119:1410
Colorectal Cancer in Clinical Practice: Prevention, Early Detection, and Management, 125:1549
Colorectal Cancer—Multimodality Management, 125:1551
Colorectal Disease for Physicians and Surgeons, 116:501
Current Clinical Practice. Diseases of the Liver and Bile Ducts. Diagnosis and Treatment, 116:775
Development of the Gastrointestinal Tract, 120:1883
Diseases of the Gallbladder and Bile Ducts: Diagnosis & Treatment, 122:2089
Diseases of the Gastrointestinal Mucosa. The Acid Related Disorders, 122:1181
Diseases of the Liver and Biliary System, 124:579
Double Contrast Gastrointestinal Radiology, 121:1022
Drug Development: Molecular Targets for GI Disease, 121:498
Drug Therapy for Gastroinetstinal and Liver Diseases, 124:1159
Encyclopedia of Human Nutrition, 117:278
Endoscopic Evaluation and Treatment of Swallowing Disorders, 122:585
Endosonography in Gastroenterology, 118:234
Esophageal Surgery, 125:625
The Esophagogastric Junction, 116:224
Evidence-Based Gastroenterology, 124:861, 124:1996
Evidence Based Gastroenterology and Hepatology, 120:1559
Fast Facts: Irritable Bowel Syndrome, 120:1559
Fast Facts-Coeliac Disease, 119:595
The First Year-Crohn's Disease and Ulcerative Colitis: An Essential Guide for the Newly Diagnosed, 123:953
Fundamentals of Gastrointestinal Radiology, 122:1541
Gastritis, 119:1409
Gastroenteritis Viruses, 123:651
Gastroenterological Endoscopy, 125:270
Gastroenterologyand Hepatology for the Primary Care Provider: Principles, Practice and Guidelines for Referral, 124:1160
Gastroenterology Teaching Project 004: Inflammatory Bowel Disease–Pathology, 125:990
Gastroenterology Teaching Project 005: Irritable Bowel Syndrome, 125:990

Gastroenterology Teaching Project 007: Pancreatitis, 125:991
Gastroenterology Teaching Project 006: Viral Hepatitis, 125:991
Gastroesophageal Reflux Disease, 120:583
Gastrointestinal and Hepatobiliary Pathophysiology, 118:636
Gastrointestinal Disease–An Endoscopic Approach, 125:989
Gastrointestinal Disease in Primary Care, 119:1803
Gastrointestinal Health, 117:1261
Gastrointestinal Imaging: Case Review, 121:228
Gastrointestinal Imaging: Case Review Series, 122:1541
Gastrointestinal Motility, 120:1056
Gastrointestinal Mucosal Repair and Experimental Therapeutics, 124:1159
Gastrointestinal Oncology: Principles and Practice, 124:265
Gastrointestinal Polyps, 124:266
Gastrointestinal Radiology: A Pattern Approach, 124:1557
Gastrointestinal Radiology Companion: Imaging Fundamentals, 117:743
Gut Ecology, 124:1998
Handbook of Gastroenterology, 116:500
Handbook of Liver Disease, 116:500
Healing Heartburn, 124:860
Helicobacter pylori: Molecular and Cellular Biology, 121:740
Helicobacter pylori Handbook, 117:1024
Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment, 119:1409
Hepatitis B and C. Management and Treatment, 122:1181
Hepatitis B and the Prevention of Primary Cancer of the Liver, 124:1997
Hepatitis C Virus, 116:224
Hepatitis C Virus: From Laboratory to Clinic, 124:1996
Hepatobiliary, Splenic & Pancreatic Disease in Children. Medical & Surgical Treatment, 116:775
Hepatobiliary Diseases. Pathophysiology and Imaging, 123:1745
Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd edition, 118:984
A History of Gastroenterology at the Millennium, 121:738
I.B.S. Relief: A Doctor, a Dietitian and a Psychologist Provide a Team Approach to Managing Irritable Bowel Syndrome, 116:1501
Infections of the Gastrointestinal Tract, 125:1550
Inflammatory Bowel Disease: A Clinican's Guide, 124:860
Inflammatory Bowel Disease: A Guide for Patients and Their Families, 116:776
Inflammatory Bowel Disease: Clinical Diagnosis and Management, 120:1057
Inflammatory Bowel Diseases, 118:1276
Inner Hygiene: Constipation and the Pursuit of Health in Modern Society., 120:317
Innervation of the Gastrointestinal Tract, 125:1907
Innovative Concepts in Inflammatory Bowel Disease, 119:876
Intestinal Failure, 123:2154
Irritable Bowel Syndrome, 125:625
Johns Hopkins Manual for Gastrointestinal Endoscopy Nursing, 124:579
Laparoscopic Colorectal Surgery, 118:806
The Liver: Biology and Pathobiology, 4th edition, 125:1909
Liver Disease: Diagnosis and Management, 120:584
Liver Disease in Children, 121:1523
Living with Hepatitis B: A Survivor's Guide, 123:1745
Living with Hepatitis C: A Survivor's Guide, 123:650
Longitudinal Endosonography: Atlas and Manual for Use in the Upper Gastrointestinal Tract, 122:2088
Malignant Liver Tumors: Current and Emerging Therapies, 119:876
Management of Chronic Viral Hepatitis, 123:2154
Medical Imaging in Gastroenterology and Hepatology, 125:626
Merde: Excursions in Scientific, Cultural and Socio-Historical Coprology, 119:1174
Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine, 123:650
Methods in Disease: Investigating the Gastrointestinal Tract, 116:1009
Microlaparoscopy, 121:228
My Mom Has Hepatitis C, 120:1056
Natural Ways to Digestive Health-Interfaces Between Conventional and Alternative Medicine, 121:498
Neoplasms of the Colon, Rectum, and Anus, 119:1803
The New Eating Right for a Bad Gut, 119:876
Nutrition and Women's Cancer, 117:278
Nutrition in the Infant: Problems and Practical Procedures, 122:241
Origins and Directions of Inflammatory Bowel Disease, Early Studies of the "Nonspecific" Inflammatory Bowel Diseases, 124:861
The Oxford Textbook of Clinical Hepatology, 118:449
Oxidative Stress and Digestive Diseases, 125:1279
Pancreatic Cancer, 125:1552
Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment, 116:1268
Pathology of the Gallbladder, Biliary Tracts, and Pancreas, 121:1022
Pathology and Genetics of Tumors of the Digestive System, 121:1258
Pathology of the Pancreas, Gallbladder, Extrahepatic Biliary Tract, and Ampullary Region, 125:1553
Pediatric Gastroenterology and Nutrition in Clinical Practice, 123:2155
Pediatric Gastrointestinal Disease, 121:739
Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis and Management, 119:273
Positive Options for Crohn's Disease, Self-Help and Treatment, 120:317
Positive Options for Living with Your Ostomy: Self-Help and Treatment, 123:952
Practical Gastroenterology: A Comprehensive Guide, 123:389
Practice of Therapeutic Endoscopy, 121:227
Principles and Practice of Surgery for the Colon, Rectum and Anus, 116:1502
Prognosis and Outcomes in Surgical Disease, 119:273
Proteins of Iron Metabolism, 125:1906
Rome II: The Functional Gastrointestinal Disorders, 121:1523
Schiff's Diseases of the Liver, 116:1501
Schuster Atlas of Gastrointestinal Motility in Health and Disease, 125:1906
Selected Topics in Clinical Oncology, 120:583
Shackelford's Surgery of the Alimentary Tract, 5th Edition, 123:951
Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Treatment, 125:1549
Sleisenger & Fordtran's Gastrointestinal and Liver Disease Review and Assessment to Accompany Sleisenger & Fordtran's Gastrointestinal and Liver Disease, 116:1269
Small Bowel Disorders, 121:1257
Stolen Glory: The McKinley Assassination, 124:266
Surgery of the Anus, Rectum and Colon, 119:1173
Surgery of the Liver and Biliary Tract, 121:1524
Surgical Treatment of Familial Polyposis Coli, 118:1275
Textbook of Anal Diseases, 116:1011

Textbook of Bilio-Pancreatic Diseases, 116:776
Textbook of Gastroenterology, 3rd edition, 118:984
Textbook of Gastroenterology Self-Assessment Review, 122:1182
Therapeutic Roles of Selective COX-2 Inhibitors, 122:241
Therapies for Viral Hepatitis, 117:506
Therapy of Digestive Disorders: A Companion to Sleisinger and Fordtran's Gastrointestinal and Liver Disease, 118:1275
The Transplant Patient: Biological, Psychiatric, and Ethical Issues in Organ Transplantation, 124:580
20 Common Problems: Gastroenterology, 122:2088
Ultrasound of Abdominal Transplantation, 124:1556
Undergraduate Teaching Project in Gastroenterology: Liver Disease Teaching Materials, 116:1270
Upper Digestive Surgery: Oesophagus, Stomach and Small Intestine, 119:1173
Upper Gastrointestinal Surgery: A Companion to Specialist Surgical Practice, 122:835
Using and Understanding Medical Statistics, 122:835
Viral Hepatitis, 117:506
Wilson's Disease: A Clinician's Guide to Recognition, Diagnosis, and Management, 122:1542

Prisoners, hepatitis C in, treatment of, 125:1543-ss

Probiotic agents
applications of, 119:291-ce
E. coli as, in ulcerative colitis, 118:630-ss
in inflammatory bowel disease, 116:1107, 116:1246-e, 120:622, 120:1297-ss
and intestinal epithelial function (humans, mice), 121:511-tmig, 121:580
for postinfectious irritable bowel syndrome, 124:1662
for pouchitis, 119:287-tmig, 119:305, 119:584-e, 124:1636
in prevention of pouchitis onset, 124:1173-tmig, 124:1202, 124:1535-e

Proctalgia fugax
definition of, 116:735-aga
differential diagnosis of, 122:1701
tests for diagnosis or management of
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga

Proctitis/proctocolitis of infancy, dietary protein–induced, 120:1026-aga

Proctocolectomy, restorative, surgical strategy in, 123:1403-ss

Progastrin
and colon carcinogenesis (mice), 119:2-tmig, 119:162
stimulation of colonic epithelial mitosis (mice), 124:1348

Prognosis, in surgical disease, 119:273-pmr

Progressive familial intrahepatic cholestasis
hepatocanalicular bile salt export pump deficiency in, 117:1370, 117:1496-e
hepatocyte transplantation and liver repopulation in (mice), 119:1720
mutation in human bile salt exporter pump causes, 116:4-gn
partial external biliary diversion in, 125:1227-cr
type 3, multidrug resistance 3 gene (*MDR3*) defect in, 120:1448, 120:1549-e

Prokinetic agents
and bacterial translocation in cirrhosis, 120:314-ss
for nausea and vomiting, 120:263-aga, 125:1860

Proleukin. *See* Interleukin(s), IL-2

Pro-opiomelanocortin deficiency, mice with, obesity reversal by melanocortin in, 117:1039-gn

Propofol
for advanced upper endoscopy, cost-effectiveness of, 123:8, 123:373-e
for endoscopy sedation, 124:1162-c

Propranolol
and bacterial translocation in cirrhosis (rat), 120:314-ss
effects on portal hypertension, 118:802-ss
for portal hypertension in cirrhosis, 121:240-tmig, 121:382, 121:487-e
portal pressure response to, 122:1543-c, 122:1544-c
and postprandial hemodynamics in cirrhosis, 122:915
in prevention of variceal bleeding, 123:735
optimal use of, 124:2005-c

Prostacyclin (PGI_2), and adaptive cytoprotection in gastric mucosa, 120:134

Prostaglandin E2 receptor-1 (EP-1), and human visceral pain hypersensitivity, 124:18

Prostaglandin E-receptor subtype EP_3
and duodenal bicarbonate secretion (mice), 117:1037-tmig, 117:1128
and intestinal mucosal integrity (mice), 117:1037-tmig, 117:1128

Prostaglandins
gastric mucosal production of, COX-2 inhibitors and, 120:784-tmig, 120:867, 121:1262-c
low-dose aspirin therapy and, 117:1-tmig, 117:17, 117:1506-c
and neurotensin stimulation of chloride secretion in human colon, 119:348
PGE_2
and EP_4 receptor-mediated mucin exocytosis, 117:1352
receptors, modulation of jejunal afferents (rat), 119:1580
production, via COX-2
in colorectal cancer, 121:1339
and postoperative ileus (mice, rats), 121:1269-tmig, 121:1354
in protection against hepatic ischemic injury, 125:917-srr
and radioprotective effect of lipopolysaccharide in intestine (mice), 118:1106
in regulation of intestinal inflammation, in IL-10-deficient mice, 123:1527
renal synthesis of, cyclooxygenase 2 inhibition and, in cirrhosis (rat), 116:1024-tmig, 116:1167

Prostate apoptosis response 4 (Par-4) gene, regulation of, by NSAIDs, 118:1012

Protease, serine 1 (PRSS1). *See* Trypsinogen, cationic

Protease-activated receptors, mediation of gut relaxation (guinea pig, mouse), 116:586

Protease inhibitor
GI toxicity and GI-associated drug interactions of, 120:607
in prevention of hepatic fibrosis (rat), 120:1784
in protection against hepatic ischemic injury, 125:917-srr

Proteasome
in indomethacin-induced gastropathy, 116:865, 116:994-e
and inositol trisphosphate receptor down-regulation in pancreatic acinar cells (rat), 116:1194

Protectin, *Helicobacter pylori* bound to, protection from complement lysis, 120:332-tmig, 120:470

Protein
absorption, in pancreatic insufficiency (dog), 116:431

dietary
requirements for, 122:1677
and up-regulation of dipeptide transport (rat), 116:354
intestinal absorption of, apical NHE3 activity and, 122:1314
requirements, in parenteral nutrition, 121:970-aga
restriction, effects on intestinal substrate oxidation (pig), 121:1167
transport, vesicle-based, in gastrointestinal epithelial cells, 116:438-srr
Proteinase, in visceral hyperalgesia (rat), 122:1034
Proteinase-activated receptor 2 (PAR-2), in visceral hyperalgesia (rat), 122:1034
Protein-energy malnutrition
assessment of, 122:1677
clinical features of, in children, 122:1677
effects on tissue mass and function, 122:1677
history-taking in, 122:1677
physical examination in, 122:1677
serum proteins in, 122:1677
Protein kinase A, and CFTR activation, effects on chloride secretion from homozygous ΔF508 murine intestines, 116:1379
Protein kinase C (PKC)
in IGF-I signaling pathway for colonic epithelial cell migration, 116:64
isoforms
in cirrhotic rat aortas, 119:2-tmig, 119:201
in inflamed colonic circular muscle (dog), 122:483
and proliferative and apoptotic signaling in colon cancer cells, 117:848
PKC-β1, overexpression, suppression of NSAID-induced apoptosis in gastric epithelial cells, 118:457-tmig, 118:507
PKC-β_{II}, and Wnt/APC/β-catenin signal transduction pathway in colon cancer, 117:1499-ss
PKC-δ, and colon carcinogenesis, 120:1700, 120:1868-e
PKCz, and IL-1α-induced COX-2 expression in intestinal myofibroblasts, 124:1855
and regulation of hepatocellular bile acid transport, 117:433-srr
Protein kinase II, cGMP-dependent, in intestinal fluid homeostasis (mice), 118:108
Protein-sparing therapy, 121:966-aga, 121:970-aga
recommendations for, 121:970-aga
Proteolysis, autophagic, regulation by hepatocyte hydration, $p38^{MAPK}$ in, 116:921
Prothrombin gene
G20210A mutation, and portal or hepatic venous thrombosis, 120:1059-c
mutation, and portal vein thrombosis, 116:2-tmig, 116:144, 116:213-e
Prothrombin time (PT), evaluation of, 123:1367-aga
Proton pump, as target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis, 120:377
Proton pump inhibitors
in dyspepsia management, 122:1270, 122:1521-e
efficacy of, *Helicobacter pylori* and, 117:1-tmig, 117:11
and esophageal cancer, 125:1912-c
for *Helicobacter pylori* eradication, 123:1763, 125:639-c
intravenous, in Zollinger-Ellison syndrome, efficacy of, 118:649-tmig, 118:696
long-term therapy with
efficacy and safety of, 119:1176-c, 119:1177-c
and gastric cancer risk, 119:1176-c
in GERD, efficacy and safety of, 118:649-tmig, 118:661, 118:795-e
for NSAID gastropathy, 119:521-srr
restoration of gastric acid secretion after therapy with, 123:1588
for ulcers with adherent clots, 123:632-e, 125:276-c
Prucalopride
for functional constipation, 120:331-tmig, 120:354
for irritable bowel syndrome, 123:2108-aga
Pruritus, in Alagille syndrome, 124:1155-ss
Pseudomyxoma peritonei, 124:1727-im
Pseudo-obstruction
acute colonic, neostigmine for, 118:443-ss
clinical features of, 116:980-vodd
current approaches to, 116:980-vodd
diagnosis of, 116:980-vodd
etiology of, 116:980-vodd
intestinal, acquired myopathic, autoimmune enteric leiomyositis and, 122:1132-cr
pathophysiology of, 116:980-vodd
treatment of, 116:980-vodd
Pseudotumor cerebri, in obesity, 123:882-aga
Pseudoxanthoma elasticum, gastrointestinal bleeding in, 124:1595
Psoriasis, NOD2/CARD15 and, 124:521-srr
Psychiatric disorders, in hepatitis C, 123:402-tmig, 123:476, 124:1711
Psychological problems
in irritable bowel syndrome and comorbid conditions, 122:1139-srr, 122:1701
in obesity, 123:882-aga
Psychotherapy
for chronic functional dyspepsia, 119:609-tmig, 119:661, 119:869-e
for functional bowel disorders, 125:19, 125:249-e
in irritable bowel syndrome, 124:303, 125:1554-c
Psychotropic agents, in treatment of irritable bowel syndrome, 120:652
***PTEN* gene,** and TNF-α regulation of *Cdx-2* expression in colonic epithelium, 123:1163, 123:1395-e
***$p16^{INK4}$* tumor suppressor**
in gastrointestinal malignancy, 116:234-tmig, 116:394, 116:483-e
inactivation, in hepatocellular carcinoma, 116:234-tmig, 116:394, 116:483-e
$p16^{INK4a}$ tumor suppressor
expression, in human colonic neoplasia, 119:929
promoter, mutations of, and PSC-associated cholangiocarcinoma, 123:1090
Publications
citation analysis for, 122:257-ce
submission of papers to AGA journals and, 123:5-ce, 123:877-aga
Public policy
Bush administration and gastroenterology, 120:333-gn
HCFA policy hurts gastroenterologists and Medicare patients, AGA charges, 120:3-gn
Publishing. *See also* Politics and publishing
PubMed Central (E-biomed) and, 117:293-gn, 117:1040-gn
Pudendal nerve terminal motor latency, in fecal incontinence, 124:1672
Purinergic signaling, in gastrointestinal epithelial secretion and hepatobiliary function, 116:964-srr
Push enteroscopy, versus wireless capsule endoscopy, for detection of small-bowel lesions, 119:1431-rc

p53/VP22 fusion protein, in enhancement of gene therapy, 123:608, 123:639-e
$p21^{Waf-1/Cip1}$, expression, in hyperplastic polyposis, 119:323
$p21^{waf1/cip1}$, up-regulation, and suppression of NSAID-induced apoptosis in gastric epithelial cells by PKCβ1 overexpression, 118:457-tmig, 118:507
Pyoderma gangrenosum, 118:654-im
peristomal, 119:873-ss
in ulcerative colitis, 124:1595
Pyrrolidinedithiocarbamate (PDTC), and 5-fluorouracil, combination of, effects on therapeutic-to-toxic ratio (mice), 118:2-tmig, 118:81

QUADRATE study, 123:1763, 125:639-c
Quality of life
after ileal pouch anal anastomosis, 124:1173-tmig, 124:1202, 124:1535-e, 124:1636
with azathioprine therapy for Crohn's disease, 118:995-tmig, 118:1018, 118:1281-c
in cirrhosis, branched-chain amino acid supplements and, 124:1723-tmig, 124:1792, 124:1980-e
health-related, after ileal pouch anal anastomosis for ulcerative colitis, 122:1179-ss
in irritable bowel syndrome, 119:654, 123:1686-srr, 123:2108-aga
obesity and, 123:882-aga
in short-bowel syndrome, 124:1111-aga

Rab4
and regulated exocytosis in pancreatic acini (rat), 116:943
regulation by cholecystokinin, 116:943
Rab17, and IgA transcytosis in small intestine (mice), 116:610
Race
and response to antiviral therapy in hepatitis C, 122:1198-gn
and therapy response in hepatitis C, 119:1186-tmig, 119:1317
Racecadotril, in acute diarrhea in children, efficacy and tolerability of, 120:783-tmig, 120:799
Radiation enteropathy, amelioration by recombinant soluble TGF-β type II receptor (mice), 119:1185-tmig, 119:1286
Radiation therapy
nausea and vomiting caused by, 120:263-aga
for pancreatic cancer, AGA technical review on, 117:1464-aga
Radiofrequency energy, for gastroesophageal reflux disease, 125:668, 125:970-e
Radiographic evaluation
in acute mesenteric ischemia, 118:954
in occult gastrointestinal bleeding, 118:201-aga
Radiology
double contrast, 121:1022-pmr
gastrointestinal, 124:1557-pmr
case review of, 121:228-pmr
fundamentals of, book on, 122:1541-pmr
gastroenterologist training in, 124:1090-aga
in small bowel disease, 123:963-tmig, 123:999, 123:1385-e, 125:276-c, 125:998-c
Radionuclide imaging, in biliary tract, 124:1686
Raman spectroscopy, 120:749
RANTES, secretion, in human pancreas, cytokine regulation of, 119:211
Rapamycin
inhibition of hepatic fibrinogenesis in vivo (rat), 117:1038-tmig, 117:1198, 117:1244-e
inhibition of stellate cell proliferation in vivo (rat), 117:1038-tmig, 117:1198, 117:1244-e
Rapid Communications
Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions, 122:606
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret, 121:767
CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease, 121:246
Claudins regulate the intestinal barrier in response to immune mediators, 118:1001
The contribution of *NOD2* gene mutations to the risk and site of disease in inflammatory bowel disease, 122:866
Corticotropin-releasing factor receptor 1-deficient mice do not develop postoperative gastric ileus, 125:654
Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat, 125:1303
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, 117:761
Enteric involvement of severe acute respiratory syndrome–associated coronavirus infection, 125:1011
The frequency of the HIV-protective CC chemokine receptor 5-D32/D32 genotype is increased in hepatitis C, 122:1721
Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors, 125:660
Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1, 121:1040
Germline variants of *EXO1* gene in patients with atypical hereditary nonpolyposis colorectal cancer, 120:1580
Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin, 120:337
Hyperleptinemia prevents increased plasma ghrelin concentration during short-term moderate caloric restriction in rats, 124:1188
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA, 125:9
Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease, 122:7, 125:633-c
Methylene Blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis, 124:880
Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1, 117:770
The molecular classification of the clinical manifestations of Crohn's disease, 122:853
Neural stem cells express RET, produce nitric oxide, and survive transplantation in the gastrointestinal tract, 121:757
A randomized trial comparing wireless capsule endoscopy with push enteroscopy for the detection of small-bowel lesions, 119:1431
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase, 125:292
Rho kinase blockade prevents inflammation via nuclear factor kB inhibition: evidence in Crohn's disease and experimental colitis, 124:1180

A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis, 117:7
SPINK1/PST1 polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis, 119:615
6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients, 125:298
Vagal stimulation rapidly increases leptin secretion in human stomach, 122:259
WNT1 inducible signaling pathway protein 3 *(WISP-3)*, a novel target gene in colorectal carcinomas with microsatellite instability, 121:1275

Ras protein, Ha-, activation by TGF-α, in pancreatic cancer with Ki-*ras* mutations, 116:1441

Reactive oxygen species (ROS)
ethanol-induced mitochondrial dysfunction and, 122:2049-srr
in Fas-induced acute liver failure (mice), 121:1451
and IL-1α-induced COX-2 expression in intestinal myofibroblasts, 124:1855
and IL-8 release in colonocytes, 122:1047

Recertification, via Continuous Professional Development, 121:754-gn

Rectal cancer. *See* Colorectal cancer

Rectal compliance
and fecal incontinence, 124:1672
testing, in fecal incontinence, 124:1672

Rectal distention
barostat testing, in irritable bowel syndrome, 122:1771, 122:2075-e
in irritable bowel syndrome, 124:863-c
responsivity to, stress and (rat), 123:1216
sensitivity to
in differential diagnosis of irritable bowel syndrome, 122:1771, 122:2075-e, 124:863-c
in irritable bowel syndrome, 118:815-tmig, 118:842, 118:972-e, 119:1418-c

Rectal examination, under anesthesia, for evaluation of perianal fistulas in Crohn's disease, 121:1064

Rectal sensation
and fecal incontinence, 124:1672
testing
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga

Rectoanal sensation, testing, in fecal incontinence, 124:1672

Rectum
circumferential wall tension, measurement of, AGA technical review on, 116:735-aga
compliance, measurement of, AGA technical review on, 116:735-aga
hypersensitivity, in childhood, 120:31, 120:287-e
motor response to distention or fluid infusion, in anorectal disorders
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
muscle tone, measurement of, AGA technical review on, 116:735-aga
neoplasms of, 119:1803-pmr
primary squamous cell carcinoma of, HPV type 16 and, 120:988-cr, 120:1046-e
specialized mechanoreceptors in (guinea pig), 125:786
surgery of, 119:1173-pmr

Red meat, irradiation of, 116:785-gn

Refeeding, of severely malnourished patient, 122:1677

Reflux esophagitis. *See* Esophagitis, reflux

***Reg* gene mutation,** and enterochromaffin-like cell tumor development, 116:1310, 116:1489-e

Rehydration therapy, in acute diarrhea in children, 120:783-tmig, 120:799

Reimbursement
for ambulatory endoscopy centers, 122:849-gn
HCFA policy and, 120:3-gn

Rel proteins
in gastrointestinal diseases, 118:1208-srr
transcriptional activity of, regulation by phosphorylation, 118:1208-srr

Renal dysfunction, caused by systemic amyloidosis complicating Crohn's disease, dimethylsulfoxide for, 117:1031-c

Renal failure
chronic, and chronic pancreatitis, 120:682
dialysis-related amyloidosis and gastrointestinal symptoms in, 116:217-ss

Renin-angiotensin system
in cirrhosis, 122:1658
in hepatic stellate cells, 125:117
tissue, in hepatic fibrosis (rat), 123:1667

Renovascular hypertension, giant cyst of liver and, 121:745-c

Reperfusion injury. *See* Ischemia-reperfusion injury

Representational difference analysis, of novel bacterial sequence associated with Crohn's disease, 119:23, 119:254-e

Rescriptor. *See* Delavirdine

Research and development
advances in enteric neuroscience, 116:5-ce
AGA policy initiatives on, 123:664-gn
basic and clinical, bridging gap between, 124:6-ce, 124:1178-ce
clinical, 121:515-ce
NIH Clinical Research Loan Repayment Program for, 121:1035-gn
collaboration in, 125:268-ss
and conflicts of interest, 125:7-ce
discovery-based, and fishing, 125:290-ce
funding for, 122:603-ce
in Germany, 120:334-gn
in Japan, 120:1074-gn
gastroenterologist training in, 124:1092-aga
on gene therapy, public access to, 120:786-gn
human subjects in, protection of, 123:1761-ce
increased need for PhDs in, 123:664-gn
at interface of molecular biology and clinical epidemiology, 122:1199-ce
investigators for, 122:603-ce
methodologies for, 123:650-pmr
new FDA rules and, 116:1025-gn
NIDDK special emphasis program announcements, 125:5-gn
NIH budget and, 116:3-gn, 116:1025-gn
NIH roadmap for, to improve health, 125:1573-gn
opportunities for, and human resources, 122:603-ce
and patient care, principles of, 125:7-ce
patient-oriented, NIH budget and, 116:3-gn
physiological mouse genomics and, 123:405-ce
randomized controlled trials in, reporting, 121:755-ce
translational, 116:1285-ce, 123:665-ce
truth survival in, 124:1153-ss
on xenotransplantation, public access to, 120:786-gn

Resting energy expenditure, calculation of, 123:882-aga

Retinal pigment epithelium (RPE), in gastrointestinal polyposis, 124:1595

Retinoblastoma gene, and APC-induced cell cycle arrest, 123:751, 123:935-e

Retinoblastoma pathway, in colonic adenomas, 120:1680
Retinoic acid, metabolism, ethanol-induced CYP4502E1 and (rat), 120:179
Retinoic acid receptor/retinoid x receptor (RARα/RXRα)
and cholesterol and bile acid metabolism, 120:1054-ss
nuclear levels, in obstructive cholestasis, and regulation of Mrp2 expression (rat), 123:599
Retinoids, in pancreatic exocrine development (mice), 123:1331
Retinopathy, interferon-related, 124:1711
RET protein
expression, in neural stem cells, 121:757-rc
with *HSCR* mutations, functional analysis of, 121:24
Retrovir. *See* Zidovudine
Retroviral vectors, gene transfer using, during growth factor-stimulated liver hyperplasia (rat), 118:591
Rh B glycoprotein, hepatic expression of (mice), 124:1432
Rh C glycoprotein, hepatic expression of (mice), 124:1432
Rheumatoid arthritis, disease severity in, *H. pylori* and, 116:503-c
Rho, activation via Edg-5, and growth inhibition of hepatocytes by sphingosine 1-phosphate (rat), 124:459
RhoA, in cell migration, polyamine depletion and, 123:196
Rho GTPase, and gastrin-regulated expression of PAI-2, 123:271
Rho kinase
in intestinal inflammation, 124:1180-rc
regulation of tight junction function, 121:566
and tight junction assembly in intestinal epithelia, 121:566
Ribavirin
for hepatitis C
adverse effects and side effects of, 123:2082
effectiveness of, 122:1195-tmig, 122:1303, 122:1525-e, 124:584-c
with interferon, adverse effects and side effects of, 124:1711
plus interferon, 123:1061, 123:2082, 125:1284-c
adherence to therapy and response to, 123:1061
and T-cell responses, 123:1070
and interferon, combination of, for HCV, 121:1017-ss
cost-effectiveness of, 118:1268-ss
T-cell reactivity and, 118:248-tmig, 118:346
interferon and, for hepatitis C
in African Americans, 119:1385-srr
response to, race and, 119:1186-tmig, 119:1317
Rice, boiled, antisecretory effect on gut, 116:1282-tmig, 116:1342
Riolan, Jean the Younger, 124:607
Risedronate, for osteoporosis, gastroesophageal effects of, 119:609-tmig, 119:631, 119:866-e
Risk stratification, for NSAID-related upper GI events, 123:1006
Ritonavir, GI toxicity and GI-associated drug interactions of, 120:607
Rituximab, for immune-mediated thrombocytopenia associated with Crohn's disease, 124:583-c
RNA (ribonucleic acid), short interfering double-stranded. *See* siRNA
RNA (ribonucleic acid) interference, in hepatitis C, 125:1546-ss
Rodgers, Griffin P., 121:241-gn
Rofecoxib
and angiogenesis in human colorectal cancer liver metastases, 125:647-tmig, 125:716
for Barrett's esophagus, 123:1-tmig, 123:50
effects on gastroduodenal mucosa, 117:776, 117:1002-e, 118:638-c, 118:640-c
gastrointestinal safety of, 119:521-srr
and human gastric mucosal prostaglandin production, 120:784-tmig, 120:867, 121:1262-c
in prevention of colorectal neoplasia, 125:404
in prevention of intestinal polyposis, 122:234-ss
and relapse of inflammatory bowel disease, 125:637-c
and risk of lower GI events, 124:281-tmig, 124:288
and risk of upper GI events, 123:1006
Rokitansky, Karl von, 120:9000
Rome criteria, in differentiation between organic and nonorganic intestinal disease, 123:401-tmig, 123:450
Röntgen, Wilhelm Conrad, 125:issue 5
Rosiglitazone
suppression of colon carcinogenesis (mice), 124:281-tmig, 124:361, 124:564-e
therapeutic potential in colitis, 118:228-ss
Rotavirus
diarrhea caused by, neural mechanisms in, 118:651-gn
vaccine, CDC study of, 117:758-gn
Rumination, pathogenesis of, 116:1006-ss
Ryanodine receptors, activation, and calcium waves in pancreatic acinar cells (rat), 122:415

Saccharomyces boulardii, soluble factor produced by, inhibition of NF-κB-mediated IL-8 gene expression (abstract), 125:606-aga
Sacral nerve stimulation, for fecal incontinence, 121:511-tmig, 121:536, 124:1672
Saline infusion, in anorectal disorders
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
Saliva, in immune response to *H. pylori* oral vaccination (mice), 118:749
Salivary glands, epithelium of, water transport by, 122:545-srr
Salmon, Daniel Elmer, 119:1453
***Salmonella* spp.**
aortitis caused by, 120:1322-im
AvrA effector of, suppression of NF-κB activation by, 124:1550-ss
ceftriaxone-resistant, from antibiotic-treated cattle, 119:3-gn
liver injury by, toll-like receptor 2 and (mice), 123:1265
multidrug-resistant, 117:3-gn
mutant, as vectors for gene therapy, 121:224-ss
Salmonella typhimurium
extraintestinal dissemination, by CD18-expressing phagocytes, 118:803-ss
HCV-NS3-transformed, oral immunization with, HCV-specific CTL induced by (mice), 121:1158
Salsalate, gastrointestinal events related to, risk of, 120:594
Santorini, Giovanni Domenico, 120:805
Saquinavir, GI toxicity and GI-associated drug interactions of, 120:607
Sarcoidosis, interferon contraindicated with, 124:1711
Sargramostim, for inflammatory bowel disease, 122:1592
Satiety
melanin concentrating hormone receptor and, 117:524-gn
studies of, orphan receptors in, 117:524-gn

SC-560, and NSAID-induced gastric damage (rat), 119:610-tmig, 119:706
Scatology, 119:1174-pmr
Schatzki ring. *See* Lower esophageal ring
Schindler, Rudolf, 117:326
Schistosomiasis, hepatitis C with and without, immune responses in, 121:646
Schönlein-Henoch purpura
gastrointestinal involvement in, 124:1595
ischemic necrosis of bile ducts in, 117:211-cr
Scleroderma
antibody-mediated gastrointestinal dysmotility in, 123:1144
hide-bound bowel sign in, 124:1179-im
skin signs in, 124:1595
Sclerosing cholangitis, ERCP in, 124:1686
Sclerotherapy
balloon endoscopic, for gastric fundal varices, 117:514-c
emergency, for variceal bleeding in cirrhosis, comparison with vasoactive drug therapy, 124:1174-tmig, 124:1277
endoscopic ultrasound guidance for, 122:1631
Second messengers, in hormonal regulation of bile flow, 116:1024-tmig, 116:1176
Secretagogues, and inositol trisphosphate receptor down-regulation in pancreatic acinar cells (rat), 116:1194
Secretin
for autism, 117:524-gn, 118:250-gn
cholangiocyte response to, cholinergic modulation of, 117:191
response to, in cholestasis, 117:167
synthetic, protective effect against post-ERCP pancreatitis (abstract), 125:605-aga
Secretin cells, tumorigenesis in, early region of simian virus 40 in (mice), 119:1305
Secretin receptor, in gastrinoma, 122:500-cr
dominant negative action of, 122:500-cr
Secretory leukocyte protease inhibitor, and regulation of hepatic ischemia-reperfusion injury (mice), 117:953
Secretory leukocyte proteinase inhibitor, secretion of, by human intestinal epithelial cells, 118:996-tmig, 118:1061
Sedation, and small-caliber esophagogastroduodenoscopy, 117:1265-tmig, 117:1301, 117:1492-e, 118:987-c, 119:878-c
Selected Summaries
Acute HCV: the early bird catches the virus, 122:1175
An advance in the treatment of portal hypertension?, 118:802
Air apparent: studies of gas and bloating in IBS, 122:576
"A la carte" treatment of portal hypertension or just "hors d'oeuvres," 124:1993
Alcoholic steatosis: the Kupffer cell a villain?, 120:581
All *kid*ding aside with the use of lamivudine in children with chronic hepatitis B, 123:1741
Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution, 117:740
Another link in the iron chain?, 118:632
Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis, 121:1019
The appendix in ulcerative colitis: a not so innocent bystander, 117:272
Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy, 120:576
Are two tests better than one?, 122:236
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?), 124:572
Aspirin and the prevention of colorectal neoplasia, 125:1539
Awakening the sleeping post-surgical abdomen, 122:1177
Baclofen effects on esophageal function: a possible therapy for GERD?, 123:1736
Barraging the biliary tree, 122:1533
Barrett's esophagus: the long and the short of It, 119:1165
The benefits of dietary fiber on glycemic control in type 2 diabetes: relevance to gastroenterologists, 119:1168
Better pale than yellow, 117:1017
Bile acids regulate their own synthesis: the nuclear connection, 120:1557
β-Blocker plus nitrate for primary prophylaxis of variceal bleeding, 119:1170
Budesonide versus mesalamine for active Crohn's disease, 116:1263
Burst appendix or technology bust, 123:381
Calcium, chemoprevention, and cancer: a small step forward (a long way to go), 116:1261
Can gastrografin heal the obstructed bowel?, 124:852
Celiac sprue as a possible cause of symptoms in presumed irritable bowel syndrome, 122:2086
Cesarean for C? Possibly. . ., 120:1555
A CF modifier means meconium in mouse and man, 119:268
Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis, 119:1797
Chemoprevention of colon cancer: have you had your multivitamin today?, 116:1003
Chemoprevention of intestinal polyposis by COX-2 inhibition: from mouse to man, 122:234
Chest pain and serotonin: a possible link?, 121:495
Cholecystectomy after treatment of choledocholithiasis: on firmer ground, 125:617
Collaboration is the key: identification of a celiac protein, 125:268
Colonoscopy versus double-contrast barium enema, 119:1402
Combo cap takes a big bite, yet a smoothie to swallow, 125:621
Confined treatment, 125:1543
Cost analysis of antireflux surgery versus medical management, 122:1178
Cost-effectiveness of screening for colorectal cancer: the dollar is in the details, 124:856
Costs of GERD: facts and fiction, 125:981
Coughing, wheezing, and acid, 123:1398
The curse of the functional dyspeptic: too sensitive a visceral afferent nervous system?, 116:495
Decisions, decisions, decisions, 118:1268
Diagnostic testing after fecal occult blood testing: compliance is the issue, 118:980
Dialysis-related amyloidosis: an important cause of gastrointestinal symptoms in patients with end-stage renal disease, 116:217
Diet and colon cancer: strike out the bran, 119:591
Diet and disease: the "phyte" over intestinal cholesterol, 121:1255
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C?, 117:738

Does surveillance endoscopy improve life expectancy in those with Barrett's esophagus?, 121:1516
Dollars and sense in preventing esophageal cancer, 125:1268
Early trypsinogen activation in acute pancreatitis, 116:770
Effectiveness of colonoscopy in preventing colorectal cancer, 121:1521
Effective therapy for advanced gastrointestinal stromal tumors, 124:1151
Elimination of *Helicobacter pylori* or acid in high-risk users of aspirin or nonsteroidal medications: final answer?, 122:238
Endoscopic blockade to prevent resurfacing of esophageal varices, 124:1545
Endoscopy for upper gastrointestinal symptoms: sooner rather that later, 119:872
Enterocyte apoptosis and TPN-associated intestinal mucosal atrophy: a view of the chicken or the egg?, 125:1273
Escape from the *Smad* world by colon cancer, 116:1496
The expanding spectrum of clinical uses for botulinum toxin: healing of chronic anal fissures, 116:221
Expansion of criteria for liver transplantation in HCC: a slippery slope?, 122:579
Extended lymphadenectomy for carcinoma of the head of the pancreas, 116:1499
Fantastic voyage through the gut, 122:828
Floating the molecular machinery for T-cell activation, 117:503
Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy," 122:2082
Garlic breath explained: why brushing your teeth won't help, 117:1248
Gastric neurostimulation for gastroparesis: time to pick up the pace, 125:979
The genesis of IBD genetics, 123:2148
Gene therapy for food allergy, 119:269
The genetics of Shwachman diamond syndrome, 125:1541
Genetic testing for hereditary nonpolyposis colorectal cancer: are we there yet?, 118:230
Getting fat in the ICU, 119:592
Giving cancer therapy a shot in the arm, 117:1015
Glial cells, mucosal integrity, and inflammatory bowel disease, 116:493
Growing pains, 118:633
H. pylori and nonulcer dyspepsia: not guilty as charged, 117:270
HCV and C282Y: a sinister synergism?, 116:494
Health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis: right answer-wrong question, 122:1179
Helicobacter eradication versus prompt endoscopy for dyspepsia, 120:1298
Helicobacter pylori and nonulcer dyspepsia: looking beyond the bug, 121:735
Hello, Mr. Clips–Could you chip in please?, 125:1896
Hemoclips-clips to clasp the bleeder, 123:1399
The hepatitis B vaccine: sorting through the B.S. about M.S., 120:1880
Hepatitis C: beyond the liver, 124:1157
Hepatitis C for half a century, 119:1405
Hepatogenous diabetes: reduced insulin sensitivity and increased awareness, 119:1800
Hepatoportal thromboses are no longer idiopathic, 119:874
Herbal remedies for the liver: myths, proofs, and treatments?, 117:1250
Hereditary diffuse gastric cancer: more answers or more questions?, 122:830
Hereditary hemochromatosis and cancer risk: more fuel to the fire?, 121:1251
Hirschsprung lost his nerve, 125:1900
How do intestinal T cells sense the dietary and microbial environment?, 118:444
How safe are the safest IBD drugs?, 124:1986
5-HT$_3$ antagonist therapy of bulimia nervosa: a peripherally active agent for a central nervous system eating disorder?, 119:272
Human M cells delivered in a box, 121:1520
Hypercholesterolemia in primary biliary cirrhosis: getting to the heart of the matter?, 124:854
IBD indirect costs: the sleeping giant?, 125:982
Identifying the motilin receptor: science, serendipity, or simply business?, 117:1502
Impeding gastroesophageal refluxate: a new application of an old medication, 125:984
The importance of autoimmune pancreatitis, 121:1518
Increasing the *RISC* for HCV, 125:1546
Infliximab at 5 years—tweaking the recipe for success?, 125:1902
Infliximab for the treatment of fistulas in patients with Crohn's disease, 117:1247
Infliximab for ulcerative colitis: is there a placebo (effect) in the house?, 124:1990-ss
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, 125:1544
In search of Vulcan: where are all the iron men (and women)?, 123:947
Insights into milk protein allergy: microenvironment matters, 124:259
Interferon therapy prevents hepatocellular carcinoma in some patients with chronic HCV: the role of fibrosis, 118:446
Interferon treatment of HCV: do we need a virological response?, 122:237
Intestinal mucin and colorectal cancer: it's not just goo, 123:648
Intravenous albumin reduces mortality in patients with spontaneous bacterial peritonitis, 118:231
Iron and *HFE* mutations in nonalcoholic steatohepatitis: innocent bystanders or accessories to the crime?, 125:615
Is antibody testing for inflammatory bowel disease clinically useful?, 116:1001
Is the appendix a vestigial organ? its role in ulcerative colitis, 121:730
Is constipation caused by a loss of colonic interstitial cells of cajal?, 125:264
Is hepatic fibrosis reversible with therapy in hepatitis C?, 120:579
Is it HELLPful to consider the hanging LCHAD in pregnancy-associated liver disease?, 124:1548
Is Stretta ready for prime time?, 123:643
Is there a place for placebos?, 121:1253
Is TIPS shunt effective for secondary prophylaxis of gastric variceal hemorrhage?, 125:262
Itchin' for a diversion, 124:1155
Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air?, 125:1898

Lamivudine for chronic hepatitis B: the magic bullet or just another bright prospect?, 116:1498
Lamivudine for hepatitis B: the end of the beginning?, 121:222
Leptin signaling and obesity: weight and see, 124:1546
Look Ma, no blades, 124:1991-ss
Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?, 124:1988-ss
Making end points meet, 116:1266
Management of gastric varices, 120:1875
Management of GERD in the millennium: is there room for endoscopy?, 121:1249
Management of refractory ascites: are TIPS or taps tops?, 120:311
Manipulating intestinal cholesterol absorption and hepatic cholesterol and bile acid metabolism by activation of deorphanized nuclear receptors, 120:1054
A marker for predictions of HCC recurrence post-resection?, 123:2152
MARS: a new treatment for hepatorenal failure, 119:1799
The mesalamine wars heat up-enter balsalazide, 124:574
Methotrexate for the maintenance of remission in Crohn's disease, 120:1553
Methotrexate in IBD - move over 6-MP? Not so fast, 123:1737
Molecular dissection of the mechanisms through which enteropathogenic *Escherichia coli* induce diarrhea, 121:496
Molecular staging of colorectal cancer: a step forward, 116:769
More than food trafficks into the esophagus, 123:946
More therapy for hepatorenal syndrome, 116:1264
Mucosal vaccination: "all politics are local," 116:497
Mutant *Salmonella* as vectors for gene therapy, 121:224
NASH: can we iron out the pathogenesis?, 118:981
NEC, EGF, milk, and spit, 123:383
Necrotizing enterocolitis: a closer look, 121:1016
Neostigmine for acute colonic pseudoobstruction: new use for an old drug?, 118:443
New insights into microbially initiated gastric malignancies: beyond the usual suspects, 123:1739
New insights into the pathogenesis of rumination: what's coming up next?, 116:1006
The NOD2 gene and Crohn's disease: another triumph for molecular genetics, 122:826
A novel development in oral rehydration therapy, 119:591
Novel medical therapies for Crohn's disease: is there room for growth?, 120:308
And now. . .fattening the lower esophageal sphincter, 123:944
Nutritional therapy for alcoholic hepatitis: new life for an old idea, 120:1053
Nutrition in the ICU: are all systematics go?, 117:1500
Occult HBV infection–both hidden and mysterious, 125:1903
One if by gut and two if IV, 122:1536
Pancreatic bicarbonate secretion: role of CFTR and the sodium-bicarbonate cotransporter, 117:275
A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells, 118:1272
Pathogenesis of sodium retention in preascites: have we reached the heart of the problem?, 124:858
Patients with biliary microlithiasis: are they a separate breed?, 121:1014
p53 at the crossroads of colitis and cancer, 120:1877
Peristomal pyoderma gangrenosum, 119:873
Peritoneal dialysis: an under-appreciated cause of acute pancreatitis, 119:1407
Persistence and pathogenesis: a great defense facilitates a good offense, 122:2084
Persistent colonic inflammation in postinfectious IBS: symptom cause or curiosity?, 121:493
The politics of *H. pylori*-challenged mice: liberal permissiveness versus conservative restriction, 124:577
Population screening and treatment of *Helicobacter pylori*, 119:1795
Portopulmonary hypertension: an increasingly important complication of cirrhosis, 125:622
The potassium channel and how it works, 116:216
A potential new hepatitis agent: making SEN-se of the data, 121:734
PPAR-γ ligand antidiabetic drugs: good news for colitis?, 118:228
Predicting the outcome of hepatitis C virus infection, 120:312
The premalignant lesions for pancreatic cancer: will Pan-INs pan out?, 123:645
Prevention of colorectal cancer: tumor progression, chemoprevention, and Cox-2 inhibition, 119:267
The prevention of hepatocellular carcinoma by interferon: the story continues, 120:1301
Prevention of varices rebleeding: are drugs better after all?, 122:832
Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers, 123:379
Primary sclerosing cholangitis: a premalignant condition, 123:647
Probiotic therapy with *E. coli* for ulcerative colitis: take the good with the bad, 118:630
The problem of delayed emesis after cancer chemotherapy: a possible new treatment, 117:737
Prokinetics reduce bacterial translocation in cirrhosis: will sweeping the gut keep the fluid clean?, 120:314
Prophylactic pancreatic duct stenting: a panacea?, 125:1274
Protecting the pouch: diversion is not the answer, 123:1403
Protein shakes, 122:582
In pursuit of the hidden, the occult, and the obscure, 117:273
The road not taken, 120:1878
A role for the appendix in inflammatory bowel disease? cut it out, 125:1270
The role of PPARγ in colon cancer: is it as simple as APC?, 125:619
Seek and ye shall find, 123:1401
Separating bad from worse in Barrett's esophagus, 125:260
Setback for systemic therapy of esophageal cancer: right concept, disappointing result, 117:1020
Signaling to colon cancer, 117:1499
Single-stage operations for Hirschsprung's disease – pushing the envelope, 120:1299
Small bowel photography: the jury needs evidence, 124:1150
Some TIPS for the prevention of recurrent variceal hemorrhage?, 123:384
The stomach and weight reduction: the role of ghrelin, 124:575
Stopping the unstoppable?, 118:1270
Stress management, 116:773

Suppression of pathogenesis: bacteria lead the way, 124:1550
Surgeon-related factors and outcome in rectal cancer, 116:220
Surveying the masses, 119:1403
Sympathetic hyperactivity in pre-ascites, 122:1538
Taking control of fecal incontinence: early results of an artificial sphincter device, 116:1005
Terlipressin and albumin for HRS: an advance in therapy?, 124:1552
Therapy for HCV nonresponders: is two enough?, 121:1017
Transcription factors and cholangiocyte development, 124:263
Transforming growth factor β and tumor-suppressing pathways: it doesn't matter how you get there, as long as you get there, 117:500
Transplantation for hepatitis C: good news and bad news, 117:502
Treatment of Crohn's disease: is blocking adhesion the answer?, 125:1276
Treatment of hepatoportal venous thrombosis: the role of anticoagulation, 120:578
The Trojan horse or the New York shuttle?, 118:803
Truth is not determined by a majority vote, 124:1153
Turbo probiotics for IBD, 120:1297
Turning on T-cell death and turning off Crohn's disease, 119:1166
Understanding the course, 124:261
Urgent endoscopy with endoscopic therapy for acute diverticular bleeding, 118:978
Ursodiol prevents UC-associated CRC, 121:491
Viral discrimination and subversion of host defense at the epithelial gateway, 123:947
Virtual colonography-a step forward?, 124:258
Virtual virtual colonoscopy?, 121:221
What is the right age cutoff got immediate endoscopic investigation of dyspepsia?, 123:2149
What lies beyond the view of the sigmoidoscope?, 120:1051
What's right and what's left?, 120:1049
What will you be when you grow up?, 121:732
Whomsoever ignores the natural history of the hepatitis C virus is doomed to treat it, 122:578
Why patients on long-term intravenous hyperalimentation are prone to infections, 116:1495
Will the safest analgesic please stand up, 122:1535
The winner after 7 rounds - fecal occult blood testing!, 122:2081
Yield of colonoscopy for non-acute rectal bleeding, 123:2151
Zeroing in on the "Holy Grail," 125:266

Selectins, differential role of, in experimental colitis, 120:1072-tmig, 120:1162

Selective estrogen receptor modulators, for osteoporosis treatment, 124:795-aga

Selective serotonin reuptake inhibitors (SSRIs)
for depression, in patients with liver disease, 124:1711
for irritable bowel syndrome, 120:652, 123:2108-aga

Sensory-evoked potentials, in anorectal disorders, AGA technical review on, 116:735-aga

SEN virus, and hepatitis, 121:734-ss

Sepsis
hepatobiliary dysfunction in, protective role of carbon monoxide from heme catabolism in (rat), 120:1227, 120:1288-e
NF-κB activity during, regulation of, 124:118

Serine protease
and digestive enzyme secretion in pancreatic acinar cells, 120:1818
myenteric neurons excited by, in small intestine (guinea pig), 123:1554

Serine protease inhibitor
and F-actin redistribution in acinar cells, 122:591-e, 124:583-e
Kazal type 1 (SPINK1). *See also* **Pancreatic secretory trypsin inhibitor**
gene mutations
in chronic pancreatitis, 120:1060-e
and tropical calcific pancreatitis, 123:1020, 123:1026
and type II diabetes mellitus, 123:1026

SERMs. *See* **Selective estrogen receptor modulators**

Serology, of CagA-positive *H. pylori* infection, 117:745-e

Serotonin
and anorexia in inflammatory bowel disease (rat), 118:457-tmig, 118:544, 118:625-e
and chest pain, 121:495-ss
effects in gastrointestinal tract (rat), 123:217
in irritable bowel syndrome and comorbid conditions, 122:1139-srr
and luminal factor-stimulated pancreatic secretion (rat), 118:1197
in postinfectious irritable bowel syndrome, 124:1662
release, by enterochromaffin cells
D-glucose and, 121:1400
in small intestine (guinea pig, human), 117:1363
transporter, polymorphism, in irritable bowel syndrome, 125:401-tmig, 123:425

Serotonin antagonists, for postinfectious irritable bowel syndrome, 124:1662

Serotonin receptors, 5-HT_3, and afferent nerve sensitivity to intestinal anaphylaxis (rat), 119:1267

Sertraline, effects on chest pain of noncardiac origin, 121:495-ss

Severe acute respiratory syndrome (SARS), coronavirus associated with, 124:1724-gn
diarrhea caused by, 125:1011-rc

Sex differences. *See* **Gender difference**

Sexual abuse, and irritable bowel syndrome and comorbid conditions, 122:1139-srr, 122:1701, 122:2032-srr

Sexual function
female, ulcerative colitis and, 122:15, 122:226-e
irritable bowel syndrome and, 123:1686-srr

Shear stress, and aortic eNOS up-regulation in cirrhosis (rat), 122:1869

Shiga, Kiyoshi, 124:1192

Short-bowel syndrome
bile acid replacement therapy for, 116:1-tmig, 116:15
dietary management in, 124:1105-aga, 124:1111-aga
fluid and electrolyte management in, 124:1111-aga, 124:1651
incidence of, 124:1111-aga
intestinal adaptation in, 124:1111-aga
intestinal failure in, 124:1615
plasma citrulline as marker for, 119:1425-tmig, 119:1496
intestinal transplantation in
AGA medical position statement on, 124:1105-aga
AGA technical review on, 124:1111-aga
long-term outcome in, 117:1057-tmig, 117:1043
low-dose growth hormone in, 124:293, 124:561-e
medication absorption in, 124:1105-aga, 124:1111-aga
parenteral nutrition in, 124:1105-aga, 124:1111-aga
pathophysiology of, 124:1111-aga

prevalence of, 124:1111-aga
and quality of life, 124:1111-aga
surgery in, 124:1105-aga, 124:1111-aga
survival in, 124:1111-aga
treatment of
glucagon-like peptide 2 in, 120:783-tmig, 120:806, 120:1041-e
medical, 124:1105-aga, 124:1111-aga

Short-chain fatty acids
and expression of Hsp25 in colonic mucosa, 121:511-tmig, 121:631
for pouchitis, 124:1636

Shwachman-Diamond syndrome, genetics of, 125:1541-ss

3′-Sialyllactose sodium salt, for *H. pylori* infection (rhesus monkey), 117:1265-tmig, 117:1316

Sialyl Tn, expression in pancreatic intraepithelial neoplasms, 123:1052

Sibutramine
adverse effects and side effects of, 123:882-aga
for obesity, 120:669, 123:879-aga, 123:882-aga, 124:877-gn

Sigmoidoscopy
in colorectal cancer screening, 119:837-srr
in Chinese, 124:608
efficacy of, 122:236-ss
limitations of, 120:1049-ss, 120:1051-ss
recommendations for, 124:544-aga
screening
on-site services for, utilization of, 122:1226
by RNs vs. MDs, frequency of missed polyps in, 117:291-tmig, 117:312, 117:486-e
utilization of, 117:291-tmig, 117:304, 117:486-e

Signal transducer and activator of transcription (STAT). *See also* Stat3; STAT3
activation by IFN-α, in human hepatocytes, 122:1019
STAT6, in eosinophilic esophagitis induced by intratracheal IL-13, 125:1419

Sildenafil
in animal models of diabetic gastropathy, 120:576-ss
effects on esophageal motility, in achalasia, 118:247-tmig, 118:253

Simian immunodeficiency virus infection, mucosal CD4⁺ T-cell depletion and enteropathy in (Rhesus macaque), 116:1023-tmig, 116:1115

Simian virus 40
early region, and tumor induction in secretin-expressing cells (mice), 119:1305
recombinant replication-deficient, in liver-directed gene therapy (Gunn rat), 119:1348

Simvastatin, induction of hepatic *mdr* expression (rat), 117:678

Single-photon emission computed tomography (SPECT), of pooling of gastric secretions in proximal stomach, 123:2157-c

Sinusitis, and gastroesophageal reflux disease, in children without neurological deficits, 121:1294

Sinusoidal obstruction syndrome, prevention of, by matrix metalloproteinase inhibition (rat), 125:882

siRNA, inhibition of hepatitis B virus replication in vivo (mice), 125:9-rc

Sitosterolemia, dietary cholesterol accumulation in, 121:1255-ss

Skin signs
of gastrointestinal disease, 124:1595
in Sweet's syndrome, 124:287-im

Skin tags, in perianal Crohn's disease, 125:1503-aga, 125:1508-aga

Skin ulcers, in hepatitis C, 121:245-im

SLC21A8 gene, human hepatocyte-specific organic anion transporter encoded by, 122:1545-c

Sleep, irritable bowel syndrome and, 123:1686-srr

Smad4/Dpc4, in pancreatic intraductal neoplasia, 124:1958-srr

***Smad* gene.** *See also* **Transforming growth factor β/SMAD pathway**
and colon cancer (mice), 116:1496-ss

Small intestine
aging-related changes in, 122:1688
bacterial overgrowth of, treatment of, 117:755-tmig, 117:794
barrier function, impairment after bacterial exposure, zonulin and, 123:1607
biopsy of, in obscure gastrointestinal bleeding, 118:201-aga
calcium waves in, neural regulation of (guinea pig), 118:892
capsule endoscopy in, 124:1150-ss
cholera toxin-induced secretion in, NK-1 and NK-2 receptors and (rat), 119:890-tmig, 119:1037
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
Crohn's disease in, thymus-expressed chemokine and CCR9⁺ lymphocytes in, 121:246-rc
development of, defects of, in AR/EGF/TGF-α triple null mice, 121:68
disorders of, 121:1257-pmr
diagnosis of, 117:273-ss
double-balloon enteroscopy in, 125:1556-c
epithelium
atrophic changes, Th2 cell dysregulation and (mice), 124:672
differentiation of, *Elf3* in (mice), 122:1455
goblet cell transformation in, Th2 cell dysregulation and (mice), 124:672
morphogenesis of, *Elf3* in (mice), 122:1455
sensitivity to chemotherapy, stress and (rat), 124:660
water transport by, 122:545-srr
fluid homeostasis in, cGMP-dependent protein kinase II and (mice), 118:108
function, after ischemia-reperfusion injury, modulation by sodium-coupled solute (rat), 123:810
functional disorders of, intestinal failure in, 124:1615
glucose-6 phosphatase expression in diabetes and (rat), 117:132
fasting and (rat), 117:132
IgA transcytosis in (mice), 116:610
imaging of, 123:388-pmr
inflammation-induced motor dysfunction in, interstitial cells of Cajal and (mice), 119:1590
integrity of, COX in (mice), 122:1913, 125:637-c
motility, GRP receptor blockade and, 120:331-tmig, 120:361
mucosa
defects of, in AR/EGF/TGF-α triple null mice, 121:68
protein synthesis in, insulin and, 118:299
muscle in, tachykinin receptor NK_1 on, immunohistochemical demonstration of (guinea pig), 120:1140
myenteric neurons in, excitation by serine proteases (guinea pig), 123:1554
nucleoside transporter expression in, nutritional regulation of (rat), 119:1623
obstruction of, therapeutic effect of gastrografin in, 124:852-ss
pain and biomechanical responses to distention in, in systemic sclerosis, 124:1230
permeability
along villus-crypt axis (rat), 119:1029
as predictive marker for IBD relapse, 119:1-tmig, 119:15

radiographic evaluation of, in obscure gastrointestinal bleeding, 118: 201-aga
surgery of, 119:1173-pmr
tumors of, c-K-*ras* mutations in, 118: 995-tmig, 118:1045
villous atrophy
azathioprine-induced, 124:1950-cr
enterocyte mass in, plasma citrulline as marker for, 124:1210
wireless capsule endoscopy versus push enteroscopy in, 119:1431-rc

Small intestine transplantation, donor muscularis in, molecular and functional alterations in, 122:1886

Smoking
cessation, and course of Crohn's disease, 120:1071-tmig, 120:1093
and chronic pancreatitis, 120:682
and familial pancreatic cancer, 124:1292
and inflammatory bowel disease, 124: 521-srr
and painful chronic pancreatitis, 118: 235-c
and pouchitis, 124:1636
and response to infliximab for Crohn's disease, 123:661-tmig, 123:707

Smooth muscle
enteric, persistent postinfective dysfunction, immunologic factors and COX-2 in (mice), 120:1713
esophageal, potassium channels in, inhibition by SNAP-25, 122:993
gastrointestinal, relaxation, protease-activated receptors and (guinea pig, mouse), 116:586
hyperreactive, in irritable bowel syndrome and comorbid conditions, 122:1139-srr
intestinal
calcium-activated potassium channels in, effects of monochloramine on (rabbit), 117:906
postoperative dysfunction, nitric oxide in (rodent), 118:247-tmig, 118: 316
jejunal, sodium channel in, 122:178

Smooth muscle antibody, in liver disease, 120:239-srr

Smooth muscle cells
enteric, plasticity, 117:1438-srr
intestinal, mechanosensitive calcium channels in, 117:900

Smooth muscle relaxants, in treatment of irritable bowel syndrome, 120:652

SNAP-25, and potassium channels in esophageal smooth muscle, 122: 993

SNARE protein, and potassium channels in esophageal smooth muscle, 122:993

Social learning, in irritable bowel syndrome, 121:751-tmig, 121:799

Sodium
colonic absorption of, carbon dioxide and (rat), 122:318
membrane permeability to, modulation by oxidative stress, in hepatoma cells (rat), 118:395
renal handling of, in cirrhosis, 122:1658
retention, in preascites, pathogenesis of, 124:858-ss

Sodium-bicarbonate cotransporter
NBC1, in duodenal bicarbonate secretion (rabbit), 119:406
in pancreatic bicarbonate secretion, 117: 275-ss

Sodium channel
in gastric sensory neurons
gastric injury and (rat), 122:178
gastritis and (rat), 122:752, 122:823-e
in jejunal circular smooth muscle, 122: 178

Sodium-coupled solute, modulation of gut function after ischemia-reperfusion injury (rat), 123:810

Sodium fluoride, for osteoporosis treatment, 124:795-aga

Sodium/hydrogen antiporter (sodium/hydrogen exchanger)
activity, and intracellular signaling in hepatic stellate cells (rat), 116: 1024-tmig, 116:1155
and hepatic fibrosis (rat), 120:545, 120: 572-e
and hepatic stellate cell activation (rat), 120:545, 120:572-e
intestinal, inhibition by CFTR (mice), 125:1148
and intestinal dipeptide absorption, 122: 1322
NHE1, in duodenal bicarbonate secretion (rabbit), 119:406

Sodium/potassium/chloride cotransporter, and anion secretion during cAMP stimulation of duodenum (mice), 123:531

Sodium/proton exchange, defective, in congenital sodium diarrhea, 119:1506

Somatization, in irritable bowel syndrome and comorbid conditions, 122:1139-srr

Somatostatin
amylin and (mice), 123:247
effects on hepatic venous pressure gradient during variceal bleeding, 121:110
inhibition of ET-1-induced hepatic stellate cell contraction (rat), 121: 915
release from gastric D-cells, regulation by nitric oxide (rabbit), 123:566
suppression of, in *Helicobacter pylori* gastritis, 123:566
for variceal bleeding in cirrhosis, comparison with emergency sclerotherapy, 124:1174-tmig, 124: 1277

Somatostatin receptors
and dopamine receptors, cooperation between, 119:4-gn
gene polymorphism, in human pancreatic cancer cells, 120:200
in hepatic stellate cells (rat), 121:915
sst_2, and jejunal afferent nerves (rat), 121:358

Sonic hedgehog, and gastric epithelial morphogenesis and maintenance (humans, mice), 121:240-tmig, 121:317, 121:485-e

Sorbitol, for constipation, 119:1766-aga

Spain, digestive disease science in, 121: 1035-gn

Specialized intestinal metaplasia, and cancer of esophagus and esophagogastric junction, 116: 277

Special Notice, 117:1516
acknowledgment of deceased AGA members, 125:1291

Special Reports and Reviews
Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease, 120:1009
Alcohol and mitochondria: a dysfunctional relationship, 122:2049
Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury, 125:1246
Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy, 123:1350
Autoantibodies in liver disease, 120:239
Autoimmune hepatitis: clinical challenges, 120:1502
Biological actions and therapeutic potential of the glucagon-like peptides, 122:531
Biological clocks and the digestive system, 119:536
The burden of selected digestive diseases in the United States, 122:1500
A "catastrophic hypothesis" for pancreas cancer progression, 124:1958
Chromosomal organization of candidate genes involved in cholesterol

gallstone formation: a murine gallstone map, 120:221
Colon cancer screening, 119:837
Contributions of molecular motor enzymes to vesicle-based protein transport in gastrointestinal epithelial cells, 116:438
Current concepts of celiac disease pathogenesis, 119:234
Development of the human gastrointestinal tract: twenty years of progress, 116:702
Emerging concepts in colorectal neoplasia, 123:862
Emerging roles of purinergic signaling in gastrointestinal epithelial secretion and hepatobiliary function, 116:964
An evidence-based approach to gastroenterology diagnosis, 116:1230
Evolving pathophysiologic models of functional gastrointestinal disorders, 122:2032
18-Fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract, 125:1235
Gender differences in irritable bowel syndrome, 123:1686
The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis, 119:854
The genetics of inflammatory bowel disease, 124:521
Ghrelin for the gastroenterologist: history and potential, 125:1492
Hemochromatosis gene modifies course of hepatitis C viral infection, 124:1509
Hepatitis C in African Americans: summary of a workshop, 119:1385
Immunology of the healthy liver: old questions and new insights, 120:250
Lipoxins: pro-resolution lipid mediatros in intestinal inflammation, 124:1043
The lymphoid liver: considerations on pathways to autoimmune injury, 120:1485
Management of hepatitis B: 2000—summary of a workshop, 120:1828
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection, 120:1000
Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics, 125:597
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC, 116:1453
NF-κB/Rel/IκB: implications in gastrointestinal diseases, 118:1208
Nitric oxide in mucosal defense: a little goes a long way, 119:512
Nonalcoholic steatohepatitis, 121:710
Nonsteroidal anti-inflammatory drug gastropathy, 119:521
Oxidants and antioxidants in alcohol-induced liver disease, 124:778
Pathology of mouse models of intestinal cancer: consensus report and recommendations, 124:762
Patterns of endoscopy use in the United States, 118:619
Pharmacogenetics and clinical gastroenterology, 125:240
Plasticity in the enteric nervous system, 117:1438
Protective strategies against ischemic injury of the liver, 125:917
Recent insides on the mechanisms of liver preconditioning, 125:1480
Refractory celiac disease, 119:243-srr
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease, 122:512
The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction, 117:218
Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers, 117:433
Suppressors of cytokine signaling: relevance to gastrointestinal function and disease, 123:2064
Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?, 122:1139
Treatment of fistulizing Crohn's disease, 119:1132
Tumor necrosis factor: biology and therapeutic inhibitors, 119:1148
Validity of randomized clinical trials in GASTROENTEROLOGY during 1994-2000, 122:1156
Water transport by epithelia of the digestive tract, 122:545
Wilson disease, 125:1868

Spectroscopy, for evaluation of dysplasia in Barrett's esophagus, 120:1607

Sphincter of Oddi
dysfunction, 124:1686
biliary sphincterotomy for, pancreatic stenting after, 117:283-c
type III, abdominal pain in, pathophysiology of, 116:900, 116:996-e
manometry of, 124:1686

Sphincterotomy, for anal fissure, 124:235-aga

Sphingolipids, and *H. pylori*-induced IL-8 production in gastric cancer cell lines, 116:1330

Sphingomyelin, dietary, and intestinal cholesterol absorption, 122:947

Sphingosine 1-phosphate, growth inhibition of hepatocytes by (rat), 124:459

Spiegel, Allen M., new director of NIDDK, 118:4-gn

Spinal cord, stimulation, and ulcerative colitis, 117:215-cr, 117:1256-c

SPINK1. *See* **Serine protease inhibitor, Kazal type 1 (SPINK1)**

SPINK1/PST1, polymorphisms, as disease modifiers in familial and idiopathic chronic pancreatitis, 119:615

Spiro, Howard M., Julius M. Friedenwald Medal presented to, 118:1229-aga

Splenic artery, aneurysms of, 123:1427-im

Splenic vein, thrombosis, increased levels of factor VIII:C as risk factor for, 120:1563-c

Splenorenal shunt, 117:6-im

Spondyloarthropathy, enterogenic, clonal T-cell expansions in, 119:1745-cr

Spontaneous bacterial peritonitis
acute, treatment of, 120:726
current management of, 120:726
primary prophylaxis for, 120:726
recurrent, prevention of, 120:726
reduced mortality in, with intravenous albumin, 118:231-ss

Sprue. *See* **Celiac disease**

Squamous cell carcinoma, primary rectal, HPV type 16 and, 120:988-cr, 120:1046-e

Src, in TUDC- and hypo-osmolarity-induced choleresis, 124:1476

Src kinase, activation of, and intestinal epithelial response to TNF-α (rat), 122:331

Starch, resistant, 118:1235-aga

Starling, Ernest H., 124:1766

Starvation
ghrelin signaling in, gastric afferent vagal nerve and (rat), 123:1120
metabolic changes in, 122:1677

STAT3, activated, and malignant phenotype in human pancreatic cancer, 125:649-tmig, 125:891
Stat3, antiapoptotic signaling by, in pancreatic cancer, 123:2052
Statins
as antimetastatic agents, 122:253-tmig, 122:308, 122:565-e
in pancreatic cancer, 123:1747-c
cytotoxic activity of, in pancreatic cancer, 123:1747-c
induction of hepatic *mdr* expression (rat), 117:678
and sulindac-induced apoptosis in colon cancer cells, 117:755-tmig, 117:838
Statistics, use of, book on, 122:835-pmr
Stavudine, GI toxicity and GI-associated drug interactions of, 120:607
Steatohepatitis
alcoholic, and nonalcoholic, in same patient, 123:1705-aga
nonalcoholic, 121:710-srr
clinical features of, 121:710-srr
conditions associated with, 121:710-srr
diagnosis of, 121:710-srr
diagnostic criteria for, 122:840-c
epidemiology of, 121:710-srr
grading of, 123:1705-aga
hepatic iron and, 118:981-ss
and hepatocellular carcinoma, 123:134, 123:375-e
histologic criteria for, 123:1705-aga
histology of, 121:710-srr
insulin resistance and mitochondrial abnormalities in, 120:1183, 120:1281-e
iron overload and, 123:1705-aga
laboratory findings in, 121:710-srr
natural history of, 121:710-srr, 123:134, 123:375-e
in obesity, 123:1705-aga
predictors of, 121:91
pathogenesis of, 121:710-srr
staging of, 123:1705-aga
treatment of, 121:710-srr
Steatorrhea, pancreatic, bacterial or porcine lipase and diet in (dog), 116:431
Steatosis
hepatic, insulin resistance and, 118:986-c
hepatitis C virus proteins and, 122:352, 122:568-e
Stellate cells
hepatic
activation of, Na^+/H^+ exchanger and (rat), 120:545, 120:572-e
antifibrogenic effects of aldosterone antagonists in, 124:504
antifibrogenic effects of Smad7 in (rat), 125:2-tmig, 125:178
apoptosis
peripheral-type benzodiazepine receptor expression and, 120:1212, 120:1285-e
stimulation of, and inhibition of hepatic fibrosis (humans, rats), 121:512-tmig, 121:685
caspase 9-dependent killing of, by Kupffer cells, 123:845
contraction
angiotensin II and, 118:996-tmig, 118:1149, 118:1261-e
endothelin-1-induced, suppression by somatostatin (rat), 121:915
and increased intrahepatic vascular resistance in chronic liver disease, 118:996-tmig, 118:1149, 118:1261-e
migration of, and liver fibrosis, 124:147
phenotypic and functional properties of (rat), 117:1038-tmig, 117:1205, 117:1244-e
profibrogenic and proinflammatory actions, PPAR-γ ligands and, 119:288-tmig, 119:466
proliferation
angiotensin II and, 118:996-tmig, 118:1149, 118:1261-e
PPAR-β signaling in, 124:184
rapamycin and (rat), 117:1038-tmig, 117:1198, 117:1244-e
renin-angiotensin system in, 125:117
sodium/hydrogen exchange and intracellular signaling in (rat), 116:1024-tmig, 116:1155
nitrovasodilator action in, 119:288-tmig, 119:479
pancreatic, and alcoholic pancreatic fibrosis (rat), 118:650-tmig, 118:780
PDGF-induced proliferation and migration of, nitrovasodilators and, 119:288-tmig, 119:479
PPAR-γ activation in, and inhibition of hepatic fibrosis by thiazolidinediones (rat), 122:1924
Stem cell factor, and development of interstitial cells of Cajal (mice), 117:522-tmig, 117:584
Stem cell research, federal funding for, 119:1187-gn, 121:753-gn
Stem cells
colonic, identification and isolation of, based on integrin expression patterns, 123:1941
human, differentiation into hepatocytes (mice), 124:1891
intestinal, molecular characterization of (mice), 125:266-ss
lineage specification, in liver development, β-catenin and, 124:202
neural
nitric oxide production and nNOS expression in, 121:757-rc
RET expression in, 121:757-rc
transplantation into gastrointestinal tract, 121:757-rc
Stem cell transplantation
bone marrow, into liver, 123:654-c
in primary AL amyloidosis, 122:2026-cr
Stensen, Niels, 120:38:00
Stents/stenting
pancreatic, after biliary sphincterotomy for sphincter of Oddi dysfunction, 117:283-c
pancreatic duct, and post-ERCP pancreatitis, 125:1274-ss
for postoperative bile duct strictures, long-term results with, 122:1533-ss
Steroids
for Crohn's disease, 123:393-c
for inflammatory bowel disease, natural history of, 121:239-tmig, 121:255
for moderate and severe ulcerative colitis, comparison with unfractionated heparin, 119:889-tmig, 119:8903
and response to intravenous azathioprine for Crohn's disease, 118:1281-c
for ulcerative colitis, comparison with unfractionated heparin, 120:1306-c, 120:1307-c
Sterol 12α-hydroxylase, regulation of (rat), 118:599
Sterol carrier protein 2, in hepatic lipid metabolism and enterohepatic sterol circulation (mice), 119:1708
Sterols, enterohepatic circulation of, sterol carrier protein 2 and (mice), 119:1708
Stimulator of Fe transport (SFT), duodenal expression of, in anemia and hemochromatosis, 120:1404
Stomach. *See also* Gastric
abscess in, 124:599-im
aging-related changes in, 122:1688
antral distention, perception of, measurement of, 124:1220
antro-fundic dysfunctions, in functional dyspepsia, 124:1220
blood flow in, interdigestive, regulation by motilin (dog), 123:1578
calcium receptor expression in (rat), 116:118
cancer. *See* **Gastric cancer**
claudin expression and subcellular localization in, heterogeneity of (rat), 120:411
development of, 116:702-srr

electrical stimulation of (dog), 118:247-tmig, 118:258, 118:433-e
endocrine carcinoma of, 117:510-c
prognosis for, 116:532
endoscopic mucosal resection in, perforations caused by, endoscopic closure using clips, 125:1896-ss
epithelial hyperplasia in, NF-κB2 dysregulation in, 118:1208-srr
epithelium of, water transport by, 122:545-srr
fundic distention, perception of, measurement of, 124:1220
fundic gland polyps, clinical management of, 125:1462
heregulin and its receptors in, 117:1119
human antral gastrin cells, calcium-sensing receptor in, mechanism of action of, 120:1128, 120:1279-e
inflammation in. *See also* **Gastritis**
Helicobacter pylori oipA and, 123:414
macrophage migration inhibitory factor and (rat), 121:619
and sodium currents in gastric sensory neurons (rat), 122:394
intestinal metaplasia in, induced by Cdx2 ectopic expression (transgenic mice), 122:689, 125:996-c
leptin and leptin receptor expression in, 117:509-c
low-grade MALT lymphoma of, 120:1884-c
mucosa
antral, leptin receptors and STAT-3 in (rat), 121:1417
damaged, CINC-2β and *Reg* gene expression in (rat), 119:1610
metastatic calcification in, 119:894-im
mucosal defense in, gastric NOS expression and (rat), 123:173
mucous layer of, acid channels in (rat), 119:1297, 119:1397-e
muscles of, COX-2 expression and function in (mice), 122:1442
neuroendocrine system of, leptin and, 123:1751-c
neuromuscular function, in chronic *Helicobacter pylori* infection (mice), 123:1205
normal versus inflamed, and response to intragastric acid (rat), 125:1410
pH in, effects of omeprazole on, CYP2C19 polymorphism and, 119:609-tmig, 119:670
primary B-cell lymphoma of, 119:1185-tmig, 119:1191
proximal
motor function, in functional dyspepsia, 121:1054
pooling of gastric secretions in, SPECT imaging of, 123:2157-c
sensorimotor function, nitrergic and α_2-adrenergic modulation of, 116:510-tmig, 116:573
surgery of, 119:1173-pmr
susceptibility to low pH, *H. pylori cagA* 3′ repeat region and, 117:342
Stress
chronic, and intestinal inflammation (rat), 123:1099
colonic motor activity in, peripheral CRF in (rat), 119:1569
effect on colonic epithelial barrier, interferon-γ and myosin light chain kinase in (mice), 125:795
and epithelial sensitivity to chemotherapy (rat), 124:660
and IBS symptoms, 123:2108-aga
and induction of EGF-like growth factors in gastric epithelial cells (rat), 120:108
psychological, and gastrointestinal permeability (rat), 119:1019
reactivity to, in irritable bowel syndrome and comorbid conditions, 122:1139-srr
and responsivity to colonic distention (rat), 123:1216
Stress management, 116:773-ss
Stress response, biobehavioral, and gender differences in IBS, 123:1686-srr
Stretta device, in treatment of gastroesophageal reflux disease, 123:643-ss
Stromal tumors, gastrointestinal
activating mutation in, 124:596-gn
familial, with dysphagia and germline mutation of KIT gene, 122:1493-cr
PDGFR α gain-of-function mutations and, 125:660-rc, 125:967-e
treatment of, 124:1151-ss
Stromelysin
gene polymorphism, and primary sclerosing cholangitis, 121:124
gene promoter, variants, in primary biliary cirrhosis, 122:247-c
Stromelysin-1, expression, IL-12 enhancement of T cell responses and, 117:1069, 117:1238-e
Strongyloidosis, treatment of, 119:1805-c
Structural biology
tools for, 123:1350-srr
and viral hepatitis, 123:1350-srr
Student Loan Interest Deduction Act, 120:1320-gn
Subclavian artery, aberrant retroesophageal left, esophageal compression by, 117:1270-im
Sucrase-isomaltase
deficiency of, congenital, 125:1678
as epithelial cAMP-dependent chloride channel, 120:117, 120:299-e, 121:741-c
Sulfasalazine
adverse effects and side effects of, 124:1986-ss
inhibition of nuclear factor κB activation, molecular mechanism of, 119:1209
plasma levels, after single oral dose, 117:1514-c
Sulindac
chemopreventive effects of, lovastatin and, 117:755-tmig, 117:838
for familial adenomatous polyposis, long-term effectiveness of, 122:641
hepatobiliary transport of, 117:755-tmig, 117:962
for primary chemoprevention of familial adenomatous polyposis, 123:379-ss
secretion into bile, 117:962
Superantigens, colonic bacterial, and colitis (mice), 125:1785
Superior mesenteric arteriovenous fistula, and portal hypertension, 125:653-im
Superior mesenteric artery
embolus, management of, 118:954
thrombosis, management of, 118:954
Superior mesenteric artery syndrome, 121:516-im
Superior mesenteric venous, thrombosis, management of, 118:954
Superoxide, and inducible NOS expression in hepatocytes (rat), 118:608
Superoxide dismutase (SOD)
manganese, polymorphism in, and alcoholic liver disease susceptibility, 124:2000-c
mitochondrial targeting sequence of, homozygosity for alanine in, and risk for alcoholic liver disease, 120:1318-tmig, 120:1468
nonpeptidyl mimic of, prevention of Fas-induced acute liver failure (mice), 121:1451
and reduction of alcohol-induced liver injury (rat), 120:1241
Suppressors of cytokine signaling (SOCS), in gastrointestinal function and disease, 123:2064-srr
Suprahyoid muscle, strengthening exercise for, in patients with dysphagia due to abnormal UES opening, 122:1314

Surgery
of alimentary tract, 123:951-pmr
anal, 119:1173-pmr
antireflux
cancer risk after, 121:1270-tmig, 121:1286, 121:1506-e
esophageal manometry before, 121:5, 121:214-e
bariatric
complications of, 123:882-aga
for obesity, 123:879-aga, 123:882-aga
patients, medical management of, 123:882-aga
for chronic mesenteric ischemia, 118:954
in chronic pancreatitis, pain relief resulting from, 116:1023-tmig, 116:1132, 116:1252-e, 117:1026-c, 118:235-c
colonic, 119:1173-pmr
in colonic ischemia, 118:954
for constipation, 119:1761-aga, 119:1766-aga
esophageal, 125:625-pmr
for familial polyposis coli, 118:1275-pmr
for fistulous Crohn's disease, 119:1132-srr
gastric
lack of association with Barrett's esophagus, 121:1281, 121:1502-e, 123:954-c
lack of association with esophageal cancer, 121:1281, 121:1502-e, 123:954-c
gastroenterologist training in, 124:1091-aga
for gastrointestinal bleeding, 118:201-aga
laparoscopic
colorectal, 118:806-pmr
for obesity, 123:882-aga
of liver and biliary tract, 121:1524-pmr
minimally invasive, 116:513-ce
for pancreatic cancer, AGA technical review on, 117:1464-aga
protective strategies in, against hepatic ischemic injury, 125:917-srr
rectal, 119:1173-pmr
in short-bowel syndrome, 124:1105-aga, 124:1111-aga
for ulcerative colitis, effect on fertility and sexual function in women, 122:15, 122:226-e
upper gastrointestinal tract, 119:1173-pmr, 122:835-pmr

Survivin
deficiency of, modulation of Fas-induced apoptosis, via mitochondrial pathways (mice), 123:619
in liver, 124:1565-c

Sustiva. *See* Efavirenz

Swallowing
central control of, 121:420-cr
CNS nitric oxide in, 119:287-tmig, 119:377
in congenital central hypoventilation syndrome, 122:1258
lower esophageal sphincter relaxation in, 122:1184-c
rehabilitative exercise for, in patients with dysphagia due to abnormal UES opening, 122:1314

Swallowing disorders. *See also* Dysphagia
endoscopic evaluation and treatment of, 122:585-pmr

Sweet's syndrome, 124:287-im

Sympathetic nervous system
in cirrhosis, 122:1658
hyperactivity, in pre-ascitic and ascitic cirrhosis, 122:1538-ss

Symptom diaries, in anorectal disorders, AGA technical review on, 116:735-aga

Symptom questionnaires, in anorectal disorders, AGA technical review on, 116:735-aga

Syringohydromyelia, 119:614-im

Systemic sclerosis, duodenal distention in, pain and biomechanical responses to, 124:1230

Tachykinin receptor, NK_1, immunohistochemical demonstration of, on intestinal muscle and epithelia (guinea pig), 120:1140

Tachykinins
in enterotoxigenic-induced secretion (rat), 119:890-tmig, 119:1037
in human sigmoid circular muscle, 119:51
and nerve-mediated contractions in human esophagus, 120:1-tmig, 120:39
and peristalsis in isolated distal colon (guinea pig), 120:938

Tacrolimus
adverse effects and side effects of, 125:380
for autoimmune hepatitis, 120:1502-srr
for Crohn's disease, with fistulous complications, 119:1132-srr, 125:380
for Crohn's fistula, 124:1595
for perianal Crohn's disease, 125:1503-aga, 125:1508-aga

***TAP2* gene,** polymorphism, and hepatitis C infection, 116:1023-tmig, 116:1149

Tartikoff, Lily, and CRC screening, 120:333-gn

Taste receptors, cloning of, 116:1284-gn

Taurolithocholic acid-3 sulfate, hepatocyte apoptosis induced by, mechanisms of (rat), 122:1411

Tauroursodeoxycholate
choleresis induced by, integrins and Src in, 124:1476
effect on taurolithocholic acid-3 sulfate-induced apoptosis in hepatocytes (rat), 122:1411

Tauroursodesoxycholate, choleresis induced by, mechanisms of, 121:407

3TC. *See* Lamivudine

T cells. *See* T lymphocytes (T cells)

***TCF1* gene,** mutations of, in colorectal cancer, 124:1311

Technological advances, effects on gastroenterology, 116:787-ce

Tegaserod
for irritable bowel syndrome, 123:2108-aga
and orocecal transit in constipation-predominant IBS, 118:463
pharmacology of, 118:463

Telangiectasia. *See also* Hereditary hemorrhagic telangiectasia (HHT)
bleeding, of gastrointestinal tract, abnormal von Willebrand factor in, 120:346
cuticular, 124:1595

Telomerase, in immortalization of fetal hepatocytes, 124:283-tmig, 124:432, 124:568-e

Telomeres, and carcinogenesis, 119:891-gn

Temporomandibular joint disorder, comorbidity with irritable bowel syndrome, 122:1139-srr

Tenofovir disoproxil fumarate, antiviral effect in lamivudine-resistant hepatitis B, 124:586-c

Tensostat, for gastric perception studies, 118:641-c

Terlipressin
and *N*-acetylcysteine, in hepatorenal syndrome, 123:2160-c
and albumin, for hepatorenal syndrome, 124:1552-ss
and hepatorenal syndrome in cirrhotic patients, 122:922
for variceal bleeding in cirrhosis, comparison with emergency sclerotherapy, 124:1174-tmig, 124:1277

Thalidomide
cessation of, intractable insomnia after, 120:1567-c

for Crohn's disease, 119:596-c
open-label trials of, 117:1265-tmig, 117:1271, 117:1278, 117:1485-e
for inflammatory bowel disease, 122: 1592
suppression of alcoholic liver injury, mechanism of action of (rat), 123:291
Theophylline, oxidative metabolism of, in cirrhosis, 116:915, 117:1025-c
Thermal ablation, for Barrett's esophagus, 122:1569
Thiazolidinediones, inhibition of hepatic fibrosis (rat), 122:1924
6-Thioguanine, for inflammatory bowel disease, liver injury caused by, 125:298-rc
Thiopurine methyltransferase
activity of, 122:838-c, 122:2082-ss
deficiency, 125:240-srr
in Crohn's disease, diagnosis of, 121: 500-c
phenotype-genotype correlation in, 121:500-c
gene mutations, and myelosuppression with azathioprine therapy for Crohn's disease, 118:995-tmig, 118:1025
Thiopurines, pharmacogenetics of, 122: 838-c
This Month at the NIH, 123:6
Digestive Sciences Integrated Review Group, 125:651-gn
NIDDK Hepatotoxicity Clinical Research Network, 125:1008-gn
NIH roadmap: accelerating medical discovery to improve health, 125: 1573
Research funding opportunities in complementary and alternative medicine, 124:1995
This Month in GASTROENTEROLOGY
Absorption of incompletely degrades gliadin peptides in patients with active celiac disease, 125:647
Accuracy of colonic polyp detection by RNs and MDs, 117:291
Achalasia and HLA phenotypes, 117:1
Acid-induced nausea in dyspeptic patients, 116:509
Activated STAT3 may contribute to malignant phenotype of human pancreatic cancer, 125:649
Activation of MAP kinase pathways by acid exposure of Barrett's esophagus may contribute to carcinogenesis, 122:253
Acute diarrhea in children: is rehydration therapy enough?, 120:783
Advances in developing gene therapy for Crohn's disease, 123:1758-tmig
Advances in hepatic xenotransplantation for treatment of liver failure and cirrhosis, 124:282
Alcoholic pancreatic fibrosis and stellate cells, 118:650
Alterations in enteric nerves and interstitial cells of Cajal are associated with slow-transit constipation and megacolon, 123:1422
Altered vesicular trafficking and mistargeting of polarized membrane domains in cholestatic hepatocytes, 121:1033
Alternatives to intact liver transplantation: immortalizing human fetal hepatocytes without disrupting their differentiation potential, 124:283
Angiotensin II receptor antagonists for treatment of portal hypertension in cirrhosis, 121:240
Antisecretory effects of boiled rice on the gut, 116:1282
APC and cell cycle regulation, 123:662
APC 1307K and the risk of colorectal cancer, 120:331
Apoptosis in GI inflammatory diseases, 116:509
Assessing levator ani function improves diagnosis and management of anal incontinence, 123:1421
Asymptomatic Barrett's: implications for screening, 123:402
B-boxes and barriers, 123:662
Bile acid therapy for the short-bowel syndrome, 116:1
Bone loss and inflammation, 119:889
Budesonide for treatment dependent autoimmune hepatitis, 119:1185
Can baseline adenoma characteristics predict the recurrence of advanced adenomas?, 120:1071
Can calprotectin simplify the diagnosis of irritable bowel syndrome?, 123:401
Can screening impact cancer mortality in HNPCC?, 118:815
Can symptoms alone be used for the diagnosis of pouchitis?, 121:239
Cardiotrophin-1 is up-regulated in regenerating liver and is cytoprotective, 125:3
CDAI versus PCDAI in pediatric Crohn's disease, 116:509
Cereal fiber may reduce the risk of gastric cardia cancer, 120:331
Chest pain in achalasia, 116:1281
Childhood viral infections and IBD, 116: 783
Cholesterol gallstones, DCA, and large bowel transit times, 119:609
Cholesterol gallstones and apoE, 118:650
Chromoendoscopy for detection of colonic mucosal neoplasms in ulcerative colitis, 124:873
Chronic visceral pain and IBS, 119:1185
Cigarette smoke and IBD, 117:756
Clinicopathological significance and relationship to microsatellite instability of DNA methylation in sporadic colorectal cancers, 122: 1196
Clues to who will or won't respond to infliximab: a smoking gun?, 123: 661
Colonic distention in patients with IBS, 116:1
Colonic epithelial PPAR-γ expression is determined by enteric flora and is impaired in patients with ulcerative colitis, 124:1174
Colonic luminal contents induce cyclooxygenase 2 transcription, 120:332
Colonization with *H. pylori Cag*$^+$ strains leads to enhanced levels of MMP-7 within inflamed mucosa: potential contributor to increased cancer risk, 125:1005
Colorectal cancer treatment prospects, 118:2
Combination therapy for PBC, 117:756
Continuous estrogen-progestagen treatment does not prevent rebleeding from gastrointestinal angiodysplasia, 121:1033
Cortical topography of the anorectum, 117:1
COX-2 expression in CRCs of HNPCC, 117:291
Cox-2 inhibition and renal function in cirrhosis, 116:1024
COX-2 inhibition by rofecoxib may negatively regulate angiogenesis in human colorectal cancer liver metastases, 125:647
COX-2 inhibitors may prevent dysplasia and adenocarcinoma associated with Barrett's esophagus, 123:1
COX-2 inhibits spare gastroprotective prostaglandins, 120:784
The Crohn's disease-associated gene, CARD15/NOD2, may be an antibacterial factor in human intestinal epithelial cells, 124:875
Cyclooxygenase 2 expression in Barrett's esophagus, 118:457
The CYP2C19 polymorphism and effects of omeprazole treatment, 119:609
Cytokine polymorphisms in autoimmune hepatitis, 117:522

Cytokine regulation of intestinal epithelial NOD2/CARD15 gene expression, 124:875
Detection of Barrett's esophagus, 119:609
Detection of hepatoma relapses, 119:287
Development of rhythmicity in the GI tract, 117:521
Diet and colorectal cancer: maybe "something to it" after all, 122:1715
Dietary calcium enhances host resistance to infectious diarrheal diseases, 125:286
Differences among enteric flora species: some capable of inducing whereas other inhibiting colitis, 125:1
Does gastrin enhance colon cancer?, 119:1
Does *H. pylori* eradication halt the development of gastric carcinogenesis?, 119:1
Does the Wilson's disease protein only inhibit copper excretion?, 117:1266
Do genes determine susceptibility to alcoholic liver disease?, 120:1318
ECL-induced apoptosis, 118:457
Effectiveness of medical treatment for chronic hepatitis C, 122:1195
Effect of duodenal iron absorption on iron homeostasis, 120:1317
Effects of NSAIDs on the liver and colon, 117:755
Effects of octreotide on portal hypertension, 120:02:00
Electrical stimulation of the stomach, 118:247
Emergency sclerotherapy versus vasoactive drugs in the treatment of variceal bleeding in cirrhotic patients: a meta-analysis, 124:1174
EMR for the treatment of early cancer and high-grade dysplasia in Barrett's esophagus, 118:649
Endogenous PPARγ mediates inflammation in ischemia-reperfusion injury, 120:332
Enteric flora and mucosal lymphocytes maintain physiological expression of cytoprotective colonic heat shock proteins, 124:1175
Enzyme-sensing molecular beacons for early and more sensitive detection of dysplastic intestinal adenomas: endoscopic application around the corner?, 122:254
Epigenetic alterations in human hepatocellular carcinoma, 116:234
Erythromycin is effective in clearing gastric blood before emergency endoscopy, 123:1
Esophageal double-peaked waves, 118:457
Esophageal manometry for the diagnosis of achalasia, 120:783
Esophagogastric cancer micrometastases, 116:509
Exposure to gluten and autoimmunity, 117:291
Expression of the calcium-binding protein, s100A4, is associated with more aggressive colon cancers, 123:1423
Extended treatment for hepatitis B with lamivudine, 119:1
Family history of colorectal cancer may increase IBD-associated CRC, 120:1317
Farnesyl transferase inhibitors, Ras, and EGF receptor ligands, 117:521
Fat digestion modulates gastrointestinal symptoms, 120:1071
Fatty liver and uncoupling proteins, 116:1024
FII and FV mutations in portal venous thrombosis, 116:2
Folate and colon cancer, 119:1
Gallbladder bile in Crohn's disease, 116:1282
Gallbladder disease in the United States, 117:522
Gallbladder hypomotility in pregnancy, 116:234
Gallbladder mucin and cholesterol gallstones, 116:784
Gap junctions and bile flow, 116:1024
Gastric atrophy and acid suppression, 117:291
Gastric cancer and *H. pylori*, 118:1
Gastric sensorimotor function in dyspepsia, 116:510
Gene altered Kupffer cells for the treatment of hepatic diseases, 124:3
Genes and IBD, 123:661
Glial-derived neurotrophic factors regulate apoptosis in colonic epithelial cells, 124:1721
Global distribution of *H. pylori* genotypes, 116:783
Glucagon-like peptide 2 administration for the treatment of short-bowel syndrome, 120:783
Glucocorticoid resistance in UC, 118:816
The good and bad about TIPS for the treatment of refractory ascites in cirrhosis, 123:1757
H. pylori and healing of reflux esophagitis, 117:1
H. pylori and ulcer bleeding in NSAID users, 116:1281
H. pylori colonization of nonhuman primates, 116:1
H. pylori-induced gastric MALTomas, 117:2
H. pylori infection of the duodenum, 116:233
HCV: a smart virus?, 116:2
HCV in blood donors, 116:784
HCV replication and hepatic cell cycle, 118:2
HCV-specific T-cell reactivity may determine treatment response, 118:248
The H63D mutation of hereditary hemochromatosis is not clinically significant, 122:599
Healing of Crohn's lesions with anti-TNF, 116:1023
Hepatic fibrosis revisited, 117:1038
Hepatic transplantation with HCV-positive grafts in HCV-associated liver failure, 117:2
Hepatitis B viral genotype and clinical outcome, 118:458
Hepatitis C infection impairs patient and allograft survival after liver transplantation, 122:848
Hepatitis C viral kinetics and peginterferon α2a, 120:1318
Hepatitis in heart transplant recipients, 119:889
Heredity and social learning both contribute to irritable bowel syndrome, 121:751
Hiatal hernias and GERD, 118:650
High-dose ursodeoxycholic acid provides benefit to patients with primary biliary cirrhosis, 121:752
A high prevalence of psychiatric disorders in patients with hepatitis C, 123:402
How do NSAIDs cause gastric injury?, 119:609
How do short-chain fatty acids protect colonic mucosa, 121:511
Hox genes and the gut, 117:1266
Human papilloma virus and the risk of anal canal cancer, 120:784
IBD: complications and pathogenesis, 116:233
IBD and the risk for colorectal cancer, 120:783
Identifying causes of 6-mercaptopurine resistance in patients with inflammatory bowel diseases by measuring 6-MP metabolic profiles, 122:848
Immune intervention in IBD, 117:521
Immune responses in acute *H. pylori* infection, 118:247
Immune responses in pathogenesis of pancreatitis, 118:458

Immunization with *H. pylori* urease in humans, 116:783
Immunohistochemical effects of TNF-α antibody in Crohn's disease, 116:1
The importance of chemokines in the development of *C. difficile* toxin-induced intestinal inflammation, 122:600
Inflammation and *H. pylori*, 116:1281
From inflammation to fibrosis in hepatitis C, 125:1570
From inflammation to fibrosis in IBD, 125:1570
Inflammatory bowel disease is not associated with an increased risk of lymphoma, 121:1034
Inhibition of cyclooxygenase-2 prevents the development of experimental hepatic fibrosis, 125:286
Inhibition of hepatic fibrosis by stimulating apoptosis of hepatic stellate cells, 121:512
Initial results of etanercept, a human soluble tumor necrosis factor receptor:Fc fusion protein, for treatment of active Crohn's disease, 121:1033
Insights into how *Giardia* causes diarrhea, 123:964
Insights into intestinal bicarbonate secretion, 122:600
Insights into the development of acute respiratory distress syndrome associated with acute pancreatitis, 122:2
Insights into the genetic and functional significance of NOD2 variants associated with Crohn's disease, 124:2
Interferon and hepatic fibrosis, 116:234
Interferon-ribavirin treatment for chronic hepatitis C, 117:292
Interferon treatment reduces mortality from hepatocellular carcinoma, 123:402
The interleukin 1 receptor antagonist gene allele 2 predicts pouchitis following pouch-anal anastomosis in ulcerative colitis, 121:751
Interleukin 10 reduces postherapeutic ERCP-induced pancreatitis, 120:332
Intestinal damage in SIV, 116:1023
Intestinal ethanol production in obesity: implications for fatty liver?, 119:1185
Intestinal trefoil factor in colon cancer, 118:1
Intraepithelial lymphocytes in celiac disease, 118:816
Intravenous azathioprine for Crohn's disease, 117:521
Intravenous hydrocortisone premedication prevents antibodies to infliximab in Crohn's disease, 124:874
Iron status and hemochromatosis gene mutations in chronic hepatitis C, 116:2
Irritable bowel syndrome in children, 120:01:00
Ischemic injury of the liver, 116:2
Isosorbide-5-mononitrate does not reduce the incidence of first variceal bleeding in patients unable to take β-blockers, 121:752
Is the molecular evolution of hepatitis C quasispecies in post-liver transplant patients related to outcome of recurrent hepatitis?, 123:1422
JC virus in the gastrointestinal tract, 119:1185
Kappa opioids and visceral nociception, 117:292
Keratinocyte growth factor and its receptor in healing esophageal ulcers, 122:254
K-*ras* mutations and human GI tract tumors, 118:995
Leukotrienes, cancer, and apoptosis, 119:889
Lipases, diets, and pancreatic steatorrhea, 116:234
Liver transplantation for HCV, 117:522
Localization of mutant Wilson disease protein, 120:784
Long-chain fatty acids and appetite suppression, 119:889
Long-term effects of histamine receptor blockade on nocturnal gastric acid breakthrough, 122:599
Long-term lamivudine therapy of hepatitis B reduces hepatic necroinflammatory activity and reverses fibrosis, 124:1
Long-term nutritional supplementation with oral branch chain amino acids prevents progressive hepatic failure and improves surrogate markers and perceived health status, 124:1723
Long-term outcome of patients with short bowel syndrome, 117:1037
Loss of intestinal cells of Cajal in insulin-dependent diabetes, 121:240
Macrophage migration inhibitory factor plays an important role in the pathogenesis of severe acute pancreatitis, 124:595
MALToma and the *Helicobacter* genus, 118:815
Mechanism of infliximab anti-inflammatory action: induction of monocyte apoptosis, 121:1034
Mechanisms for gastrointestinal motility, 120:331
Medical therapy is as effective as endoscopic banding for prevention of variceal bleeding, 123:963
6-Mercaptopurine treatment of childbearing patients with IBD is safe, 124:1
Mesalamine in IBD, 116:509
Meta-analysis: cagA guilty, 125:1569
Methotrexate for PBC, 117:292
Microarray-based genomics: a new tool for the study of the gastrointestinal tract, 122:1196
Microsatellite instability and genetic testing for HNPCC, 120:01:00
Microsatellite instability may improve prognosis for patients with colorectal cancer, 119:889
Modulation of barrier function during apoptosis, 119:1425
More about NOD2/CARD15: a susceptibility gene of Crohn's disease, 123:1
More evidence for the efficacy of NSAIDs in chemoprevention of colorectal polyps, 125:285
The motilin-related peptide: a novel gastric peptide hormone, 119:287
Mucin and colon cancer hepatic metastasis, 116:233
NAFLD and radiologic imaging, 123:662
Na^+/H^+ exchange and PDGF-induced hepatic stellate cell growth, 116:1024
The natural history of corticosteroid therapy for IBD in the community, 121:239
New approach for treatment on pancreatic cancer?, 121:512
A new colorectal cancer susceptibility gene, 116:783
New developments in patients with IBD, 117:1037
New findings related to the treatment of *H. pylori*, 119:287
New insights in cryptosporidial infections of the GI tract, 118:248
New insights into HIV-associated diarrheal disease, 124:282
New insights into pancreatic acinar cell dysfunction in cystic fibrosis, 121:752
New insights into the development of hepatic fibrosis, 118:996
New insights into the pathogenesis of celiac disease, 116:510

New insights into the use of PPIs, 118: 649
New insights to circulatory changes in portal hypertension, 119:1
New insights to gastroesophageal acid regurgitation, 117:1037
New insights to the pathogenesis of acute pancreatitis, 119:609
New insights to the pathogenesis of constipation, 118:1
New insights to the prevention of hepatic fibrosis, 119:287
A new model of chronic reflux esophagitis, 116:1
A new neuropeptide involved in the regulation of GI motility, 116:2
New radiographic techniques for the detection of colonic lesions, 119: 287
New therapies for IBD?, 118:247
A new treatment for colonic motility disorders?, 119:889
New treatment modalities for inflammatory bowel disease, 120:1317
NO (nitric oxide)-aspirin: a GI-safe aspirin with antiplatelet, anti-inflammatory, and analgesic activities?, 124:593
No more "just knock me out"?, 125: 1569
Normal aminotransferases and mild liver histology in patients with hepatitis C predict a more favorable natural history, 124:1
Novel approaches to patients with persistent HCV, 118:649
A novel approach to treat GERD?, 118:1
A novel biomarker for the detection of colon cancer: tropomyosin (TC22), 123:2
A novel form of hepatic transplantation?, 118:248
A novel goblet cell-specific protein, RELMβ/FIZZ2, regulated by normal enteric bacteria, 1251296
Novel infectivity-enhanced, cyclooxygenase 2 promoter-based conditional replicative adenovirus for the treatment of pancreatic cancer, 125:1006
A novel mutation in classical hemochromatosis, 116:1282
Novel predictive markers of relapse in patients with quiescent IBD?, 119:1
Novel strategies for the treatment of IBD, 119:889
A novel treatment for *H. pylori*?, 117: 1265
Novel treatment of neuroendocrine tumors, 118:650
NSAID-induced apoptosis and PKC isoforms, 118:457
NSAIDs in the prevention of IBD-associated colon cancer?, 118:248
Optical coherence tomography in the diagnosis of specialized intestinal metaplasia, 120:01:00
oral budesonide is effective for treatment of collagenous colitis, 123:964
Oral contraceptives and FNH, 118:458
Oral tolerance in the gut, 118:2
Organic anion transporters during hepatic regeneration, 117:1266
Outcomes in nonalcoholic fatty liver disease, 116:1282
Oxidants potentiate agonist-induced Cl-secretion in intestinal epithelial T84 cells, 120:02:00
Pain in alcohol-induced chronic pancreatitis, 116:1023
Pancreatic cancer and obesity, 120:1072
Paneth cells abundantly express NOD2, a gene in which mutations have been associated with the development of Crohn's disease, 125:1
Pathophysiology of the diarrhea of collagenous colitis, 123:401
Pentoxifylline and acute alcoholic hepatitis, 119:1426
Pharmacogenomics and the treatment of irritable bowel syndrome, 123: 401
Phenotypic expression of *HFE* mutations in patients with hepatic iron overload, 116:233
Phosphatidylinositol 3-kinase and intestinal differentiation, 120:1317
Photodynamic therapy with best supportive care improves survival in patients with nonresectable cholangiocarcinoma, 1251295
p53 mutations may affect the prognosis of gastric carcinomas, 118:995
Portal hypertension and acute variceal bleeding, 117:522
Postomeprazole rebound gastric acid secretion, 116:233
Postoperative ileus is maintained by intestinal immune infiltrates that activate neural pathways in mice, 125:1005
A potpourri on Crohn's disease, 117:2
A potpourri on IBD, 117:755, 118:995
A potpourri on intestinal motility, 119:1
A potpourri on liver disease, 117:1038
PPAR-γ ligands prevent experimentally induced colon carcinogenesis in mice, 124:281
Predicting patterns of Crohn's disease through genetic markers, 122: 847
Predictive factors of cirrhosis development in ursodeoxycholic acid-treated patients with primary biliary cirrhosis, 122:599
Predictors for relapse in ulcerative colitis, 120:01:00
Predictors of post-TIPS mortality, 118:2
Preliminary studies of budesonide in the treatment of collagenous colitis, 122:1
Prevention of colorectal cancer by aspirin: is it cost-effective?, 122:1
Prevention of neonatal necrotizing enterocolitis, 117:521
Primary biliary cirrhosis in the United States, 119:1425
Primary gastric lymphoma, 119:1185
Probiotics: why are they good for the gut?, 121:511
Probiotics in the prevention of acute onset of pouchitis: improved quality of life of patients with ileal pouch-anal anastomosis, 124:1173
Probiotic therapy for pouchitis, 119:287
Prognostic factors in patients with Zollinger-Ellison syndrome and MEN-1, 116:233
Prognostic significance of elevated COX-2 expression in esophageal adenocarcinoma, 122:1715
Prognostic value of measuring circulating colorectal cancer cells, 120:1071
Prophylaxis against ERCP-induced acute pancreatitis, 124:1722
Prostaglandins and duodenal bicarbonate secretion in mice and men?, 117: 1037
Protectin-bound *H. pylori* prevents complement-induced lysis, 120:332
Protection from attack of the human intestinal epithelium, 118:996
Protective role of induced heat-shock protein 70 in experimentally induced acute pancreatitis, 122:2
Prucalopride for the treatment of functional constipation, 120:331
Psychological treatment of functional dyspepsia, 119:609
Quantitative assessment of oral-pharyngeal dysphagia, 118:649
Race and response to therapy in chronic hepatitis C, 119:1185
Reduced fibroblast migration in patients with inflammatory bowel disease may affect the wound-healing response, 1251295
Reflux, esophagitis and mechanical ventilation, 116:1281
Regional cerebral activation in IBS, 118: 815

Risk association between *H. pylori* and noncardiac gastric cancer is much greater than previously reported, 121:751
Risk factors for diabetes mellitus in chronic pancreatitis, 119:1185
Risk of cancer in the Peutz-Jeghers syndrome, 119:1425
Risk of community-acquired SBP, 117:292
A role for intestinal epithelial cells in immune responses?, 116:783, 116:1023
The role of CNS nitric oxide in esophageal function, 119:287
The role of ICAM-1 in acute pancreatitis, 116:510
Role of leptins in cirrhotic patients, 119:1426
The role of nitric oxide in postoperative ileus, 118:247
The role of tachykinins in enterotoxigenic-induced secretion, 119:889
Role of tachykinins in nerve-mediated contractions in the human esophagus, 120:01:00
Role of TNF in intestinal GVHD, 116:510
Sacral nerve stimulation to treat neurogenic and idiopathic fecal incontinence, 121:511
Safety of low-dose aspirin, 117:1
Screening for Barrett's: light at the end of the tunnel?, 125:1569
Selectins in experimental colitis, 120:1072
Serotonin, anorexia, and IBD, 118:457
Smad7 inhibits experimental fibrogenesis in vivo, 125:2
Smoking cessation and Crohn's disease, 120:1071
Sonic hedgehog (Shh) and gastric gland morphogenesis?, 121:240
Spinal NO and visceral hyperalgesia, 116:1282
Statins as antimetastatic agents, 122:253
Step-down therapy of GERD can decrease costs without adversely affecting quality of life, 121:1034
Subclinical intestinal inflammation in first-degreee relatives of patients with Crohn's disease, 124:1721
TAP polymorphisms in HCV infection, 116:1023
The TGF-β II receptor protein ameliorates radiation enteropathy, 119:1185
Thalidomide therapy in Crohn's disease, 117:1265
TIPS for portal hypertensive gastropathy in cirrhotic patients, 118:816
Toll-like receptors in inflammatory bowel diseases: what are they and why are they significant?, 122:1716
Transcription factors in acute pancreatitis, 116:234
Transmission of *Helicobacter pylori* in children, 121:239
Treatment for osteoporosis, 119:609
Treatment of DALMs, 117:1265
Treatment of small intestinal bacterial overgrowth, 117:755
Trefoil peptides and gastric cancer, 119:609
Trypsin activation induced by an activation-peptide mutation in hereditary pancreatitis, 119:287
Trysinogen mutations in chronic pancreatitis, 117:1
Tumor necrosis factor polymorphisms may be associated with genetic susceptibility for nonalcoholic fatty liver disease, 122:253
Uncontrolled overexpression of interleukin 15 in refractory celiac sprue perpetuates epithelial damage and promotes the emergence of T cell clonal proliferations, 125:648
Unsedated small-caliber endoscopy, 117:1265
Urocortin reduces gastric emptying and body weight, 116:1281
Ursodeoxycholic acid reduces the risk of developing colorectal cancer in patients with ulcerative colitis and sclerosing cholangitis, 124:873
Use of recombinant human IL-10 for the treatment of Crohn's disease, 119:1425
Use of selective COX-2 inhibitors is associated with lower risk of lower GI bleeding, 124:281
Using a novel approach, selective expression of vascular growth factors is found in focal nodular hyperplasia of the liver, 124:594
Utilization of screening signoidoscopy, 117:291
A vaccine for hepatitis C?, 117:1266
Value of ASCA and pANCA in indeterminate colitis, 122:1195
VEGF and its receptors in pancreatic cancer, 119:1185
Viagra-like drugs for achalasia?, 118:247
Video capsule endoscopy superior to small bowel radiographs for evaluation of small bowel disease, 123:963
Virtual colonography for screening of colorectal cancers: ready for prime time?, 125:285
What causes Mallory bodies?, 122:1715
When should TIPS be considered before standard medical therapy for refractory ascites?, 124:594
Why infliximab, but not etanercept, is effective for treatment of Crohn's disease, 124:1722

Thrombin, with heater probe, in treatment of bleeding peptic ulcer, 125:396

Thrombin-activatable fibrinolysis inhibitor, deficiency of, in cirrhosis, 121:131

Thrombocytopenia
immune-mediated, with Crohn's disease, rituximab for, 124:583-c
with pegylated interferon, for hepatitis C, 124:1711

Thromboembolic disease, obesity and, 123:882-aga

Thrombophilia, and colonic ischemia, 121:561, 121:724-e

Thrombophilic gene mutations, and portal or hepatic venous thrombosis, 120:1059-c

Thrombosis
acquired and hereditary risk factors for, and colonic ischemia, 121:561, 121:724-e
and factor V Leiden, and inflammatory bowel disease, 116:778-c
hepatoportal, causes of, 119:874-ss
mesenteric venous, in cirrhosis, 123:1409-c
portal, in cirrhosis, 123:1409-c
risk of, in inflammatory bowel disease, 117:280-c

Thurman, Ronald G., 121:513-gn

Thymus-expressed chemokine, in small intestinal Crohn's disease, 121:246-rc

Thyroid disease, with pegylated interferon, for hepatitis C, 124:1711

Thyroid hormone, in regulation of sterol 12α-hydroxylase (rat), 118:599

Tight junctions
assembly in intestinal epithelia, Rho kinase and, 121:566
function, regulation by Rho kinase, 121:566

Time-resolved fluorescence, 120:749

Tin protoporphyrin, inhibition of heme oxygenase, 118:477

TIPS. *See* Transjugular intrahepatic portosystemic shunt (TIPS)

Tissue plasminogen activator, promotion of tumor growth and angiogenesis in pancreas, 122:806-vidd

Tissue transglutaminase
antibodies to
assay, compliance with gluten-free diet and, 122:588-c
in dermatitis herpetiformis, 117:749-c
as autoantigen, 119:234-srr

T lymphocytes (T cells). *See also* **Natural killer T cells**
activation
costimulation with IL-12 during, tissue injury caused by, 117:1069, 117:1238-e
inhibitors, therapy with, for inflammatory bowel disease, 122:1592
molecular machinery for, 117:503-ss
analysis of, in CMV-induced liver-restricted complications of liver transplantation, 122:1201
antigen presentation to, by colonocytes, in normal and diseased states (mice), 119:1548
apoptosis, in Crohn's disease, 119:1166-ss
autoreactive clones, in primary biliary cirrhosis, 125:1379
$CD4^+$
in acute experimental pancreatitis (mice), 118:458-tmig, 118:582, 118:626-e, 119:881-c
$\alpha_4\beta$--^{lo}, and protection of gastric mucosa against *H. felis* (mice), 119:109
in cerulein-induced pancreatitis, 119:881-c
depletion, and intestinal damage in SIV-infected Rhesus macaques, 116:650
in gastric mucosa, in acute *H. pylori* infection (Rhesus macaque), 118:247-tmig, 118:307
of lamina propria, HIV-1 infection and, 120:607
mucosal, HAART-related increase in, 120:984-cr
naive, priming of, by liver sinusoidal endothelial cells (mice), 116:1428
response to HBcAg/HBeAg, regulation of, 116:650, 116:765-e
$TCR\alpha^-\beta^+$, in colitis, in $TCR\alpha^{-/-}$ mice, 119:983
$CD8^+$
apoptosis, in liver, 120:250-srr
migration of, in inflamed small intestine, 125:491
in celiac disease, cytokine expression in, 123:667, 125:1560-c
characteristics of, in colitis, in $TCR\alpha^{-/-}$ mice, 119:983
clonal expansion, in enterogenic spondyloarthropathy, 119:1745-cr
and colitis, in Tgϵ26 mice, 120:900
colitogenic CD4 subset of, localization of (mice), 123:1949
development of, in liver, 120:250-srr
differentiation antigens. *See* **CD (cluster of differentiation)**
engineered, for IL-10 delivery to gut, 123:1877, 123:2140-e
gluten-specific responses, in celiac disease, diversity of, 122:1729, 122:2072-e
gut-homing, ex vivo IL-10 gene transfer to, 123:1877, 123:2140-e
HBV-specific $CD8^+$
direct ex vivo analysis of, 117:1386
pathogenetic role of, in hepatitis B, 117:1386
HCV-specific, induction by oral immunization with *Salmonella* carrier for HCV DNA (mice), 121:1158
HCV-specific $CD4^+$, and hepatitis C recurrence, 117:756-tmig, 117:933, 117:1012-e, 118:807-c
after liver transplantation, 117:756-tmig, 117:926, 117:1012-e
HCV-specific reactivity, and response to interferon/ribavirin treatment, 118:248-tmig, 118:346
helper
H. pylori-specific, in low-grade gastric MALToma, 117:1105
Th1. *See also* **Immune response, Th1/Th2-type; Immune response, Th1-like**
in acute *H. pylori* infection (Rhesus macaque), 118:247-tmig, 118:307
indoleamine 2,3-dioxygenase and (mice), 125:1762
polarization, inhibitors, therapy with, for inflammatory bowel disease, 122:1592
Th2, dysregulation of, and small intestinal transformation (mice), 124:672
Th1/Th2, defective response by, in Whipple's disease, 123:1468
IL-10-transduced, and prevention of colitis in SCID mice, 123:1865, 123:2140-e
impaired regulation of B-cell growth, in *H. pylori*-related gastric MALToma, 117:1105
intestinal
antigen recognition by, 118:444-ss
$\gamma\delta$, alkylamine-reactive, in host defense and immune regulation, 118:444-ss
response to high-molecular-weight glutenins, in celiac disease, 125:537
intraepithelial
$CD94^+$, in celiac disease, 118:816-tmig, 118:867
in celiac disease, IL-15 and, 125:648-tmig, 125:730
intrahepatic activation of, and bystander hepatitis (mice), 123:1252
lamina propria, defective apoptosis in gastrointestinal inflammatory states, 116:509-tmig, 116:557
liver, IFN-γ-induced apoptosis, Kupffer cells and (rat), 116:666
migration to sites of inflammation, interferon gamma and, 119:129, 119:260-e
mucosal
apoptosis and proliferation of, caspases and, 122:1334
and intestinal inflammation (mice), 118:880, 118:974-e
in primary biliary cirrhosis, quantitation and phenotypic analysis of, 123:1031
proliferation, costimulation by intestinal epithelial cells, CD58 in, 116:1023-tmig, 116:1054
regulatory $CD8^+$, expansion, after interaction with intestinal epithelial cells, 123:1516
responses in patients with chronic hepatitis C, peginterferon α-2A and, 123:1070
Th1-type cytotoxic, H^+,K^+-ATPase–specific, in autoimmune gastritis, 120:377
toll-like receptors on, in liver injury by *Salmonella* (mice), 123:1265

Tolerance, oral, interferon gamma induction during, and reduced T-cell migration, 119:129, 119:260-e

Toll-like receptors
in inflammatory bowel disease, 122:1716-tmig, 122:1987
in liver injury by *Salmonella* (mice), 123:1265

Torre's syndrome, clinical characteristics of, 124:1595

Total parenteral nutrition
in critical care, 117:1500-ss
intestinal mucosal atrophy with, 125:1273-ss

Toxins
and chronic pancreatitis, 120:682
and liver chemistry tests, 123:1367-aga

Toxoplasma gondii
acute ileitis caused by, development of, CD154/CD40 pathway in (mice), 122:752, 122:823-e

inflammatory response to, regulation of, 125:491
Toxoplasmosis, ileitis after, regulation by TGF-β-producing intraepithelial lymphocytes (mice), 120:914
Tp53, in pancreatic intraductal neoplasia, 124:1958-srr
Trace elements, nutritional use of, 122:834-pmr
TRAIL. *See* Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
Training programs, in gastroenterology, 119:550. *See also* Education and training
Transcription factor
Cdx1, expression, during intestinal development, 119:961
Cdx2
activation domain, phosphorylation of, effects on transactivation capacity, 121:1437
ectopic expression in transgenic mice, gastric intestinal metaplasia induced by, 122:689, 125:996-c
in enterocyte differentiation, 118:115
expression, during intestinal development, 119:961
function, phosphorylation of activation domain and, 121:1437
interaction with lactase gene promoter, 118:115
and intestine-specific expression of guanylyl cyclase C, 119:89
E2F, and APC-induced cell cycle arrest, 123:751, 123:935-e
Elf3, in intestinal development (mice), 122:1455
ethanol metabolites and, in pancreatic acinar cells (rat), 122:106
NF-κB/Rel/IκB
activating kinases, 118:1208-srr
knockout mouse models of, 118:1208-srr
antiapoptotic functions of, 118:1208-srr
in gastrointestinal diseases, 118:1208-srr
gene functions, knockout mouse models of, 118:1208-srr
target genes for, 118:1208-srr
Transepithelial signaling, in human stomach, 120:1128, 120:1279-e
Transferrin receptor
duodenal expression of, in anemia and hemochromatosis, 120:1404
and HFE protein binding, in hemochromatosis, 121:1489-srr
TFR2, gene mutation, in hemochromatosis type 3, 122:1295
Transforming growth factor-α
activation of Ha-Ras–ERK cascade, in pancreatic cancer with Ki-*ras* mutations, 116:1441
antiapoptotic role in gastric pit cells, nuclear factor κB and, 121:56
and gastric lipase gene expression, 116:831
in gastrointestinal development and mucosal integrity (mice), 121:68
overexpression of
and expansion of Pdx1-expressing pancreatic epithelium (mice), 117:1416
and islet neogenesis (mice), 117:1416
Transforming growth factor-β
in hepatic fibrosis (rat), 120:1784
and LPS-related impairment of liver regeneration (mice), 123:352
receptor, amelioration of radiation enteropathy (mice), 119:1185-tmig, 119:1286
and regulation of ileitis after intracellular parasite infection (mice), 120:914
TGF-β1, and leukocyte recruitment in colon cancer, 122:1121
TGF-β2, and apoptosis in intestinal mucosa (mice), 122:1364
TGF-β3, and apoptosis in intestinal mucosa (mice), 122:1364
and transcriptional regulation of *h-sgk* serine-threonine protein kinase gene in human intestine, 116:1081
and tumorigenesis in colon cancer (mice), 116:1496-ss
and tumor-suppressing pathway in colon, 117:500-ss
Transforming growth factor β/SMAD pathway
in colon carcinogenesis, 119:854-srr
in hepatic fibrogenesis (rat), 125:2-tmig, 125:178
Transgenic mice
cell-specific targeting of genes in, keratin 19 promoter for, 120:1728
keratin 19, 120:1728
Transjugular intrahepatic portosystemic shunt (TIPS)
complications of, 124:1700
duplex sonography and, 116:1272-c, 117:511-c
dysfunction of, 124:1700
fistulae with, 124:1700
for gastric variceal bleeding, 118:1270-ss, 124:1700, 125:262-ss
hemolysis with, 124:1700
hepatic encephalopathy with, 124:1700
for hepatorenal syndrome, 122:1658
indications for, 124:594-tmig, 124:634, 124:1700
infection of, 117:514-c, 124:1700
mortality rate for, 124:1700
outcome with, predictors of, 118:2-tmig, 118:138
for portal hypertensive gastropathy in cirrhosis, 118:816-tmig, 118:905
in prevention of recurrent variceal hemorrhage, 123:384-ss
in prevention of variceal hemorrhage, 125:262-ss
puncture with, 124:1700
for refractory ascites, 120:311-ss, 123:1757-tmig, 123:1839, 125:997-c
for refractory bleeding from ruptured gastric varices, 118:1270-ss
stent occlusion with, 124:1700
technique for, 124:1700
thrombosis with, 124:1700
vegetative infection of, 116:779-c
Transporter associated with antigen processing 2 *(TAP2)* gene, polymorphism, and hepatitis C infection, 116:1023-tmig, 116:1149
Traveler's diarrhea, resistance to, dietary calcium and, 125:286-tmig, 125:469
Treatment, of gastrointestinal disorders, book on, 118:1275-pmr
Trefoil factor family 1, gene *(TFF1),* mutations of, in gastric cancer, 119:609-tmig, 119:691
Trefoil factors. *See also* Intestinal trefoil factor
in goblet cells, and susceptibility to colonic injury, 118:1272-ss
and mucins, interaction of, 118:70
TFF1, expression, regulation by gastrin, 125:510
Treves, Frederick, 125:676
Tricyclic antidepressants
for functional bowel disorders, 125:19, 125:249-e
for irritable bowel syndrome, 123:2108-aga, 125:19, 125:249-e
for postinfectious irritable bowel syndrome, 124:1662
Trier, Jerry S., presentation of Julius M. Friedenwald medal to, 116:1457-aga
Triiodothyronine
and keratinocyte growth factor, synergistic enhancement of liver hyperplasia (rat), 118:591
receptor subtypes, and postnatal intestinal development (mice), 116:1367
Triiodothyronine knockout mice, intestinal development in, 116:1367

Trinitrobenzene sulfonic acid, colitis induced by
abrogation by IL-2-IgG2b fusion protein (mice), 117:858
apoptosis of Th1 T cells in, anti-IL-12 treatment and, 117:1078, 117:1238-e
IL-16 in (mice), 119:972
indoleamine 2,3-dioxygenase and (mice), 125:1762
prevention, by dietary glycine (rat), 125:775
Th1 and Th2 cytokine responses in (mice), 119:724
TrkA, expression by tumor-associated arteries in hepatocarcinogenesis (mice), 122:1978
Troglitazone
hepatotoxicity of, 117:759-ce
suppression of colon carcinogenesis (mice), 124:281-tmig, 124:361, 124:564-e
therapeutic potential in colitis, 118:228-ss, 121:1019-ss
Tropomyosin, novel isoform (TC22), in colon cancer, 123:2-tmig, 123:152
Trypsin
activation, induced by activation-peptide mutation, in hereditary pancreatitis, 119:288-tmig, 119:461
pathologic activation of, in acute pancreatitis, neutrophils and (mice), 122:973, 122:1166-e
Trypsin inhibitor gene (*PSTI*), mutations, and pancreatitis, 121:1310, 121:1509-e
Trypsinogen
cationic, mutations
and chronic pancreatitis, 120:682
nomenclature for, 119:277-c
interstitial, in necrotizing pancreatitis (rat), 117:717, 118:452-c
mutations, in chronic pancreatitis, 117:1-tmig, 117:7-rc, 117:1508-c, 117:1509-c, 119:277-c, 120:682
Tube feeding, enteral
complications of, 122:1677
principles of, 122:1677
Tuberculosis, ileocecal, 120:1076-im
Tumor necrosis factor (TNF)
biological effects of, 119:1148-srr
cell sources of, 119:1148-srr
engineered human antibody to (CDP571), for active Crohn's disease, 120:1317-tmig, 120:1330
gene for, 119:1148-srr
and mucosal inflammation, 119:1148-srr
production of
inhibitors of, 119:1148-srr
by intraepithelial T cells, in celiac disease, 125:1560-c
stimuli for, 119:1148-srr
transcriptional and posttranscriptional regulation of, 119:1148-srr
and reduced fibroblast migration in inflammatory bowel disease, 125:1295-tmig, 125:1341
signaling
inhibitors of, 119:1148-srr
through TNFRI and TNFRII, 119:1148-srr
Tumor necrosis factor α (TNF-α)
and alcohol-induced liver injury (mice), 117:942
antiapoptotic mechanisms in pancreatic cells, pancreatitis-associated protein I activation and (rat), 119:816
antibody. *See also* Infliximab
for Crohn's fistula, 124:1595
effects in Crohn's disease, 116:1-tmig, 116:22, 116:1023-tmig, 116:1029
in Crohn's disease, 117:2-tmig, 117:73
expression, IL-12 enhancement of T cell responses and, 117:1069, 117:1238-e
in fulminant hepatic failure, 119:446
and hepatocellular apoptosis in ischemic liver (mice), 122:202
humanized monoclonal antibody to, for fistulous Crohn's disease, 119:1132-srr
and ICAM-1-triggered liver regeneration (mice), 124:692
inhibition, amelioration of intestinal graft-versus-host disease (mice), 116:510-tmig, 116:593
and invasion of Src-activated intestinal cells (rat), 122:331
in LPS-related impairment of liver regeneration (mice), 123:352
and NOD2/CARD15 gene expression in epithelial cells, 124:875-tmig, 124:1001, 124:1145-e
polymorphisms
in Crohn's disease, 117:1037-tmig, 117:1062
proinflammatory, and risk of atrophic gastritis and gastric cancer, 125:364
and susceptibility for nonalcoholic fatty liver disease, 122:253-tmig, 122:274
signaling pathway in colonocytes, mesalamine and (mice), 116:509-tmig, 116:602
suppression of, by thalidomide, in prevention of alcoholic liver injury (rat), 123:291
targeting
in treatment of Crohn's disease, 121:1033-tmig, 121:1088, 121:1145, 121:1242-e
in treatment of TNBS-induced colitis (mice), 121:1270-tmig, 121:1372
T-cell production of, in celiac disease, 125:1560-c
Tumor necrosis factor (TNF) inhibitors
biologic therapy with, for inflammatory bowel disease, 122:1592
for fistulous Crohn's disease, 119:1132-srr
Tumor necrosis factor (TNF) receptor 2, in colonic epithelial hyperplasia and chronic intestinal inflammation (mice), 122:134
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
in colon, 122:659
hepatotoxicity of, 119:3-gn
and killing of hepatic stellate cells by activated Kupffer cells, 123:845
receptors for, in colon, 122:659
Tumors
ampullary, endoscopic ultrasound of, 122:1631
biliary, endoscopic ultrasound of, 122:1631
fine-needle injection therapy for, endoscopic ultrasound guidance for, 122:1631
gastrointestinal
c-K-*ras* mutations in, 118:995-tmig, 118:1045
pathology and genetics of, 121:1258-pmr
intestinal, intestinal failure caused by, 124:1615
mucinous, appendiceal, 122:1200-im
pancreatic, progression, promotion by t-PA, 122:806-vidd
submucosal, endoscopic ultrasound of, 122:1631
Tumor suppressor gene, p53. *See* p53
Twins, gastroesophageal reflux disease in, 122:55
Twin study, of inflammatory bowel disease, in Swedish cohort, long-term follow-up in, 124:1767
Tyor, Malcolm P., M.D., 125:288-gn
Tyrosine kinase genes, and colorectal cancer, 125:4-gn

Ubiquitin, and inositol trisphosphate receptor down-regulation in pancreatic acinar cells (rat), 116:1194

Ubiquitin B gene, molecular misreading of, and hepatic Mallory body formation, 122:1878
UDP-glucuronosyltransferase
gene polymorphisms, and hepatocellular carcinoma, 121:1136
in human liver and colon, 116:149
UGT1A7, gene polymorphisms, and pancreatic disease, 124:1802
UGT2B4, induction in hepatocytes, FXR and, 124:1926
***UGT1A1* gene,** and G6PD deficiency, and neonatal hyperbilirubinemia, 123:127
Ulcerative colitis (UC). *See also* **Inflammatory bowel disease (IBD)**
adenoma-like dysplasia-associated lesion or mass (DALM) in, treatment of, 117:1265-tmig, 117:1288, 117:1295, 117:1488-e, 118:1277-c
appendix in, 117:272-ss
atypical p-ANCA antigen in, 119:310
backwash ileitis in, and colorectal cancer risk, 120:783-tmig, 120:841
brain-gut interactions in, 118:807-c
chromoendoscopy in, 124:873-tmig, 124:880-rc, 124:1135-e
ciprofloxacin and, 117:280-c, 117:282-c
colonic butyrate metabolism in vivo and colonic permeability in, 117:745-c
colorectal cancer in
backwash ileitis and, 122:245-c
prevention of, by ursodeoxycholic acid, 121:491-ss, 124:873-tmig, 124:889, 124:1139-e
defective apoptosis of lamina propria T cells in, 116:509-tmig, 116:557
epithelial barrier defects in, 116:233-tmig, 116:301, 121:1269-tmig, 121:1320
and female fecundity, 122:15, 122:226-e
flat low-grade dysplasia in, progression to advanced neoplasia, 125:1311, 125:1531-e
genetics of, 117:755-tmig, 117:806, 124:521-srr
glucocorticoid responsiveness in, predictor of, 118:816-tmig, 118:859, 119:1177-c
HLA associations in, 123:661-tmig, 123:714
Hodgkin's disease risk with, 119:647
humanized $\alpha_4\beta$- antibody for (abstract), 125:606-aga
ileal pouch anal anastomosis for, health-related quality of life after, 122:1179-ss
IL-1 receptor antagonist gene in, 117:755-tmig, 117:806
improvement of, after appendectomy, 119:502-cr
infliximab for, 124:1990-ss
intravenous cyclosporine in, 125:1025
lymphoma risk in, 121:1034-tmig, 121:1080, 121:1239-e, 123:653-c
MDR1 C3435T gene polymorphism and, 124:26, 125:1919-c
mortality in, 125:1576, 125:1881-e
newly diagnosed, guide for patient with, 123:953-pmr
and peristomal pyoderma gangrenosum, 119:873-ss
p53 gene in, and cancer, 120:1877-ss
polypectomy in, 119:879-c
pouchitis in, after pouch-anal anastomosis, IL-1ra allele 2 as predictor of, 121:751-tmig, 121:805
PPAR-γ gene expression in, impairment of, 124:1174-tmig, 124:1265, 124:1538-e
probiotic therapy with *E. coli* in, 118:630-ss
refractory, laparoscopic appendectomy with, 120:1562-c
relapse, predictive markers of, 119:1-tmig, 119:15, 120:1-tmig, 120:13, 121:1261-c
restorative proctocolectomy in, surgical strategy in, 123:1403-ss
role of appendix in, 121:730-ss
skin lesions in, 124:1595
spinal cord stimulation and, 117:215-cr, 117:1256-c
steroid therapy for, natural history of, 121:239-tmig, 121:255
susceptibility to
HLADRB1*0103 and, 119:1491
IKBL+738(C) and, 119:1491
treatment of
basalazide for, 124:574-ss
heparin and steroids in, comparison of, 119:895
IV cyclosporine as single therapy for, 121:1530-c
IV cyclosporine versus IV corticosteroids as single therapy for, 120:1317-tmig, 120:1323, 120:1541-e
mesalamine for, 124:574-ss
V_H gene usage in, 121:15
Ulcerative enteritis, in celiac disease, 120:1526-aga
Ulcers. *See also* **Peptic ulcer disease**
anal, in perianal Crohn's disease, 125:1508-aga
duodenal
clinical presentation of, *Helicobacter pylori* virulence factors and, 123:414
healing of, 119:521-srr
NSAID-related, risk factors for, 123:1006
outcome in, *Helicobacter pylori* virulence factors and, 123:414
prevention of, 119:521-srr
recurrence risk, IL-1β polymorphisms and, 123:92
esophageal, healing of, keratinocyte growth factor and, 122:254-tmig, 122:458
gastric
bisphosphonate therapy for osteoporosis and, 119:609-tmig, 119:631, 119:866-e
healing of, 119:521-srr
macrophage migration inhibitory factor and (rat), 121:619
NSAID-related, risk factors for, 123:1006
prevention of, 119:521-srr
VEGF and angiopoietin-1 gene therapy for, 121:1040-rc
gastroduodenal, rofecoxib and, 118:638-c, 118:640-c
intestinal, in Buerger's disease, 125:911-cr
Ultrasound
abdominal, 123:388-pmr
of abdominal transplantation, 124:1556-pmr
anal
AGA medical position statement on, 116:732-aga
AGA technical review on, 116:735-aga
in appendicitis, 123:992, 125:272-c
Doppler, in acute mesenteric ischemia, 118:954
duplex, and TIPS, 116:1272-c, 117:511-c
endoanal, in fecal incontinence, 124:1672
endoscopic. *See* **Endoscopic ultrasound (EUS)**
intraluminal, characterization of esophageal contraction, 116:29
Uncoupling protein 2, lipid-induced expression in hepatocytes (rat), 116:1024-tmig, 116:1184
United Network for Organ Sharing (UNOS), policy on liver allocation, 117:523-gn
Upper esophageal sphincter, abnormal opening, dysphagia due to, rehabilitative exercise for, 122:1314
Upper gastrointestinal tract
cancer of, book on, 125:987-pmr
longitudinal endosonography in, atlas and manual for, 122:2088-pmr

pathology and pathophysiology of, AGA slide collection on, 125:987-pmr
surgery of, 119:1173-pmr, 122:835-pmr
Urease, *Helicobacter pylori,* and gastric acid resistance, 123:187
Uridine diphosphate-glucuronosyltransferase, UGT1A1, deficiency of, 125:240-srr
Urocortin, and colonic motor activity in stress (rat), 119:1569
Uroguanylin, increased, in osmotic diarrhea (mice), 121:1191
Ursodeoxycholic acid
adverse effects and side effects of, 121:501-c
in biliary obstruction (mice), 123:1238
and budesonide, combined, for primary biliary cirrhosis, 117:756-tmig, 117:918
as chemopreventive agent in ulcerative colitis and primary sclerosing cholangitis, 124:873-tmig, 124:889, 124:1139-e
and cirrhosis development in primary biliary cirrhosis, 122:599-tmig, 122:652
and hepatocellular transporter expression (mice), 121:170
high-dose therapy with, in primary sclerosing cholangitis, 121:752-tmig, 121:900
and impaired liver sinusoidal bile acid uptake in Amish kindred, 119:188, 120:321-c
and lichenoid eruption, 122:1547-c
for nonalcoholic fatty liver disease, 122:1649
prevention of colorectal cancer in ulcerative colitis, 121:491-ss, 124:873-tmig, 124:889, 124:1139-e
therapy with, lichenoid eruptions caused by, 121:501-c
Ursodiol. *See* Ursodeoxycholic acid

Vagotomy, effects on cholangiocyte proliferation and secretion, 117:191
Vagus nerve
and ghrelin's functions (rat), 123:1120
and motor control of lower esophageal sphincter, $GABA_B$ receptors in, 120:1749
stimulation, and leptin secretion, 122:259-rc
subdiaphragmatic, stimulation of, LES sphincter relaxation caused by (mice), 119:1600
Variceal bleeding
acute
octreotide for, meta-analysis of, 120:946
portal hypertension and, 117:522-tmig, 117:626
treatment of, 120:726
endoscopic sclerotherapy for, complications of, 120:336-im
first
isosorbide-5-mononitrate and, in β-blocker intolerant patients, 121:752-tmig, 121:908
prevention of, 120:726
in β-blocker intolerant patients, 121:752-tmig, 121:908
gastric
management of, 120:1875-ss
prevention of, TIPS for, 125:262-ss
refractory, response to TIPS, 118:1270-ss
hepatic venous pressure gradient during, somatostatin and, 121:110
prevention of, 123:728
β-blocker plus nitrate for, 119:1170-ss
endoscopic banding for, 123:728, 123:735, 123:963-tmig, 123:1013, 123:1388-e
medical therapy for, 123:728, 123:735, 123:963-tmig, 123:1013, 123:1388-e
propranolol for, optimal use of, 124:2005-c
TIPS for, 124:1700, 125:262-ss
recurrent
in cirrhotic patient, and anticoagulation therapy for portal vein thrombosis, 122:2095-c
prevention of, 120:726, 122:832-ss
endoscopic banding for, 123:728, 123:963-tmig, 123:1013, 123:1388-e
medical therapy for, 123:728, 123:963-tmig, 123:1013, 123:1388-e
TIPS for, 123:384-ss
risk stratification in, hepatic venous pressure gradient and, 121:110
secondary prevention of, TIPS for, 124:1700, 125:262-ss
TIPS for, 124:1700, 125:262-ss
treatment of, emergency sclerotherapy versus vasoactive drugs for, 124:1174-tmig, 124:1277
Varices
esophageal, recurrence, prevention of, 124:1545-ss
gastric
fundal, balloon endoscopic sclerotherapy for, 117:514-c
prevalence of, 122:1620
risk for first hemorrhage with, 122:1620
TIPS for, 118:1270-ss, 124:1700, 125:262-ss
prevention of, 120:726
Vascular adhesion protein 1, circulating soluble, and MAO activity in chronic liver disease, 119:1096
Vascular cell adhesion molecule (VCAM)
and leukocyte recruitment in colon cancer, 122:1121
VCAM-1
blockade, and inflammatory response in murine model of Crohn's disease, 121:1428
in experimental colitis (rat), 116:874
Vascular endothelial growth factor (VEGF)
and aortic eNOS up-regulation in cirrhosis (rat), 122:1869
and COX-2 angiogenic pathway in colorectal cancer, 121:1339
gene therapy, for gastric ulcers, 121:1040-rc
in pancreatic cancer, 119:1186-tmig, 119:1358
Vascular endothelial growth factor receptors, in pancreatic cancer, 119:1186-tmig, 119:1358
Vascular reactivity, in cirrhosis
regulation of, angiotensin II and, 118:565
selective alteration of, 118:765
Vasoactive agents, in intrahepatic portal hypertension and fibrogenesis, 118:996-tmig, 118:1149, 118:1261-e
Vasoactive intestinal polypeptide (VIP)
and bile secretion (rat), 117:420
effects on gastric enterochromaffin-like cell proliferation (rat), 116:623
therapeutic effects in trinitrobenzene sulfonic acid model of Crohn's disease (mice), 124:961
Vasoconstriction, PKC-dependent, in portal hypertension, octreotide and (rat), 120:975
Vasoconstrictors, for hepatorenal syndrome, 122:1658
Vasodilation, arterial, in cirrhosis, site and mechanism of, 122:1658
Vasopressin
modulation of bile flow, gap-junctional communication in, 116:1024-tmig, 116:1176
for variceal bleeding in cirrhosis, comparison with emergency sclerotherapy, 124:1174-tmig, 124:1277
Vasopressin receptor antagonist, for hyponatremia in cirrhosis and ascites, 124:933
Vater, Abraham, 118:379
Velculescu, Victor E., 125:4-gn

Veno-occlusive disease, prevention of, by matrix metalloproteinase inhibition (rat), 125:882
Venous decompression, for hepatopulmonary syndrome in Budd-Chiari syndrome, 122:896
Vesicle-associated membrane protein 2, in gastric parietal cells, 123:281
Vibrio cholerae, infectivity of, gut transit and, 123:403-gn
Video capsule endoscopy, in small bowel disease, 123:963-tmig, 123:999, 123:1385-e, 125:276-c, 125:998-c
Videx. *See* Didanosine
Viewpoints in Digestive Diseases, Pitfalls in the analysis of electrogastrographic recordings, 117:453
Villous atrophy, enterocyte mass in, plasma citrulline as marker for, 124:1210
Vinson, Porter P., 117:1526
Vioxx, gastrointestinal effects of, 117:4-gn
Viracept. *See* Nelfinavir
VIRAHEP-C clinical trial, 122:1198-gn
Viral infections, in childhood, and subsequent inflammatory bowel disease, 116:783-tmig, 116:796, 116:988-e, 117:1253-c
Viramune. *See* Nevirapine
Virtual colonoscopy
detection of colorectal lesions with, 124:258-ss, 125:285-tmig, 125:304, 125:311
screening with, 124:258-ss, 125:285-tmig, 125:304, 125:311, 125:608-e
techniques for, 124:544-aga
Virus
colonic epithelial defense against, TRAIL and its receptors in, 122:659
gastroenteritis caused by, 123:651-pmr
structural biology of, 123:1350-srr
Virus-like particles
hepatitis C
characterization of, 117:1266-tmig
as potential vaccine candidate, 117:1266-tmig, 117:1397
synthesized in insect cells, 117:1266-tmig, 117:1397
Norwalk virus, oral delivery of, 117:40, 117:255-e
Visceral hyperalgesia
duodenal-specific, in sphincter of Oddi dysfunction type III, 116:900, 116:996-e
in irritable bowel syndrome and comorbid conditions, 122:1139-srr
proteinases and PAR-2 in (rat), 122:1034
spinal nitric oxide in (rat), 116:1282-tmig, 116:1399
Visceral hypersensitivity, in irritable bowel syndrome, 123:2108-aga
Visceral pain
facilitation and attenuation of, from rostroventral medulla (rat), 122:1006
hypersensitivity to, EP-1 receptor and, 124:18
kappa opioids and, 117:292-tmig, 117:388
new rat model of, 119:1185-tmig, 119:1276
peripheral NMDA receptors in (rat), 120:1737
treatment of, 116:1250-e
Visceral pain sensitivity
EP-1 receptor and, 124:18
in health, gender differences in, 123:1686-srr
in irritable bowel syndrome, gender differences in, 123:1686-srr
Visceral sensation
enhancement of, from supraspinal sites (rat), 122:1006
proteinases and PAR-2 in (rat), 122:1034
Visceral stimulation
central processing of, in irritable bowel syndrome, gender differences in, 124:1738, 124:1975-e
subliminal, cerebral cortical registration of, 122:290
Vitamin C, intragastric, omeprazole for *H. pylori* and, 119:287-tmig, 119:339
Vitamin D
deficiency, in Crohn's disease, treatment by tanning bed UV B radiation, 121:1485-cr
for osteoporosis treatment, 124:795-aga
Vitamin D receptor, genotype, as predictor of bone mineral density in primary biliary cirrhosis, 118:145, 119:599-c, 119:1805-c
Volume expansion, for hepatorenal syndrome, 122:1658
Vomiting. *See also* **Emesis; Nausea and vomiting**
cyclic, 120:263-aga
gastric electrical stimulation and (dog), 124:401
von Hippel-Lindau (VHL) disease, 120:788-im
pancreatic involvement in, 119:1087
von Willebrand factor
abnormalities of, in bleeding angiodysplasias, 120:346
Helicobacter pylori binding to, 124:1846, 124:1983-e
von Willebrand's disease, and hereditary hemorrhagic telangiectasia, 124:1595
VPA-985, for hyponatremia in cirrhosis and ascites, 124:933

Walsh, John, 120:335-ce
In memoriam, 119:289-gn
Wasting disease, Th2 cell dysregulation and (mice), 124:672
Water drinking, capacity for, in functional dyspepsia, noninvasive assessment of, 121:1054
Water immersion stress, induction of Hsp60 expression and protection against pancreatitis (rat), 119:220, 121:744-c
Water transport, by epithelia, 122:545-srr
Web of Science database, 122:257-ce
Weight gain, as health risk, 123:882-aga
Weight loss
in elderly
causes of, 122:1688
drugs causing, 122:1688
mnemonic for, 122:1688
in obesity, health benefits of, 123:882-aga
plasma ghrelin levels after, 124:575-ss
Weiss, Soma, 121:541
Whipple, George Hoyt, 117:576
Whipple's disease
defective cellular immune response in, 123:1468
skin lesions in, 124:1595
Wilson's disease, 125:1868-srr
ATP7B protein mutants in
as aggresomes, 121:1264-c
localization of, 120:784-tmig, 120:967, 124:335, 125:1911-c
properties of, 120:784-tmig, 120:967, 121:1264-c
cell therapy for (rat), 122:438
clinical presentation of, 125:1868-srr
clinician's guide to, 122:1542-pmr
diagnosis of, 125:1868-srr
gene product (ATP7B)
localization in hepatocytes (rat), 118:921
role in biliary copper excretion (human, rat), 118:921
genetics of, 125:1868-srr
nodular fatty infiltration of liver in, 122:258-im
pathophysiology of, 118:921, 125:1868-srr

screening for, 125:1868-srr
treatment of, 125:1868-srr
Wilson's disease protein
function, copper load and, 117:1266-tmig, 117:1380
localization in human liver, 117:1266-tmig, 117:1380
WISP (Wnt-inducible signaling pathway) proteins
as targets for gastrointestinal carcinomas, 123:392-c
WISP-3
gene mutations
in colorectal cancer with microsatellite instability, 121:1275-rc, 121:1497-e
in gastric cancer with microsatellite instability, 125:1563-c
in microsatellite unstable gastrointestinal carcinoma, 124:270-c
Women
in biomedical science, 121:243-ce
colon cancer in, microsatellite mutator phenotype with hypermethylated *hMLH1* gene, 119:597-c
in gastroenterology, demand for, 122:256-gn
Women's health issues, in digestive diseases, gastroenterologist training in, 124:1101-aga

Xanthomas, in Alagille syndrome, 124:1155-ss
X chromosome, inflammatory bowel disease susceptibility locus on, 120:834
Xenical (orlistat), concerns about safety and efficacy of, 117:4-gn
Xenin, in neuroendocrine tumors of duodenal origin, 123:1616
Xenotransplantation
information on, FDA seeks to increase access to, 120:786-gn
of liver, 120:749
X-ray crystallography, in structural biology, 123:1350-srr

Yamada, Tadataka, 118:460-gn
Julius M. Friedenwald Medal presented to, 124:1965-aga
Yellow nail syndrome, chylous ascites in, octreotide for, 116:1017-c

Zalcitabine, GI toxicity and GI-associated drug interactions of, 120:607
ZDV. *See* Zidovudine
ZDV-3TC, GI toxicity and GI-associated drug interactions of, 120:607
Zebrafish, lipid metabolism in, 121:1-gn
Ziagen. *See* Abacavir
Zidovudine, GI toxicity and GI-associated drug interactions of, 120:607
Zollinger, Robert Milton, 118:771
Zollinger-Ellison syndrome (ZES)
acid suppression therapy in, 118:649-tmig, 118:696
enterochromaffin-like (ECL) cell changes in, 123:68, 125:827-c
gastrinoma resection in, 117:758-gn
lung cancer and, 120:1271-cr
and MEN-1, prognostic factors in, 116:233-tmig, 116:286
Zonulin, and bacteria-related impairment of small intestinal barrier function, 123:1607